0	We	_	_	O
1	previously	_	_	O
2	reported	_	_	O
3	that	_	_	O
4	treatment	_	_	O
5	of	_	_	O
6	patients	_	_	O
7	with	_	_	O
8	symptomatic	_	_	O
9	advanced	_	_	O
10	non-small	_	_	O
11	cell	_	_	O
12	lung	_	_	O
13	cancer	_	_	O
14	with	_	_	O
15	single	_	_	O
16	agent	_	_	O
17	Gemcitabine	_	_	O
18	(	_	_	O
19	GEM	_	_	O
20	)	_	_	O
21	resulted	_	_	O
22	in	_	_	O
23	a	_	_	O
24	superior	_	_	O
25	clinical-benefit	_	_	O
26	response	_	_	O
27	rate	_	_	O
28	(	_	_	O
29	RR	_	_	O
30	)	_	_	O
31	compared	_	_	O
32	to	_	_	O
33	cisplatin-based	_	_	O
34	combination	_	_	O
35	chemotherapy	_	_	O
36	.	_	_	O

37	We	_	_	O
38	now	_	_	O
39	report	_	_	O
40	the	_	_	O
41	detailed	_	_	O
42	individual	_	_	O
43	symptom	_	_	O
44	control	_	_	O
45	analysis	_	_	O
46	,	_	_	O
47	and	_	_	O
48	the	_	_	O
49	influence	_	_	O
50	of	_	_	O
51	cisplatin-use	_	_	O
52	,	_	_	O
53	age	_	_	O
54	,	_	_	O
55	performance	_	_	O
56	status	_	_	O
57	(	_	_	O
58	PS	_	_	O
59	)	_	_	O
60	and	_	_	O
61	duration	_	_	O
62	of	_	_	O
63	treatment	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	received	_	_	O
67	either	_	_	O
68	GEM	_	_	O
69	(	_	_	O
70	1000	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	,	_	_	O
76	days	_	_	O
77	1	_	_	O
78	,	_	_	O
79	8	_	_	O
80	and	_	_	O
81	15	_	_	O
82	)	_	_	O
83	or	_	_	O
84	cisplatin	_	_	O
85	(	_	_	O
86	100	_	_	O
87	mg/m	_	_	O
88	(	_	_	O
89	2	_	_	O
90	)	_	_	O
91	,	_	_	O
92	day	_	_	O
93	1	_	_	O
94	)	_	_	O
95	plus	_	_	O
96	Vindesine	_	_	O
97	(	_	_	O
98	3	_	_	O
99	mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	,	_	_	O
104	days	_	_	O
105	1	_	_	O
106	and	_	_	O
107	15	_	_	O
108	)	_	_	O
109	(	_	_	O
110	PV	_	_	O
111	)	_	_	O
112	,	_	_	O
113	both	_	_	O
114	every	_	_	O
115	4	_	_	O
116	weeks	_	_	O
117	.	_	_	O

118	Scores	_	_	O
119	of	_	_	O
120	9	_	_	O
121	symptoms	_	_	O
122	were	_	_	O
123	listed	_	_	O
124	weekly	_	_	O
125	by	_	_	O
126	the	_	_	O
127	patient	_	_	O
128	on	_	_	O
129	visual	_	_	O
130	analogue	_	_	O
131	scales	_	_	O
132	.	_	_	O

133	Improvement	_	_	O
134	of	_	_	O
135	a	_	_	O
136	symptom	_	_	O
137	was	_	_	O
138	defined	_	_	O
139	as	_	_	O
140	2	_	_	O
141	consecutive	_	_	O
142	cycles	_	_	O
143	of	_	_	O
144	improvement	_	_	O
145	over	_	_	O
146	baseline	_	_	O
147	.	_	_	O

148	Baseline	_	_	O
149	symptoms	_	_	O
150	in	_	_	O
151	the	_	_	O
152	169	_	_	O
153	patients	_	_	O
154	were	_	_	O
155	well	_	_	O
156	balanced	_	_	O
157	between	_	_	O
158	the	_	_	O
159	2	_	_	O
160	arms	_	_	O
161	(	_	_	O
162	84	_	_	O
163	GEM	_	_	O
164	,	_	_	O
165	85	_	_	O
166	PV	_	_	O
167	)	_	_	O
168	.	_	_	O

169	Both	_	_	B-Premise
170	patients	_	_	I-Premise
171	with	_	_	I-Premise
172	objective	_	_	I-Premise
173	response	_	_	I-Premise
174	and	_	_	I-Premise
175	disease	_	_	I-Premise
176	stabilisation	_	_	I-Premise
177	had	_	_	I-Premise
178	clearly	_	_	I-Premise
179	better	_	_	I-Premise
180	symptom	_	_	I-Premise
181	control	_	_	I-Premise
182	than	_	_	I-Premise
183	those	_	_	I-Premise
184	with	_	_	I-Premise
185	disease	_	_	I-Premise
186	progression	_	_	I-Premise
187	.	_	_	I-Premise

188	Symptom	_	_	B-Premise
189	control	_	_	I-Premise
190	in	_	_	I-Premise
191	both	_	_	I-Premise
192	arms	_	_	I-Premise
193	was	_	_	I-Premise
194	similar	_	_	I-Premise
195	for	_	_	I-Premise
196	'disease-specific	_	_	I-Premise
197	'	_	_	I-Premise
198	symptoms	_	_	I-Premise
199	such	_	_	I-Premise
200	as	_	_	I-Premise
201	cough	_	_	I-Premise
202	,	_	_	I-Premise
203	dyspnea	_	_	I-Premise
204	,	_	_	I-Premise
205	pain	_	_	I-Premise
206	or	_	_	I-Premise
207	haemoptysis	_	_	I-Premise
208	.	_	_	I-Premise

209	Compared	_	_	B-Premise
210	to	_	_	I-Premise
211	PV	_	_	I-Premise
212	,	_	_	I-Premise
213	a	_	_	I-Premise
214	significantly	_	_	I-Premise
215	larger	_	_	I-Premise
216	number	_	_	I-Premise
217	of	_	_	I-Premise
218	GEM-patients	_	_	I-Premise
219	had	_	_	I-Premise
220	better	_	_	I-Premise
221	scores	_	_	I-Premise
222	for	_	_	I-Premise
223	'constitutional	_	_	I-Premise
224	'	_	_	I-Premise
225	items	_	_	I-Premise
226	such	_	_	I-Premise
227	as	_	_	I-Premise
228	anorexia	_	_	I-Premise
229	(	_	_	I-Premise
230	P=0.007	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	ability	_	_	I-Premise
234	to	_	_	I-Premise
235	carry	_	_	I-Premise
236	on	_	_	I-Premise
237	with	_	_	I-Premise
238	daily	_	_	I-Premise
239	activities	_	_	I-Premise
240	(	_	_	I-Premise
241	P=0.04	_	_	I-Premise
242	)	_	_	I-Premise
243	and	_	_	I-Premise
244	overall	_	_	I-Premise
245	impression	_	_	I-Premise
246	of	_	_	I-Premise
247	quality-of-life	_	_	I-Premise
248	(	_	_	I-Premise
249	P=0.008	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Symptom	_	_	B-Premise
253	control	_	_	I-Premise
254	was	_	_	I-Premise
255	very	_	_	I-Premise
256	similar	_	_	I-Premise
257	in	_	_	I-Premise
258	younger	_	_	I-Premise
259	(	_	_	I-Premise
260	<	_	_	I-Premise
261	65	_	_	I-Premise
262	years	_	_	I-Premise
263	)	_	_	I-Premise
264	versus	_	_	I-Premise
265	older	_	_	I-Premise
266	(	_	_	I-Premise
267	>	_	_	I-Premise
268	/=65	_	_	I-Premise
269	years	_	_	I-Premise
270	)	_	_	I-Premise
271	patients	_	_	I-Premise
272	,	_	_	I-Premise
273	and	_	_	I-Premise
274	only	_	_	I-Premise
275	slightly	_	_	I-Premise
276	better	_	_	I-Premise
277	in	_	_	I-Premise
278	those	_	_	I-Premise
279	with	_	_	I-Premise
280	a	_	_	I-Premise
281	Karnofsky	_	_	I-Premise
282	PS	_	_	I-Premise
283	>	_	_	I-Premise
284	/=80	_	_	I-Premise
285	%	_	_	I-Premise
286	compared	_	_	I-Premise
287	to	_	_	I-Premise
288	those	_	_	I-Premise
289	<	_	_	I-Premise
290	80	_	_	I-Premise
291	%	_	_	I-Premise
292	.	_	_	I-Premise

293	Most	_	_	B-Premise
294	of	_	_	I-Premise
295	the	_	_	I-Premise
296	symptom	_	_	I-Premise
297	improvement	_	_	I-Premise
298	occurred	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	first	_	_	I-Premise
302	3	_	_	I-Premise
303	cycles	_	_	I-Premise
304	,	_	_	I-Premise
305	with	_	_	I-Premise
306	some	_	_	I-Premise
307	further	_	_	I-Premise
308	symptom	_	_	I-Premise
309	improvement	_	_	I-Premise
310	in	_	_	I-Premise
311	the	_	_	I-Premise
312	following	_	_	I-Premise
313	cycles	_	_	I-Premise
314	in	_	_	I-Premise
315	the	_	_	I-Premise
316	GEM-arm	_	_	I-Premise
317	only	_	_	I-Premise
318	.	_	_	I-Premise

319	Both	_	_	B-Claim
320	GEM	_	_	I-Claim
321	and	_	_	I-Claim
322	PV	_	_	I-Claim
323	yield	_	_	I-Claim
324	a	_	_	I-Claim
325	symptom	_	_	I-Claim
326	control	_	_	I-Claim
327	rate	_	_	I-Claim
328	much	_	_	I-Claim
329	higher	_	_	I-Claim
330	than	_	_	I-Claim
331	expected	_	_	I-Claim
332	by	_	_	I-Claim
333	the	_	_	I-Claim
334	objective	_	_	I-Claim
335	tumour	_	_	I-Claim
336	RR	_	_	I-Claim
337	.	_	_	I-Claim

338	GEM	_	_	B-Claim
339	is	_	_	I-Claim
340	equally	_	_	I-Claim
341	effective	_	_	I-Claim
342	in	_	_	I-Claim
343	controlling	_	_	I-Claim
344	'disease-specific	_	_	I-Claim
345	'	_	_	I-Claim
346	symptoms	_	_	I-Claim
347	,	_	_	I-Claim
348	but	_	_	I-Claim
349	superior	_	_	I-Claim
350	in	_	_	I-Claim
351	controlling	_	_	I-Claim
352	'constitutional	_	_	I-Claim
353	'	_	_	I-Claim
354	symptoms	_	_	I-Claim
355	.	_	_	I-Claim

356	Most	_	_	B-Premise
357	of	_	_	I-Premise
358	the	_	_	I-Premise
359	symptom	_	_	I-Premise
360	control	_	_	I-Premise
361	was	_	_	I-Premise
362	achieved	_	_	I-Premise
363	during	_	_	I-Premise
364	the	_	_	I-Premise
365	first	_	_	I-Premise
366	3	_	_	I-Premise
367	cycles	_	_	I-Premise
368	of	_	_	I-Premise
369	treatment	_	_	I-Premise
370	,	_	_	I-Premise
371	with	_	_	I-Premise
372	some	_	_	I-Premise
373	further	_	_	I-Premise
374	improvement	_	_	I-Premise
375	thereafter	_	_	I-Premise
376	in	_	_	I-Premise
377	the	_	_	I-Premise
378	GEM-arm	_	_	I-Premise
379	only	_	_	I-Premise
380	.	_	_	I-Premise


0	The	_	_	O
1	objective	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QoL	_	_	O
14	)	_	_	O
15	of	_	_	O
16	ovarian	_	_	O
17	cancer	_	_	O
18	patients	_	_	O
19	treated	_	_	O
20	with	_	_	O
21	paclitaxel/carboplatin	_	_	O
22	(	_	_	O
23	TC	_	_	O
24	)	_	_	O
25	versus	_	_	O
26	paclitaxel/cisplatin	_	_	O
27	(	_	_	O
28	PT	_	_	O
29	)	_	_	O
30	and	_	_	O
31	to	_	_	O
32	determine	_	_	O
33	the	_	_	O
34	impact	_	_	O
35	of	_	_	O
36	treatment	_	_	O
37	toxicity	_	_	O
38	on	_	_	O
39	the	_	_	O
40	various	_	_	O
41	QoL	_	_	O
42	domains	_	_	O
43	.	_	_	O

44	In	_	_	O
45	this	_	_	O
46	phase	_	_	O
47	III	_	_	O
48	trial	_	_	O
49	,	_	_	O
50	798	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	ovarian	_	_	O
54	cancer	_	_	O
55	stages	_	_	O
56	IIB-IV	_	_	O
57	were	_	_	O
58	randomly	_	_	O
59	assigned	_	_	O
60	to	_	_	O
61	receive	_	_	O
62	TC	_	_	O
63	or	_	_	O
64	PT	_	_	O
65	.	_	_	O

66	The	_	_	O
67	primary	_	_	O
68	end	_	_	O
69	point	_	_	O
70	was	_	_	O
71	progression-free	_	_	O
72	survival	_	_	O
73	;	_	_	O
74	secondary	_	_	O
75	end	_	_	O
76	points	_	_	O
77	included	_	_	O
78	toxicity	_	_	O
79	,	_	_	O
80	QoL	_	_	O
81	,	_	_	O
82	and	_	_	O
83	response	_	_	O
84	to	_	_	O
85	treatment	_	_	O
86	.	_	_	O

87	Patients	_	_	O
88	completed	_	_	O
89	the	_	_	O
90	European	_	_	O
91	Organisation	_	_	O
92	for	_	_	O
93	Research	_	_	O
94	and	_	_	O
95	Treatment	_	_	O
96	of	_	_	O
97	Cancer	_	_	O
98	QLQ-C30	_	_	O
99	before	_	_	O
100	treatment	_	_	O
101	,	_	_	O
102	within	_	_	O
103	3	_	_	O
104	days	_	_	O
105	before	_	_	O
106	the	_	_	O
107	second	_	_	O
108	and	_	_	O
109	the	_	_	O
110	fourth	_	_	O
111	chemotherapy	_	_	O
112	cycle	_	_	O
113	,	_	_	O
114	and	_	_	O
115	3	_	_	O
116	weeks	_	_	O
117	after	_	_	O
118	completion	_	_	O
119	of	_	_	O
120	chemotherapy	_	_	O
121	.	_	_	O

122	Previously	_	_	O
123	reported	_	_	O
124	data	_	_	O
125	showed	_	_	O
126	that	_	_	O
127	patients	_	_	O
128	undergoing	_	_	O
129	TC	_	_	O
130	or	_	_	O
131	PT	_	_	O
132	did	_	_	O
133	not	_	_	O
134	differ	_	_	O
135	in	_	_	O
136	progression-free	_	_	O
137	survival	_	_	O
138	and	_	_	O
139	overall	_	_	O
140	survival	_	_	O
141	.	_	_	O

142	However	_	_	O
143	,	_	_	O
144	the	_	_	O
145	TC	_	_	O
146	arm	_	_	O
147	was	_	_	O
148	superior	_	_	O
149	,	_	_	O
150	indicating	_	_	O
151	a	_	_	O
152	better	_	_	O
153	overall	_	_	O
154	QoL	_	_	O
155	compared	_	_	O
156	with	_	_	O
157	the	_	_	O
158	PT	_	_	O
159	arm	_	_	O
160	.	_	_	O

161	Controlling	_	_	O
162	for	_	_	O
163	toxicity	_	_	O
164	and	_	_	O
165	age	_	_	O
166	,	_	_	O
167	a	_	_	O
168	significant	_	_	O
169	treatment	_	_	O
170	by	_	_	O
171	assessment	_	_	O
172	time	_	_	O
173	interaction	_	_	O
174	was	_	_	O
175	found	_	_	O
176	for	_	_	O
177	four	_	_	O
178	QoL	_	_	O
179	functioning	_	_	O
180	scales	_	_	O
181	and	_	_	O
182	three	_	_	O
183	symptoms	_	_	O
184	scales	_	_	O
185	.	_	_	O

186	Patients	_	_	B-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	TC	_	_	I-Premise
190	arm	_	_	I-Premise
191	showed	_	_	I-Premise
192	better	_	_	I-Premise
193	means	_	_	I-Premise
194	scores	_	_	I-Premise
195	after	_	_	I-Premise
196	treatment	_	_	I-Premise
197	on	_	_	I-Premise
198	overall	_	_	I-Premise
199	QoL	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	.012	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	physical	_	_	I-Premise
207	functioning	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	.012	_	_	I-Premise
212	)	_	_	I-Premise
213	,	_	_	I-Premise
214	role	_	_	I-Premise
215	functioning	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	.005	_	_	I-Premise
220	)	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	cognitive	_	_	I-Premise
224	functioning	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.024	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	compared	_	_	I-Premise
232	with	_	_	I-Premise
233	the	_	_	I-Premise
234	PT	_	_	I-Premise
235	arm	_	_	I-Premise
236	.	_	_	I-Premise

237	Concerning	_	_	B-Premise
238	symptom	_	_	I-Premise
239	experience	_	_	I-Premise
240	,	_	_	I-Premise
241	patients	_	_	I-Premise
242	undergoing	_	_	I-Premise
243	TC	_	_	I-Premise
244	showed	_	_	I-Premise
245	less	_	_	I-Premise
246	nausea	_	_	I-Premise
247	and	_	_	I-Premise
248	vomiting	_	_	I-Premise
249	(	_	_	I-Premise
250	P	_	_	I-Premise
251	<	_	_	I-Premise
252	.001	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	less	_	_	I-Premise
256	appetite	_	_	I-Premise
257	loss	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	<	_	_	I-Premise
261	.001	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	less	_	_	I-Premise
266	fatigue	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	.033	_	_	I-Premise
271	)	_	_	I-Premise
272	after	_	_	I-Premise
273	completion	_	_	I-Premise
274	of	_	_	I-Premise
275	treatment	_	_	I-Premise
276	compared	_	_	I-Premise
277	with	_	_	I-Premise
278	patients	_	_	I-Premise
279	undergoing	_	_	I-Premise
280	PT	_	_	I-Premise
281	.	_	_	I-Premise

282	The	_	_	B-Claim
283	TC	_	_	I-Claim
284	regimen	_	_	I-Claim
285	achieved	_	_	I-Claim
286	better	_	_	I-Claim
287	QoL	_	_	I-Claim
288	outcomes	_	_	I-Claim
289	compared	_	_	I-Claim
290	with	_	_	I-Claim
291	the	_	_	I-Claim
292	PT	_	_	I-Claim
293	regimen	_	_	I-Claim
294	.	_	_	I-Claim

295	Thus	_	_	B-Claim
296	,	_	_	I-Claim
297	clinicians	_	_	I-Claim
298	may	_	_	I-Claim
299	consider	_	_	I-Claim
300	replacing	_	_	I-Claim
301	cisplatin	_	_	I-Claim
302	with	_	_	I-Claim
303	carboplatin	_	_	I-Claim
304	when	_	_	I-Claim
305	treating	_	_	I-Claim
306	ovarian	_	_	I-Claim
307	cancer	_	_	I-Claim
308	patients	_	_	I-Claim
309	with	_	_	I-Claim
310	chemotherapy	_	_	I-Claim
311	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	health-related	_	_	O
3	quality	_	_	O
4	of	_	_	O
5	life	_	_	O
6	(	_	_	O
7	HRQOL	_	_	O
8	)	_	_	O
9	in	_	_	O
10	patients	_	_	O
11	with	_	_	O
12	metastatic	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	receiving	_	_	O
16	the	_	_	O
17	combination	_	_	O
18	of	_	_	O
19	doxorubicin	_	_	O
20	and	_	_	O
21	paclitaxel	_	_	O
22	(	_	_	O
23	AT	_	_	O
24	)	_	_	O
25	or	_	_	O
26	doxorubicin	_	_	O
27	and	_	_	O
28	cyclophosphamide	_	_	O
29	(	_	_	O
30	AC	_	_	O
31	)	_	_	O
32	as	_	_	O
33	first-line	_	_	O
34	chemotherapy	_	_	O
35	treatment	_	_	O
36	.	_	_	O

37	Eligible	_	_	O
38	patients	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	275	_	_	O
43	)	_	_	O
44	with	_	_	O
45	anthracycline-naive	_	_	O
46	measurable	_	_	O
47	metastatic	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	were	_	_	O
51	randomly	_	_	O
52	assigned	_	_	O
53	to	_	_	O
54	AT	_	_	O
55	(	_	_	O
56	doxorubicin	_	_	O
57	60	_	_	O
58	mg/m	_	_	O
59	(	_	_	O
60	2	_	_	O
61	)	_	_	O
62	as	_	_	O
63	an	_	_	O
64	intravenous	_	_	O
65	bolus	_	_	O
66	plus	_	_	O
67	paclitaxel	_	_	O
68	175	_	_	O
69	mg/m	_	_	O
70	(	_	_	O
71	2	_	_	O
72	)	_	_	O
73	as	_	_	O
74	a	_	_	O
75	3-hour	_	_	O
76	infusion	_	_	O
77	)	_	_	O
78	or	_	_	O
79	AC	_	_	O
80	(	_	_	O
81	doxorubicin	_	_	O
82	60	_	_	O
83	mg/m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	plus	_	_	O
88	cyclophosphamide	_	_	O
89	600	_	_	O
90	mg/m	_	_	O
91	(	_	_	O
92	2	_	_	O
93	)	_	_	O
94	)	_	_	O
95	every	_	_	O
96	3	_	_	O
97	weeks	_	_	O
98	for	_	_	O
99	a	_	_	O
100	maximum	_	_	O
101	of	_	_	O
102	six	_	_	O
103	cycles	_	_	O
104	.	_	_	O

105	Dose	_	_	O
106	escalation	_	_	O
107	of	_	_	O
108	paclitaxel	_	_	O
109	(	_	_	O
110	200	_	_	O
111	mg/m	_	_	O
112	(	_	_	O
113	2	_	_	O
114	)	_	_	O
115	)	_	_	O
116	and	_	_	O
117	cyclophosphamide	_	_	O
118	(	_	_	O
119	750	_	_	O
120	mg/m	_	_	O
121	(	_	_	O
122	2	_	_	O
123	)	_	_	O
124	)	_	_	O
125	was	_	_	O
126	planned	_	_	O
127	at	_	_	O
128	cycle	_	_	O
129	2	_	_	O
130	to	_	_	O
131	reach	_	_	O
132	equivalent	_	_	O
133	myelosuppression	_	_	O
134	in	_	_	O
135	the	_	_	O
136	two	_	_	O
137	groups	_	_	O
138	.	_	_	O

139	HRQOL	_	_	O
140	was	_	_	O
141	assessed	_	_	O
142	with	_	_	O
143	the	_	_	O
144	European	_	_	O
145	Organization	_	_	O
146	for	_	_	O
147	Research	_	_	O
148	and	_	_	O
149	Treatment	_	_	O
150	of	_	_	O
151	Cancer	_	_	O
152	(	_	_	O
153	EORTC	_	_	O
154	)	_	_	O
155	Quality	_	_	O
156	of	_	_	O
157	Life	_	_	O
158	Questionnaire	_	_	O
159	C30	_	_	O
160	and	_	_	O
161	the	_	_	O
162	EORTC	_	_	O
163	Breast	_	_	O
164	Module	_	_	O
165	at	_	_	O
166	baseline	_	_	O
167	and	_	_	O
168	the	_	_	O
169	start	_	_	O
170	of	_	_	O
171	cycles	_	_	O
172	2	_	_	O
173	,	_	_	O
174	4	_	_	O
175	,	_	_	O
176	and	_	_	O
177	6	_	_	O
178	,	_	_	O
179	and	_	_	O
180	3	_	_	O
181	months	_	_	O
182	after	_	_	O
183	the	_	_	O
184	last	_	_	O
185	cycle	_	_	O
186	.	_	_	O

187	Seventy-nine	_	_	O
188	percent	_	_	O
189	of	_	_	O
190	the	_	_	O
191	patients	_	_	O
192	(	_	_	O
193	n	_	_	O
194	=	_	_	O
195	219	_	_	O
196	)	_	_	O
197	completed	_	_	O
198	a	_	_	O
199	baseline	_	_	O
200	measure	_	_	O
201	.	_	_	O

202	However	_	_	O
203	,	_	_	O
204	there	_	_	B-Premise
205	were	_	_	I-Premise
206	no	_	_	I-Premise
207	statistically	_	_	I-Premise
208	significant	_	_	I-Premise
209	differences	_	_	I-Premise
210	in	_	_	I-Premise
211	HRQOL	_	_	I-Premise
212	between	_	_	I-Premise
213	the	_	_	I-Premise
214	two	_	_	I-Premise
215	treatment	_	_	I-Premise
216	groups	_	_	I-Premise
217	.	_	_	I-Premise

218	In	_	_	B-Premise
219	both	_	_	I-Premise
220	groups	_	_	I-Premise
221	,	_	_	I-Premise
222	selected	_	_	I-Premise
223	aspects	_	_	I-Premise
224	of	_	_	I-Premise
225	HRQOL	_	_	I-Premise
226	were	_	_	I-Premise
227	impaired	_	_	I-Premise
228	over	_	_	I-Premise
229	time	_	_	I-Premise
230	,	_	_	I-Premise
231	with	_	_	I-Premise
232	increased	_	_	I-Premise
233	fatigue	_	_	I-Premise
234	,	_	_	I-Premise
235	although	_	_	B-Premise
236	some	_	_	I-Premise
237	clinically	_	_	I-Premise
238	significant	_	_	I-Premise
239	improvements	_	_	I-Premise
240	in	_	_	I-Premise
241	emotional	_	_	I-Premise
242	functioning	_	_	I-Premise
243	were	_	_	I-Premise
244	seen	_	_	I-Premise
245	,	_	_	I-Premise
246	as	_	_	I-Premise
247	well	_	_	I-Premise
248	as	_	_	I-Premise
249	a	_	_	I-Premise
250	reduction	_	_	I-Premise
251	in	_	_	I-Premise
252	pain	_	_	I-Premise
253	over	_	_	I-Premise
254	time	_	_	I-Premise
255	.	_	_	I-Premise

256	Overall	_	_	B-Claim
257	,	_	_	I-Claim
258	global	_	_	I-Claim
259	quality	_	_	I-Claim
260	of	_	_	I-Claim
261	life	_	_	I-Claim
262	was	_	_	I-Claim
263	maintained	_	_	I-Claim
264	in	_	_	I-Claim
265	both	_	_	I-Claim
266	treatment	_	_	I-Claim
267	groups	_	_	I-Claim
268	.	_	_	I-Claim

269	This	_	_	B-Claim
270	information	_	_	I-Claim
271	is	_	_	I-Claim
272	important	_	_	I-Claim
273	when	_	_	I-Claim
274	advising	_	_	I-Claim
275	women	_	_	I-Claim
276	patients	_	_	I-Claim
277	of	_	_	I-Claim
278	the	_	_	I-Claim
279	expected	_	_	I-Claim
280	HRQOL	_	_	I-Claim
281	consequences	_	_	I-Claim
282	of	_	_	I-Claim
283	treatment	_	_	I-Claim
284	regimens	_	_	I-Claim
285	and	_	_	I-Claim
286	should	_	_	I-Claim
287	help	_	_	I-Claim
288	clinicians	_	_	I-Claim
289	and	_	_	I-Claim
290	their	_	_	I-Claim
291	patients	_	_	I-Claim
292	make	_	_	I-Claim
293	informed	_	_	I-Claim
294	treatment	_	_	I-Claim
295	decisions	_	_	I-Claim
296	.	_	_	I-Claim


0	Research	_	_	O
1	suggests	_	_	O
2	that	_	_	O
3	cancer	_	_	O
4	rehabilitation	_	_	O
5	reduces	_	_	O
6	fatigue	_	_	O
7	in	_	_	O
8	survivors	_	_	O
9	of	_	_	O
10	cancer	_	_	O
11	.	_	_	O

12	To	_	_	O
13	date	_	_	O
14	,	_	_	O
15	it	_	_	O
16	is	_	_	O
17	unclear	_	_	O
18	what	_	_	O
19	type	_	_	O
20	of	_	_	O
21	rehabilitation	_	_	O
22	is	_	_	O
23	most	_	_	O
24	beneficial	_	_	O
25	.	_	_	O

26	This	_	_	O
27	randomized	_	_	O
28	controlled	_	_	O
29	trial	_	_	O
30	compared	_	_	O
31	the	_	_	O
32	effect	_	_	O
33	on	_	_	O
34	cancer-related	_	_	O
35	fatigue	_	_	O
36	of	_	_	O
37	physical	_	_	O
38	training	_	_	O
39	combined	_	_	O
40	with	_	_	O
41	cognitive	_	_	O
42	behavioral	_	_	O
43	therapy	_	_	O
44	with	_	_	O
45	physical	_	_	O
46	training	_	_	O
47	alone	_	_	O
48	and	_	_	O
49	with	_	_	O
50	no	_	_	O
51	intervention	_	_	O
52	.	_	_	O

53	In	_	_	O
54	this	_	_	O
55	multicenter	_	_	O
56	randomized	_	_	O
57	controlled	_	_	O
58	trial	_	_	O
59	,	_	_	O
60	147	_	_	O
61	survivors	_	_	O
62	of	_	_	O
63	cancer	_	_	O
64	were	_	_	O
65	randomly	_	_	O
66	assigned	_	_	O
67	to	_	_	O
68	a	_	_	O
69	group	_	_	O
70	that	_	_	O
71	received	_	_	O
72	physical	_	_	O
73	training	_	_	O
74	combined	_	_	O
75	with	_	_	O
76	cognitive-behavioral	_	_	O
77	therapy	_	_	O
78	(	_	_	O
79	PT+CBT	_	_	O
80	group	_	_	O
81	,	_	_	O
82	n=76	_	_	O
83	)	_	_	O
84	or	_	_	O
85	to	_	_	O
86	a	_	_	O
87	group	_	_	O
88	that	_	_	O
89	received	_	_	O
90	physical	_	_	O
91	training	_	_	O
92	alone	_	_	O
93	(	_	_	O
94	PT	_	_	O
95	group	_	_	O
96	,	_	_	O
97	n=71	_	_	O
98	)	_	_	O
99	.	_	_	O

100	In	_	_	O
101	addition	_	_	O
102	,	_	_	O
103	a	_	_	O
104	nonintervention	_	_	O
105	control	_	_	O
106	group	_	_	O
107	(	_	_	O
108	WLC	_	_	O
109	group	_	_	O
110	)	_	_	O
111	consisting	_	_	O
112	of	_	_	O
113	62	_	_	O
114	survivors	_	_	O
115	of	_	_	O
116	cancer	_	_	O
117	who	_	_	O
118	were	_	_	O
119	on	_	_	O
120	the	_	_	O
121	waiting	_	_	O
122	lists	_	_	O
123	of	_	_	O
124	rehabilitation	_	_	O
125	centers	_	_	O
126	elsewhere	_	_	O
127	was	_	_	O
128	included	_	_	O
129	.	_	_	O

130	The	_	_	O
131	study	_	_	O
132	was	_	_	O
133	conducted	_	_	O
134	at	_	_	O
135	4	_	_	O
136	rehabilitation	_	_	O
137	centers	_	_	O
138	in	_	_	O
139	the	_	_	O
140	Netherlands	_	_	O
141	.	_	_	O

142	All	_	_	O
143	patients	_	_	O
144	were	_	_	O
145	survivors	_	_	O
146	of	_	_	O
147	cancer	_	_	O
148	.	_	_	O

149	Physical	_	_	O
150	training	_	_	O
151	consisting	_	_	O
152	of	_	_	O
153	2	_	_	O
154	hours	_	_	O
155	of	_	_	O
156	individual	_	_	O
157	training	_	_	O
158	and	_	_	O
159	group	_	_	O
160	sports	_	_	O
161	took	_	_	O
162	place	_	_	O
163	twice	_	_	O
164	weekly	_	_	O
165	,	_	_	O
166	and	_	_	O
167	cognitive-behavioral	_	_	O
168	therapy	_	_	O
169	took	_	_	O
170	place	_	_	O
171	once	_	_	O
172	weekly	_	_	O
173	for	_	_	O
174	2	_	_	O
175	hours	_	_	O
176	.	_	_	O

177	Fatigue	_	_	O
178	was	_	_	O
179	assessed	_	_	O
180	with	_	_	O
181	the	_	_	O
182	Multidimensional	_	_	O
183	Fatigue	_	_	O
184	Inventory	_	_	O
185	before	_	_	O
186	and	_	_	O
187	immediately	_	_	O
188	after	_	_	O
189	intervention	_	_	O
190	(	_	_	O
191	12	_	_	O
192	weeks	_	_	O
193	after	_	_	O
194	enrollment	_	_	O
195	)	_	_	O
196	.	_	_	O

197	The	_	_	O
198	WLC	_	_	O
199	group	_	_	O
200	completed	_	_	O
201	questionnaires	_	_	O
202	at	_	_	O
203	the	_	_	O
204	same	_	_	O
205	time	_	_	O
206	points	_	_	O
207	.	_	_	O

208	Baseline	_	_	O
209	fatigue	_	_	O
210	did	_	_	O
211	not	_	_	O
212	differ	_	_	O
213	significantly	_	_	O
214	among	_	_	O
215	the	_	_	O
216	3	_	_	O
217	groups	_	_	O
218	.	_	_	O

219	Over	_	_	B-Premise
220	time	_	_	I-Premise
221	,	_	_	I-Premise
222	levels	_	_	I-Premise
223	of	_	_	I-Premise
224	fatigue	_	_	I-Premise
225	significantly	_	_	I-Premise
226	decreased	_	_	I-Premise
227	in	_	_	I-Premise
228	all	_	_	I-Premise
229	domains	_	_	I-Premise
230	in	_	_	I-Premise
231	all	_	_	I-Premise
232	groups	_	_	I-Premise
233	,	_	_	I-Premise
234	except	_	_	B-Premise
235	in	_	_	I-Premise
236	mental	_	_	I-Premise
237	fatigue	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	WLC	_	_	I-Premise
241	group	_	_	I-Premise
242	.	_	_	I-Premise

243	Analyses	_	_	B-Premise
244	of	_	_	I-Premise
245	variance	_	_	I-Premise
246	of	_	_	I-Premise
247	postintervention	_	_	I-Premise
248	fatigue	_	_	I-Premise
249	showed	_	_	I-Premise
250	statistically	_	_	I-Premise
251	significant	_	_	I-Premise
252	group	_	_	I-Premise
253	effects	_	_	I-Premise
254	on	_	_	I-Premise
255	general	_	_	I-Premise
256	fatigue	_	_	I-Premise
257	,	_	_	I-Premise
258	on	_	_	I-Premise
259	physical	_	_	I-Premise
260	and	_	_	I-Premise
261	mental	_	_	I-Premise
262	fatigue	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	on	_	_	I-Premise
266	reduced	_	_	I-Premise
267	activation	_	_	I-Premise
268	but	_	_	I-Premise
269	not	_	_	I-Premise
270	on	_	_	I-Premise
271	reduced	_	_	I-Premise
272	motivation	_	_	I-Premise
273	.	_	_	I-Premise

274	Compared	_	_	B-Premise
275	with	_	_	I-Premise
276	the	_	_	I-Premise
277	WLC	_	_	I-Premise
278	group	_	_	I-Premise
279	,	_	_	I-Premise
280	the	_	_	I-Premise
281	PT	_	_	I-Premise
282	group	_	_	I-Premise
283	reported	_	_	I-Premise
284	significantly	_	_	I-Premise
285	greater	_	_	I-Premise
286	decline	_	_	I-Premise
287	in	_	_	I-Premise
288	4	_	_	I-Premise
289	domains	_	_	I-Premise
290	of	_	_	I-Premise
291	fatigue	_	_	I-Premise
292	,	_	_	I-Premise
293	whereas	_	_	I-Premise
294	the	_	_	I-Premise
295	PT+CBT	_	_	I-Premise
296	group	_	_	I-Premise
297	reported	_	_	I-Premise
298	significantly	_	_	I-Premise
299	greater	_	_	I-Premise
300	decline	_	_	I-Premise
301	in	_	_	I-Premise
302	physical	_	_	I-Premise
303	fatigue	_	_	I-Premise
304	only	_	_	I-Premise
305	.	_	_	I-Premise

306	No	_	_	B-Premise
307	significant	_	_	I-Premise
308	differences	_	_	I-Premise
309	in	_	_	I-Premise
310	decline	_	_	I-Premise
311	in	_	_	I-Premise
312	fatigue	_	_	I-Premise
313	were	_	_	I-Premise
314	found	_	_	I-Premise
315	between	_	_	I-Premise
316	the	_	_	I-Premise
317	PT+CBT	_	_	I-Premise
318	and	_	_	I-Premise
319	PT	_	_	I-Premise
320	groups	_	_	I-Premise
321	.	_	_	I-Premise

322	Physical	_	_	B-Premise
323	training	_	_	I-Premise
324	combined	_	_	I-Premise
325	with	_	_	I-Premise
326	cognitive-behavioral	_	_	I-Premise
327	therapy	_	_	I-Premise
328	and	_	_	I-Premise
329	physical	_	_	I-Premise
330	training	_	_	I-Premise
331	alone	_	_	I-Premise
332	had	_	_	I-Premise
333	significant	_	_	I-Premise
334	and	_	_	I-Premise
335	beneficial	_	_	I-Premise
336	effects	_	_	I-Premise
337	on	_	_	I-Premise
338	fatigue	_	_	I-Premise
339	compared	_	_	I-Premise
340	with	_	_	I-Premise
341	no	_	_	I-Premise
342	intervention	_	_	I-Premise
343	.	_	_	I-Premise

344	Physical	_	_	B-Claim
345	training	_	_	I-Claim
346	was	_	_	I-Claim
347	equally	_	_	I-Claim
348	effective	_	_	I-Claim
349	as	_	_	I-Claim
350	or	_	_	I-Claim
351	more	_	_	I-Claim
352	effective	_	_	I-Claim
353	than	_	_	I-Claim
354	physical	_	_	I-Claim
355	training	_	_	I-Claim
356	combined	_	_	I-Claim
357	with	_	_	I-Claim
358	cognitive-behavioral	_	_	I-Claim
359	therapy	_	_	I-Claim
360	in	_	_	I-Claim
361	reducing	_	_	I-Claim
362	cancer-related	_	_	I-Claim
363	fatigue	_	_	I-Claim
364	,	_	_	I-Claim
365	suggesting	_	_	O
366	that	_	_	O
367	cognitive-behavioral	_	_	B-Claim
368	therapy	_	_	I-Claim
369	did	_	_	I-Claim
370	not	_	_	I-Claim
371	have	_	_	I-Claim
372	additional	_	_	I-Claim
373	beneficial	_	_	I-Claim
374	effects	_	_	I-Claim
375	beyond	_	_	I-Claim
376	the	_	_	I-Claim
377	benefits	_	_	I-Claim
378	of	_	_	I-Claim
379	physical	_	_	I-Claim
380	training	_	_	I-Claim
381	.	_	_	I-Claim


0	The	_	_	O
1	standard	_	_	O
2	treatment	_	_	O
3	for	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	clinically	_	_	O
7	resectable	_	_	O
8	rectal	_	_	O
9	cancer	_	_	O
10	is	_	_	O
11	surgery	_	_	O
12	.	_	_	O

13	Postoperative	_	_	B-Claim
14	radiochemotherapy	_	_	I-Claim
15	(	_	_	I-Claim
16	RCT	_	_	I-Claim
17	)	_	_	I-Claim
18	is	_	_	I-Claim
19	recommended	_	_	I-Claim
20	for	_	_	I-Claim
21	advanced	_	_	I-Claim
22	disease	_	_	I-Claim
23	(	_	_	I-Claim
24	pT3/4	_	_	I-Claim
25	or	_	_	I-Claim
26	pN+	_	_	I-Claim
27	)	_	_	I-Claim
28	.	_	_	I-Claim

29	In	_	_	O
30	recent	_	_	O
31	years	_	_	O
32	,	_	_	O
33	encouraging	_	_	O
34	results	_	_	O
35	of	_	_	O
36	pre-operative	_	_	O
37	radiotherapy	_	_	O
38	have	_	_	O
39	been	_	_	O
40	reported	_	_	O
41	.	_	_	O

42	This	_	_	O
43	prospective	_	_	O
44	randomized	_	_	O
45	phase-III-trial	_	_	O
46	(	_	_	O
47	CAO/ARO/AIO-94	_	_	O
48	)	_	_	O
49	compares	_	_	O
50	the	_	_	O
51	efficacy	_	_	O
52	of	_	_	O
53	neoadjuvant	_	_	O
54	RCT	_	_	O
55	to	_	_	O
56	standard	_	_	O
57	postoperative	_	_	O
58	RCT	_	_	O
59	.	_	_	O

60	We	_	_	O
61	report	_	_	O
62	on	_	_	O
63	the	_	_	O
64	design	_	_	O
65	of	_	_	O
66	the	_	_	O
67	study	_	_	O
68	and	_	_	O
69	first	_	_	O
70	results	_	_	O
71	with	_	_	O
72	regard	_	_	O
73	to	_	_	O
74	toxicity	_	_	O
75	of	_	_	O
76	RCT	_	_	O
77	and	_	_	O
78	postoperative	_	_	O
79	morbidity	_	_	O
80	.	_	_	O

81	Patients	_	_	O
82	with	_	_	O
83	locally	_	_	O
84	advanced	_	_	O
85	operable	_	_	O
86	rectal	_	_	O
87	cancer	_	_	O
88	(	_	_	O
89	uT3/4	_	_	O
90	or	_	_	O
91	uN+	_	_	O
92	,	_	_	O
93	Mason	_	_	O
94	CS	_	_	O
95	III/IV	_	_	O
96	)	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	pre	_	_	O
102	or	_	_	O
103	postoperative	_	_	O
104	RCT	_	_	O
105	:	_	_	O
106	A	_	_	O
107	total	_	_	O
108	dose	_	_	O
109	of	_	_	O
110	50.4	_	_	O
111	Gy	_	_	O
112	(	_	_	O
113	single	_	_	O
114	dose	_	_	O
115	1.8	_	_	O
116	Gy	_	_	O
117	)	_	_	O
118	was	_	_	O
119	applied	_	_	O
120	to	_	_	O
121	the	_	_	O
122	tumour	_	_	O
123	and	_	_	O
124	the	_	_	O
125	pelvic	_	_	O
126	lymph	_	_	O
127	nodes	_	_	O
128	.	_	_	O

129	5-FU	_	_	O
130	(	_	_	O
131	1000	_	_	O
132	mg/m2/d	_	_	O
133	)	_	_	O
134	was	_	_	O
135	administered	_	_	O
136	concomitantly	_	_	O
137	in	_	_	O
138	the	_	_	O
139	1th	_	_	O
140	and	_	_	O
141	5th	_	_	O
142	week	_	_	O
143	of	_	_	O
144	radiation	_	_	O
145	as	_	_	O
146	120	_	_	O
147	h-continuous	_	_	O
148	infusion	_	_	O
149	.	_	_	O

150	Four	_	_	O
151	additional	_	_	O
152	cycles	_	_	O
153	of	_	_	O
154	5-FU-chemotherapy	_	_	O
155	(	_	_	O
156	500	_	_	O
157	mg/m2/d	_	_	O
158	,	_	_	O
159	i.v.-bolus	_	_	O
160	)	_	_	O
161	were	_	_	O
162	applied	_	_	O
163	.	_	_	O

164	RCT	_	_	O
165	was	_	_	O
166	identical	_	_	O
167	in	_	_	O
168	both	_	_	O
169	arms	_	_	O
170	except	_	_	O
171	for	_	_	O
172	a	_	_	O
173	small-volume	_	_	O
174	boost	_	_	O
175	of	_	_	O
176	5.4	_	_	O
177	Gy	_	_	O
178	postoperatively	_	_	O
179	.	_	_	O

180	The	_	_	O
181	time	_	_	O
182	interval	_	_	O
183	between	_	_	O
184	RCT	_	_	O
185	and	_	_	O
186	surgery	_	_	O
187	was	_	_	O
188	4-6	_	_	O
189	weeks	_	_	O
190	in	_	_	O
191	both	_	_	O
192	arms	_	_	O
193	.	_	_	O

194	Techniques	_	_	O
195	of	_	_	O
196	surgery	_	_	O
197	were	_	_	O
198	standardized	_	_	O
199	and	_	_	O
200	included	_	_	O
201	total	_	_	O
202	mesorectal	_	_	O
203	excision	_	_	O
204	.	_	_	O

205	Primary	_	_	O
206	endpoints	_	_	O
207	of	_	_	O
208	the	_	_	O
209	study	_	_	O
210	are	_	_	O
211	5-year	_	_	O
212	survival	_	_	O
213	and	_	_	O
214	local	_	_	O
215	and	_	_	O
216	distant	_	_	O
217	control	_	_	O
218	.	_	_	O

219	Secondary	_	_	O
220	endpoints	_	_	O
221	include	_	_	O
222	the	_	_	O
223	rate	_	_	O
224	of	_	_	O
225	curative	_	_	O
226	(	_	_	O
227	R0	_	_	O
228	)	_	_	O
229	resection	_	_	O
230	and	_	_	O
231	sphincter	_	_	O
232	saving	_	_	O
233	procedures	_	_	O
234	,	_	_	O
235	toxicity	_	_	O
236	of	_	_	O
237	RCT	_	_	O
238	,	_	_	O
239	surgical	_	_	O
240	complications	_	_	O
241	and	_	_	O
242	quality	_	_	O
243	of	_	_	O
244	life	_	_	O
245	.	_	_	O

246	As	_	_	O
247	of	_	_	O
248	July	_	_	O
249	2002	_	_	O
250	,	_	_	O
251	805	_	_	O
252	patients	_	_	O
253	were	_	_	O
254	randomized	_	_	O
255	from	_	_	O
256	26	_	_	O
257	participating	_	_	O
258	institutions	_	_	O
259	.	_	_	O

260	Acute	_	_	B-Premise
261	toxicity	_	_	I-Premise
262	(	_	_	I-Premise
263	WHO	_	_	I-Premise
264	)	_	_	I-Premise
265	of	_	_	I-Premise
266	RCT	_	_	I-Premise
267	was	_	_	I-Premise
268	low	_	_	I-Premise
269	,	_	_	I-Premise
270	with	_	_	I-Premise
271	less	_	_	I-Premise
272	than	_	_	I-Premise
273	15	_	_	I-Premise
274	%	_	_	I-Premise
275	of	_	_	I-Premise
276	patients	_	_	I-Premise
277	experiencing	_	_	I-Premise
278	grade	_	_	I-Premise
279	3	_	_	I-Premise
280	or	_	_	I-Premise
281	higher	_	_	I-Premise
282	toxicity	_	_	I-Premise
283	:	_	_	O
284	The	_	_	B-Premise
285	principal	_	_	I-Premise
286	toxicity	_	_	I-Premise
287	was	_	_	I-Premise
288	diarrhea	_	_	I-Premise
289	,	_	_	I-Premise
290	with	_	_	I-Premise
291	12	_	_	I-Premise
292	%	_	_	I-Premise
293	in	_	_	I-Premise
294	the	_	_	I-Premise
295	postoperative	_	_	I-Premise
296	RCT-arm	_	_	I-Premise
297	and	_	_	I-Premise
298	11	_	_	I-Premise
299	%	_	_	I-Premise
300	in	_	_	I-Premise
301	the	_	_	I-Premise
302	pre-operative	_	_	I-Premise
303	RCT-arm	_	_	I-Premise
304	having	_	_	I-Premise
305	grade	_	_	I-Premise
306	3-	_	_	I-Premise
307	,	_	_	I-Premise
308	and	_	_	I-Premise
309	1	_	_	I-Premise
310	%	_	_	I-Premise
311	in	_	_	I-Premise
312	either	_	_	I-Premise
313	arm	_	_	I-Premise
314	having	_	_	I-Premise
315	grade	_	_	I-Premise
316	4-diarrhea	_	_	I-Premise
317	.	_	_	I-Premise

318	Erythema	_	_	B-Premise
319	,	_	_	I-Premise
320	nausea	_	_	I-Premise
321	and	_	_	I-Premise
322	leukopenia	_	_	I-Premise
323	were	_	_	I-Premise
324	the	_	_	I-Premise
325	next	_	_	I-Premise
326	common	_	_	I-Premise
327	toxicities	_	_	I-Premise
328	,	_	_	I-Premise
329	with	_	_	I-Premise
330	less	_	_	I-Premise
331	than	_	_	I-Premise
332	3	_	_	I-Premise
333	%	_	_	I-Premise
334	of	_	_	I-Premise
335	patients	_	_	I-Premise
336	in	_	_	I-Premise
337	either	_	_	I-Premise
338	arm	_	_	I-Premise
339	suffering	_	_	I-Premise
340	grade	_	_	I-Premise
341	3	_	_	I-Premise
342	or	_	_	I-Premise
343	greater	_	_	I-Premise
344	leukopenia	_	_	I-Premise
345	or	_	_	I-Premise
346	nausea	_	_	I-Premise
347	.	_	_	I-Premise

348	Postoperative	_	_	B-Premise
349	complication	_	_	I-Premise
350	rates	_	_	I-Premise
351	were	_	_	I-Premise
352	similar	_	_	I-Premise
353	in	_	_	I-Premise
354	both	_	_	I-Premise
355	arms	_	_	I-Premise
356	,	_	_	I-Premise
357	with	_	_	I-Premise
358	12	_	_	I-Premise
359	%	_	_	I-Premise
360	(	_	_	I-Premise
361	postop	_	_	I-Premise
362	.	_	_	I-Premise

363	RCT	_	_	I-Premise
364	)	_	_	I-Premise
365	and	_	_	I-Premise
366	12	_	_	I-Premise
367	%	_	_	I-Premise
368	(	_	_	I-Premise
369	pre-op	_	_	I-Premise
370	.	_	_	I-Premise

371	RCT	_	_	I-Premise
372	)	_	_	I-Premise
373	of	_	_	I-Premise
374	patients	_	_	I-Premise
375	,	_	_	I-Premise
376	respectively	_	_	I-Premise
377	,	_	_	I-Premise
378	suffering	_	_	I-Premise
379	from	_	_	I-Premise
380	anastomotic	_	_	I-Premise
381	leakage	_	_	I-Premise
382	,	_	_	I-Premise
383	3	_	_	I-Premise
384	%	_	_	I-Premise
385	(	_	_	I-Premise
386	postop	_	_	I-Premise
387	.	_	_	I-Premise

388	RCT	_	_	I-Premise
389	)	_	_	I-Premise
390	and	_	_	I-Premise
391	3	_	_	I-Premise
392	%	_	_	I-Premise
393	(	_	_	I-Premise
394	pre-op	_	_	I-Premise
395	.	_	_	I-Premise

396	RCT	_	_	I-Premise
397	)	_	_	I-Premise
398	from	_	_	I-Premise
399	postoperative	_	_	I-Premise
400	bleeding	_	_	I-Premise
401	,	_	_	I-Premise
402	and	_	_	I-Premise
403	6	_	_	I-Premise
404	%	_	_	I-Premise
405	(	_	_	I-Premise
406	postop	_	_	I-Premise
407	.	_	_	I-Premise

408	RCT	_	_	I-Premise
409	)	_	_	I-Premise
410	and	_	_	I-Premise
411	4	_	_	I-Premise
412	%	_	_	I-Premise
413	(	_	_	I-Premise
414	pre-op	_	_	I-Premise
415	.	_	_	I-Premise

416	RCT	_	_	I-Premise
417	)	_	_	I-Premise
418	from	_	_	I-Premise
419	delayed	_	_	I-Premise
420	wound	_	_	I-Premise
421	healing	_	_	I-Premise
422	.	_	_	I-Premise

423	The	_	_	B-Claim
424	patient	_	_	I-Claim
425	accrual	_	_	I-Claim
426	to	_	_	I-Claim
427	the	_	_	I-Claim
428	trial	_	_	I-Claim
429	is	_	_	I-Claim
430	satisfactory	_	_	I-Claim
431	.	_	_	O

432	Neoadjuvant	_	_	B-Claim
433	RCT	_	_	I-Claim
434	is	_	_	I-Claim
435	well	_	_	I-Claim
436	tolerated	_	_	I-Claim
437	and	_	_	I-Claim
438	bears	_	_	I-Claim
439	no	_	_	I-Claim
440	higher	_	_	I-Claim
441	risk	_	_	I-Claim
442	for	_	_	I-Claim
443	postoperative	_	_	I-Claim
444	morbidity	_	_	I-Claim
445	.	_	_	I-Claim


0	Sentinel	_	_	O
1	lymph	_	_	O
2	node	_	_	O
3	resection	_	_	O
4	(	_	_	O
5	SNR	_	_	O
6	)	_	_	O
7	may	_	_	O
8	reduce	_	_	O
9	morbidity	_	_	O
10	while	_	_	O
11	providing	_	_	O
12	the	_	_	O
13	same	_	_	O
14	clinical	_	_	O
15	utility	_	_	O
16	as	_	_	O
17	conventional	_	_	O
18	axillary	_	_	O
19	dissection	_	_	O
20	(	_	_	O
21	AD	_	_	O
22	)	_	_	O
23	.	_	_	O

24	National	_	_	O
25	Surgical	_	_	O
26	Adjuvant	_	_	O
27	Breast	_	_	O
28	and	_	_	O
29	Bowel	_	_	O
30	Project	_	_	O
31	(	_	_	O
32	NSABP	_	_	O
33	)	_	_	O
34	B-32	_	_	O
35	is	_	_	O
36	a	_	_	O
37	randomized	_	_	O
38	phase	_	_	O
39	III	_	_	O
40	trial	_	_	O
41	comparing	_	_	O
42	SNR	_	_	O
43	immediately	_	_	O
44	followed	_	_	O
45	by	_	_	O
46	AD	_	_	O
47	(	_	_	O
48	SNAD	_	_	O
49	)	_	_	O
50	to	_	_	O
51	SNR	_	_	O
52	and	_	_	O
53	subsequent	_	_	O
54	AD	_	_	O
55	if	_	_	O
56	SN	_	_	O
57	is	_	_	O
58	positive	_	_	O
59	.	_	_	O

60	We	_	_	O
61	report	_	_	O
62	the	_	_	O
63	definitive	_	_	O
64	patient-reported	_	_	O
65	outcomes	_	_	O
66	(	_	_	O
67	PRO	_	_	O
68	)	_	_	O
69	comparisons	_	_	O
70	.	_	_	O

71	Eligible	_	_	O
72	patients	_	_	O
73	had	_	_	O
74	clinically	_	_	O
75	node-negative	_	_	O
76	,	_	_	O
77	operable	_	_	O
78	invasive	_	_	O
79	breast	_	_	O
80	cancer	_	_	O
81	.	_	_	O

82	The	_	_	O
83	PRO	_	_	O
84	substudy	_	_	O
85	included	_	_	O
86	all	_	_	O
87	SN-negative	_	_	O
88	participants	_	_	O
89	enrolled	_	_	O
90	May	_	_	O
91	2001	_	_	O
92	to	_	_	O
93	February	_	_	O
94	2004	_	_	O
95	at	_	_	O
96	community	_	_	O
97	institutions	_	_	O
98	in	_	_	O
99	the	_	_	O
100	United	_	_	O
101	States	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	749	_	_	O
106	;	_	_	O
107	78	_	_	O
108	%	_	_	O
109	age	_	_	O
110	>	_	_	O
111	or	_	_	O
112	=	_	_	O
113	50	_	_	O
114	;	_	_	O
115	87	_	_	O
116	%	_	_	O
117	clinical	_	_	O
118	tumor	_	_	O
119	size	_	_	O
120	<	_	_	O
121	or	_	_	O
122	=	_	_	O
123	2.0	_	_	O
124	cm	_	_	O
125	;	_	_	O
126	84	_	_	O
127	%	_	_	O
128	lumpectomy	_	_	O
129	;	_	_	O
130	87	_	_	O
131	%	_	_	O
132	white	_	_	O
133	)	_	_	O
134	.	_	_	O

135	They	_	_	O
136	completed	_	_	O
137	questionnaires	_	_	O
138	presurgery	_	_	O
139	,	_	_	O
140	1	_	_	O
141	and	_	_	O
142	2	_	_	O
143	to	_	_	O
144	3	_	_	O
145	weeks	_	_	O
146	postoperatively	_	_	O
147	,	_	_	O
148	and	_	_	O
149	every	_	_	O
150	6	_	_	O
151	months	_	_	O
152	through	_	_	O
153	year	_	_	O
154	3	_	_	O
155	.	_	_	O

156	Arm	_	_	O
157	symptoms	_	_	O
158	,	_	_	O
159	arm	_	_	O
160	use	_	_	O
161	avoidance	_	_	O
162	,	_	_	O
163	activity	_	_	O
164	limitations	_	_	O
165	,	_	_	O
166	and	_	_	O
167	quality	_	_	O
168	of	_	_	O
169	life	_	_	O
170	(	_	_	O
171	QOL	_	_	O
172	)	_	_	O
173	were	_	_	O
174	compared	_	_	O
175	with	_	_	O
176	intent-to-treat	_	_	O
177	two-sample	_	_	O
178	t-tests	_	_	O
179	and	_	_	O
180	repeated	_	_	O
181	measures	_	_	O
182	analyses	_	_	O
183	.	_	_	O

184	Arm	_	_	B-Premise
185	symptoms	_	_	I-Premise
186	were	_	_	I-Premise
187	significantly	_	_	I-Premise
188	more	_	_	I-Premise
189	bothersome	_	_	I-Premise
190	for	_	_	I-Premise
191	SNAD	_	_	I-Premise
192	compared	_	_	I-Premise
193	with	_	_	I-Premise
194	SNR	_	_	I-Premise
195	patients	_	_	I-Premise
196	at	_	_	I-Premise
197	6	_	_	I-Premise
198	months	_	_	I-Premise
199	(	_	_	I-Premise
200	mean	_	_	I-Premise
201	,	_	_	I-Premise
202	4.8	_	_	I-Premise
203	v	_	_	I-Premise
204	3.0	_	_	I-Premise
205	;	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	.001	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	at	_	_	I-Premise
212	12	_	_	I-Premise
213	months	_	_	I-Premise
214	(	_	_	I-Premise
215	3.6	_	_	I-Premise
216	v	_	_	I-Premise
217	2.5	_	_	I-Premise
218	;	_	_	I-Premise
219	P	_	_	I-Premise
220	=	_	_	I-Premise
221	.006	_	_	I-Premise
222	)	_	_	I-Premise
223	.	_	_	I-Premise

224	Longitudinally	_	_	B-Premise
225	,	_	_	I-Premise
226	SNAD	_	_	I-Premise
227	patients	_	_	I-Premise
228	were	_	_	I-Premise
229	more	_	_	I-Premise
230	likely	_	_	I-Premise
231	to	_	_	I-Premise
232	experience	_	_	I-Premise
233	ipsilateral	_	_	I-Premise
234	arm	_	_	I-Premise
235	and	_	_	I-Premise
236	breast	_	_	I-Premise
237	symptoms	_	_	I-Premise
238	,	_	_	I-Premise
239	restricted	_	_	I-Premise
240	work	_	_	I-Premise
241	and	_	_	I-Premise
242	social	_	_	I-Premise
243	activity	_	_	I-Premise
244	,	_	_	I-Premise
245	and	_	_	I-Premise
246	impaired	_	_	I-Premise
247	QOL	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	or	_	_	I-Premise
252	=	_	_	I-Premise
253	.002	_	_	I-Premise
254	all	_	_	I-Premise
255	items	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	From	_	_	B-Premise
259	12	_	_	I-Premise
260	to	_	_	I-Premise
261	36	_	_	I-Premise
262	months	_	_	I-Premise
263	,	_	_	I-Premise
264	fewer	_	_	I-Premise
265	than	_	_	I-Premise
266	15	_	_	I-Premise
267	%	_	_	I-Premise
268	of	_	_	I-Premise
269	either	_	_	I-Premise
270	SNAD	_	_	I-Premise
271	or	_	_	I-Premise
272	SNR	_	_	I-Premise
273	patients	_	_	I-Premise
274	reported	_	_	I-Premise
275	moderate	_	_	I-Premise
276	or	_	_	I-Premise
277	greater	_	_	I-Premise
278	severity	_	_	I-Premise
279	of	_	_	I-Premise
280	any	_	_	I-Premise
281	given	_	_	I-Premise
282	symptom	_	_	I-Premise
283	or	_	_	I-Premise
284	activity	_	_	I-Premise
285	limitation	_	_	I-Premise
286	.	_	_	I-Premise

287	Arm	_	_	B-Claim
288	morbidity	_	_	I-Claim
289	was	_	_	I-Claim
290	greater	_	_	I-Claim
291	with	_	_	I-Claim
292	SNAD	_	_	I-Claim
293	than	_	_	I-Claim
294	with	_	_	I-Claim
295	SNR	_	_	I-Claim
296	.	_	_	I-Claim

297	Despite	_	_	O
298	considerable	_	_	O
299	fears	_	_	O
300	about	_	_	O
301	complications	_	_	O
302	from	_	_	O
303	AD	_	_	O
304	for	_	_	O
305	breast	_	_	O
306	cancer	_	_	O
307	,	_	_	O
308	this	_	_	B-Claim
309	study	_	_	I-Claim
310	demonstrates	_	_	I-Claim
311	that	_	_	I-Claim
312	initial	_	_	I-Claim
313	problems	_	_	I-Claim
314	with	_	_	I-Claim
315	either	_	_	I-Claim
316	surgery	_	_	I-Claim
317	resolve	_	_	I-Claim
318	over	_	_	I-Claim
319	time	_	_	I-Claim
320	.	_	_	I-Claim


0	Postcancer	_	_	B-Claim
1	fatigue	_	_	I-Claim
2	is	_	_	I-Claim
3	a	_	_	I-Claim
4	frequently	_	_	I-Claim
5	occurring	_	_	I-Claim
6	problem	_	_	I-Claim
7	,	_	_	I-Claim
8	impairing	_	_	I-Claim
9	quality	_	_	I-Claim
10	of	_	_	I-Claim
11	life	_	_	I-Claim
12	.	_	_	I-Claim

13	Until	_	_	O
14	now	_	_	O
15	,	_	_	O
16	little	_	_	O
17	is	_	_	O
18	known	_	_	O
19	about	_	_	O
20	(	_	_	O
21	neuro	_	_	O
22	)	_	_	O
23	physiological	_	_	O
24	factors	_	_	O
25	determining	_	_	O
26	postcancer	_	_	O
27	fatigue	_	_	O
28	.	_	_	O

29	For	_	_	O
30	non-cancer	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	chronic	_	_	O
34	fatigue	_	_	O
35	syndrome	_	_	O
36	,	_	_	O
37	certain	_	_	O
38	characteristics	_	_	O
39	of	_	_	O
40	brain	_	_	O
41	morphology	_	_	O
42	and	_	_	O
43	metabolism	_	_	O
44	have	_	_	O
45	been	_	_	O
46	identified	_	_	O
47	in	_	_	O
48	previous	_	_	O
49	studies	_	_	O
50	.	_	_	O

51	We	_	_	O
52	investigated	_	_	O
53	whether	_	_	O
54	these	_	_	O
55	volumetric	_	_	O
56	and	_	_	O
57	metabolic	_	_	O
58	traits	_	_	O
59	are	_	_	O
60	a	_	_	O
61	reflection	_	_	O
62	of	_	_	O
63	fatigue	_	_	O
64	in	_	_	O
65	general	_	_	O
66	and	_	_	O
67	thus	_	_	O
68	also	_	_	O
69	of	_	_	O
70	importance	_	_	O
71	for	_	_	O
72	postcancer	_	_	O
73	fatigue	_	_	O
74	.	_	_	O

75	Fatigued	_	_	O
76	patients	_	_	O
77	were	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	either	_	_	O
82	the	_	_	O
83	intervention	_	_	O
84	condition	_	_	O
85	(	_	_	O
86	cognitive	_	_	O
87	behavior	_	_	O
88	therapy	_	_	O
89	)	_	_	O
90	or	_	_	O
91	the	_	_	O
92	waiting	_	_	O
93	list	_	_	O
94	condition	_	_	O
95	.	_	_	O

96	Twenty-five	_	_	O
97	patients	_	_	O
98	in	_	_	O
99	the	_	_	O
100	intervention	_	_	O
101	condition	_	_	O
102	and	_	_	O
103	fourteen	_	_	O
104	patients	_	_	O
105	in	_	_	O
106	the	_	_	O
107	waiting	_	_	O
108	list	_	_	O
109	condition	_	_	O
110	were	_	_	O
111	assessed	_	_	O
112	twice	_	_	O
113	,	_	_	O
114	at	_	_	O
115	baseline	_	_	O
116	and	_	_	O
117	six	_	_	O
118	months	_	_	O
119	later	_	_	O
120	.	_	_	O

121	Baseline	_	_	O
122	measurements	_	_	O
123	of	_	_	O
124	20	_	_	O
125	fatigued	_	_	O
126	patients	_	_	O
127	were	_	_	O
128	compared	_	_	O
129	with	_	_	O
130	20	_	_	O
131	matched	_	_	O
132	non-fatigued	_	_	O
133	controls	_	_	O
134	.	_	_	O

135	All	_	_	O
136	participants	_	_	O
137	had	_	_	O
138	completed	_	_	O
139	treatment	_	_	O
140	of	_	_	O
141	a	_	_	O
142	malignant	_	_	O
143	,	_	_	O
144	solid	_	_	O
145	tumor	_	_	O
146	minimal	_	_	O
147	one	_	_	O
148	year	_	_	O
149	earlier	_	_	O
150	.	_	_	O

151	Global	_	_	O
152	brain	_	_	O
153	volumes	_	_	O
154	,	_	_	O
155	subcortical	_	_	O
156	brain	_	_	O
157	volumes	_	_	O
158	,	_	_	O
159	metabolite	_	_	O
160	tissue	_	_	O
161	concentrations	_	_	O
162	,	_	_	O
163	and	_	_	O
164	metabolite	_	_	O
165	ratios	_	_	O
166	were	_	_	O
167	primary	_	_	O
168	outcome	_	_	O
169	measures	_	_	O
170	.	_	_	O

171	Volumetric	_	_	O
172	and	_	_	O
173	metabolic	_	_	O
174	parameters	_	_	O
175	were	_	_	O
176	not	_	_	O
177	significantly	_	_	O
178	different	_	_	O
179	between	_	_	O
180	fatigued	_	_	O
181	and	_	_	O
182	non-fatigued	_	_	O
183	patients	_	_	O
184	.	_	_	O

185	Change	_	_	B-Premise
186	scores	_	_	I-Premise
187	of	_	_	I-Premise
188	volumetric	_	_	I-Premise
189	and	_	_	I-Premise
190	metabolic	_	_	I-Premise
191	parameters	_	_	I-Premise
192	from	_	_	I-Premise
193	baseline	_	_	I-Premise
194	to	_	_	I-Premise
195	follow-up	_	_	I-Premise
196	were	_	_	I-Premise
197	not	_	_	I-Premise
198	significantly	_	_	I-Premise
199	different	_	_	I-Premise
200	between	_	_	I-Premise
201	patients	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	therapy	_	_	I-Premise
205	and	_	_	I-Premise
206	the	_	_	I-Premise
207	waiting	_	_	I-Premise
208	list	_	_	I-Premise
209	group	_	_	I-Premise
210	.	_	_	I-Premise

211	Patients	_	_	B-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	therapy	_	_	I-Premise
215	group	_	_	I-Premise
216	reported	_	_	I-Premise
217	a	_	_	I-Premise
218	significant	_	_	I-Premise
219	larger	_	_	I-Premise
220	decrease	_	_	I-Premise
221	in	_	_	I-Premise
222	fatigue	_	_	I-Premise
223	scores	_	_	I-Premise
224	than	_	_	I-Premise
225	patients	_	_	I-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	waiting	_	_	I-Premise
229	list	_	_	I-Premise
230	group	_	_	I-Premise
231	.	_	_	I-Premise

232	No	_	_	B-Premise
233	relation	_	_	I-Premise
234	was	_	_	I-Premise
235	found	_	_	I-Premise
236	between	_	_	I-Premise
237	postcancer	_	_	I-Premise
238	fatigue	_	_	I-Premise
239	and	_	_	I-Premise
240	the	_	_	I-Premise
241	studied	_	_	I-Premise
242	volumetric	_	_	I-Premise
243	and	_	_	I-Premise
244	metabolic	_	_	I-Premise
245	markers	_	_	I-Premise
246	.	_	_	I-Premise

247	This	_	_	B-Claim
248	may	_	_	I-Claim
249	suggest	_	_	I-Claim
250	that	_	_	I-Claim
251	,	_	_	I-Claim
252	although	_	_	I-Claim
253	postcancer	_	_	I-Claim
254	fatigue	_	_	I-Claim
255	and	_	_	I-Claim
256	chronic	_	_	I-Claim
257	fatigue	_	_	I-Claim
258	syndrome	_	_	I-Claim
259	show	_	_	I-Claim
260	strong	_	_	I-Claim
261	resemblances	_	_	I-Claim
262	as	_	_	I-Claim
263	a	_	_	I-Claim
264	clinical	_	_	I-Claim
265	syndrome	_	_	I-Claim
266	,	_	_	I-Claim
267	the	_	_	I-Claim
268	underlying	_	_	I-Claim
269	physiology	_	_	I-Claim
270	is	_	_	I-Claim
271	different	_	_	I-Claim
272	.	_	_	I-Claim


0	The	_	_	O
1	efficacy	_	_	O
2	of	_	_	O
3	a	_	_	O
4	home-based	_	_	O
5	physical	_	_	O
6	activity	_	_	O
7	(	_	_	O
8	PA	_	_	O
9	)	_	_	O
10	intervention	_	_	O
11	for	_	_	O
12	colorectal	_	_	O
13	cancer	_	_	O
14	patients	_	_	O
15	versus	_	_	O
16	contact	_	_	O
17	control	_	_	O
18	was	_	_	O
19	evaluated	_	_	O
20	in	_	_	O
21	a	_	_	O
22	randomized	_	_	O
23	controlled	_	_	O
24	trial	_	_	O
25	.	_	_	O

26	Forty-six	_	_	O
27	patients	_	_	O
28	(	_	_	O
29	mean	_	_	O
30	age	_	_	O
31	=	_	_	O
32	57.3	_	_	O
33	years	_	_	O
34	[	_	_	O
35	SD	_	_	O
36	=	_	_	O
37	9.7	_	_	O
38	]	_	_	O
39	,	_	_	O
40	57	_	_	O
41	%	_	_	O
42	female	_	_	O
43	,	_	_	O
44	mean	_	_	O
45	=	_	_	O
46	2.99	_	_	O
47	years	_	_	O
48	post-diagnosis	_	_	O
49	[	_	_	O
50	SD	_	_	O
51	=	_	_	O
52	1.64	_	_	O
53	]	_	_	O
54	)	_	_	O
55	who	_	_	O
56	had	_	_	O
57	completed	_	_	O
58	treatment	_	_	O
59	for	_	_	O
60	stages	_	_	O
61	1-3	_	_	O
62	colorectal	_	_	O
63	cancer	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	telephone	_	_	O
68	counseling	_	_	O
69	to	_	_	O
70	support	_	_	O
71	PA	_	_	O
72	(	_	_	O
73	PA	_	_	O
74	group	_	_	O
75	,	_	_	O
76	n	_	_	O
77	=	_	_	O
78	20	_	_	O
79	)	_	_	O
80	or	_	_	O
81	contact	_	_	O
82	control	_	_	O
83	(	_	_	O
84	control	_	_	O
85	group	_	_	O
86	,	_	_	O
87	n	_	_	O
88	=	_	_	O
89	26	_	_	O
90	)	_	_	O
91	.	_	_	O

92	PA	_	_	O
93	group	_	_	O
94	participants	_	_	O
95	received	_	_	O
96	3	_	_	O
97	months	_	_	O
98	of	_	_	O
99	PA	_	_	O
100	counseling	_	_	O
101	(	_	_	O
102	based	_	_	O
103	on	_	_	O
104	the	_	_	O
105	transtheoretical	_	_	O
106	model	_	_	O
107	and	_	_	O
108	the	_	_	O
109	social	_	_	O
110	cognitive	_	_	O
111	theory	_	_	O
112	)	_	_	O
113	delivered	_	_	O
114	via	_	_	O
115	telephone	_	_	O
116	,	_	_	O
117	as	_	_	O
118	well	_	_	O
119	as	_	_	O
120	weekly	_	_	O
121	PA	_	_	O
122	tip	_	_	O
123	sheets	_	_	O
124	.	_	_	O

125	Assessments	_	_	O
126	of	_	_	O
127	PA	_	_	O
128	(	_	_	O
129	Seven-day	_	_	O
130	Physical	_	_	O
131	Activity	_	_	O
132	Recall	_	_	O
133	[	_	_	O
134	7-day	_	_	O
135	PAR	_	_	O
136	]	_	_	O
137	and	_	_	O
138	Community	_	_	O
139	Healthy	_	_	O
140	Activities	_	_	O
141	Model	_	_	O
142	Program	_	_	O
143	for	_	_	O
144	Seniors	_	_	O
145	[	_	_	O
146	CHAMPS	_	_	O
147	]	_	_	O
148	)	_	_	O
149	,	_	_	O
150	submaximal	_	_	O
151	aerobic	_	_	O
152	fitness	_	_	O
153	(	_	_	O
154	Treadwalk	_	_	O
155	test	_	_	O
156	)	_	_	O
157	,	_	_	O
158	motivational	_	_	O
159	readiness	_	_	O
160	for	_	_	O
161	PA	_	_	O
162	,	_	_	O
163	and	_	_	O
164	psychosocial	_	_	O
165	outcomes	_	_	O
166	were	_	_	O
167	conducted	_	_	O
168	at	_	_	O
169	baseline	_	_	O
170	,	_	_	O
171	3	_	_	O
172	,	_	_	O
173	6	_	_	O
174	,	_	_	O
175	and	_	_	O
176	12	_	_	O
177	months	_	_	O
178	post-baseline	_	_	O
179	.	_	_	O

180	Objective	_	_	O
181	accelerometer	_	_	O
182	data	_	_	O
183	were	_	_	O
184	collected	_	_	O
185	at	_	_	O
186	the	_	_	O
187	same	_	_	O
188	time	_	_	O
189	points	_	_	O
190	.	_	_	O

191	The	_	_	B-Premise
192	PA	_	_	I-Premise
193	group	_	_	I-Premise
194	reported	_	_	I-Premise
195	significant	_	_	I-Premise
196	increases	_	_	I-Premise
197	in	_	_	I-Premise
198	minutes	_	_	I-Premise
199	of	_	_	I-Premise
200	PA	_	_	I-Premise
201	at	_	_	I-Premise
202	3	_	_	I-Premise
203	months	_	_	I-Premise
204	(	_	_	I-Premise
205	7-day	_	_	I-Premise
206	PAR	_	_	I-Premise
207	)	_	_	I-Premise
208	and	_	_	I-Premise
209	caloric	_	_	I-Premise
210	expenditure	_	_	I-Premise
211	(	_	_	I-Premise
212	CHAMPS	_	_	I-Premise
213	)	_	_	I-Premise
214	compared	_	_	I-Premise
215	with	_	_	I-Premise
216	the	_	_	I-Premise
217	control	_	_	I-Premise
218	group	_	_	I-Premise
219	,	_	_	I-Premise
220	but	_	_	B-Premise
221	the	_	_	I-Premise
222	group	_	_	I-Premise
223	differences	_	_	I-Premise
224	were	_	_	I-Premise
225	attenuated	_	_	I-Premise
226	over	_	_	I-Premise
227	time	_	_	I-Premise
228	.	_	_	I-Premise

229	The	_	_	B-Premise
230	PA	_	_	I-Premise
231	group	_	_	I-Premise
232	showed	_	_	I-Premise
233	significant	_	_	I-Premise
234	improvements	_	_	I-Premise
235	in	_	_	I-Premise
236	fitness	_	_	I-Premise
237	at	_	_	I-Premise
238	3	_	_	I-Premise
239	,	_	_	I-Premise
240	6	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	12	_	_	I-Premise
244	months	_	_	I-Premise
245	versus	_	_	I-Premise
246	the	_	_	I-Premise
247	control	_	_	I-Premise
248	group	_	_	I-Premise
249	.	_	_	I-Premise

250	Improvements	_	_	B-Premise
251	in	_	_	I-Premise
252	motivational	_	_	I-Premise
253	readiness	_	_	I-Premise
254	for	_	_	I-Premise
255	PA	_	_	I-Premise
256	were	_	_	I-Premise
257	reported	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	PA	_	_	I-Premise
261	group	_	_	I-Premise
262	only	_	_	I-Premise
263	at	_	_	I-Premise
264	3	_	_	I-Premise
265	months	_	_	I-Premise
266	.	_	_	I-Premise

267	No	_	_	B-Premise
268	significant	_	_	I-Premise
269	group	_	_	I-Premise
270	differences	_	_	I-Premise
271	were	_	_	I-Premise
272	found	_	_	I-Premise
273	for	_	_	I-Premise
274	fatigue	_	_	I-Premise
275	,	_	_	I-Premise
276	self-reported	_	_	I-Premise
277	physical	_	_	I-Premise
278	functioning	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	quality	_	_	I-Premise
282	of	_	_	I-Premise
283	life	_	_	I-Premise
284	at	_	_	I-Premise
285	3	_	_	I-Premise
286	,	_	_	I-Premise
287	6	_	_	I-Premise
288	,	_	_	I-Premise
289	and	_	_	I-Premise
290	12	_	_	I-Premise
291	months	_	_	I-Premise
292	.	_	_	I-Premise

293	A	_	_	B-Claim
294	home-based	_	_	I-Claim
295	intervention	_	_	I-Claim
296	improved	_	_	I-Claim
297	survivors	_	_	I-Claim
298	'	_	_	I-Claim
299	PA	_	_	I-Claim
300	and	_	_	I-Claim
301	motivational	_	_	I-Claim
302	readiness	_	_	I-Claim
303	at	_	_	I-Claim
304	3	_	_	I-Claim
305	months	_	_	I-Claim
306	and	_	_	I-Claim
307	increased	_	_	I-Claim
308	submaximal	_	_	I-Claim
309	aerobic	_	_	I-Claim
310	fitness	_	_	I-Claim
311	at	_	_	I-Claim
312	3	_	_	I-Claim
313	,	_	_	I-Claim
314	6	_	_	I-Claim
315	,	_	_	I-Claim
316	and	_	_	I-Claim
317	12	_	_	I-Claim
318	months	_	_	I-Claim
319	.	_	_	I-Claim


0	Cancer	_	_	O
1	treatment	_	_	O
2	can	_	_	O
3	profoundly	_	_	O
4	impact	_	_	O
5	the	_	_	O
6	patient	_	_	O
7	's	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	.	_	_	O

15	It	_	_	O
16	has	_	_	O
17	been	_	_	O
18	well	_	_	O
19	documented	_	_	O
20	that	_	_	O
21	there	_	_	O
22	are	_	_	O
23	gender	_	_	O
24	differences	_	_	O
25	in	_	_	O
26	the	_	_	O
27	symptoms	_	_	O
28	associated	_	_	O
29	with	_	_	O
30	cancer	_	_	O
31	treatment	_	_	O
32	.	_	_	O

33	This	_	_	O
34	study	_	_	O
35	explores	_	_	O
36	the	_	_	O
37	impact	_	_	O
38	of	_	_	O
39	gender	_	_	O
40	on	_	_	O
41	QOL	_	_	O
42	for	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	newly	_	_	O
46	diagnosed	_	_	O
47	advanced	_	_	O
48	cancer	_	_	O
49	.	_	_	O

50	A	_	_	O
51	randomized	_	_	O
52	,	_	_	O
53	controlled	_	_	O
54	clinical	_	_	O
55	trial	_	_	O
56	in	_	_	O
57	patients	_	_	O
58	receiving	_	_	O
59	radiotherapy	_	_	O
60	for	_	_	O
61	advanced	_	_	O
62	cancer	_	_	O
63	demonstrated	_	_	O
64	maintenance	_	_	O
65	of	_	_	O
66	QOL	_	_	O
67	with	_	_	O
68	a	_	_	O
69	six	_	_	O
70	session	_	_	O
71	multidisciplinary	_	_	O
72	structured	_	_	O
73	intervention	_	_	O
74	compared	_	_	O
75	to	_	_	O
76	controls	_	_	O
77	.	_	_	O

78	This	_	_	O
79	current	_	_	O
80	study	_	_	O
81	reports	_	_	O
82	the	_	_	O
83	gender	_	_	O
84	differences	_	_	O
85	in	_	_	O
86	that	_	_	O
87	trial	_	_	O
88	.	_	_	O

89	Outcome	_	_	O
90	measures	_	_	O
91	included	_	_	O
92	the	_	_	O
93	functional	_	_	O
94	assessment	_	_	O
95	of	_	_	O
96	cancer	_	_	O
97	therapy-general	_	_	O
98	(	_	_	O
99	FACT-G	_	_	O
100	)	_	_	O
101	,	_	_	O
102	linear	_	_	O
103	analog	_	_	O
104	self-assessment	_	_	O
105	(	_	_	O
106	LASA	_	_	O
107	)	_	_	O
108	,	_	_	O
109	and	_	_	O
110	profile	_	_	O
111	of	_	_	O
112	mood	_	_	O
113	states	_	_	O
114	(	_	_	O
115	POMS	_	_	O
116	)	_	_	O
117	at	_	_	O
118	baseline	_	_	O
119	and	_	_	O
120	weeks	_	_	O
121	4	_	_	O
122	,	_	_	O
123	27	_	_	O
124	,	_	_	O
125	and	_	_	O
126	52	_	_	O
127	.	_	_	O

128	Kruskal-Wallis	_	_	O
129	was	_	_	O
130	used	_	_	O
131	to	_	_	O
132	compare	_	_	O
133	QOL	_	_	O
134	scores	_	_	O
135	.	_	_	O

136	One	_	_	O
137	hundred	_	_	O
138	thirty-one	_	_	O
139	patients	_	_	O
140	(	_	_	O
141	45	_	_	O
142	women	_	_	O
143	and	_	_	O
144	86	_	_	O
145	men	_	_	O
146	,	_	_	O
147	mean	_	_	O
148	age	_	_	O
149	58.7	_	_	O
150	)	_	_	O
151	participated	_	_	O
152	in	_	_	O
153	the	_	_	O
154	clinical	_	_	O
155	trial	_	_	O
156	.	_	_	O

157	At	_	_	B-Premise
158	week	_	_	I-Premise
159	4	_	_	I-Premise
160	postintervention	_	_	I-Premise
161	,	_	_	I-Premise
162	women	_	_	I-Premise
163	in	_	_	I-Premise
164	the	_	_	I-Premise
165	intervention	_	_	I-Premise
166	group	_	_	I-Premise
167	had	_	_	I-Premise
168	statistically	_	_	I-Premise
169	significant	_	_	I-Premise
170	improvement	_	_	I-Premise
171	in	_	_	I-Premise
172	their	_	_	I-Premise
173	FACT-G	_	_	I-Premise
174	score	_	_	I-Premise
175	,	_	_	I-Premise
176	FACT-G	_	_	I-Premise
177	physical	_	_	I-Premise
178	well-being	_	_	I-Premise
179	subscale	_	_	I-Premise
180	,	_	_	I-Premise
181	LASA	_	_	I-Premise
182	fatigue	_	_	I-Premise
183	,	_	_	I-Premise
184	POMS	_	_	I-Premise
185	total	_	_	I-Premise
186	score	_	_	I-Premise
187	,	_	_	I-Premise
188	POMS	_	_	I-Premise
189	fatigue-inertia	_	_	I-Premise
190	subscale	_	_	I-Premise
191	,	_	_	I-Premise
192	and	_	_	I-Premise
193	POMS	_	_	I-Premise
194	confusion-bewilderment	_	_	I-Premise
195	subscale	_	_	I-Premise
196	(	_	_	I-Premise
197	p	_	_	I-Premise
198	<	_	_	I-Premise
199	0.05	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Men	_	_	B-Premise
203	receiving	_	_	I-Premise
204	the	_	_	I-Premise
205	intervention	_	_	I-Premise
206	had	_	_	I-Premise
207	a	_	_	I-Premise
208	smaller	_	_	I-Premise
209	decrease	_	_	I-Premise
210	in	_	_	I-Premise
211	FACT-G	_	_	I-Premise
212	score	_	_	I-Premise
213	compared	_	_	I-Premise
214	to	_	_	I-Premise
215	controls	_	_	I-Premise
216	(	_	_	I-Premise
217	p	_	_	I-Premise
218	=	_	_	I-Premise
219	0.048	_	_	I-Premise
220	)	_	_	I-Premise
221	and	_	_	I-Premise
222	also	_	_	I-Premise
223	worsened	_	_	I-Premise
224	on	_	_	I-Premise
225	the	_	_	I-Premise
226	LASA	_	_	I-Premise
227	financial	_	_	I-Premise
228	(	_	_	I-Premise
229	p	_	_	I-Premise
230	=	_	_	I-Premise
231	0.02	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	At	_	_	B-Premise
235	week	_	_	I-Premise
236	27	_	_	I-Premise
237	,	_	_	I-Premise
238	the	_	_	I-Premise
239	only	_	_	I-Premise
240	gender	_	_	I-Premise
241	difference	_	_	I-Premise
242	was	_	_	I-Premise
243	that	_	_	I-Premise
244	intervention	_	_	I-Premise
245	group	_	_	I-Premise
246	men	_	_	I-Premise
247	had	_	_	I-Premise
248	more	_	_	I-Premise
249	POMS	_	_	I-Premise
250	anger-hostility	_	_	I-Premise
251	(	_	_	I-Premise
252	p	_	_	I-Premise
253	=	_	_	I-Premise
254	0.009	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	By	_	_	B-Premise
258	week	_	_	I-Premise
259	52	_	_	I-Premise
260	,	_	_	I-Premise
261	there	_	_	I-Premise
262	were	_	_	I-Premise
263	no	_	_	I-Premise
264	statistically	_	_	I-Premise
265	significant	_	_	I-Premise
266	gender	_	_	I-Premise
267	differences	_	_	I-Premise
268	in	_	_	I-Premise
269	any	_	_	I-Premise
270	of	_	_	I-Premise
271	the	_	_	I-Premise
272	QOL	_	_	I-Premise
273	measures	_	_	I-Premise
274	.	_	_	I-Premise

275	Gender-based	_	_	B-Claim
276	differences	_	_	I-Claim
277	appear	_	_	I-Claim
278	to	_	_	I-Claim
279	play	_	_	I-Claim
280	a	_	_	I-Claim
281	role	_	_	I-Claim
282	in	_	_	I-Claim
283	the	_	_	I-Claim
284	early	_	_	I-Claim
285	,	_	_	I-Claim
286	but	_	_	I-Claim
287	not	_	_	I-Claim
288	late	_	_	I-Claim
289	,	_	_	I-Claim
290	response	_	_	I-Claim
291	to	_	_	I-Claim
292	a	_	_	I-Claim
293	multidisciplinary	_	_	I-Claim
294	intervention	_	_	I-Claim
295	to	_	_	I-Claim
296	improve	_	_	I-Claim
297	QOL	_	_	I-Claim
298	for	_	_	I-Claim
299	patients	_	_	I-Claim
300	with	_	_	I-Claim
301	advanced	_	_	I-Claim
302	cancer	_	_	I-Claim
303	,	_	_	I-Claim
304	suggesting	_	_	O
305	that	_	_	O
306	early	_	_	B-Claim
307	interventions	_	_	I-Claim
308	can	_	_	I-Claim
309	be	_	_	I-Claim
310	tailored	_	_	I-Claim
311	for	_	_	I-Claim
312	each	_	_	I-Claim
313	gender	_	_	I-Claim
314	.	_	_	I-Claim


0	Surgical	_	_	O
1	resection	_	_	O
2	enhances	_	_	O
3	long-term	_	_	O
4	survival	_	_	O
5	after	_	_	O
6	lung	_	_	O
7	cancer	_	_	O
8	,	_	_	O
9	but	_	_	O
10	survivors	_	_	O
11	face	_	_	O
12	functional	_	_	O
13	deficits	_	_	O
14	and	_	_	O
15	report	_	_	O
16	on	_	_	O
17	poor	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	long	_	_	O
22	time	_	_	O
23	after	_	_	O
24	surgery	_	_	O
25	.	_	_	O

26	This	_	_	O
27	study	_	_	O
28	evaluated	_	_	O
29	short	_	_	O
30	and	_	_	O
31	long-term	_	_	O
32	effects	_	_	O
33	of	_	_	O
34	supervised	_	_	O
35	group	_	_	O
36	exercise	_	_	O
37	training	_	_	O
38	on	_	_	O
39	health-related	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	and	_	_	O
44	physical	_	_	O
45	performance	_	_	O
46	in	_	_	O
47	patients	_	_	O
48	,	_	_	O
49	who	_	_	O
50	were	_	_	O
51	radically	_	_	O
52	operated	_	_	O
53	for	_	_	O
54	lung	_	_	O
55	cancer	_	_	O
56	.	_	_	O

57	A	_	_	O
58	randomized	_	_	O
59	,	_	_	O
60	assessor-blinded	_	_	O
61	,	_	_	O
62	controlled	_	_	O
63	trial	_	_	O
64	was	_	_	O
65	performed	_	_	O
66	on	_	_	O
67	78	_	_	O
68	patients	_	_	O
69	undergoing	_	_	O
70	lung	_	_	O
71	cancer	_	_	O
72	surgery	_	_	O
73	.	_	_	O

74	The	_	_	O
75	intervention	_	_	O
76	group	_	_	O
77	(	_	_	O
78	IG	_	_	O
79	,	_	_	O
80	n=41	_	_	O
81	)	_	_	O
82	participated	_	_	O
83	in	_	_	O
84	supervised	_	_	O
85	out-patient	_	_	O
86	exercise	_	_	O
87	training	_	_	O
88	sessions	_	_	O
89	,	_	_	O
90	one	_	_	O
91	hour	_	_	O
92	once	_	_	O
93	a	_	_	O
94	week	_	_	O
95	for	_	_	O
96	ten	_	_	O
97	weeks	_	_	O
98	.	_	_	O

99	The	_	_	O
100	sessions	_	_	O
101	were	_	_	O
102	based	_	_	O
103	on	_	_	O
104	aerobic	_	_	O
105	exercises	_	_	O
106	with	_	_	O
107	target	_	_	O
108	intensity	_	_	O
109	of	_	_	O
110	60-80	_	_	O
111	%	_	_	O
112	of	_	_	O
113	work	_	_	O
114	capacity	_	_	O
115	,	_	_	O
116	resistance	_	_	O
117	training	_	_	O
118	and	_	_	O
119	dyspnoea	_	_	O
120	management	_	_	O
121	.	_	_	O

122	The	_	_	O
123	control	_	_	O
124	group	_	_	O
125	(	_	_	O
126	CG	_	_	O
127	,	_	_	O
128	n=37	_	_	O
129	)	_	_	O
130	received	_	_	O
131	one	_	_	O
132	individual	_	_	O
133	instruction	_	_	O
134	in	_	_	O
135	exercise	_	_	O
136	training	_	_	O
137	.	_	_	O

138	Measurements	_	_	O
139	consisted	_	_	O
140	of	_	_	O
141	:	_	_	O
142	health-related	_	_	O
143	quality	_	_	O
144	of	_	_	O
145	life	_	_	O
146	(	_	_	O
147	SF36	_	_	O
148	)	_	_	O
149	,	_	_	O
150	six	_	_	O
151	minute	_	_	O
152	walk	_	_	O
153	test	_	_	O
154	(	_	_	O
155	6MWT	_	_	O
156	)	_	_	O
157	and	_	_	O
158	lung	_	_	O
159	function	_	_	O
160	(	_	_	O
161	spirometry	_	_	O
162	)	_	_	O
163	,	_	_	O
164	assessed	_	_	O
165	three	_	_	O
166	weeks	_	_	O
167	after	_	_	O
168	surgery	_	_	O
169	and	_	_	O
170	after	_	_	O
171	four	_	_	O
172	and	_	_	O
173	twelve	_	_	O
174	months	_	_	O
175	.	_	_	O

176	Both	_	_	O
177	groups	_	_	O
178	were	_	_	O
179	comparable	_	_	O
180	at	_	_	O
181	baseline	_	_	O
182	on	_	_	O
183	demographic	_	_	O
184	characteristic	_	_	O
185	and	_	_	O
186	outcome	_	_	O
187	values	_	_	O
188	.	_	_	O

189	We	_	_	B-Premise
190	found	_	_	I-Premise
191	a	_	_	I-Premise
192	statistically	_	_	I-Premise
193	significant	_	_	I-Premise
194	effect	_	_	I-Premise
195	after	_	_	I-Premise
196	four	_	_	I-Premise
197	months	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	bodily	_	_	I-Premise
201	pain	_	_	I-Premise
202	domain	_	_	I-Premise
203	of	_	_	I-Premise
204	SF36	_	_	I-Premise
205	,	_	_	I-Premise
206	with	_	_	I-Premise
207	an	_	_	I-Premise
208	estimated	_	_	I-Premise
209	mean	_	_	I-Premise
210	difference	_	_	I-Premise
211	(	_	_	I-Premise
212	EMD	_	_	I-Premise
213	)	_	_	I-Premise
214	of	_	_	I-Premise
215	15.3	_	_	I-Premise
216	(	_	_	I-Premise
217	95	_	_	I-Premise
218	%	_	_	I-Premise
219	CI:4	_	_	I-Premise
220	to	_	_	I-Premise
221	26.6	_	_	I-Premise
222	,	_	_	I-Premise
223	p=0.01	_	_	I-Premise
224	)	_	_	I-Premise
225	and	_	_	I-Premise
226	a	_	_	I-Premise
227	trend	_	_	I-Premise
228	in	_	_	I-Premise
229	favour	_	_	I-Premise
230	of	_	_	I-Premise
231	the	_	_	I-Premise
232	intervention	_	_	I-Premise
233	for	_	_	I-Premise
234	role	_	_	I-Premise
235	physical	_	_	I-Premise
236	functioning	_	_	I-Premise
237	(	_	_	I-Premise
238	EMD	_	_	I-Premise
239	12.04	_	_	I-Premise
240	,	_	_	I-Premise
241	95	_	_	I-Premise
242	%	_	_	I-Premise
243	CI	_	_	I-Premise
244	:	_	_	I-Premise
245	-1	_	_	I-Premise
246	to	_	_	I-Premise
247	25.1	_	_	I-Premise
248	,	_	_	I-Premise
249	p=0.07	_	_	I-Premise
250	)	_	_	I-Premise
251	and	_	_	I-Premise
252	physical	_	_	I-Premise
253	component	_	_	I-Premise
254	summary	_	_	I-Premise
255	(	_	_	I-Premise
256	EMD	_	_	I-Premise
257	3.76	_	_	I-Premise
258	,	_	_	I-Premise
259	95	_	_	I-Premise
260	%	_	_	I-Premise
261	CI	_	_	I-Premise
262	:	_	_	I-Premise
263	-0.1	_	_	I-Premise
264	to	_	_	I-Premise
265	7.6	_	_	I-Premise
266	,	_	_	I-Premise
267	p=0.06	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	At	_	_	B-Premise
271	12	_	_	I-Premise
272	months	_	_	I-Premise
273	,	_	_	I-Premise
274	the	_	_	I-Premise
275	tendency	_	_	I-Premise
276	was	_	_	I-Premise
277	reversed	_	_	I-Premise
278	,	_	_	I-Premise
279	with	_	_	I-Premise
280	the	_	_	I-Premise
281	CG	_	_	I-Premise
282	presenting	_	_	I-Premise
283	overall	_	_	I-Premise
284	slightly	_	_	I-Premise
285	better	_	_	I-Premise
286	measures	_	_	I-Premise
287	.	_	_	I-Premise

288	We	_	_	B-Claim
289	found	_	_	I-Claim
290	no	_	_	I-Claim
291	effect	_	_	I-Claim
292	of	_	_	I-Claim
293	the	_	_	I-Claim
294	intervention	_	_	I-Claim
295	on	_	_	I-Claim
296	6MWT	_	_	I-Claim
297	or	_	_	I-Claim
298	lung	_	_	I-Claim
299	volumes	_	_	I-Claim
300	at	_	_	I-Claim
301	any	_	_	I-Claim
302	time-point	_	_	I-Claim
303	.	_	_	I-Claim

304	Supervised	_	_	B-Claim
305	compared	_	_	I-Claim
306	to	_	_	I-Claim
307	unsupervised	_	_	I-Claim
308	exercise	_	_	I-Claim
309	training	_	_	I-Claim
310	resulted	_	_	I-Claim
311	in	_	_	I-Claim
312	no	_	_	I-Claim
313	improvement	_	_	I-Claim
314	in	_	_	I-Claim
315	health-related	_	_	I-Claim
316	quality	_	_	I-Claim
317	of	_	_	I-Claim
318	life	_	_	I-Claim
319	,	_	_	I-Claim
320	except	_	_	B-Claim
321	for	_	_	I-Claim
322	the	_	_	I-Claim
323	bodily	_	_	I-Claim
324	pain	_	_	I-Claim
325	domain	_	_	I-Claim
326	,	_	_	I-Claim
327	four	_	_	I-Claim
328	months	_	_	I-Claim
329	after	_	_	I-Claim
330	lung	_	_	I-Claim
331	cancer	_	_	I-Claim
332	surgery	_	_	I-Claim
333	.	_	_	I-Claim

334	No	_	_	B-Claim
335	effects	_	_	I-Claim
336	of	_	_	I-Claim
337	the	_	_	I-Claim
338	intervention	_	_	I-Claim
339	were	_	_	I-Claim
340	found	_	_	I-Claim
341	for	_	_	I-Claim
342	any	_	_	I-Claim
343	outcome	_	_	I-Claim
344	after	_	_	I-Claim
345	one	_	_	I-Claim
346	year	_	_	I-Claim
347	.	_	_	I-Claim


0	We	_	_	O
1	analyzed	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	survival	_	_	O
5	of	_	_	O
6	children	_	_	O
7	under	_	_	O
8	6	_	_	O
9	years	_	_	O
10	of	_	_	O
11	age	_	_	O
12	(	_	_	O
13	<	_	_	O
14	6	_	_	O
15	years	_	_	O
16	)	_	_	O
17	enrolled	_	_	O
18	upon	_	_	O
19	the	_	_	O
20	Children	_	_	O
21	's	_	_	O
22	Cancer	_	_	O
23	Group	_	_	O
24	(	_	_	O
25	CCG	_	_	O
26	)	_	_	O
27	-945	_	_	O
28	high-grade	_	_	O
29	glioma	_	_	O
30	(	_	_	O
31	HGG	_	_	O
32	)	_	_	O
33	study	_	_	O
34	to	_	_	O
35	determine	_	_	O
36	the	_	_	O
37	impact	_	_	O
38	of	_	_	O
39	intrinsic	_	_	O
40	biological	_	_	O
41	characteristics	_	_	O
42	as	_	_	O
43	well	_	_	O
44	as	_	_	O
45	treatment	_	_	O
46	upon	_	_	O
47	both	_	_	O
48	survival	_	_	O
49	and	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	(	_	_	O
54	QOL	_	_	O
55	)	_	_	O
56	in	_	_	O
57	this	_	_	O
58	younger	_	_	O
59	age	_	_	O
60	population	_	_	O
61	.	_	_	O

62	Analyses	_	_	O
63	were	_	_	O
64	undertaken	_	_	O
65	on	_	_	O
66	patients	_	_	O
67	<	_	_	O
68	6	_	_	O
69	years	_	_	O
70	with	_	_	O
71	institutionally	_	_	O
72	diagnosed	_	_	O
73	HGG	_	_	O
74	enrolled	_	_	O
75	on	_	_	O
76	the	_	_	O
77	CCG-945	_	_	O
78	trial	_	_	O
79	.	_	_	O

80	Comparisons	_	_	O
81	of	_	_	O
82	survival	_	_	O
83	were	_	_	O
84	performed	_	_	O
85	for	_	_	O
86	patients	_	_	O
87	<	_	_	O
88	3	_	_	O
89	years	_	_	O
90	of	_	_	O
91	age	_	_	O
92	(	_	_	O
93	<	_	_	O
94	3	_	_	O
95	years	_	_	O
96	)	_	_	O
97	(	_	_	O
98	treated	_	_	O
99	with	_	_	O
100	intent	_	_	O
101	to	_	_	O
102	avoid	_	_	O
103	irradiation	_	_	O
104	)	_	_	O
105	versus	_	_	O
106	those	_	_	O
107	between	_	_	O
108	3	_	_	O
109	and	_	_	O
110	6	_	_	O
111	years	_	_	O
112	of	_	_	O
113	age	_	_	O
114	(	_	_	O
115	3-6	_	_	O
116	years	_	_	O
117	)	_	_	O
118	(	_	_	O
119	treated	_	_	O
120	with	_	_	O
121	irradiation	_	_	O
122	and	_	_	O
123	chemotherapy	_	_	O
124	)	_	_	O
125	at	_	_	O
126	diagnosis	_	_	O
127	.	_	_	O

128	Discordance	_	_	O
129	between	_	_	O
130	the	_	_	O
131	institutional	_	_	O
132	diagnoses	_	_	O
133	of	_	_	O
134	HGG	_	_	O
135	and	_	_	O
136	consensus-reviewed	_	_	O
137	diagnoses	_	_	O
138	led	_	_	O
139	us	_	_	O
140	to	_	_	O
141	perform	_	_	O
142	further	_	_	O
143	survival	_	_	O
144	analyses	_	_	O
145	for	_	_	O
146	both	_	_	O
147	groups	_	_	O
148	.	_	_	O

149	We	_	_	O
150	compared	_	_	O
151	the	_	_	O
152	two	_	_	O
153	groups	_	_	O
154	of	_	_	O
155	patients	_	_	O
156	for	_	_	O
157	biological	_	_	O
158	markers	_	_	O
159	,	_	_	O
160	and	_	_	O
161	evaluated	_	_	O
162	the	_	_	O
163	neuropsychological	_	_	O
164	and	_	_	O
165	QOL	_	_	O
166	outcomes	_	_	O
167	of	_	_	O
168	long-term	_	_	O
169	survivors	_	_	O
170	.	_	_	O

171	Patients	_	_	B-Premise
172	<	_	_	I-Premise
173	3	_	_	I-Premise
174	years	_	_	I-Premise
175	(	_	_	I-Premise
176	n	_	_	I-Premise
177	=	_	_	I-Premise
178	49	_	_	I-Premise
179	,	_	_	I-Premise
180	19.5	_	_	I-Premise
181	%	_	_	I-Premise
182	of	_	_	I-Premise
183	all	_	_	I-Premise
184	enrolled	_	_	I-Premise
185	patients	_	_	I-Premise
186	)	_	_	I-Premise
187	at	_	_	I-Premise
188	diagnosis	_	_	I-Premise
189	had	_	_	I-Premise
190	a	_	_	I-Premise
191	10-year	_	_	I-Premise
192	EFS	_	_	I-Premise
193	and	_	_	I-Premise
194	OS	_	_	I-Premise
195	of	_	_	I-Premise
196	29	_	_	I-Premise
197		_	_	I-Premise
198	6.5	_	_	I-Premise
199	%	_	_	I-Premise
200	and	_	_	I-Premise
201	37.5	_	_	I-Premise
202		_	_	I-Premise
203	7	_	_	I-Premise
204	%	_	_	I-Premise
205	,	_	_	I-Premise
206	respectively	_	_	I-Premise
207	,	_	_	I-Premise
208	while	_	_	I-Premise
209	for	_	_	I-Premise
210	patients	_	_	I-Premise
211	3-6	_	_	I-Premise
212	years	_	_	I-Premise
213	(	_	_	I-Premise
214	n	_	_	I-Premise
215	=	_	_	I-Premise
216	34	_	_	I-Premise
217	,	_	_	I-Premise
218	13.5	_	_	I-Premise
219	%	_	_	I-Premise
220	of	_	_	I-Premise
221	all	_	_	I-Premise
222	enrolled	_	_	I-Premise
223	patients	_	_	I-Premise
224	)	_	_	I-Premise
225	10-year	_	_	I-Premise
226	EFS	_	_	I-Premise
227	and	_	_	I-Premise
228	OS	_	_	I-Premise
229	were	_	_	I-Premise
230	35	_	_	I-Premise
231		_	_	I-Premise
232	8	_	_	I-Premise
233	%	_	_	I-Premise
234	and	_	_	I-Premise
235	36	_	_	I-Premise
236		_	_	I-Premise
237	8	_	_	I-Premise
238	%	_	_	I-Premise
239	,	_	_	I-Premise
240	respectively	_	_	I-Premise
241	.	_	_	I-Premise

242	Molecular	_	_	B-Premise
243	marker	_	_	I-Premise
244	analysis	_	_	I-Premise
245	showed	_	_	I-Premise
246	that	_	_	I-Premise
247	a	_	_	I-Premise
248	smaller	_	_	I-Premise
249	proportion	_	_	I-Premise
250	of	_	_	I-Premise
251	patients	_	_	I-Premise
252	<	_	_	I-Premise
253	3	_	_	I-Premise
254	years	_	_	I-Premise
255	harbored	_	_	I-Premise
256	TP53	_	_	I-Premise
257	mutations	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	=	_	_	I-Premise
261	0.05	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Analysis	_	_	B-Premise
265	of	_	_	I-Premise
266	QOL	_	_	I-Premise
267	outcomes	_	_	I-Premise
268	with	_	_	I-Premise
269	a	_	_	I-Premise
270	median	_	_	I-Premise
271	length	_	_	I-Premise
272	of	_	_	I-Premise
273	follow-up	_	_	I-Premise
274	of	_	_	I-Premise
275	15.1	_	_	I-Premise
276	years	_	_	I-Premise
277	(	_	_	I-Premise
278	9.5-19.2	_	_	I-Premise
279	)	_	_	I-Premise
280	showed	_	_	I-Premise
281	comparable	_	_	I-Premise
282	results	_	_	I-Premise
283	.	_	_	I-Premise

284	QOL	_	_	B-Claim
285	and	_	_	I-Claim
286	survival	_	_	I-Claim
287	data	_	_	I-Claim
288	were	_	_	I-Claim
289	similar	_	_	I-Claim
290	for	_	_	I-Claim
291	the	_	_	I-Claim
292	two	_	_	I-Claim
293	groups	_	_	I-Claim
294	.	_	_	I-Claim

295	A	_	_	B-Claim
296	larger	_	_	I-Claim
297	prospective	_	_	I-Claim
298	study	_	_	I-Claim
299	is	_	_	I-Claim
300	justified	_	_	I-Claim
301	to	_	_	I-Claim
302	study	_	_	I-Claim
303	the	_	_	I-Claim
304	efficacy	_	_	I-Claim
305	of	_	_	I-Claim
306	chemotherapy	_	_	I-Claim
307	only	_	_	I-Claim
308	regimens	_	_	I-Claim
309	in	_	_	I-Claim
310	younger	_	_	I-Claim
311	children	_	_	I-Claim
312	.	_	_	I-Claim


0	Debilitating	_	_	B-Claim
1	hot	_	_	I-Claim
2	flushes	_	_	I-Claim
3	and	_	_	I-Claim
4	sleep	_	_	I-Claim
5	dysfunction	_	_	I-Claim
6	often	_	_	I-Claim
7	affect	_	_	I-Claim
8	survivors	_	_	I-Claim
9	of	_	_	I-Claim
10	breast	_	_	I-Claim
11	cancer	_	_	I-Claim
12	,	_	_	I-Claim
13	most	_	_	I-Claim
14	notably	_	_	I-Claim
15	in	_	_	I-Claim
16	those	_	_	I-Claim
17	taking	_	_	I-Claim
18	anti-oestrogen	_	_	I-Claim
19	medications	_	_	I-Claim
20	.	_	_	I-Claim

21	Conventional	_	_	B-Claim
22	treatments	_	_	I-Claim
23	have	_	_	I-Claim
24	been	_	_	I-Claim
25	only	_	_	I-Claim
26	partially	_	_	I-Claim
27	effective	_	_	I-Claim
28	in	_	_	I-Claim
29	diminishing	_	_	I-Claim
30	these	_	_	I-Claim
31	issues	_	_	I-Claim
32	,	_	_	I-Claim
33	and	_	_	I-Claim
34	some	_	_	I-Claim
35	have	_	_	I-Claim
36	serious	_	_	I-Claim
37	risks	_	_	I-Claim
38	.	_	_	I-Claim

39	We	_	_	O
40	did	_	_	O
41	a	_	_	O
42	pilot	_	_	O
43	study	_	_	O
44	to	_	_	O
45	investigate	_	_	O
46	our	_	_	O
47	hypothesis	_	_	O
48	that	_	_	O
49	stellate-ganglion	_	_	O
50	block	_	_	O
51	can	_	_	O
52	be	_	_	O
53	a	_	_	O
54	safe	_	_	O
55	and	_	_	O
56	effective	_	_	O
57	treatment	_	_	O
58	for	_	_	O
59	hot	_	_	O
60	flushes	_	_	O
61	and	_	_	O
62	sleep	_	_	O
63	dysfunction	_	_	O
64	in	_	_	O
65	this	_	_	O
66	patient	_	_	O
67	population	_	_	O
68	.	_	_	O

69	13	_	_	O
70	survivors	_	_	O
71	of	_	_	O
72	breast	_	_	O
73	cancer	_	_	O
74	(	_	_	O
75	in	_	_	O
76	remission	_	_	O
77	)	_	_	O
78	with	_	_	O
79	severe	_	_	O
80	hot	_	_	O
81	flushes	_	_	O
82	and	_	_	O
83	night	_	_	O
84	awakenings	_	_	O
85	were	_	_	O
86	treated	_	_	O
87	with	_	_	O
88	stellate-ganglion	_	_	O
89	block	_	_	O
90	at	_	_	O
91	the	_	_	O
92	anterolateral	_	_	O
93	aspect	_	_	O
94	of	_	_	O
95	the	_	_	O
96	C6	_	_	O
97	vertebra	_	_	O
98	on	_	_	O
99	the	_	_	O
100	right	_	_	O
101	side	_	_	O
102	under	_	_	O
103	fluoroscopy	_	_	O
104	.	_	_	O

105	Patients	_	_	O
106	recorded	_	_	O
107	hot	_	_	O
108	flushes	_	_	O
109	in	_	_	O
110	a	_	_	O
111	daily	_	_	O
112	diary	_	_	O
113	by	_	_	O
114	use	_	_	O
115	of	_	_	O
116	the	_	_	O
117	Hot-Flash	_	_	O
118	Score	_	_	O
119	,	_	_	O
120	devised	_	_	O
121	by	_	_	O
122	Sloan	_	_	O
123	and	_	_	O
124	colleagues	_	_	O
125	,	_	_	O
126	and	_	_	O
127	night	_	_	O
128	awakenings	_	_	O
129	by	_	_	O
130	use	_	_	O
131	of	_	_	O
132	the	_	_	O
133	Pittsburgh	_	_	O
134	Sleep	_	_	O
135	Quality	_	_	O
136	Index	_	_	O
137	.	_	_	O

138	Both	_	_	O
139	instruments	_	_	O
140	were	_	_	O
141	used	_	_	O
142	1	_	_	O
143	week	_	_	O
144	before	_	_	O
145	the	_	_	O
146	procedure	_	_	O
147	[	_	_	O
148	A40	_	_	O
149	]	_	_	O
150	and	_	_	O
151	then	_	_	O
152	weekly	_	_	O
153	after	_	_	O
154	the	_	_	O
155	procedure	_	_	O
156	for	_	_	O
157	12	_	_	O
158	weeks	_	_	O
159	.	_	_	O

160	We	_	_	O
161	used	_	_	O
162	the	_	_	O
163	generalised-estimating-equations	_	_	O
164	method	_	_	O
165	to	_	_	O
166	analyse	_	_	O
167	the	_	_	O
168	longitudinal	_	_	O
169	measurements	_	_	O
170	of	_	_	O
171	the	_	_	O
172	number	_	_	O
173	of	_	_	O
174	hot	_	_	O
175	flushes	_	_	O
176	and	_	_	O
177	night	_	_	O
178	awakenings	_	_	O
179	over	_	_	O
180	time	_	_	O
181	.	_	_	O

182	This	_	_	O
183	method	_	_	O
184	is	_	_	O
185	a	_	_	O
186	popular	_	_	O
187	approach	_	_	O
188	to	_	_	O
189	analysing	_	_	O
190	datasets	_	_	O
191	that	_	_	O
192	have	_	_	O
193	repeated	_	_	O
194	measures	_	_	O
195	from	_	_	O
196	the	_	_	O
197	same	_	_	O
198	person	_	_	O
199	,	_	_	O
200	and	_	_	O
201	is	_	_	O
202	robust	_	_	O
203	because	_	_	O
204	it	_	_	O
205	does	_	_	O
206	not	_	_	O
207	need	_	_	O
208	the	_	_	O
209	complete	_	_	O
210	distribution	_	_	O
211	of	_	_	O
212	the	_	_	O
213	outcomes	_	_	O
214	to	_	_	O
215	be	_	_	O
216	specified	_	_	O
217	.	_	_	O

218	This	_	_	O
219	trial	_	_	O
220	is	_	_	O
221	registered	_	_	O
222	on	_	_	O
223	the	_	_	O
224	International	_	_	O
225	Standard	_	_	O
226	Randomised	_	_	O
227	Controlled	_	_	O
228	Trial	_	_	O
229	Number	_	_	O
230	register	_	_	O
231	(	_	_	O
232	ISRCTN14318565	_	_	O
233	)	_	_	O
234	.	_	_	O

235	There	_	_	O
236	were	_	_	O
237	no	_	_	O
238	adverse	_	_	O
239	events	_	_	O
240	resulting	_	_	O
241	from	_	_	O
242	the	_	_	O
243	stellate-ganglion	_	_	O
244	block	_	_	O
245	,	_	_	O
246	although	_	_	O
247	patients	_	_	O
248	had	_	_	O
249	temporary	_	_	O
250	Horner	_	_	O
251	's	_	_	O
252	syndrome	_	_	O
253	indicating	_	_	O
254	the	_	_	O
255	effectiveness	_	_	O
256	of	_	_	O
257	the	_	_	O
258	block	_	_	O
259	.	_	_	O

260	Five	_	_	O
261	patients	_	_	O
262	had	_	_	O
263	only	_	_	O
264	one	_	_	O
265	stellate-ganglion	_	_	O
266	block	_	_	O
267	and	_	_	O
268	eight	_	_	O
269	had	_	_	O
270	two	_	_	O
271	stellate-ganglion	_	_	O
272	blocks	_	_	O
273	.	_	_	O

274	The	_	_	B-Premise
275	total	_	_	I-Premise
276	number	_	_	I-Premise
277	of	_	_	I-Premise
278	hot	_	_	I-Premise
279	flushes	_	_	I-Premise
280	decreased	_	_	I-Premise
281	from	_	_	I-Premise
282	a	_	_	I-Premise
283	mean	_	_	I-Premise
284	of	_	_	I-Premise
285	79.4	_	_	I-Premise
286	(	_	_	I-Premise
287	SD	_	_	I-Premise
288	37.4	_	_	I-Premise
289	)	_	_	I-Premise
290	per	_	_	I-Premise
291	week	_	_	I-Premise
292	before	_	_	I-Premise
293	the	_	_	I-Premise
294	procedure	_	_	I-Premise
295	to	_	_	I-Premise
296	a	_	_	I-Premise
297	mean	_	_	I-Premise
298	of	_	_	I-Premise
299	49.9	_	_	I-Premise
300	(	_	_	I-Premise
301	SD	_	_	I-Premise
302	39.9	_	_	I-Premise
303	)	_	_	I-Premise
304	per	_	_	I-Premise
305	week	_	_	I-Premise
306	during	_	_	I-Premise
307	the	_	_	I-Premise
308	first	_	_	I-Premise
309	2	_	_	I-Premise
310	weeks	_	_	I-Premise
311	after	_	_	I-Premise
312	the	_	_	I-Premise
313	procedure	_	_	I-Premise
314	(	_	_	I-Premise
315	p=0.0002	_	_	I-Premise
316	)	_	_	I-Premise
317	.	_	_	I-Premise

318	The	_	_	B-Premise
319	total	_	_	I-Premise
320	number	_	_	I-Premise
321	of	_	_	I-Premise
322	hot	_	_	I-Premise
323	flushes	_	_	I-Premise
324	continued	_	_	I-Premise
325	to	_	_	I-Premise
326	decrease	_	_	I-Premise
327	over	_	_	I-Premise
328	the	_	_	I-Premise
329	remaining	_	_	I-Premise
330	follow-up	_	_	I-Premise
331	period	_	_	I-Premise
332	(	_	_	I-Premise
333	weeks	_	_	I-Premise
334	3-12	_	_	I-Premise
335	)	_	_	I-Premise
336	,	_	_	I-Premise
337	and	_	_	I-Premise
338	stabilised	_	_	I-Premise
339	at	_	_	I-Premise
340	a	_	_	I-Premise
341	mean	_	_	I-Premise
342	of	_	_	I-Premise
343	8.1	_	_	I-Premise
344	(	_	_	I-Premise
345	SD	_	_	I-Premise
346	5.6	_	_	I-Premise
347	)	_	_	I-Premise
348	per	_	_	I-Premise
349	week	_	_	I-Premise
350	(	_	_	I-Premise
351	p	_	_	I-Premise
352	<	_	_	I-Premise
353	0.0001	_	_	I-Premise
354	)	_	_	I-Premise
355	.	_	_	I-Premise

356	The	_	_	B-Premise
357	number	_	_	I-Premise
358	of	_	_	I-Premise
359	very	_	_	I-Premise
360	severe	_	_	I-Premise
361	hot	_	_	I-Premise
362	flushes	_	_	I-Premise
363	was	_	_	I-Premise
364	decreased	_	_	I-Premise
365	to	_	_	I-Premise
366	near	_	_	I-Premise
367	zero	_	_	I-Premise
368	by	_	_	I-Premise
369	the	_	_	I-Premise
370	end	_	_	I-Premise
371	of	_	_	I-Premise
372	the	_	_	I-Premise
373	follow-up	_	_	I-Premise
374	period	_	_	I-Premise
375	(	_	_	I-Premise
376	week	_	_	I-Premise
377	12	_	_	I-Premise
378	;	_	_	I-Premise
379	p	_	_	I-Premise
380	<	_	_	I-Premise
381	0.0001	_	_	I-Premise
382	)	_	_	I-Premise
383	.	_	_	I-Premise

384	Night	_	_	B-Premise
385	awakenings	_	_	I-Premise
386	decreased	_	_	I-Premise
387	from	_	_	I-Premise
388	a	_	_	I-Premise
389	mean	_	_	I-Premise
390	of	_	_	I-Premise
391	19.5	_	_	I-Premise
392	(	_	_	I-Premise
393	SD	_	_	I-Premise
394	14.8	_	_	I-Premise
395	)	_	_	I-Premise
396	per	_	_	I-Premise
397	week	_	_	I-Premise
398	before	_	_	I-Premise
399	the	_	_	I-Premise
400	procedure	_	_	I-Premise
401	to	_	_	I-Premise
402	a	_	_	I-Premise
403	mean	_	_	I-Premise
404	of	_	_	I-Premise
405	7.3	_	_	I-Premise
406	(	_	_	I-Premise
407	SD	_	_	I-Premise
408	7.1	_	_	I-Premise
409	)	_	_	I-Premise
410	per	_	_	I-Premise
411	week	_	_	I-Premise
412	during	_	_	I-Premise
413	the	_	_	I-Premise
414	first	_	_	I-Premise
415	2	_	_	I-Premise
416	weeks	_	_	I-Premise
417	after	_	_	I-Premise
418	the	_	_	I-Premise
419	procedure	_	_	I-Premise
420	(	_	_	I-Premise
421	p	_	_	I-Premise
422	<	_	_	I-Premise
423	0.0001	_	_	I-Premise
424	)	_	_	I-Premise
425	.	_	_	I-Premise

426	The	_	_	B-Premise
427	total	_	_	I-Premise
428	number	_	_	I-Premise
429	of	_	_	I-Premise
430	night	_	_	I-Premise
431	awakenings	_	_	I-Premise
432	continued	_	_	I-Premise
433	to	_	_	I-Premise
434	decrease	_	_	I-Premise
435	over	_	_	I-Premise
436	the	_	_	I-Premise
437	remaining	_	_	I-Premise
438	follow-up	_	_	I-Premise
439	period	_	_	I-Premise
440	(	_	_	I-Premise
441	weeks	_	_	I-Premise
442	3-12	_	_	I-Premise
443	)	_	_	I-Premise
444	and	_	_	I-Premise
445	stabilised	_	_	I-Premise
446	at	_	_	I-Premise
447	a	_	_	I-Premise
448	mean	_	_	I-Premise
449	of	_	_	I-Premise
450	1.4	_	_	I-Premise
451	(	_	_	I-Premise
452	SD	_	_	I-Premise
453	1.2	_	_	I-Premise
454	)	_	_	I-Premise
455	per	_	_	I-Premise
456	week	_	_	I-Premise
457	(	_	_	I-Premise
458	p	_	_	I-Premise
459	<	_	_	I-Premise
460	0.0001	_	_	I-Premise
461	)	_	_	I-Premise
462	.	_	_	I-Premise

463	The	_	_	B-Claim
464	findings	_	_	I-Claim
465	of	_	_	I-Claim
466	this	_	_	I-Claim
467	study	_	_	I-Claim
468	suggest	_	_	I-Claim
469	that	_	_	I-Claim
470	stellate-ganglion	_	_	I-Claim
471	block	_	_	I-Claim
472	can	_	_	I-Claim
473	provide	_	_	I-Claim
474	survivors	_	_	I-Claim
475	of	_	_	I-Claim
476	breast	_	_	I-Claim
477	cancer	_	_	I-Claim
478	with	_	_	I-Claim
479	relief	_	_	I-Claim
480	from	_	_	I-Claim
481	hot	_	_	I-Claim
482	flushes	_	_	I-Claim
483	and	_	_	I-Claim
484	sleep	_	_	I-Claim
485	dysfunction	_	_	I-Claim
486	with	_	_	I-Claim
487	few	_	_	I-Claim
488	or	_	_	I-Claim
489	no	_	_	I-Claim
490	side-effects	_	_	I-Claim
491	.	_	_	I-Claim

492	Long-term	_	_	B-Claim
493	relief	_	_	I-Claim
494	of	_	_	I-Claim
495	symptoms	_	_	I-Claim
496	has	_	_	I-Claim
497	the	_	_	I-Claim
498	potential	_	_	I-Claim
499	to	_	_	I-Claim
500	improve	_	_	I-Claim
501	overall	_	_	I-Claim
502	quality	_	_	I-Claim
503	of	_	_	I-Claim
504	life	_	_	I-Claim
505	and	_	_	I-Claim
506	increase	_	_	I-Claim
507	compliance	_	_	I-Claim
508	with	_	_	I-Claim
509	anti-oestrogen	_	_	I-Claim
510	medications	_	_	I-Claim
511	for	_	_	I-Claim
512	breast	_	_	I-Claim
513	cancer	_	_	I-Claim
514	.	_	_	I-Claim


0	One	_	_	O
1	attempt	_	_	O
2	to	_	_	O
3	improve	_	_	O
4	long-term	_	_	O
5	survival	_	_	O
6	in	_	_	O
7	patients	_	_	O
8	with	_	_	O
9	advanced	_	_	O
10	ovarian	_	_	O
11	cancer	_	_	O
12	was	_	_	O
13	thought	_	_	O
14	to	_	_	O
15	be	_	_	O
16	the	_	_	O
17	addition	_	_	O
18	of	_	_	O
19	more	_	_	O
20	non-cross-resistant	_	_	O
21	drugs	_	_	O
22	to	_	_	O
23	platinum-paclitaxel	_	_	O
24	combination	_	_	O
25	regimens	_	_	O
26	.	_	_	O

27	Gemcitabine	_	_	O
28	was	_	_	O
29	among	_	_	O
30	the	_	_	O
31	candidates	_	_	O
32	for	_	_	O
33	a	_	_	O
34	third	_	_	O
35	drug	_	_	O
36	.	_	_	O

37	We	_	_	O
38	performed	_	_	O
39	a	_	_	O
40	prospective	_	_	O
41	,	_	_	O
42	randomized	_	_	O
43	,	_	_	O
44	phase	_	_	O
45	III	_	_	O
46	,	_	_	O
47	intergroup	_	_	O
48	trial	_	_	O
49	to	_	_	O
50	compare	_	_	O
51	carboplatin	_	_	O
52	plus	_	_	O
53	paclitaxel	_	_	O
54	(	_	_	O
55	TC	_	_	O
56	;	_	_	O
57	area	_	_	O
58	under	_	_	O
59	the	_	_	O
60	curve	_	_	O
61	[	_	_	O
62	AUC	_	_	O
63	]	_	_	O
64	5	_	_	O
65	and	_	_	O
66	175	_	_	O
67	mg/m	_	_	O
68	(	_	_	O
69	2	_	_	O
70	)	_	_	O
71	,	_	_	O
72	respectively	_	_	O
73	)	_	_	O
74	with	_	_	O
75	the	_	_	O
76	same	_	_	O
77	combination	_	_	O
78	and	_	_	O
79	additional	_	_	O
80	gemcitabine	_	_	O
81	800	_	_	O
82	mg/m	_	_	O
83	(	_	_	O
84	2	_	_	O
85	)	_	_	O
86	on	_	_	O
87	days	_	_	O
88	1	_	_	O
89	and	_	_	O
90	8	_	_	O
91	(	_	_	O
92	TCG	_	_	O
93	)	_	_	O
94	in	_	_	O
95	previously	_	_	O
96	untreated	_	_	O
97	patients	_	_	O
98	with	_	_	O
99	advanced	_	_	O
100	epithelial	_	_	O
101	ovarian	_	_	O
102	cancer	_	_	O
103	.	_	_	O

104	TC	_	_	O
105	was	_	_	O
106	administered	_	_	O
107	intravenously	_	_	O
108	(	_	_	O
109	IV	_	_	O
110	)	_	_	O
111	on	_	_	O
112	day	_	_	O
113	1	_	_	O
114	every	_	_	O
115	21	_	_	O
116	days	_	_	O
117	for	_	_	O
118	a	_	_	O
119	planned	_	_	O
120	minimum	_	_	O
121	of	_	_	O
122	six	_	_	O
123	courses	_	_	O
124	.	_	_	O

125	Gemcitabine	_	_	O
126	was	_	_	O
127	administered	_	_	O
128	by	_	_	O
129	IV	_	_	O
130	on	_	_	O
131	days	_	_	O
132	1	_	_	O
133	and	_	_	O
134	8	_	_	O
135	of	_	_	O
136	each	_	_	O
137	cycle	_	_	O
138	in	_	_	O
139	the	_	_	O
140	TCG	_	_	O
141	arm	_	_	O
142	.	_	_	O

143	Between	_	_	O
144	2002	_	_	O
145	and	_	_	O
146	2004	_	_	O
147	,	_	_	O
148	1,742	_	_	O
149	patients	_	_	O
150	were	_	_	O
151	randomly	_	_	O
152	assigned	_	_	O
153	;	_	_	O
154	882	_	_	O
155	and	_	_	O
156	860	_	_	O
157	patients	_	_	O
158	received	_	_	O
159	TC	_	_	O
160	and	_	_	O
161	TCG	_	_	O
162	,	_	_	O
163	respectively	_	_	O
164	.	_	_	O

165	Grades	_	_	B-Premise
166	3	_	_	I-Premise
167	to	_	_	I-Premise
168	4	_	_	I-Premise
169	hematologic	_	_	I-Premise
170	toxicity	_	_	I-Premise
171	and	_	_	I-Premise
172	fatigue	_	_	I-Premise
173	occurred	_	_	I-Premise
174	more	_	_	I-Premise
175	frequently	_	_	I-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	TCG	_	_	I-Premise
179	arm	_	_	I-Premise
180	.	_	_	I-Premise

181	Accordingly	_	_	O
182	,	_	_	O
183	quality-of-life	_	_	B-Claim
184	analysis	_	_	I-Claim
185	during	_	_	I-Claim
186	chemotherapy	_	_	I-Claim
187	showed	_	_	I-Claim
188	a	_	_	I-Claim
189	disadvantage	_	_	I-Claim
190	in	_	_	I-Claim
191	the	_	_	I-Claim
192	TCG	_	_	I-Claim
193	arm	_	_	I-Claim
194	.	_	_	I-Claim

195	Although	_	_	B-Premise
196	objective	_	_	I-Premise
197	response	_	_	I-Premise
198	was	_	_	I-Premise
199	slightly	_	_	I-Premise
200	higher	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	TCG	_	_	I-Premise
204	arm	_	_	I-Premise
205	,	_	_	I-Premise
206	this	_	_	B-Premise
207	did	_	_	I-Premise
208	not	_	_	I-Premise
209	translate	_	_	I-Premise
210	into	_	_	I-Premise
211	improved	_	_	I-Premise
212	progression-free	_	_	I-Premise
213	survival	_	_	I-Premise
214	(	_	_	I-Premise
215	PFS	_	_	I-Premise
216	)	_	_	I-Premise
217	or	_	_	I-Premise
218	overall	_	_	I-Premise
219	survival	_	_	I-Premise
220	(	_	_	I-Premise
221	OS	_	_	I-Premise
222	)	_	_	I-Premise
223	.	_	_	I-Premise

224	Median	_	_	B-Premise
225	PFS	_	_	I-Premise
226	was	_	_	I-Premise
227	17.8	_	_	I-Premise
228	months	_	_	I-Premise
229	for	_	_	I-Premise
230	the	_	_	I-Premise
231	TCG	_	_	I-Premise
232	arm	_	_	I-Premise
233	and	_	_	I-Premise
234	19.3	_	_	I-Premise
235	months	_	_	I-Premise
236	for	_	_	I-Premise
237	the	_	_	I-Premise
238	TC	_	_	I-Premise
239	arm	_	_	I-Premise
240	(	_	_	I-Premise
241	hazard	_	_	I-Premise
242	ratio	_	_	I-Premise
243	[	_	_	I-Premise
244	HR	_	_	I-Premise
245	]	_	_	I-Premise
246	,	_	_	I-Premise
247	1.18	_	_	I-Premise
248	;	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	,	_	_	I-Premise
253	1.06	_	_	I-Premise
254	to	_	_	I-Premise
255	1.32	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=	_	_	I-Premise
259	.0044	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Median	_	_	B-Premise
263	OS	_	_	I-Premise
264	was	_	_	I-Premise
265	49.5	_	_	I-Premise
266	for	_	_	I-Premise
267	the	_	_	I-Premise
268	TCG	_	_	I-Premise
269	arm	_	_	I-Premise
270	and	_	_	I-Premise
271	51.5	_	_	I-Premise
272	months	_	_	I-Premise
273	for	_	_	I-Premise
274	the	_	_	I-Premise
275	TC	_	_	I-Premise
276	arm	_	_	I-Premise
277	(	_	_	I-Premise
278	HR	_	_	I-Premise
279	,	_	_	I-Premise
280	1.05	_	_	I-Premise
281	;	_	_	I-Premise
282	95	_	_	I-Premise
283	%	_	_	I-Premise
284	CI	_	_	I-Premise
285	,	_	_	I-Premise
286	0.91	_	_	I-Premise
287	to	_	_	I-Premise
288	1.20	_	_	I-Premise
289	;	_	_	I-Premise
290	P	_	_	I-Premise
291	=	_	_	I-Premise
292	.5106	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Claim
296	addition	_	_	I-Claim
297	of	_	_	I-Claim
298	gemcitabine	_	_	I-Claim
299	to	_	_	I-Claim
300	carboplatin	_	_	I-Claim
301	plus	_	_	I-Claim
302	paclitaxel	_	_	I-Claim
303	increased	_	_	I-Claim
304	treatment	_	_	I-Claim
305	burden	_	_	I-Claim
306	,	_	_	I-Claim
307	reduced	_	_	I-Claim
308	PFS	_	_	I-Claim
309	time	_	_	I-Claim
310	,	_	_	I-Claim
311	and	_	_	I-Claim
312	did	_	_	I-Claim
313	not	_	_	I-Claim
314	improve	_	_	I-Claim
315	OS	_	_	I-Claim
316	in	_	_	I-Claim
317	patients	_	_	I-Claim
318	with	_	_	I-Claim
319	advanced	_	_	I-Claim
320	epithelial	_	_	I-Claim
321	ovarian	_	_	I-Claim
322	cancer	_	_	I-Claim
323	.	_	_	I-Claim

324	Therefore	_	_	B-Claim
325	,	_	_	I-Claim
326	we	_	_	I-Claim
327	recommend	_	_	I-Claim
328	no	_	_	I-Claim
329	additional	_	_	I-Claim
330	clinical	_	_	I-Claim
331	use	_	_	I-Claim
332	of	_	_	I-Claim
333	TCG	_	_	I-Claim
334	in	_	_	I-Claim
335	this	_	_	I-Claim
336	population	_	_	I-Claim
337	.	_	_	I-Claim


0	The	_	_	O
1	CO.20	_	_	O
2	trial	_	_	O
3	randomized	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	K-RAS	_	_	O
7	wild-type	_	_	O
8	,	_	_	O
9	chemotherapy-refractory	_	_	O
10	,	_	_	O
11	metastatic	_	_	O
12	colorectal	_	_	O
13	cancer	_	_	O
14	to	_	_	O
15	receive	_	_	O
16	cetuximab	_	_	O
17	(	_	_	O
18	CET	_	_	O
19	)	_	_	O
20	plus	_	_	O
21	brivanib	_	_	O
22	alaninate	_	_	O
23	(	_	_	O
24	BRIV	_	_	O
25	)	_	_	O
26	or	_	_	O
27	CET	_	_	O
28	plus	_	_	O
29	placebo	_	_	O
30	(	_	_	O
31	CET/placebo	_	_	O
32	)	_	_	O
33	.	_	_	O

34	Quality	_	_	O
35	of	_	_	O
36	life	_	_	O
37	(	_	_	O
38	QoL	_	_	O
39	)	_	_	O
40	was	_	_	O
41	assessed	_	_	O
42	using	_	_	O
43	the	_	_	O
44	European	_	_	O
45	Organization	_	_	O
46	for	_	_	O
47	Research	_	_	O
48	and	_	_	O
49	Treatment	_	_	O
50	of	_	_	O
51	Cancer	_	_	O
52	Quality	_	_	O
53	of	_	_	O
54	Life	_	_	O
55	Questionnaire	_	_	O
56	C30	_	_	O
57	at	_	_	O
58	baseline	_	_	O
59	and	_	_	O
60	at	_	_	O
61	2	_	_	O
62	,	_	_	O
63	4	_	_	O
64	,	_	_	O
65	6	_	_	O
66	,	_	_	O
67	8	_	_	O
68	,	_	_	O
69	12	_	_	O
70	,	_	_	O
71	16	_	_	O
72	,	_	_	O
73	and	_	_	O
74	24	_	_	O
75	weeks	_	_	O
76	until	_	_	O
77	disease	_	_	O
78	progression	_	_	O
79	.	_	_	O

80	Predefined	_	_	O
81	coprimary	_	_	O
82	QoL	_	_	O
83	endpoints	_	_	O
84	were	_	_	O
85	time	_	_	O
86	to	_	_	O
87	deterioration	_	_	O
88	(	_	_	O
89	first	_	_	O
90	worsening	_	_	O
91	from	_	_	O
92	baseline	_	_	O
93	of	_	_	O
94		_	_	O
95	10	_	_	O
96	points	_	_	O
97	)	_	_	O
98	on	_	_	O
99	the	_	_	O
100	Physical	_	_	O
101	Function	_	_	O
102	(	_	_	O
103	PF	_	_	O
104	)	_	_	O
105	and	_	_	O
106	Global	_	_	O
107	(	_	_	O
108	GHS	_	_	O
109	)	_	_	O
110	scales	_	_	O
111	.	_	_	O

112	Of	_	_	O
113	750	_	_	O
114	randomized	_	_	O
115	patients	_	_	O
116	,	_	_	O
117	721	_	_	O
118	(	_	_	O
119	358	_	_	O
120	of	_	_	O
121	whom	_	_	O
122	received	_	_	O
123	CET/BRIV	_	_	O
124	)	_	_	O
125	were	_	_	O
126	assessable	_	_	O
127	for	_	_	O
128	QoL	_	_	O
129	.	_	_	O

130	QoL	_	_	O
131	compliance	_	_	O
132	and	_	_	O
133	baseline	_	_	O
134	PF	_	_	O
135	and	_	_	O
136	GHS	_	_	O
137	scores	_	_	O
138	did	_	_	O
139	not	_	_	O
140	differ	_	_	O
141	by	_	_	O
142	treatment	_	_	O
143	arm	_	_	O
144	.	_	_	O

145	The	_	_	B-Premise
146	median	_	_	I-Premise
147	time	_	_	I-Premise
148	to	_	_	I-Premise
149	deterioration	_	_	I-Premise
150	was	_	_	I-Premise
151	1.6	_	_	I-Premise
152	months	_	_	I-Premise
153	versus	_	_	I-Premise
154	1.1	_	_	I-Premise
155	months	_	_	I-Premise
156	for	_	_	I-Premise
157	GHS	_	_	I-Premise
158	(	_	_	I-Premise
159	P	_	_	I-Premise
160	=.02	_	_	I-Premise
161	)	_	_	I-Premise
162	and	_	_	I-Premise
163	5.6	_	_	I-Premise
164	months	_	_	I-Premise
165	versus	_	_	I-Premise
166	1.7	_	_	I-Premise
167	months	_	_	I-Premise
168	for	_	_	I-Premise
169	PF	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	<	_	_	I-Premise
173	.0001	_	_	I-Premise
174	)	_	_	I-Premise
175	favoring	_	_	I-Premise
176	CET/placebo	_	_	I-Premise
177	.	_	_	I-Premise

178	Secondary	_	_	B-Premise
179	analysis	_	_	I-Premise
180	favored	_	_	I-Premise
181	CET/placebo	_	_	I-Premise
182	for	_	_	I-Premise
183	QOL	_	_	I-Premise
184	response	_	_	I-Premise
185	on	_	_	I-Premise
186	the	_	_	I-Premise
187	PF	_	_	I-Premise
188	,	_	_	I-Premise
189	Cognitive	_	_	I-Premise
190	Function	_	_	I-Premise
191	,	_	_	I-Premise
192	Fatigue	_	_	I-Premise
193	,	_	_	I-Premise
194	Nausea	_	_	I-Premise
195	,	_	_	I-Premise
196	Appetite	_	_	I-Premise
197	,	_	_	I-Premise
198	and	_	_	I-Premise
199	Diarrhea	_	_	I-Premise
200	scales	_	_	I-Premise
201	.	_	_	I-Premise

202	A	_	_	B-Premise
203	greater	_	_	I-Premise
204	percentage	_	_	I-Premise
205	of	_	_	I-Premise
206	patients	_	_	I-Premise
207	on	_	_	I-Premise
208	the	_	_	I-Premise
209	CET/BRIV	_	_	I-Premise
210	arm	_	_	I-Premise
211	had	_	_	I-Premise
212	PF	_	_	I-Premise
213	worsening	_	_	I-Premise
214	at	_	_	I-Premise
215	6	_	_	I-Premise
216	weeks	_	_	I-Premise
217	(	_	_	I-Premise
218	31	_	_	I-Premise
219	%	_	_	I-Premise
220	vs	_	_	I-Premise
221	17	_	_	I-Premise
222	%	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Clinical	_	_	B-Premise
226	adverse	_	_	I-Premise
227	events	_	_	I-Premise
228	of	_	_	I-Premise
229		_	_	I-Premise
230	grade	_	_	I-Premise
231	3	_	_	I-Premise
232	were	_	_	I-Premise
233	more	_	_	I-Premise
234	common	_	_	I-Premise
235	with	_	_	I-Premise
236	CET/BRIV	_	_	I-Premise
237	than	_	_	I-Premise
238	with	_	_	I-Premise
239	CET/placebo	_	_	I-Premise
240	,	_	_	I-Premise
241	including	_	_	I-Premise
242	fatigue	_	_	I-Premise
243	(	_	_	I-Premise
244	25	_	_	I-Premise
245	%	_	_	I-Premise
246	vs	_	_	I-Premise
247	11	_	_	I-Premise
248	%	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	hypertension	_	_	I-Premise
252	,	_	_	I-Premise
253	rash	_	_	I-Premise
254	,	_	_	I-Premise
255	diarrhea	_	_	I-Premise
256	,	_	_	I-Premise
257	abdominal	_	_	I-Premise
258	pain	_	_	I-Premise
259	,	_	_	I-Premise
260	dehydration	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	anorexia	_	_	I-Premise
264	.	_	_	I-Premise

265	Compared	_	_	B-Claim
266	with	_	_	I-Claim
267	CET/placebo	_	_	I-Claim
268	,	_	_	I-Claim
269	the	_	_	I-Claim
270	combination	_	_	I-Claim
271	of	_	_	I-Claim
272	CET/BRIV	_	_	I-Claim
273	worsened	_	_	I-Claim
274	time	_	_	I-Claim
275	to	_	_	I-Claim
276	QoL	_	_	I-Claim
277	deterioration	_	_	I-Claim
278	for	_	_	I-Claim
279	patients	_	_	I-Claim
280	with	_	_	I-Claim
281	K-RAS	_	_	I-Claim
282	wild-type	_	_	I-Claim
283	,	_	_	I-Claim
284	chemotherapy-refractory	_	_	I-Claim
285	,	_	_	I-Claim
286	metastatic	_	_	I-Claim
287	colorectal	_	_	I-Claim
288	cancer	_	_	I-Claim
289	on	_	_	I-Claim
290	the	_	_	I-Claim
291	PF	_	_	I-Claim
292	and	_	_	I-Claim
293	GHS	_	_	I-Claim
294	scales	_	_	I-Claim
295	of	_	_	I-Claim
296	European	_	_	I-Claim
297	Organization	_	_	I-Claim
298	for	_	_	I-Claim
299	Research	_	_	I-Claim
300	and	_	_	I-Claim
301	Treatment	_	_	I-Claim
302	of	_	_	I-Claim
303	Cancer	_	_	I-Claim
304	Quality	_	_	I-Claim
305	of	_	_	I-Claim
306	Life	_	_	I-Claim
307	Questionnaire	_	_	I-Claim
308	C30	_	_	I-Claim
309	.	_	_	I-Claim

310	This	_	_	B-Claim
311	result	_	_	I-Claim
312	may	_	_	I-Claim
313	be	_	_	I-Claim
314	due	_	_	I-Claim
315	to	_	_	I-Claim
316	higher	_	_	I-Claim
317	rates	_	_	I-Claim
318	of	_	_	I-Claim
319	fatigue	_	_	I-Claim
320	and	_	_	I-Claim
321	gastrointestinal	_	_	I-Claim
322	adverse	_	_	I-Claim
323	events	_	_	I-Claim
324	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	sought	_	_	O
3	to	_	_	O
4	continue	_	_	O
5	research	_	_	O
6	on	_	_	O
7	psychosocial	_	_	O
8	interventions	_	_	O
9	for	_	_	O
10	patients	_	_	O
11	being	_	_	O
12	treated	_	_	O
13	with	_	_	O
14	radiation	_	_	O
15	therapy	_	_	O
16	across	_	_	O
17	multiple	_	_	O
18	centers	_	_	O
19	and	_	_	O
20	to	_	_	O
21	replicate	_	_	O
22	positive	_	_	O
23	findings	_	_	O
24	of	_	_	O
25	a	_	_	O
26	single-center	_	_	O
27	study	_	_	O
28	of	_	_	O
29	patients	_	_	O
30	being	_	_	O
31	treated	_	_	O
32	with	_	_	O
33	chemotherapy	_	_	O
34	.	_	_	O

35	The	_	_	O
36	primary	_	_	O
37	objective	_	_	O
38	of	_	_	O
39	this	_	_	O
40	study	_	_	O
41	was	_	_	O
42	to	_	_	O
43	determine	_	_	O
44	if	_	_	O
45	a	_	_	O
46	stress	_	_	O
47	management	_	_	O
48	intervention	_	_	O
49	was	_	_	O
50	effective	_	_	O
51	in	_	_	O
52	improving	_	_	O
53	quality	_	_	O
54	of	_	_	O
55	life	_	_	O
56	and	_	_	O
57	decreasing	_	_	O
58	psychological	_	_	O
59	distress	_	_	O
60	in	_	_	O
61	patients	_	_	O
62	undergoing	_	_	O
63	radiotherapy	_	_	O
64	for	_	_	O
65	cancer	_	_	O
66	.	_	_	O

67	A	_	_	O
68	total	_	_	O
69	of	_	_	O
70	310	_	_	O
71	patients	_	_	O
72	about	_	_	O
73	to	_	_	O
74	begin	_	_	O
75	radiotherapy	_	_	O
76	treatment	_	_	O
77	were	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	receive	_	_	O
82	usual	_	_	O
83	care	_	_	O
84	only	_	_	O
85	or	_	_	O
86	self-administered	_	_	O
87	stress	_	_	O
88	management	_	_	O
89	training	_	_	O
90	.	_	_	O

91	Quality-of-life	_	_	O
92	assessments	_	_	O
93	occurred	_	_	O
94	at	_	_	O
95	baseline	_	_	O
96	and	_	_	O
97	for	_	_	O
98	3	_	_	O
99	weeks	_	_	O
100	after	_	_	O
101	the	_	_	O
102	beginning	_	_	O
103	of	_	_	O
104	radiotherapy	_	_	O
105	treatment	_	_	O
106	.	_	_	O

107	Overall	_	_	B-Premise
108	,	_	_	I-Premise
109	patients	_	_	I-Premise
110	assigned	_	_	I-Premise
111	to	_	_	I-Premise
112	receive	_	_	I-Premise
113	stress	_	_	I-Premise
114	management	_	_	I-Premise
115	training	_	_	I-Premise
116	did	_	_	I-Premise
117	not	_	_	I-Premise
118	report	_	_	I-Premise
119	significantly	_	_	I-Premise
120	less	_	_	I-Premise
121	psychological	_	_	I-Premise
122	distress	_	_	I-Premise
123	on	_	_	I-Premise
124	the	_	_	I-Premise
125	Medical	_	_	I-Premise
126	Outcomes	_	_	I-Premise
127	Study	_	_	I-Premise
128	36-Item	_	_	I-Premise
129	Short	_	_	I-Premise
130	Form	_	_	I-Premise
131	(	_	_	I-Premise
132	SF-36	_	_	I-Premise
133	)	_	_	I-Premise
134	Mental	_	_	I-Premise
135	Component	_	_	I-Premise
136	Summary	_	_	I-Premise
137	Scale	_	_	I-Premise
138	than	_	_	I-Premise
139	did	_	_	I-Premise
140	those	_	_	I-Premise
141	assigned	_	_	I-Premise
142	to	_	_	I-Premise
143	usual	_	_	I-Premise
144	care	_	_	I-Premise
145	.	_	_	I-Premise

146	When	_	_	O
147	divided	_	_	O
148	into	_	_	O
149	subgroups	_	_	O
150	based	_	_	O
151	on	_	_	O
152	the	_	_	O
153	SF-36	_	_	O
154	Mental	_	_	O
155	Component	_	_	O
156	Summary	_	_	O
157	Scale	_	_	O
158	scores	_	_	O
159	immediately	_	_	O
160	after	_	_	O
161	their	_	_	O
162	first	_	_	O
163	radiotherapy	_	_	O
164	treatment	_	_	O
165	,	_	_	O
166	patients	_	_	B-Premise
167	with	_	_	I-Premise
168	above-average	_	_	I-Premise
169	levels	_	_	I-Premise
170	of	_	_	I-Premise
171	psychological	_	_	I-Premise
172	distress	_	_	I-Premise
173	(	_	_	I-Premise
174	scores	_	_	I-Premise
175	<	_	_	I-Premise
176	or	_	_	I-Premise
177	=	_	_	I-Premise
178	50	_	_	I-Premise
179	)	_	_	I-Premise
180	who	_	_	I-Premise
181	were	_	_	I-Premise
182	randomly	_	_	I-Premise
183	assigned	_	_	I-Premise
184	to	_	_	I-Premise
185	the	_	_	I-Premise
186	intervention	_	_	I-Premise
187	condition	_	_	I-Premise
188	reported	_	_	I-Premise
189	significant	_	_	I-Premise
190	improvement	_	_	I-Premise
191	in	_	_	I-Premise
192	their	_	_	I-Premise
193	distress	_	_	I-Premise
194	compared	_	_	I-Premise
195	with	_	_	I-Premise
196	those	_	_	I-Premise
197	assigned	_	_	I-Premise
198	to	_	_	I-Premise
199	usual	_	_	I-Premise
200	care	_	_	I-Premise
201	only	_	_	I-Premise
202	on	_	_	I-Premise
203	the	_	_	I-Premise
204	SF-36	_	_	I-Premise
205	Mental	_	_	I-Premise
206	Health	_	_	I-Premise
207	Subscale	_	_	I-Premise
208	and	_	_	I-Premise
209	the	_	_	I-Premise
210	Center	_	_	I-Premise
211	for	_	_	I-Premise
212	Epidemiologic	_	_	I-Premise
213	Studies	_	_	I-Premise
214	Depression	_	_	I-Premise
215	Scale	_	_	I-Premise
216	.	_	_	I-Premise

217	This	_	_	B-Claim
218	study	_	_	I-Claim
219	found	_	_	I-Claim
220	that	_	_	I-Claim
221	self-administered	_	_	I-Claim
222	stress	_	_	I-Claim
223	management	_	_	I-Claim
224	training	_	_	I-Claim
225	is	_	_	I-Claim
226	effective	_	_	I-Claim
227	only	_	_	I-Claim
228	in	_	_	I-Claim
229	those	_	_	I-Claim
230	radiotherapy	_	_	I-Claim
231	patients	_	_	I-Claim
232	with	_	_	I-Claim
233	initially	_	_	I-Claim
234	higher	_	_	I-Claim
235	levels	_	_	I-Claim
236	of	_	_	I-Claim
237	psychological	_	_	I-Claim
238	distress	_	_	I-Claim
239	.	_	_	I-Claim

240	Additional	_	_	B-Claim
241	research	_	_	I-Claim
242	should	_	_	I-Claim
243	examine	_	_	I-Claim
244	the	_	_	I-Claim
245	benefits	_	_	I-Claim
246	of	_	_	I-Claim
247	stress	_	_	I-Claim
248	management	_	_	I-Claim
249	training	_	_	I-Claim
250	targeted	_	_	I-Claim
251	specifically	_	_	I-Claim
252	to	_	_	I-Claim
253	patients	_	_	I-Claim
254	experiencing	_	_	I-Claim
255	heightened	_	_	I-Claim
256	distress	_	_	I-Claim
257	.	_	_	I-Claim


0	Both	_	_	O
1	Billroth	_	_	O
2	I	_	_	O
3	(	_	_	O
4	B-I	_	_	O
5	)	_	_	O
6	and	_	_	O
7	Roux-en-Y	_	_	O
8	(	_	_	O
9	R-Y	_	_	O
10	)	_	_	O
11	reconstructions	_	_	O
12	are	_	_	O
13	commonly	_	_	O
14	performed	_	_	O
15	as	_	_	O
16	standard	_	_	O
17	procedures	_	_	O
18	,	_	_	O
19	but	_	_	O
20	it	_	_	O
21	has	_	_	O
22	yet	_	_	O
23	to	_	_	O
24	be	_	_	O
25	determined	_	_	O
26	which	_	_	O
27	reconstruction	_	_	O
28	is	_	_	O
29	better	_	_	O
30	for	_	_	O
31	patients	_	_	O
32	.	_	_	O

33	A	_	_	O
34	randomized	_	_	O
35	prospective	_	_	O
36	phase	_	_	O
37	II	_	_	O
38	trial	_	_	O
39	with	_	_	O
40	body	_	_	O
41	weight	_	_	O
42	loss	_	_	O
43	at	_	_	O
44	1	_	_	O
45	year	_	_	O
46	after	_	_	O
47	surgery	_	_	O
48	as	_	_	O
49	a	_	_	O
50	primary	_	_	O
51	endpoint	_	_	O
52	was	_	_	O
53	performed	_	_	O
54	to	_	_	O
55	address	_	_	O
56	this	_	_	O
57	issue	_	_	O
58	.	_	_	O

59	The	_	_	O
60	current	_	_	O
61	report	_	_	O
62	delivers	_	_	O
63	data	_	_	O
64	on	_	_	O
65	the	_	_	O
66	quality	_	_	O
67	of	_	_	O
68	life	_	_	O
69	and	_	_	O
70	degree	_	_	O
71	of	_	_	O
72	postoperative	_	_	O
73	dysfunction	_	_	O
74	,	_	_	O
75	which	_	_	O
76	were	_	_	O
77	the	_	_	O
78	secondary	_	_	O
79	endpoints	_	_	O
80	of	_	_	O
81	this	_	_	O
82	study	_	_	O
83	.	_	_	O

84	Gastric	_	_	O
85	cancer	_	_	O
86	patients	_	_	O
87	who	_	_	O
88	underwent	_	_	O
89	distal	_	_	O
90	gastrectomy	_	_	O
91	were	_	_	O
92	intraoperatively	_	_	O
93	randomized	_	_	O
94	to	_	_	O
95	B-I	_	_	O
96	or	_	_	O
97	R-Y	_	_	O
98	.	_	_	O

99	Postsurgical	_	_	O
100	QOL	_	_	O
101	was	_	_	O
102	evaluated	_	_	O
103	using	_	_	O
104	the	_	_	O
105	EORTC	_	_	O
106	QLQ-C30	_	_	O
107	and	_	_	O
108	DAUGS	_	_	O
109	20	_	_	O
110	.	_	_	O

111	Between	_	_	O
112	August	_	_	O
113	2005	_	_	O
114	and	_	_	O
115	December	_	_	O
116	2008	_	_	O
117	,	_	_	O
118	332	_	_	O
119	patients	_	_	O
120	were	_	_	O
121	enrolled	_	_	O
122	in	_	_	O
123	a	_	_	O
124	randomized	_	_	O
125	trial	_	_	O
126	comparing	_	_	O
127	B-I	_	_	O
128	versus	_	_	O
129	R-Y	_	_	O
130	.	_	_	O

131	A	_	_	O
132	mail	_	_	O
133	survey	_	_	O
134	questionnaire	_	_	O
135	sent	_	_	O
136	to	_	_	O
137	327	_	_	O
138	patients	_	_	O
139	was	_	_	O
140	completed	_	_	O
141	by	_	_	O
142	268	_	_	O
143	(	_	_	O
144	86.2	_	_	O
145	%	_	_	O
146	)	_	_	O
147	of	_	_	O
148	them	_	_	O
149	.	_	_	O

150	EORTC	_	_	O
151	QLQ-C30	_	_	O
152	scores	_	_	O
153	were	_	_	O
154	as	_	_	O
155	follows	_	_	O
156	:	_	_	O
157	global	_	_	O
158	health	_	_	O
159	status	_	_	O
160	was	_	_	O
161	similar	_	_	O
162	in	_	_	O
163	each	_	_	O
164	group	_	_	O
165	(	_	_	O
166	B-I	_	_	O
167	73.5	_	_	O
168		_	_	O
169	18.8	_	_	O
170	,	_	_	O
171	R-Y	_	_	O
172	73.2	_	_	O
173		_	_	O
174	20.2	_	_	O
175	,	_	_	O
176	p	_	_	O
177	=	_	_	O
178	0.87	_	_	O
179	)	_	_	O
180	.	_	_	O

181	Scores	_	_	O
182	of	_	_	O
183	five	_	_	O
184	functional	_	_	O
185	scales	_	_	O
186	were	_	_	O
187	also	_	_	O
188	similar	_	_	O
189	.	_	_	O

190	Only	_	_	B-Premise
191	the	_	_	I-Premise
192	dyspnea	_	_	I-Premise
193	symptom	_	_	I-Premise
194	scale	_	_	I-Premise
195	showed	_	_	I-Premise
196	superior	_	_	I-Premise
197	results	_	_	I-Premise
198	for	_	_	I-Premise
199	R-Y	_	_	I-Premise
200	than	_	_	I-Premise
201	for	_	_	I-Premise
202	B-I	_	_	I-Premise
203	(	_	_	I-Premise
204	B-I	_	_	I-Premise
205	13.6	_	_	I-Premise
206		_	_	I-Premise
207	17.9	_	_	I-Premise
208	,	_	_	I-Premise
209	R-Y	_	_	I-Premise
210	8.6	_	_	I-Premise
211		_	_	I-Premise
212	16.3	_	_	I-Premise
213	,	_	_	I-Premise
214	p	_	_	I-Premise
215	=	_	_	I-Premise
216	0.02	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	With	_	_	B-Premise
220	respect	_	_	I-Premise
221	to	_	_	I-Premise
222	DAUGS	_	_	I-Premise
223	20	_	_	I-Premise
224	,	_	_	I-Premise
225	the	_	_	I-Premise
226	total	_	_	I-Premise
227	score	_	_	I-Premise
228	did	_	_	I-Premise
229	not	_	_	I-Premise
230	differ	_	_	I-Premise
231	significantly	_	_	I-Premise
232	between	_	_	I-Premise
233	the	_	_	I-Premise
234	R-Y	_	_	I-Premise
235	and	_	_	I-Premise
236	B-I	_	_	I-Premise
237	groups	_	_	I-Premise
238	(	_	_	I-Premise
239	24.8	_	_	I-Premise
240	vs.	_	_	I-Premise
241	23.6	_	_	I-Premise
242	,	_	_	I-Premise
243	p	_	_	I-Premise
244	=	_	_	I-Premise
245	0.41	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Only	_	_	B-Premise
249	reflux	_	_	I-Premise
250	symptoms	_	_	I-Premise
251	were	_	_	I-Premise
252	significantly	_	_	I-Premise
253	worse	_	_	I-Premise
254	for	_	_	I-Premise
255	B-I	_	_	I-Premise
256	than	_	_	I-Premise
257	for	_	_	I-Premise
258	R-Y	_	_	I-Premise
259	(	_	_	I-Premise
260	0.7	_	_	I-Premise
261		_	_	I-Premise
262	0.6	_	_	I-Premise
263	vs.	_	_	I-Premise
264	0.5	_	_	I-Premise
265		_	_	I-Premise
266	0.6	_	_	I-Premise
267	,	_	_	I-Premise
268	p	_	_	I-Premise
269	=	_	_	I-Premise
270	0.01	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Claim
274	B-I	_	_	I-Claim
275	and	_	_	I-Claim
276	R-Y	_	_	I-Claim
277	techniques	_	_	I-Claim
278	were	_	_	I-Claim
279	generally	_	_	I-Claim
280	equivalent	_	_	I-Claim
281	in	_	_	I-Claim
282	terms	_	_	I-Claim
283	of	_	_	I-Claim
284	postoperative	_	_	I-Claim
285	QOL	_	_	I-Claim
286	and	_	_	I-Claim
287	dysfunction	_	_	I-Claim
288	.	_	_	I-Claim

289	Both	_	_	B-Claim
290	procedures	_	_	I-Claim
291	seem	_	_	I-Claim
292	acceptable	_	_	I-Claim
293	as	_	_	I-Claim
294	standard	_	_	I-Claim
295	reconstructions	_	_	I-Claim
296	after	_	_	I-Claim
297	distal	_	_	I-Claim
298	gastrectomy	_	_	I-Claim
299	with	_	_	I-Claim
300	regard	_	_	I-Claim
301	to	_	_	I-Claim
302	postoperative	_	_	I-Claim
303	QOL	_	_	I-Claim
304	and	_	_	I-Claim
305	dysfunction	_	_	I-Claim
306	.	_	_	I-Claim


0	Delirium	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	serious	_	_	I-Claim
4	and	_	_	I-Claim
5	common	_	_	I-Claim
6	postoperative	_	_	I-Claim
7	complication	_	_	I-Claim
8	,	_	_	O
9	especially	_	_	O
10	in	_	_	O
11	frail	_	_	O
12	elderly	_	_	O
13	patients	_	_	O
14	.	_	_	O

15	The	_	_	O
16	aim	_	_	O
17	of	_	_	O
18	this	_	_	O
19	study	_	_	O
20	was	_	_	O
21	to	_	_	O
22	evaluate	_	_	O
23	the	_	_	O
24	effect	_	_	O
25	of	_	_	O
26	a	_	_	O
27	geriatric	_	_	O
28	liaison	_	_	O
29	intervention	_	_	O
30	in	_	_	O
31	comparison	_	_	O
32	with	_	_	O
33	standard	_	_	O
34	care	_	_	O
35	on	_	_	O
36	the	_	_	O
37	incidence	_	_	O
38	of	_	_	O
39	postoperative	_	_	O
40	delirium	_	_	O
41	in	_	_	O
42	frail	_	_	O
43	elderly	_	_	O
44	cancer	_	_	O
45	patients	_	_	O
46	treated	_	_	O
47	with	_	_	O
48	an	_	_	O
49	elective	_	_	O
50	surgical	_	_	O
51	procedure	_	_	O
52	for	_	_	O
53	a	_	_	O
54	solid	_	_	O
55	tumour	_	_	O
56	.	_	_	O

57	Patients	_	_	O
58	over	_	_	O
59	65	_	_	O
60	years	_	_	O
61	of	_	_	O
62	age	_	_	O
63	who	_	_	O
64	were	_	_	O
65	undergoing	_	_	O
66	elective	_	_	O
67	surgery	_	_	O
68	for	_	_	O
69	a	_	_	O
70	solid	_	_	O
71	tumour	_	_	O
72	were	_	_	O
73	recruited	_	_	O
74	to	_	_	O
75	a	_	_	O
76	multicentre	_	_	O
77	,	_	_	O
78	prospective	_	_	O
79	,	_	_	O
80	randomized	_	_	O
81	,	_	_	O
82	controlled	_	_	O
83	trial	_	_	O
84	.	_	_	O

85	The	_	_	O
86	patients	_	_	O
87	were	_	_	O
88	randomized	_	_	O
89	to	_	_	O
90	standard	_	_	O
91	treatment	_	_	O
92	versus	_	_	O
93	a	_	_	O
94	geriatric	_	_	O
95	liaison	_	_	O
96	intervention	_	_	O
97	.	_	_	O

98	The	_	_	O
99	intervention	_	_	O
100	consisted	_	_	O
101	of	_	_	O
102	a	_	_	O
103	preoperative	_	_	O
104	geriatric	_	_	O
105	consultation	_	_	O
106	,	_	_	O
107	an	_	_	O
108	individual	_	_	O
109	treatment	_	_	O
110	plan	_	_	O
111	targeted	_	_	O
112	at	_	_	O
113	risk	_	_	O
114	factors	_	_	O
115	for	_	_	O
116	delirium	_	_	O
117	,	_	_	O
118	daily	_	_	O
119	visits	_	_	O
120	by	_	_	O
121	a	_	_	O
122	geriatric	_	_	O
123	nurse	_	_	O
124	during	_	_	O
125	the	_	_	O
126	hospital	_	_	O
127	stay	_	_	O
128	and	_	_	O
129	advice	_	_	O
130	on	_	_	O
131	managing	_	_	O
132	any	_	_	O
133	problems	_	_	O
134	encountered	_	_	O
135	.	_	_	O

136	The	_	_	O
137	primary	_	_	O
138	outcome	_	_	O
139	was	_	_	O
140	the	_	_	O
141	incidence	_	_	O
142	of	_	_	O
143	postoperative	_	_	O
144	delirium	_	_	O
145	.	_	_	O

146	The	_	_	O
147	secondary	_	_	O
148	outcome	_	_	O
149	measures	_	_	O
150	were	_	_	O
151	the	_	_	O
152	severity	_	_	O
153	of	_	_	O
154	delirium	_	_	O
155	,	_	_	O
156	length	_	_	O
157	of	_	_	O
158	hospital	_	_	O
159	stay	_	_	O
160	,	_	_	O
161	complications	_	_	O
162	,	_	_	O
163	mortality	_	_	O
164	,	_	_	O
165	care	_	_	O
166	dependency	_	_	O
167	,	_	_	O
168	quality	_	_	O
169	of	_	_	O
170	life	_	_	O
171	,	_	_	O
172	return	_	_	O
173	to	_	_	O
174	an	_	_	O
175	independent	_	_	O
176	preoperative	_	_	O
177	living	_	_	O
178	situation	_	_	O
179	and	_	_	O
180	additional	_	_	O
181	care	_	_	O
182	at	_	_	O
183	home	_	_	O
184	.	_	_	O

185	In	_	_	O
186	total	_	_	O
187	,	_	_	O
188	the	_	_	O
189	data	_	_	O
190	of	_	_	O
191	260	_	_	O
192	patients	_	_	O
193	were	_	_	O
194	analysed	_	_	O
195	.	_	_	O

196	Delirium	_	_	B-Premise
197	occurred	_	_	I-Premise
198	in	_	_	I-Premise
199	31	_	_	I-Premise
200	patients	_	_	I-Premise
201	(	_	_	I-Premise
202	11.9	_	_	I-Premise
203	%	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	and	_	_	I-Premise
207	there	_	_	I-Premise
208	was	_	_	I-Premise
209	no	_	_	I-Premise
210	significant	_	_	I-Premise
211	difference	_	_	I-Premise
212	between	_	_	I-Premise
213	the	_	_	I-Premise
214	incidence	_	_	I-Premise
215	of	_	_	I-Premise
216	delirium	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	intervention	_	_	I-Premise
220	group	_	_	I-Premise
221	and	_	_	I-Premise
222	the	_	_	I-Premise
223	usual-care	_	_	I-Premise
224	group	_	_	I-Premise
225	(	_	_	I-Premise
226	9.4	_	_	I-Premise
227	%	_	_	I-Premise
228	vs.	_	_	I-Premise
229	14.3	_	_	I-Premise
230	%	_	_	I-Premise
231	,	_	_	I-Premise
232	OR	_	_	I-Premise
233	:	_	_	I-Premise
234	0.63	_	_	I-Premise
235	,	_	_	I-Premise
236	95	_	_	I-Premise
237	%	_	_	I-Premise
238	CI	_	_	I-Premise
239	:	_	_	I-Premise
240	0.29-1.35	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	Within	_	_	B-Claim
244	this	_	_	I-Claim
245	study	_	_	I-Claim
246	,	_	_	I-Claim
247	a	_	_	I-Claim
248	geriatric	_	_	I-Claim
249	liaison	_	_	I-Claim
250	intervention	_	_	I-Claim
251	based	_	_	I-Claim
252	on	_	_	I-Claim
253	frailty	_	_	I-Claim
254	for	_	_	I-Claim
255	the	_	_	I-Claim
256	prevention	_	_	I-Claim
257	of	_	_	I-Claim
258	postoperative	_	_	I-Claim
259	delirium	_	_	I-Claim
260	in	_	_	I-Claim
261	frail	_	_	I-Claim
262	elderly	_	_	I-Claim
263	cancer	_	_	I-Claim
264	patients	_	_	I-Claim
265	undergoing	_	_	I-Claim
266	elective	_	_	I-Claim
267	surgery	_	_	I-Claim
268	for	_	_	I-Claim
269	a	_	_	I-Claim
270	solid	_	_	I-Claim
271	tumour	_	_	I-Claim
272	has	_	_	I-Claim
273	not	_	_	I-Claim
274	proven	_	_	I-Claim
275	to	_	_	I-Claim
276	be	_	_	I-Claim
277	effective	_	_	I-Claim
278	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	two	_	_	O
8	doses	_	_	O
9	of	_	_	O
10	gefitinib	_	_	O
11	(	_	_	O
12	Iressa	_	_	O
13	[	_	_	O
14	ZD1839	_	_	O
15	]	_	_	O
16	;	_	_	O
17	AstraZeneca	_	_	O
18	,	_	_	O
19	Wilmington	_	_	O
20	,	_	_	O
21	DE	_	_	O
22	)	_	_	O
23	,	_	_	O
24	a	_	_	O
25	novel	_	_	O
26	epidermal	_	_	O
27	growth	_	_	O
28	factor	_	_	O
29	receptor	_	_	O
30	tyrosine	_	_	O
31	kinase	_	_	O
32	inhibitor	_	_	O
33	,	_	_	O
34	in	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	pretreated	_	_	O
38	advanced	_	_	O
39	non-small-cell	_	_	O
40	lung	_	_	O
41	cancer	_	_	O
42	(	_	_	O
43	NSCLC	_	_	O
44	)	_	_	O
45	.	_	_	O

46	This	_	_	O
47	was	_	_	O
48	a	_	_	O
49	randomized	_	_	O
50	,	_	_	O
51	double-blind	_	_	O
52	,	_	_	O
53	parallel-group	_	_	O
54	,	_	_	O
55	multicenter	_	_	O
56	phase	_	_	O
57	II	_	_	O
58	trial	_	_	O
59	.	_	_	O

60	Two	_	_	O
61	hundred	_	_	O
62	ten	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	advanced	_	_	O
66	NSCLC	_	_	O
67	who	_	_	O
68	were	_	_	O
69	previously	_	_	O
70	treated	_	_	O
71	with	_	_	O
72	one	_	_	O
73	or	_	_	O
74	two	_	_	O
75	chemotherapy	_	_	O
76	regimens	_	_	O
77	(	_	_	O
78	at	_	_	O
79	least	_	_	O
80	one	_	_	O
81	containing	_	_	O
82	platinum	_	_	O
83	)	_	_	O
84	were	_	_	O
85	randomly	_	_	O
86	assigned	_	_	O
87	to	_	_	O
88	receive	_	_	O
89	either	_	_	O
90	250-mg	_	_	O
91	or	_	_	O
92	500-mg	_	_	O
93	oral	_	_	O
94	doses	_	_	O
95	of	_	_	O
96	gefitinib	_	_	O
97	once	_	_	O
98	daily	_	_	O
99	.	_	_	O

100	Efficacy	_	_	B-Premise
101	was	_	_	I-Premise
102	similar	_	_	I-Premise
103	for	_	_	I-Premise
104	the	_	_	I-Premise
105	250-	_	_	I-Premise
106	and	_	_	I-Premise
107	500-mg/d	_	_	I-Premise
108	groups	_	_	I-Premise
109	.	_	_	I-Premise

110	Objective	_	_	B-Premise
111	tumor	_	_	I-Premise
112	response	_	_	I-Premise
113	rates	_	_	I-Premise
114	were	_	_	I-Premise
115	18.4	_	_	I-Premise
116	%	_	_	I-Premise
117	(	_	_	I-Premise
118	95	_	_	I-Premise
119	%	_	_	I-Premise
120	confidence	_	_	I-Premise
121	interval	_	_	I-Premise
122	[	_	_	I-Premise
123	CI	_	_	I-Premise
124	]	_	_	I-Premise
125	,	_	_	I-Premise
126	11.5	_	_	I-Premise
127	to	_	_	I-Premise
128	27.3	_	_	I-Premise
129	)	_	_	I-Premise
130	and	_	_	I-Premise
131	19.0	_	_	I-Premise
132	%	_	_	I-Premise
133	(	_	_	I-Premise
134	95	_	_	I-Premise
135	%	_	_	I-Premise
136	CI	_	_	I-Premise
137	,	_	_	I-Premise
138	12.1	_	_	I-Premise
139	to	_	_	I-Premise
140	27.9	_	_	I-Premise
141	)	_	_	I-Premise
142	;	_	_	I-Premise
143	among	_	_	I-Premise
144	evaluable	_	_	I-Premise
145	patients	_	_	I-Premise
146	,	_	_	I-Premise
147	symptom	_	_	I-Premise
148	improvement	_	_	I-Premise
149	rates	_	_	I-Premise
150	were	_	_	I-Premise
151	40.3	_	_	I-Premise
152	%	_	_	I-Premise
153	(	_	_	I-Premise
154	95	_	_	I-Premise
155	%	_	_	I-Premise
156	CI	_	_	I-Premise
157	,	_	_	I-Premise
158	28.5	_	_	I-Premise
159	to	_	_	I-Premise
160	53.0	_	_	I-Premise
161	)	_	_	I-Premise
162	and	_	_	I-Premise
163	37.0	_	_	I-Premise
164	%	_	_	I-Premise
165	(	_	_	I-Premise
166	95	_	_	I-Premise
167	%	_	_	I-Premise
168	CI	_	_	I-Premise
169	,	_	_	I-Premise
170	26.0	_	_	I-Premise
171	to	_	_	I-Premise
172	49.1	_	_	I-Premise
173	)	_	_	I-Premise
174	;	_	_	I-Premise
175	median	_	_	I-Premise
176	progression-free	_	_	I-Premise
177	survival	_	_	I-Premise
178	times	_	_	I-Premise
179	were	_	_	I-Premise
180	2.7	_	_	I-Premise
181	and	_	_	I-Premise
182	2.8	_	_	I-Premise
183	months	_	_	I-Premise
184	;	_	_	I-Premise
185	and	_	_	I-Premise
186	median	_	_	I-Premise
187	overall	_	_	I-Premise
188	survival	_	_	I-Premise
189	times	_	_	I-Premise
190	were	_	_	I-Premise
191	7.6	_	_	I-Premise
192	and	_	_	I-Premise
193	8.0	_	_	I-Premise
194	months	_	_	I-Premise
195	,	_	_	I-Premise
196	respectively	_	_	I-Premise
197	.	_	_	I-Premise

198	Symptom	_	_	B-Premise
199	improvements	_	_	I-Premise
200	were	_	_	I-Premise
201	recorded	_	_	I-Premise
202	for	_	_	I-Premise
203	69.2	_	_	I-Premise
204	%	_	_	I-Premise
205	(	_	_	I-Premise
206	250	_	_	I-Premise
207	mg/d	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	85.7	_	_	I-Premise
211	%	_	_	I-Premise
212	(	_	_	I-Premise
213	500	_	_	I-Premise
214	mg/d	_	_	I-Premise
215	)	_	_	I-Premise
216	of	_	_	I-Premise
217	patients	_	_	I-Premise
218	with	_	_	I-Premise
219	a	_	_	I-Premise
220	tumor	_	_	I-Premise
221	response	_	_	I-Premise
222	.	_	_	I-Premise

223	Adverse	_	_	B-Premise
224	events	_	_	I-Premise
225	(	_	_	I-Premise
226	AEs	_	_	I-Premise
227	)	_	_	I-Premise
228	at	_	_	I-Premise
229	both	_	_	I-Premise
230	dose	_	_	I-Premise
231	levels	_	_	I-Premise
232	were	_	_	I-Premise
233	generally	_	_	I-Premise
234	mild	_	_	I-Premise
235	(	_	_	I-Premise
236	grade	_	_	I-Premise
237	1	_	_	I-Premise
238	or	_	_	I-Premise
239	2	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	consisted	_	_	I-Premise
243	mainly	_	_	I-Premise
244	of	_	_	I-Premise
245	skin	_	_	I-Premise
246	reactions	_	_	I-Premise
247	and	_	_	I-Premise
248	diarrhea	_	_	I-Premise
249	.	_	_	I-Premise

250	Drug-related	_	_	B-Premise
251	toxicities	_	_	I-Premise
252	were	_	_	I-Premise
253	more	_	_	I-Premise
254	frequent	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	higher-dose	_	_	I-Premise
258	group	_	_	I-Premise
259	.	_	_	I-Premise

260	Withdrawal	_	_	B-Premise
261	due	_	_	I-Premise
262	to	_	_	I-Premise
263	drug-related	_	_	I-Premise
264	AEs	_	_	I-Premise
265	was	_	_	I-Premise
266	1.9	_	_	I-Premise
267	%	_	_	I-Premise
268	and	_	_	I-Premise
269	9.4	_	_	I-Premise
270	%	_	_	I-Premise
271	for	_	_	I-Premise
272	patients	_	_	I-Premise
273	receiving	_	_	I-Premise
274	gefitinib	_	_	I-Premise
275	250	_	_	I-Premise
276	and	_	_	I-Premise
277	500	_	_	I-Premise
278	mg/d	_	_	I-Premise
279	,	_	_	I-Premise
280	respectively	_	_	I-Premise
281	.	_	_	I-Premise

282	Gefitinib	_	_	B-Claim
283	showed	_	_	I-Claim
284	clinically	_	_	I-Claim
285	meaningful	_	_	I-Claim
286	antitumor	_	_	I-Claim
287	activity	_	_	I-Claim
288	and	_	_	I-Claim
289	provided	_	_	I-Claim
290	symptom	_	_	I-Claim
291	relief	_	_	I-Claim
292	as	_	_	I-Claim
293	second-	_	_	I-Claim
294	and	_	_	I-Claim
295	third-line	_	_	I-Claim
296	treatment	_	_	I-Claim
297	in	_	_	I-Claim
298	these	_	_	I-Claim
299	patients	_	_	I-Claim
300	.	_	_	I-Claim

301	At	_	_	B-Claim
302	250	_	_	I-Claim
303	mg/d	_	_	I-Claim
304	,	_	_	I-Claim
305	gefitinib	_	_	I-Claim
306	had	_	_	I-Claim
307	a	_	_	I-Claim
308	favorable	_	_	I-Claim
309	AE	_	_	I-Claim
310	profile	_	_	I-Claim
311	.	_	_	I-Claim

312	Gefitinib	_	_	B-Claim
313	250	_	_	I-Claim
314	mg/d	_	_	I-Claim
315	is	_	_	I-Claim
316	an	_	_	I-Claim
317	important	_	_	I-Claim
318	,	_	_	I-Claim
319	novel	_	_	I-Claim
320	treatment	_	_	I-Claim
321	option	_	_	I-Claim
322	for	_	_	I-Claim
323	patients	_	_	I-Claim
324	with	_	_	I-Claim
325	pretreated	_	_	I-Claim
326	advanced	_	_	I-Claim
327	NSCLC	_	_	I-Claim
328	.	_	_	I-Claim


0	Data	_	_	O
1	from	_	_	O
2	experimental	_	_	O
3	studies	_	_	O
4	suggest	_	_	O
5	that	_	_	O
6	octreotide	_	_	B-Claim
7	,	_	_	I-Claim
8	the	_	_	I-Claim
9	long	_	_	I-Claim
10	acting	_	_	I-Claim
11	somatostatin	_	_	I-Claim
12	analogue	_	_	I-Claim
13	,	_	_	I-Claim
14	improves	_	_	I-Claim
15	survival	_	_	I-Claim
16	of	_	_	I-Claim
17	animals	_	_	I-Claim
18	with	_	_	I-Claim
19	pancreatic	_	_	I-Claim
20	cancer	_	_	I-Claim
21	.	_	_	I-Claim

22	To	_	_	O
23	assess	_	_	O
24	the	_	_	O
25	antitumour	_	_	O
26	effect	_	_	O
27	of	_	_	O
28	octreotide	_	_	O
29	,	_	_	O
30	a	_	_	O
31	randomized	_	_	O
32	trial	_	_	O
33	was	_	_	O
34	performed	_	_	O
35	comparing	_	_	O
36	octreotide	_	_	O
37	with	_	_	O
38	supportive	_	_	O
39	care	_	_	O
40	in	_	_	O
41	advanced	_	_	O
42	pancreatic	_	_	O
43	cancer	_	_	O
44	patients	_	_	O
45	.	_	_	O

46	All	_	_	O
47	patients	_	_	O
48	,	_	_	O
49	aged	_	_	O
50	59-75	_	_	O
51	years	_	_	O
52	,	_	_	O
53	were	_	_	O
54	not	_	_	O
55	liable	_	_	O
56	to	_	_	O
57	radical	_	_	O
58	surgical	_	_	O
59	treatment	_	_	O
60	and	_	_	O
61	were	_	_	O
62	not	_	_	O
63	submitted	_	_	O
64	to	_	_	O
65	other	_	_	O
66	treatments	_	_	O
67	(	_	_	O
68	chemo	_	_	O
69	and/or	_	_	O
70	radiotherapy	_	_	O
71	)	_	_	O
72	.	_	_	O

73	Six	_	_	O
74	patients	_	_	O
75	were	_	_	O
76	enrolled	_	_	O
77	,	_	_	O
78	4	_	_	O
79	of	_	_	O
80	these	_	_	O
81	treated	_	_	O
82	with	_	_	O
83	octreotide	_	_	O
84	(	_	_	O
85	500	_	_	O
86	micrograms	_	_	O
87	two	_	_	O
88	times	_	_	O
89	a	_	_	O
90	day	_	_	O
91	subcutaneous	_	_	O
92	for	_	_	O
93	six	_	_	O
94	months	_	_	O
95	)	_	_	O
96	and	_	_	O
97	the	_	_	O
98	other	_	_	O
99	2	_	_	O
100	were	_	_	O
101	inserted	_	_	O
102	a	_	_	O
103	control	_	_	O
104	group	_	_	O
105	.	_	_	O

106	The	_	_	B-Premise
107	patients	_	_	I-Premise
108	treated	_	_	I-Premise
109	with	_	_	I-Premise
110	octreotide	_	_	I-Premise
111	showed	_	_	I-Premise
112	a	_	_	I-Premise
113	significant	_	_	I-Premise
114	advantage	_	_	I-Premise
115	in	_	_	I-Premise
116	quality	_	_	I-Premise
117	of	_	_	I-Premise
118	life	_	_	I-Premise
119	(	_	_	I-Premise
120	restored	_	_	I-Premise
121	appetite	_	_	I-Premise
122	,	_	_	I-Premise
123	improvement	_	_	I-Premise
124	of	_	_	I-Premise
125	digestion	_	_	I-Premise
126	and	_	_	I-Premise
127	intestine	_	_	I-Premise
128	function	_	_	I-Premise
129	,	_	_	I-Premise
130	remission	_	_	I-Premise
131	of	_	_	I-Premise
132	abdominal	_	_	I-Premise
133	pain	_	_	I-Premise
134	and	_	_	I-Premise
135	preservation	_	_	I-Premise
136	of	_	_	I-Premise
137	baseline	_	_	I-Premise
138	body	_	_	I-Premise
139	weight	_	_	I-Premise
140	)	_	_	I-Premise
141	with	_	_	I-Premise
142	a	_	_	I-Premise
143	mean	_	_	I-Premise
144	>	_	_	I-Premise
145	80	_	_	I-Premise
146	of	_	_	I-Premise
147	karnofsky	_	_	I-Premise
148	performance	_	_	I-Premise
149	score	_	_	I-Premise
150	.	_	_	I-Premise

151	Monitoring	_	_	B-Premise
152	of	_	_	I-Premise
153	tumour	_	_	I-Premise
154	size	_	_	I-Premise
155	changes	_	_	I-Premise
156	(	_	_	I-Premise
157	US-TC	_	_	I-Premise
158	)	_	_	I-Premise
159	over	_	_	I-Premise
160	the	_	_	I-Premise
161	6	_	_	I-Premise
162	months	_	_	I-Premise
163	study	_	_	I-Premise
164	period	_	_	I-Premise
165	,	_	_	I-Premise
166	showed	_	_	I-Premise
167	slackened	_	_	I-Premise
168	neoplastic	_	_	I-Premise
169	growth	_	_	I-Premise
170	in	_	_	I-Premise
171	all	_	_	I-Premise
172	treated	_	_	I-Premise
173	patients	_	_	I-Premise
174	,	_	_	I-Premise
175	whereas	_	_	B-Premise
176	neoplasm	_	_	I-Premise
177	grew	_	_	I-Premise
178	according	_	_	I-Premise
179	to	_	_	I-Premise
180	an	_	_	I-Premise
181	almost	_	_	I-Premise
182	exponential	_	_	I-Premise
183	trend	_	_	I-Premise
184	in	_	_	I-Premise
185	untreated	_	_	I-Premise
186	patients	_	_	I-Premise
187	.	_	_	O

188	Also	_	_	O
189	survival	_	_	B-Premise
190	was	_	_	I-Premise
191	better	_	_	I-Premise
192	in	_	_	I-Premise
193	treated	_	_	I-Premise
194	patients	_	_	I-Premise
195	:	_	_	O
196	in	_	_	O
197	particular	_	_	O
198	,	_	_	O
199	2	_	_	O
200	patients	_	_	O
201	out	_	_	O
202	of	_	_	O
203	4	_	_	O
204	who	_	_	O
205	completed	_	_	O
206	the	_	_	O
207	study	_	_	O
208	underwent	_	_	O
209	follow-up	_	_	O
210	until	_	_	O
211	they	_	_	O
212	died	_	_	O
213	12	_	_	O
214	and	_	_	O
215	16	_	_	O
216	months	_	_	O
217	after	_	_	O
218	beginning	_	_	O
219	of	_	_	O
220	treatment	_	_	O
221	,	_	_	O
222	respectively	_	_	O
223	.	_	_	O

224	Karnofsky	_	_	B-Premise
225	performance	_	_	I-Premise
226	score	_	_	I-Premise
227	was	_	_	I-Premise
228	particularly	_	_	I-Premise
229	high	_	_	I-Premise
230	in	_	_	I-Premise
231	both	_	_	I-Premise
232	patients	_	_	I-Premise
233	.	_	_	I-Premise

234	This	_	_	O
235	supports	_	_	O
236	the	_	_	O
237	view	_	_	O
238	that	_	_	O
239	octreotide	_	_	B-Claim
240	is	_	_	I-Claim
241	endowed	_	_	I-Claim
242	with	_	_	I-Claim
243	antiproliferative	_	_	I-Claim
244	activity	_	_	I-Claim
245	.	_	_	I-Claim

246	In	_	_	O
247	conclusion	_	_	O
248	octreotide	_	_	B-Claim
249	therapy	_	_	I-Claim
250	seems	_	_	I-Claim
251	to	_	_	I-Claim
252	confer	_	_	I-Claim
253	a	_	_	I-Claim
254	survival	_	_	I-Claim
255	benefit	_	_	I-Claim
256	and	_	_	I-Claim
257	a	_	_	I-Claim
258	better	_	_	I-Claim
259	quality	_	_	I-Claim
260	of	_	_	I-Claim
261	life	_	_	I-Claim
262	in	_	_	I-Claim
263	advanced	_	_	I-Claim
264	pancreatic	_	_	I-Claim
265	tumour	_	_	I-Claim
266	.	_	_	I-Claim

267	Additional	_	_	O
268	studies	_	_	O
269	are	_	_	O
270	needed	_	_	O
271	to	_	_	O
272	confirm	_	_	O
273	these	_	_	O
274	results	_	_	O
275	and	_	_	O
276	to	_	_	O
277	clarify	_	_	O
278	other	_	_	O
279	questions	_	_	O
280	about	_	_	O
281	dose	_	_	O
282	and	_	_	O
283	somatostatin	_	_	O
284	receptors	_	_	O
285	in	_	_	O
286	this	_	_	O
287	kind	_	_	O
288	of	_	_	O
289	tumour	_	_	O
290	.	_	_	O


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	oral	_	_	O
8	bexarotene	_	_	O
9	(	_	_	O
10	Targretin	_	_	O
11	capsules	_	_	O
12	;	_	_	O
13	Ligand	_	_	O
14	Pharmaceuticals	_	_	O
15	Incorporated	_	_	O
16	,	_	_	O
17	San	_	_	O
18	Diego	_	_	O
19	,	_	_	O
20	Calif	_	_	O
21	)	_	_	O
22	.	_	_	O

23	The	_	_	O
24	effects	_	_	O
25	of	_	_	O
26	2	_	_	O
27	randomized	_	_	O
28	doses	_	_	O
29	of	_	_	O
30	6.5	_	_	O
31	mg/m	_	_	O
32	(	_	_	O
33	2	_	_	O
34	)	_	_	O
35	per	_	_	O
36	day	_	_	O
37	(	_	_	O
38	with	_	_	O
39	crossover	_	_	O
40	for	_	_	O
41	progression	_	_	O
42	)	_	_	O
43	vs	_	_	O
44	650	_	_	O
45	mg/m	_	_	O
46	(	_	_	O
47	2	_	_	O
48	)	_	_	O
49	per	_	_	O
50	day	_	_	O
51	(	_	_	O
52	later	_	_	O
53	modified	_	_	O
54	to	_	_	O
55	300	_	_	O
56	mg/m	_	_	O
57	(	_	_	O
58	2	_	_	O
59	)	_	_	O
60	per	_	_	O
61	day	_	_	O
62	)	_	_	O
63	were	_	_	O
64	evaluated	_	_	O
65	in	_	_	O
66	an	_	_	O
67	open-label	_	_	O
68	,	_	_	O
69	multicenter	_	_	O
70	,	_	_	O
71	phase	_	_	O
72	2	_	_	O
73	and	_	_	O
74	3	_	_	O
75	study	_	_	O
76	conducted	_	_	O
77	between	_	_	O
78	February	_	_	O
79	1997	_	_	O
80	and	_	_	O
81	November	_	_	O
82	1998	_	_	O
83	.	_	_	O

84	Eighteen	_	_	O
85	international	_	_	O
86	cutaneous	_	_	O
87	T-cell	_	_	O
88	lymphoma	_	_	O
89	clinics	_	_	O
90	at	_	_	O
91	academic	_	_	O
92	referral	_	_	O
93	centers	_	_	O
94	.	_	_	O

95	Fifty-eight	_	_	O
96	patients	_	_	O
97	with	_	_	O
98	biopsy-proven	_	_	O
99	stage	_	_	O
100	IA	_	_	O
101	through	_	_	O
102	IIA	_	_	O
103	cutaneous	_	_	O
104	T-cell	_	_	O
105	lymphoma	_	_	O
106	that	_	_	O
107	was	_	_	O
108	refractory	_	_	O
109	to	_	_	O
110	(	_	_	O
111	or	_	_	O
112	patients	_	_	O
113	were	_	_	O
114	intolerant	_	_	O
115	of	_	_	O
116	)	_	_	O
117	treatment	_	_	O
118	or	_	_	O
119	had	_	_	O
120	reached	_	_	O
121	at	_	_	O
122	least	_	_	O
123	a	_	_	O
124	6-month	_	_	O
125	response	_	_	O
126	plateau	_	_	O
127	under	_	_	O
128	at	_	_	O
129	least	_	_	O
130	2	_	_	O
131	forms	_	_	O
132	of	_	_	O
133	prior	_	_	O
134	therapy	_	_	O
135	(	_	_	O
136	median	_	_	O
137	of	_	_	O
138	3.5	_	_	O
139	prior	_	_	O
140	therapies	_	_	O
141	)	_	_	O
142	.	_	_	O

143	Bexarotene	_	_	O
144	(	_	_	O
145	Targretin	_	_	O
146	capsules	_	_	O
147	)	_	_	O
148	administered	_	_	O
149	once	_	_	O
150	daily	_	_	O
151	with	_	_	O
152	meal	_	_	O
153	for	_	_	O
154	16	_	_	O
155	weeks	_	_	O
156	or	_	_	O
157	longer	_	_	O
158	.	_	_	O

159	Primary	_	_	O
160	end	_	_	O
161	point	_	_	O
162	classification	_	_	O
163	of	_	_	O
164	overall	_	_	O
165	response	_	_	O
166	rate	_	_	O
167	of	_	_	O
168	complete	_	_	O
169	and	_	_	O
170	partial	_	_	O
171	remissions	_	_	O
172	determined	_	_	O
173	by	_	_	O
174	either	_	_	O
175	the	_	_	O
176	Physician	_	_	O
177	's	_	_	O
178	Global	_	_	O
179	Assessment	_	_	O
180	of	_	_	O
181	Clinical	_	_	O
182	Condition	_	_	O
183	or	_	_	O
184	the	_	_	O
185	objective	_	_	O
186	Composite	_	_	O
187	Assessment	_	_	O
188	of	_	_	O
189	Index	_	_	O
190	Lesion	_	_	O
191	Severity	_	_	O
192	.	_	_	O

193	Body	_	_	O
194	surface	_	_	O
195	area	_	_	O
196	,	_	_	O
197	time	_	_	O
198	to	_	_	O
199	response	_	_	O
200	,	_	_	O
201	duration	_	_	O
202	of	_	_	O
203	disease	_	_	O
204	control	_	_	O
205	,	_	_	O
206	time	_	_	O
207	to	_	_	O
208	disease	_	_	O
209	progression	_	_	O
210	,	_	_	O
211	individual	_	_	O
212	index	_	_	O
213	lesion	_	_	O
214	signs	_	_	O
215	and	_	_	O
216	symptoms	_	_	O
217	,	_	_	O
218	and	_	_	O
219	quality	_	_	O
220	of	_	_	O
221	life	_	_	O
222	parameters	_	_	O
223	were	_	_	O
224	secondary	_	_	O
225	outcomes	_	_	O
226	.	_	_	O

227	Responses	_	_	B-Premise
228	(	_	_	I-Premise
229	>	_	_	I-Premise
230	or	_	_	I-Premise
231	=	_	_	I-Premise
232	50	_	_	I-Premise
233	%	_	_	I-Premise
234	improvement	_	_	I-Premise
235	)	_	_	I-Premise
236	were	_	_	I-Premise
237	seen	_	_	I-Premise
238	in	_	_	I-Premise
239	3	_	_	I-Premise
240	(	_	_	I-Premise
241	20	_	_	I-Premise
242	%	_	_	I-Premise
243	)	_	_	I-Premise
244	of	_	_	I-Premise
245	15	_	_	I-Premise
246	patients	_	_	I-Premise
247	with	_	_	I-Premise
248	an	_	_	I-Premise
249	initial	_	_	I-Premise
250	dose	_	_	I-Premise
251	at	_	_	I-Premise
252	6.5	_	_	I-Premise
253	mg/m	_	_	I-Premise
254	(	_	_	I-Premise
255	2	_	_	I-Premise
256	)	_	_	I-Premise
257	per	_	_	I-Premise
258	day	_	_	I-Premise
259	(	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	confidence	_	_	I-Premise
263	interval	_	_	I-Premise
264	[	_	_	I-Premise
265	CI	_	_	I-Premise
266	]	_	_	I-Premise
267	,	_	_	I-Premise
268	0	_	_	I-Premise
269	%	_	_	I-Premise
270	-40	_	_	I-Premise
271	%	_	_	I-Premise
272	)	_	_	I-Premise
273	,	_	_	I-Premise
274	15	_	_	I-Premise
275	(	_	_	I-Premise
276	54	_	_	I-Premise
277	%	_	_	I-Premise
278	)	_	_	I-Premise
279	of	_	_	I-Premise
280	28	_	_	I-Premise
281	patients	_	_	I-Premise
282	at	_	_	I-Premise
283	300	_	_	I-Premise
284	mg/m	_	_	I-Premise
285	(	_	_	I-Premise
286	2	_	_	I-Premise
287	)	_	_	I-Premise
288	per	_	_	I-Premise
289	day	_	_	I-Premise
290	(	_	_	I-Premise
291	95	_	_	I-Premise
292	%	_	_	I-Premise
293	CI	_	_	I-Premise
294	,	_	_	I-Premise
295	35	_	_	I-Premise
296	%	_	_	I-Premise
297	-72	_	_	I-Premise
298	%	_	_	I-Premise
299	)	_	_	I-Premise
300	,	_	_	I-Premise
301	and	_	_	I-Premise
302	10	_	_	I-Premise
303	(	_	_	I-Premise
304	67	_	_	I-Premise
305	%	_	_	I-Premise
306	)	_	_	I-Premise
307	of	_	_	I-Premise
308	15	_	_	I-Premise
309	patients	_	_	I-Premise
310	at	_	_	I-Premise
311	above	_	_	I-Premise
312	300	_	_	I-Premise
313	mg/m	_	_	I-Premise
314	(	_	_	I-Premise
315	2	_	_	I-Premise
316	)	_	_	I-Premise
317	per	_	_	I-Premise
318	day	_	_	I-Premise
319	(	_	_	I-Premise
320	95	_	_	I-Premise
321	%	_	_	I-Premise
322	CI	_	_	I-Premise
323	,	_	_	I-Premise
324	43	_	_	I-Premise
325	%	_	_	I-Premise
326	-91	_	_	I-Premise
327	%	_	_	I-Premise
328	)	_	_	I-Premise
329	.	_	_	I-Premise

330	The	_	_	B-Premise
331	rate	_	_	I-Premise
332	of	_	_	I-Premise
333	progressive	_	_	I-Premise
334	disease	_	_	I-Premise
335	was	_	_	I-Premise
336	47	_	_	I-Premise
337	%	_	_	I-Premise
338	,	_	_	I-Premise
339	21	_	_	I-Premise
340	%	_	_	I-Premise
341	,	_	_	I-Premise
342	and	_	_	I-Premise
343	13	_	_	I-Premise
344	%	_	_	I-Premise
345	at	_	_	I-Premise
346	the	_	_	I-Premise
347	same	_	_	I-Premise
348	dose	_	_	I-Premise
349	levels	_	_	I-Premise
350	,	_	_	I-Premise
351	respectively	_	_	I-Premise
352	.	_	_	I-Premise

353	Eight	_	_	B-Premise
354	(	_	_	I-Premise
355	73	_	_	I-Premise
356	%	_	_	I-Premise
357	)	_	_	I-Premise
358	of	_	_	I-Premise
359	11	_	_	I-Premise
360	patients	_	_	I-Premise
361	crossing	_	_	I-Premise
362	over	_	_	I-Premise
363	from	_	_	I-Premise
364	6.5	_	_	I-Premise
365	mg/m	_	_	I-Premise
366	(	_	_	I-Premise
367	2	_	_	I-Premise
368	)	_	_	I-Premise
369	per	_	_	I-Premise
370	day	_	_	I-Premise
371	to	_	_	I-Premise
372	higher	_	_	I-Premise
373	doses	_	_	I-Premise
374	subsequently	_	_	I-Premise
375	responded	_	_	I-Premise
376	.	_	_	I-Premise

377	The	_	_	B-Premise
378	median	_	_	I-Premise
379	duration	_	_	I-Premise
380	of	_	_	I-Premise
381	response	_	_	I-Premise
382	from	_	_	I-Premise
383	start	_	_	I-Premise
384	of	_	_	I-Premise
385	therapy	_	_	I-Premise
386	could	_	_	I-Premise
387	not	_	_	I-Premise
388	be	_	_	I-Premise
389	estimated	_	_	I-Premise
390	for	_	_	I-Premise
391	the	_	_	I-Premise
392	15	_	_	I-Premise
393	patients	_	_	I-Premise
394	at	_	_	I-Premise
395	300	_	_	I-Premise
396	mg/m	_	_	I-Premise
397	(	_	_	I-Premise
398	2	_	_	I-Premise
399	)	_	_	I-Premise
400	per	_	_	I-Premise
401	day	_	_	I-Premise
402	owing	_	_	I-Premise
403	to	_	_	I-Premise
404	low	_	_	I-Premise
405	relapse	_	_	I-Premise
406	rates	_	_	I-Premise
407	in	_	_	I-Premise
408	2	_	_	I-Premise
409	patients	_	_	I-Premise
410	(	_	_	I-Premise
411	13	_	_	I-Premise
412	%	_	_	I-Premise
413	)	_	_	I-Premise
414	;	_	_	I-Premise
415	at	_	_	I-Premise
416	higher	_	_	I-Premise
417	doses	_	_	I-Premise
418	it	_	_	I-Premise
419	was	_	_	I-Premise
420	516	_	_	I-Premise
421	days	_	_	I-Premise
422	.	_	_	I-Premise

423	The	_	_	B-Premise
424	following	_	_	I-Premise
425	drug-related	_	_	I-Premise
426	adverse	_	_	I-Premise
427	effects	_	_	I-Premise
428	were	_	_	I-Premise
429	reversible	_	_	I-Premise
430	and	_	_	I-Premise
431	treatable	_	_	I-Premise
432	:	_	_	I-Premise
433	hypertriglyceridemia	_	_	I-Premise
434	(	_	_	I-Premise
435	46	_	_	I-Premise
436	patients	_	_	I-Premise
437	[	_	_	I-Premise
438	79	_	_	I-Premise
439	%	_	_	I-Premise
440	]	_	_	I-Premise
441	)	_	_	I-Premise
442	,	_	_	I-Premise
443	hypercholesterolemia	_	_	I-Premise
444	(	_	_	I-Premise
445	28	_	_	I-Premise
446	patients	_	_	I-Premise
447	[	_	_	I-Premise
448	48	_	_	I-Premise
449	%	_	_	I-Premise
450	]	_	_	I-Premise
451	)	_	_	I-Premise
452	,	_	_	I-Premise
453	headache	_	_	I-Premise
454	(	_	_	I-Premise
455	27	_	_	I-Premise
456	patients	_	_	I-Premise
457	[	_	_	I-Premise
458	47	_	_	I-Premise
459	%	_	_	I-Premise
460	]	_	_	I-Premise
461	)	_	_	I-Premise
462	,	_	_	I-Premise
463	central	_	_	I-Premise
464	hypothyroidism	_	_	I-Premise
465	(	_	_	I-Premise
466	23	_	_	I-Premise
467	patients	_	_	I-Premise
468	[	_	_	I-Premise
469	40	_	_	I-Premise
470	%	_	_	I-Premise
471	]	_	_	I-Premise
472	)	_	_	I-Premise
473	,	_	_	I-Premise
474	asthenia	_	_	I-Premise
475	(	_	_	I-Premise
476	21	_	_	I-Premise
477	patients	_	_	I-Premise
478	[	_	_	I-Premise
479	36	_	_	I-Premise
480	%	_	_	I-Premise
481	]	_	_	I-Premise
482	)	_	_	I-Premise
483	,	_	_	I-Premise
484	and	_	_	I-Premise
485	leukopenia	_	_	I-Premise
486	(	_	_	I-Premise
487	16	_	_	I-Premise
488	patients	_	_	I-Premise
489	[	_	_	I-Premise
490	28	_	_	I-Premise
491	%	_	_	I-Premise
492	]	_	_	I-Premise
493	)	_	_	I-Premise
494	.	_	_	I-Premise

495	No	_	_	B-Premise
496	cases	_	_	I-Premise
497	of	_	_	I-Premise
498	drug-related	_	_	I-Premise
499	neutropenic	_	_	I-Premise
500	fever	_	_	I-Premise
501	,	_	_	I-Premise
502	sepsis	_	_	I-Premise
503	,	_	_	I-Premise
504	or	_	_	I-Premise
505	death	_	_	I-Premise
506	occurred	_	_	I-Premise
507	.	_	_	I-Premise

508	Pancreatitis	_	_	B-Premise
509	occurred	_	_	I-Premise
510	in	_	_	I-Premise
511	3	_	_	I-Premise
512	patients	_	_	I-Premise
513	with	_	_	I-Premise
514	triglyceride	_	_	I-Premise
515	levels	_	_	I-Premise
516	higher	_	_	I-Premise
517	than	_	_	I-Premise
518	14.69	_	_	I-Premise
519	mmol/L	_	_	I-Premise
520	(	_	_	I-Premise
521	1300	_	_	I-Premise
522	mg/dL	_	_	I-Premise
523	)	_	_	I-Premise
524	,	_	_	I-Premise
525	all	_	_	I-Premise
526	of	_	_	I-Premise
527	whom	_	_	I-Premise
528	were	_	_	I-Premise
529	taking	_	_	I-Premise
530	300	_	_	I-Premise
531	mg/m	_	_	I-Premise
532	(	_	_	I-Premise
533	2	_	_	I-Premise
534	)	_	_	I-Premise
535	or	_	_	I-Premise
536	more	_	_	I-Premise
537	of	_	_	I-Premise
538	oral	_	_	I-Premise
539	bexarotene	_	_	I-Premise
540	per	_	_	I-Premise
541	day	_	_	I-Premise
542	.	_	_	I-Premise

543	Bexarotene	_	_	B-Claim
544	(	_	_	I-Claim
545	Targretin	_	_	I-Claim
546	capsules	_	_	I-Claim
547	)	_	_	I-Claim
548	(	_	_	I-Claim
549	the	_	_	I-Claim
550	first	_	_	I-Claim
551	retinoid	_	_	I-Claim
552	X	_	_	I-Claim
553	receptor-selective	_	_	I-Claim
554	rexinoid	_	_	I-Claim
555	)	_	_	I-Claim
556	was	_	_	I-Claim
557	well	_	_	I-Claim
558	tolerated	_	_	I-Claim
559	and	_	_	I-Claim
560	effective	_	_	I-Claim
561	as	_	_	I-Claim
562	an	_	_	I-Claim
563	oral	_	_	I-Claim
564	treatment	_	_	I-Claim
565	for	_	_	I-Claim
566	15	_	_	I-Claim
567	(	_	_	I-Claim
568	54	_	_	I-Claim
569	%	_	_	I-Claim
570	)	_	_	I-Claim
571	of	_	_	I-Claim
572	28	_	_	I-Claim
573	patients	_	_	I-Claim
574	with	_	_	I-Claim
575	refractory	_	_	I-Claim
576	or	_	_	I-Claim
577	persistent	_	_	I-Claim
578	early-stage	_	_	I-Claim
579	cutaneous	_	_	I-Claim
580	T-cell	_	_	I-Claim
581	lymphoma	_	_	I-Claim
582	at	_	_	I-Claim
583	doses	_	_	I-Claim
584	of	_	_	I-Claim
585	300	_	_	I-Claim
586	mg/m	_	_	I-Claim
587	(	_	_	I-Claim
588	2	_	_	I-Claim
589	)	_	_	I-Claim
590	per	_	_	I-Claim
591	day	_	_	I-Claim
592	.	_	_	I-Claim

593	Hypertriglyceridemia	_	_	B-Claim
594	and	_	_	I-Claim
595	hypothyroidism	_	_	I-Claim
596	require	_	_	I-Claim
597	monitoring	_	_	I-Claim
598	but	_	_	I-Claim
599	are	_	_	I-Claim
600	reversible	_	_	I-Claim
601	and	_	_	I-Claim
602	manageable	_	_	I-Claim
603	with	_	_	I-Claim
604	concomitant	_	_	I-Claim
605	medication	_	_	I-Claim
606	.	_	_	I-Claim


0	The	_	_	O
1	primary	_	_	O
2	goal	_	_	O
3	of	_	_	O
4	this	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	evaluate	_	_	O
9	the	_	_	O
10	feasibility	_	_	O
11	and	_	_	O
12	effectiveness	_	_	O
13	of	_	_	O
14	a	_	_	O
15	structured	_	_	O
16	,	_	_	O
17	multidisciplinary	_	_	O
18	intervention	_	_	O
19	targeted	_	_	O
20	to	_	_	O
21	maintain	_	_	O
22	the	_	_	O
23	overall	_	_	O
24	quality	_	_	O
25	of	_	_	O
26	life	_	_	O
27	(	_	_	O
28	QOL	_	_	O
29	)	_	_	O
30	,	_	_	O
31	which	_	_	O
32	is	_	_	O
33	more	_	_	O
34	comprehensive	_	_	O
35	than	_	_	O
36	psychosocial	_	_	O
37	distress	_	_	O
38	,	_	_	O
39	of	_	_	O
40	patients	_	_	O
41	undergoing	_	_	O
42	radiation	_	_	O
43	therapy	_	_	O
44	for	_	_	O
45	advanced-stage	_	_	O
46	cancer	_	_	O
47	.	_	_	O

48	Radiation	_	_	O
49	therapy	_	_	O
50	patients	_	_	O
51	with	_	_	O
52	advanced	_	_	O
53	cancer	_	_	O
54	and	_	_	O
55	an	_	_	O
56	estimated	_	_	O
57	5-year	_	_	O
58	survival	_	_	O
59	rate	_	_	O
60	of	_	_	O
61	0	_	_	O
62	%	_	_	O
63	to	_	_	O
64	50	_	_	O
65	%	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	assigned	_	_	O
69	to	_	_	O
70	either	_	_	O
71	an	_	_	O
72	eight-session	_	_	O
73	structured	_	_	O
74	multidisciplinary	_	_	O
75	intervention	_	_	O
76	arm	_	_	O
77	or	_	_	O
78	a	_	_	O
79	standard	_	_	O
80	care	_	_	O
81	arm	_	_	O
82	.	_	_	O

83	The	_	_	O
84	eight	_	_	O
85	90-minute	_	_	O
86	sessions	_	_	O
87	addressed	_	_	O
88	the	_	_	O
89	five	_	_	O
90	domains	_	_	O
91	of	_	_	O
92	QOL	_	_	O
93	including	_	_	O
94	cognitive	_	_	O
95	,	_	_	O
96	physical	_	_	O
97	,	_	_	O
98	emotional	_	_	O
99	,	_	_	O
100	spiritual	_	_	O
101	,	_	_	O
102	and	_	_	O
103	social	_	_	O
104	functioning	_	_	O
105	.	_	_	O

106	The	_	_	O
107	primary	_	_	O
108	end	_	_	O
109	point	_	_	O
110	of	_	_	O
111	maintaining	_	_	O
112	overall	_	_	O
113	QOL	_	_	O
114	was	_	_	O
115	assessed	_	_	O
116	by	_	_	O
117	a	_	_	O
118	single-item	_	_	O
119	linear	_	_	O
120	analog	_	_	O
121	scale	_	_	O
122	(	_	_	O
123	Linear	_	_	O
124	Analog	_	_	O
125	Scale	_	_	O
126	of	_	_	O
127	Assessment	_	_	O
128	or	_	_	O
129	modified	_	_	O
130	Spitzer	_	_	O
131	Uniscale	_	_	O
132	)	_	_	O
133	.	_	_	O

134	QOL	_	_	O
135	was	_	_	O
136	assessed	_	_	O
137	at	_	_	O
138	baseline	_	_	O
139	,	_	_	O
140	week	_	_	O
141	4	_	_	O
142	(	_	_	O
143	end	_	_	O
144	of	_	_	O
145	multidisciplinary	_	_	O
146	intervention	_	_	O
147	)	_	_	O
148	,	_	_	O
149	week	_	_	O
150	8	_	_	O
151	,	_	_	O
152	and	_	_	O
153	week	_	_	O
154	27	_	_	O
155	.	_	_	O

156	Of	_	_	B-Premise
157	the	_	_	I-Premise
158	103	_	_	I-Premise
159	participants	_	_	I-Premise
160	,	_	_	I-Premise
161	overall	_	_	I-Premise
162	QOL	_	_	I-Premise
163	at	_	_	I-Premise
164	week	_	_	I-Premise
165	4	_	_	I-Premise
166	was	_	_	I-Premise
167	maintained	_	_	I-Premise
168	by	_	_	I-Premise
169	the	_	_	I-Premise
170	patients	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	intervention	_	_	I-Premise
174	(	_	_	I-Premise
175	n	_	_	I-Premise
176	=	_	_	I-Premise
177	49	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	whereas	_	_	I-Premise
181	QOL	_	_	I-Premise
182	at	_	_	I-Premise
183	week	_	_	I-Premise
184	4	_	_	I-Premise
185	significantly	_	_	I-Premise
186	decreased	_	_	I-Premise
187	for	_	_	I-Premise
188	patients	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	control	_	_	I-Premise
192	group	_	_	I-Premise
193	(	_	_	I-Premise
194	n	_	_	I-Premise
195	=	_	_	I-Premise
196	54	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	This	_	_	B-Premise
200	change	_	_	I-Premise
201	reflected	_	_	I-Premise
202	a	_	_	I-Premise
203	3-point	_	_	I-Premise
204	increase	_	_	I-Premise
205	from	_	_	I-Premise
206	baseline	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	intervention	_	_	I-Premise
210	group	_	_	I-Premise
211	and	_	_	I-Premise
212	a	_	_	I-Premise
213	9-point	_	_	I-Premise
214	decrease	_	_	I-Premise
215	from	_	_	I-Premise
216	baseline	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	control	_	_	I-Premise
220	group	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	.009	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	Intervention	_	_	B-Premise
228	participants	_	_	I-Premise
229	maintained	_	_	I-Premise
230	their	_	_	I-Premise
231	QOL	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	controls	_	_	I-Premise
235	gradually	_	_	I-Premise
236	returned	_	_	I-Premise
237	to	_	_	I-Premise
238	baseline	_	_	I-Premise
239	by	_	_	I-Premise
240	the	_	_	I-Premise
241	end	_	_	I-Premise
242	of	_	_	I-Premise
243	the	_	_	I-Premise
244	6-month	_	_	I-Premise
245	follow-up	_	_	I-Premise
246	period	_	_	I-Premise
247	.	_	_	I-Premise

248	Although	_	_	B-Claim
249	intervention	_	_	I-Claim
250	participants	_	_	I-Claim
251	maintained	_	_	I-Claim
252	and	_	_	I-Claim
253	actually	_	_	I-Claim
254	improved	_	_	I-Claim
255	their	_	_	I-Claim
256	QOL	_	_	I-Claim
257	during	_	_	I-Claim
258	radiation	_	_	I-Claim
259	therapy	_	_	I-Claim
260	,	_	_	I-Claim
261	control	_	_	I-Claim
262	participants	_	_	I-Claim
263	experienced	_	_	I-Claim
264	a	_	_	I-Claim
265	significant	_	_	I-Claim
266	decrease	_	_	I-Claim
267	in	_	_	I-Claim
268	their	_	_	I-Claim
269	QOL	_	_	I-Claim
270	.	_	_	O

271	Thus	_	_	B-Claim
272	,	_	_	I-Claim
273	a	_	_	I-Claim
274	structured	_	_	I-Claim
275	multidisciplinary	_	_	I-Claim
276	intervention	_	_	I-Claim
277	can	_	_	I-Claim
278	help	_	_	I-Claim
279	maintain	_	_	I-Claim
280	or	_	_	I-Claim
281	even	_	_	I-Claim
282	improve	_	_	I-Claim
283	QOL	_	_	I-Claim
284	in	_	_	I-Claim
285	patients	_	_	I-Claim
286	with	_	_	I-Claim
287	advanced	_	_	I-Claim
288	cancer	_	_	I-Claim
289	who	_	_	I-Claim
290	are	_	_	I-Claim
291	undergoing	_	_	I-Claim
292	cancer	_	_	I-Claim
293	treatment	_	_	I-Claim
294	.	_	_	I-Claim


0	Major	_	_	O
1	depressive	_	_	O
2	disorder	_	_	O
3	develops	_	_	O
4	in	_	_	O
5	up	_	_	O
6	to	_	_	O
7	half	_	_	O
8	the	_	_	O
9	patients	_	_	O
10	undergoing	_	_	O
11	treatment	_	_	O
12	for	_	_	O
13	head	_	_	O
14	and	_	_	O
15	neck	_	_	O
16	cancer	_	_	O
17	,	_	_	O
18	resulting	_	_	O
19	in	_	_	O
20	significant	_	_	O
21	morbidity	_	_	O
22	;	_	_	O
23	therefore	_	_	O
24	,	_	_	O
25	preventing	_	_	O
26	depression	_	_	O
27	during	_	_	O
28	cancer	_	_	O
29	treatment	_	_	O
30	may	_	_	O
31	be	_	_	O
32	of	_	_	O
33	great	_	_	O
34	benefit	_	_	O
35	.	_	_	O

36	To	_	_	O
37	determine	_	_	O
38	whether	_	_	O
39	prophylactic	_	_	O
40	use	_	_	O
41	of	_	_	O
42	the	_	_	O
43	antidepressant	_	_	O
44	escitalopram	_	_	O
45	oxalate	_	_	O
46	would	_	_	O
47	decrease	_	_	O
48	the	_	_	O
49	incidence	_	_	O
50	of	_	_	O
51	depression	_	_	O
52	in	_	_	O
53	patients	_	_	O
54	receiving	_	_	O
55	primary	_	_	O
56	therapy	_	_	O
57	for	_	_	O
58	head	_	_	O
59	and	_	_	O
60	neck	_	_	O
61	cancer	_	_	O
62	.	_	_	O

63	A	_	_	O
64	randomized	_	_	O
65	,	_	_	O
66	double-blind	_	_	O
67	,	_	_	O
68	placebo-controlled	_	_	O
69	trial	_	_	O
70	of	_	_	O
71	escitalopram	_	_	O
72	vs	_	_	O
73	placebo	_	_	O
74	was	_	_	O
75	conducted	_	_	O
76	in	_	_	O
77	a	_	_	O
78	group	_	_	O
79	of	_	_	O
80	nondepressed	_	_	O
81	patients	_	_	O
82	diagnosed	_	_	O
83	as	_	_	O
84	having	_	_	O
85	head	_	_	O
86	and	_	_	O
87	neck	_	_	O
88	cancer	_	_	O
89	who	_	_	O
90	were	_	_	O
91	about	_	_	O
92	to	_	_	O
93	enter	_	_	O
94	cancer	_	_	O
95	treatment	_	_	O
96	.	_	_	O

97	Patients	_	_	O
98	were	_	_	O
99	stratified	_	_	O
100	by	_	_	O
101	sex	_	_	O
102	,	_	_	O
103	site	_	_	O
104	,	_	_	O
105	stage	_	_	O
106	(	_	_	O
107	early	_	_	O
108	vs	_	_	O
109	advanced	_	_	O
110	)	_	_	O
111	,	_	_	O
112	and	_	_	O
113	primary	_	_	O
114	modality	_	_	O
115	of	_	_	O
116	treatment	_	_	O
117	(	_	_	O
118	radiation	_	_	O
119	vs	_	_	O
120	surgery	_	_	O
121	)	_	_	O
122	.	_	_	O

123	The	_	_	O
124	primary	_	_	O
125	outcome	_	_	O
126	measure	_	_	O
127	was	_	_	O
128	the	_	_	O
129	number	_	_	O
130	of	_	_	O
131	participants	_	_	O
132	who	_	_	O
133	developed	_	_	O
134	moderate	_	_	O
135	or	_	_	O
136	greater	_	_	O
137	depression	_	_	O
138	(	_	_	O
139	scores	_	_	O
140	on	_	_	O
141	the	_	_	O
142	Quick	_	_	O
143	Inventory	_	_	O
144	of	_	_	O
145	Depressive	_	_	O
146	Symptomology-Self	_	_	O
147	Rated	_	_	O
148	of	_	_	O
149	11	_	_	O
150	)	_	_	O
151	.	_	_	O

152	From	_	_	O
153	January	_	_	O
154	6	_	_	O
155	,	_	_	O
156	2008	_	_	O
157	,	_	_	O
158	to	_	_	O
159	December	_	_	O
160	28	_	_	O
161	,	_	_	O
162	2011	_	_	O
163	,	_	_	O
164	148	_	_	O
165	patients	_	_	O
166	were	_	_	O
167	randomized	_	_	O
168	.	_	_	O

169	Significantly	_	_	B-Premise
170	fewer	_	_	I-Premise
171	patients	_	_	I-Premise
172	receiving	_	_	I-Premise
173	escitalopram	_	_	I-Premise
174	developed	_	_	I-Premise
175	depression	_	_	I-Premise
176	(	_	_	I-Premise
177	24.6	_	_	I-Premise
178	%	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	placebo	_	_	I-Premise
182	group	_	_	I-Premise
183	vs	_	_	I-Premise
184	10.0	_	_	I-Premise
185	%	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	escitalopram	_	_	I-Premise
189	group	_	_	I-Premise
190	;	_	_	I-Premise
191	stratified	_	_	I-Premise
192	log-rank	_	_	I-Premise
193	test	_	_	I-Premise
194	,	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	.04	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	A	_	_	O
201	Cox	_	_	O
202	proportional	_	_	O
203	hazards	_	_	O
204	regression	_	_	O
205	model	_	_	O
206	compared	_	_	O
207	the	_	_	O
208	2	_	_	O
209	treatment	_	_	O
210	groups	_	_	O
211	after	_	_	O
212	controlling	_	_	O
213	for	_	_	O
214	age	_	_	O
215	,	_	_	O
216	baseline	_	_	O
217	smoking	_	_	O
218	status	_	_	O
219	,	_	_	O
220	and	_	_	O
221	stratification	_	_	O
222	variables	_	_	O
223	.	_	_	O

224	The	_	_	B-Premise
225	hazard	_	_	I-Premise
226	ratio	_	_	I-Premise
227	of	_	_	I-Premise
228	0.37	_	_	I-Premise
229	(	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	,	_	_	I-Premise
234	0.14-0.96	_	_	I-Premise
235	)	_	_	I-Premise
236	demonstrated	_	_	I-Premise
237	an	_	_	I-Premise
238	advantage	_	_	I-Premise
239	of	_	_	I-Premise
240	escitalopram	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.04	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Patients	_	_	B-Premise
248	undergoing	_	_	I-Premise
249	radiotherapy	_	_	I-Premise
250	as	_	_	I-Premise
251	the	_	_	I-Premise
252	initial	_	_	I-Premise
253	modality	_	_	I-Premise
254	were	_	_	I-Premise
255	significantly	_	_	I-Premise
256	more	_	_	I-Premise
257	likely	_	_	I-Premise
258	to	_	_	I-Premise
259	develop	_	_	I-Premise
260	depression	_	_	I-Premise
261	than	_	_	I-Premise
262	those	_	_	I-Premise
263	undergoing	_	_	I-Premise
264	surgery	_	_	I-Premise
265	(	_	_	I-Premise
266	radiotherapy	_	_	I-Premise
267	compared	_	_	I-Premise
268	with	_	_	I-Premise
269	surgery	_	_	I-Premise
270	group	_	_	I-Premise
271	;	_	_	I-Premise
272	hazard	_	_	I-Premise
273	ratio	_	_	I-Premise
274	,	_	_	I-Premise
275	3.6	_	_	I-Premise
276	;	_	_	I-Premise
277	95	_	_	I-Premise
278	%	_	_	I-Premise
279	CI	_	_	I-Premise
280	,	_	_	I-Premise
281	1.38-9.40	_	_	I-Premise
282	;	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	.009	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	Patients	_	_	B-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	escitalopram	_	_	I-Premise
292	group	_	_	I-Premise
293	who	_	_	I-Premise
294	completed	_	_	I-Premise
295	the	_	_	I-Premise
296	study	_	_	I-Premise
297	and	_	_	I-Premise
298	were	_	_	I-Premise
299	not	_	_	I-Premise
300	depressed	_	_	I-Premise
301	rated	_	_	I-Premise
302	their	_	_	I-Premise
303	overall	_	_	I-Premise
304	quality	_	_	I-Premise
305	of	_	_	I-Premise
306	life	_	_	I-Premise
307	as	_	_	I-Premise
308	significantly	_	_	I-Premise
309	better	_	_	I-Premise
310	for	_	_	I-Premise
311	3	_	_	I-Premise
312	consecutive	_	_	I-Premise
313	months	_	_	I-Premise
314	after	_	_	I-Premise
315	cessation	_	_	I-Premise
316	of	_	_	I-Premise
317	drug	_	_	I-Premise
318	use	_	_	I-Premise
319	.	_	_	I-Premise

320	In	_	_	B-Claim
321	nondepressed	_	_	I-Claim
322	patients	_	_	I-Claim
323	undergoing	_	_	I-Claim
324	treatment	_	_	I-Claim
325	for	_	_	I-Claim
326	head	_	_	I-Claim
327	and	_	_	I-Claim
328	neck	_	_	I-Claim
329	cancer	_	_	I-Claim
330	,	_	_	I-Claim
331	prophylactic	_	_	I-Claim
332	escitalopram	_	_	I-Claim
333	reduced	_	_	I-Claim
334	the	_	_	I-Claim
335	risk	_	_	I-Claim
336	of	_	_	I-Claim
337	developing	_	_	I-Claim
338	depression	_	_	I-Claim
339	by	_	_	I-Claim
340	more	_	_	I-Claim
341	than	_	_	I-Claim
342	50	_	_	I-Claim
343	%	_	_	I-Claim
344	.	_	_	I-Claim

345	In	_	_	B-Claim
346	nondepressed	_	_	I-Claim
347	patients	_	_	I-Claim
348	who	_	_	I-Claim
349	completed	_	_	I-Claim
350	the	_	_	I-Claim
351	trial	_	_	I-Claim
352	,	_	_	I-Claim
353	quality	_	_	I-Claim
354	of	_	_	I-Claim
355	life	_	_	I-Claim
356	was	_	_	I-Claim
357	also	_	_	I-Claim
358	significantly	_	_	I-Claim
359	better	_	_	I-Claim
360	for	_	_	I-Claim
361	3	_	_	I-Claim
362	consecutive	_	_	I-Claim
363	months	_	_	I-Claim
364	after	_	_	I-Claim
365	cessation	_	_	I-Claim
366	of	_	_	I-Claim
367	drug	_	_	I-Claim
368	use	_	_	I-Claim
369	in	_	_	I-Claim
370	the	_	_	I-Claim
371	escitalopram	_	_	I-Claim
372	group	_	_	I-Claim
373	.	_	_	I-Claim

374	These	_	_	B-Claim
375	findings	_	_	I-Claim
376	have	_	_	I-Claim
377	important	_	_	I-Claim
378	implications	_	_	I-Claim
379	for	_	_	I-Claim
380	the	_	_	I-Claim
381	treatment	_	_	I-Claim
382	of	_	_	I-Claim
383	patients	_	_	I-Claim
384	with	_	_	I-Claim
385	head	_	_	I-Claim
386	and	_	_	I-Claim
387	neck	_	_	I-Claim
388	cancer	_	_	I-Claim
389	.	_	_	I-Claim


0	In	_	_	O
1	a	_	_	O
2	prospective	_	_	O
3	randomized	_	_	O
4	study	_	_	O
5	,	_	_	O
6	287	_	_	O
7	patients	_	_	O
8	with	_	_	O
9	advanced	_	_	O
10	non-small	_	_	O
11	cell	_	_	O
12	lung	_	_	O
13	cancer	_	_	O
14	(	_	_	O
15	NSCLC	_	_	O
16	)	_	_	O
17	stage	_	_	O
18	IIIb	_	_	O
19	or	_	_	O
20	IV	_	_	O
21	with	_	_	O
22	ECOG	_	_	O
23	performance	_	_	O
24	status	_	_	O
25	(	_	_	O
26	PS	_	_	O
27	)	_	_	O
28	0-1	_	_	O
29	or	_	_	O
30	2	_	_	O
31	were	_	_	O
32	randomly	_	_	O
33	assigned	_	_	O
34	to	_	_	O
35	receive	_	_	O
36	either	_	_	O
37	best	_	_	O
38	supportive	_	_	O
39	care	_	_	O
40	(	_	_	O
41	BSC	_	_	O
42	)	_	_	O
43	or	_	_	O
44	supportive	_	_	O
45	care	_	_	O
46	plus	_	_	O
47	combination	_	_	O
48	chemotherapy	_	_	O
49	(	_	_	O
50	IEP	_	_	O
51	regimen	_	_	O
52	:	_	_	O
53	ifosfamide	_	_	O
54	3	_	_	O
55	gm/m2	_	_	O
56	IV	_	_	O
57	with	_	_	O
58	mesna	_	_	O
59	uroprotection	_	_	O
60	,	_	_	O
61	epirubicin	_	_	O
62	60	_	_	O
63	mg/m2	_	_	O
64	IV	_	_	O
65	on	_	_	O
66	day	_	_	O
67	1	_	_	O
68	and	_	_	O
69	cisplatin	_	_	O
70	60	_	_	O
71	mg/m2	_	_	O
72	IV	_	_	O
73	on	_	_	O
74	day	_	_	O
75	2	_	_	O
76	;	_	_	O
77	or	_	_	O
78	MVP	_	_	O
79	regimen	_	_	O
80	:	_	_	O
81	mitomycin-C	_	_	O
82	8	_	_	O
83	mg/m2	_	_	O
84	,	_	_	O
85	cisplatin	_	_	O
86	100	_	_	O
87	mg/m2	_	_	O
88	IV	_	_	O
89	on	_	_	O
90	day	_	_	O
91	1	_	_	O
92	,	_	_	O
93	vinblastine	_	_	O
94	4	_	_	O
95	mg/m2	_	_	O
96	IV	_	_	O
97	on	_	_	O
98	days	_	_	O
99	1	_	_	O
100	and	_	_	O
101	15	_	_	O
102	)	_	_	O
103	.	_	_	O

104	Serial	_	_	O
105	assessment	_	_	O
106	of	_	_	O
107	Karnofsky	_	_	O
108	performance	_	_	O
109	status	_	_	O
110	(	_	_	O
111	KPS	_	_	O
112	)	_	_	O
113	,	_	_	O
114	modified	_	_	O
115	Functional	_	_	O
116	Living	_	_	O
117	Index-Cancer	_	_	O
118	(	_	_	O
119	T-FLIC	_	_	O
120	)	_	_	O
121	and	_	_	O
122	modified	_	_	O
123	Quality	_	_	O
124	of	_	_	O
125	Life-Index	_	_	O
126	(	_	_	O
127	T-QLI	_	_	O
128	)	_	_	O
129	were	_	_	O
130	used	_	_	O
131	to	_	_	O
132	estimate	_	_	O
133	the	_	_	O
134	quality	_	_	O
135	of	_	_	O
136	life	_	_	O
137	.	_	_	O

138	Interviews	_	_	O
139	were	_	_	O
140	done	_	_	O
141	at	_	_	O
142	entry	_	_	O
143	,	_	_	O
144	at	_	_	O
145	the	_	_	O
146	third	_	_	O
147	month	_	_	O
148	and	_	_	O
149	at	_	_	O
150	2	_	_	O
151	months	_	_	O
152	post	_	_	O
153	complete	_	_	O
154	treatment	_	_	O
155	.	_	_	O

156	At	_	_	O
157	least	_	_	O
158	two	_	_	O
159	courses	_	_	O
160	of	_	_	O
161	chemotherapy	_	_	O
162	were	_	_	O
163	considered	_	_	O
164	to	_	_	O
165	be	_	_	O
166	adequate	_	_	O
167	for	_	_	O
168	response	_	_	O
169	evaluation	_	_	O
170	.	_	_	O

171	Patients	_	_	O
172	were	_	_	O
173	treated	_	_	O
174	for	_	_	O
175	a	_	_	O
176	total	_	_	O
177	of	_	_	O
178	four	_	_	O
179	to	_	_	O
180	six	_	_	O
181	courses	_	_	O
182	or	_	_	O
183	until	_	_	O
184	progression	_	_	O
185	of	_	_	O
186	disease	_	_	O
187	.	_	_	O

188	Partial	_	_	B-Premise
189	response	_	_	I-Premise
190	rates	_	_	I-Premise
191	were	_	_	I-Premise
192	40	_	_	I-Premise
193	and	_	_	I-Premise
194	41.7	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	IEP	_	_	I-Premise
198	and	_	_	I-Premise
199	MVP	_	_	I-Premise
200	arms	_	_	I-Premise
201	.	_	_	I-Premise

202	Median	_	_	B-Premise
203	survival	_	_	I-Premise
204	durations	_	_	I-Premise
205	were	_	_	I-Premise
206	5.9	_	_	I-Premise
207	and	_	_	I-Premise
208	8.1	_	_	I-Premise
209	months	_	_	I-Premise
210	for	_	_	I-Premise
211	the	_	_	I-Premise
212	IEP	_	_	I-Premise
213	and	_	_	I-Premise
214	MVP	_	_	I-Premise
215	chemotherapy	_	_	I-Premise
216	arms	_	_	I-Premise
217	,	_	_	I-Premise
218	and	_	_	I-Premise
219	4.1	_	_	I-Premise
220	months	_	_	I-Premise
221	for	_	_	I-Premise
222	BSC	_	_	I-Premise
223	(	_	_	I-Premise
224	log-rank	_	_	I-Premise
225	test	_	_	I-Premise
226	:	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0.0003	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	One	_	_	B-Premise
233	year	_	_	I-Premise
234	survival	_	_	I-Premise
235	was	_	_	I-Premise
236	13	_	_	I-Premise
237	,	_	_	I-Premise
238	29.8	_	_	I-Premise
239	and	_	_	I-Premise
240	39.3	_	_	I-Premise
241	%	_	_	I-Premise
242	for	_	_	I-Premise
243	the	_	_	I-Premise
244	BSC	_	_	I-Premise
245	,	_	_	I-Premise
246	IEP	_	_	I-Premise
247	and	_	_	I-Premise
248	MVP	_	_	I-Premise
249	regimens	_	_	I-Premise
250	,	_	_	I-Premise
251	respectively	_	_	I-Premise
252	.	_	_	I-Premise

253	Two	_	_	B-Premise
254	years	_	_	I-Premise
255	survival	_	_	I-Premise
256	was	_	_	I-Premise
257	7.8	_	_	I-Premise
258	,	_	_	I-Premise
259	6.4	_	_	I-Premise
260	and	_	_	I-Premise
261	13.1	_	_	I-Premise
262	%	_	_	I-Premise
263	for	_	_	I-Premise
264	the	_	_	I-Premise
265	BSC	_	_	I-Premise
266	,	_	_	I-Premise
267	IEP	_	_	I-Premise
268	and	_	_	I-Premise
269	MVP	_	_	I-Premise
270	regimens	_	_	I-Premise
271	,	_	_	I-Premise
272	respectively	_	_	I-Premise
273	.	_	_	I-Premise

274	Improvement	_	_	B-Premise
275	in	_	_	I-Premise
276	quality	_	_	I-Premise
277	of	_	_	I-Premise
278	life	_	_	I-Premise
279	(	_	_	I-Premise
280	QOL	_	_	I-Premise
281	)	_	_	I-Premise
282	scores	_	_	I-Premise
283	at	_	_	I-Premise
284	the	_	_	I-Premise
285	first	_	_	I-Premise
286	,	_	_	I-Premise
287	second	_	_	I-Premise
288	and	_	_	I-Premise
289	third	_	_	I-Premise
290	interview	_	_	I-Premise
291	were	_	_	I-Premise
292	seen	_	_	I-Premise
293	in	_	_	I-Premise
294	chemotherapy	_	_	I-Premise
295	arms	_	_	I-Premise
296	only	_	_	I-Premise
297	,	_	_	I-Premise
298	not	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	BSC	_	_	I-Premise
302	arm	_	_	I-Premise
303	.	_	_	I-Premise

304	We	_	_	O
305	conclude	_	_	O
306	that	_	_	O
307	combination	_	_	B-Claim
308	chemotherapy	_	_	I-Claim
309	improves	_	_	I-Claim
310	the	_	_	I-Claim
311	quality	_	_	I-Claim
312	of	_	_	I-Claim
313	life	_	_	I-Claim
314	as	_	_	I-Claim
315	well	_	_	I-Claim
316	as	_	_	I-Claim
317	prolonging	_	_	I-Claim
318	the	_	_	I-Claim
319	survival	_	_	I-Claim
320	of	_	_	I-Claim
321	patients	_	_	I-Claim
322	with	_	_	I-Claim
323	advanced	_	_	I-Claim
324	NSCLC	_	_	I-Claim
325	.	_	_	I-Claim


0	Low	_	_	B-Claim
1	anterior	_	_	I-Claim
2	resection	_	_	I-Claim
3	with	_	_	I-Claim
4	coloanal	_	_	I-Claim
5	anastomosis	_	_	I-Claim
6	prevents	_	_	I-Claim
7	a	_	_	I-Claim
8	definitive	_	_	I-Claim
9	stoma	_	_	I-Claim
10	in	_	_	I-Claim
11	patients	_	_	I-Claim
12	with	_	_	I-Claim
13	distal	_	_	I-Claim
14	rectal	_	_	I-Claim
15	cancer	_	_	I-Claim
16	.	_	_	I-Claim

17	However	_	_	B-Premise
18	,	_	_	I-Premise
19	imperative	_	_	I-Premise
20	stool	_	_	I-Premise
21	urge	_	_	I-Premise
22	,	_	_	I-Premise
23	stool	_	_	I-Premise
24	fragmentation	_	_	I-Premise
25	,	_	_	I-Premise
26	prolonged	_	_	I-Premise
27	stooling	_	_	I-Premise
28	sessions	_	_	I-Premise
29	,	_	_	I-Premise
30	and	_	_	I-Premise
31	minor	_	_	I-Premise
32	problems	_	_	I-Premise
33	of	_	_	I-Premise
34	incontinence	_	_	I-Premise
35	are	_	_	I-Premise
36	frequently	_	_	I-Premise
37	observed	_	_	I-Premise
38	in	_	_	I-Premise
39	the	_	_	I-Premise
40	postoperative	_	_	I-Premise
41	situation	_	_	I-Premise
42	and	_	_	I-Premise
43	negatively	_	_	I-Premise
44	affect	_	_	I-Premise
45	quality	_	_	I-Premise
46	of	_	_	I-Premise
47	life	_	_	I-Premise
48	.	_	_	I-Premise

49	Therefore	_	_	O
50	,	_	_	O
51	the	_	_	O
52	colonic	_	_	O
53	J-pouch	_	_	O
54	was	_	_	O
55	originally	_	_	O
56	constructed	_	_	O
57	to	_	_	O
58	create	_	_	O
59	a	_	_	O
60	stool	_	_	O
61	reservoir	_	_	O
62	.	_	_	O

63	In	_	_	O
64	a	_	_	O
65	randomized	_	_	O
66	,	_	_	O
67	prospective	_	_	O
68	study	_	_	O
69	,	_	_	O
70	the	_	_	O
71	short	_	_	O
72	(	_	_	O
73	5	_	_	O
74	cm	_	_	O
75	)	_	_	O
76	colonic	_	_	O
77	J-pouch	_	_	O
78	was	_	_	O
79	tested	_	_	O
80	for	_	_	O
81	function	_	_	O
82	and	_	_	O
83	continence	_	_	O
84	vs.	_	_	O
85	straight	_	_	O
86	coloanal	_	_	O
87	anastomosis	_	_	O
88	.	_	_	O

89	Over	_	_	O
90	a	_	_	O
91	period	_	_	O
92	of	_	_	O
93	30	_	_	O
94	months	_	_	O
95	,	_	_	O
96	74	_	_	O
97	consecutive	_	_	O
98	patients	_	_	O
99	(	_	_	O
100	55	_	_	O
101	males	_	_	O
102	)	_	_	O
103	with	_	_	O
104	rectal	_	_	O
105	cancer	_	_	O
106	in	_	_	O
107	the	_	_	O
108	lower	_	_	O
109	and	_	_	O
110	middle	_	_	O
111	third	_	_	O
112	of	_	_	O
113	the	_	_	O
114	rectum	_	_	O
115	were	_	_	O
116	included	_	_	O
117	and	_	_	O
118	randomized	_	_	O
119	into	_	_	O
120	two	_	_	O
121	groups	_	_	O
122	.	_	_	O

123	Anastomosis	_	_	O
124	was	_	_	O
125	performed	_	_	O
126	either	_	_	O
127	as	_	_	O
128	a	_	_	O
129	coloanal	_	_	O
130	or	_	_	O
131	a	_	_	O
132	colon-pouch-anal	_	_	O
133	anastomosis	_	_	O
134	.	_	_	O

135	The	_	_	O
136	standardized	_	_	O
137	surgical	_	_	O
138	procedure	_	_	O
139	included	_	_	O
140	mobilization	_	_	O
141	of	_	_	O
142	the	_	_	O
143	left	_	_	O
144	hemicolon	_	_	O
145	,	_	_	O
146	central	_	_	O
147	ligation	_	_	O
148	of	_	_	O
149	the	_	_	O
150	inferior	_	_	O
151	mesenteric	_	_	O
152	artery	_	_	O
153	and	_	_	O
154	vein	_	_	O
155	,	_	_	O
156	preaortal	_	_	O
157	lymph	_	_	O
158	node	_	_	O
159	dissection	_	_	O
160	,	_	_	O
161	autonomic	_	_	O
162	nerve	_	_	O
163	preservation	_	_	O
164	,	_	_	O
165	and	_	_	O
166	total	_	_	O
167	mesorectal	_	_	O
168	excision	_	_	O
169	.	_	_	O

170	The	_	_	O
171	anastomosis	_	_	O
172	was	_	_	O
173	performed	_	_	O
174	at	_	_	O
175	the	_	_	O
176	upper	_	_	O
177	anal	_	_	O
178	canal	_	_	O
179	or	_	_	O
180	at	_	_	O
181	the	_	_	O
182	intersphincteric	_	_	O
183	level	_	_	O
184	.	_	_	O

185	All	_	_	O
186	patients	_	_	O
187	were	_	_	O
188	evaluated	_	_	O
189	preoperatively	_	_	O
190	and	_	_	O
191	six	_	_	O
192	months	_	_	O
193	postoperatively	_	_	O
194	for	_	_	O
195	fecal	_	_	O
196	continence	_	_	O
197	,	_	_	O
198	including	_	_	O
199	sphincter	_	_	O
200	manometry	_	_	O
201	and	_	_	O
202	defecation	_	_	O
203	habits	_	_	O
204	.	_	_	O

205	In	_	_	O
206	addition	_	_	O
207	,	_	_	O
208	quality	_	_	O
209	of	_	_	O
210	life	_	_	O
211	was	_	_	O
212	determined	_	_	O
213	by	_	_	O
214	use	_	_	O
215	of	_	_	O
216	a	_	_	O
217	standardized	_	_	O
218	questionnaire	_	_	O
219	(	_	_	O
220	European	_	_	O
221	Organization	_	_	O
222	for	_	_	O
223	Research	_	_	O
224	and	_	_	O
225	Treatment	_	_	O
226	of	_	_	O
227	Cancer	_	_	O
228	,	_	_	O
229	EORTC-QLQ-C30	_	_	O
230	)	_	_	O
231	.	_	_	O

232	Thirty-seven	_	_	O
233	patients	_	_	O
234	were	_	_	O
235	randomized	_	_	O
236	into	_	_	O
237	each	_	_	O
238	group	_	_	O
239	.	_	_	O

240	In	_	_	O
241	general	_	_	O
242	,	_	_	O
243	problems	_	_	B-Premise
244	with	_	_	I-Premise
245	continence	_	_	I-Premise
246	for	_	_	I-Premise
247	liquids	_	_	I-Premise
248	or	_	_	I-Premise
249	gas	_	_	I-Premise
250	occurred	_	_	I-Premise
251	less	_	_	I-Premise
252	frequently	_	_	I-Premise
253	in	_	_	I-Premise
254	the	_	_	I-Premise
255	colonic	_	_	I-Premise
256	J-pouch	_	_	I-Premise
257	group	_	_	I-Premise
258	6	_	_	I-Premise
259	months	_	_	I-Premise
260	after	_	_	I-Premise
261	surgery	_	_	I-Premise
262	.	_	_	I-Premise

263	The	_	_	B-Premise
264	frequency	_	_	I-Premise
265	of	_	_	I-Premise
266	bowel	_	_	I-Premise
267	movements	_	_	I-Premise
268	was	_	_	I-Premise
269	lower	_	_	I-Premise
270	in	_	_	I-Premise
271	the	_	_	I-Premise
272	J-pouch	_	_	I-Premise
273	group	_	_	I-Premise
274	(	_	_	I-Premise
275	2.5	_	_	I-Premise
276	per	_	_	I-Premise
277	day	_	_	I-Premise
278	)	_	_	I-Premise
279	than	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	coloanal	_	_	I-Premise
283	group	_	_	I-Premise
284	(	_	_	I-Premise
285	4.7	_	_	I-Premise
286	per	_	_	I-Premise
287	day	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Importantly	_	_	O
291	,	_	_	O
292	in	_	_	B-Premise
293	a	_	_	I-Premise
294	manometric	_	_	I-Premise
295	study	_	_	I-Premise
296	at	_	_	I-Premise
297	the	_	_	I-Premise
298	same	_	_	I-Premise
299	postoperative	_	_	I-Premise
300	point	_	_	I-Premise
301	,	_	_	I-Premise
302	neorectal	_	_	I-Premise
303	capacity	_	_	I-Premise
304	was	_	_	I-Premise
305	decreased	_	_	I-Premise
306	to	_	_	I-Premise
307	a	_	_	I-Premise
308	similar	_	_	I-Premise
309	degree	_	_	I-Premise
310	in	_	_	I-Premise
311	both	_	_	I-Premise
312	groups	_	_	I-Premise
313	compared	_	_	I-Premise
314	with	_	_	I-Premise
315	the	_	_	I-Premise
316	preoperative	_	_	I-Premise
317	rectal	_	_	I-Premise
318	volume	_	_	I-Premise
319	.	_	_	I-Premise

320	Thus	_	_	O
321	,	_	_	O
322	the	_	_	B-Premise
323	expected	_	_	I-Premise
324	and	_	_	I-Premise
325	postulated	_	_	I-Premise
326	reservoir	_	_	I-Premise
327	effect	_	_	I-Premise
328	could	_	_	I-Premise
329	not	_	_	I-Premise
330	be	_	_	I-Premise
331	achieved	_	_	I-Premise
332	by	_	_	I-Premise
333	forming	_	_	I-Premise
334	a	_	_	I-Premise
335	5-cm	_	_	I-Premise
336	colonic	_	_	I-Premise
337	J-pouch	_	_	I-Premise
338	.	_	_	I-Premise

339	The	_	_	B-Claim
340	colonic	_	_	I-Claim
341	J-pouch	_	_	I-Claim
342	was	_	_	I-Claim
343	superior	_	_	I-Claim
344	with	_	_	I-Claim
345	regard	_	_	I-Claim
346	to	_	_	I-Claim
347	continence	_	_	I-Claim
348	for	_	_	I-Claim
349	gas	_	_	I-Claim
350	and	_	_	I-Claim
351	liquids	_	_	I-Claim
352	compared	_	_	I-Claim
353	with	_	_	I-Claim
354	a	_	_	I-Claim
355	straight	_	_	I-Claim
356	coloanal	_	_	I-Claim
357	anastomosis	_	_	I-Claim
358	.	_	_	I-Claim

359	Furthermore	_	_	O
360	,	_	_	O
361	stool	_	_	B-Claim
362	frequency	_	_	I-Claim
363	was	_	_	I-Claim
364	significantly	_	_	I-Claim
365	lower	_	_	I-Claim
366	in	_	_	I-Claim
367	the	_	_	I-Claim
368	J-pouch	_	_	I-Claim
369	group	_	_	I-Claim
370	than	_	_	I-Claim
371	in	_	_	I-Claim
372	the	_	_	I-Claim
373	coloanal	_	_	I-Claim
374	reconstruction	_	_	I-Claim
375	group	_	_	I-Claim
376	.	_	_	I-Claim

377	However	_	_	O
378	,	_	_	O
379	because	_	_	B-Premise
380	neorectal	_	_	I-Premise
381	capacity	_	_	I-Premise
382	decreased	_	_	I-Premise
383	equally	_	_	I-Premise
384	in	_	_	I-Premise
385	both	_	_	I-Premise
386	groups	_	_	I-Premise
387	,	_	_	I-Premise
388	we	_	_	B-Claim
389	speculate	_	_	I-Claim
390	that	_	_	I-Claim
391	the	_	_	I-Claim
392	advantage	_	_	I-Claim
393	of	_	_	I-Claim
394	the	_	_	I-Claim
395	colonic	_	_	I-Claim
396	J-pouch	_	_	I-Claim
397	is	_	_	I-Claim
398	not	_	_	I-Claim
399	in	_	_	I-Claim
400	the	_	_	I-Claim
401	creation	_	_	I-Claim
402	of	_	_	I-Claim
403	a	_	_	I-Claim
404	larger	_	_	I-Claim
405	neorectal	_	_	I-Claim
406	reservoir	_	_	I-Claim
407	but	_	_	I-Claim
408	rather	_	_	I-Claim
409	may	_	_	I-Claim
410	be	_	_	I-Claim
411	related	_	_	I-Claim
412	to	_	_	I-Claim
413	decreased	_	_	I-Claim
414	motility	_	_	I-Claim
415	.	_	_	I-Claim


0	Non-randomised	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	suggested	_	_	O
4	that	_	_	O
5	the	_	_	B-Claim
6	postoperative	_	_	I-Claim
7	complications	_	_	I-Claim
8	of	_	_	I-Claim
9	(	_	_	I-Claim
10	Campos	_	_	I-Claim
11	LS	_	_	I-Claim
12	,	_	_	I-Claim
13	Limberger	_	_	I-Claim
14	LF	_	_	I-Claim
15	,	_	_	I-Claim
16	Stein	_	_	I-Claim
17	AT	_	_	I-Claim
18	,	_	_	I-Claim
19	Kalil	_	_	I-Claim
20	AN	_	_	I-Claim
21	)	_	_	I-Claim
22	laparoscopic	_	_	I-Claim
23	radical	_	_	I-Claim
24	hysterectomy	_	_	I-Claim
25	are	_	_	I-Claim
26	similar	_	_	I-Claim
27	to	_	_	I-Claim
28	those	_	_	I-Claim
29	in	_	_	I-Claim
30	abdominal	_	_	I-Claim
31	radical	_	_	I-Claim
32	hysterectomy	_	_	I-Claim
33	.	_	_	I-Claim

34	However	_	_	O
35	,	_	_	O
36	no	_	_	O
37	study	_	_	O
38	evaluating	_	_	O
39	postoperative	_	_	O
40	pain	_	_	O
41	comparing	_	_	O
42	both	_	_	O
43	techniques	_	_	O
44	has	_	_	O
45	been	_	_	O
46	published	_	_	O
47	thus	_	_	O
48	far	_	_	O
49	.	_	_	O

50	Our	_	_	O
51	objective	_	_	O
52	was	_	_	O
53	to	_	_	O
54	compare	_	_	O
55	pain	_	_	O
56	intensity	_	_	O
57	and	_	_	O
58	other	_	_	O
59	perioperative	_	_	O
60	outcomes	_	_	O
61	between	_	_	O
62	laparoscopic	_	_	O
63	radical	_	_	O
64	hysterectomy	_	_	O
65	(	_	_	O
66	LRH	_	_	O
67	)	_	_	O
68	and	_	_	O
69	abdominal	_	_	O
70	radical	_	_	O
71	hysterectomy	_	_	O
72	(	_	_	O
73	ARH	_	_	O
74	)	_	_	O
75	in	_	_	O
76	early	_	_	O
77	cervical	_	_	O
78	cancer	_	_	O
79	.	_	_	O

80	This	_	_	O
81	single	_	_	O
82	centre	_	_	O
83	,	_	_	O
84	randomised	_	_	O
85	,	_	_	O
86	controlled	_	_	O
87	trial	_	_	O
88	enrolled	_	_	O
89	30	_	_	O
90	cervical	_	_	O
91	cancer	_	_	O
92	patients	_	_	O
93	who	_	_	O
94	were	_	_	O
95	clinically	_	_	O
96	staged	_	_	O
97	IA2	_	_	O
98	with	_	_	O
99	lymph	_	_	O
100	vascular	_	_	O
101	invasion	_	_	O
102	and	_	_	O
103	IB	_	_	O
104	according	_	_	O
105	to	_	_	O
106	the	_	_	O
107	FIGO	_	_	O
108	(	_	_	O
109	International	_	_	O
110	Federation	_	_	O
111	of	_	_	O
112	Gynaecology	_	_	O
113	and	_	_	O
114	Obstetrics	_	_	O
115	)	_	_	O
116	classification	_	_	O
117	,	_	_	O
118	and	_	_	O
119	underwent	_	_	O
120	LRH	_	_	O
121	or	_	_	O
122	ARH	_	_	O
123	between	_	_	O
124	late	_	_	O
125	1999	_	_	O
126	and	_	_	O
127	early	_	_	O
128	2004	_	_	O
129	.	_	_	O

130	Postoperative	_	_	O
131	pain	_	_	O
132	,	_	_	O
133	as	_	_	O
134	measured	_	_	O
135	by	_	_	O
136	a	_	_	O
137	10-point	_	_	O
138	numerical	_	_	O
139	rate	_	_	O
140	scale	_	_	O
141	,	_	_	O
142	was	_	_	O
143	considered	_	_	O
144	the	_	_	O
145	primary	_	_	O
146	endpoint	_	_	O
147	.	_	_	O

148	Postoperative	_	_	O
149	pain	_	_	O
150	was	_	_	O
151	assessed	_	_	O
152	every	_	_	O
153	six	_	_	O
154	hours	_	_	O
155	during	_	_	O
156	a	_	_	O
157	patient	_	_	O
158	's	_	_	O
159	usual	_	_	O
160	postoperative	_	_	O
161	care	_	_	O
162	.	_	_	O

163	Perioperative	_	_	O
164	outcomes	_	_	O
165	were	_	_	O
166	also	_	_	O
167	registered	_	_	O
168	.	_	_	O

169	Both	_	_	O
170	surgical	_	_	O
171	techniques	_	_	O
172	were	_	_	O
173	executed	_	_	O
174	by	_	_	O
175	the	_	_	O
176	same	_	_	O
177	surgical	_	_	O
178	team	_	_	O
179	.	_	_	O

180	Secondary	_	_	O
181	outcomes	_	_	O
182	included	_	_	O
183	intraoperative	_	_	O
184	and	_	_	O
185	other	_	_	O
186	postoperative	_	_	O
187	surgicopathological	_	_	O
188	factors	_	_	O
189	and	_	_	O
190	5-year	_	_	O
191	survival	_	_	O
192	rates	_	_	O
193	.	_	_	O

194	IA2	_	_	O
195	patients	_	_	O
196	with	_	_	O
197	lymphatic	_	_	O
198	vascular	_	_	O
199	space	_	_	O
200	invasion	_	_	O
201	and	_	_	O
202	IB	_	_	O
203	cervical	_	_	O
204	cancer	_	_	O
205	patients	_	_	O
206	were	_	_	O
207	randomised	_	_	O
208	to	_	_	O
209	either	_	_	O
210	the	_	_	O
211	LRH	_	_	O
212	group	_	_	O
213	(	_	_	O
214	16	_	_	O
215	patients	_	_	O
216	)	_	_	O
217	or	_	_	O
218	the	_	_	O
219	ARH	_	_	O
220	group	_	_	O
221	(	_	_	O
222	14	_	_	O
223	patients	_	_	O
224	)	_	_	O
225	.	_	_	O

226	Four	_	_	B-Premise
227	patients	_	_	I-Premise
228	(	_	_	I-Premise
229	25	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	in	_	_	I-Premise
233	the	_	_	I-Premise
234	LRH	_	_	I-Premise
235	group	_	_	I-Premise
236	and	_	_	I-Premise
237	5	_	_	I-Premise
238	patients	_	_	I-Premise
239	(	_	_	I-Premise
240	36	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	ARH	_	_	I-Premise
246	group	_	_	I-Premise
247	presented	_	_	I-Premise
248	with	_	_	I-Premise
249	transoperative	_	_	I-Premise
250	or	_	_	I-Premise
251	serious	_	_	I-Premise
252	postoperative	_	_	I-Premise
253	complications	_	_	I-Premise
254	.	_	_	I-Premise

255	All	_	_	B-Premise
256	of	_	_	I-Premise
257	the	_	_	I-Premise
258	transoperative	_	_	I-Premise
259	complications	_	_	I-Premise
260	occurred	_	_	I-Premise
261	in	_	_	I-Premise
262	the	_	_	I-Premise
263	LRH	_	_	I-Premise
264	group	_	_	I-Premise
265	.	_	_	I-Premise

266	The	_	_	B-Premise
267	relative	_	_	I-Premise
268	risk	_	_	I-Premise
269	of	_	_	I-Premise
270	presenting	_	_	I-Premise
271	with	_	_	I-Premise
272	complications	_	_	I-Premise
273	was	_	_	I-Premise
274	0.70	_	_	I-Premise
275	;	_	_	I-Premise
276	CI	_	_	I-Premise
277	95	_	_	I-Premise
278	%	_	_	I-Premise
279	(	_	_	I-Premise
280	0.23-2.11	_	_	I-Premise
281	)	_	_	I-Premise
282	;	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	0.694	_	_	I-Premise
286	.	_	_	I-Premise

287	LRH	_	_	B-Premise
288	group	_	_	I-Premise
289	mean	_	_	I-Premise
290	pain	_	_	I-Premise
291	score	_	_	I-Premise
292	was	_	_	I-Premise
293	significantly	_	_	I-Premise
294	lower	_	_	I-Premise
295	than	_	_	I-Premise
296	ARH	_	_	I-Premise
297	after	_	_	I-Premise
298	36	_	_	I-Premise
299	h	_	_	I-Premise
300	of	_	_	I-Premise
301	observation	_	_	I-Premise
302	(	_	_	I-Premise
303	P	_	_	I-Premise
304	=	_	_	I-Premise
305	0.044	_	_	I-Premise
306	;	_	_	I-Premise
307	mean	_	_	I-Premise
308	difference	_	_	I-Premise
309	score	_	_	I-Premise
310	:	_	_	I-Premise
311	1.42	_	_	I-Premise
312	;	_	_	I-Premise
313	95	_	_	I-Premise
314	%	_	_	I-Premise
315	CI	_	_	I-Premise
316	:	_	_	I-Premise
317	0.04-2.80	_	_	I-Premise
318	)	_	_	I-Premise
319	.	_	_	I-Premise

320	The	_	_	O
321	survival	_	_	O
322	results	_	_	O
323	will	_	_	O
324	be	_	_	O
325	published	_	_	O
326	elsewhere	_	_	O
327	.	_	_	O

328	LRH	_	_	B-Claim
329	provided	_	_	I-Claim
330	lower	_	_	I-Claim
331	pain	_	_	I-Claim
332	scores	_	_	I-Claim
333	after	_	_	I-Claim
334	36	_	_	I-Claim
335	h	_	_	I-Claim
336	of	_	_	I-Claim
337	observation	_	_	I-Claim
338	in	_	_	I-Claim
339	this	_	_	I-Claim
340	series	_	_	I-Claim
341	.	_	_	I-Claim

342	The	_	_	B-Claim
343	perioperative	_	_	I-Claim
344	and	_	_	I-Claim
345	serious	_	_	I-Claim
346	postoperative	_	_	I-Claim
347	complications	_	_	I-Claim
348	ratios	_	_	I-Claim
349	were	_	_	I-Claim
350	comparable	_	_	I-Claim
351	between	_	_	I-Claim
352	the	_	_	I-Claim
353	groups	_	_	I-Claim
354	.	_	_	I-Claim


0	Fatigue	_	_	O
1	is	_	_	O
2	one	_	_	O
3	of	_	_	O
4	the	_	_	O
5	most	_	_	O
6	common	_	_	O
7	symptoms	_	_	O
8	experienced	_	_	O
9	by	_	_	O
10	patients	_	_	O
11	with	_	_	O
12	cancer	_	_	O
13	.	_	_	O

14	This	_	_	O
15	trial	_	_	O
16	was	_	_	O
17	developed	_	_	O
18	to	_	_	O
19	evaluate	_	_	O
20	the	_	_	O
21	efficacy	_	_	O
22	of	_	_	O
23	long-acting	_	_	O
24	methylphenidate	_	_	O
25	for	_	_	O
26	improving	_	_	O
27	cancer-related	_	_	O
28	fatigue	_	_	O
29	and	_	_	O
30	to	_	_	O
31	assess	_	_	O
32	its	_	_	O
33	toxicities	_	_	O
34	.	_	_	O

35	Adults	_	_	O
36	with	_	_	O
37	cancer	_	_	O
38	were	_	_	O
39	randomly	_	_	O
40	assigned	_	_	O
41	in	_	_	O
42	a	_	_	O
43	double-blinded	_	_	O
44	manner	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	methylphenidate	_	_	O
48	(	_	_	O
49	target	_	_	O
50	dose	_	_	O
51	,	_	_	O
52	54	_	_	O
53	mg/d	_	_	O
54	)	_	_	O
55	or	_	_	O
56	placebo	_	_	O
57	for	_	_	O
58	4	_	_	O
59	weeks	_	_	O
60	.	_	_	O

61	The	_	_	O
62	Brief	_	_	O
63	Fatigue	_	_	O
64	Inventory	_	_	O
65	was	_	_	O
66	the	_	_	O
67	primary	_	_	O
68	outcome	_	_	O
69	measure	_	_	O
70	,	_	_	O
71	while	_	_	O
72	secondary	_	_	O
73	outcome	_	_	O
74	measures	_	_	O
75	included	_	_	O
76	a	_	_	O
77	Symptom	_	_	O
78	Experience	_	_	O
79	Diary	_	_	O
80	(	_	_	O
81	SED	_	_	O
82	)	_	_	O
83	,	_	_	O
84	the	_	_	O
85	Short	_	_	O
86	Form-36	_	_	O
87	(	_	_	O
88	SF-36	_	_	O
89	)	_	_	O
90	Vitality	_	_	O
91	Subscale	_	_	O
92	,	_	_	O
93	a	_	_	O
94	linear	_	_	O
95	analog	_	_	O
96	self-assessment	_	_	O
97	,	_	_	O
98	the	_	_	O
99	Pittsburgh	_	_	O
100	Sleep	_	_	O
101	Quality	_	_	O
102	Index	_	_	O
103	,	_	_	O
104	and	_	_	O
105	the	_	_	O
106	Subject	_	_	O
107	Global	_	_	O
108	Impression	_	_	O
109	of	_	_	O
110	Change	_	_	O
111	.	_	_	O

112	In	_	_	O
113	total	_	_	O
114	,	_	_	O
115	148	_	_	O
116	patients	_	_	O
117	were	_	_	O
118	enrolled	_	_	O
119	.	_	_	O

120	Using	_	_	B-Premise
121	an	_	_	I-Premise
122	area	_	_	I-Premise
123	under	_	_	I-Premise
124	the	_	_	I-Premise
125	serum	_	_	I-Premise
126	concentration-time	_	_	I-Premise
127	curve	_	_	I-Premise
128	analysis	_	_	I-Premise
129	,	_	_	I-Premise
130	there	_	_	I-Premise
131	was	_	_	I-Premise
132	no	_	_	I-Premise
133	evidence	_	_	I-Premise
134	that	_	_	I-Premise
135	methylphenidate	_	_	I-Premise
136	,	_	_	I-Premise
137	as	_	_	I-Premise
138	compared	_	_	I-Premise
139	with	_	_	I-Premise
140	placebo	_	_	I-Premise
141	,	_	_	I-Premise
142	improved	_	_	I-Premise
143	the	_	_	I-Premise
144	primary	_	_	I-Premise
145	end	_	_	I-Premise
146	point	_	_	I-Premise
147	of	_	_	I-Premise
148	cancer-related	_	_	I-Premise
149	fatigue	_	_	I-Premise
150	in	_	_	I-Premise
151	this	_	_	I-Premise
152	patient	_	_	I-Premise
153	population	_	_	I-Premise
154	(	_	_	I-Premise
155	P	_	_	I-Premise
156	=	_	_	I-Premise
157	.35	_	_	I-Premise
158	)	_	_	I-Premise
159	.	_	_	I-Premise

160	Comparisons	_	_	B-Premise
161	of	_	_	I-Premise
162	secondary	_	_	I-Premise
163	end	_	_	I-Premise
164	points	_	_	I-Premise
165	,	_	_	I-Premise
166	including	_	_	I-Premise
167	clinically	_	_	I-Premise
168	significant	_	_	I-Premise
169	changes	_	_	I-Premise
170	in	_	_	I-Premise
171	quality-of-life	_	_	I-Premise
172	variables	_	_	I-Premise
173	and	_	_	I-Premise
174	cancer-related	_	_	I-Premise
175	fatigue	_	_	I-Premise
176	change	_	_	I-Premise
177	from	_	_	I-Premise
178	baseline	_	_	I-Premise
179	,	_	_	I-Premise
180	were	_	_	I-Premise
181	similarly	_	_	I-Premise
182	negative	_	_	I-Premise
183	.	_	_	I-Premise

184	However	_	_	B-Premise
185	,	_	_	I-Premise
186	a	_	_	I-Premise
187	subset	_	_	I-Premise
188	analysis	_	_	I-Premise
189	suggested	_	_	I-Premise
190	that	_	_	I-Premise
191	patients	_	_	I-Premise
192	with	_	_	I-Premise
193	more	_	_	I-Premise
194	severe	_	_	I-Premise
195	fatigue	_	_	I-Premise
196	and/or	_	_	I-Premise
197	with	_	_	I-Premise
198	more	_	_	I-Premise
199	advanced	_	_	I-Premise
200	disease	_	_	I-Premise
201	did	_	_	I-Premise
202	have	_	_	I-Premise
203	some	_	_	I-Premise
204	fatigue	_	_	I-Premise
205	improvement	_	_	I-Premise
206	with	_	_	I-Premise
207	methylphenidate	_	_	I-Premise
208	(	_	_	I-Premise
209	eg	_	_	I-Premise
210	,	_	_	I-Premise
211	in	_	_	I-Premise
212	patients	_	_	I-Premise
213	with	_	_	I-Premise
214	stage	_	_	I-Premise
215	III	_	_	I-Premise
216	or	_	_	I-Premise
217	IV	_	_	I-Premise
218	disease	_	_	I-Premise
219	,	_	_	I-Premise
220	the	_	_	I-Premise
221	mean	_	_	I-Premise
222	improvement	_	_	I-Premise
223	in	_	_	I-Premise
224	usual	_	_	I-Premise
225	fatigue	_	_	I-Premise
226	was	_	_	I-Premise
227	19.7	_	_	I-Premise
228	with	_	_	I-Premise
229	methylphenidate	_	_	I-Premise
230	v	_	_	I-Premise
231	2.1	_	_	I-Premise
232	with	_	_	I-Premise
233	placebo	_	_	I-Premise
234	;	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	.02	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	There	_	_	B-Premise
241	was	_	_	I-Premise
242	a	_	_	I-Premise
243	significant	_	_	I-Premise
244	difference	_	_	I-Premise
245	in	_	_	I-Premise
246	self-reported	_	_	I-Premise
247	toxicities	_	_	I-Premise
248	(	_	_	I-Premise
249	SED	_	_	I-Premise
250	)	_	_	I-Premise
251	,	_	_	I-Premise
252	with	_	_	I-Premise
253	increased	_	_	I-Premise
254	levels	_	_	I-Premise
255	of	_	_	I-Premise
256	nervousness	_	_	I-Premise
257	and	_	_	I-Premise
258	appetite	_	_	I-Premise
259	loss	_	_	I-Premise
260	in	_	_	I-Premise
261	the	_	_	I-Premise
262	methylphenidate	_	_	I-Premise
263	arm	_	_	I-Premise
264	.	_	_	I-Premise

265	This	_	_	B-Claim
266	clinical	_	_	I-Claim
267	trial	_	_	I-Claim
268	was	_	_	I-Claim
269	unable	_	_	I-Claim
270	to	_	_	I-Claim
271	support	_	_	I-Claim
272	the	_	_	I-Claim
273	primary	_	_	I-Claim
274	prestudy	_	_	I-Claim
275	hypothesis	_	_	I-Claim
276	that	_	_	I-Claim
277	the	_	_	I-Claim
278	chosen	_	_	I-Claim
279	long-acting	_	_	I-Claim
280	methylphenidate	_	_	I-Claim
281	product	_	_	I-Claim
282	would	_	_	I-Claim
283	decrease	_	_	I-Claim
284	cancer-related	_	_	I-Claim
285	fatigue	_	_	I-Claim
286	.	_	_	I-Claim


0	In	_	_	O
1	1980	_	_	O
2	the	_	_	O
3	EORTC-BCCG	_	_	O
4	initiated	_	_	O
5	a	_	_	O
6	multicentre	_	_	O
7	randomised	_	_	O
8	clinical	_	_	O
9	trial	_	_	O
10	comparing	_	_	O
11	modified	_	_	O
12	radical	_	_	O
13	mastectomy	_	_	O
14	(	_	_	O
15	MRM	_	_	O
16	)	_	_	O
17	with	_	_	O
18	breast-conserving	_	_	O
19	therapy	_	_	O
20	(	_	_	O
21	BCT	_	_	O
22	)	_	_	O
23	in	_	_	O
24	stage	_	_	O
25	I	_	_	O
26	and	_	_	O
27	II	_	_	O
28	breast	_	_	O
29	cancer	_	_	O
30	.	_	_	O

31	The	_	_	O
32	main	_	_	O
33	endpoint	_	_	O
34	of	_	_	O
35	the	_	_	O
36	trial	_	_	O
37	was	_	_	O
38	survival	_	_	O
39	.	_	_	O

40	A	_	_	O
41	brief	_	_	O
42	quality	_	_	O
43	of	_	_	O
44	life	_	_	O
45	(	_	_	O
46	QoL	_	_	O
47	)	_	_	O
48	questionnaire	_	_	O
49	consisting	_	_	O
50	of	_	_	O
51	two	_	_	O
52	multi-item	_	_	O
53	scales	_	_	O
54	(	_	_	O
55	body	_	_	O
56	image	_	_	O
57	and	_	_	O
58	fear	_	_	O
59	of	_	_	O
60	recurrence	_	_	O
61	)	_	_	O
62	and	_	_	O
63	two	_	_	O
64	single	_	_	O
65	items	_	_	O
66	(	_	_	O
67	satisfaction	_	_	O
68	with	_	_	O
69	treatment	_	_	O
70	and	_	_	O
71	cosmetic	_	_	O
72	result	_	_	O
73	)	_	_	O
74	was	_	_	O
75	included	_	_	O
76	in	_	_	O
77	the	_	_	O
78	trial	_	_	O
79	.	_	_	O

80	A	_	_	O
81	cosmetic	_	_	O
82	evaluation	_	_	O
83	of	_	_	O
84	the	_	_	O
85	breast	_	_	O
86	after	_	_	O
87	conservative	_	_	O
88	surgery	_	_	O
89	was	_	_	O
90	also	_	_	O
91	performed	_	_	O
92	.	_	_	O

93	This	_	_	O
94	report	_	_	O
95	concentrates	_	_	O
96	on	_	_	O
97	the	_	_	O
98	results	_	_	O
99	of	_	_	O
100	the	_	_	O
101	QoL	_	_	O
102	study	_	_	O
103	and	_	_	O
104	the	_	_	O
105	cosmetic	_	_	O
106	evaluation	_	_	O
107	.	_	_	O

108	Multitrait	_	_	O
109	scaling	_	_	O
110	analysis	_	_	O
111	was	_	_	O
112	employed	_	_	O
113	to	_	_	O
114	verify	_	_	O
115	the	_	_	O
116	hypothesised	_	_	O
117	scale	_	_	O
118	structure	_	_	O
119	of	_	_	O
120	the	_	_	O
121	questionnaire	_	_	O
122	.	_	_	O

123	Treatment	_	_	O
124	comparison	_	_	O
125	of	_	_	O
126	the	_	_	O
127	QoL	_	_	O
128	scores	_	_	O
129	at	_	_	O
130	2	_	_	O
131	years	_	_	O
132	post-treatment	_	_	O
133	was	_	_	O
134	performed	_	_	O
135	using	_	_	O
136	a	_	_	O
137	stratified	_	_	O
138	Wilcoxon	_	_	O
139	rank	_	_	O
140	sum	_	_	O
141	test	_	_	O
142	.	_	_	O

143	Both	_	_	O
144	patients	_	_	O
145	'	_	_	O
146	and	_	_	O
147	doctors	_	_	O
148	'	_	_	O
149	ratings	_	_	O
150	of	_	_	O
151	the	_	_	O
152	cosmetic	_	_	O
153	result	_	_	O
154	were	_	_	O
155	documented	_	_	O
156	on	_	_	O
157	the	_	_	O
158	clinical	_	_	O
159	follow-up	_	_	O
160	form	_	_	O
161	.	_	_	O

162	A	_	_	O
163	multivariate	_	_	O
164	analysis	_	_	O
165	was	_	_	O
166	performed	_	_	O
167	to	_	_	O
168	identify	_	_	O
169	which	_	_	O
170	factors	_	_	O
171	influenced	_	_	O
172	the	_	_	O
173	cosmetic	_	_	O
174	outcome	_	_	O
175	.	_	_	O

176	In	_	_	O
177	total	_	_	O
178	,	_	_	O
179	127	_	_	O
180	patients	_	_	O
181	in	_	_	O
182	the	_	_	O
183	MRM	_	_	O
184	arm	_	_	O
185	and	_	_	O
186	151	_	_	O
187	in	_	_	O
188	the	_	_	O
189	BCT	_	_	O
190	arm	_	_	O
191	completed	_	_	O
192	a	_	_	O
193	QoL	_	_	O
194	questionnaire	_	_	O
195	at	_	_	O
196	approximately	_	_	O
197	2	_	_	O
198	years	_	_	O
199	after	_	_	O
200	randomisation	_	_	O
201	(	_	_	O
202	months	_	_	O
203	25-36	_	_	O
204	)	_	_	O
205	.	_	_	O

206	The	_	_	B-Premise
207	Cronbach	_	_	I-Premise
208	's	_	_	I-Premise
209	alpha	_	_	I-Premise
210	coefficients	_	_	I-Premise
211	were	_	_	I-Premise
212	0.79	_	_	I-Premise
213	and	_	_	I-Premise
214	0.73	_	_	I-Premise
215	for	_	_	I-Premise
216	the	_	_	I-Premise
217	body	_	_	I-Premise
218	image	_	_	I-Premise
219	and	_	_	I-Premise
220	fear	_	_	I-Premise
221	of	_	_	I-Premise
222	recurrence	_	_	I-Premise
223	scales	_	_	I-Premise
224	,	_	_	I-Premise
225	respectively	_	_	I-Premise
226	.	_	_	I-Premise

227	Significant	_	_	B-Premise
228	benefit	_	_	I-Premise
229	in	_	_	I-Premise
230	body	_	_	I-Premise
231	image	_	_	I-Premise
232	and	_	_	I-Premise
233	satisfaction	_	_	I-Premise
234	with	_	_	I-Premise
235	treatment	_	_	I-Premise
236	was	_	_	I-Premise
237	observed	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	BCT	_	_	I-Premise
241	patients	_	_	I-Premise
242	.	_	_	I-Premise

243	No	_	_	B-Premise
244	significant	_	_	I-Premise
245	difference	_	_	I-Premise
246	was	_	_	I-Premise
247	observed	_	_	I-Premise
248	in	_	_	I-Premise
249	fear	_	_	I-Premise
250	of	_	_	I-Premise
251	recurrence	_	_	I-Premise
252	between	_	_	I-Premise
253	the	_	_	I-Premise
254	two	_	_	I-Premise
255	groups	_	_	I-Premise
256	.	_	_	I-Premise

257	Ratings	_	_	B-Premise
258	of	_	_	I-Premise
259	cosmetic	_	_	I-Premise
260	results	_	_	I-Premise
261	decreased	_	_	I-Premise
262	with	_	_	I-Premise
263	time	_	_	I-Premise
264	,	_	_	I-Premise
265	in	_	_	I-Premise
266	line	_	_	I-Premise
267	with	_	_	I-Premise
268	clinical	_	_	I-Premise
269	observations	_	_	I-Premise
270	of	_	_	I-Premise
271	long-term	_	_	I-Premise
272	side-effects	_	_	I-Premise
273	of	_	_	I-Premise
274	radiotherapy	_	_	I-Premise
275	.	_	_	I-Premise

276	Wide	_	_	B-Claim
277	excision	_	_	I-Claim
278	appeared	_	_	I-Claim
279	to	_	_	I-Claim
280	be	_	_	I-Claim
281	the	_	_	I-Claim
282	most	_	_	I-Claim
283	important	_	_	I-Claim
284	predictive	_	_	I-Claim
285	factor	_	_	I-Claim
286	for	_	_	I-Claim
287	poor	_	_	I-Claim
288	cosmetic	_	_	I-Claim
289	result	_	_	I-Claim
290	.	_	_	I-Claim

291	In	_	_	B-Claim
292	this	_	_	I-Claim
293	multicentre	_	_	I-Claim
294	randomised	_	_	I-Claim
295	study	_	_	I-Claim
296	,	_	_	I-Claim
297	BCT	_	_	I-Claim
298	helped	_	_	I-Claim
299	to	_	_	I-Claim
300	maintain	_	_	I-Claim
301	the	_	_	I-Claim
302	patients	_	_	I-Claim
303	'	_	_	I-Claim
304	body	_	_	I-Claim
305	image	_	_	I-Claim
306	,	_	_	I-Claim
307	resulted	_	_	I-Claim
308	in	_	_	I-Claim
309	higher	_	_	I-Claim
310	satisfaction	_	_	I-Claim
311	with	_	_	I-Claim
312	treatment	_	_	I-Claim
313	and	_	_	I-Claim
314	yielded	_	_	I-Claim
315	no	_	_	I-Claim
316	significant	_	_	I-Claim
317	difference	_	_	I-Claim
318	from	_	_	I-Claim
319	MRM	_	_	I-Claim
320	with	_	_	I-Claim
321	respect	_	_	I-Claim
322	to	_	_	I-Claim
323	fear	_	_	I-Claim
324	of	_	_	I-Claim
325	recurrence	_	_	I-Claim
326	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	cost-effectiveness	_	_	O
4	of	_	_	O
5	Mohs	_	_	O
6	micrographic	_	_	O
7	surgery	_	_	O
8	(	_	_	O
9	MMS	_	_	O
10	)	_	_	O
11	compared	_	_	O
12	with	_	_	O
13	the	_	_	O
14	surgical	_	_	O
15	excision	_	_	O
16	for	_	_	O
17	both	_	_	O
18	primary	_	_	O
19	and	_	_	O
20	recurrent	_	_	O
21	basal	_	_	O
22	cell	_	_	O
23	carcinoma	_	_	O
24	(	_	_	O
25	BCC	_	_	O
26	)	_	_	O
27	.	_	_	O

28	A	_	_	O
29	cost-effectiveness	_	_	O
30	study	_	_	O
31	performed	_	_	O
32	alongside	_	_	O
33	a	_	_	O
34	prospective	_	_	O
35	randomized	_	_	O
36	clinical	_	_	O
37	trial	_	_	O
38	in	_	_	O
39	which	_	_	O
40	MMS	_	_	O
41	was	_	_	O
42	compared	_	_	O
43	with	_	_	O
44	surgical	_	_	O
45	excision	_	_	O
46	.	_	_	O

47	The	_	_	O
48	study	_	_	O
49	was	_	_	O
50	carried	_	_	O
51	out	_	_	O
52	from	_	_	O
53	1999	_	_	O
54	to	_	_	O
55	2002	_	_	O
56	at	_	_	O
57	the	_	_	O
58	dermatology	_	_	O
59	outpatient	_	_	O
60	clinic	_	_	O
61	of	_	_	O
62	the	_	_	O
63	University	_	_	O
64	Hospital	_	_	O
65	Maastricht	_	_	O
66	,	_	_	O
67	Maastricht	_	_	O
68	,	_	_	O
69	The	_	_	O
70	Netherlands	_	_	O
71	.	_	_	O

72	A	_	_	O
73	total	_	_	O
74	of	_	_	O
75	408	_	_	O
76	primary	_	_	O
77	(	_	_	O
78	374	_	_	O
79	patients	_	_	O
80	)	_	_	O
81	and	_	_	O
82	204	_	_	O
83	recurrent	_	_	O
84	(	_	_	O
85	191	_	_	O
86	patients	_	_	O
87	)	_	_	O
88	cases	_	_	O
89	of	_	_	O
90	facial	_	_	O
91	BCC	_	_	O
92	were	_	_	O
93	included	_	_	O
94	.	_	_	O

95	The	_	_	O
96	mean	_	_	O
97	total	_	_	O
98	treatment	_	_	O
99	costs	_	_	O
100	of	_	_	O
101	MMS	_	_	O
102	and	_	_	O
103	surgical	_	_	O
104	excision	_	_	O
105	for	_	_	O
106	both	_	_	O
107	primary	_	_	O
108	and	_	_	O
109	recurrent	_	_	O
110	BCC	_	_	O
111	and	_	_	O
112	the	_	_	O
113	incremental	_	_	O
114	cost-effectiveness	_	_	O
115	ratio	_	_	O
116	,	_	_	O
117	calculated	_	_	O
118	as	_	_	O
119	the	_	_	O
120	difference	_	_	O
121	in	_	_	O
122	costs	_	_	O
123	between	_	_	O
124	MMS	_	_	O
125	and	_	_	O
126	surgical	_	_	O
127	excision	_	_	O
128	divided	_	_	O
129	by	_	_	O
130	their	_	_	O
131	difference	_	_	O
132	in	_	_	O
133	effectiveness	_	_	O
134	.	_	_	O

135	The	_	_	O
136	resulting	_	_	O
137	ratio	_	_	O
138	is	_	_	O
139	defined	_	_	O
140	as	_	_	O
141	the	_	_	O
142	incremental	_	_	O
143	costs	_	_	O
144	of	_	_	O
145	MMS	_	_	O
146	compared	_	_	O
147	with	_	_	O
148	surgical	_	_	O
149	excision	_	_	O
150	to	_	_	O
151	prevent	_	_	O
152	1	_	_	O
153	additional	_	_	O
154	recurrence	_	_	O
155	.	_	_	O

156	Compared	_	_	B-Premise
157	with	_	_	I-Premise
158	surgical	_	_	I-Premise
159	excision	_	_	I-Premise
160	,	_	_	I-Premise
161	the	_	_	I-Premise
162	total	_	_	I-Premise
163	treatment	_	_	I-Premise
164	costs	_	_	I-Premise
165	of	_	_	I-Premise
166	MMS	_	_	I-Premise
167	are	_	_	I-Premise
168	significantly	_	_	I-Premise
169	higher	_	_	I-Premise
170	(	_	_	I-Premise
171	cost	_	_	I-Premise
172	difference	_	_	I-Premise
173	:	_	_	I-Premise
174	primary	_	_	I-Premise
175	BCC	_	_	I-Premise
176	,	_	_	I-Premise
177	254	_	_	I-Premise
178	euros	_	_	I-Premise
179	;	_	_	I-Premise
180	95	_	_	I-Premise
181	%	_	_	I-Premise
182	confidence	_	_	I-Premise
183	interval	_	_	I-Premise
184	,	_	_	I-Premise
185	181-324	_	_	I-Premise
186	euros	_	_	I-Premise
187	;	_	_	I-Premise
188	recurrent	_	_	I-Premise
189	BCC	_	_	I-Premise
190	,	_	_	I-Premise
191	249	_	_	I-Premise
192	euros	_	_	I-Premise
193	;	_	_	I-Premise
194	95	_	_	I-Premise
195	%	_	_	I-Premise
196	confidence	_	_	I-Premise
197	interval	_	_	I-Premise
198	,	_	_	I-Premise
199	175-323	_	_	I-Premise
200	euros	_	_	I-Premise
201	)	_	_	I-Premise
202	.	_	_	I-Premise

203	For	_	_	B-Premise
204	primary	_	_	I-Premise
205	BCC	_	_	I-Premise
206	,	_	_	I-Premise
207	the	_	_	I-Premise
208	incremental	_	_	I-Premise
209	cost-effectiveness	_	_	I-Premise
210	ratio	_	_	I-Premise
211	was	_	_	I-Premise
212	29,231	_	_	I-Premise
213	euros	_	_	I-Premise
214	,	_	_	I-Premise
215	while	_	_	I-Premise
216	the	_	_	I-Premise
217	ratio	_	_	I-Premise
218	for	_	_	I-Premise
219	recurrent	_	_	I-Premise
220	BCC	_	_	I-Premise
221	amounted	_	_	I-Premise
222	to	_	_	I-Premise
223	8094	_	_	I-Premise
224	euros	_	_	I-Premise
225	.	_	_	I-Premise

226	The	_	_	B-Premise
227	acceptability	_	_	I-Premise
228	curves	_	_	I-Premise
229	showed	_	_	I-Premise
230	that	_	_	I-Premise
231	for	_	_	I-Premise
232	these	_	_	I-Premise
233	ratios	_	_	I-Premise
234	,	_	_	I-Premise
235	the	_	_	I-Premise
236	probability	_	_	I-Premise
237	of	_	_	I-Premise
238	MMS	_	_	I-Premise
239	being	_	_	I-Premise
240	more	_	_	I-Premise
241	cost-effective	_	_	I-Premise
242	than	_	_	I-Premise
243	surgical	_	_	I-Premise
244	excision	_	_	I-Premise
245	never	_	_	I-Premise
246	reached	_	_	I-Premise
247	50	_	_	I-Premise
248	%	_	_	I-Premise
249	.	_	_	I-Premise

250	At	_	_	B-Claim
251	present	_	_	I-Claim
252	,	_	_	I-Claim
253	it	_	_	I-Claim
254	does	_	_	I-Claim
255	not	_	_	I-Claim
256	seem	_	_	I-Claim
257	cost-effective	_	_	I-Claim
258	to	_	_	I-Claim
259	introduce	_	_	I-Claim
260	MMS	_	_	I-Claim
261	on	_	_	I-Claim
262	a	_	_	I-Claim
263	large	_	_	I-Claim
264	scale	_	_	I-Claim
265	for	_	_	I-Claim
266	both	_	_	I-Claim
267	primary	_	_	I-Claim
268	and	_	_	I-Claim
269	recurrent	_	_	I-Claim
270	BCC	_	_	I-Claim
271	.	_	_	I-Claim

272	However	_	_	O
273	,	_	_	O
274	because	_	_	B-Premise
275	a	_	_	I-Premise
276	5-year	_	_	I-Premise
277	period	_	_	I-Premise
278	is	_	_	I-Premise
279	normally	_	_	I-Premise
280	required	_	_	I-Premise
281	to	_	_	I-Premise
282	determine	_	_	I-Premise
283	definite	_	_	I-Premise
284	recurrence	_	_	I-Premise
285	rates	_	_	I-Premise
286	,	_	_	O
287	it	_	_	B-Claim
288	is	_	_	I-Claim
289	possible	_	_	I-Claim
290	that	_	_	I-Claim
291	MMS	_	_	I-Claim
292	may	_	_	I-Claim
293	become	_	_	I-Claim
294	a	_	_	I-Claim
295	cost-effective	_	_	I-Claim
296	treatment	_	_	I-Claim
297	for	_	_	I-Claim
298	recurrent	_	_	I-Claim
299	BCC	_	_	I-Claim
300	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	determine	_	_	O
7	the	_	_	O
8	effectiveness	_	_	O
9	of	_	_	O
10	a	_	_	O
11	mindfulness-based	_	_	O
12	stress-reduction	_	_	O
13	(	_	_	O
14	MBSR	_	_	O
15	)	_	_	O
16	program	_	_	O
17	on	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	(	_	_	O
22	QOL	_	_	O
23	)	_	_	O
24	and	_	_	O
25	psychosocial	_	_	O
26	outcomes	_	_	O
27	in	_	_	O
28	women	_	_	O
29	with	_	_	O
30	early-stage	_	_	O
31	breast	_	_	O
32	cancer	_	_	O
33	,	_	_	O
34	using	_	_	O
35	a	_	_	O
36	three-arm	_	_	O
37	randomized	_	_	O
38	controlled	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	(	_	_	O
42	RCT	_	_	O
43	)	_	_	O
44	.	_	_	O

45	This	_	_	O
46	RCT	_	_	O
47	consisting	_	_	O
48	of	_	_	O
49	172	_	_	O
50	women	_	_	O
51	,	_	_	O
52	aged	_	_	O
53	20-65	_	_	O
54	with	_	_	O
55	stage	_	_	O
56	I	_	_	O
57	or	_	_	O
58	II	_	_	O
59	breast	_	_	O
60	cancer	_	_	O
61	consisted	_	_	O
62	of	_	_	O
63	the	_	_	O
64	8-week	_	_	O
65	MBSR	_	_	O
66	,	_	_	O
67	which	_	_	O
68	was	_	_	O
69	compared	_	_	O
70	to	_	_	O
71	a	_	_	O
72	nutrition	_	_	O
73	education	_	_	O
74	program	_	_	O
75	(	_	_	O
76	NEP	_	_	O
77	)	_	_	O
78	and	_	_	O
79	usual	_	_	O
80	supportive	_	_	O
81	care	_	_	O
82	(	_	_	O
83	UC	_	_	O
84	)	_	_	O
85	.	_	_	O

86	Follow-up	_	_	O
87	was	_	_	O
88	performed	_	_	O
89	at	_	_	O
90	three	_	_	O
91	post-intervention	_	_	O
92	points	_	_	O
93	:	_	_	O
94	4	_	_	O
95	months	_	_	O
96	,	_	_	O
97	1	_	_	O
98	,	_	_	O
99	and	_	_	O
100	2	_	_	O
101	years	_	_	O
102	.	_	_	O

103	Standardized	_	_	O
104	,	_	_	O
105	validated	_	_	O
106	self-administered	_	_	O
107	questionnaires	_	_	O
108	were	_	_	O
109	adopted	_	_	O
110	to	_	_	O
111	assess	_	_	O
112	psychosocial	_	_	O
113	variables	_	_	O
114	.	_	_	O

115	Statistical	_	_	O
116	analysis	_	_	O
117	included	_	_	O
118	descriptive	_	_	O
119	and	_	_	O
120	regression	_	_	O
121	analyses	_	_	O
122	incorporating	_	_	O
123	both	_	_	O
124	intention-to-treat	_	_	O
125	and	_	_	O
126	post	_	_	O
127	hoc	_	_	O
128	multivariable	_	_	O
129	approaches	_	_	O
130	of	_	_	O
131	the	_	_	O
132	163	_	_	O
133	women	_	_	O
134	with	_	_	O
135	complete	_	_	O
136	data	_	_	O
137	at	_	_	O
138	baseline	_	_	O
139	,	_	_	O
140	those	_	_	O
141	who	_	_	O
142	were	_	_	O
143	randomized	_	_	O
144	to	_	_	O
145	MBSR	_	_	O
146	experienced	_	_	O
147	a	_	_	O
148	significant	_	_	O
149	improvement	_	_	O
150	in	_	_	O
151	the	_	_	O
152	primary	_	_	O
153	measures	_	_	O
154	of	_	_	O
155	QOL	_	_	O
156	and	_	_	O
157	coping	_	_	O
158	outcomes	_	_	O
159	compared	_	_	O
160	to	_	_	O
161	the	_	_	O
162	NEP	_	_	O
163	,	_	_	O
164	UC	_	_	O
165	,	_	_	O
166	or	_	_	O
167	both	_	_	O
168	,	_	_	O
169	including	_	_	O
170	the	_	_	O
171	spirituality	_	_	O
172	subscale	_	_	O
173	of	_	_	O
174	the	_	_	O
175	FACT-B	_	_	O
176	as	_	_	O
177	well	_	_	O
178	as	_	_	O
179	dealing	_	_	O
180	with	_	_	O
181	illness	_	_	O
182	scale	_	_	O
183	increases	_	_	O
184	in	_	_	O
185	active	_	_	O
186	behavioral	_	_	O
187	coping	_	_	O
188	and	_	_	O
189	active	_	_	O
190	cognitive	_	_	O
191	coping	_	_	O
192	.	_	_	O

193	Secondary	_	_	B-Premise
194	outcome	_	_	I-Premise
195	improvements	_	_	I-Premise
196	resulting	_	_	I-Premise
197	in	_	_	I-Premise
198	significant	_	_	I-Premise
199	between-group	_	_	I-Premise
200	contrasts	_	_	I-Premise
201	favoring	_	_	I-Premise
202	the	_	_	I-Premise
203	MBSR	_	_	I-Premise
204	group	_	_	I-Premise
205	at	_	_	I-Premise
206	4	_	_	I-Premise
207	months	_	_	I-Premise
208	included	_	_	I-Premise
209	meaningfulness	_	_	I-Premise
210	,	_	_	I-Premise
211	depression	_	_	I-Premise
212	,	_	_	I-Premise
213	paranoid	_	_	I-Premise
214	ideation	_	_	I-Premise
215	,	_	_	I-Premise
216	hostility	_	_	I-Premise
217	,	_	_	I-Premise
218	anxiety	_	_	I-Premise
219	,	_	_	I-Premise
220	unhappiness	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	emotional	_	_	I-Premise
224	control	_	_	I-Premise
225	.	_	_	I-Premise

226	Results	_	_	B-Premise
227	tended	_	_	I-Premise
228	to	_	_	I-Premise
229	decline	_	_	I-Premise
230	at	_	_	I-Premise
231	12	_	_	I-Premise
232	months	_	_	I-Premise
233	and	_	_	I-Premise
234	even	_	_	I-Premise
235	more	_	_	I-Premise
236	at	_	_	I-Premise
237	24	_	_	I-Premise
238	months	_	_	I-Premise
239	,	_	_	I-Premise
240	though	_	_	I-Premise
241	at	_	_	I-Premise
242	all	_	_	I-Premise
243	times	_	_	I-Premise
244	,	_	_	I-Premise
245	they	_	_	I-Premise
246	were	_	_	I-Premise
247	as	_	_	I-Premise
248	robust	_	_	I-Premise
249	in	_	_	I-Premise
250	women	_	_	I-Premise
251	with	_	_	I-Premise
252	lower	_	_	I-Premise
253	expectation	_	_	I-Premise
254	of	_	_	I-Premise
255	effect	_	_	I-Premise
256	as	_	_	I-Premise
257	in	_	_	I-Premise
258	those	_	_	I-Premise
259	with	_	_	I-Premise
260	higher	_	_	I-Premise
261	expectation	_	_	I-Premise
262	.	_	_	I-Premise

263	The	_	_	B-Claim
264	MBSR	_	_	I-Claim
265	intervention	_	_	I-Claim
266	appears	_	_	I-Claim
267	to	_	_	I-Claim
268	benefit	_	_	I-Claim
269	psychosocial	_	_	I-Claim
270	adjustment	_	_	I-Claim
271	in	_	_	I-Claim
272	cancer	_	_	I-Claim
273	patients	_	_	I-Claim
274	,	_	_	I-Claim
275	over	_	_	I-Claim
276	and	_	_	I-Claim
277	above	_	_	I-Claim
278	the	_	_	I-Claim
279	effects	_	_	I-Claim
280	of	_	_	I-Claim
281	usual	_	_	I-Claim
282	care	_	_	I-Claim
283	or	_	_	I-Claim
284	a	_	_	I-Claim
285	credible	_	_	I-Claim
286	control	_	_	I-Claim
287	condition	_	_	I-Claim
288	.	_	_	I-Claim

289	The	_	_	B-Claim
290	universality	_	_	I-Claim
291	of	_	_	I-Claim
292	effects	_	_	I-Claim
293	across	_	_	I-Claim
294	levels	_	_	I-Claim
295	of	_	_	I-Claim
296	expectation	_	_	I-Claim
297	indicates	_	_	I-Claim
298	a	_	_	I-Claim
299	potential	_	_	I-Claim
300	to	_	_	I-Claim
301	utilize	_	_	I-Claim
302	this	_	_	I-Claim
303	stress	_	_	I-Claim
304	reduction	_	_	I-Claim
305	approach	_	_	I-Claim
306	as	_	_	I-Claim
307	complementary	_	_	I-Claim
308	therapy	_	_	I-Claim
309	in	_	_	I-Claim
310	oncologic	_	_	I-Claim
311	practice	_	_	I-Claim
312	.	_	_	I-Claim


0	In	_	_	O
1	an	_	_	O
2	international	_	_	O
3	,	_	_	O
4	randomized	_	_	O
5	phase	_	_	O
6	III	_	_	O
7	trial	_	_	O
8	,	_	_	O
9	sunitinib	_	_	O
10	demonstrated	_	_	O
11	statistically	_	_	O
12	significant	_	_	O
13	efficacy	_	_	O
14	over	_	_	O
15	interferon	_	_	O
16	alfa	_	_	O
17	(	_	_	O
18	IFN-alpha	_	_	O
19	)	_	_	O
20	as	_	_	O
21	first-line	_	_	O
22	therapy	_	_	O
23	in	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	metastatic	_	_	O
27	renal	_	_	O
28	cell	_	_	O
29	carcinoma	_	_	O
30	(	_	_	O
31	mRCC	_	_	O
32	)	_	_	O
33	(	_	_	O
34	progression-free	_	_	O
35	survival	_	_	O
36	time	_	_	O
37	,	_	_	O
38	11	_	_	O
39	v	_	_	O
40	5	_	_	O
41	months	_	_	O
42	,	_	_	O
43	respectively	_	_	O
44	;	_	_	O
45	P	_	_	O
46	<	_	_	O
47	.001	_	_	O
48	;	_	_	O
49	objective	_	_	O
50	response	_	_	O
51	rate	_	_	O
52	,	_	_	O
53	31	_	_	O
54	%	_	_	O
55	v	_	_	O
56	6	_	_	O
57	%	_	_	O
58	,	_	_	O
59	respectively	_	_	O
60	;	_	_	O
61	P	_	_	O
62	<	_	_	O
63	.001	_	_	O
64	)	_	_	O
65	.	_	_	O

66	We	_	_	O
67	report	_	_	O
68	health-related	_	_	O
69	quality-of-life	_	_	O
70	(	_	_	O
71	QOL	_	_	O
72	)	_	_	O
73	results	_	_	O
74	from	_	_	O
75	this	_	_	O
76	trial	_	_	O
77	.	_	_	O

78	Seven	_	_	O
79	hundred	_	_	O
80	fifty	_	_	O
81	mRCC	_	_	O
82	patients	_	_	O
83	were	_	_	O
84	randomly	_	_	O
85	assigned	_	_	O
86	to	_	_	O
87	sunitinib	_	_	O
88	(	_	_	O
89	6-week	_	_	O
90	cycles	_	_	O
91	:	_	_	O
92	50	_	_	O
93	mg	_	_	O
94	orally	_	_	O
95	once	_	_	O
96	daily	_	_	O
97	for	_	_	O
98	4	_	_	O
99	weeks	_	_	O
100	,	_	_	O
101	followed	_	_	O
102	by	_	_	O
103	2	_	_	O
104	weeks	_	_	O
105	off	_	_	O
106	)	_	_	O
107	or	_	_	O
108	IFN-alpha	_	_	O
109	(	_	_	O
110	9	_	_	O
111	million	_	_	O
112	units	_	_	O
113	subcutaneous	_	_	O
114	injections	_	_	O
115	,	_	_	O
116	three	_	_	O
117	times	_	_	O
118	weekly	_	_	O
119	)	_	_	O
120	.	_	_	O

121	QOL	_	_	O
122	measures	_	_	O
123	included	_	_	O
124	the	_	_	O
125	Functional	_	_	O
126	Assessment	_	_	O
127	of	_	_	O
128	Cancer	_	_	O
129	Therapy-General	_	_	O
130	(	_	_	O
131	FACT-G	_	_	O
132	)	_	_	O
133	,	_	_	O
134	the	_	_	O
135	FACT-Kidney	_	_	O
136	Symptom	_	_	O
137	Index-15	_	_	O
138	item	_	_	O
139	(	_	_	O
140	FKSI-15	_	_	O
141	)	_	_	O
142	,	_	_	O
143	and	_	_	O
144	the	_	_	O
145	EuroQoL-5D	_	_	O
146	's	_	_	O
147	utility	_	_	O
148	score	_	_	O
149	(	_	_	O
150	EQ-5D	_	_	O
151	Index	_	_	O
152	)	_	_	O
153	and	_	_	O
154	its	_	_	O
155	visual	_	_	O
156	analog	_	_	O
157	scale	_	_	O
158	(	_	_	O
159	EQ-VAS	_	_	O
160	)	_	_	O
161	.	_	_	O

162	The	_	_	O
163	primary	_	_	O
164	QOL	_	_	O
165	end	_	_	O
166	point	_	_	O
167	was	_	_	O
168	the	_	_	O
169	FKSI	_	_	O
170	Disease-Related	_	_	O
171	Symptoms	_	_	O
172	(	_	_	O
173	FKSI-DRS	_	_	O
174	)	_	_	O
175	subscale	_	_	O
176	.	_	_	O

177	Higher	_	_	O
178	scores	_	_	O
179	indicated	_	_	O
180	better	_	_	O
181	outcomes	_	_	O
182	(	_	_	O
183	better	_	_	O
184	QOL	_	_	O
185	or	_	_	O
186	fewer	_	_	O
187	symptoms	_	_	O
188	)	_	_	O
189	.	_	_	O

190	Data	_	_	O
191	were	_	_	O
192	analyzed	_	_	O
193	for	_	_	O
194	the	_	_	O
195	intent-to-treat	_	_	O
196	population	_	_	O
197	using	_	_	O
198	mixed-effects	_	_	O
199	models	_	_	O
200	,	_	_	O
201	supplemented	_	_	O
202	with	_	_	O
203	pattern-mixture	_	_	O
204	models	_	_	O
205	.	_	_	O

206	Patients	_	_	B-Premise
207	receiving	_	_	I-Premise
208	sunitinib	_	_	I-Premise
209	reported	_	_	I-Premise
210	higher	_	_	I-Premise
211	FKSI-15	_	_	I-Premise
212	and	_	_	I-Premise
213	FKSI-DRS	_	_	I-Premise
214	scores	_	_	I-Premise
215	at	_	_	I-Premise
216	each	_	_	I-Premise
217	cycle	_	_	I-Premise
218	than	_	_	I-Premise
219	those	_	_	I-Premise
220	receiving	_	_	I-Premise
221	IFN-alpha	_	_	I-Premise
222	,	_	_	I-Premise
223	with	_	_	I-Premise
224	a	_	_	I-Premise
225	significant	_	_	I-Premise
226	difference	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	overall	_	_	I-Premise
230	least	_	_	I-Premise
231	squares	_	_	I-Premise
232	means	_	_	I-Premise
233	(	_	_	I-Premise
234	3.27	_	_	I-Premise
235	and	_	_	I-Premise
236	1.98	_	_	I-Premise
237	,	_	_	I-Premise
238	respectively	_	_	I-Premise
239	;	_	_	I-Premise
240	P	_	_	I-Premise
241	<	_	_	I-Premise
242	.0001	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	Similarly	_	_	O
246	,	_	_	O
247	differences	_	_	B-Premise
248	in	_	_	I-Premise
249	least	_	_	I-Premise
250	squares	_	_	I-Premise
251	means	_	_	I-Premise
252	for	_	_	I-Premise
253	FACT-G	_	_	I-Premise
254	(	_	_	I-Premise
255	and	_	_	I-Premise
256	all	_	_	I-Premise
257	subscales	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	EQ-5D	_	_	I-Premise
261	Index	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	EQ-VAS	_	_	I-Premise
265	were	_	_	I-Premise
266	all	_	_	I-Premise
267	significantly	_	_	I-Premise
268	favorable	_	_	I-Premise
269	for	_	_	I-Premise
270	sunitinib	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	<	_	_	I-Premise
274	.01	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	Per	_	_	O
278	pre-established	_	_	O
279	thresholds	_	_	O
280	,	_	_	O
281	between-treatment	_	_	O
282	differences	_	_	O
283	in	_	_	O
284	the	_	_	O
285	mean	_	_	O
286	scores	_	_	O
287	were	_	_	O
288	clinically	_	_	O
289	meaningful	_	_	O
290	after	_	_	O
291	cycle	_	_	O
292	4	_	_	O
293	for	_	_	O
294	FKSI-DRS	_	_	O
295	and	_	_	O
296	at	_	_	O
297	all	_	_	O
298	assessments	_	_	O
299	for	_	_	O
300	FKSI-15	_	_	O
301	,	_	_	O
302	FACT-G	_	_	O
303	,	_	_	O
304	and	_	_	O
305	the	_	_	O
306	FACT-G	_	_	O
307	functional	_	_	O
308	well-being	_	_	O
309	subscale	_	_	O
310	.	_	_	O

311	Sunitinib	_	_	B-Claim
312	provides	_	_	I-Claim
313	superior	_	_	I-Claim
314	QOL	_	_	I-Claim
315	compared	_	_	I-Claim
316	with	_	_	I-Claim
317	IFN-alpha	_	_	I-Claim
318	in	_	_	I-Claim
319	mRCC	_	_	I-Claim
320	patients	_	_	I-Claim
321	.	_	_	I-Claim


0	The	_	_	O
1	Medical	_	_	O
2	Research	_	_	O
3	Council	_	_	O
4	CR07/National	_	_	O
5	Cancer	_	_	O
6	Institute	_	_	O
7	of	_	_	O
8	Canada	_	_	O
9	Clinical	_	_	O
10	Trials	_	_	O
11	Group	_	_	O
12	C016	_	_	O
13	(	_	_	O
14	MRC	_	_	O
15	CR07/NCIC	_	_	O
16	CTG	_	_	O
17	C016	_	_	O
18	)	_	_	O
19	trial	_	_	O
20	showed	_	_	O
21	that	_	_	O
22	,	_	_	O
23	in	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	operable	_	_	O
27	rectal	_	_	O
28	cancer	_	_	O
29	,	_	_	O
30	short-course	_	_	O
31	preoperative	_	_	O
32	radiotherapy	_	_	O
33	(	_	_	O
34	PRE	_	_	O
35	)	_	_	O
36	reduced	_	_	O
37	the	_	_	O
38	rate	_	_	O
39	of	_	_	O
40	local	_	_	O
41	recurrence	_	_	O
42	compared	_	_	O
43	with	_	_	O
44	surgery	_	_	O
45	followed	_	_	O
46	by	_	_	O
47	selective	_	_	O
48	postoperative	_	_	O
49	chemoradiotherapy	_	_	O
50	for	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	a	_	_	O
54	positive	_	_	O
55	circumferential	_	_	O
56	resection	_	_	O
57	margin	_	_	O
58	.	_	_	O

59	However	_	_	O
60	,	_	_	O
61	the	_	_	O
62	advantages	_	_	O
63	of	_	_	O
64	giving	_	_	O
65	PRE	_	_	O
66	to	_	_	O
67	all	_	_	O
68	patients	_	_	O
69	needs	_	_	O
70	to	_	_	O
71	be	_	_	O
72	balanced	_	_	O
73	against	_	_	O
74	any	_	_	O
75	negative	_	_	O
76	impact	_	_	O
77	on	_	_	O
78	patients	_	_	O
79	'	_	_	O
80	quality	_	_	O
81	of	_	_	O
82	life	_	_	O
83	.	_	_	O

84	All	_	_	O
85	1,350	_	_	O
86	patients	_	_	O
87	were	_	_	O
88	asked	_	_	O
89	to	_	_	O
90	complete	_	_	O
91	the	_	_	O
92	Medical	_	_	O
93	Outcomes	_	_	O
94	Study	_	_	O
95	Short-Form	_	_	O
96	36-item	_	_	O
97	(	_	_	O
98	MOS	_	_	O
99	SF-36	_	_	O
100	)	_	_	O
101	and	_	_	O
102	the	_	_	O
103	European	_	_	O
104	Organisation	_	_	O
105	for	_	_	O
106	Research	_	_	O
107	and	_	_	O
108	Treatment	_	_	O
109	of	_	_	O
110	Cancer	_	_	O
111	Quality	_	_	O
112	of	_	_	O
113	Life	_	_	O
114	Questionnaire	_	_	O
115	Colorectal	_	_	O
116	38-item	_	_	O
117	(	_	_	O
118	EORTC	_	_	O
119	QLQ-CR38	_	_	O
120	)	_	_	O
121	questionnaires	_	_	O
122	.	_	_	O

123	A	_	_	O
124	priori	_	_	O
125	hypotheses	_	_	O
126	related	_	_	O
127	to	_	_	O
128	the	_	_	O
129	impact	_	_	O
130	of	_	_	O
131	treatment	_	_	O
132	on	_	_	O
133	sexual	_	_	O
134	,	_	_	O
135	bowel	_	_	O
136	,	_	_	O
137	and	_	_	O
138	physical	_	_	O
139	function	_	_	O
140	and	_	_	O
141	general	_	_	O
142	health	_	_	O
143	.	_	_	O

144	Male	_	_	B-Premise
145	sexual	_	_	I-Premise
146	dysfunction	_	_	I-Premise
147	was	_	_	I-Premise
148	significantly	_	_	I-Premise
149	increased	_	_	I-Premise
150	following	_	_	I-Premise
151	surgery	_	_	I-Premise
152	(	_	_	I-Premise
153	P	_	_	I-Premise
154	<	_	_	I-Premise
155	.001	_	_	I-Premise
156	)	_	_	I-Premise
157	,	_	_	I-Premise
158	although	_	_	B-Premise
159	there	_	_	I-Premise
160	was	_	_	I-Premise
161	no	_	_	I-Premise
162	difference	_	_	I-Premise
163	between	_	_	I-Premise
164	treatment	_	_	I-Premise
165	arms	_	_	I-Premise
166	.	_	_	I-Premise

167	However	_	_	O
168	,	_	_	O
169	a	_	_	O
170	treatment	_	_	O
171	difference	_	_	O
172	had	_	_	O
173	emerged	_	_	O
174	at	_	_	O
175	6	_	_	O
176	months	_	_	O
177	(	_	_	O
178	PRE	_	_	O
179	patients	_	_	O
180	reporting	_	_	O
181	significantly	_	_	O
182	greater	_	_	O
183	dysfunction	_	_	O
184	;	_	_	O
185	P	_	_	O
186	=	_	_	O
187	.004	_	_	O
188	)	_	_	O
189	,	_	_	O
190	which	_	_	O
191	persisted	_	_	O
192	out	_	_	O
193	to	_	_	O
194	at	_	_	O
195	least	_	_	O
196	2	_	_	O
197	years	_	_	O
198	(	_	_	O
199	an	_	_	O
200	insufficient	_	_	O
201	number	_	_	O
202	of	_	_	O
203	female	_	_	O
204	patients	_	_	O
205	completed	_	_	O
206	the	_	_	O
207	sexual	_	_	O
208	dysfunction	_	_	O
209	questions	_	_	O
210	to	_	_	O
211	draw	_	_	O
212	firm	_	_	O
213	conclusions	_	_	O
214	)	_	_	O
215	.	_	_	O

216	Both	_	_	B-Premise
217	treatment	_	_	I-Premise
218	groups	_	_	I-Premise
219	reported	_	_	I-Premise
220	similar	_	_	I-Premise
221	levels	_	_	I-Premise
222	of	_	_	I-Premise
223	decreased	_	_	I-Premise
224	physical	_	_	I-Premise
225	function	_	_	I-Premise
226	at	_	_	I-Premise
227	3	_	_	I-Premise
228	months	_	_	I-Premise
229	,	_	_	I-Premise
230	but	_	_	B-Premise
231	thereafter	_	_	I-Premise
232	it	_	_	I-Premise
233	returned	_	_	I-Premise
234	to	_	_	I-Premise
235	baseline	_	_	I-Premise
236	levels	_	_	I-Premise
237	.	_	_	I-Premise

238	There	_	_	B-Premise
239	was	_	_	I-Premise
240	no	_	_	I-Premise
241	evidence	_	_	I-Premise
242	of	_	_	I-Premise
243	any	_	_	I-Premise
244	major	_	_	I-Premise
245	changes	_	_	I-Premise
246	between	_	_	I-Premise
247	treatments	_	_	I-Premise
248	or	_	_	I-Premise
249	time	_	_	I-Premise
250	points	_	_	I-Premise
251	in	_	_	I-Premise
252	terms	_	_	I-Premise
253	of	_	_	I-Premise
254	general	_	_	I-Premise
255	health	_	_	I-Premise
256	or	_	_	I-Premise
257	bowel	_	_	I-Premise
258	function	_	_	I-Premise
259	,	_	_	I-Premise
260	but	_	_	B-Premise
261	exploratory	_	_	I-Premise
262	analysis	_	_	I-Premise
263	indicated	_	_	I-Premise
264	a	_	_	I-Premise
265	significant	_	_	I-Premise
266	(	_	_	I-Premise
267	P	_	_	I-Premise
268	=	_	_	I-Premise
269	.006	_	_	I-Premise
270	at	_	_	I-Premise
271	2	_	_	I-Premise
272	years	_	_	I-Premise
273	)	_	_	I-Premise
274	increase	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	level	_	_	I-Premise
278	of	_	_	I-Premise
279	fecal	_	_	I-Premise
280	incontinence	_	_	I-Premise
281	with	_	_	I-Premise
282	PRE	_	_	I-Premise
283	.	_	_	I-Premise

284	These	_	_	B-Claim
285	results	_	_	I-Claim
286	from	_	_	I-Claim
287	a	_	_	I-Claim
288	large	_	_	I-Claim
289	randomized	_	_	I-Claim
290	trial	_	_	I-Claim
291	using	_	_	I-Claim
292	validated	_	_	I-Claim
293	patient-completed	_	_	I-Claim
294	questionnaires	_	_	I-Claim
295	show	_	_	I-Claim
296	that	_	_	I-Claim
297	,	_	_	I-Claim
298	for	_	_	I-Claim
299	males	_	_	I-Claim
300	,	_	_	I-Claim
301	the	_	_	I-Claim
302	main	_	_	I-Claim
303	adverse	_	_	I-Claim
304	effect	_	_	I-Claim
305	was	_	_	I-Claim
306	sexual	_	_	I-Claim
307	dysfunction	_	_	I-Claim
308	,	_	_	I-Claim
309	and	_	_	I-Claim
310	the	_	_	I-Claim
311	main	_	_	I-Claim
312	cause	_	_	I-Claim
313	of	_	_	I-Claim
314	this	_	_	I-Claim
315	was	_	_	I-Claim
316	surgery	_	_	I-Claim
317	,	_	_	I-Claim
318	but	_	_	O
319	that	_	_	O
320	PRE	_	_	B-Claim
321	also	_	_	I-Claim
322	affected	_	_	I-Claim
323	sexual	_	_	I-Claim
324	and	_	_	I-Claim
325	some	_	_	I-Claim
326	aspects	_	_	I-Claim
327	of	_	_	I-Claim
328	bowel	_	_	I-Claim
329	functioning	_	_	I-Claim
330	.	_	_	I-Claim


0	Persistent	_	_	O
1	insomnia	_	_	O
2	is	_	_	O
3	a	_	_	O
4	common	_	_	O
5	complaint	_	_	O
6	in	_	_	O
7	cancer	_	_	O
8	survivors	_	_	O
9	,	_	_	O
10	but	_	_	O
11	is	_	_	O
12	seldom	_	_	O
13	satisfactorily	_	_	O
14	addressed	_	_	O
15	.	_	_	O

16	The	_	_	O
17	adaptation	_	_	O
18	to	_	_	O
19	cancer	_	_	O
20	care	_	_	O
21	of	_	_	O
22	a	_	_	O
23	validated	_	_	O
24	,	_	_	O
25	cost-effective	_	_	O
26	intervention	_	_	O
27	may	_	_	O
28	offer	_	_	O
29	a	_	_	O
30	practicable	_	_	O
31	solution	_	_	O
32	.	_	_	O

33	The	_	_	O
34	aim	_	_	O
35	of	_	_	O
36	this	_	_	O
37	study	_	_	O
38	was	_	_	O
39	to	_	_	O
40	investigate	_	_	O
41	the	_	_	O
42	clinical	_	_	O
43	effectiveness	_	_	O
44	of	_	_	O
45	protocol-driven	_	_	O
46	cognitive	_	_	O
47	behavior	_	_	O
48	therapy	_	_	O
49	(	_	_	O
50	CBT	_	_	O
51	)	_	_	O
52	for	_	_	O
53	insomnia	_	_	O
54	,	_	_	O
55	delivered	_	_	O
56	by	_	_	O
57	oncology	_	_	O
58	nurses	_	_	O
59	.	_	_	O

60	Randomized	_	_	O
61	,	_	_	O
62	controlled	_	_	O
63	,	_	_	O
64	pragmatic	_	_	O
65	,	_	_	O
66	two-center	_	_	O
67	trial	_	_	O
68	of	_	_	O
69	CBT	_	_	O
70	versus	_	_	O
71	treatment	_	_	O
72	as	_	_	O
73	usual	_	_	O
74	(	_	_	O
75	TAU	_	_	O
76	)	_	_	O
77	in	_	_	O
78	150	_	_	O
79	patients	_	_	O
80	(	_	_	O
81	103	_	_	O
82	females	_	_	O
83	;	_	_	O
84	mean	_	_	O
85	age	_	_	O
86	,	_	_	O
87	61	_	_	O
88	years	_	_	O
89	.	_	_	O
90	)	_	_	O

91	who	_	_	O
92	had	_	_	O
93	completed	_	_	O
94	active	_	_	O
95	therapy	_	_	O
96	for	_	_	O
97	breast	_	_	O
98	,	_	_	O
99	prostate	_	_	O
100	,	_	_	O
101	colorectal	_	_	O
102	,	_	_	O
103	or	_	_	O
104	gynecological	_	_	O
105	cancer	_	_	O
106	.	_	_	O

107	The	_	_	O
108	study	_	_	O
109	conformed	_	_	O
110	to	_	_	O
111	CONSORT	_	_	O
112	guidelines	_	_	O
113	.	_	_	O

114	Primary	_	_	O
115	outcomes	_	_	O
116	were	_	_	O
117	sleep	_	_	O
118	diary	_	_	O
119	measures	_	_	O
120	at	_	_	O
121	baseline	_	_	O
122	,	_	_	O
123	post-treatment	_	_	O
124	,	_	_	O
125	and	_	_	O
126	6-month	_	_	O
127	follow-up	_	_	O
128	.	_	_	O

129	Actigraphic	_	_	O
130	sleep	_	_	O
131	,	_	_	O
132	health-related	_	_	O
133	quality	_	_	O
134	of	_	_	O
135	life	_	_	O
136	(	_	_	O
137	QOL	_	_	O
138	)	_	_	O
139	,	_	_	O
140	psychopathology	_	_	O
141	,	_	_	O
142	and	_	_	O
143	fatigue	_	_	O
144	were	_	_	O
145	secondary	_	_	O
146	measures	_	_	O
147	.	_	_	O

148	CBT	_	_	O
149	comprised	_	_	O
150	five	_	_	O
151	,	_	_	O
152	small	_	_	O
153	group	_	_	O
154	sessions	_	_	O
155	across	_	_	O
156	consecutive	_	_	O
157	weeks	_	_	O
158	,	_	_	O
159	after	_	_	O
160	a	_	_	O
161	manualized	_	_	O
162	protocol	_	_	O
163	.	_	_	O

164	TAU	_	_	O
165	represented	_	_	O
166	normal	_	_	O
167	clinical	_	_	O
168	practice	_	_	O
169	;	_	_	O
170	the	_	_	O
171	appropriate	_	_	O
172	control	_	_	O
173	for	_	_	O
174	a	_	_	O
175	clinical	_	_	O
176	effectiveness	_	_	O
177	study	_	_	O
178	.	_	_	O

179	CBT	_	_	B-Premise
180	was	_	_	I-Premise
181	associated	_	_	I-Premise
182	with	_	_	I-Premise
183	mean	_	_	I-Premise
184	reductions	_	_	I-Premise
185	in	_	_	I-Premise
186	wakefulness	_	_	I-Premise
187	of	_	_	I-Premise
188	55	_	_	I-Premise
189	minutes	_	_	I-Premise
190	per	_	_	I-Premise
191	night	_	_	I-Premise
192	compared	_	_	I-Premise
193	with	_	_	I-Premise
194	no	_	_	I-Premise
195	change	_	_	I-Premise
196	in	_	_	I-Premise
197	TAU	_	_	I-Premise
198	.	_	_	I-Premise

199	These	_	_	O
200	outcomes	_	_	O
201	were	_	_	O
202	sustained	_	_	O
203	6	_	_	O
204	months	_	_	O
205	after	_	_	O
206	treatment	_	_	O
207	.	_	_	O

208	Standardized	_	_	B-Premise
209	relative	_	_	I-Premise
210	effect	_	_	I-Premise
211	sizes	_	_	I-Premise
212	were	_	_	I-Premise
213	large	_	_	I-Premise
214	for	_	_	I-Premise
215	complaints	_	_	I-Premise
216	of	_	_	I-Premise
217	difficulty	_	_	I-Premise
218	initiating	_	_	I-Premise
219	sleep	_	_	I-Premise
220	,	_	_	I-Premise
221	waking	_	_	I-Premise
222	from	_	_	I-Premise
223	sleep	_	_	I-Premise
224	during	_	_	I-Premise
225	the	_	_	I-Premise
226	night	_	_	I-Premise
227	,	_	_	I-Premise
228	and	_	_	I-Premise
229	for	_	_	I-Premise
230	sleep	_	_	I-Premise
231	efficiency	_	_	I-Premise
232	(	_	_	I-Premise
233	percentage	_	_	I-Premise
234	of	_	_	I-Premise
235	time	_	_	I-Premise
236	in	_	_	I-Premise
237	bed	_	_	I-Premise
238	spent	_	_	I-Premise
239	asleep	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	CBT	_	_	B-Premise
243	was	_	_	I-Premise
244	associated	_	_	I-Premise
245	with	_	_	I-Premise
246	moderate	_	_	I-Premise
247	to	_	_	I-Premise
248	large	_	_	I-Premise
249	effect	_	_	I-Premise
250	sizes	_	_	I-Premise
251	for	_	_	I-Premise
252	five	_	_	I-Premise
253	of	_	_	I-Premise
254	seven	_	_	I-Premise
255	QOL	_	_	I-Premise
256	outcomes	_	_	I-Premise
257	,	_	_	I-Premise
258	including	_	_	I-Premise
259	significant	_	_	I-Premise
260	reduction	_	_	I-Premise
261	in	_	_	I-Premise
262	daytime	_	_	I-Premise
263	fatigue	_	_	I-Premise
264	.	_	_	I-Premise

265	There	_	_	B-Premise
266	was	_	_	I-Premise
267	no	_	_	I-Premise
268	significant	_	_	I-Premise
269	interaction	_	_	I-Premise
270	effect	_	_	I-Premise
271	between	_	_	I-Premise
272	any	_	_	I-Premise
273	of	_	_	I-Premise
274	these	_	_	I-Premise
275	outcomes	_	_	I-Premise
276	and	_	_	I-Premise
277	baseline	_	_	I-Premise
278	demographic	_	_	I-Premise
279	,	_	_	I-Premise
280	clinical	_	_	I-Premise
281	,	_	_	I-Premise
282	or	_	_	I-Premise
283	sleep	_	_	I-Premise
284	characteristics	_	_	I-Premise
285	.	_	_	I-Premise

286	CBT	_	_	B-Claim
287	for	_	_	I-Claim
288	insomnia	_	_	I-Claim
289	may	_	_	I-Claim
290	be	_	_	I-Claim
291	both	_	_	I-Claim
292	clinically	_	_	I-Claim
293	effective	_	_	I-Claim
294	and	_	_	I-Claim
295	feasible	_	_	I-Claim
296	to	_	_	I-Claim
297	deliver	_	_	I-Claim
298	in	_	_	I-Claim
299	real	_	_	I-Claim
300	world	_	_	I-Claim
301	practice	_	_	I-Claim
302	.	_	_	I-Claim


0	Performance	_	_	O
1	status	_	_	O
2	(	_	_	O
3	PS	_	_	O
4	)	_	_	O
5	2	_	_	O
6	patients	_	_	O
7	with	_	_	O
8	non-small	_	_	O
9	cell	_	_	O
10	lung	_	_	O
11	cancer	_	_	O
12	(	_	_	O
13	NSCLC	_	_	O
14	)	_	_	O
15	experience	_	_	O
16	more	_	_	O
17	toxicity	_	_	O
18	,	_	_	O
19	lower	_	_	O
20	response	_	_	O
21	rates	_	_	O
22	,	_	_	O
23	and	_	_	O
24	shorter	_	_	O
25	survival	_	_	O
26	times	_	_	O
27	than	_	_	O
28	healthier	_	_	O
29	patients	_	_	O
30	treated	_	_	O
31	with	_	_	O
32	standard	_	_	O
33	chemotherapy	_	_	O
34	.	_	_	O

35	Paclitaxel	_	_	O
36	poliglumex	_	_	O
37	(	_	_	O
38	PPX	_	_	O
39	)	_	_	O
40	,	_	_	O
41	a	_	_	O
42	macromolecule	_	_	O
43	drug	_	_	O
44	conjugate	_	_	O
45	of	_	_	O
46	paclitaxel	_	_	O
47	and	_	_	O
48	polyglutamic	_	_	O
49	acid	_	_	O
50	,	_	_	O
51	reduces	_	_	O
52	systemic	_	_	O
53	exposure	_	_	O
54	to	_	_	O
55	peak	_	_	O
56	concentrations	_	_	O
57	of	_	_	O
58	free	_	_	O
59	paclitaxel	_	_	O
60	and	_	_	O
61	may	_	_	O
62	lead	_	_	O
63	to	_	_	O
64	increased	_	_	O
65	concentrations	_	_	O
66	in	_	_	O
67	tumors	_	_	O
68	due	_	_	O
69	to	_	_	O
70	enhanced	_	_	O
71	vascular	_	_	O
72	permeability	_	_	O
73	.	_	_	O

74	Chemotherapy-naive	_	_	O
75	PS	_	_	O
76	2	_	_	O
77	patients	_	_	O
78	with	_	_	O
79	advanced	_	_	O
80	NSCLC	_	_	O
81	were	_	_	O
82	randomized	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	carboplatin	_	_	O
86	(	_	_	O
87	area	_	_	O
88	under	_	_	O
89	the	_	_	O
90	curve	_	_	O
91	=	_	_	O
92	6	_	_	O
93	)	_	_	O
94	and	_	_	O
95	either	_	_	O
96	PPX	_	_	O
97	(	_	_	O
98	210	_	_	O
99	mg/m/10	_	_	O
100	min	_	_	O
101	without	_	_	O
102	routine	_	_	O
103	steroid	_	_	O
104	premedication	_	_	O
105	)	_	_	O
106	or	_	_	O
107	paclitaxel	_	_	O
108	(	_	_	O
109	225	_	_	O
110	mg/m/3	_	_	O
111	h	_	_	O
112	with	_	_	O
113	standard	_	_	O
114	premedication	_	_	O
115	)	_	_	O
116	every	_	_	O
117	3	_	_	O
118	weeks	_	_	O
119	.	_	_	O

120	The	_	_	O
121	primary	_	_	O
122	end	_	_	O
123	point	_	_	O
124	was	_	_	O
125	overall	_	_	O
126	survival	_	_	O
127	.	_	_	O

128	A	_	_	O
129	total	_	_	O
130	of	_	_	O
131	400	_	_	O
132	patients	_	_	O
133	were	_	_	O
134	enrolled	_	_	O
135	.	_	_	O

136	Alopecia	_	_	B-Premise
137	,	_	_	I-Premise
138	arthralgias/myalgias	_	_	I-Premise
139	,	_	_	I-Premise
140	and	_	_	I-Premise
141	cardiac	_	_	I-Premise
142	events	_	_	I-Premise
143	were	_	_	I-Premise
144	significantly	_	_	I-Premise
145	less	_	_	I-Premise
146	frequent	_	_	I-Premise
147	with	_	_	I-Premise
148	PPX/carboplatin	_	_	I-Premise
149	,	_	_	I-Premise
150	whereas	_	_	I-Premise
151	grade	_	_	I-Premise
152	>	_	_	I-Premise
153	or	_	_	I-Premise
154	=3	_	_	I-Premise
155	neutropenia	_	_	I-Premise
156	and	_	_	I-Premise
157	grade	_	_	I-Premise
158	3	_	_	I-Premise
159	neuropathy	_	_	I-Premise
160	showed	_	_	I-Premise
161	a	_	_	I-Premise
162	trend	_	_	I-Premise
163	of	_	_	I-Premise
164	worsening	_	_	I-Premise
165	.	_	_	I-Premise

166	There	_	_	B-Premise
167	was	_	_	I-Premise
168	no	_	_	I-Premise
169	significant	_	_	I-Premise
170	difference	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	incidence	_	_	I-Premise
174	of	_	_	I-Premise
175	hypersensitivity	_	_	I-Premise
176	reactions	_	_	I-Premise
177	despite	_	_	I-Premise
178	the	_	_	I-Premise
179	absence	_	_	I-Premise
180	of	_	_	I-Premise
181	routine	_	_	I-Premise
182	premedication	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	PPX	_	_	I-Premise
186	arm	_	_	I-Premise
187	.	_	_	I-Premise

188	Overall	_	_	B-Premise
189	survival	_	_	I-Premise
190	was	_	_	I-Premise
191	similar	_	_	I-Premise
192	between	_	_	I-Premise
193	treatment	_	_	I-Premise
194	arms	_	_	I-Premise
195	(	_	_	I-Premise
196	hazard	_	_	I-Premise
197	ratio	_	_	I-Premise
198	,	_	_	I-Premise
199	0.97	_	_	I-Premise
200	;	_	_	I-Premise
201	log	_	_	I-Premise
202	rank	_	_	I-Premise
203	p	_	_	I-Premise
204	=	_	_	I-Premise
205	0.769	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Median	_	_	B-Premise
209	and	_	_	I-Premise
210	1-year	_	_	I-Premise
211	survival	_	_	I-Premise
212	rates	_	_	I-Premise
213	were	_	_	I-Premise
214	7.9	_	_	I-Premise
215	months	_	_	I-Premise
216	and	_	_	I-Premise
217	31	_	_	I-Premise
218	%	_	_	I-Premise
219	,	_	_	I-Premise
220	for	_	_	I-Premise
221	PPX	_	_	I-Premise
222	versus	_	_	I-Premise
223	8	_	_	I-Premise
224	months	_	_	I-Premise
225	and	_	_	I-Premise
226	31	_	_	I-Premise
227	%	_	_	I-Premise
228	for	_	_	I-Premise
229	paclitaxel	_	_	I-Premise
230	.	_	_	I-Premise

231	Disease	_	_	O
232	control	_	_	O
233	rates	_	_	O
234	were	_	_	O
235	64	_	_	O
236	%	_	_	O
237	and	_	_	O
238	69	_	_	O
239	%	_	_	O
240	for	_	_	O
241	PPX	_	_	O
242	and	_	_	O
243	paclitaxel	_	_	O
244	,	_	_	O
245	respectively	_	_	O
246	.	_	_	O

247	Time	_	_	O
248	to	_	_	O
249	progression	_	_	O
250	was	_	_	O
251	similar	_	_	O
252	:	_	_	O
253	3.9	_	_	O
254	months	_	_	O
255	for	_	_	O
256	PPX/carboplatin	_	_	O
257	versus	_	_	O
258	4.6	_	_	O
259	months	_	_	O
260	for	_	_	O
261	paclitaxel/carboplatin	_	_	O
262	(	_	_	O
263	p	_	_	O
264	=	_	_	O
265	0.210	_	_	O
266	)	_	_	O
267	.	_	_	O

268	PPX/carboplatin	_	_	B-Claim
269	failed	_	_	I-Claim
270	to	_	_	I-Claim
271	provide	_	_	I-Claim
272	superior	_	_	I-Claim
273	survival	_	_	I-Claim
274	compared	_	_	I-Claim
275	with	_	_	I-Claim
276	paclitaxel/carboplatin	_	_	I-Claim
277	in	_	_	I-Claim
278	the	_	_	I-Claim
279	first-line	_	_	I-Claim
280	treatment	_	_	I-Claim
281	of	_	_	I-Claim
282	PS	_	_	I-Claim
283	2	_	_	I-Claim
284	patients	_	_	I-Claim
285	with	_	_	I-Claim
286	NSCLC	_	_	I-Claim
287	,	_	_	I-Claim
288	but	_	_	B-Claim
289	the	_	_	I-Claim
290	results	_	_	I-Claim
291	with	_	_	I-Claim
292	respect	_	_	I-Claim
293	to	_	_	I-Claim
294	progression-free	_	_	I-Claim
295	survival	_	_	I-Claim
296	and	_	_	I-Claim
297	overall	_	_	I-Claim
298	survival	_	_	I-Claim
299	were	_	_	I-Claim
300	comparable	_	_	I-Claim
301	and	_	_	I-Claim
302	the	_	_	I-Claim
303	PPX	_	_	I-Claim
304	regimen	_	_	I-Claim
305	was	_	_	I-Claim
306	more	_	_	I-Claim
307	convenient	_	_	I-Claim
308	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	recombinant	_	_	O
6	human	_	_	O
7	erythropoietin	_	_	O
8	(	_	_	O
9	epoetin	_	_	O
10	beta	_	_	O
11	)	_	_	O
12	on	_	_	O
13	anemia	_	_	O
14	,	_	_	O
15	transfusion	_	_	O
16	need	_	_	O
17	,	_	_	O
18	and	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	in	_	_	O
26	severely	_	_	O
27	anemic	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	low-grade	_	_	O
31	non-Hodgkin	_	_	O
32	's	_	_	O
33	lymphoma	_	_	O
34	(	_	_	O
35	NHL	_	_	O
36	)	_	_	O
37	,	_	_	O
38	chronic	_	_	O
39	lymphocytic	_	_	O
40	leukemia	_	_	O
41	(	_	_	O
42	CLL	_	_	O
43	)	_	_	O
44	,	_	_	O
45	or	_	_	O
46	multiple	_	_	O
47	myeloma	_	_	O
48	(	_	_	O
49	MM	_	_	O
50	)	_	_	O
51	.	_	_	O

52	Transfusion-dependent	_	_	O
53	patients	_	_	O
54	with	_	_	O
55	NHL	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	106	_	_	O
60	)	_	_	O
61	,	_	_	O
62	CLL	_	_	O
63	(	_	_	O
64	n	_	_	O
65	=	_	_	O
66	126	_	_	O
67	)	_	_	O
68	,	_	_	O
69	or	_	_	O
70	MM	_	_	O
71	(	_	_	O
72	n	_	_	O
73	=	_	_	O
74	117	_	_	O
75	)	_	_	O
76	and	_	_	O
77	a	_	_	O
78	low	_	_	O
79	serum	_	_	O
80	erythropoietin	_	_	O
81	concentration	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	epoetin	_	_	O
87	beta	_	_	O
88	150	_	_	O
89	IU/kg	_	_	O
90	or	_	_	O
91	placebo	_	_	O
92	subcutaneously	_	_	O
93	three	_	_	O
94	times	_	_	O
95	a	_	_	O
96	week	_	_	O
97	for	_	_	O
98	16	_	_	O
99	weeks	_	_	O
100	.	_	_	O

101	Primary	_	_	O
102	efficacy	_	_	O
103	criteria	_	_	O
104	were	_	_	O
105	transfusion-free	_	_	O
106	and	_	_	O
107	transfusion-	_	_	O
108	and	_	_	O
109	severe	_	_	O
110	anemia-free	_	_	O
111	survival	_	_	O
112	(	_	_	O
113	hemoglobin	_	_	O
114	[	_	_	O
115	Hb	_	_	O
116	]	_	_	O
117	>	_	_	O
118	8.5	_	_	O
119	g/dL	_	_	O
120	)	_	_	O
121	between	_	_	O
122	weeks	_	_	O
123	5	_	_	O
124	to	_	_	O
125	16	_	_	O
126	.	_	_	O

127	Response	_	_	O
128	was	_	_	O
129	defined	_	_	O
130	as	_	_	O
131	an	_	_	O
132	increase	_	_	O
133	in	_	_	O
134	Hb	_	_	O
135	>	_	_	O
136	or	_	_	O
137	=	_	_	O
138	2	_	_	O
139	g/dL	_	_	O
140	with	_	_	O
141	elimination	_	_	O
142	of	_	_	O
143	transfusion	_	_	O
144	need	_	_	O
145	.	_	_	O

146	QOL	_	_	O
147	was	_	_	O
148	assessed	_	_	O
149	by	_	_	O
150	the	_	_	O
151	Functional	_	_	O
152	Assessment	_	_	O
153	of	_	_	O
154	Cancer	_	_	O
155	Therapy	_	_	O
156	scale	_	_	O
157	.	_	_	O

158	Transfusion-free	_	_	B-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	=.0012	_	_	I-Premise
162	)	_	_	I-Premise
163	survival	_	_	I-Premise
164	and	_	_	I-Premise
165	transfusion-	_	_	I-Premise
166	and	_	_	I-Premise
167	severe	_	_	I-Premise
168	anemia-free	_	_	I-Premise
169	survival	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=.0001	_	_	I-Premise
173	)	_	_	I-Premise
174	were	_	_	I-Premise
175	significantly	_	_	I-Premise
176	greater	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	epoetin	_	_	I-Premise
180	beta	_	_	I-Premise
181	group	_	_	I-Premise
182	versus	_	_	I-Premise
183	placebo	_	_	I-Premise
184	(	_	_	I-Premise
185	Wald	_	_	I-Premise
186	chi	_	_	I-Premise
187	(	_	_	I-Premise
188	2	_	_	I-Premise
189	)	_	_	I-Premise
190	test	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	giving	_	_	I-Premise
194	a	_	_	I-Premise
195	relative	_	_	I-Premise
196	risk	_	_	I-Premise
197	reduction	_	_	I-Premise
198	of	_	_	I-Premise
199	43	_	_	I-Premise
200	%	_	_	I-Premise
201	and	_	_	I-Premise
202	51	_	_	I-Premise
203	%	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	.	_	_	I-Premise

207	The	_	_	B-Premise
208	response	_	_	I-Premise
209	rate	_	_	I-Premise
210	was	_	_	I-Premise
211	67	_	_	I-Premise
212	%	_	_	I-Premise
213	and	_	_	I-Premise
214	27	_	_	I-Premise
215	%	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	epoetin	_	_	I-Premise
219	beta	_	_	I-Premise
220	versus	_	_	I-Premise
221	the	_	_	I-Premise
222	placebo	_	_	I-Premise
223	group	_	_	I-Premise
224	,	_	_	I-Premise
225	respectively	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	.0001	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	After	_	_	B-Premise
233	12	_	_	I-Premise
234	and	_	_	I-Premise
235	16	_	_	I-Premise
236	weeks	_	_	I-Premise
237	of	_	_	I-Premise
238	treatment	_	_	I-Premise
239	,	_	_	I-Premise
240	QOL	_	_	I-Premise
241	significantly	_	_	I-Premise
242	improved	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	epoetin	_	_	I-Premise
246	beta	_	_	I-Premise
247	group	_	_	I-Premise
248	compared	_	_	I-Premise
249	with	_	_	I-Premise
250	placebo	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	.05	_	_	I-Premise
255	)	_	_	I-Premise
256	;	_	_	I-Premise
257	this	_	_	B-Premise
258	improvement	_	_	I-Premise
259	correlated	_	_	I-Premise
260	with	_	_	I-Premise
261	an	_	_	I-Premise
262	increase	_	_	I-Premise
263	in	_	_	I-Premise
264	Hb	_	_	I-Premise
265	concentration	_	_	I-Premise
266	(	_	_	I-Premise
267	>	_	_	I-Premise
268	or	_	_	I-Premise
269	=	_	_	I-Premise
270	2	_	_	I-Premise
271	g/dL	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	A	_	_	O
275	target	_	_	O
276	Hb	_	_	O
277	that	_	_	O
278	could	_	_	O
279	be	_	_	O
280	generally	_	_	O
281	recommended	_	_	O
282	could	_	_	O
283	not	_	_	O
284	be	_	_	O
285	identified	_	_	O
286	.	_	_	O

287	Many	_	_	B-Claim
288	severely	_	_	I-Claim
289	anemic	_	_	I-Claim
290	and	_	_	I-Claim
291	transfusion-dependent	_	_	I-Claim
292	patients	_	_	I-Claim
293	with	_	_	I-Claim
294	advanced	_	_	I-Claim
295	MM	_	_	I-Claim
296	,	_	_	I-Claim
297	NHL	_	_	I-Claim
298	,	_	_	I-Claim
299	and	_	_	I-Claim
300	CLL	_	_	I-Claim
301	and	_	_	I-Claim
302	a	_	_	I-Claim
303	low	_	_	I-Claim
304	performance	_	_	I-Claim
305	status	_	_	I-Claim
306	benefited	_	_	I-Claim
307	from	_	_	I-Claim
308	epoetin	_	_	I-Claim
309	therapy	_	_	I-Claim
310	,	_	_	I-Claim
311	with	_	_	I-Claim
312	elimination	_	_	I-Claim
313	of	_	_	I-Claim
314	severe	_	_	I-Claim
315	anemia	_	_	I-Claim
316	and	_	_	I-Claim
317	transfusion	_	_	I-Claim
318	need	_	_	I-Claim
319	,	_	_	I-Claim
320	and	_	_	I-Claim
321	improvement	_	_	I-Claim
322	in	_	_	I-Claim
323	QOL	_	_	I-Claim
324	.	_	_	I-Claim


0	The	_	_	O
1	Australian	_	_	O
2	and	_	_	O
3	New	_	_	O
4	Zealand	_	_	O
5	Germ	_	_	O
6	Cell	_	_	O
7	Trials	_	_	O
8	Group	_	_	O
9	conducted	_	_	O
10	a	_	_	O
11	multicenter	_	_	O
12	randomized	_	_	O
13	phase	_	_	O
14	III	_	_	O
15	trial	_	_	O
16	in	_	_	O
17	men	_	_	O
18	with	_	_	O
19	good-prognosis	_	_	O
20	germ	_	_	O
21	cell	_	_	O
22	tumors	_	_	O
23	of	_	_	O
24	two	_	_	O
25	standard	_	_	O
26	chemotherapy	_	_	O
27	regimens	_	_	O
28	that	_	_	O
29	contained	_	_	O
30	bleomycin	_	_	O
31	,	_	_	O
32	etoposide	_	_	O
33	,	_	_	O
34	and	_	_	O
35	cisplatin	_	_	O
36	but	_	_	O
37	differed	_	_	O
38	in	_	_	O
39	the	_	_	O
40	scheduling	_	_	O
41	and	_	_	O
42	total	_	_	O
43	dose	_	_	O
44	of	_	_	O
45	cisplatin	_	_	O
46	,	_	_	O
47	the	_	_	O
48	total	_	_	O
49	dose	_	_	O
50	of	_	_	O
51	bleomycin	_	_	O
52	,	_	_	O
53	and	_	_	O
54	the	_	_	O
55	scheduling	_	_	O
56	and	_	_	O
57	dose	_	_	O
58	intensity	_	_	O
59	of	_	_	O
60	etoposide	_	_	O
61	.	_	_	O

62	The	_	_	O
63	trial	_	_	O
64	was	_	_	O
65	stopped	_	_	O
66	early	_	_	O
67	at	_	_	O
68	a	_	_	O
69	median	_	_	O
70	follow-up	_	_	O
71	of	_	_	O
72	33	_	_	O
73	months	_	_	O
74	after	_	_	O
75	a	_	_	O
76	planned	_	_	O
77	interim	_	_	O
78	analysis	_	_	O
79	found	_	_	O
80	a	_	_	O
81	survival	_	_	O
82	benefit	_	_	O
83	for	_	_	O
84	the	_	_	O
85	more	_	_	O
86	dose-intense	_	_	O
87	regimen	_	_	O
88	.	_	_	O

89	The	_	_	O
90	aim	_	_	O
91	of	_	_	O
92	this	_	_	O
93	analysis	_	_	O
94	was	_	_	O
95	to	_	_	O
96	determine	_	_	O
97	if	_	_	O
98	this	_	_	O
99	survival	_	_	O
100	benefit	_	_	O
101	was	_	_	O
102	maintained	_	_	O
103	with	_	_	O
104	long-term	_	_	O
105	follow-up	_	_	O
106	.	_	_	O

107	Between	_	_	O
108	February	_	_	O
109	1994	_	_	O
110	and	_	_	O
111	April	_	_	O
112	2000	_	_	O
113	,	_	_	O
114	166	_	_	O
115	men	_	_	O
116	with	_	_	O
117	good-prognosis	_	_	O
118	metastatic	_	_	O
119	germ	_	_	O
120	cell	_	_	O
121	tumors	_	_	O
122	defined	_	_	O
123	by	_	_	O
124	modified	_	_	O
125	Memorial	_	_	O
126	Sloan-Kettering	_	_	O
127	criteria	_	_	O
128	were	_	_	O
129	randomly	_	_	O
130	assigned	_	_	O
131	to	_	_	O
132	receive	_	_	O
133	3B	_	_	O
134	(	_	_	O
135	90	_	_	O
136	)	_	_	O
137	E	_	_	O
138	(	_	_	O
139	500	_	_	O
140	)	_	_	O
141	P	_	_	O
142	(	_	_	O
143	three	_	_	O
144	cycles	_	_	O
145	,	_	_	O
146	repeated	_	_	O
147	every	_	_	O
148	21	_	_	O
149	days	_	_	O
150	,	_	_	O
151	of	_	_	O
152	30	_	_	O
153	kU	_	_	O
154	bleomycin	_	_	O
155	on	_	_	O
156	days	_	_	O
157	1	_	_	O
158	,	_	_	O
159	8	_	_	O
160	,	_	_	O
161	and	_	_	O
162	15	_	_	O
163	;	_	_	O
164	100	_	_	O
165	mg/m	_	_	O
166	(	_	_	O
167	2	_	_	O
168	)	_	_	O
169	etoposide	_	_	O
170	on	_	_	O
171	days	_	_	O
172	1-5	_	_	O
173	;	_	_	O
174	and	_	_	O
175	20	_	_	O
176	mg/m	_	_	O
177	(	_	_	O
178	2	_	_	O
179	)	_	_	O
180	cisplatin	_	_	O
181	on	_	_	O
182	days	_	_	O
183	1-5	_	_	O
184	;	_	_	O
185	n	_	_	O
186	=	_	_	O
187	83	_	_	O
188	)	_	_	O
189	or	_	_	O
190	4B	_	_	O
191	(	_	_	O
192	30	_	_	O
193	)	_	_	O
194	E	_	_	O
195	(	_	_	O
196	360	_	_	O
197	)	_	_	O
198	P	_	_	O
199	(	_	_	O
200	four	_	_	O
201	cycles	_	_	O
202	,	_	_	O
203	repeated	_	_	O
204	every	_	_	O
205	21	_	_	O
206	days	_	_	O
207	,	_	_	O
208	of	_	_	O
209	30	_	_	O
210	kU	_	_	O
211	bleomycin	_	_	O
212	on	_	_	O
213	day	_	_	O
214	1	_	_	O
215	,	_	_	O
216	120	_	_	O
217	mg/m	_	_	O
218	(	_	_	O
219	2	_	_	O
220	)	_	_	O
221	etoposide	_	_	O
222	on	_	_	O
223	days	_	_	O
224	1-3	_	_	O
225	,	_	_	O
226	and	_	_	O
227	100	_	_	O
228	mg/m	_	_	O
229	(	_	_	O
230	2	_	_	O
231	)	_	_	O
232	cisplatin	_	_	O
233	on	_	_	O
234	day	_	_	O
235	1	_	_	O
236	;	_	_	O
237	n	_	_	O
238	=	_	_	O
239	83	_	_	O
240	)	_	_	O
241	.	_	_	O

242	Endpoints	_	_	O
243	included	_	_	O
244	overall	_	_	O
245	survival	_	_	O
246	,	_	_	O
247	progression-free	_	_	O
248	survival	_	_	O
249	,	_	_	O
250	and	_	_	O
251	quality	_	_	O
252	of	_	_	O
253	life	_	_	O
254	and	_	_	O
255	side	_	_	O
256	effects	_	_	O
257	,	_	_	O
258	which	_	_	O
259	were	_	_	O
260	assessed	_	_	O
261	using	_	_	O
262	the	_	_	O
263	Spitzer	_	_	O
264	Quality	_	_	O
265	of	_	_	O
266	Life	_	_	O
267	Index	_	_	O
268	and	_	_	O
269	the	_	_	O
270	GLQ-8	_	_	O
271	,	_	_	O
272	respectively	_	_	O
273	,	_	_	O
274	before	_	_	O
275	random	_	_	O
276	assignment	_	_	O
277	and	_	_	O
278	during	_	_	O
279	and	_	_	O
280	after	_	_	O
281	treatment	_	_	O
282	.	_	_	O

283	All	_	_	O
284	analyses	_	_	O
285	were	_	_	O
286	by	_	_	O
287	intention	_	_	O
288	to	_	_	O
289	treat	_	_	O
290	.	_	_	O

291	All	_	_	O
292	P	_	_	O
293	values	_	_	O
294	are	_	_	O
295	two-sided	_	_	O
296	.	_	_	O

297	The	_	_	O
298	median	_	_	O
299	follow-up	_	_	O
300	was	_	_	O
301	8.5	_	_	O
302	years	_	_	O
303	.	_	_	O

304	All	_	_	O
305	but	_	_	O
306	five	_	_	O
307	survivors	_	_	O
308	(	_	_	O
309	3	_	_	O
310	%	_	_	O
311	)	_	_	O
312	were	_	_	O
313	followed	_	_	O
314	up	_	_	O
315	for	_	_	O
316	at	_	_	O
317	least	_	_	O
318	5	_	_	O
319	years	_	_	O
320	.	_	_	O

321	Overall	_	_	B-Premise
322	survival	_	_	I-Premise
323	remained	_	_	I-Premise
324	better	_	_	I-Premise
325	in	_	_	I-Premise
326	those	_	_	I-Premise
327	assigned	_	_	I-Premise
328	to	_	_	I-Premise
329	3B	_	_	I-Premise
330	(	_	_	I-Premise
331	90	_	_	I-Premise
332	)	_	_	I-Premise
333	E	_	_	I-Premise
334	(	_	_	I-Premise
335	500	_	_	I-Premise
336	)	_	_	I-Premise
337	P	_	_	I-Premise
338	than	_	_	I-Premise
339	in	_	_	I-Premise
340	those	_	_	I-Premise
341	assigned	_	_	I-Premise
342	to	_	_	I-Premise
343	4B	_	_	I-Premise
344	(	_	_	I-Premise
345	30	_	_	I-Premise
346	)	_	_	I-Premise
347	E	_	_	I-Premise
348	(	_	_	I-Premise
349	360	_	_	I-Premise
350	)	_	_	I-Premise
351	P	_	_	I-Premise
352	(	_	_	I-Premise
353	8-year	_	_	I-Premise
354	survival	_	_	I-Premise
355	:	_	_	I-Premise
356	92	_	_	I-Premise
357	%	_	_	I-Premise
358	vs	_	_	I-Premise
359	83	_	_	I-Premise
360	%	_	_	I-Premise
361	;	_	_	I-Premise
362	hazard	_	_	I-Premise
363	ratio	_	_	I-Premise
364	of	_	_	I-Premise
365	death	_	_	I-Premise
366	=	_	_	I-Premise
367	0.38	_	_	I-Premise
368	,	_	_	I-Premise
369	95	_	_	I-Premise
370	%	_	_	I-Premise
371	confidence	_	_	I-Premise
372	interval	_	_	I-Premise
373	=	_	_	I-Premise
374	0.15	_	_	I-Premise
375	to	_	_	I-Premise
376	0.97	_	_	I-Premise
377	,	_	_	I-Premise
378	P	_	_	I-Premise
379	=	_	_	I-Premise
380	.037	_	_	I-Premise
381	)	_	_	I-Premise
382	.	_	_	I-Premise

383	Progression-free	_	_	B-Premise
384	survival	_	_	I-Premise
385	favored	_	_	I-Premise
386	3B	_	_	I-Premise
387	(	_	_	I-Premise
388	90	_	_	I-Premise
389	)	_	_	I-Premise
390	E	_	_	I-Premise
391	(	_	_	I-Premise
392	500	_	_	I-Premise
393	)	_	_	I-Premise
394	P	_	_	I-Premise
395	but	_	_	I-Premise
396	was	_	_	I-Premise
397	not	_	_	I-Premise
398	statistically	_	_	I-Premise
399	significantly	_	_	I-Premise
400	different	_	_	I-Premise
401	between	_	_	I-Premise
402	the	_	_	I-Premise
403	treatment	_	_	I-Premise
404	groups	_	_	I-Premise
405	(	_	_	I-Premise
406	8-year	_	_	I-Premise
407	progression-free	_	_	I-Premise
408	survival	_	_	I-Premise
409	,	_	_	I-Premise
410	3B	_	_	I-Premise
411	(	_	_	I-Premise
412	90	_	_	I-Premise
413	)	_	_	I-Premise
414	E	_	_	I-Premise
415	(	_	_	I-Premise
416	500	_	_	I-Premise
417	)	_	_	I-Premise
418	P	_	_	I-Premise
419	vs	_	_	I-Premise
420	4B	_	_	I-Premise
421	(	_	_	I-Premise
422	30	_	_	I-Premise
423	)	_	_	I-Premise
424	E	_	_	I-Premise
425	(	_	_	I-Premise
426	360	_	_	I-Premise
427	)	_	_	I-Premise
428	P	_	_	I-Premise
429	:	_	_	I-Premise
430	86	_	_	I-Premise
431	%	_	_	I-Premise
432	vs	_	_	I-Premise
433	79	_	_	I-Premise
434	%	_	_	I-Premise
435	;	_	_	I-Premise
436	hazard	_	_	I-Premise
437	ratio	_	_	I-Premise
438	of	_	_	I-Premise
439	progression	_	_	I-Premise
440	=	_	_	I-Premise
441	0.6	_	_	I-Premise
442	,	_	_	I-Premise
443	95	_	_	I-Premise
444	%	_	_	I-Premise
445	confidence	_	_	I-Premise
446	interval	_	_	I-Premise
447	=	_	_	I-Premise
448	0.3	_	_	I-Premise
449	to	_	_	I-Premise
450	1.1	_	_	I-Premise
451	,	_	_	I-Premise
452	P	_	_	I-Premise
453	=	_	_	I-Premise
454	.15	_	_	I-Premise
455	)	_	_	I-Premise
456	.	_	_	I-Premise

457	At	_	_	B-Claim
458	the	_	_	I-Claim
459	end	_	_	I-Claim
460	of	_	_	I-Claim
461	treatment	_	_	I-Claim
462	,	_	_	I-Claim
463	average	_	_	I-Claim
464	scores	_	_	I-Claim
465	for	_	_	I-Claim
466	most	_	_	I-Claim
467	side	_	_	I-Claim
468	effect	_	_	I-Claim
469	scales	_	_	I-Claim
470	favored	_	_	I-Claim
471	3B	_	_	I-Claim
472	(	_	_	I-Claim
473	90	_	_	I-Claim
474	)	_	_	I-Claim
475	E	_	_	I-Claim
476	(	_	_	I-Claim
477	500	_	_	I-Claim
478	)	_	_	I-Claim
479	P.	_	_	I-Claim
480	After	_	_	B-Premise
481	the	_	_	I-Premise
482	completion	_	_	I-Premise
483	of	_	_	I-Premise
484	treatment	_	_	I-Premise
485	,	_	_	I-Premise
486	average	_	_	I-Premise
487	GLQ-8	_	_	I-Premise
488	scores	_	_	I-Premise
489	for	_	_	I-Premise
490	numbness	_	_	I-Premise
491	(	_	_	I-Premise
492	P	_	_	I-Premise
493	=	_	_	I-Premise
494	.003	_	_	I-Premise
495	)	_	_	I-Premise
496	and	_	_	I-Premise
497	hair	_	_	I-Premise
498	loss	_	_	I-Premise
499	(	_	_	I-Premise
500	P	_	_	I-Premise
501	=	_	_	I-Premise
502	.04	_	_	I-Premise
503	)	_	_	I-Premise
504	and	_	_	I-Premise
505	the	_	_	I-Premise
506	Spitzer	_	_	I-Premise
507	Quality	_	_	I-Premise
508	of	_	_	I-Premise
509	Life	_	_	I-Premise
510	Index	_	_	I-Premise
511	(	_	_	I-Premise
512	P	_	_	I-Premise
513	=	_	_	I-Premise
514	.05	_	_	I-Premise
515	)	_	_	I-Premise
516	favored	_	_	I-Premise
517	3B	_	_	I-Premise
518	(	_	_	I-Premise
519	90	_	_	I-Premise
520	)	_	_	I-Premise
521	E	_	_	I-Premise
522	(	_	_	I-Premise
523	500	_	_	I-Premise
524	)	_	_	I-Premise
525	P.	_	_	I-Premise
526	The	_	_	B-Claim
527	survival	_	_	I-Claim
528	benefit	_	_	I-Claim
529	of	_	_	I-Claim
530	3B	_	_	I-Claim
531	(	_	_	I-Claim
532	90	_	_	I-Claim
533	)	_	_	I-Claim
534	E	_	_	I-Claim
535	(	_	_	I-Claim
536	500	_	_	I-Claim
537	)	_	_	I-Claim
538	P	_	_	I-Claim
539	over	_	_	I-Claim
540	4B	_	_	I-Claim
541	(	_	_	I-Claim
542	30	_	_	I-Claim
543	)	_	_	I-Claim
544	E	_	_	I-Claim
545	(	_	_	I-Claim
546	360	_	_	I-Claim
547	)	_	_	I-Claim
548	P	_	_	I-Claim
549	was	_	_	I-Claim
550	maintained	_	_	I-Claim
551	with	_	_	I-Claim
552	long-term	_	_	I-Claim
553	follow-up	_	_	I-Claim
554	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	comparatively	_	_	O
3	,	_	_	O
4	in	_	_	O
5	terms	_	_	O
6	of	_	_	O
7	quality-adjusted	_	_	O
8	survival	_	_	O
9	,	_	_	O
10	three	_	_	O
11	front-line	_	_	O
12	treatments	_	_	O
13	in	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	stage	_	_	O
17	B-	_	_	O
18	or	_	_	O
19	C-chronic	_	_	O
20	lymphocytic	_	_	O
21	leukemia	_	_	O
22	(	_	_	O
23	CLL	_	_	O
24	)	_	_	O
25	.	_	_	O

26	To	_	_	O
27	describe	_	_	O
28	better	_	_	O
29	and	_	_	O
30	compare	_	_	O
31	the	_	_	O
32	survival	_	_	O
33	after	_	_	O
34	randomization	_	_	O
35	of	_	_	O
36	patients	_	_	O
37	from	_	_	O
38	the	_	_	O
39	CLL90	_	_	O
40	trial	_	_	O
41	that	_	_	O
42	randomly	_	_	O
43	compared	_	_	O
44	ChOP	_	_	O
45	(	_	_	O
46	cyclophosphamide	_	_	O
47	,	_	_	O
48	doxorubicin	_	_	O
49	,	_	_	O
50	oncovin	_	_	O
51	,	_	_	O
52	prednisone	_	_	O
53	)	_	_	O
54	,	_	_	O
55	CAP	_	_	O
56	(	_	_	O
57	cyclophosphamide	_	_	O
58	,	_	_	O
59	doxorubicin	_	_	O
60	,	_	_	O
61	prednisone	_	_	O
62	)	_	_	O
63	and	_	_	O
64	fludarabine	_	_	O
65	in	_	_	O
66	advanced	_	_	O
67	CLL	_	_	O
68	,	_	_	O
69	we	_	_	O
70	performed	_	_	O
71	a	_	_	O
72	quality-adjusted	_	_	O
73	survival	_	_	O
74	analysis	_	_	O
75	.	_	_	O

76	This	_	_	O
77	consisted	_	_	O
78	of	_	_	O
79	defining	_	_	O
80	four	_	_	O
81	clinical	_	_	O
82	states	_	_	O
83	(	_	_	O
84	toxicity	_	_	O
85	,	_	_	O
86	treatment	_	_	O
87	free	_	_	O
88	of	_	_	O
89	toxicity	_	_	O
90	,	_	_	O
91	no	_	_	O
92	treatment	_	_	O
93	nor	_	_	O
94	symptoms	_	_	O
95	,	_	_	O
96	relapse	_	_	O
97	)	_	_	O
98	,	_	_	O
99	then	_	_	O
100	summing	_	_	O
101	up	_	_	O
102	the	_	_	O
103	average	_	_	O
104	times	_	_	O
105	spent	_	_	O
106	in	_	_	O
107	each	_	_	O
108	state	_	_	O
109	weighted	_	_	O
110	by	_	_	O
111	utility	_	_	O
112	coefficients	_	_	O
113	that	_	_	O
114	reflect	_	_	O
115	relative	_	_	O
116	value	_	_	O
117	according	_	_	O
118	to	_	_	O
119	quality	_	_	O
120	of	_	_	O
121	life	_	_	O
122	.	_	_	O

123	The	_	_	O
124	resulting	_	_	O
125	quality-adjusted	_	_	O
126	time	_	_	O
127	without	_	_	O
128	symptoms	_	_	O
129	or	_	_	O
130	toxicity	_	_	O
131	(	_	_	O
132	Q-TWIST	_	_	O
133	)	_	_	O
134	was	_	_	O
135	compared	_	_	O
136	between	_	_	O
137	randomized	_	_	O
138	groups	_	_	O
139	,	_	_	O
140	and	_	_	O
141	sensitivity	_	_	O
142	(	_	_	O
143	threshold	_	_	O
144	)	_	_	O
145	analyses	_	_	O
146	to	_	_	O
147	the	_	_	O
148	choice	_	_	O
149	of	_	_	O
150	utility	_	_	O
151	coefficients	_	_	O
152	was	_	_	O
153	performed	_	_	O
154	.	_	_	O

155	Over	_	_	B-Premise
156	73	_	_	I-Premise
157	months	_	_	I-Premise
158	after	_	_	I-Premise
159	randomization	_	_	I-Premise
160	,	_	_	I-Premise
161	the	_	_	I-Premise
162	fludarabine	_	_	I-Premise
163	group	_	_	I-Premise
164	gained	_	_	I-Premise
165	a	_	_	I-Premise
166	mean	_	_	I-Premise
167	of	_	_	I-Premise
168	45	_	_	I-Premise
169	days	_	_	I-Premise
170	of	_	_	I-Premise
171	toxicity-free	_	_	I-Premise
172	survival	_	_	I-Premise
173	at	_	_	I-Premise
174	CAP	_	_	I-Premise
175	,	_	_	I-Premise
176	and	_	_	I-Premise
177	61	_	_	I-Premise
178	days	_	_	I-Premise
179	over	_	_	I-Premise
180	ChOP	_	_	I-Premise
181	.	_	_	I-Premise

182	The	_	_	B-Premise
183	mean	_	_	I-Premise
184	TWIST	_	_	I-Premise
185	was	_	_	I-Premise
186	27.05	_	_	I-Premise
187	months	_	_	I-Premise
188	with	_	_	I-Premise
189	CAP	_	_	I-Premise
190	,	_	_	I-Premise
191	31.5	_	_	I-Premise
192	months	_	_	I-Premise
193	with	_	_	I-Premise
194	ChOP	_	_	I-Premise
195	and	_	_	I-Premise
196	32.95	_	_	I-Premise
197	months	_	_	I-Premise
198	with	_	_	I-Premise
199	fludarabine	_	_	I-Premise
200	.	_	_	I-Premise

201	The	_	_	B-Premise
202	threshold	_	_	I-Premise
203	analyses	_	_	I-Premise
204	showed	_	_	I-Premise
205	that	_	_	I-Premise
206	,	_	_	I-Premise
207	whatever	_	_	I-Premise
208	the	_	_	I-Premise
209	utility	_	_	I-Premise
210	weights	_	_	I-Premise
211	,	_	_	I-Premise
212	the	_	_	I-Premise
213	mean	_	_	I-Premise
214	Q-TWIST	_	_	I-Premise
215	was	_	_	I-Premise
216	always	_	_	I-Premise
217	greater	_	_	I-Premise
218	with	_	_	I-Premise
219	ChOP	_	_	I-Premise
220	or	_	_	I-Premise
221	fludarabine	_	_	I-Premise
222	as	_	_	I-Premise
223	compared	_	_	I-Premise
224	to	_	_	I-Premise
225	CAP	_	_	I-Premise
226	.	_	_	I-Premise

227	Fludarabine	_	_	B-Claim
228	was	_	_	I-Claim
229	consistently	_	_	I-Claim
230	a	_	_	I-Claim
231	better	_	_	I-Claim
232	treatment	_	_	I-Claim
233	than	_	_	I-Claim
234	ChOP	_	_	I-Claim
235	,	_	_	I-Claim
236	except	_	_	B-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	unlikely	_	_	I-Premise
240	case	_	_	I-Premise
241	of	_	_	I-Premise
242	high	_	_	I-Premise
243	utility	_	_	I-Premise
244	weights	_	_	I-Premise
245	attributed	_	_	I-Premise
246	to	_	_	I-Premise
247	toxicity	_	_	I-Premise
248	and	_	_	I-Premise
249	low	_	_	I-Premise
250	utility	_	_	I-Premise
251	weights	_	_	I-Premise
252	attributed	_	_	I-Premise
253	to	_	_	I-Premise
254	treatment	_	_	I-Premise
255	.	_	_	I-Premise

256	Nevertheless	_	_	O
257	,	_	_	O
258	from	_	_	B-Premise
259	a	_	_	I-Premise
260	clinical	_	_	I-Premise
261	point	_	_	I-Premise
262	of	_	_	I-Premise
263	view	_	_	I-Premise
264	,	_	_	I-Premise
265	differences	_	_	I-Premise
266	between	_	_	I-Premise
267	ChOP	_	_	I-Premise
268	and	_	_	I-Premise
269	fludarabine	_	_	I-Premise
270	were	_	_	I-Premise
271	moderate	_	_	I-Premise
272	or	_	_	I-Premise
273	event	_	_	I-Premise
274	slight	_	_	I-Premise
275	(	_	_	I-Premise
276	mean	_	_	I-Premise
277	difference	_	_	I-Premise
278	in	_	_	I-Premise
279	TWIST	_	_	I-Premise
280	of	_	_	I-Premise
281	1.45	_	_	I-Premise
282	months	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	We	_	_	O
286	conclude	_	_	O
287	that	_	_	O
288	patients	_	_	B-Claim
289	with	_	_	I-Claim
290	advanced	_	_	I-Claim
291	CLL	_	_	I-Claim
292	have	_	_	I-Claim
293	a	_	_	I-Claim
294	moderate	_	_	I-Claim
295	benefit	_	_	I-Claim
296	in	_	_	I-Claim
297	terms	_	_	I-Claim
298	of	_	_	I-Claim
299	Q-TWIST	_	_	I-Claim
300	when	_	_	I-Claim
301	treated	_	_	I-Claim
302	with	_	_	I-Claim
303	fludarabine	_	_	I-Claim
304	over	_	_	I-Claim
305	ChOP	_	_	I-Claim
306	.	_	_	I-Claim

307	These	_	_	B-Claim
308	two	_	_	I-Claim
309	treatments	_	_	I-Claim
310	are	_	_	I-Claim
311	always	_	_	I-Claim
312	superior	_	_	I-Claim
313	to	_	_	I-Claim
314	CAP	_	_	I-Claim
315	.	_	_	I-Claim


0	There	_	_	O
1	will	_	_	O
2	be	_	_	O
3	a	_	_	O
4	detectable	_	_	O
5	increase	_	_	O
6	in	_	_	O
7	overall	_	_	O
8	survival	_	_	O
9	(	_	_	O
10	OS	_	_	O
11	)	_	_	O
12	using	_	_	O
13	preoperative	_	_	O
14	(	_	_	O
15	PRE	_	_	O
16	)	_	_	O
17	as	_	_	O
18	opposed	_	_	O
19	to	_	_	O
20	perioperative	_	_	O
21	(	_	_	O
22	PERI	_	_	O
23	)	_	_	O
24	chemotherapy	_	_	O
25	in	_	_	O
26	resectable	_	_	O
27	StageI-II	_	_	O
28	non-small-cell	_	_	O
29	lung	_	_	O
30	cancer	_	_	O
31	(	_	_	O
32	NSCLC	_	_	O
33	)	_	_	O
34	.	_	_	O

35	This	_	_	O
36	multicenter	_	_	O
37	,	_	_	O
38	open-label	_	_	O
39	,	_	_	O
40	randomised	_	_	O
41	trial	_	_	O
42	with	_	_	O
43	a	_	_	O
44	22	_	_	O
45	factorial	_	_	O
46	design	_	_	O
47	first	_	_	O
48	compared	_	_	O
49	two	_	_	O
50	chemotherapy	_	_	O
51	strategies	_	_	O
52	(	_	_	O
53	PRE	_	_	O
54	versus	_	_	O
55	PERI	_	_	O
56	)	_	_	O
57	,	_	_	O
58	then	_	_	O
59	two	_	_	O
60	chemotherapy	_	_	O
61	regimens	_	_	O
62	(	_	_	O
63	gemcitabine-cisplatin	_	_	O
64	[	_	_	O
65	GP	_	_	O
66	]	_	_	O
67	versus	_	_	O
68	paclitaxel-carboplatin	_	_	O
69	[	_	_	O
70	TC	_	_	O
71	]	_	_	O
72	)	_	_	O
73	.	_	_	O

74	The	_	_	O
75	PRE	_	_	O
76	group	_	_	O
77	received	_	_	O
78	two	_	_	O
79	preoperative	_	_	O
80	cycles	_	_	O
81	followed	_	_	O
82	by	_	_	O
83	two	_	_	O
84	additional	_	_	O
85	preoperative	_	_	O
86	cycles	_	_	O
87	,	_	_	O
88	while	_	_	O
89	the	_	_	O
90	PERI	_	_	O
91	group	_	_	O
92	underwent	_	_	O
93	two	_	_	O
94	preoperative	_	_	O
95	cycles	_	_	O
96	followed	_	_	O
97	by	_	_	O
98	two	_	_	O
99	postoperative	_	_	O
100	cycles	_	_	O
101	,	_	_	O
102	the	_	_	O
103	3rd	_	_	O
104	and	_	_	O
105	4th	_	_	O
106	cycles	_	_	O
107	being	_	_	O
108	given	_	_	O
109	only	_	_	O
110	to	_	_	O
111	responders	_	_	O
112	in	_	_	O
113	both	_	_	O
114	cases	_	_	O
115	.	_	_	O

116	A	_	_	O
117	total	_	_	O
118	of	_	_	O
119	528	_	_	O
120	patients	_	_	O
121	were	_	_	O
122	randomised	_	_	O
123	,	_	_	O
124	267	_	_	O
125	of	_	_	O
126	which	_	_	O
127	were	_	_	O
128	assigned	_	_	O
129	to	_	_	O
130	the	_	_	O
131	PRE	_	_	O
132	group	_	_	O
133	and	_	_	O
134	261	_	_	O
135	to	_	_	O
136	the	_	_	O
137	PERI	_	_	O
138	group	_	_	O
139	.	_	_	O

140	Three-year	_	_	O
141	OS	_	_	O
142	did	_	_	O
143	not	_	_	O
144	differ	_	_	O
145	between	_	_	O
146	the	_	_	O
147	two	_	_	O
148	groups	_	_	O
149	(	_	_	O
150	67.4	_	_	O
151	%	_	_	O
152	and	_	_	O
153	67.7	_	_	O
154	%	_	_	O
155	,	_	_	O
156	respectively	_	_	O
157	;	_	_	O
158	hazard	_	_	O
159	ratio	_	_	O
160	(	_	_	O
161	HR	_	_	O
162	)	_	_	O
163	=1.01	_	_	O
164	[	_	_	O
165	0.79-1.30	_	_	O
166	]	_	_	O
167	,	_	_	O
168	p=0.92	_	_	O
169	)	_	_	O
170	,	_	_	O
171	nor	_	_	O
172	did	_	_	O
173	3-year	_	_	O
174	disease-free	_	_	O
175	survival	_	_	O
176	,	_	_	O
177	response	_	_	O
178	rates	_	_	O
179	,	_	_	O
180	toxicity	_	_	O
181	,	_	_	O
182	or	_	_	O
183	postoperative	_	_	O
184	mortality	_	_	O
185	.	_	_	O

186	Pathological	_	_	B-Premise
187	complete	_	_	I-Premise
188	response	_	_	I-Premise
189	was	_	_	I-Premise
190	observed	_	_	I-Premise
191	in	_	_	I-Premise
192	22	_	_	I-Premise
193	(	_	_	I-Premise
194	8.2	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	16	_	_	I-Premise
199	patients	_	_	I-Premise
200	(	_	_	I-Premise
201	6.1	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	.	_	_	I-Premise

207	Although	_	_	B-Premise
208	quality	_	_	I-Premise
209	of	_	_	I-Premise
210	life	_	_	I-Premise
211	did	_	_	I-Premise
212	not	_	_	I-Premise
213	differ	_	_	I-Premise
214	significantly	_	_	I-Premise
215	,	_	_	I-Premise
216	chemotherapy	_	_	B-Premise
217	compliance	_	_	I-Premise
218	was	_	_	I-Premise
219	significantly	_	_	I-Premise
220	higher	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	PRE	_	_	I-Premise
224	group	_	_	I-Premise
225	.	_	_	I-Premise

226	The	_	_	B-Premise
227	proportion	_	_	I-Premise
228	of	_	_	I-Premise
229	responders	_	_	I-Premise
230	who	_	_	I-Premise
231	received	_	_	I-Premise
232	Cycles	_	_	I-Premise
233	3	_	_	I-Premise
234	and	_	_	I-Premise
235	4	_	_	I-Premise
236	was	_	_	I-Premise
237	significantly	_	_	I-Premise
238	higher	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	PRE	_	_	I-Premise
242	group	_	_	I-Premise
243	(	_	_	I-Premise
244	90.4	_	_	I-Premise
245	%	_	_	I-Premise
246	versus	_	_	I-Premise
247	75.2	_	_	I-Premise
248	%	_	_	I-Premise
249	,	_	_	I-Premise
250	p=0.001	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	In	_	_	B-Premise
254	responders	_	_	I-Premise
255	,	_	_	I-Premise
256	the	_	_	I-Premise
257	dose	_	_	I-Premise
258	intensity	_	_	I-Premise
259	of	_	_	I-Premise
260	Cycles	_	_	I-Premise
261	3	_	_	I-Premise
262	and	_	_	I-Premise
263	4	_	_	I-Premise
264	was	_	_	I-Premise
265	higher	_	_	I-Premise
266	in	_	_	I-Premise
267	the	_	_	I-Premise
268	PRE	_	_	I-Premise
269	group	_	_	I-Premise
270	than	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	PERI	_	_	I-Premise
274	group	_	_	I-Premise
275	(	_	_	I-Premise
276	mean	_	_	I-Premise
277	relative	_	_	I-Premise
278	dose	_	_	I-Premise
279	intensity	_	_	I-Premise
280	of	_	_	I-Premise
281	90.4	_	_	I-Premise
282	%	_	_	I-Premise
283	versus	_	_	I-Premise
284	82.6	_	_	I-Premise
285	%	_	_	I-Premise
286	,	_	_	I-Premise
287	respectively	_	_	I-Premise
288	;	_	_	I-Premise
289	p=0.0007	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	There	_	_	B-Premise
293	was	_	_	I-Premise
294	no	_	_	I-Premise
295	difference	_	_	I-Premise
296	between	_	_	I-Premise
297	GP	_	_	I-Premise
298	and	_	_	I-Premise
299	TC	_	_	I-Premise
300	in	_	_	I-Premise
301	3-year	_	_	I-Premise
302	OS	_	_	I-Premise
303	(	_	_	I-Premise
304	HR=0.97	_	_	I-Premise
305	[	_	_	I-Premise
306	95	_	_	I-Premise
307	%	_	_	I-Premise
308	confidence	_	_	I-Premise
309	interval	_	_	I-Premise
310	(	_	_	I-Premise
311	CI	_	_	I-Premise
312	)	_	_	I-Premise
313	:	_	_	I-Premise
314	0.76-1.25	_	_	I-Premise
315	]	_	_	I-Premise
316	,	_	_	I-Premise
317	p=0.80	_	_	I-Premise
318	)	_	_	I-Premise
319	or	_	_	I-Premise
320	response	_	_	I-Premise
321	rates	_	_	I-Premise
322	.	_	_	I-Premise

323	However	_	_	O
324	,	_	_	O
325	the	_	_	B-Premise
326	regimens	_	_	I-Premise
327	'	_	_	I-Premise
328	toxicity	_	_	I-Premise
329	profiles	_	_	I-Premise
330	differed	_	_	I-Premise
331	.	_	_	I-Premise

332	This	_	_	B-Claim
333	study	_	_	I-Claim
334	failed	_	_	I-Claim
335	to	_	_	I-Claim
336	demonstrate	_	_	I-Claim
337	any	_	_	I-Claim
338	difference	_	_	I-Claim
339	in	_	_	I-Claim
340	survival	_	_	I-Claim
341	between	_	_	I-Claim
342	patients	_	_	I-Claim
343	receiving	_	_	I-Claim
344	preoperative	_	_	I-Claim
345	and	_	_	I-Claim
346	perioperative	_	_	I-Claim
347	chemotherapy	_	_	I-Claim
348	in	_	_	I-Claim
349	early-stage	_	_	I-Claim
350	NSCLC	_	_	I-Claim
351	.	_	_	I-Claim

352	The	_	_	B-Claim
353	increase	_	_	I-Claim
354	from	_	_	I-Claim
355	two	_	_	I-Claim
356	to	_	_	I-Claim
357	four	_	_	I-Claim
358	preoperative	_	_	I-Claim
359	chemotherapy	_	_	I-Claim
360	cycles	_	_	I-Claim
361	did	_	_	I-Claim
362	not	_	_	I-Claim
363	increase	_	_	I-Claim
364	the	_	_	I-Claim
365	pathological	_	_	I-Claim
366	response	_	_	I-Claim
367	rate	_	_	I-Claim
368	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	a	_	_	O
8	slow-release	_	_	O
9	formulation	_	_	O
10	of	_	_	O
11	cytarabine	_	_	O
12	(	_	_	O
13	DepoCyt	_	_	O
14	;	_	_	O
15	Chiron	_	_	O
16	Corp	_	_	O
17	,	_	_	O
18	Emeryville	_	_	O
19	,	_	_	O
20	CA	_	_	O
21	,	_	_	O
22	and	_	_	O
23	Skye	_	_	O
24	Pharma	_	_	O
25	,	_	_	O
26	Inc	_	_	O
27	,	_	_	O
28	San	_	_	O
29	Diego	_	_	O
30	,	_	_	O
31	CA	_	_	O
32	)	_	_	O
33	that	_	_	O
34	maintains	_	_	O
35	cytotoxic	_	_	O
36	concentrations	_	_	O
37	of	_	_	O
38	cytarabine	_	_	O
39	(	_	_	O
40	ara-C	_	_	O
41	)	_	_	O
42	in	_	_	O
43	the	_	_	O
44	CSF	_	_	O
45	of	_	_	O
46	most	_	_	O
47	patients	_	_	O
48	for	_	_	O
49	more	_	_	O
50	than	_	_	O
51	14	_	_	O
52	days	_	_	O
53	.	_	_	O

54	Twenty-eight	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	lymphoma	_	_	O
58	and	_	_	O
59	a	_	_	O
60	positive	_	_	O
61	CSF	_	_	O
62	cytology	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	DepoCyt	_	_	O
68	50	_	_	O
69	mg	_	_	O
70	once	_	_	O
71	every	_	_	O
72	2	_	_	O
73	weeks	_	_	O
74	or	_	_	O
75	free	_	_	O
76	ara-C	_	_	O
77	50	_	_	O
78	mg	_	_	O
79	twice	_	_	O
80	a	_	_	O
81	week	_	_	O
82	for	_	_	O
83	1	_	_	O
84	month	_	_	O
85	.	_	_	O

86	Patients	_	_	O
87	whose	_	_	O
88	CSF	_	_	O
89	cytology	_	_	O
90	converted	_	_	O
91	to	_	_	O
92	negative	_	_	O
93	and	_	_	O
94	who	_	_	O
95	did	_	_	O
96	not	_	_	O
97	have	_	_	O
98	neurologic	_	_	O
99	progression	_	_	O
100	received	_	_	O
101	an	_	_	O
102	additional	_	_	O
103	3	_	_	O
104	months	_	_	O
105	of	_	_	O
106	consolidation	_	_	O
107	therapy	_	_	O
108	and	_	_	O
109	then	_	_	O
110	4	_	_	O
111	months	_	_	O
112	of	_	_	O
113	maintenance	_	_	O
114	therapy	_	_	O
115	.	_	_	O

116	All	_	_	O
117	patients	_	_	O
118	received	_	_	O
119	dexamethasone	_	_	O
120	4	_	_	O
121	mg	_	_	O
122	orally	_	_	O
123	bid	_	_	O
124	on	_	_	O
125	days	_	_	O
126	1	_	_	O
127	through	_	_	O
128	5	_	_	O
129	of	_	_	O
130	each	_	_	O
131	2-week	_	_	O
132	cycle	_	_	O
133	.	_	_	O

134	The	_	_	B-Premise
135	response	_	_	I-Premise
136	rate	_	_	I-Premise
137	was	_	_	I-Premise
138	71	_	_	I-Premise
139	%	_	_	I-Premise
140	for	_	_	I-Premise
141	DepoCyt	_	_	I-Premise
142	and	_	_	I-Premise
143	15	_	_	I-Premise
144	%	_	_	I-Premise
145	for	_	_	I-Premise
146	ara-C	_	_	I-Premise
147	on	_	_	I-Premise
148	an	_	_	I-Premise
149	intent-to-treat	_	_	I-Premise
150	basis	_	_	I-Premise
151	(	_	_	I-Premise
152	P	_	_	I-Premise
153	=.006	_	_	I-Premise
154	)	_	_	I-Premise
155	.	_	_	I-Premise

156	All	_	_	B-Premise
157	of	_	_	I-Premise
158	the	_	_	I-Premise
159	patients	_	_	I-Premise
160	on	_	_	I-Premise
161	the	_	_	I-Premise
162	DepoCyt	_	_	I-Premise
163	arm	_	_	I-Premise
164	but	_	_	I-Premise
165	only	_	_	I-Premise
166	53	_	_	I-Premise
167	%	_	_	I-Premise
168	of	_	_	I-Premise
169	those	_	_	I-Premise
170	on	_	_	I-Premise
171	the	_	_	I-Premise
172	ara-C	_	_	I-Premise
173	arm	_	_	I-Premise
174	were	_	_	I-Premise
175	able	_	_	I-Premise
176	to	_	_	I-Premise
177	complete	_	_	I-Premise
178	the	_	_	I-Premise
179	planned	_	_	I-Premise
180	1-month	_	_	I-Premise
181	induction	_	_	I-Premise
182	therapy	_	_	I-Premise
183	regimen	_	_	I-Premise
184	.	_	_	I-Premise

185	Time	_	_	B-Premise
186	to	_	_	I-Premise
187	neurologic	_	_	I-Premise
188	progression	_	_	I-Premise
189	and	_	_	I-Premise
190	survival	_	_	I-Premise
191	trend	_	_	I-Premise
192	in	_	_	I-Premise
193	favor	_	_	I-Premise
194	of	_	_	I-Premise
195	DepoCyt	_	_	I-Premise
196	(	_	_	I-Premise
197	median	_	_	I-Premise
198	,	_	_	I-Premise
199	78.5	_	_	I-Premise
200	v	_	_	I-Premise
201	42	_	_	I-Premise
202	days	_	_	I-Premise
203	and	_	_	I-Premise
204	99.5	_	_	I-Premise
205	v	_	_	I-Premise
206	63	_	_	I-Premise
207	days	_	_	I-Premise
208	,	_	_	I-Premise
209	respectively	_	_	I-Premise
210	;	_	_	I-Premise
211	P	_	_	I-Premise
212	>	_	_	I-Premise
213	.05	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	DepoCyt	_	_	B-Premise
217	treatment	_	_	I-Premise
218	was	_	_	I-Premise
219	associated	_	_	I-Premise
220	with	_	_	I-Premise
221	an	_	_	I-Premise
222	improved	_	_	I-Premise
223	mean	_	_	I-Premise
224	change	_	_	I-Premise
225	in	_	_	I-Premise
226	Karnofsky	_	_	I-Premise
227	performance	_	_	I-Premise
228	score	_	_	I-Premise
229	at	_	_	I-Premise
230	the	_	_	I-Premise
231	end	_	_	I-Premise
232	of	_	_	I-Premise
233	induction	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	=.041	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	The	_	_	B-Premise
240	major	_	_	I-Premise
241	adverse	_	_	I-Premise
242	events	_	_	I-Premise
243	on	_	_	I-Premise
244	both	_	_	I-Premise
245	arms	_	_	I-Premise
246	were	_	_	I-Premise
247	headache	_	_	I-Premise
248	and	_	_	I-Premise
249	arachnoiditis	_	_	I-Premise
250	,	_	_	I-Premise
251	which	_	_	I-Premise
252	were	_	_	I-Premise
253	often	_	_	I-Premise
254	caused	_	_	I-Premise
255	by	_	_	I-Premise
256	the	_	_	I-Premise
257	underlying	_	_	I-Premise
258	disease	_	_	I-Premise
259	.	_	_	I-Premise

260	DepoCyt	_	_	B-Claim
261	injected	_	_	I-Claim
262	once	_	_	I-Claim
263	every	_	_	I-Claim
264	2	_	_	I-Claim
265	weeks	_	_	I-Claim
266	produced	_	_	I-Claim
267	a	_	_	I-Claim
268	high	_	_	I-Claim
269	response	_	_	I-Claim
270	rate	_	_	I-Claim
271	and	_	_	I-Claim
272	a	_	_	I-Claim
273	better	_	_	I-Claim
274	quality	_	_	I-Claim
275	of	_	_	I-Claim
276	life	_	_	I-Claim
277	as	_	_	I-Claim
278	measured	_	_	I-Claim
279	by	_	_	I-Claim
280	Karnofsky	_	_	I-Claim
281	score	_	_	I-Claim
282	relative	_	_	I-Claim
283	to	_	_	I-Claim
284	that	_	_	I-Claim
285	produced	_	_	I-Claim
286	by	_	_	I-Claim
287	free	_	_	I-Claim
288	ara-C	_	_	I-Claim
289	injected	_	_	I-Claim
290	twice	_	_	I-Claim
291	a	_	_	I-Claim
292	week	_	_	I-Claim
293	.	_	_	I-Claim


0	Patients	_	_	O
1	receiving	_	_	O
2	chemoradiation	_	_	O
3	for	_	_	O
4	cervical	_	_	O
5	cancer	_	_	O
6	are	_	_	O
7	at	_	_	O
8	risk	_	_	O
9	for	_	_	O
10	distress	_	_	O
11	,	_	_	O
12	chemoradiation-related	_	_	O
13	side-effects	_	_	O
14	,	_	_	O
15	and	_	_	O
16	immunosuppression	_	_	O
17	.	_	_	O

18	This	_	_	O
19	prospective	_	_	O
20	randomized	_	_	O
21	clinical	_	_	O
22	trial	_	_	O
23	examined	_	_	O
24	effects	_	_	O
25	of	_	_	O
26	a	_	_	O
27	complementary	_	_	O
28	therapy	_	_	O
29	,	_	_	O
30	Healing	_	_	O
31	Touch	_	_	O
32	(	_	_	O
33	HT	_	_	O
34	)	_	_	O
35	,	_	_	O
36	versus	_	_	O
37	relaxation	_	_	O
38	training	_	_	O
39	(	_	_	O
40	RT	_	_	O
41	)	_	_	O
42	and	_	_	O
43	usual	_	_	O
44	care	_	_	O
45	(	_	_	O
46	UC	_	_	O
47	)	_	_	O
48	for	_	_	O
49	(	_	_	O
50	1	_	_	O
51	)	_	_	O
52	supporting	_	_	O
53	cellular	_	_	O
54	immunity	_	_	O
55	,	_	_	O
56	(	_	_	O
57	2	_	_	O
58	)	_	_	O
59	improving	_	_	O
60	mood	_	_	O
61	and	_	_	O
62	quality	_	_	O
63	of	_	_	O
64	life	_	_	O
65	(	_	_	O
66	QOL	_	_	O
67	)	_	_	O
68	,	_	_	O
69	and	_	_	O
70	(	_	_	O
71	3	_	_	O
72	)	_	_	O
73	reducing	_	_	O
74	treatment-associated	_	_	O
75	toxicities	_	_	O
76	and	_	_	O
77	treatment	_	_	O
78	delay	_	_	O
79	in	_	_	O
80	cervical	_	_	O
81	cancer	_	_	O
82	patients	_	_	O
83	receiving	_	_	O
84	chemoradiation	_	_	O
85	.	_	_	O

86	Sixty	_	_	O
87	women	_	_	O
88	with	_	_	O
89	stages	_	_	O
90	IB1	_	_	O
91	to	_	_	O
92	IVA	_	_	O
93	cervical	_	_	O
94	cancer	_	_	O
95	were	_	_	O
96	randomly	_	_	O
97	assigned	_	_	O
98	to	_	_	O
99	receive	_	_	O
100	UC	_	_	O
101	or	_	_	O
102	4	_	_	O
103	/weekly	_	_	O
104	individual	_	_	O
105	sessions	_	_	O
106	of	_	_	O
107	either	_	_	O
108	HT	_	_	O
109	or	_	_	O
110	RT	_	_	O
111	immediately	_	_	O
112	following	_	_	O
113	radiation	_	_	O
114	during	_	_	O
115	their	_	_	O
116	6-week	_	_	O
117	chemoradiation	_	_	O
118	treatment	_	_	O
119	.	_	_	O

120	Patients	_	_	O
121	completed	_	_	O
122	psychosocial	_	_	O
123	assessments	_	_	O
124	and	_	_	O
125	blood	_	_	O
126	sampling	_	_	O
127	before	_	_	O
128	chemoradiation	_	_	O
129	at	_	_	O
130	baseline	_	_	O
131	,	_	_	O
132	weeks	_	_	O
133	4	_	_	O
134	and	_	_	O
135	6	_	_	O
136	.	_	_	O

137	Multilevel	_	_	O
138	regression	_	_	O
139	analyses	_	_	O
140	using	_	_	O
141	orthogonal	_	_	O
142	contrasts	_	_	O
143	tested	_	_	O
144	for	_	_	O
145	differences	_	_	O
146	between	_	_	O
147	treatment	_	_	O
148	conditions	_	_	O
149	over	_	_	O
150	time	_	_	O
151	.	_	_	O

152	HT	_	_	B-Premise
153	patients	_	_	I-Premise
154	had	_	_	I-Premise
155	a	_	_	I-Premise
156	minimal	_	_	I-Premise
157	decrease	_	_	I-Premise
158	in	_	_	I-Premise
159	natural	_	_	I-Premise
160	killer	_	_	I-Premise
161	cell	_	_	I-Premise
162	cytotoxicity	_	_	I-Premise
163	(	_	_	I-Premise
164	NKCC	_	_	I-Premise
165	)	_	_	I-Premise
166	over	_	_	I-Premise
167	the	_	_	I-Premise
168	course	_	_	I-Premise
169	of	_	_	I-Premise
170	treatment	_	_	I-Premise
171	whereas	_	_	I-Premise
172	NKCC	_	_	I-Premise
173	of	_	_	I-Premise
174	RT	_	_	I-Premise
175	and	_	_	I-Premise
176	UC	_	_	I-Premise
177	patients	_	_	I-Premise
178	declined	_	_	I-Premise
179	sharply	_	_	I-Premise
180	during	_	_	I-Premise
181	chemoradiation	_	_	I-Premise
182	(	_	_	I-Premise
183	group	_	_	I-Premise
184	by	_	_	I-Premise
185	time	_	_	I-Premise
186	interaction	_	_	I-Premise
187	:	_	_	I-Premise
188	p	_	_	I-Premise
189	=	_	_	I-Premise
190	0.018	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	HT	_	_	B-Premise
194	patients	_	_	I-Premise
195	showed	_	_	I-Premise
196	greater	_	_	I-Premise
197	decreases	_	_	I-Premise
198	in	_	_	I-Premise
199	two	_	_	I-Premise
200	different	_	_	I-Premise
201	indicators	_	_	I-Premise
202	of	_	_	I-Premise
203	depressed	_	_	I-Premise
204	mood	_	_	I-Premise
205	(	_	_	I-Premise
206	CES-D	_	_	I-Premise
207	depressed	_	_	I-Premise
208	mood	_	_	I-Premise
209	subscale	_	_	I-Premise
210	and	_	_	I-Premise
211	POMS	_	_	I-Premise
212	depression	_	_	I-Premise
213	scale	_	_	I-Premise
214	)	_	_	I-Premise
215	compared	_	_	I-Premise
216	to	_	_	I-Premise
217	RT	_	_	I-Premise
218	and	_	_	I-Premise
219	UC	_	_	I-Premise
220	(	_	_	I-Premise
221	group	_	_	I-Premise
222	by	_	_	I-Premise
223	time	_	_	I-Premise
224	interactions	_	_	I-Premise
225	:	_	_	I-Premise
226	p	_	_	I-Premise
227	<	_	_	I-Premise
228	0.05	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	No	_	_	B-Premise
232	between	_	_	I-Premise
233	group	_	_	I-Premise
234	differences	_	_	I-Premise
235	were	_	_	I-Premise
236	observed	_	_	I-Premise
237	in	_	_	I-Premise
238	QOL	_	_	I-Premise
239	,	_	_	I-Premise
240	treatment	_	_	I-Premise
241	delay	_	_	I-Premise
242	,	_	_	I-Premise
243	or	_	_	I-Premise
244	clinically-rated	_	_	I-Premise
245	toxicities	_	_	I-Premise
246	.	_	_	I-Premise

247	HT	_	_	B-Claim
248	may	_	_	I-Claim
249	benefit	_	_	I-Claim
250	cervical	_	_	I-Claim
251	cancer	_	_	I-Claim
252	patients	_	_	I-Claim
253	by	_	_	I-Claim
254	moderating	_	_	I-Claim
255	effects	_	_	I-Claim
256	of	_	_	I-Claim
257	chemoradiation	_	_	I-Claim
258	on	_	_	I-Claim
259	depressed	_	_	I-Claim
260	mood	_	_	I-Claim
261	and	_	_	I-Claim
262	cellular	_	_	I-Claim
263	immunity	_	_	I-Claim
264	.	_	_	I-Claim

265	Effects	_	_	B-Claim
266	of	_	_	I-Claim
267	HT	_	_	I-Claim
268	on	_	_	I-Claim
269	toxicities	_	_	I-Claim
270	,	_	_	I-Claim
271	treatment	_	_	I-Claim
272	delay	_	_	I-Claim
273	,	_	_	I-Claim
274	QOL	_	_	I-Claim
275	,	_	_	I-Claim
276	and	_	_	I-Claim
277	fatigue	_	_	I-Claim
278	were	_	_	I-Claim
279	not	_	_	I-Claim
280	observed	_	_	I-Claim
281	.	_	_	I-Claim

282	Long-term	_	_	O
283	clinical	_	_	O
284	implications	_	_	O
285	of	_	_	O
286	findings	_	_	O
287	are	_	_	O
288	not	_	_	O
289	known	_	_	O
290	.	_	_	O


0	Exercise	_	_	O
1	improves	_	_	O
2	physical	_	_	O
3	functioning	_	_	O
4	and	_	_	O
5	symptom	_	_	O
6	management	_	_	O
7	during	_	_	O
8	breast	_	_	O
9	cancer	_	_	O
10	chemotherapy	_	_	O
11	,	_	_	O
12	but	_	_	O
13	the	_	_	O
14	effects	_	_	O
15	of	_	_	O
16	different	_	_	O
17	doses	_	_	O
18	and	_	_	O
19	types	_	_	O
20	of	_	_	O
21	exercise	_	_	O
22	are	_	_	O
23	unknown	_	_	O
24	.	_	_	O

25	A	_	_	O
26	multicenter	_	_	O
27	trial	_	_	O
28	in	_	_	O
29	Canada	_	_	O
30	randomized	_	_	O
31	301	_	_	O
32	breast	_	_	O
33	cancer	_	_	O
34	patients	_	_	O
35	to	_	_	O
36	thrice-weekly	_	_	O
37	supervised	_	_	O
38	exercise	_	_	O
39	during	_	_	O
40	chemotherapy	_	_	O
41	consisting	_	_	O
42	of	_	_	O
43	either	_	_	O
44	a	_	_	O
45	standard	_	_	O
46	dose	_	_	O
47	of	_	_	O
48	25	_	_	O
49	to	_	_	O
50	30	_	_	O
51	minutes	_	_	O
52	of	_	_	O
53	aerobic	_	_	O
54	exercise	_	_	O
55	(	_	_	O
56	STAN	_	_	O
57	;	_	_	O
58	n	_	_	O
59	=	_	_	O
60	96	_	_	O
61	)	_	_	O
62	,	_	_	O
63	a	_	_	O
64	higher	_	_	O
65	dose	_	_	O
66	of	_	_	O
67	50	_	_	O
68	to	_	_	O
69	60	_	_	O
70	minutes	_	_	O
71	of	_	_	O
72	aerobic	_	_	O
73	exercise	_	_	O
74	(	_	_	O
75	HIGH	_	_	O
76	;	_	_	O
77	n	_	_	O
78	=	_	_	O
79	101	_	_	O
80	)	_	_	O
81	,	_	_	O
82	or	_	_	O
83	a	_	_	O
84	combined	_	_	O
85	dose	_	_	O
86	of	_	_	O
87	50	_	_	O
88	to	_	_	O
89	60	_	_	O
90	minutes	_	_	O
91	of	_	_	O
92	aerobic	_	_	O
93	and	_	_	O
94	resistance	_	_	O
95	exercise	_	_	O
96	(	_	_	O
97	COMB	_	_	O
98	;	_	_	O
99	n	_	_	O
100	=	_	_	O
101	104	_	_	O
102	)	_	_	O
103	.	_	_	O

104	The	_	_	O
105	primary	_	_	O
106	endpoint	_	_	O
107	was	_	_	O
108	physical	_	_	O
109	functioning	_	_	O
110	assessed	_	_	O
111	by	_	_	O
112	the	_	_	O
113	Medical	_	_	O
114	Outcomes	_	_	O
115	Survey-Short	_	_	O
116	Form	_	_	O
117	(	_	_	O
118	SF	_	_	O
119	)	_	_	O
120	-36	_	_	O
121	.	_	_	O

122	Secondary	_	_	O
123	endpoints	_	_	O
124	were	_	_	O
125	other	_	_	O
126	physical	_	_	O
127	functioning	_	_	O
128	scales	_	_	O
129	,	_	_	O
130	symptoms	_	_	O
131	,	_	_	O
132	fitness	_	_	O
133	,	_	_	O
134	and	_	_	O
135	chemotherapy	_	_	O
136	completion	_	_	O
137	.	_	_	O

138	All	_	_	O
139	statistical	_	_	O
140	tests	_	_	O
141	were	_	_	O
142	linear	_	_	O
143	mixed	_	_	O
144	model	_	_	O
145	analyses	_	_	O
146	,	_	_	O
147	and	_	_	O
148	the	_	_	O
149	P	_	_	O
150	values	_	_	O
151	were	_	_	O
152	two-sided	_	_	O
153	.	_	_	O

154	Follow-up	_	_	O
155	assessment	_	_	O
156	of	_	_	O
157	patient-reported	_	_	O
158	outcomes	_	_	O
159	was	_	_	O
160	99.0	_	_	O
161	%	_	_	O
162	.	_	_	O

163	Adjusted	_	_	B-Premise
164	linear	_	_	I-Premise
165	mixed-model	_	_	I-Premise
166	analyses	_	_	I-Premise
167	showed	_	_	I-Premise
168	that	_	_	I-Premise
169	neither	_	_	I-Premise
170	HIGH	_	_	I-Premise
171	(	_	_	I-Premise
172	+0.8	_	_	I-Premise
173	;	_	_	I-Premise
174	95	_	_	I-Premise
175	%	_	_	I-Premise
176	confidence	_	_	I-Premise
177	interval	_	_	I-Premise
178	[	_	_	I-Premise
179	CI	_	_	I-Premise
180	]	_	_	I-Premise
181	=	_	_	I-Premise
182	-0.8	_	_	I-Premise
183	to	_	_	I-Premise
184	2.4	_	_	I-Premise
185	;	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	.30	_	_	I-Premise
189	)	_	_	I-Premise
190	nor	_	_	I-Premise
191	COMB	_	_	I-Premise
192	(	_	_	I-Premise
193	+0.5	_	_	I-Premise
194	;	_	_	I-Premise
195	95	_	_	I-Premise
196	%	_	_	I-Premise
197	CI	_	_	I-Premise
198	=	_	_	I-Premise
199	-1.1	_	_	I-Premise
200	to	_	_	I-Premise
201	2.1	_	_	I-Premise
202	;	_	_	I-Premise
203	P	_	_	I-Premise
204	=	_	_	I-Premise
205	.52	_	_	I-Premise
206	]	_	_	I-Premise
207	were	_	_	I-Premise
208	superior	_	_	I-Premise
209	to	_	_	I-Premise
210	STAN	_	_	I-Premise
211	for	_	_	I-Premise
212	the	_	_	I-Premise
213	primary	_	_	I-Premise
214	outcome	_	_	I-Premise
215	.	_	_	I-Premise

216	In	_	_	B-Premise
217	secondary	_	_	I-Premise
218	analyses	_	_	I-Premise
219	not	_	_	I-Premise
220	adjusted	_	_	I-Premise
221	for	_	_	I-Premise
222	multiple	_	_	I-Premise
223	comparisons	_	_	I-Premise
224	,	_	_	I-Premise
225	HIGH	_	_	I-Premise
226	was	_	_	I-Premise
227	superior	_	_	I-Premise
228	to	_	_	I-Premise
229	STAN	_	_	I-Premise
230	for	_	_	I-Premise
231	the	_	_	I-Premise
232	SF-36	_	_	I-Premise
233	physical	_	_	I-Premise
234	component	_	_	I-Premise
235	summary	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	=	_	_	I-Premise
239	.04	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	SF-36	_	_	I-Premise
243	bodily	_	_	I-Premise
244	pain	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.02	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	and	_	_	I-Premise
252	endocrine	_	_	I-Premise
253	symptoms	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	.02	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	COMB	_	_	B-Premise
261	was	_	_	I-Premise
262	superior	_	_	I-Premise
263	to	_	_	I-Premise
264	STAN	_	_	I-Premise
265	for	_	_	I-Premise
266	endocrine	_	_	I-Premise
267	symptoms	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.009	_	_	I-Premise
272	)	_	_	I-Premise
273	and	_	_	I-Premise
274	superior	_	_	I-Premise
275	to	_	_	I-Premise
276	STAN	_	_	I-Premise
277	(	_	_	I-Premise
278	P	_	_	I-Premise
279	<	_	_	I-Premise
280	.001	_	_	I-Premise
281	)	_	_	I-Premise
282	and	_	_	I-Premise
283	HIGH	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	.001	_	_	I-Premise
288	)	_	_	I-Premise
289	for	_	_	I-Premise
290	muscular	_	_	I-Premise
291	strength	_	_	I-Premise
292	.	_	_	I-Premise

293	HIGH	_	_	B-Premise
294	was	_	_	I-Premise
295	superior	_	_	I-Premise
296	to	_	_	I-Premise
297	COMB	_	_	I-Premise
298	for	_	_	I-Premise
299	the	_	_	I-Premise
300	SF-36	_	_	I-Premise
301	bodily	_	_	I-Premise
302	pain	_	_	I-Premise
303	(	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	.04	_	_	I-Premise
307	)	_	_	I-Premise
308	and	_	_	I-Premise
309	aerobic	_	_	I-Premise
310	fitness	_	_	I-Premise
311	(	_	_	I-Premise
312	P	_	_	I-Premise
313	=	_	_	I-Premise
314	.03	_	_	I-Premise
315	)	_	_	I-Premise
316	.	_	_	I-Premise

317	No	_	_	B-Premise
318	differences	_	_	I-Premise
319	emerged	_	_	I-Premise
320	for	_	_	I-Premise
321	body	_	_	I-Premise
322	composition	_	_	I-Premise
323	or	_	_	I-Premise
324	chemotherapy	_	_	I-Premise
325	completion	_	_	I-Premise
326	.	_	_	I-Premise

327	A	_	_	B-Claim
328	higher	_	_	I-Claim
329	volume	_	_	I-Claim
330	of	_	_	I-Claim
331	aerobic	_	_	I-Claim
332	or	_	_	I-Claim
333	combined	_	_	I-Claim
334	exercise	_	_	I-Claim
335	is	_	_	I-Claim
336	achievable	_	_	I-Claim
337	and	_	_	I-Claim
338	safe	_	_	I-Claim
339	during	_	_	I-Claim
340	breast	_	_	I-Claim
341	cancer	_	_	I-Claim
342	chemotherapy	_	_	I-Claim
343	and	_	_	I-Claim
344	may	_	_	I-Claim
345	manage	_	_	I-Claim
346	declines	_	_	I-Claim
347	in	_	_	I-Claim
348	physical	_	_	I-Claim
349	functioning	_	_	I-Claim
350	and	_	_	I-Claim
351	worsening	_	_	I-Claim
352	symptoms	_	_	I-Claim
353	better	_	_	I-Claim
354	than	_	_	I-Claim
355	standard	_	_	I-Claim
356	volumes	_	_	I-Claim
357	.	_	_	I-Claim


0	For	_	_	B-Claim
1	several	_	_	I-Claim
2	decades	_	_	I-Claim
3	,	_	_	I-Claim
4	both	_	_	I-Claim
5	preoperative	_	_	I-Claim
6	intra-arterial	_	_	I-Claim
7	chemotherapy	_	_	I-Claim
8	and	_	_	I-Claim
9	preoperative	_	_	I-Claim
10	irradiation	_	_	I-Claim
11	have	_	_	I-Claim
12	been	_	_	I-Claim
13	accepted	_	_	I-Claim
14	treatments	_	_	I-Claim
15	for	_	_	I-Claim
16	patients	_	_	I-Claim
17	with	_	_	I-Claim
18	tumors	_	_	I-Claim
19	of	_	_	I-Claim
20	the	_	_	I-Claim
21	head	_	_	I-Claim
22	and	_	_	I-Claim
23	neck	_	_	I-Claim
24	.	_	_	I-Claim

25	Unfortunately	_	_	O
26	,	_	_	O
27	arguments	_	_	O
28	have	_	_	O
29	often	_	_	O
30	been	_	_	O
31	put	_	_	O
32	forward	_	_	O
33	in	_	_	O
34	favor	_	_	O
35	of	_	_	O
36	one	_	_	O
37	or	_	_	O
38	other	_	_	O
39	of	_	_	O
40	the	_	_	O
41	two	_	_	O
42	methods	_	_	O
43	,	_	_	O
44	but	_	_	O
45	without	_	_	O
46	the	_	_	O
47	performance	_	_	O
48	of	_	_	O
49	an	_	_	O
50	objective	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	investigation	_	_	O
54	.	_	_	O

55	To	_	_	O
56	resolve	_	_	O
57	this	_	_	O
58	situation	_	_	O
59	,	_	_	O
60	the	_	_	O
61	authors	_	_	O
62	have	_	_	O
63	carried	_	_	O
64	out	_	_	O
65	a	_	_	O
66	multicenter	_	_	O
67	,	_	_	O
68	randomized	_	_	O
69	prospective	_	_	O
70	study	_	_	O
71	of	_	_	O
72	selected	_	_	O
73	patients	_	_	O
74	with	_	_	O
75	a	_	_	O
76	view	_	_	O
77	to	_	_	O
78	deciding	_	_	O
79	which	_	_	O
80	method	_	_	O
81	affords	_	_	O
82	better	_	_	O
83	results	_	_	O
84	in	_	_	O
85	complex	_	_	O
86	tumor	_	_	O
87	therapy	_	_	O
88	from	_	_	O
89	the	_	_	O
90	aspects	_	_	O
91	of	_	_	O
92	survival	_	_	O
93	and	_	_	O
94	postoperative	_	_	O
95	quality	_	_	O
96	of	_	_	O
97	life	_	_	O
98	.	_	_	O

99	One	_	_	O
100	hundred	_	_	O
101	thirty-one	_	_	O
102	patients	_	_	O
103	with	_	_	O
104	operable	_	_	O
105	sublingual	_	_	O
106	or	_	_	O
107	lingual	_	_	O
108	squamous	_	_	O
109	cell	_	_	O
110	carcinoma	_	_	O
111	in	_	_	O
112	stages	_	_	O
113	T2NXM0	_	_	O
114	to	_	_	O
115	T4MXM0	_	_	O
116	were	_	_	O
117	randomized	_	_	O
118	into	_	_	O
119	2	_	_	O
120	groups	_	_	O
121	:	_	_	O
122	1	_	_	O
123	group	_	_	O
124	participated	_	_	O
125	in	_	_	O
126	preoperative	_	_	O
127	chemotherapy	_	_	O
128	with	_	_	O
129	cisplatin	_	_	O
130	and	_	_	O
131	epirubicin	_	_	O
132	(	_	_	O
133	total	_	_	O
134	doses	_	_	O
135	:	_	_	O
136	200	_	_	O
137	mg	_	_	O
138	cisplatin	_	_	O
139	,	_	_	O
140	120	_	_	O
141	mg	_	_	O
142	epirubicin	_	_	O
143	)	_	_	O
144	via	_	_	O
145	the	_	_	O
146	external	_	_	O
147	carotid	_	_	O
148	artery	_	_	O
149	,	_	_	O
150	whereas	_	_	O
151	the	_	_	O
152	other	_	_	O
153	group	_	_	O
154	received	_	_	O
155	preoperative	_	_	O
156	radiation	_	_	O
157	therapy	_	_	O
158	(	_	_	O
159	46	_	_	O
160	grays	_	_	O
161	)	_	_	O
162	.	_	_	O

163	Following	_	_	O
164	subsequent	_	_	O
165	radical	_	_	O
166	surgery	_	_	O
167	,	_	_	O
168	the	_	_	O
169	patients	_	_	O
170	received	_	_	O
171	regular	_	_	O
172	follow-up	_	_	O
173	for	_	_	O
174	5	_	_	O
175	years	_	_	O
176	.	_	_	O

177	By	_	_	O
178	the	_	_	O
179	end	_	_	O
180	of	_	_	O
181	the	_	_	O
182	5	_	_	O
183	years	_	_	O
184	,	_	_	O
185	95	_	_	O
186	of	_	_	O
187	the	_	_	O
188	131	_	_	O
189	patients	_	_	O
190	had	_	_	O
191	conformed	_	_	O
192	to	_	_	O
193	the	_	_	O
194	protocol	_	_	O
195	.	_	_	O

196	Of	_	_	O
197	those	_	_	O
198	95	_	_	O
199	,	_	_	O
200	47	_	_	O
201	had	_	_	O
202	received	_	_	O
203	preoperative	_	_	O
204	chemotherapy	_	_	O
205	and	_	_	O
206	48	_	_	O
207	preoperative	_	_	O
208	irradiation	_	_	O
209	.	_	_	O

210	After	_	_	B-Premise
211	5	_	_	I-Premise
212	years	_	_	I-Premise
213	,	_	_	I-Premise
214	18	_	_	I-Premise
215	of	_	_	I-Premise
216	the	_	_	I-Premise
217	47	_	_	I-Premise
218	patients	_	_	I-Premise
219	who	_	_	I-Premise
220	received	_	_	I-Premise
221	chemotherapy	_	_	I-Premise
222	and	_	_	I-Premise
223	15	_	_	I-Premise
224	of	_	_	I-Premise
225	the	_	_	I-Premise
226	48	_	_	I-Premise
227	patients	_	_	I-Premise
228	who	_	_	I-Premise
229	received	_	_	I-Premise
230	irradiation	_	_	I-Premise
231	were	_	_	I-Premise
232	still	_	_	I-Premise
233	alive	_	_	I-Premise
234	and	_	_	I-Premise
235	tumor	_	_	I-Premise
236	free	_	_	I-Premise
237	.	_	_	I-Premise

238	A	_	_	B-Premise
239	few	_	_	I-Premise
240	more	_	_	I-Premise
241	patients	_	_	I-Premise
242	had	_	_	I-Premise
243	died	_	_	I-Premise
244	of	_	_	I-Premise
245	recurrence	_	_	I-Premise
246	or	_	_	I-Premise
247	regional	_	_	I-Premise
248	metastasis	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	chemotherapy	_	_	I-Premise
252	group	_	_	I-Premise
253	(	_	_	I-Premise
254	23	_	_	I-Premise
255	patients	_	_	I-Premise
256	)	_	_	I-Premise
257	than	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	irradiation	_	_	I-Premise
261	group	_	_	I-Premise
262	(	_	_	I-Premise
263	20	_	_	I-Premise
264	patients	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Occurrence	_	_	B-Premise
268	of	_	_	I-Premise
269	a	_	_	I-Premise
270	second	_	_	I-Premise
271	carcinoma	_	_	I-Premise
272	was	_	_	I-Premise
273	3	_	_	I-Premise
274	times	_	_	I-Premise
275	as	_	_	I-Premise
276	frequent	_	_	I-Premise
277	in	_	_	I-Premise
278	the	_	_	I-Premise
279	irradiation	_	_	I-Premise
280	group	_	_	I-Premise
281	(	_	_	I-Premise
282	9	_	_	I-Premise
283	patients	_	_	I-Premise
284	)	_	_	I-Premise
285	as	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	chemotherapy	_	_	I-Premise
289	group	_	_	I-Premise
290	(	_	_	I-Premise
291	3	_	_	I-Premise
292	patients	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Overall	_	_	O
296	,	_	_	O
297	the	_	_	B-Claim
298	survival	_	_	I-Claim
299	rates	_	_	I-Claim
300	were	_	_	I-Claim
301	by-and-large	_	_	I-Claim
302	the	_	_	I-Claim
303	same	_	_	I-Claim
304	for	_	_	I-Claim
305	the	_	_	I-Claim
306	two	_	_	I-Claim
307	groups	_	_	I-Claim
308	.	_	_	I-Claim

309	Regarding	_	_	B-Claim
310	postoperative	_	_	I-Claim
311	quality	_	_	I-Claim
312	of	_	_	I-Claim
313	life	_	_	I-Claim
314	,	_	_	I-Claim
315	the	_	_	I-Claim
316	chemotherapy	_	_	I-Claim
317	group	_	_	I-Claim
318	presented	_	_	I-Claim
319	a	_	_	I-Claim
320	more	_	_	I-Claim
321	favorable	_	_	I-Claim
322	picture	_	_	I-Claim
323	.	_	_	I-Claim

324	The	_	_	B-Claim
325	long	_	_	I-Claim
326	term	_	_	I-Claim
327	survival	_	_	I-Claim
328	results	_	_	I-Claim
329	subsequent	_	_	I-Claim
330	to	_	_	I-Claim
331	preoperative	_	_	I-Claim
332	intra-arterial	_	_	I-Claim
333	chemotherapy	_	_	I-Claim
334	or	_	_	I-Claim
335	preoperative	_	_	I-Claim
336	radiotherapy	_	_	I-Claim
337	were	_	_	I-Claim
338	practically	_	_	I-Claim
339	the	_	_	I-Claim
340	same	_	_	I-Claim
341	.	_	_	I-Claim

342	Regarding	_	_	B-Claim
343	postoperative	_	_	I-Claim
344	quality	_	_	I-Claim
345	of	_	_	I-Claim
346	life	_	_	I-Claim
347	,	_	_	I-Claim
348	patients	_	_	I-Claim
349	who	_	_	I-Claim
350	underwent	_	_	I-Claim
351	intra-arterial	_	_	I-Claim
352	chemotherapy	_	_	I-Claim
353	appeared	_	_	I-Claim
354	to	_	_	I-Claim
355	be	_	_	I-Claim
356	in	_	_	I-Claim
357	a	_	_	I-Claim
358	slightly	_	_	I-Claim
359	more	_	_	I-Claim
360	favorable	_	_	I-Claim
361	situation	_	_	I-Claim
362	.	_	_	I-Claim

363	The	_	_	O
364	authors	_	_	O
365	consider	_	_	O
366	it	_	_	O
367	important	_	_	O
368	to	_	_	O
369	stress	_	_	O
370	these	_	_	O
371	findings	_	_	O
372	,	_	_	O
373	as	_	_	O
374	they	_	_	O
375	are	_	_	O
376	not	_	_	O
377	aware	_	_	O
378	of	_	_	O
379	a	_	_	O
380	similar	_	_	O
381	randomized	_	_	O
382	study	_	_	O
383	of	_	_	O
384	patients	_	_	O
385	with	_	_	O
386	tumors	_	_	O
387	of	_	_	O
388	the	_	_	O
389	oral	_	_	O
390	cavity	_	_	O
391	.	_	_	O


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	medroxyprogesterone	_	_	O
6	acetate	_	_	O
7	(	_	_	O
8	MPA	_	_	O
9	)	_	_	O
10	on	_	_	O
11	appetite	_	_	O
12	,	_	_	O
13	weight	_	_	O
14	,	_	_	O
15	and	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QL	_	_	O
21	)	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	advanced-stage	_	_	O
26	,	_	_	O
27	incurable	_	_	O
28	,	_	_	O
29	non-hormone-sensitive	_	_	O
30	cancer	_	_	O
31	.	_	_	O

32	Two	_	_	O
33	hundred	_	_	O
34	six	_	_	O
35	eligible	_	_	O
36	patients	_	_	O
37	were	_	_	O
38	randomized	_	_	O
39	between	_	_	O
40	double-blind	_	_	O
41	MPA	_	_	O
42	500	_	_	O
43	mg	_	_	O
44	twice	_	_	O
45	daily	_	_	O
46	or	_	_	O
47	placebo	_	_	O
48	.	_	_	O

49	Appetite	_	_	O
50	(	_	_	O
51	0	_	_	O
52	to	_	_	O
53	10	_	_	O
54	numerical	_	_	O
55	rating	_	_	O
56	scale	_	_	O
57	)	_	_	O
58	,	_	_	O
59	weight	_	_	O
60	,	_	_	O
61	and	_	_	O
62	QL	_	_	O
63	(	_	_	O
64	European	_	_	O
65	Organization	_	_	O
66	for	_	_	O
67	Research	_	_	O
68	and	_	_	O
69	Treatment	_	_	O
70	of	_	_	O
71	Cancer	_	_	O
72	Quality	_	_	O
73	of	_	_	O
74	Life	_	_	O
75	Questionnaire	_	_	O
76	[	_	_	O
77	EORTC-QLQ-C30	_	_	O
78	]	_	_	O
79	)	_	_	O
80	were	_	_	O
81	assessed	_	_	O
82	before	_	_	O
83	the	_	_	O
84	start	_	_	O
85	of	_	_	O
86	treatment	_	_	O
87	(	_	_	O
88	t	_	_	O
89	=	_	_	O
90	0	_	_	O
91	)	_	_	O
92	,	_	_	O
93	and	_	_	O
94	6	_	_	O
95	weeks	_	_	O
96	(	_	_	O
97	t	_	_	O
98	=	_	_	O
99	6	_	_	O
100	)	_	_	O
101	and	_	_	O
102	12	_	_	O
103	weeks	_	_	O
104	(	_	_	O
105	t	_	_	O
106	=	_	_	O
107	12	_	_	O
108	)	_	_	O
109	thereafter	_	_	O
110	.	_	_	O

111	One	_	_	O
112	hundred	_	_	O
113	thirty-four	_	_	O
114	patients	_	_	O
115	(	_	_	O
116	68	_	_	O
117	MPA	_	_	O
118	and	_	_	O
119	66	_	_	O
120	placebo	_	_	O
121	)	_	_	O
122	were	_	_	O
123	assessable	_	_	O
124	at	_	_	O
125	t	_	_	O
126	=	_	_	O
127	6	_	_	O
128	and	_	_	O
129	99	_	_	O
130	patients	_	_	O
131	(	_	_	O
132	53	_	_	O
133	MPA	_	_	O
134	and	_	_	O
135	46	_	_	O
136	placebo	_	_	O
137	)	_	_	O
138	at	_	_	O
139	t	_	_	O
140	=	_	_	O
141	12	_	_	O
142	.	_	_	O

143	A	_	_	B-Premise
144	beneficial	_	_	I-Premise
145	effect	_	_	I-Premise
146	of	_	_	I-Premise
147	MPA	_	_	I-Premise
148	on	_	_	I-Premise
149	appetite	_	_	I-Premise
150	was	_	_	I-Premise
151	observed	_	_	I-Premise
152	after	_	_	I-Premise
153	both	_	_	I-Premise
154	6	_	_	I-Premise
155	weeks	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	=	_	_	I-Premise
159	.008	_	_	I-Premise
160	)	_	_	I-Premise
161	and	_	_	I-Premise
162	12	_	_	I-Premise
163	weeks	_	_	I-Premise
164	(	_	_	I-Premise
165	P	_	_	I-Premise
166	=	_	_	I-Premise
167	.01	_	_	I-Premise
168	)	_	_	I-Premise
169	of	_	_	I-Premise
170	treatment	_	_	I-Premise
171	.	_	_	I-Premise

172	After	_	_	B-Premise
173	12	_	_	I-Premise
174	weeks	_	_	I-Premise
175	,	_	_	I-Premise
176	a	_	_	I-Premise
177	mean	_	_	I-Premise
178	weight	_	_	I-Premise
179	gain	_	_	I-Premise
180	of	_	_	I-Premise
181	0.6	_	_	I-Premise
182	+/-	_	_	I-Premise
183	4.4	_	_	I-Premise
184	kg	_	_	I-Premise
185	was	_	_	I-Premise
186	seen	_	_	I-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	MPA	_	_	I-Premise
190	,	_	_	I-Premise
191	versus	_	_	I-Premise
192	an	_	_	I-Premise
193	ongoing	_	_	I-Premise
194	mean	_	_	I-Premise
195	weight	_	_	I-Premise
196	loss	_	_	I-Premise
197	of	_	_	I-Premise
198	1.4	_	_	I-Premise
199	+/-	_	_	I-Premise
200	4.6	_	_	I-Premise
201	kg	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	placebo	_	_	I-Premise
205	group	_	_	I-Premise
206	.	_	_	I-Premise

207	This	_	_	B-Premise
208	difference	_	_	I-Premise
209	of	_	_	I-Premise
210	2.0	_	_	I-Premise
211	kg	_	_	I-Premise
212	was	_	_	I-Premise
213	statistically	_	_	I-Premise
214	significant	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.04	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	During	_	_	B-Premise
222	the	_	_	I-Premise
223	study	_	_	I-Premise
224	,	_	_	I-Premise
225	several	_	_	I-Premise
226	areas	_	_	I-Premise
227	of	_	_	I-Premise
228	QL	_	_	I-Premise
229	deteriorated	_	_	I-Premise
230	in	_	_	I-Premise
231	the	_	_	I-Premise
232	total	_	_	I-Premise
233	group	_	_	I-Premise
234	of	_	_	I-Premise
235	patients	_	_	I-Premise
236	.	_	_	I-Premise

237	With	_	_	B-Claim
238	the	_	_	I-Claim
239	exception	_	_	I-Claim
240	of	_	_	I-Claim
241	an	_	_	I-Claim
242	improvement	_	_	I-Claim
243	in	_	_	I-Claim
244	appetite	_	_	I-Claim
245	and	_	_	I-Claim
246	possible	_	_	I-Claim
247	also	_	_	I-Claim
248	a	_	_	I-Claim
249	reduction	_	_	I-Claim
250	in	_	_	I-Claim
251	nausea	_	_	I-Claim
252	and	_	_	I-Claim
253	vomiting	_	_	I-Claim
254	,	_	_	I-Claim
255	no	_	_	I-Claim
256	measurable	_	_	I-Claim
257	beneficial	_	_	I-Claim
258	effects	_	_	I-Claim
259	of	_	_	I-Claim
260	MPA	_	_	I-Claim
261	on	_	_	I-Claim
262	QL	_	_	I-Claim
263	could	_	_	I-Claim
264	be	_	_	I-Claim
265	demonstrated	_	_	I-Claim
266	.	_	_	I-Claim

267	The	_	_	B-Premise
268	side	_	_	I-Premise
269	effects	_	_	I-Premise
270	profile	_	_	I-Premise
271	of	_	_	I-Premise
272	MPA	_	_	I-Premise
273	was	_	_	I-Premise
274	favorable	_	_	I-Premise
275	:	_	_	I-Premise
276	only	_	_	I-Premise
277	a	_	_	I-Premise
278	trend	_	_	I-Premise
279	toward	_	_	I-Premise
280	an	_	_	I-Premise
281	increase	_	_	I-Premise
282	in	_	_	I-Premise
283	(	_	_	I-Premise
284	usually	_	_	I-Premise
285	mild	_	_	I-Premise
286	)	_	_	I-Premise
287	peripheral	_	_	I-Premise
288	edema	_	_	I-Premise
289	was	_	_	I-Premise
290	observed	_	_	I-Premise
291	.	_	_	I-Premise

292	In	_	_	B-Claim
293	weight-losing	_	_	I-Claim
294	,	_	_	I-Claim
295	advanced-stage	_	_	I-Claim
296	non-hormone-sensitive	_	_	I-Claim
297	cancer	_	_	I-Claim
298	patients	_	_	I-Claim
299	,	_	_	I-Claim
300	MPA	_	_	I-Claim
301	exhibits	_	_	I-Claim
302	a	_	_	I-Claim
303	mild	_	_	I-Claim
304	side	_	_	I-Claim
305	effects	_	_	I-Claim
306	profile	_	_	I-Claim
307	,	_	_	I-Claim
308	has	_	_	I-Claim
309	a	_	_	I-Claim
310	beneficial	_	_	I-Claim
311	effect	_	_	I-Claim
312	on	_	_	I-Claim
313	appetite	_	_	I-Claim
314	,	_	_	I-Claim
315	and	_	_	I-Claim
316	may	_	_	I-Claim
317	prevent	_	_	I-Claim
318	further	_	_	I-Claim
319	weight	_	_	I-Claim
320	loss	_	_	I-Claim
321	.	_	_	I-Claim

322	However	_	_	B-Claim
323	,	_	_	I-Claim
324	general	_	_	I-Claim
325	QL	_	_	I-Claim
326	in	_	_	I-Claim
327	the	_	_	I-Claim
328	present	_	_	I-Claim
329	study	_	_	I-Claim
330	was	_	_	I-Claim
331	not	_	_	I-Claim
332	measurably	_	_	I-Claim
333	influenced	_	_	I-Claim
334	by	_	_	I-Claim
335	MPA	_	_	I-Claim
336	treatment	_	_	I-Claim
337	.	_	_	I-Claim


0	Cerebral	_	_	B-Claim
1	metastasis	_	_	I-Claim
2	is	_	_	I-Claim
3	a	_	_	I-Claim
4	common	_	_	I-Claim
5	oncologic	_	_	I-Claim
6	problem	_	_	I-Claim
7	that	_	_	I-Claim
8	occurs	_	_	I-Claim
9	in	_	_	I-Claim
10	15-30	_	_	I-Claim
11	%	_	_	I-Claim
12	of	_	_	I-Claim
13	cancer	_	_	I-Claim
14	patients	_	_	I-Claim
15	;	_	_	I-Claim
16	approximately	_	_	O
17	half	_	_	O
18	such	_	_	O
19	metastases	_	_	O
20	are	_	_	O
21	single	_	_	O
22	.	_	_	O

23	Previous	_	_	O
24	retrospective	_	_	O
25	studies	_	_	O
26	and	_	_	O
27	two	_	_	O
28	randomized	_	_	O
29	trials	_	_	O
30	reported	_	_	O
31	that	_	_	O
32	the	_	_	O
33	addition	_	_	O
34	of	_	_	O
35	surgical	_	_	O
36	extirpation	_	_	O
37	prior	_	_	O
38	to	_	_	O
39	radiation	_	_	O
40	therapy	_	_	O
41	increased	_	_	O
42	survival	_	_	O
43	,	_	_	O
44	neurologic	_	_	O
45	function	_	_	O
46	,	_	_	O
47	and	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	compared	_	_	O
52	with	_	_	O
53	radiation	_	_	O
54	alone	_	_	O
55	in	_	_	O
56	patients	_	_	O
57	with	_	_	O
58	a	_	_	O
59	single	_	_	O
60	brain	_	_	O
61	metastasis	_	_	O
62	.	_	_	O

63	A	_	_	O
64	randomized	_	_	O
65	controlled	_	_	O
66	trial	_	_	O
67	was	_	_	O
68	conducted	_	_	O
69	in	_	_	O
70	which	_	_	O
71	patients	_	_	O
72	with	_	_	O
73	a	_	_	O
74	single	_	_	O
75	brain	_	_	O
76	metastasis	_	_	O
77	were	_	_	O
78	allocated	_	_	O
79	to	_	_	O
80	undergo	_	_	O
81	radiation	_	_	O
82	alone	_	_	O
83	or	_	_	O
84	surgery	_	_	O
85	plus	_	_	O
86	radiation	_	_	O
87	.	_	_	O

88	Radiation	_	_	O
89	consisted	_	_	O
90	of	_	_	O
91	3000	_	_	O
92	centigray	_	_	O
93	to	_	_	O
94	the	_	_	O
95	whole	_	_	O
96	brain	_	_	O
97	in	_	_	O
98	10	_	_	O
99	fractions	_	_	O
100	.	_	_	O

101	Forty-three	_	_	O
102	patients	_	_	O
103	received	_	_	O
104	radiation	_	_	O
105	alone	_	_	O
106	and	_	_	O
107	41	_	_	O
108	patients	_	_	O
109	surgery	_	_	O
110	plus	_	_	O
111	radiation	_	_	O
112	.	_	_	O

113	All	_	_	O
114	but	_	_	O
115	two	_	_	O
116	of	_	_	O
117	the	_	_	O
118	study	_	_	O
119	patients	_	_	O
120	died	_	_	O
121	.	_	_	O

122	No	_	_	B-Premise
123	difference	_	_	I-Premise
124	in	_	_	I-Premise
125	survival	_	_	I-Premise
126	was	_	_	I-Premise
127	detected	_	_	I-Premise
128	between	_	_	I-Premise
129	the	_	_	I-Premise
130	groups	_	_	I-Premise
131	;	_	_	I-Premise
132	the	_	_	B-Premise
133	median	_	_	I-Premise
134	survival	_	_	I-Premise
135	for	_	_	I-Premise
136	the	_	_	I-Premise
137	radiation	_	_	I-Premise
138	group	_	_	I-Premise
139	was	_	_	I-Premise
140	6.3	_	_	I-Premise
141	months	_	_	I-Premise
142	(	_	_	I-Premise
143	95	_	_	I-Premise
144	%	_	_	I-Premise
145	confidence	_	_	I-Premise
146	interval	_	_	I-Premise
147	,	_	_	I-Premise
148	3-11.4	_	_	I-Premise
149	)	_	_	I-Premise
150	compared	_	_	I-Premise
151	with	_	_	I-Premise
152	5.6	_	_	I-Premise
153	months	_	_	I-Premise
154	for	_	_	I-Premise
155	the	_	_	I-Premise
156	surgery	_	_	I-Premise
157	plus	_	_	I-Premise
158	radiation	_	_	I-Premise
159	group	_	_	I-Premise
160	(	_	_	I-Premise
161	95	_	_	I-Premise
162	%	_	_	I-Premise
163	confidence	_	_	I-Premise
164	interval	_	_	I-Premise
165	,	_	_	I-Premise
166	3.9-7.2	_	_	I-Premise
167	)	_	_	I-Premise
168	(	_	_	I-Premise
169	P	_	_	I-Premise
170	=	_	_	I-Premise
171	0.24	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	Most	_	_	B-Premise
175	patients	_	_	I-Premise
176	died	_	_	I-Premise
177	within	_	_	I-Premise
178	the	_	_	I-Premise
179	first	_	_	I-Premise
180	year	_	_	I-Premise
181	(	_	_	I-Premise
182	69.8	_	_	I-Premise
183	%	_	_	I-Premise
184	in	_	_	I-Premise
185	the	_	_	I-Premise
186	radiation	_	_	I-Premise
187	arm	_	_	I-Premise
188	vs.	_	_	I-Premise
189	87.8	_	_	I-Premise
190	%	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	surgery	_	_	I-Premise
194	plus	_	_	I-Premise
195	radiation	_	_	I-Premise
196	arm	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	There	_	_	B-Premise
200	were	_	_	I-Premise
201	no	_	_	I-Premise
202	significant	_	_	I-Premise
203	differences	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	30-day	_	_	I-Premise
207	mortality	_	_	I-Premise
208	,	_	_	I-Premise
209	morbidity	_	_	I-Premise
210	,	_	_	I-Premise
211	or	_	_	I-Premise
212	causes	_	_	I-Premise
213	of	_	_	I-Premise
214	death	_	_	I-Premise
215	.	_	_	I-Premise

216	Extracranial	_	_	B-Premise
217	metastases	_	_	I-Premise
218	was	_	_	I-Premise
219	an	_	_	I-Premise
220	important	_	_	I-Premise
221	predictor	_	_	I-Premise
222	of	_	_	I-Premise
223	mortality	_	_	I-Premise
224	(	_	_	I-Premise
225	relative	_	_	I-Premise
226	risk	_	_	I-Premise
227	,	_	_	I-Premise
228	2.3	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	mean	_	_	I-Premise
233	proportion	_	_	I-Premise
234	of	_	_	I-Premise
235	days	_	_	I-Premise
236	that	_	_	I-Premise
237	the	_	_	I-Premise
238	Karnofsky	_	_	I-Premise
239	performance	_	_	I-Premise
240	status	_	_	I-Premise
241	was	_	_	I-Premise
242	>	_	_	I-Premise
243	or	_	_	I-Premise
244	=	_	_	I-Premise
245	70	_	_	I-Premise
246	%	_	_	I-Premise
247	did	_	_	I-Premise
248	not	_	_	I-Premise
249	differ	_	_	I-Premise
250	between	_	_	I-Premise
251	the	_	_	I-Premise
252	2	_	_	I-Premise
253	groups	_	_	I-Premise
254	.	_	_	I-Premise

255	This	_	_	B-Claim
256	trial	_	_	I-Claim
257	failed	_	_	I-Claim
258	to	_	_	I-Claim
259	demonstrate	_	_	I-Claim
260	that	_	_	I-Claim
261	the	_	_	I-Claim
262	addition	_	_	I-Claim
263	of	_	_	I-Claim
264	surgery	_	_	I-Claim
265	to	_	_	I-Claim
266	radiation	_	_	I-Claim
267	therapy	_	_	I-Claim
268	improved	_	_	I-Claim
269	outcome	_	_	I-Claim
270	of	_	_	I-Claim
271	patients	_	_	I-Claim
272	with	_	_	I-Claim
273	a	_	_	I-Claim
274	single	_	_	I-Claim
275	brain	_	_	I-Claim
276	metastasis	_	_	I-Claim
277	.	_	_	I-Claim

278	Thus	_	_	B-Claim
279	,	_	_	I-Claim
280	the	_	_	I-Claim
281	efficacy	_	_	I-Claim
282	of	_	_	I-Claim
283	surgery	_	_	I-Claim
284	plus	_	_	I-Claim
285	radiation	_	_	I-Claim
286	compared	_	_	I-Claim
287	with	_	_	I-Claim
288	radiation	_	_	I-Claim
289	alone	_	_	I-Claim
290	needs	_	_	I-Claim
291	to	_	_	I-Claim
292	be	_	_	I-Claim
293	addressed	_	_	I-Claim
294	by	_	_	I-Claim
295	further	_	_	I-Claim
296	clinical	_	_	I-Claim
297	trials	_	_	I-Claim
298	and/or	_	_	I-Claim
299	a	_	_	I-Claim
300	meta-analysis	_	_	I-Claim
301	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	uterine	_	_	O
4	artery	_	_	O
5	embolization	_	_	O
6	(	_	_	O
7	UAE	_	_	O
8	)	_	_	O
9	is	_	_	O
10	a	_	_	O
11	cost-effective	_	_	O
12	alternative	_	_	O
13	to	_	_	O
14	hysterectomy	_	_	O
15	for	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	symptomatic	_	_	O
19	uterine	_	_	O
20	fibroids	_	_	O
21	,	_	_	O
22	the	_	_	O
23	authors	_	_	O
24	performed	_	_	O
25	an	_	_	O
26	economic	_	_	O
27	evaluation	_	_	O
28	alongside	_	_	O
29	the	_	_	O
30	multicenter	_	_	O
31	randomized	_	_	O
32	EMMY	_	_	O
33	(	_	_	O
34	EMbolization	_	_	O
35	versus	_	_	O
36	hysterectoMY	_	_	O
37	)	_	_	O
38	trial	_	_	O
39	.	_	_	O

40	Between	_	_	O
41	February	_	_	O
42	2002	_	_	O
43	and	_	_	O
44	February	_	_	O
45	2004	_	_	O
46	,	_	_	O
47	177	_	_	O
48	patients	_	_	O
49	were	_	_	O
50	randomized	_	_	O
51	to	_	_	O
52	undergo	_	_	O
53	UAE	_	_	O
54	(	_	_	O
55	n	_	_	O
56	=	_	_	O
57	88	_	_	O
58	)	_	_	O
59	or	_	_	O
60	hysterectomy	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	89	_	_	O
65	)	_	_	O
66	and	_	_	O
67	followed	_	_	O
68	up	_	_	O
69	until	_	_	O
70	24	_	_	O
71	months	_	_	O
72	after	_	_	O
73	initial	_	_	O
74	treatment	_	_	O
75	allocation	_	_	O
76	.	_	_	O

77	Conditional	_	_	O
78	on	_	_	O
79	the	_	_	O
80	equivalence	_	_	O
81	of	_	_	O
82	clinical	_	_	O
83	outcome	_	_	O
84	,	_	_	O
85	a	_	_	O
86	cost	_	_	O
87	minimization	_	_	O
88	analysis	_	_	O
89	was	_	_	O
90	performed	_	_	O
91	according	_	_	O
92	to	_	_	O
93	the	_	_	O
94	intention	_	_	O
95	to	_	_	O
96	treat	_	_	O
97	principle	_	_	O
98	.	_	_	O

99	Costs	_	_	O
100	included	_	_	O
101	health	_	_	O
102	care	_	_	O
103	costs	_	_	O
104	inside	_	_	O
105	and	_	_	O
106	outside	_	_	O
107	the	_	_	O
108	hospital	_	_	O
109	as	_	_	O
110	well	_	_	O
111	as	_	_	O
112	costs	_	_	O
113	related	_	_	O
114	to	_	_	O
115	absence	_	_	O
116	from	_	_	O
117	work	_	_	O
118	(	_	_	O
119	societal	_	_	O
120	perspective	_	_	O
121	)	_	_	O
122	.	_	_	O

123	Cumulative	_	_	O
124	standardized	_	_	O
125	costs	_	_	O
126	were	_	_	O
127	estimated	_	_	O
128	as	_	_	O
129	volumes	_	_	O
130	multiplied	_	_	O
131	with	_	_	O
132	prices	_	_	O
133	.	_	_	O

134	The	_	_	O
135	nonparametric	_	_	O
136	bootstrap	_	_	O
137	method	_	_	O
138	was	_	_	O
139	used	_	_	O
140	to	_	_	O
141	quantify	_	_	O
142	differences	_	_	O
143	in	_	_	O
144	mean	_	_	O
145	(	_	_	O
146	95	_	_	O
147	%	_	_	O
148	confidence	_	_	O
149	interval	_	_	O
150	[	_	_	O
151	CI	_	_	O
152	]	_	_	O
153	)	_	_	O
154	costs	_	_	O
155	between	_	_	O
156	the	_	_	O
157	strategies	_	_	O
158	.	_	_	O

159	In	_	_	O
160	total	_	_	O
161	,	_	_	O
162	81	_	_	O
163	patients	_	_	O
164	underwent	_	_	O
165	UAE	_	_	O
166	and	_	_	O
167	75	_	_	O
168	underwent	_	_	O
169	hysterectomy	_	_	O
170	.	_	_	O

171	In	_	_	O
172	the	_	_	O
173	UAE	_	_	O
174	group	_	_	O
175	,	_	_	O
176	19	_	_	O
177	patients	_	_	O
178	(	_	_	O
179	23	_	_	O
180	%	_	_	O
181	)	_	_	O
182	underwent	_	_	O
183	secondary	_	_	O
184	hysterectomies	_	_	O
185	.	_	_	O

186	The	_	_	B-Premise
187	mean	_	_	I-Premise
188	total	_	_	I-Premise
189	costs	_	_	I-Premise
190	per	_	_	I-Premise
191	patient	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	UAE	_	_	I-Premise
195	group	_	_	I-Premise
196	were	_	_	I-Premise
197	significantly	_	_	I-Premise
198	lower	_	_	I-Premise
199	than	_	_	I-Premise
200	those	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	hysterectomy	_	_	I-Premise
204	group	_	_	I-Premise
205	(	_	_	I-Premise
206	$	_	_	I-Premise
207	11,626	_	_	I-Premise
208	vs	_	_	I-Premise
209	$	_	_	I-Premise
210	18,563	_	_	I-Premise
211	;	_	_	I-Premise
212	mean	_	_	I-Premise
213	difference	_	_	I-Premise
214	,	_	_	I-Premise
215	-	_	_	I-Premise
216	$	_	_	I-Premise
217	6,936	_	_	I-Premise
218	[	_	_	I-Premise
219	-37	_	_	I-Premise
220	%	_	_	I-Premise
221	]	_	_	I-Premise
222	,	_	_	I-Premise
223	95	_	_	I-Premise
224	%	_	_	I-Premise
225	CI	_	_	I-Premise
226	:	_	_	I-Premise
227	-	_	_	I-Premise
228	$	_	_	I-Premise
229	9,548	_	_	I-Premise
230	,	_	_	I-Premise
231	$	_	_	I-Premise
232	4,281	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	The	_	_	B-Premise
236	direct	_	_	I-Premise
237	medical	_	_	I-Premise
238	in-hospital	_	_	I-Premise
239	costs	_	_	I-Premise
240	were	_	_	I-Premise
241	significantly	_	_	I-Premise
242	lower	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	UAE	_	_	I-Premise
246	group	_	_	I-Premise
247	:	_	_	I-Premise
248	$	_	_	I-Premise
249	6,688	_	_	I-Premise
250	vs	_	_	I-Premise
251	$	_	_	I-Premise
252	8,313	_	_	I-Premise
253	(	_	_	I-Premise
254	mean	_	_	I-Premise
255	difference	_	_	I-Premise
256	,	_	_	I-Premise
257	-	_	_	I-Premise
258	$	_	_	I-Premise
259	1,624	_	_	I-Premise
260	[	_	_	I-Premise
261	-20	_	_	I-Premise
262	%	_	_	I-Premise
263	]	_	_	I-Premise
264	,	_	_	I-Premise
265	95	_	_	I-Premise
266	%	_	_	I-Premise
267	CI	_	_	I-Premise
268	:	_	_	I-Premise
269	-	_	_	I-Premise
270	$	_	_	I-Premise
271	2,605	_	_	I-Premise
272	,	_	_	I-Premise
273	-	_	_	I-Premise
274	$	_	_	I-Premise
275	586	_	_	I-Premise
276	)	_	_	I-Premise
277	.	_	_	I-Premise

278	Direct	_	_	B-Premise
279	medical	_	_	I-Premise
280	out-of-hospital	_	_	I-Premise
281	and	_	_	I-Premise
282	direct	_	_	I-Premise
283	nonmedical	_	_	I-Premise
284	costs	_	_	I-Premise
285	were	_	_	I-Premise
286	low	_	_	I-Premise
287	in	_	_	I-Premise
288	both	_	_	I-Premise
289	groups	_	_	I-Premise
290	(	_	_	I-Premise
291	mean	_	_	I-Premise
292	cost	_	_	I-Premise
293	difference	_	_	I-Premise
294	,	_	_	I-Premise
295	$	_	_	I-Premise
296	156	_	_	I-Premise
297	in	_	_	I-Premise
298	favor	_	_	I-Premise
299	of	_	_	I-Premise
300	hysterectomy	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	The	_	_	B-Premise
304	costs	_	_	I-Premise
305	related	_	_	I-Premise
306	to	_	_	I-Premise
307	absence	_	_	I-Premise
308	from	_	_	I-Premise
309	work	_	_	I-Premise
310	differed	_	_	I-Premise
311	significantly	_	_	I-Premise
312	between	_	_	I-Premise
313	the	_	_	I-Premise
314	treatment	_	_	I-Premise
315	strategies	_	_	I-Premise
316	in	_	_	I-Premise
317	favor	_	_	I-Premise
318	of	_	_	I-Premise
319	UAE	_	_	I-Premise
320	(	_	_	I-Premise
321	mean	_	_	I-Premise
322	difference	_	_	I-Premise
323	,	_	_	I-Premise
324	-	_	_	I-Premise
325	$	_	_	I-Premise
326	5,453	_	_	I-Premise
327	;	_	_	I-Premise
328	95	_	_	I-Premise
329	%	_	_	I-Premise
330	CI	_	_	I-Premise
331	:	_	_	I-Premise
332	-	_	_	I-Premise
333	$	_	_	I-Premise
334	7,718	_	_	I-Premise
335	,	_	_	I-Premise
336	-	_	_	I-Premise
337	$	_	_	I-Premise
338	3,107	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	The	_	_	O
342	costs	_	_	O
343	of	_	_	O
344	absence	_	_	O
345	from	_	_	O
346	work	_	_	O
347	accounted	_	_	O
348	for	_	_	O
349	79	_	_	O
350	%	_	_	O
351	of	_	_	O
352	the	_	_	O
353	difference	_	_	O
354	in	_	_	O
355	total	_	_	O
356	costs	_	_	O
357	.	_	_	O

358	The	_	_	B-Premise
359	24-month	_	_	I-Premise
360	cumulative	_	_	I-Premise
361	cost	_	_	I-Premise
362	of	_	_	I-Premise
363	UAE	_	_	I-Premise
364	is	_	_	I-Premise
365	lower	_	_	I-Premise
366	than	_	_	I-Premise
367	that	_	_	I-Premise
368	of	_	_	I-Premise
369	hysterectomy	_	_	I-Premise
370	.	_	_	I-Premise

371	From	_	_	B-Claim
372	a	_	_	I-Claim
373	societal	_	_	I-Claim
374	economic	_	_	I-Claim
375	perspective	_	_	I-Claim
376	,	_	_	I-Claim
377	UAE	_	_	I-Claim
378	is	_	_	I-Claim
379	the	_	_	I-Claim
380	superior	_	_	I-Claim
381	treatment	_	_	I-Claim
382	strategy	_	_	I-Claim
383	in	_	_	I-Claim
384	women	_	_	I-Claim
385	with	_	_	I-Claim
386	symptomatic	_	_	I-Claim
387	uterine	_	_	I-Claim
388	fibroids	_	_	I-Claim
389	.	_	_	I-Claim


0	Prospective	_	_	B-Claim
1	investigations	_	_	I-Claim
2	of	_	_	I-Claim
3	complete	_	_	I-Claim
4	decongestive	_	_	I-Claim
5	lymphatic	_	_	I-Claim
6	physiotherapy	_	_	I-Claim
7	(	_	_	I-Claim
8	CDPT	_	_	I-Claim
9	)	_	_	I-Claim
10	,	_	_	I-Claim
11	including	_	_	I-Claim
12	manual	_	_	I-Claim
13	lymphatic	_	_	I-Claim
14	drainage	_	_	I-Claim
15	(	_	_	I-Claim
16	MLD	_	_	I-Claim
17	)	_	_	I-Claim
18	,	_	_	I-Claim
19	have	_	_	I-Claim
20	validated	_	_	I-Claim
21	the	_	_	I-Claim
22	efficacy	_	_	I-Claim
23	of	_	_	I-Claim
24	these	_	_	I-Claim
25	interventions	_	_	I-Claim
26	for	_	_	I-Claim
27	the	_	_	I-Claim
28	initial	_	_	I-Claim
29	reduction	_	_	I-Claim
30	of	_	_	I-Claim
31	edema	_	_	I-Claim
32	and	_	_	I-Claim
33	long-term	_	_	I-Claim
34	maintenance	_	_	I-Claim
35	of	_	_	I-Claim
36	limb	_	_	I-Claim
37	volume	_	_	I-Claim
38	in	_	_	I-Claim
39	lymphedema	_	_	I-Claim
40	.	_	_	I-Claim

41	However	_	_	O
42	,	_	_	O
43	CDPT	_	_	O
44	demands	_	_	O
45	substantial	_	_	O
46	time	_	_	O
47	and	_	_	O
48	effort	_	_	O
49	from	_	_	O
50	patients	_	_	O
51	to	_	_	O
52	maintain	_	_	O
53	these	_	_	O
54	benefits	_	_	O
55	;	_	_	O
56	the	_	_	B-Claim
57	treatments	_	_	I-Claim
58	are	_	_	I-Claim
59	not	_	_	I-Claim
60	always	_	_	I-Claim
61	well-accepted	_	_	I-Claim
62	,	_	_	I-Claim
63	and	_	_	O
64	patients	_	_	B-Claim
65	may	_	_	I-Claim
66	suffer	_	_	I-Claim
67	from	_	_	I-Claim
68	a	_	_	I-Claim
69	deterioration	_	_	I-Claim
70	in	_	_	I-Claim
71	quality-of-life	_	_	I-Claim
72	or	_	_	I-Claim
73	a	_	_	I-Claim
74	time-dependent	_	_	I-Claim
75	loss	_	_	I-Claim
76	of	_	_	I-Claim
77	initial	_	_	I-Claim
78	treatment	_	_	I-Claim
79	benefits	_	_	I-Claim
80	.	_	_	I-Claim

81	A	_	_	O
82	new	_	_	O
83	device	_	_	O
84	designed	_	_	O
85	for	_	_	O
86	home	_	_	O
87	use	_	_	O
88	by	_	_	O
89	the	_	_	O
90	patient	_	_	O
91	,	_	_	O
92	the	_	_	O
93	Flexitouch	_	_	O
94	,	_	_	O
95	has	_	_	O
96	been	_	_	O
97	developed	_	_	O
98	to	_	_	O
99	mechanically	_	_	O
100	simulate	_	_	O
101	MLD	_	_	O
102	.	_	_	O

103	We	_	_	O
104	have	_	_	O
105	undertaken	_	_	O
106	a	_	_	O
107	prospective	_	_	O
108	,	_	_	O
109	randomized	_	_	O
110	,	_	_	O
111	crossover	_	_	O
112	study	_	_	O
113	of	_	_	O
114	the	_	_	O
115	efficacy	_	_	O
116	of	_	_	O
117	the	_	_	O
118	Flexitouch	_	_	O
119	,	_	_	O
120	when	_	_	O
121	compared	_	_	O
122	to	_	_	O
123	massage	_	_	O
124	,	_	_	O
125	in	_	_	O
126	the	_	_	O
127	self-administered	_	_	O
128	maintenance	_	_	O
129	therapy	_	_	O
130	of	_	_	O
131	lymphedema	_	_	O
132	.	_	_	O

133	A	_	_	O
134	prospective	_	_	O
135	,	_	_	O
136	randomized	_	_	O
137	,	_	_	O
138	crossover	_	_	O
139	study	_	_	O
140	of	_	_	O
141	maintenance	_	_	O
142	therapy	_	_	O
143	was	_	_	O
144	performed	_	_	O
145	in	_	_	O
146	10	_	_	O
147	patients	_	_	O
148	with	_	_	O
149	unilateral	_	_	O
150	breast	_	_	O
151	cancer-associated	_	_	O
152	lymphedema	_	_	O
153	of	_	_	O
154	the	_	_	O
155	arm	_	_	O
156	.	_	_	O

157	Each	_	_	O
158	observation	_	_	O
159	phase	_	_	O
160	included	_	_	O
161	self-administered	_	_	O
162	treatment	_	_	O
163	with	_	_	O
164	the	_	_	O
165	Flexitouch	_	_	O
166	or	_	_	O
167	massage	_	_	O
168	,	_	_	O
169	1	_	_	O
170	hour	_	_	O
171	daily	_	_	O
172	for	_	_	O
173	14	_	_	O
174	days	_	_	O
175	,	_	_	O
176	respectively	_	_	O
177	,	_	_	O
178	followed	_	_	O
179	by	_	_	O
180	crossover	_	_	O
181	to	_	_	O
182	the	_	_	O
183	alternate	_	_	O
184	treatment	_	_	O
185	phase	_	_	O
186	.	_	_	O

187	Each	_	_	O
188	treatment	_	_	O
189	phase	_	_	O
190	was	_	_	O
191	preceded	_	_	O
192	by	_	_	O
193	a	_	_	O
194	1	_	_	O
195	week	_	_	O
196	treatment	_	_	O
197	washout	_	_	O
198	,	_	_	O
199	with	_	_	O
200	use	_	_	O
201	of	_	_	O
202	garment	_	_	O
203	only	_	_	O
204	.	_	_	O

205	The	_	_	O
206	sequence	_	_	O
207	of	_	_	O
208	treatment	_	_	O
209	was	_	_	O
210	randomly	_	_	O
211	assigned	_	_	O
212	.	_	_	O

213	The	_	_	O
214	potential	_	_	O
215	impact	_	_	O
216	of	_	_	O
217	treatment	_	_	O
218	modality	_	_	O
219	on	_	_	O
220	quality	_	_	O
221	of	_	_	O
222	life	_	_	O
223	was	_	_	O
224	assessed	_	_	O
225	with	_	_	O
226	serial	_	_	O
227	administration	_	_	O
228	of	_	_	O
229	the	_	_	O
230	SF-36	_	_	O
231	.	_	_	O

232	Statistical	_	_	O
233	analysis	_	_	O
234	disclosed	_	_	O
235	that	_	_	O
236	the	_	_	O
237	order	_	_	O
238	of	_	_	O
239	treatment	_	_	O
240	had	_	_	O
241	no	_	_	O
242	outcome	_	_	O
243	influence	_	_	O
244	,	_	_	O
245	permitting	_	_	O
246	10	_	_	O
247	comparisons	_	_	O
248	within	_	_	O
249	each	_	_	O
250	treatment	_	_	O
251	group	_	_	O
252	.	_	_	O

253	Post-treatment	_	_	B-Premise
254	arm	_	_	I-Premise
255	volume	_	_	I-Premise
256	reduced	_	_	I-Premise
257	significantly	_	_	I-Premise
258	after	_	_	I-Premise
259	the	_	_	I-Premise
260	Flexitouch	_	_	I-Premise
261	,	_	_	I-Premise
262	but	_	_	I-Premise
263	not	_	_	I-Premise
264	after	_	_	I-Premise
265	self-administered	_	_	I-Premise
266	massage	_	_	I-Premise
267	.	_	_	I-Premise

268	The	_	_	B-Premise
269	patients	_	_	I-Premise
270	'	_	_	I-Premise
271	mean	_	_	I-Premise
272	weight	_	_	I-Premise
273	decreased	_	_	I-Premise
274	significantly	_	_	I-Premise
275	with	_	_	I-Premise
276	Flexitouch	_	_	I-Premise
277	use	_	_	I-Premise
278	,	_	_	I-Premise
279	but	_	_	I-Premise
280	not	_	_	I-Premise
281	with	_	_	I-Premise
282	massage	_	_	I-Premise
283	.	_	_	I-Premise

284	The	_	_	B-Premise
285	Flexitouch	_	_	I-Premise
286	device	_	_	I-Premise
287	was	_	_	I-Premise
288	apparently	_	_	I-Premise
289	well-tolerated	_	_	I-Premise
290	and	_	_	I-Premise
291	accepted	_	_	I-Premise
292	by	_	_	I-Premise
293	patients	_	_	I-Premise
294	.	_	_	I-Premise

295	Serial	_	_	B-Premise
296	SF-36	_	_	I-Premise
297	administration	_	_	I-Premise
298	showed	_	_	I-Premise
299	no	_	_	I-Premise
300	deterioration	_	_	I-Premise
301	in	_	_	I-Premise
302	physical	_	_	I-Premise
303	or	_	_	I-Premise
304	psychosocial	_	_	I-Premise
305	scores	_	_	I-Premise
306	compared	_	_	I-Premise
307	to	_	_	I-Premise
308	baseline	_	_	I-Premise
309	measurements	_	_	I-Premise
310	;	_	_	I-Premise
311	there	_	_	B-Premise
312	were	_	_	I-Premise
313	no	_	_	I-Premise
314	statistical	_	_	I-Premise
315	differences	_	_	I-Premise
316	in	_	_	I-Premise
317	scores	_	_	I-Premise
318	when	_	_	I-Premise
319	the	_	_	I-Premise
320	two	_	_	I-Premise
321	treatment	_	_	I-Premise
322	modalities	_	_	I-Premise
323	were	_	_	I-Premise
324	compared	_	_	I-Premise
325	.	_	_	I-Premise

326	This	_	_	B-Claim
327	short-term	_	_	I-Claim
328	prospective	_	_	I-Claim
329	evaluation	_	_	I-Claim
330	of	_	_	I-Claim
331	the	_	_	I-Claim
332	Flexitouch	_	_	I-Claim
333	suggests	_	_	I-Claim
334	that	_	_	I-Claim
335	the	_	_	I-Claim
336	device	_	_	I-Claim
337	may	_	_	I-Claim
338	provide	_	_	I-Claim
339	better	_	_	I-Claim
340	maintenance	_	_	I-Claim
341	edema	_	_	I-Claim
342	control	_	_	I-Claim
343	than	_	_	I-Claim
344	self-adiminstered	_	_	I-Claim
345	massage	_	_	I-Claim
346	in	_	_	I-Claim
347	breast	_	_	I-Claim
348	cancer-associated	_	_	I-Claim
349	lymphedema	_	_	I-Claim
350	.	_	_	I-Claim

351	The	_	_	B-Claim
352	apparent	_	_	I-Claim
353	ease	_	_	I-Claim
354	of	_	_	I-Claim
355	use	_	_	I-Claim
356	and	_	_	I-Claim
357	reliability	_	_	I-Claim
358	of	_	_	I-Claim
359	response	_	_	I-Claim
360	to	_	_	I-Claim
361	the	_	_	I-Claim
362	device	_	_	I-Claim
363	suggest	_	_	I-Claim
364	that	_	_	I-Claim
365	further	_	_	I-Claim
366	broad-scale	_	_	I-Claim
367	testing	_	_	I-Claim
368	is	_	_	I-Claim
369	warranted	_	_	I-Claim
370	.	_	_	I-Claim


0	Patients	_	_	B-Claim
1	receiving	_	_	I-Claim
2	chemotherapy	_	_	I-Claim
3	for	_	_	I-Claim
4	cancer	_	_	I-Claim
5	often	_	_	I-Claim
6	develop	_	_	I-Claim
7	anemia	_	_	I-Claim
8	,	_	_	I-Claim
9	which	_	_	I-Claim
10	can	_	_	I-Claim
11	contribute	_	_	I-Claim
12	to	_	_	I-Claim
13	increased	_	_	I-Claim
14	morbidity	_	_	I-Claim
15	and	_	_	I-Claim
16	reduced	_	_	I-Claim
17	quality	_	_	I-Claim
18	of	_	_	I-Claim
19	life	_	_	I-Claim
20	(	_	_	I-Claim
21	QOL	_	_	I-Claim
22	)	_	_	I-Claim
23	.	_	_	I-Claim

24	Chemotherapy-induced	_	_	B-Claim
25	anemia	_	_	I-Claim
26	can	_	_	I-Claim
27	be	_	_	I-Claim
28	successfully	_	_	I-Claim
29	treated	_	_	I-Claim
30	using	_	_	I-Claim
31	recombinant	_	_	I-Claim
32	human	_	_	I-Claim
33	erythropoietin	_	_	I-Claim
34	(	_	_	I-Claim
35	rHuEPO	_	_	I-Claim
36	)	_	_	I-Claim
37	.	_	_	I-Claim

38	To	_	_	O
39	demonstrate	_	_	O
40	the	_	_	O
41	effectiveness	_	_	O
42	of	_	_	O
43	once-weekly	_	_	O
44	(	_	_	O
45	QW	_	_	O
46	)	_	_	O
47	rHuEPO	_	_	O
48	dosing	_	_	O
49	to	_	_	O
50	effect	_	_	O
51	improved	_	_	O
52	hemoglobin	_	_	O
53	levels	_	_	O
54	,	_	_	O
55	decreased	_	_	O
56	transfusion	_	_	O
57	use	_	_	O
58	,	_	_	O
59	and	_	_	O
60	improved	_	_	O
61	functional	_	_	O
62	outcomes	_	_	O
63	and	_	_	O
64	QOL	_	_	O
65	in	_	_	O
66	pediatric	_	_	O
67	leukemic	_	_	O
68	patients	_	_	O
69	(	_	_	O
70	ALL	_	_	O
71	)	_	_	O
72	receiving	_	_	O
73	maintenance	_	_	O
74	chemotherapy	_	_	O
75	.	_	_	O

76	This	_	_	O
77	was	_	_	O
78	a	_	_	O
79	prospective	_	_	O
80	randomized	_	_	O
81	,	_	_	O
82	single-center	_	_	O
83	,	_	_	O
84	open-label	_	_	O
85	,	_	_	O
86	12-week	_	_	O
87	case-control	_	_	O
88	study	_	_	O
89	of	_	_	O
90	epoetin	_	_	O
91	alfa	_	_	O
92	in	_	_	O
93	pediatric	_	_	O
94	patients	_	_	O
95	with	_	_	O
96	acute	_	_	O
97	lymphoblastic	_	_	O
98	leukemia	_	_	O
99	(	_	_	O
100	ALL	_	_	O
101	)	_	_	O
102	in	_	_	O
103	remission	_	_	O
104	receiving	_	_	O
105	maintenance	_	_	O
106	chemotherapy	_	_	O
107	.	_	_	O

108	Sixty	_	_	O
109	patients	_	_	O
110	were	_	_	O
111	randomly	_	_	O
112	assigned	_	_	O
113	to	_	_	O
114	receive	_	_	O
115	either	_	_	O
116	epoetin	_	_	O
117	alfa	_	_	O
118	(	_	_	O
119	rHuEPO	_	_	O
120	group	_	_	O
121	=	_	_	O
122	30	_	_	O
123	cases	_	_	O
124	,	_	_	O
125	17	_	_	O
126	males	_	_	O
127	and	_	_	O
128	13	_	_	O
129	females	_	_	O
130	,	_	_	O
131	age	_	_	O
132	;	_	_	O
133	6.8	_	_	O
134	+/-	_	_	O
135	2.33	_	_	O
136	years	_	_	O
137	)	_	_	O
138	,	_	_	O
139	or	_	_	O
140	no	_	_	O
141	epoetin	_	_	O
142	alfa	_	_	O
143	(	_	_	O
144	control	_	_	O
145	group	_	_	O
146	=	_	_	O
147	30	_	_	O
148	cases	_	_	O
149	,	_	_	O
150	16	_	_	O
151	males	_	_	O
152	and	_	_	O
153	14	_	_	O
154	females	_	_	O
155	,	_	_	O
156	age	_	_	O
157	;	_	_	O
158	6.76	_	_	O
159	+/-	_	_	O
160	2.28	_	_	O
161	years	_	_	O
162	)	_	_	O
163	.	_	_	O

164	Both	_	_	O
165	groups	_	_	O
166	were	_	_	O
167	matched	_	_	O
168	as	_	_	O
169	regard	_	_	O
170	age	_	_	O
171	,	_	_	O
172	sex	_	_	O
173	,	_	_	O
174	baseline	_	_	O
175	Hb	_	_	O
176	concentration	_	_	O
177	,	_	_	O
178	remission	_	_	O
179	state	_	_	O
180	,	_	_	O
181	chemotherapy	_	_	O
182	regimen	_	_	O
183	,	_	_	O
184	numbers	_	_	O
185	and	_	_	O
186	amount	_	_	O
187	of	_	_	O
188	blood	_	_	O
189	transfusion	_	_	O
190	,	_	_	O
191	and	_	_	O
192	leukemia	_	_	O
193	state	_	_	O
194	(	_	_	O
195	both	_	_	O
196	were	_	_	O
197	low	_	_	O
198	and	_	_	O
199	standard	_	_	O
200	risk	_	_	O
201	)	_	_	O
202	.	_	_	O

203	Epoetin	_	_	O
204	alfa	_	_	O
205	was	_	_	O
206	administered	_	_	O
207	at	_	_	O
208	a	_	_	O
209	dose	_	_	O
210	of	_	_	O
211	450	_	_	O
212	IU/kg	_	_	O
213	,	_	_	O
214	once	_	_	O
215	weekly	_	_	O
216	,	_	_	O
217	subcutaneously	_	_	O
218	(	_	_	O
219	s.c.	_	_	O
220	)	_	_	O
221	for	_	_	O
222	12	_	_	O
223	consecutive	_	_	O
224	weeks	_	_	O
225	.	_	_	O

226	Endpoints	_	_	O
227	were	_	_	O
228	changes	_	_	O
229	in	_	_	O
230	hematologic	_	_	O
231	and	_	_	O
232	QOL	_	_	O
233	parameters	_	_	O
234	.	_	_	O

235	Among	_	_	B-Premise
236	the	_	_	I-Premise
237	30	_	_	I-Premise
238	patients	_	_	I-Premise
239	evaluable	_	_	I-Premise
240	for	_	_	I-Premise
241	hematologic	_	_	I-Premise
242	response	_	_	I-Premise
243	,	_	_	I-Premise
244	the	_	_	I-Premise
245	mean	_	_	I-Premise
246	increase	_	_	I-Premise
247	in	_	_	I-Premise
248	Hb	_	_	I-Premise
249	from	_	_	I-Premise
250	baseline	_	_	I-Premise
251	to	_	_	I-Premise
252	time	_	_	I-Premise
253	of	_	_	I-Premise
254	final	_	_	I-Premise
255	evaluation	_	_	I-Premise
256	was	_	_	I-Premise
257	3.08	_	_	I-Premise
258	+/-	_	_	I-Premise
259	1.48	_	_	I-Premise
260	g/dl	_	_	I-Premise
261	(	_	_	I-Premise
262	p	_	_	I-Premise
263	<	_	_	I-Premise
264	0.001	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	An	_	_	B-Premise
268	increase	_	_	I-Premise
269	in	_	_	I-Premise
270	Hb	_	_	I-Premise
271	of	_	_	I-Premise
272	>	_	_	I-Premise
273	or	_	_	I-Premise
274	=	_	_	I-Premise
275	2	_	_	I-Premise
276	g/dl	_	_	I-Premise
277	,	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	absence	_	_	I-Premise
281	of	_	_	I-Premise
282	blood	_	_	I-Premise
283	transfusion	_	_	I-Premise
284	,	_	_	I-Premise
285	occurred	_	_	I-Premise
286	in	_	_	I-Premise
287	70	_	_	I-Premise
288	%	_	_	I-Premise
289	of	_	_	I-Premise
290	patients	_	_	I-Premise
291	(	_	_	I-Premise
292	21	_	_	I-Premise
293	of	_	_	I-Premise
294	30	_	_	I-Premise
295	patients	_	_	I-Premise
296	)	_	_	I-Premise
297	who	_	_	I-Premise
298	were	_	_	I-Premise
299	on	_	_	I-Premise
300	the	_	_	I-Premise
301	study	_	_	I-Premise
302	for	_	_	I-Premise
303	>	_	_	I-Premise
304	or	_	_	I-Premise
305	=	_	_	I-Premise
306	30	_	_	I-Premise
307	days	_	_	I-Premise
308	.	_	_	I-Premise

309	The	_	_	B-Premise
310	overall	_	_	I-Premise
311	response	_	_	I-Premise
312	rate	_	_	I-Premise
313	(	_	_	I-Premise
314	Hb	_	_	I-Premise
315	increase	_	_	I-Premise
316	>	_	_	I-Premise
317	or	_	_	I-Premise
318	=	_	_	I-Premise
319	2	_	_	I-Premise
320	g/dl	_	_	I-Premise
321	or	_	_	I-Premise
322	Hb	_	_	I-Premise
323	>	_	_	I-Premise
324	or	_	_	I-Premise
325	=	_	_	I-Premise
326	12	_	_	I-Premise
327	g/dl	_	_	I-Premise
328	in	_	_	I-Premise
329	the	_	_	I-Premise
330	absence	_	_	I-Premise
331	of	_	_	I-Premise
332	blood	_	_	I-Premise
333	transfusion	_	_	I-Premise
334	)	_	_	I-Premise
335	was	_	_	I-Premise
336	90	_	_	I-Premise
337	%	_	_	I-Premise
338	(	_	_	I-Premise
339	27	_	_	I-Premise
340	of	_	_	I-Premise
341	30	_	_	I-Premise
342	patients	_	_	I-Premise
343	)	_	_	I-Premise
344	.	_	_	I-Premise

345	In	_	_	B-Premise
346	30	_	_	I-Premise
347	patients	_	_	I-Premise
348	who	_	_	I-Premise
349	were	_	_	I-Premise
350	evaluable	_	_	I-Premise
351	for	_	_	I-Premise
352	QOL	_	_	I-Premise
353	assessment	_	_	I-Premise
354	,	_	_	I-Premise
355	epoetin-alpha	_	_	I-Premise
356	therapy	_	_	I-Premise
357	was	_	_	I-Premise
358	found	_	_	I-Premise
359	to	_	_	I-Premise
360	significantly	_	_	I-Premise
361	(	_	_	I-Premise
362	p	_	_	I-Premise
363	<	_	_	I-Premise
364	0.001	_	_	I-Premise
365	)	_	_	I-Premise
366	improve	_	_	I-Premise
367	mean	_	_	I-Premise
368	cancer	_	_	I-Premise
369	linear	_	_	I-Premise
370	analog	_	_	I-Premise
371	scale	_	_	I-Premise
372	(	_	_	I-Premise
373	CLAS	_	_	I-Premise
374	)	_	_	I-Premise
375	scores	_	_	I-Premise
376	for	_	_	I-Premise
377	energy	_	_	I-Premise
378	level	_	_	I-Premise
379	,	_	_	I-Premise
380	ability	_	_	I-Premise
381	to	_	_	I-Premise
382	perform	_	_	I-Premise
383	daily	_	_	I-Premise
384	activity	_	_	I-Premise
385	,	_	_	I-Premise
386	and	_	_	I-Premise
387	overall	_	_	I-Premise
388	QOL	_	_	I-Premise
389	from	_	_	I-Premise
390	baseline	_	_	I-Premise
391	to	_	_	I-Premise
392	the	_	_	I-Premise
393	time	_	_	I-Premise
394	of	_	_	I-Premise
395	final	_	_	I-Premise
396	evaluation	_	_	I-Premise
397	.	_	_	I-Premise

398	QW	_	_	B-Premise
399	epoetin-alpha	_	_	I-Premise
400	was	_	_	I-Premise
401	found	_	_	I-Premise
402	to	_	_	I-Premise
403	be	_	_	I-Premise
404	well	_	_	I-Premise
405	tolerated	_	_	I-Premise
406	.	_	_	I-Premise

407	Treatment	_	_	B-Claim
408	with	_	_	I-Claim
409	QW	_	_	I-Claim
410	epoetin-alpha	_	_	I-Claim
411	was	_	_	I-Claim
412	found	_	_	I-Claim
413	to	_	_	I-Claim
414	increase	_	_	I-Claim
415	Hb	_	_	I-Claim
416	levels	_	_	I-Claim
417	,	_	_	I-Claim
418	decrease	_	_	I-Claim
419	transfusion	_	_	I-Claim
420	requirement	_	_	I-Claim
421	,	_	_	I-Claim
422	and	_	_	I-Claim
423	improve	_	_	I-Claim
424	functional	_	_	I-Claim
425	status	_	_	I-Claim
426	and	_	_	I-Claim
427	QOL	_	_	I-Claim
428	in	_	_	I-Claim
429	anemic	_	_	I-Claim
430	patients	_	_	I-Claim
431	with	_	_	I-Claim
432	ALL	_	_	I-Claim
433	in	_	_	I-Claim
434	maintenance	_	_	I-Claim
435	receiving	_	_	I-Claim
436	chemotherapy	_	_	I-Claim
437	.	_	_	I-Claim

438	The	_	_	B-Claim
439	once-weekly	_	_	I-Claim
440	schedule	_	_	I-Claim
441	is	_	_	I-Claim
442	convenient	_	_	I-Claim
443	,	_	_	I-Claim
444	safe	_	_	I-Claim
445	,	_	_	I-Claim
446	and	_	_	I-Claim
447	may	_	_	I-Claim
448	reduce	_	_	I-Claim
449	the	_	_	I-Claim
450	burden	_	_	I-Claim
451	on	_	_	I-Claim
452	patients	_	_	I-Claim
453	,	_	_	I-Claim
454	parents	_	_	I-Claim
455	,	_	_	I-Claim
456	and	_	_	I-Claim
457	their	_	_	I-Claim
458	caregivers	_	_	I-Claim
459	by	_	_	I-Claim
460	reducing	_	_	I-Claim
461	the	_	_	I-Claim
462	number	_	_	I-Claim
463	of	_	_	I-Claim
464	visits	_	_	I-Claim
465	to	_	_	I-Claim
466	the	_	_	I-Claim
467	clinic	_	_	I-Claim
468	.	_	_	I-Claim


0	Quality	_	_	O
1	of	_	_	O
2	life	_	_	O
3	is	_	_	O
4	an	_	_	O
5	important	_	_	O
6	outcome	_	_	O
7	measure	_	_	O
8	in	_	_	O
9	the	_	_	O
10	care	_	_	O
11	of	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	cancer	_	_	O
15	.	_	_	O

16	We	_	_	O
17	developed	_	_	O
18	a	_	_	O
19	new	_	_	O
20	scoring	_	_	O
21	system	_	_	O
22	specifically	_	_	O
23	for	_	_	O
24	the	_	_	O
25	evaluation	_	_	O
26	of	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	upper	_	_	O
30	gastrointestinal	_	_	O
31	cancer	_	_	O
32	and	_	_	O
33	postoperative	_	_	O
34	gastrointestinal	_	_	O
35	dysfunction	_	_	O
36	.	_	_	O

37	This	_	_	O
38	study	_	_	O
39	was	_	_	O
40	undertaken	_	_	O
41	to	_	_	O
42	evaluate	_	_	O
43	the	_	_	O
44	scoring	_	_	O
45	system	_	_	O
46	's	_	_	O
47	validity	_	_	O
48	in	_	_	O
49	comparing	_	_	O
50	outcomes	_	_	O
51	after	_	_	O
52	gastric	_	_	O
53	resection	_	_	O
54	.	_	_	O

55	Patients	_	_	O
56	with	_	_	O
57	gastric	_	_	O
58	cancer	_	_	O
59	,	_	_	O
60	3	_	_	O
61	months	_	_	O
62	to	_	_	O
63	3	_	_	O
64	years	_	_	O
65	postoperatively	_	_	O
66	,	_	_	O
67	were	_	_	O
68	surveyed	_	_	O
69	using	_	_	O
70	the	_	_	O
71	survey	_	_	O
72	instrument	_	_	O
73	.	_	_	O

74	Postoperative	_	_	O
75	dysfunction	_	_	O
76	scores	_	_	O
77	and	_	_	O
78	the	_	_	O
79	status	_	_	O
80	of	_	_	O
81	resuming	_	_	O
82	activities	_	_	O
83	of	_	_	O
84	daily	_	_	O
85	living	_	_	O
86	were	_	_	O
87	compared	_	_	O
88	with	_	_	O
89	the	_	_	O
90	surgical	_	_	O
91	procedure	_	_	O
92	performed	_	_	O
93	by	_	_	O
94	analysis	_	_	O
95	of	_	_	O
96	variance	_	_	O
97	and	_	_	O
98	multiple-comparison	_	_	O
99	techniques	_	_	O
100	.	_	_	O

101	Of	_	_	O
102	211	_	_	O
103	patients	_	_	O
104	surveyed	_	_	O
105	,	_	_	O
106	165	_	_	O
107	(	_	_	O
108	119	_	_	O
109	men	_	_	O
110	,	_	_	O
111	46	_	_	O
112	women	_	_	O
113	;	_	_	O
114	mean	_	_	O
115	age	_	_	O
116	,	_	_	O
117	65.1	_	_	O
118		_	_	O
119	10.5	_	_	O
120	years	_	_	O
121	)	_	_	O
122	responded	_	_	O
123	.	_	_	O

124	Procedures	_	_	O
125	included	_	_	O
126	distal	_	_	O
127	gastrectomy	_	_	O
128	in	_	_	O
129	100	_	_	O
130	,	_	_	O
131	total	_	_	O
132	gastrectomy	_	_	O
133	in	_	_	O
134	57	_	_	O
135	,	_	_	O
136	and	_	_	O
137	pylorus-preserving	_	_	O
138	gastrectomy	_	_	O
139	in	_	_	O
140	8	_	_	O
141	.	_	_	O

142	The	_	_	O
143	overall	_	_	O
144	dysfunction	_	_	O
145	score	_	_	O
146	was	_	_	O
147	61.8	_	_	O
148		_	_	O
149	15.5	_	_	O
150	.	_	_	O

151	The	_	_	B-Premise
152	dysfunction	_	_	I-Premise
153	score	_	_	I-Premise
154	was	_	_	I-Premise
155	58.9	_	_	I-Premise
156		_	_	I-Premise
157	15.0	_	_	I-Premise
158	after	_	_	I-Premise
159	distal	_	_	I-Premise
160	gastrectomy	_	_	I-Premise
161	,	_	_	I-Premise
162	66.8	_	_	I-Premise
163		_	_	I-Premise
164	14.1	_	_	I-Premise
165	after	_	_	I-Premise
166	total	_	_	I-Premise
167	gastrectomy	_	_	I-Premise
168	,	_	_	I-Premise
169	and	_	_	I-Premise
170	62.4	_	_	I-Premise
171		_	_	I-Premise
172	21.6	_	_	I-Premise
173	after	_	_	I-Premise
174	pylorus-preserving	_	_	I-Premise
175	gastrectomy	_	_	I-Premise
176	.	_	_	I-Premise

177	These	_	_	B-Premise
178	values	_	_	I-Premise
179	differed	_	_	I-Premise
180	significantly	_	_	I-Premise
181	among	_	_	I-Premise
182	the	_	_	I-Premise
183	groups	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	.007	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	Dysfunction	_	_	B-Premise
191	scores	_	_	I-Premise
192	according	_	_	I-Premise
193	to	_	_	I-Premise
194	postoperative	_	_	I-Premise
195	activity	_	_	I-Premise
196	status	_	_	I-Premise
197	were	_	_	I-Premise
198	49.1	_	_	I-Premise
199		_	_	I-Premise
200	15.6	_	_	I-Premise
201	in	_	_	I-Premise
202	71	_	_	I-Premise
203	patients	_	_	I-Premise
204	who	_	_	I-Premise
205	resumed	_	_	I-Premise
206	their	_	_	I-Premise
207	activities	_	_	I-Premise
208	,	_	_	I-Premise
209	56.9	_	_	I-Premise
210		_	_	I-Premise
211	15.7	_	_	I-Premise
212	in	_	_	I-Premise
213	39	_	_	I-Premise
214	patients	_	_	I-Premise
215	with	_	_	I-Premise
216	reduced	_	_	I-Premise
217	activities	_	_	I-Premise
218	,	_	_	I-Premise
219	57.3	_	_	I-Premise
220		_	_	I-Premise
221	8.8	_	_	I-Premise
222	in	_	_	I-Premise
223	15	_	_	I-Premise
224	patients	_	_	I-Premise
225	with	_	_	I-Premise
226	minimal	_	_	I-Premise
227	activities	_	_	I-Premise
228	,	_	_	I-Premise
229	and	_	_	I-Premise
230	63.3	_	_	I-Premise
231		_	_	I-Premise
232	11.8	_	_	I-Premise
233	(	_	_	I-Premise
234	P	_	_	I-Premise
235	<	_	_	I-Premise
236	.05	_	_	I-Premise
237	)	_	_	I-Premise
238	in	_	_	I-Premise
239	16	_	_	I-Premise
240	patients	_	_	I-Premise
241	who	_	_	I-Premise
242	did	_	_	I-Premise
243	not	_	_	I-Premise
244	resume	_	_	I-Premise
245	activities	_	_	I-Premise
246	because	_	_	I-Premise
247	of	_	_	I-Premise
248	poor	_	_	I-Premise
249	physical	_	_	I-Premise
250	condition	_	_	I-Premise
251	.	_	_	I-Premise

252	This	_	_	B-Claim
253	scoring	_	_	I-Claim
254	system	_	_	I-Claim
255	for	_	_	I-Claim
256	postoperative	_	_	I-Claim
257	gastrointestinal	_	_	I-Claim
258	dysfunction	_	_	I-Claim
259	provides	_	_	I-Claim
260	an	_	_	I-Claim
261	objective	_	_	I-Claim
262	measure	_	_	I-Claim
263	of	_	_	I-Claim
264	dysfunction	_	_	I-Claim
265	related	_	_	I-Claim
266	to	_	_	I-Claim
267	specific	_	_	I-Claim
268	surgical	_	_	I-Claim
269	procedures	_	_	I-Claim
270	and	_	_	I-Claim
271	correlates	_	_	I-Claim
272	with	_	_	I-Claim
273	activities	_	_	I-Claim
274	of	_	_	I-Claim
275	daily	_	_	I-Claim
276	living	_	_	I-Claim
277	in	_	_	I-Claim
278	the	_	_	I-Claim
279	postoperative	_	_	I-Claim
280	period	_	_	I-Claim
281	.	_	_	I-Claim


0	Analgesia	_	_	B-Claim
1	and	_	_	I-Claim
2	early	_	_	I-Claim
3	quality	_	_	I-Claim
4	of	_	_	I-Claim
5	recovery	_	_	I-Claim
6	may	_	_	I-Claim
7	be	_	_	I-Claim
8	improved	_	_	I-Claim
9	by	_	_	I-Claim
10	epidural	_	_	I-Claim
11	analgesia	_	_	I-Claim
12	.	_	_	I-Claim

13	We	_	_	O
14	aimed	_	_	O
15	to	_	_	O
16	assess	_	_	O
17	the	_	_	O
18	effect	_	_	O
19	of	_	_	O
20	receiving	_	_	O
21	epidural	_	_	O
22	analgesia	_	_	O
23	on	_	_	O
24	surgical	_	_	O
25	adverse	_	_	O
26	events	_	_	O
27	and	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	after	_	_	O
32	laparotomy	_	_	O
33	for	_	_	O
34	endometrial	_	_	O
35	cancer	_	_	O
36	.	_	_	O

37	Patients	_	_	O
38	were	_	_	O
39	enrolled	_	_	O
40	in	_	_	O
41	an	_	_	O
42	international	_	_	O
43	,	_	_	O
44	multicentre	_	_	O
45	,	_	_	O
46	prospective	_	_	O
47	randomised	_	_	O
48	trial	_	_	O
49	of	_	_	O
50	outcomes	_	_	O
51	for	_	_	O
52	laparoscopic	_	_	O
53	versus	_	_	O
54	open	_	_	O
55	surgical	_	_	O
56	treatment	_	_	O
57	for	_	_	O
58	the	_	_	O
59	management	_	_	O
60	of	_	_	O
61	apparent	_	_	O
62	stage	_	_	O
63	I	_	_	O
64	endometrial	_	_	O
65	cancer	_	_	O
66	(	_	_	O
67	LACE	_	_	O
68	trial	_	_	O
69	)	_	_	O
70	.	_	_	O

71	The	_	_	O
72	current	_	_	O
73	analysis	_	_	O
74	focussed	_	_	O
75	on	_	_	O
76	patients	_	_	O
77	who	_	_	O
78	received	_	_	O
79	an	_	_	O
80	open	_	_	O
81	abdominal	_	_	O
82	hysterectomy	_	_	O
83	via	_	_	O
84	vertical	_	_	O
85	midline	_	_	O
86	incision	_	_	O
87	only	_	_	O
88	(	_	_	O
89	n=257	_	_	O
90	)	_	_	O
91	,	_	_	O
92	examining	_	_	O
93	outcomes	_	_	O
94	in	_	_	O
95	patients	_	_	O
96	who	_	_	O
97	did	_	_	O
98	(	_	_	O
99	n=108	_	_	O
100	)	_	_	O
101	and	_	_	O
102	did	_	_	O
103	not	_	_	O
104	(	_	_	O
105	n=149	_	_	O
106	)	_	_	O
107	receive	_	_	O
108	epidural	_	_	O
109	analgesia	_	_	O
110	.	_	_	O

111	Baseline	_	_	O
112	characteristics	_	_	O
113	were	_	_	O
114	comparable	_	_	O
115	between	_	_	O
116	patients	_	_	O
117	with	_	_	O
118	or	_	_	O
119	without	_	_	O
120	epidural	_	_	O
121	analgesia	_	_	O
122	.	_	_	O

123	More	_	_	B-Premise
124	patients	_	_	I-Premise
125	without	_	_	I-Premise
126	epidural	_	_	I-Premise
127	(	_	_	I-Premise
128	34	_	_	I-Premise
129	%	_	_	I-Premise
130	)	_	_	I-Premise
131	ceased	_	_	I-Premise
132	opioid	_	_	I-Premise
133	analgesia	_	_	I-Premise
134	3-5	_	_	I-Premise
135	days	_	_	I-Premise
136	after	_	_	I-Premise
137	surgery	_	_	I-Premise
138	compared	_	_	I-Premise
139	to	_	_	I-Premise
140	patients	_	_	I-Premise
141	who	_	_	I-Premise
142	had	_	_	I-Premise
143	an	_	_	I-Premise
144	epidural	_	_	I-Premise
145	(	_	_	I-Premise
146	7	_	_	I-Premise
147	%	_	_	I-Premise
148	;	_	_	I-Premise
149	p	_	_	I-Premise
150	<	_	_	I-Premise
151	0.01	_	_	I-Premise
152	)	_	_	I-Premise
153	.	_	_	I-Premise

154	Postoperative	_	_	B-Premise
155	complications	_	_	I-Premise
156	(	_	_	I-Premise
157	any	_	_	I-Premise
158	grade	_	_	I-Premise
159	)	_	_	I-Premise
160	occurred	_	_	I-Premise
161	in	_	_	I-Premise
162	86	_	_	I-Premise
163	%	_	_	I-Premise
164	of	_	_	I-Premise
165	patients	_	_	I-Premise
166	with	_	_	I-Premise
167	and	_	_	I-Premise
168	in	_	_	I-Premise
169	66	_	_	I-Premise
170	%	_	_	I-Premise
171	of	_	_	I-Premise
172	patients	_	_	I-Premise
173	without	_	_	I-Premise
174	an	_	_	I-Premise
175	epidural	_	_	I-Premise
176	(	_	_	I-Premise
177	p	_	_	I-Premise
178	<	_	_	I-Premise
179	0.01	_	_	I-Premise
180	)	_	_	I-Premise
181	but	_	_	O
182	there	_	_	B-Premise
183	was	_	_	I-Premise
184	no	_	_	I-Premise
185	difference	_	_	I-Premise
186	in	_	_	I-Premise
187	serious	_	_	I-Premise
188	adverse	_	_	I-Premise
189	events	_	_	I-Premise
190	(	_	_	I-Premise
191	p=0.19	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	Epidural	_	_	B-Premise
195	analgesia	_	_	I-Premise
196	was	_	_	I-Premise
197	associated	_	_	I-Premise
198	with	_	_	I-Premise
199	increased	_	_	I-Premise
200	length	_	_	I-Premise
201	of	_	_	I-Premise
202	stay	_	_	I-Premise
203	(	_	_	I-Premise
204	up	_	_	I-Premise
205	to	_	_	I-Premise
206	48	_	_	I-Premise
207	days	_	_	I-Premise
208	compared	_	_	I-Premise
209	to	_	_	I-Premise
210	up	_	_	I-Premise
211	to	_	_	I-Premise
212	34	_	_	I-Premise
213	days	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	non-epidural	_	_	I-Premise
217	group	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	There	_	_	B-Claim
221	was	_	_	I-Claim
222	no	_	_	I-Claim
223	difference	_	_	I-Claim
224	in	_	_	I-Claim
225	postoperative	_	_	I-Claim
226	quality	_	_	I-Claim
227	of	_	_	I-Claim
228	life	_	_	I-Claim
229	up	_	_	I-Claim
230	to	_	_	I-Claim
231	six	_	_	I-Claim
232	months	_	_	I-Claim
233	after	_	_	I-Claim
234	surgery	_	_	I-Claim
235	.	_	_	I-Claim

236	Epidural	_	_	B-Claim
237	analgesia	_	_	I-Claim
238	was	_	_	I-Claim
239	associated	_	_	I-Claim
240	with	_	_	I-Claim
241	an	_	_	I-Claim
242	increase	_	_	I-Claim
243	in	_	_	I-Claim
244	any	_	_	I-Claim
245	,	_	_	I-Claim
246	but	_	_	I-Claim
247	not	_	_	I-Claim
248	serious	_	_	I-Claim
249	,	_	_	I-Claim
250	postoperative	_	_	I-Claim
251	complications	_	_	I-Claim
252	and	_	_	I-Claim
253	length	_	_	I-Claim
254	of	_	_	I-Claim
255	stay	_	_	I-Claim
256	after	_	_	I-Claim
257	abdominal	_	_	I-Claim
258	hysterectomy	_	_	I-Claim
259	.	_	_	I-Claim

260	Randomised	_	_	B-Claim
261	controlled	_	_	I-Claim
262	trials	_	_	I-Claim
263	are	_	_	I-Claim
264	needed	_	_	I-Claim
265	to	_	_	I-Claim
266	examine	_	_	I-Claim
267	the	_	_	I-Claim
268	effect	_	_	I-Claim
269	of	_	_	I-Claim
270	epidural	_	_	I-Claim
271	analgesia	_	_	I-Claim
272	on	_	_	I-Claim
273	surgical	_	_	I-Claim
274	adverse	_	_	I-Claim
275	events	_	_	I-Claim
276	,	_	_	I-Claim
277	especially	_	_	O
278	as	_	_	O
279	the	_	_	B-Claim
280	present	_	_	I-Claim
281	data	_	_	I-Claim
282	do	_	_	I-Claim
283	not	_	_	I-Claim
284	support	_	_	I-Claim
285	a	_	_	I-Claim
286	quality	_	_	I-Claim
287	of	_	_	I-Claim
288	life	_	_	I-Claim
289	benefit	_	_	I-Claim
290	with	_	_	I-Claim
291	epidural	_	_	I-Claim
292	analgesia	_	_	I-Claim
293	.	_	_	I-Claim


0	Cancer-related	_	_	B-Claim
1	fatigue	_	_	I-Claim
2	is	_	_	I-Claim
3	the	_	_	I-Claim
4	most	_	_	I-Claim
5	disabling	_	_	I-Claim
6	symptom	_	_	I-Claim
7	experienced	_	_	I-Claim
8	by	_	_	I-Claim
9	breast	_	_	I-Claim
10	cancer	_	_	I-Claim
11	patients	_	_	I-Claim
12	following	_	_	I-Claim
13	the	_	_	I-Claim
14	cancer	_	_	I-Claim
15	treatment	_	_	I-Claim
16	.	_	_	I-Claim

17	The	_	_	B-Premise
18	positive	_	_	I-Premise
19	effects	_	_	I-Premise
20	of	_	_	I-Premise
21	physical	_	_	I-Premise
22	activity	_	_	I-Premise
23	in	_	_	I-Premise
24	the	_	_	I-Premise
25	rehabilitation	_	_	I-Premise
26	of	_	_	I-Premise
27	breast	_	_	I-Premise
28	cancer	_	_	I-Premise
29	patients	_	_	I-Premise
30	are	_	_	I-Premise
31	documented	_	_	I-Premise
32	in	_	_	I-Premise
33	several	_	_	I-Premise
34	studies	_	_	I-Premise
35	.	_	_	I-Premise

36	In	_	_	O
37	a	_	_	O
38	randomized	_	_	O
39	controlled	_	_	O
40	study	_	_	O
41	the	_	_	O
42	effects	_	_	O
43	of	_	_	O
44	a	_	_	O
45	structured	_	_	O
46	physical	_	_	O
47	training	_	_	O
48	program	_	_	O
49	on	_	_	O
50	fatigue	_	_	O
51	and	_	_	O
52	health-related	_	_	O
53	quality	_	_	O
54	of	_	_	O
55	life	_	_	O
56	were	_	_	O
57	evaluated	_	_	O
58	.	_	_	O

59	63	_	_	O
60	breast	_	_	O
61	cancer	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	cancer-related	_	_	O
65	chronic	_	_	O
66	fatigue	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	at	_	_	O
70	the	_	_	O
71	beginning	_	_	O
72	of	_	_	O
73	the	_	_	O
74	inpatient	_	_	O
75	rehabilitation	_	_	O
76	.	_	_	O

77	The	_	_	O
78	control	_	_	O
79	group	_	_	O
80	received	_	_	O
81	the	_	_	O
82	standard	_	_	O
83	complex	_	_	O
84	rehabilitation	_	_	O
85	program	_	_	O
86	,	_	_	O
87	the	_	_	O
88	intervention	_	_	O
89	group	_	_	O
90	a	_	_	O
91	structured	_	_	O
92	physical	_	_	O
93	training	_	_	O
94	program	_	_	O
95	and	_	_	O
96	additional	_	_	O
97	muscle	_	_	O
98	strength	_	_	O
99	and	_	_	O
100	aerobic	_	_	O
101	exercises	_	_	O
102	.	_	_	O

103	The	_	_	O
104	effects	_	_	O
105	of	_	_	O
106	the	_	_	O
107	treatment	_	_	O
108	were	_	_	O
109	evaluated	_	_	O
110	by	_	_	O
111	questionnaires	_	_	O
112	at	_	_	O
113	the	_	_	O
114	start	_	_	O
115	of	_	_	O
116	rehabilitation	_	_	O
117	(	_	_	O
118	t1	_	_	O
119	)	_	_	O
120	,	_	_	O
121	end	_	_	O
122	of	_	_	O
123	rehabilitation	_	_	O
124	(	_	_	O
125	t2	_	_	O
126	)	_	_	O
127	,	_	_	O
128	and	_	_	O
129	3	_	_	O
130	months	_	_	O
131	after	_	_	O
132	t2	_	_	O
133	(	_	_	O
134	t3	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Isometric	_	_	O
138	muscle	_	_	O
139	strength	_	_	O
140	and	_	_	O
141	aerobic	_	_	O
142	capacity	_	_	O
143	were	_	_	O
144	evaluated	_	_	O
145	at	_	_	O
146	t1	_	_	O
147	and	_	_	O
148	t2	_	_	O
149	.	_	_	O

150	There	_	_	B-Premise
151	was	_	_	I-Premise
152	an	_	_	I-Premise
153	improvement	_	_	I-Premise
154	of	_	_	I-Premise
155	muscle	_	_	I-Premise
156	strength	_	_	I-Premise
157	at	_	_	I-Premise
158	the	_	_	I-Premise
159	end	_	_	I-Premise
160	of	_	_	I-Premise
161	rehabilitation	_	_	I-Premise
162	for	_	_	I-Premise
163	both	_	_	I-Premise
164	groups	_	_	I-Premise
165	.	_	_	I-Premise

166	The	_	_	B-Premise
167	increase	_	_	I-Premise
168	from	_	_	I-Premise
169	t1	_	_	I-Premise
170	to	_	_	I-Premise
171	t2	_	_	I-Premise
172	was	_	_	I-Premise
173	significantly	_	_	I-Premise
174	higher	_	_	I-Premise
175	for	_	_	I-Premise
176	the	_	_	I-Premise
177	training	_	_	I-Premise
178	group	_	_	I-Premise
179	.	_	_	I-Premise

180	The	_	_	B-Premise
181	scores	_	_	I-Premise
182	for	_	_	I-Premise
183	global	_	_	I-Premise
184	quality	_	_	I-Premise
185	of	_	_	I-Premise
186	life	_	_	I-Premise
187	,	_	_	I-Premise
188	physical	_	_	I-Premise
189	well-being	_	_	I-Premise
190	,	_	_	I-Premise
191	and	_	_	I-Premise
192	functionality	_	_	I-Premise
193	increased	_	_	I-Premise
194	from	_	_	I-Premise
195	t1	_	_	I-Premise
196	to	_	_	I-Premise
197	t2	_	_	I-Premise
198	,	_	_	I-Premise
199	but	_	_	B-Premise
200	further	_	_	I-Premise
201	improvement	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	follow-up	_	_	I-Premise
205	(	_	_	I-Premise
206	t3	_	_	I-Premise
207	)	_	_	I-Premise
208	was	_	_	I-Premise
209	only	_	_	I-Premise
210	observed	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	training	_	_	I-Premise
214	group	_	_	I-Premise
215	.	_	_	I-Premise

216	The	_	_	B-Premise
217	cancer-related	_	_	I-Premise
218	fatigue	_	_	I-Premise
219	was	_	_	I-Premise
220	significantly	_	_	I-Premise
221	reduced	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	training	_	_	I-Premise
225	group	_	_	I-Premise
226	from	_	_	I-Premise
227	t1	_	_	I-Premise
228	to	_	_	I-Premise
229	t3	_	_	I-Premise
230	,	_	_	I-Premise
231	however	_	_	I-Premise
232	,	_	_	I-Premise
233	not	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	control	_	_	I-Premise
237	group	_	_	I-Premise
238	.	_	_	I-Premise

239	Structured	_	_	B-Claim
240	physical	_	_	I-Claim
241	training	_	_	I-Claim
242	programs	_	_	I-Claim
243	initiated	_	_	I-Claim
244	during	_	_	I-Claim
245	inpatient	_	_	I-Claim
246	rehabilitation	_	_	I-Claim
247	and	_	_	I-Claim
248	continuously	_	_	I-Claim
249	practiced	_	_	I-Claim
250	in	_	_	I-Claim
251	the	_	_	I-Claim
252	time	_	_	I-Claim
253	thereafter	_	_	I-Claim
254	can	_	_	I-Claim
255	improve	_	_	I-Claim
256	symptoms	_	_	I-Claim
257	of	_	_	I-Claim
258	chronic	_	_	I-Claim
259	fatigue	_	_	I-Claim
260	and	_	_	I-Claim
261	quality	_	_	I-Claim
262	of	_	_	I-Claim
263	life	_	_	I-Claim
264	in	_	_	I-Claim
265	breast	_	_	I-Claim
266	cancer	_	_	I-Claim
267	patients	_	_	I-Claim
268	.	_	_	I-Claim


0	The	_	_	O
1	standard	_	_	O
2	treatment	_	_	O
3	for	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	clinically	_	_	O
7	resectable	_	_	O
8	rectal	_	_	O
9	cancer	_	_	O
10	is	_	_	O
11	surgery	_	_	O
12	.	_	_	O

13	Postoperative	_	_	B-Claim
14	radiochemotherapy	_	_	I-Claim
15	is	_	_	I-Claim
16	recommended	_	_	I-Claim
17	for	_	_	I-Claim
18	patients	_	_	I-Claim
19	with	_	_	I-Claim
20	advanced	_	_	I-Claim
21	disease	_	_	I-Claim
22	(	_	_	I-Claim
23	pT3/4	_	_	I-Claim
24	or	_	_	I-Claim
25	pN+	_	_	I-Claim
26	)	_	_	I-Claim
27	.	_	_	I-Claim

28	In	_	_	B-Claim
29	recent	_	_	I-Claim
30	years	_	_	I-Claim
31	,	_	_	I-Claim
32	encouraging	_	_	I-Claim
33	results	_	_	I-Claim
34	of	_	_	I-Claim
35	preoperative	_	_	I-Claim
36	radiotherapy	_	_	I-Claim
37	have	_	_	I-Claim
38	been	_	_	I-Claim
39	reported	_	_	I-Claim
40	.	_	_	I-Claim

41	This	_	_	O
42	prospective	_	_	O
43	randomized	_	_	O
44	phase-III	_	_	O
45	trial	_	_	O
46	(	_	_	O
47	CAO/ARO/AIO-94	_	_	O
48	)	_	_	O
49	compares	_	_	O
50	the	_	_	O
51	efficacy	_	_	O
52	of	_	_	O
53	neoadjuvant	_	_	O
54	radiochemotherapy	_	_	O
55	to	_	_	O
56	standard	_	_	O
57	postoperative	_	_	O
58	radiochemotherapy	_	_	O
59	.	_	_	O

60	We	_	_	O
61	report	_	_	O
62	on	_	_	O
63	the	_	_	O
64	design	_	_	O
65	of	_	_	O
66	the	_	_	O
67	study	_	_	O
68	and	_	_	O
69	first	_	_	O
70	results	_	_	O
71	with	_	_	O
72	regard	_	_	O
73	to	_	_	O
74	toxicity	_	_	O
75	of	_	_	O
76	radiochemotherapy	_	_	O
77	and	_	_	O
78	postoperative	_	_	O
79	morbidity	_	_	O
80	.	_	_	O

81	Patients	_	_	O
82	with	_	_	O
83	locally	_	_	O
84	advanced	_	_	O
85	operable	_	_	O
86	rectal	_	_	O
87	cancer	_	_	O
88	(	_	_	O
89	uT3/4	_	_	O
90	or	_	_	O
91	uN+	_	_	O
92	,	_	_	O
93	Mason	_	_	O
94	CS	_	_	O
95	III/IV	_	_	O
96	)	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	pre-	_	_	O
102	or	_	_	O
103	postoperative	_	_	O
104	radiochemotherapy	_	_	O
105	:	_	_	O
106	A	_	_	O
107	total	_	_	O
108	dose	_	_	O
109	of	_	_	O
110	50.4	_	_	O
111	Gy	_	_	O
112	(	_	_	O
113	single	_	_	O
114	dose	_	_	O
115	1.8	_	_	O
116	Gy	_	_	O
117	)	_	_	O
118	was	_	_	O
119	applied	_	_	O
120	to	_	_	O
121	the	_	_	O
122	tumor	_	_	O
123	and	_	_	O
124	the	_	_	O
125	pelvic	_	_	O
126	lymph	_	_	O
127	nodes	_	_	O
128	.	_	_	O

129	5-FU	_	_	O
130	(	_	_	O
131	1,000	_	_	O
132	mg/m2/d	_	_	O
133	)	_	_	O
134	was	_	_	O
135	administered	_	_	O
136	concomitantly	_	_	O
137	in	_	_	O
138	the	_	_	O
139	first	_	_	O
140	and	_	_	O
141	fifth	_	_	O
142	week	_	_	O
143	of	_	_	O
144	radiation	_	_	O
145	as	_	_	O
146	120-h	_	_	O
147	continuous	_	_	O
148	infusion	_	_	O
149	.	_	_	O

150	Four	_	_	O
151	additional	_	_	O
152	cycles	_	_	O
153	of	_	_	O
154	5-FU	_	_	O
155	chemotherapy	_	_	O
156	(	_	_	O
157	500	_	_	O
158	mg/m2/d	_	_	O
159	,	_	_	O
160	i.v	_	_	O
161	.	_	_	O

162	bolus	_	_	O
163	)	_	_	O
164	were	_	_	O
165	applied	_	_	O
166	.	_	_	O

167	Radiochemotherapy	_	_	O
168	was	_	_	O
169	identical	_	_	O
170	in	_	_	O
171	both	_	_	O
172	arms	_	_	O
173	except	_	_	O
174	for	_	_	O
175	a	_	_	O
176	small-volume	_	_	O
177	boost	_	_	O
178	of	_	_	O
179	5.4	_	_	O
180	Gy	_	_	O
181	in	_	_	O
182	the	_	_	O
183	postoperative	_	_	O
184	setting	_	_	O
185	.	_	_	O

186	Time	_	_	O
187	interval	_	_	O
188	between	_	_	O
189	radiochemotherapy	_	_	O
190	and	_	_	O
191	surgery	_	_	O
192	was	_	_	O
193	4-6	_	_	O
194	weeks	_	_	O
195	in	_	_	O
196	both	_	_	O
197	arms	_	_	O
198	.	_	_	O

199	Techniques	_	_	O
200	of	_	_	O
201	surgery	_	_	O
202	were	_	_	O
203	standardized	_	_	O
204	and	_	_	O
205	included	_	_	O
206	total	_	_	O
207	mesorectal	_	_	O
208	excision	_	_	O
209	.	_	_	O

210	In	_	_	O
211	addition	_	_	O
212	,	_	_	O
213	stratification	_	_	O
214	according	_	_	O
215	to	_	_	O
216	surgeons	_	_	O
217	involved	_	_	O
218	has	_	_	O
219	been	_	_	O
220	provided	_	_	O
221	for	_	_	O
222	.	_	_	O

223	Primary	_	_	O
224	endpoints	_	_	O
225	of	_	_	O
226	the	_	_	O
227	study	_	_	O
228	are	_	_	O
229	5-year	_	_	O
230	overall-survival	_	_	O
231	,	_	_	O
232	local	_	_	O
233	and	_	_	O
234	distant	_	_	O
235	control	_	_	O
236	,	_	_	O
237	secondary	_	_	O
238	endpoints	_	_	O
239	include	_	_	O
240	rate	_	_	O
241	of	_	_	O
242	curative	_	_	O
243	(	_	_	O
244	R0	_	_	O
245	)	_	_	O
246	resections	_	_	O
247	and	_	_	O
248	sphincter	_	_	O
249	saving	_	_	O
250	procedures	_	_	O
251	,	_	_	O
252	toxicity	_	_	O
253	of	_	_	O
254	radiochemotherapy	_	_	O
255	,	_	_	O
256	surgical	_	_	O
257	complications	_	_	O
258	and	_	_	O
259	quality	_	_	O
260	of	_	_	O
261	life	_	_	O
262	.	_	_	O

263	As	_	_	O
264	of	_	_	O
265	15th	_	_	O
266	November	_	_	O
267	2000	_	_	O
268	,	_	_	O
269	628	_	_	O
270	patients	_	_	O
271	were	_	_	O
272	randomized	_	_	O
273	from	_	_	O
274	26	_	_	O
275	participating	_	_	O
276	institutions	_	_	O
277	:	_	_	O
278	310	_	_	O
279	patients	_	_	O
280	were	_	_	O
281	randomized	_	_	O
282	to	_	_	O
283	postoperative	_	_	O
284	radiochemotherapy	_	_	O
285	,	_	_	O
286	318	_	_	O
287	patients	_	_	O
288	to	_	_	O
289	preoperative	_	_	O
290	radiochemotherapy	_	_	O
291	.	_	_	O

292	Acute	_	_	B-Premise
293	toxicity	_	_	I-Premise
294	(	_	_	I-Premise
295	WHO	_	_	I-Premise
296	)	_	_	I-Premise
297	of	_	_	I-Premise
298	radiochemotherapy	_	_	I-Premise
299	was	_	_	I-Premise
300	low	_	_	I-Premise
301	,	_	_	I-Premise
302	with	_	_	I-Premise
303	less	_	_	I-Premise
304	than	_	_	I-Premise
305	15	_	_	I-Premise
306	%	_	_	I-Premise
307	of	_	_	I-Premise
308	patients	_	_	I-Premise
309	experiencing	_	_	I-Premise
310	Grade	_	_	I-Premise
311	3	_	_	I-Premise
312	or	_	_	I-Premise
313	higher	_	_	I-Premise
314	toxicity	_	_	I-Premise
315	:	_	_	O
316	The	_	_	B-Premise
317	principal	_	_	I-Premise
318	toxicity	_	_	I-Premise
319	was	_	_	I-Premise
320	diarrhea	_	_	I-Premise
321	,	_	_	I-Premise
322	with	_	_	I-Premise
323	12	_	_	I-Premise
324	%	_	_	I-Premise
325	in	_	_	I-Premise
326	the	_	_	I-Premise
327	postoperative	_	_	I-Premise
328	radiochemotherapy	_	_	I-Premise
329	arm	_	_	I-Premise
330	and	_	_	I-Premise
331	10	_	_	I-Premise
332	%	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	preoperative	_	_	I-Premise
336	radiochemotherapy	_	_	I-Premise
337	arm	_	_	I-Premise
338	having	_	_	I-Premise
339	Grade-3	_	_	I-Premise
340	,	_	_	I-Premise
341	and	_	_	I-Premise
342	1	_	_	I-Premise
343	%	_	_	I-Premise
344	in	_	_	I-Premise
345	either	_	_	I-Premise
346	arm	_	_	I-Premise
347	having	_	_	I-Premise
348	Grade-4	_	_	I-Premise
349	diarrhea	_	_	I-Premise
350	.	_	_	I-Premise

351	Erythema	_	_	B-Premise
352	,	_	_	I-Premise
353	nausea	_	_	I-Premise
354	and	_	_	I-Premise
355	leukopenia	_	_	I-Premise
356	were	_	_	I-Premise
357	the	_	_	I-Premise
358	next	_	_	I-Premise
359	common	_	_	I-Premise
360	toxicities	_	_	I-Premise
361	,	_	_	I-Premise
362	with	_	_	I-Premise
363	less	_	_	I-Premise
364	than	_	_	I-Premise
365	3	_	_	I-Premise
366	%	_	_	I-Premise
367	of	_	_	I-Premise
368	patients	_	_	I-Premise
369	in	_	_	I-Premise
370	either	_	_	I-Premise
371	arm	_	_	I-Premise
372	suffering	_	_	I-Premise
373	Grade	_	_	I-Premise
374	3	_	_	I-Premise
375	or	_	_	I-Premise
376	greater	_	_	I-Premise
377	leukopenia	_	_	I-Premise
378	or	_	_	I-Premise
379	nausea	_	_	I-Premise
380	.	_	_	I-Premise

381	Postoperative	_	_	B-Premise
382	complication	_	_	I-Premise
383	rates	_	_	I-Premise
384	were	_	_	I-Premise
385	similar	_	_	I-Premise
386	in	_	_	I-Premise
387	both	_	_	I-Premise
388	arms	_	_	I-Premise
389	,	_	_	I-Premise
390	with	_	_	I-Premise
391	12	_	_	I-Premise
392	%	_	_	I-Premise
393	(	_	_	I-Premise
394	postoperative	_	_	I-Premise
395	radiochemotherapy	_	_	I-Premise
396	)	_	_	I-Premise
397	and	_	_	I-Premise
398	13	_	_	I-Premise
399	%	_	_	I-Premise
400	(	_	_	I-Premise
401	preoperative	_	_	I-Premise
402	radiochemotherapy	_	_	I-Premise
403	)	_	_	I-Premise
404	of	_	_	I-Premise
405	patients	_	_	I-Premise
406	,	_	_	I-Premise
407	respectively	_	_	I-Premise
408	,	_	_	I-Premise
409	suffering	_	_	I-Premise
410	from	_	_	I-Premise
411	anastomotic	_	_	I-Premise
412	leakage	_	_	I-Premise
413	,	_	_	I-Premise
414	4	_	_	I-Premise
415	%	_	_	I-Premise
416	(	_	_	I-Premise
417	postoperative	_	_	I-Premise
418	radiochemotherapy	_	_	I-Premise
419	)	_	_	I-Premise
420	and	_	_	I-Premise
421	3	_	_	I-Premise
422	%	_	_	I-Premise
423	(	_	_	I-Premise
424	preoperative	_	_	I-Premise
425	radiochemotherapy	_	_	I-Premise
426	)	_	_	I-Premise
427	from	_	_	I-Premise
428	postoperative	_	_	I-Premise
429	bleeding	_	_	I-Premise
430	,	_	_	I-Premise
431	and	_	_	I-Premise
432	6	_	_	I-Premise
433	%	_	_	I-Premise
434	(	_	_	I-Premise
435	postoperative	_	_	I-Premise
436	radiochemotherapy	_	_	I-Premise
437	)	_	_	I-Premise
438	and	_	_	I-Premise
439	5	_	_	I-Premise
440	%	_	_	I-Premise
441	(	_	_	I-Premise
442	preoperative	_	_	I-Premise
443	radiochemotherapy	_	_	I-Premise
444	)	_	_	I-Premise
445	from	_	_	I-Premise
446	delayed	_	_	I-Premise
447	wound	_	_	I-Premise
448	healing	_	_	I-Premise
449	.	_	_	I-Premise

450	The	_	_	B-Claim
451	patient	_	_	I-Claim
452	accrual	_	_	I-Claim
453	of	_	_	I-Claim
454	our	_	_	I-Claim
455	trial	_	_	I-Claim
456	is	_	_	I-Claim
457	satisfactory	_	_	I-Claim
458	,	_	_	I-Claim
459	neoadjuvant	_	_	B-Claim
460	radiochemotherapy	_	_	I-Claim
461	is	_	_	I-Claim
462	well	_	_	I-Claim
463	tolerated	_	_	I-Claim
464	and	_	_	I-Claim
465	bears	_	_	I-Claim
466	no	_	_	I-Claim
467	higher	_	_	I-Claim
468	risk	_	_	I-Claim
469	for	_	_	I-Claim
470	postoperative	_	_	I-Claim
471	morbidity	_	_	I-Claim
472	.	_	_	I-Claim


0	In	_	_	O
1	a	_	_	O
2	phase	_	_	O
3	3	_	_	O
4	trial	_	_	O
5	comparing	_	_	O
6	the	_	_	O
7	efficacy	_	_	O
8	and	_	_	O
9	safety	_	_	O
10	of	_	_	O
11	axitinib	_	_	O
12	versus	_	_	O
13	sorafenib	_	_	O
14	as	_	_	O
15	second-line	_	_	O
16	treatment	_	_	O
17	for	_	_	O
18	metastatic	_	_	O
19	renal	_	_	O
20	cell	_	_	O
21	carcinoma	_	_	O
22	,	_	_	O
23	patients	_	_	O
24	given	_	_	O
25	axitinib	_	_	O
26	had	_	_	O
27	a	_	_	O
28	longer	_	_	O
29	progression-free	_	_	O
30	survival	_	_	O
31	(	_	_	O
32	PFS	_	_	O
33	)	_	_	O
34	.	_	_	O

35	Here	_	_	O
36	,	_	_	O
37	we	_	_	O
38	report	_	_	O
39	overall	_	_	O
40	survival	_	_	O
41	and	_	_	O
42	updated	_	_	O
43	efficacy	_	_	O
44	,	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	,	_	_	O
49	and	_	_	O
50	safety	_	_	O
51	results	_	_	O
52	.	_	_	O

53	Eligible	_	_	O
54	patients	_	_	O
55	had	_	_	O
56	clear	_	_	O
57	cell	_	_	O
58	metastatic	_	_	O
59	renal	_	_	O
60	cell	_	_	O
61	carcinoma	_	_	O
62	,	_	_	O
63	progressive	_	_	O
64	disease	_	_	O
65	after	_	_	O
66	one	_	_	O
67	approved	_	_	O
68	systemic	_	_	O
69	treatment	_	_	O
70	,	_	_	O
71	and	_	_	O
72	an	_	_	O
73	Eastern	_	_	O
74	Cooperative	_	_	O
75	Oncology	_	_	O
76	Group	_	_	O
77	performance	_	_	O
78	status	_	_	O
79	(	_	_	O
80	ECOG	_	_	O
81	PS	_	_	O
82	)	_	_	O
83	of	_	_	O
84	0-1	_	_	O
85	.	_	_	O

86	723	_	_	O
87	patients	_	_	O
88	were	_	_	O
89	stratified	_	_	O
90	by	_	_	O
91	ECOG	_	_	O
92	PS	_	_	O
93	and	_	_	O
94	previous	_	_	O
95	treatment	_	_	O
96	and	_	_	O
97	randomly	_	_	O
98	allocated	_	_	O
99	(	_	_	O
100	1:1	_	_	O
101	)	_	_	O
102	to	_	_	O
103	receive	_	_	O
104	axitinib	_	_	O
105	(	_	_	O
106	5	_	_	O
107	mg	_	_	O
108	twice	_	_	O
109	daily	_	_	O
110	;	_	_	O
111	n=361	_	_	O
112	)	_	_	O
113	or	_	_	O
114	sorafenib	_	_	O
115	(	_	_	O
116	400	_	_	O
117	mg	_	_	O
118	twice	_	_	O
119	daily	_	_	O
120	;	_	_	O
121	n=362	_	_	O
122	)	_	_	O
123	.	_	_	O

124	The	_	_	O
125	primary	_	_	O
126	endpoint	_	_	O
127	was	_	_	O
128	PFS	_	_	O
129	assessed	_	_	O
130	by	_	_	O
131	a	_	_	O
132	masked	_	_	O
133	,	_	_	O
134	independent	_	_	O
135	radiology	_	_	O
136	review	_	_	O
137	committee	_	_	O
138	.	_	_	O

139	We	_	_	O
140	assessed	_	_	O
141	patient-reported	_	_	O
142	outcomes	_	_	O
143	using	_	_	O
144	validated	_	_	O
145	questionnaires	_	_	O
146	.	_	_	O

147	Baseline	_	_	O
148	characteristics	_	_	O
149	and	_	_	O
150	development	_	_	O
151	of	_	_	O
152	hypertension	_	_	O
153	on	_	_	O
154	treatment	_	_	O
155	were	_	_	O
156	studied	_	_	O
157	as	_	_	O
158	prognostic	_	_	O
159	factors	_	_	O
160	.	_	_	O

161	Efficacy	_	_	O
162	was	_	_	O
163	assessed	_	_	O
164	in	_	_	O
165	the	_	_	O
166	intention-to-treat	_	_	O
167	population	_	_	O
168	,	_	_	O
169	and	_	_	O
170	safety	_	_	O
171	was	_	_	O
172	assessed	_	_	O
173	in	_	_	O
174	patients	_	_	O
175	who	_	_	O
176	received	_	_	O
177	at	_	_	O
178	least	_	_	O
179	one	_	_	O
180	dose	_	_	O
181	of	_	_	O
182	the	_	_	O
183	study	_	_	O
184	drug	_	_	O
185	.	_	_	O

186	Median	_	_	B-Premise
187	overall	_	_	I-Premise
188	survival	_	_	I-Premise
189	was	_	_	I-Premise
190	20.1	_	_	I-Premise
191	months	_	_	I-Premise
192	(	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	16.7-23.4	_	_	I-Premise
197	)	_	_	I-Premise
198	with	_	_	I-Premise
199	axitinib	_	_	I-Premise
200	and	_	_	I-Premise
201	19.2	_	_	I-Premise
202	months	_	_	I-Premise
203	(	_	_	I-Premise
204	17.5-22.3	_	_	I-Premise
205	)	_	_	I-Premise
206	with	_	_	I-Premise
207	sorafenib	_	_	I-Premise
208	(	_	_	I-Premise
209	hazard	_	_	I-Premise
210	ratio	_	_	I-Premise
211	[	_	_	I-Premise
212	HR	_	_	I-Premise
213	]	_	_	I-Premise
214	0.969	_	_	I-Premise
215	,	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	0.800-1.174	_	_	I-Premise
220	;	_	_	I-Premise
221	one-sided	_	_	I-Premise
222	p=0.3744	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Median	_	_	B-Premise
226	investigator-assessed	_	_	I-Premise
227	PFS	_	_	I-Premise
228	was	_	_	I-Premise
229	8.3	_	_	I-Premise
230	months	_	_	I-Premise
231	(	_	_	I-Premise
232	95	_	_	I-Premise
233	%	_	_	I-Premise
234	CI	_	_	I-Premise
235	6.7-9.2	_	_	I-Premise
236	)	_	_	I-Premise
237	with	_	_	I-Premise
238	axitinib	_	_	I-Premise
239	and	_	_	I-Premise
240	57	_	_	I-Premise
241	months	_	_	I-Premise
242	(	_	_	I-Premise
243	4.7-6.5	_	_	I-Premise
244	)	_	_	I-Premise
245	with	_	_	I-Premise
246	sorafenib	_	_	I-Premise
247	(	_	_	I-Premise
248	HR	_	_	I-Premise
249	0.656	_	_	I-Premise
250	,	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	CI	_	_	I-Premise
254	0.552-0.779	_	_	I-Premise
255	;	_	_	I-Premise
256	one-sided	_	_	I-Premise
257	p	_	_	I-Premise
258	<	_	_	I-Premise
259	0.0001	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Patient-reported	_	_	B-Premise
263	outcomes	_	_	I-Premise
264	scores	_	_	I-Premise
265	were	_	_	I-Premise
266	similar	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	treatment	_	_	I-Premise
270	groups	_	_	I-Premise
271	at	_	_	I-Premise
272	baseline	_	_	I-Premise
273	,	_	_	I-Premise
274	were	_	_	I-Premise
275	maintained	_	_	I-Premise
276	during	_	_	I-Premise
277	treatment	_	_	I-Premise
278	,	_	_	I-Premise
279	but	_	_	B-Premise
280	decreased	_	_	I-Premise
281	at	_	_	I-Premise
282	end-of-treatment	_	_	I-Premise
283	.	_	_	I-Premise

284	Common	_	_	B-Premise
285	grade	_	_	I-Premise
286	3	_	_	I-Premise
287	or	_	_	I-Premise
288	higher	_	_	I-Premise
289	treatment-related	_	_	I-Premise
290	adverse	_	_	I-Premise
291	events	_	_	I-Premise
292	were	_	_	I-Premise
293	hypertension	_	_	I-Premise
294	(	_	_	I-Premise
295	60	_	_	I-Premise
296	[	_	_	I-Premise
297	17	_	_	I-Premise
298	%	_	_	I-Premise
299	]	_	_	I-Premise
300	)	_	_	I-Premise
301	,	_	_	I-Premise
302	diarrhoea	_	_	I-Premise
303	(	_	_	I-Premise
304	40	_	_	I-Premise
305	[	_	_	I-Premise
306	11	_	_	I-Premise
307	%	_	_	I-Premise
308	]	_	_	I-Premise
309	)	_	_	I-Premise
310	,	_	_	I-Premise
311	and	_	_	I-Premise
312	fatigue	_	_	I-Premise
313	(	_	_	I-Premise
314	37	_	_	I-Premise
315	[	_	_	I-Premise
316	10	_	_	I-Premise
317	%	_	_	I-Premise
318	]	_	_	I-Premise
319	)	_	_	I-Premise
320	in	_	_	I-Premise
321	359	_	_	I-Premise
322	axitinib-treated	_	_	I-Premise
323	patients	_	_	I-Premise
324	and	_	_	I-Premise
325	hand-foot	_	_	I-Premise
326	syndrome	_	_	I-Premise
327	(	_	_	I-Premise
328	61	_	_	I-Premise
329	[	_	_	I-Premise
330	17	_	_	I-Premise
331	%	_	_	I-Premise
332	]	_	_	I-Premise
333	)	_	_	I-Premise
334	,	_	_	I-Premise
335	hypertension	_	_	I-Premise
336	(	_	_	I-Premise
337	43	_	_	I-Premise
338	[	_	_	I-Premise
339	12	_	_	I-Premise
340	%	_	_	I-Premise
341	]	_	_	I-Premise
342	)	_	_	I-Premise
343	,	_	_	I-Premise
344	and	_	_	I-Premise
345	diarrhoea	_	_	I-Premise
346	(	_	_	I-Premise
347	27	_	_	I-Premise
348	[	_	_	I-Premise
349	8	_	_	I-Premise
350	%	_	_	I-Premise
351	]	_	_	I-Premise
352	)	_	_	I-Premise
353	in	_	_	I-Premise
354	355	_	_	I-Premise
355	sorafenib-treated	_	_	I-Premise
356	patients	_	_	I-Premise
357	.	_	_	I-Premise

358	In	_	_	B-Premise
359	a	_	_	I-Premise
360	post-hoc	_	_	I-Premise
361	12-week	_	_	I-Premise
362	landmark	_	_	I-Premise
363	analysis	_	_	I-Premise
364	,	_	_	I-Premise
365	median	_	_	I-Premise
366	overall	_	_	I-Premise
367	survival	_	_	I-Premise
368	was	_	_	I-Premise
369	longer	_	_	I-Premise
370	in	_	_	I-Premise
371	patients	_	_	I-Premise
372	with	_	_	I-Premise
373	a	_	_	I-Premise
374	diastolic	_	_	I-Premise
375	blood	_	_	I-Premise
376	pressure	_	_	I-Premise
377	of	_	_	I-Premise
378	90	_	_	I-Premise
379	mm	_	_	I-Premise
380	Hg	_	_	I-Premise
381	or	_	_	I-Premise
382	greater	_	_	I-Premise
383	than	_	_	I-Premise
384	in	_	_	I-Premise
385	those	_	_	I-Premise
386	with	_	_	I-Premise
387	a	_	_	I-Premise
388	diastolic	_	_	I-Premise
389	blood	_	_	I-Premise
390	pressure	_	_	I-Premise
391	of	_	_	I-Premise
392	less	_	_	I-Premise
393	than	_	_	I-Premise
394	90	_	_	I-Premise
395	mm	_	_	I-Premise
396	Hg	_	_	I-Premise
397	:	_	_	I-Premise
398	20.7	_	_	I-Premise
399	months	_	_	I-Premise
400	(	_	_	I-Premise
401	95	_	_	I-Premise
402	%	_	_	I-Premise
403	CI	_	_	I-Premise
404	18.4-24.6	_	_	I-Premise
405	)	_	_	I-Premise
406	versus	_	_	I-Premise
407	12.9	_	_	I-Premise
408	months	_	_	I-Premise
409	(	_	_	I-Premise
410	10.1-20.4	_	_	I-Premise
411	)	_	_	I-Premise
412	in	_	_	I-Premise
413	the	_	_	I-Premise
414	axitinib	_	_	I-Premise
415	group	_	_	I-Premise
416	(	_	_	I-Premise
417	p=0.0116	_	_	I-Premise
418	)	_	_	I-Premise
419	,	_	_	I-Premise
420	and	_	_	I-Premise
421	20.2	_	_	I-Premise
422	months	_	_	I-Premise
423	(	_	_	I-Premise
424	17.1-32.0	_	_	I-Premise
425	)	_	_	I-Premise
426	versus	_	_	I-Premise
427	14.8	_	_	I-Premise
428	months	_	_	I-Premise
429	(	_	_	I-Premise
430	12.0-17.7	_	_	I-Premise
431	)	_	_	I-Premise
432	in	_	_	I-Premise
433	the	_	_	I-Premise
434	sorafenib	_	_	I-Premise
435	group	_	_	I-Premise
436	(	_	_	I-Premise
437	one-sided	_	_	I-Premise
438	p=0.0020	_	_	I-Premise
439	)	_	_	I-Premise
440	.	_	_	I-Premise

441	Although	_	_	O
442	overall	_	_	B-Claim
443	survival	_	_	I-Claim
444	,	_	_	I-Claim
445	a	_	_	I-Claim
446	secondary	_	_	I-Claim
447	endpoint	_	_	I-Claim
448	for	_	_	I-Claim
449	the	_	_	I-Claim
450	study	_	_	I-Claim
451	,	_	_	I-Claim
452	did	_	_	I-Claim
453	not	_	_	I-Claim
454	differ	_	_	I-Claim
455	between	_	_	I-Claim
456	the	_	_	I-Claim
457	two	_	_	I-Claim
458	groups	_	_	I-Claim
459	,	_	_	I-Claim
460	investigator-assessed	_	_	B-Claim
461	PFS	_	_	I-Claim
462	remained	_	_	I-Claim
463	longer	_	_	I-Claim
464	in	_	_	I-Claim
465	the	_	_	I-Claim
466	axitinib	_	_	I-Claim
467	group	_	_	I-Claim
468	compared	_	_	I-Claim
469	with	_	_	I-Claim
470	the	_	_	I-Claim
471	sorafenib	_	_	I-Claim
472	group	_	_	I-Claim
473	.	_	_	I-Claim

474	These	_	_	B-Claim
475	results	_	_	I-Claim
476	establish	_	_	I-Claim
477	axitinib	_	_	I-Claim
478	as	_	_	I-Claim
479	a	_	_	I-Claim
480	second-line	_	_	I-Claim
481	treatment	_	_	I-Claim
482	option	_	_	I-Claim
483	for	_	_	I-Claim
484	patients	_	_	I-Claim
485	with	_	_	I-Claim
486	metastatic	_	_	I-Claim
487	renal	_	_	I-Claim
488	cell	_	_	I-Claim
489	carcinoma	_	_	I-Claim
490	.	_	_	I-Claim


0	Imatinib	_	_	B-Claim
1	(	_	_	I-Claim
2	Gleevec	_	_	I-Claim
3	)	_	_	I-Claim
4	,	_	_	I-Claim
5	a	_	_	I-Claim
6	highly	_	_	I-Claim
7	effective	_	_	I-Claim
8	specific	_	_	I-Claim
9	tyrosine	_	_	I-Claim
10	kinase	_	_	I-Claim
11	inhibitor	_	_	I-Claim
12	,	_	_	I-Claim
13	demonstrates	_	_	I-Claim
14	a	_	_	I-Claim
15	better	_	_	I-Claim
16	side	_	_	I-Claim
17	effect	_	_	I-Claim
18	profile	_	_	I-Claim
19	than	_	_	I-Claim
20	interferon-alpha	_	_	I-Claim
21	(	_	_	I-Claim
22	IFN	_	_	I-Claim
23	)	_	_	I-Claim
24	,	_	_	I-Claim
25	which	_	_	I-Claim
26	impairs	_	_	I-Claim
27	patients	_	_	I-Claim
28	'	_	_	I-Claim
29	quality	_	_	I-Claim
30	of	_	_	I-Claim
31	life	_	_	I-Claim
32	(	_	_	I-Claim
33	QoL	_	_	I-Claim
34	)	_	_	I-Claim
35	.	_	_	I-Claim

36	This	_	_	O
37	phase	_	_	O
38	III	_	_	O
39	international	_	_	O
40	study	_	_	O
41	evaluated	_	_	O
42	QoL	_	_	O
43	outcomes	_	_	O
44	in	_	_	O
45	1,106	_	_	O
46	newly	_	_	O
47	diagnosed	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	chronic-phase	_	_	O
51	chronic	_	_	O
52	myeloid	_	_	O
53	leukemia	_	_	O
54	(	_	_	O
55	CML	_	_	O
56	)	_	_	O
57	who	_	_	O
58	were	_	_	O
59	randomized	_	_	O
60	to	_	_	O
61	receive	_	_	O
62	either	_	_	O
63	imatinib	_	_	O
64	400	_	_	O
65	mg	_	_	O
66	daily	_	_	O
67	or	_	_	O
68	IFN	_	_	O
69	up	_	_	O
70	to	_	_	O
71	5	_	_	O
72	MU/m	_	_	O
73	(	_	_	O
74	2	_	_	O
75	)	_	_	O
76	/d	_	_	O
77	with	_	_	O
78	cytarabine	_	_	O
79	(	_	_	O
80	Ara-C	_	_	O
81	)	_	_	O
82	20	_	_	O
83	mg/m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	/d	_	_	O
88	added	_	_	O
89	for	_	_	O
90	10	_	_	O
91	days	_	_	O
92	every	_	_	O
93	month	_	_	O
94	(	_	_	O
95	IFN	_	_	O
96	+	_	_	O
97	LDAC	_	_	O
98	)	_	_	O
99	.	_	_	O

100	Crossover	_	_	O
101	to	_	_	O
102	the	_	_	O
103	other	_	_	O
104	treatment	_	_	O
105	arm	_	_	O
106	was	_	_	O
107	permitted	_	_	O
108	due	_	_	O
109	to	_	_	O
110	a	_	_	O
111	lack	_	_	O
112	of	_	_	O
113	efficacy	_	_	O
114	or	_	_	O
115	treatment	_	_	O
116	intolerance	_	_	O
117	.	_	_	O

118	QoL	_	_	O
119	was	_	_	O
120	assessed	_	_	O
121	with	_	_	O
122	the	_	_	O
123	Functional	_	_	O
124	Assessment	_	_	O
125	of	_	_	O
126	Cancer	_	_	O
127	Therapy-Biologic	_	_	O
128	Response	_	_	O
129	Modifiers	_	_	O
130	(	_	_	O
131	FACT-BRM	_	_	O
132	)	_	_	O
133	at	_	_	O
134	baseline	_	_	O
135	,	_	_	O
136	monthly	_	_	O
137	for	_	_	O
138	6	_	_	O
139	months	_	_	O
140	and	_	_	O
141	then	_	_	O
142	at	_	_	O
143	months	_	_	O
144	9	_	_	O
145	,	_	_	O
146	12	_	_	O
147	,	_	_	O
148	and	_	_	O
149	18	_	_	O
150	.	_	_	O

151	The	_	_	O
152	Trial	_	_	O
153	Outcome	_	_	O
154	Index	_	_	O
155	(	_	_	O
156	TOI	_	_	O
157	;	_	_	O
158	a	_	_	O
159	composite	_	_	O
160	endpoint	_	_	O
161	of	_	_	O
162	physical/functional/treatment-specific	_	_	O
163	subscales	_	_	O
164	)	_	_	O
165	was	_	_	O
166	the	_	_	O
167	primary	_	_	O
168	endpoint	_	_	O
169	.	_	_	O

170	Secondary	_	_	O
171	endpoints	_	_	O
172	measured	_	_	O
173	were	_	_	O
174	social/family	_	_	O
175	well-being	_	_	O
176	(	_	_	O
177	SFWB	_	_	O
178	)	_	_	O
179	and	_	_	O
180	emotional	_	_	O
181	well-being	_	_	O
182	(	_	_	O
183	EWB	_	_	O
184	)	_	_	O
185	.	_	_	O

186	QoL	_	_	O
187	was	_	_	O
188	analyzed	_	_	O
189	for	_	_	O
190	the	_	_	O
191	first	_	_	O
192	18	_	_	O
193	months	_	_	O
194	of	_	_	O
195	treatment	_	_	O
196	using	_	_	O
197	mixed	_	_	O
198	effects	_	_	O
199	growth	_	_	O
200	curve	_	_	O
201	models	_	_	O
202	.	_	_	O

203	The	_	_	O
204	primary	_	_	O
205	analyses	_	_	O
206	were	_	_	O
207	intention-to-treat	_	_	O
208	(	_	_	O
209	ITT	_	_	O
210	)	_	_	O
211	;	_	_	O
212	secondary	_	_	O
213	analyses	_	_	O
214	incorporated	_	_	O
215	crossover	_	_	O
216	as	_	_	O
217	a	_	_	O
218	time-dependent	_	_	O
219	covariate	_	_	O
220	.	_	_	O

221	A	_	_	O
222	total	_	_	O
223	of	_	_	O
224	1,049	_	_	O
225	patients	_	_	O
226	completed	_	_	O
227	at	_	_	O
228	least	_	_	O
229	one	_	_	O
230	QoL	_	_	O
231	assessment	_	_	O
232	.	_	_	O

233	Two	_	_	B-Premise
234	hundred	_	_	I-Premise
235	sixty-one	_	_	I-Premise
236	patients	_	_	I-Premise
237	(	_	_	I-Premise
238	50	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	crossed	_	_	I-Premise
242	over	_	_	I-Premise
243	from	_	_	I-Premise
244	IFN	_	_	I-Premise
245	to	_	_	I-Premise
246	imatinib	_	_	I-Premise
247	and	_	_	I-Premise
248	11	_	_	I-Premise
249	(	_	_	I-Premise
250	2	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	crossed	_	_	I-Premise
254	over	_	_	I-Premise
255	from	_	_	I-Premise
256	imatinib	_	_	I-Premise
257	to	_	_	I-Premise
258	IFN	_	_	I-Premise
259	.	_	_	I-Premise

260	There	_	_	B-Premise
261	was	_	_	I-Premise
262	a	_	_	I-Premise
263	significant	_	_	I-Premise
264	decline	_	_	I-Premise
265	in	_	_	I-Premise
266	TOI	_	_	I-Premise
267	scores	_	_	I-Premise
268	for	_	_	I-Premise
269	the	_	_	I-Premise
270	IFN	_	_	I-Premise
271	treatment	_	_	I-Premise
272	arm	_	_	I-Premise
273	compared	_	_	I-Premise
274	with	_	_	I-Premise
275	preservation	_	_	I-Premise
276	of	_	_	I-Premise
277	baseline	_	_	I-Premise
278	TOI	_	_	I-Premise
279	scores	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	imatinib	_	_	I-Premise
283	arm	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	.001	_	_	I-Premise
288	,	_	_	I-Premise
289	ITT	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	Mean	_	_	B-Premise
293	social/family	_	_	I-Premise
294	and	_	_	I-Premise
295	EWB	_	_	I-Premise
296	scores	_	_	I-Premise
297	were	_	_	I-Premise
298	22.8	_	_	I-Premise
299	and	_	_	I-Premise
300	19.5	_	_	I-Premise
301	,	_	_	I-Premise
302	respectively	_	_	I-Premise
303	,	_	_	I-Premise
304	for	_	_	I-Premise
305	imatinib	_	_	I-Premise
306	and	_	_	I-Premise
307	21.6	_	_	I-Premise
308	and	_	_	I-Premise
309	17.6	_	_	I-Premise
310	,	_	_	I-Premise
311	respectively	_	_	I-Premise
312	,	_	_	I-Premise
313	for	_	_	I-Premise
314	IFN	_	_	I-Premise
315	(	_	_	I-Premise
316	P	_	_	I-Premise
317	<	_	_	I-Premise
318	.001	_	_	I-Premise
319	,	_	_	I-Premise
320	ITT	_	_	I-Premise
321	)	_	_	I-Premise
322	.	_	_	I-Premise

323	After	_	_	B-Premise
324	crossing	_	_	I-Premise
325	over	_	_	I-Premise
326	from	_	_	I-Premise
327	IFN	_	_	I-Premise
328	to	_	_	I-Premise
329	imatinib	_	_	I-Premise
330	,	_	_	I-Premise
331	patients	_	_	I-Premise
332	experienced	_	_	I-Premise
333	a	_	_	I-Premise
334	significant	_	_	I-Premise
335	(	_	_	I-Premise
336	P	_	_	I-Premise
337	<	_	_	I-Premise
338	.001	_	_	I-Premise
339	)	_	_	I-Premise
340	increase	_	_	I-Premise
341	in	_	_	I-Premise
342	TOI	_	_	I-Premise
343	scores	_	_	I-Premise
344	.	_	_	I-Premise

345	Imatinib	_	_	B-Claim
346	offers	_	_	I-Claim
347	clear	_	_	I-Claim
348	QoL	_	_	I-Claim
349	advantages	_	_	I-Claim
350	over	_	_	I-Claim
351	IFN	_	_	I-Claim
352	as	_	_	I-Claim
353	first-line	_	_	I-Claim
354	treatment	_	_	I-Claim
355	of	_	_	I-Claim
356	chronic-phase	_	_	I-Claim
357	CML	_	_	I-Claim
358	.	_	_	I-Claim

359	In	_	_	O
360	addition	_	_	O
361	,	_	_	O
362	patients	_	_	B-Claim
363	who	_	_	I-Claim
364	crossed	_	_	I-Claim
365	over	_	_	I-Claim
366	to	_	_	I-Claim
367	imatinib	_	_	I-Claim
368	reported	_	_	I-Claim
369	higher	_	_	I-Claim
370	QoL	_	_	I-Claim
371	than	_	_	I-Claim
372	those	_	_	I-Claim
373	who	_	_	I-Claim
374	remained	_	_	I-Claim
375	on	_	_	I-Claim
376	IFN	_	_	I-Claim
377	.	_	_	I-Claim


0	The	_	_	O
1	management	_	_	O
2	of	_	_	O
3	recurrent	_	_	O
4	ovarian	_	_	O
5	cancer	_	_	O
6	remains	_	_	O
7	controversial	_	_	O
8	.	_	_	O

9	Single-agent	_	_	O
10	topotecan	_	_	O
11	is	_	_	O
12	an	_	_	O
13	established	_	_	O
14	treatment	_	_	O
15	option	_	_	O
16	,	_	_	O
17	and	_	_	O
18	preliminary	_	_	O
19	evidence	_	_	O
20	suggests	_	_	O
21	improved	_	_	O
22	tumor	_	_	O
23	control	_	_	O
24	by	_	_	O
25	combining	_	_	O
26	topotecan	_	_	O
27	with	_	_	O
28	etoposide	_	_	O
29	or	_	_	O
30	gemcitabine	_	_	O
31	.	_	_	O

32	Women	_	_	O
33	with	_	_	O
34	relapsed	_	_	O
35	ovarian	_	_	O
36	cancer	_	_	O
37	after	_	_	O
38	primary	_	_	O
39	surgery	_	_	O
40	and	_	_	O
41	platinum-based	_	_	O
42	chemotherapy	_	_	O
43	were	_	_	O
44	randomly	_	_	O
45	assigned	_	_	O
46	to	_	_	O
47	topotecan	_	_	O
48	monotherapy	_	_	O
49	1.25	_	_	O
50	mg/m	_	_	O
51	(	_	_	O
52	2	_	_	O
53	)	_	_	O
54	/d	_	_	O
55	,	_	_	O
56	topotecan	_	_	O
57	1.0	_	_	O
58	mg/m	_	_	O
59	(	_	_	O
60	2	_	_	O
61	)	_	_	O
62	plus	_	_	O
63	oral	_	_	O
64	etoposide	_	_	O
65	50	_	_	O
66	mg/d	_	_	O
67	,	_	_	O
68	or	_	_	O
69	topotecan	_	_	O
70	0.5	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	/d	_	_	O
76	plus	_	_	O
77	gemcitabine	_	_	O
78	800	_	_	O
79	mg/m	_	_	O
80	(	_	_	O
81	2	_	_	O
82	)	_	_	O
83	on	_	_	O
84	day	_	_	O
85	1	_	_	O
86	and	_	_	O
87	600	_	_	O
88	mg/m	_	_	O
89	(	_	_	O
90	2	_	_	O
91	)	_	_	O
92	on	_	_	O
93	day	_	_	O
94	8	_	_	O
95	every	_	_	O
96	3	_	_	O
97	weeks	_	_	O
98	.	_	_	O

99	Patients	_	_	O
100	were	_	_	O
101	stratified	_	_	O
102	for	_	_	O
103	platinum-refractory	_	_	O
104	and	_	_	O
105	platinum-sensitive	_	_	O
106	disease	_	_	O
107	according	_	_	O
108	to	_	_	O
109	a	_	_	O
110	recurrence-free	_	_	O
111	interval	_	_	O
112	of	_	_	O
113	less	_	_	O
114	or	_	_	O
115	more	_	_	O
116	than	_	_	O
117	12	_	_	O
118	months	_	_	O
119	,	_	_	O
120	respectively	_	_	O
121	.	_	_	O

122	The	_	_	O
123	primary	_	_	O
124	end	_	_	O
125	point	_	_	O
126	was	_	_	O
127	overall	_	_	O
128	survival	_	_	O
129	.	_	_	O

130	Secondary	_	_	O
131	end	_	_	O
132	points	_	_	O
133	included	_	_	O
134	progression-free	_	_	O
135	survival	_	_	O
136	,	_	_	O
137	objective	_	_	O
138	response	_	_	O
139	rates	_	_	O
140	,	_	_	O
141	toxicity	_	_	O
142	,	_	_	O
143	and	_	_	O
144	quality	_	_	O
145	of	_	_	O
146	life	_	_	O
147	(	_	_	O
148	as	_	_	O
149	measured	_	_	O
150	by	_	_	O
151	the	_	_	O
152	European	_	_	O
153	Organisation	_	_	O
154	for	_	_	O
155	Research	_	_	O
156	and	_	_	O
157	Treatment	_	_	O
158	of	_	_	O
159	Cancer	_	_	O
160	[	_	_	O
161	EORTC	_	_	O
162	]	_	_	O
163	30-item	_	_	O
164	Quality-of-Life	_	_	O
165	Questionnaire	_	_	O
166	)	_	_	O
167	.	_	_	O

168	The	_	_	O
169	trial	_	_	O
170	enrolled	_	_	O
171	502	_	_	O
172	patients	_	_	O
173	with	_	_	O
174	a	_	_	O
175	mean	_	_	O
176	age	_	_	O
177	of	_	_	O
178	60.5	_	_	O
179	years	_	_	O
180	(	_	_	O
181	+/-	_	_	O
182	10.2	_	_	O
183	years	_	_	O
184	)	_	_	O
185	,	_	_	O
186	208	_	_	O
187	of	_	_	O
188	whom	_	_	O
189	were	_	_	O
190	platinum	_	_	O
191	resistant	_	_	O
192	.	_	_	O

193	Median	_	_	B-Premise
194	overall	_	_	I-Premise
195	survival	_	_	I-Premise
196	was	_	_	I-Premise
197	17.2	_	_	I-Premise
198	months	_	_	I-Premise
199	(	_	_	I-Premise
200	95	_	_	I-Premise
201	%	_	_	I-Premise
202	CI	_	_	I-Premise
203	,	_	_	I-Premise
204	13.5	_	_	I-Premise
205	to	_	_	I-Premise
206	21.9	_	_	I-Premise
207	months	_	_	I-Premise
208	)	_	_	I-Premise
209	with	_	_	I-Premise
210	topotecan	_	_	I-Premise
211	,	_	_	I-Premise
212	17.8	_	_	I-Premise
213	months	_	_	I-Premise
214	(	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	,	_	_	I-Premise
219	13.7	_	_	I-Premise
220	to	_	_	I-Premise
221	20.0	_	_	I-Premise
222	months	_	_	I-Premise
223	)	_	_	I-Premise
224	with	_	_	I-Premise
225	topotecan	_	_	I-Premise
226	plus	_	_	I-Premise
227	etoposide	_	_	I-Premise
228	(	_	_	I-Premise
229	log-rank	_	_	I-Premise
230	P	_	_	I-Premise
231	=	_	_	I-Premise
232	.7647	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	and	_	_	I-Premise
236	15.2	_	_	I-Premise
237	months	_	_	I-Premise
238	(	_	_	I-Premise
239	95	_	_	I-Premise
240	%	_	_	I-Premise
241	CI	_	_	I-Premise
242	,	_	_	I-Premise
243	11.3	_	_	I-Premise
244	to	_	_	I-Premise
245	20.9	_	_	I-Premise
246	months	_	_	I-Premise
247	)	_	_	I-Premise
248	with	_	_	I-Premise
249	topotecan	_	_	I-Premise
250	plus	_	_	I-Premise
251	gemcitabine	_	_	I-Premise
252	(	_	_	I-Premise
253	log-rank	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.2344	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Platinum-sensitive	_	_	B-Premise
260	patients	_	_	I-Premise
261	lived	_	_	I-Premise
262	significantly	_	_	I-Premise
263	longer	_	_	I-Premise
264	than	_	_	I-Premise
265	platinum-refractory	_	_	I-Premise
266	patients	_	_	I-Premise
267	(	_	_	I-Premise
268	21.9	_	_	I-Premise
269	v	_	_	I-Premise
270	10.6	_	_	I-Premise
271	months	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	O
275	median	_	_	O
276	progression-free	_	_	O
277	survival	_	_	O
278	was	_	_	O
279	7.0	_	_	O
280	,	_	_	O
281	7.8	_	_	O
282	,	_	_	O
283	and	_	_	O
284	6.3	_	_	O
285	months	_	_	O
286	,	_	_	O
287	respectively	_	_	O
288	.	_	_	O

289	Objective	_	_	O
290	response	_	_	O
291	rates	_	_	O
292	were	_	_	O
293	27.8	_	_	O
294	%	_	_	O
295	,	_	_	O
296	36.1	_	_	O
297	%	_	_	O
298	,	_	_	O
299	and	_	_	O
300	31.6	_	_	O
301	%	_	_	O
302	,	_	_	O
303	respectively	_	_	O
304	.	_	_	O

305	Patients	_	_	B-Premise
306	under	_	_	I-Premise
307	combined	_	_	I-Premise
308	treatment	_	_	I-Premise
309	were	_	_	I-Premise
310	at	_	_	I-Premise
311	higher	_	_	I-Premise
312	risk	_	_	I-Premise
313	of	_	_	I-Premise
314	severe	_	_	I-Premise
315	thrombocytopenia	_	_	I-Premise
316	.	_	_	I-Premise

317	Nonplatinum	_	_	B-Claim
318	topotecan	_	_	I-Claim
319	combinations	_	_	I-Claim
320	do	_	_	I-Claim
321	not	_	_	I-Claim
322	provide	_	_	I-Claim
323	a	_	_	I-Claim
324	survival	_	_	I-Claim
325	advantage	_	_	I-Claim
326	over	_	_	I-Claim
327	topotecan	_	_	I-Claim
328	alone	_	_	I-Claim
329	in	_	_	I-Claim
330	women	_	_	I-Claim
331	with	_	_	I-Claim
332	relapsed	_	_	I-Claim
333	ovarian	_	_	I-Claim
334	cancer	_	_	I-Claim
335	.	_	_	I-Claim


0	Cutaneous	_	_	B-Claim
1	T-cell	_	_	I-Claim
2	lymphoma	_	_	I-Claim
3	(	_	_	I-Claim
4	CTCL	_	_	I-Claim
5	)	_	_	I-Claim
6	can	_	_	I-Claim
7	be	_	_	I-Claim
8	associated	_	_	I-Claim
9	with	_	_	I-Claim
10	painful	_	_	I-Claim
11	,	_	_	I-Claim
12	pruritic	_	_	I-Claim
13	,	_	_	I-Claim
14	disfiguring	_	_	I-Claim
15	lesions	_	_	I-Claim
16	.	_	_	I-Claim

17	As	_	_	O
18	part	_	_	O
19	of	_	_	O
20	a	_	_	O
21	multicenter	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	phase	_	_	O
25	III	_	_	O
26	trial	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	heavily	_	_	O
31	pretreated	_	_	O
32	advanced	_	_	O
33	and/or	_	_	O
34	recurrent	_	_	O
35	CTCL	_	_	O
36	,	_	_	O
37	the	_	_	O
38	effects	_	_	O
39	of	_	_	O
40	an	_	_	O
41	interleukin-2	_	_	O
42	receptor-targeted	_	_	O
43	fusion	_	_	O
44	protein	_	_	O
45	,	_	_	O
46	denileukin	_	_	O
47	diftitox	_	_	O
48	(	_	_	O
49	DAB389IL-2	_	_	O
50	,	_	_	O
51	ONTAK	_	_	O
52	)	_	_	O
53	,	_	_	O
54	on	_	_	O
55	patient-rated	_	_	O
56	overall	_	_	O
57	quality	_	_	O
58	of	_	_	O
59	life	_	_	O
60	(	_	_	O
61	QOL	_	_	O
62	)	_	_	O
63	,	_	_	O
64	skin	_	_	O
65	appearance	_	_	O
66	,	_	_	O
67	and	_	_	O
68	pruritus	_	_	O
69	severity	_	_	O
70	were	_	_	O
71	evaluated	_	_	O
72	.	_	_	O

73	A	_	_	O
74	total	_	_	O
75	of	_	_	O
76	71	_	_	O
77	patients	_	_	O
78	with	_	_	O
79	stage	_	_	O
80	IB-IVA	_	_	O
81	CTCL	_	_	O
82	received	_	_	O
83	intravenous	_	_	O
84	denileukin	_	_	O
85	diftitox	_	_	O
86	9	_	_	O
87	microg/kg/day	_	_	O
88	or	_	_	O
89	18	_	_	O
90	microg/kg/day	_	_	O
91	over	_	_	O
92	15-60	_	_	O
93	minutes	_	_	O
94	for	_	_	O
95	5	_	_	O
96	consecutive	_	_	O
97	days	_	_	O
98	on	_	_	O
99	an	_	_	O
100	outpatient	_	_	O
101	basis	_	_	O
102	;	_	_	O
103	cycles	_	_	O
104	were	_	_	O
105	planned	_	_	O
106	for	_	_	O
107	every	_	_	O
108	21	_	_	O
109	days	_	_	O
110	for	_	_	O
111	a	_	_	O
112	total	_	_	O
113	of	_	_	O
114	8	_	_	O
115	cycles	_	_	O
116	over	_	_	O
117	6	_	_	O
118	months	_	_	O
119	.	_	_	O

120	Prior	_	_	O
121	to	_	_	O
122	each	_	_	O
123	treatment	_	_	O
124	cycle	_	_	O
125	,	_	_	O
126	patients	_	_	O
127	were	_	_	O
128	evaluated	_	_	O
129	for	_	_	O
130	disease	_	_	O
131	response	_	_	O
132	and	_	_	O
133	were	_	_	O
134	asked	_	_	O
135	to	_	_	O
136	self-rate	_	_	O
137	their	_	_	O
138	overall	_	_	O
139	QOL	_	_	O
140	via	_	_	O
141	the	_	_	O
142	Functional	_	_	O
143	Assessment	_	_	O
144	of	_	_	O
145	Cancer	_	_	O
146	Therapy-General	_	_	O
147	(	_	_	O
148	FACT-G	_	_	O
149	)	_	_	O
150	questionnaire	_	_	O
151	,	_	_	O
152	skin	_	_	O
153	appearance	_	_	O
154	(	_	_	O
155	7-point	_	_	O
156	scale	_	_	O
157	)	_	_	O
158	,	_	_	O
159	and	_	_	O
160	pruritus	_	_	O
161	severity	_	_	O
162	(	_	_	O
163	10-cm	_	_	O
164	visual	_	_	O
165	analogue	_	_	O
166	scale	_	_	O
167	)	_	_	O
168	.	_	_	O

169	Composite	_	_	B-Premise
170	FACT-G	_	_	I-Premise
171	and	_	_	I-Premise
172	most	_	_	I-Premise
173	individual	_	_	I-Premise
174	subscale	_	_	I-Premise
175	scores	_	_	I-Premise
176	(	_	_	I-Premise
177	physical	_	_	I-Premise
178	,	_	_	I-Premise
179	social/family	_	_	I-Premise
180	,	_	_	I-Premise
181	emotional	_	_	I-Premise
182	,	_	_	I-Premise
183	and	_	_	I-Premise
184	functional	_	_	I-Premise
185	well	_	_	I-Premise
186	being	_	_	I-Premise
187	)	_	_	I-Premise
188	in	_	_	I-Premise
189	documented	_	_	I-Premise
190	responders	_	_	I-Premise
191	(	_	_	I-Premise
192	n	_	_	I-Premise
193	=	_	_	I-Premise
194	21	_	_	I-Premise
195	)	_	_	I-Premise
196	gradually	_	_	I-Premise
197	increased	_	_	I-Premise
198	during	_	_	I-Premise
199	the	_	_	I-Premise
200	study	_	_	I-Premise
201	period	_	_	I-Premise
202	,	_	_	I-Premise
203	generally	_	_	I-Premise
204	reaching	_	_	I-Premise
205	statistical	_	_	I-Premise
206	significance	_	_	I-Premise
207	(	_	_	I-Premise
208	P	_	_	I-Premise
209	<	_	_	I-Premise
210	0.05	_	_	I-Premise
211	)	_	_	I-Premise
212	by	_	_	I-Premise
213	cycle	_	_	I-Premise
214	3	_	_	I-Premise
215	,	_	_	I-Premise
216	and	_	_	I-Premise
217	were	_	_	I-Premise
218	significantly	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	or	_	_	I-Premise
223	=	_	_	I-Premise
224	0.041	_	_	I-Premise
225	)	_	_	I-Premise
226	higher	_	_	I-Premise
227	than	_	_	I-Premise
228	the	_	_	I-Premise
229	scores	_	_	I-Premise
230	of	_	_	I-Premise
231	nonresponders	_	_	I-Premise
232	at	_	_	I-Premise
233	endpoint	_	_	I-Premise
234	.	_	_	I-Premise

235	Additionally	_	_	B-Premise
236	for	_	_	I-Premise
237	responders	_	_	I-Premise
238	,	_	_	I-Premise
239	assessments	_	_	I-Premise
240	of	_	_	I-Premise
241	skin	_	_	I-Premise
242	severity	_	_	I-Premise
243	and	_	_	I-Premise
244	pruritus	_	_	I-Premise
245	severity	_	_	I-Premise
246	showed	_	_	I-Premise
247	significant	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	or	_	_	I-Premise
252	=	_	_	I-Premise
253	0.05	_	_	I-Premise
254	)	_	_	I-Premise
255	improvements	_	_	I-Premise
256	at	_	_	I-Premise
257	study	_	_	I-Premise
258	endpoint	_	_	I-Premise
259	compared	_	_	I-Premise
260	with	_	_	I-Premise
261	baseline	_	_	I-Premise
262	.	_	_	I-Premise

263	Adverse	_	_	B-Premise
264	transfusion-related	_	_	I-Premise
265	events	_	_	I-Premise
266	(	_	_	I-Premise
267	eg	_	_	I-Premise
268	,	_	_	I-Premise
269	hypersensitivity	_	_	I-Premise
270	reactions	_	_	I-Premise
271	,	_	_	I-Premise
272	flu-like	_	_	I-Premise
273	syndrome	_	_	I-Premise
274	)	_	_	I-Premise
275	were	_	_	I-Premise
276	common	_	_	I-Premise
277	during	_	_	I-Premise
278	cycles	_	_	I-Premise
279	1	_	_	I-Premise
280	and	_	_	I-Premise
281	2	_	_	I-Premise
282	,	_	_	I-Premise
283	and	_	_	I-Premise
284	vascular-leak	_	_	I-Premise
285	syndrome	_	_	I-Premise
286	occurred	_	_	I-Premise
287	in	_	_	I-Premise
288	25	_	_	I-Premise
289	%	_	_	I-Premise
290	of	_	_	I-Premise
291	patients	_	_	I-Premise
292	.	_	_	I-Premise

293	Denileukin	_	_	B-Claim
294	diftitox	_	_	I-Claim
295	was	_	_	I-Claim
296	not	_	_	I-Claim
297	associated	_	_	I-Claim
298	with	_	_	I-Claim
299	any	_	_	I-Claim
300	clinically	_	_	I-Claim
301	significant	_	_	I-Claim
302	myelosuppression	_	_	I-Claim
303	.	_	_	I-Claim

304	Heavily	_	_	B-Claim
305	pretreated	_	_	I-Claim
306	patients	_	_	I-Claim
307	with	_	_	I-Claim
308	advanced	_	_	I-Claim
309	and/or	_	_	I-Claim
310	recurrent	_	_	I-Claim
311	CTCL	_	_	I-Claim
312	who	_	_	I-Claim
313	responded	_	_	I-Claim
314	to	_	_	I-Claim
315	denileukin	_	_	I-Claim
316	diftitox	_	_	I-Claim
317	therapy	_	_	I-Claim
318	showed	_	_	I-Claim
319	significant	_	_	I-Claim
320	improvements	_	_	I-Claim
321	in	_	_	I-Claim
322	self-rated	_	_	I-Claim
323	overall	_	_	I-Claim
324	QOL	_	_	I-Claim
325	,	_	_	I-Claim
326	skin	_	_	I-Claim
327	appearance	_	_	I-Claim
328	,	_	_	I-Claim
329	and	_	_	I-Claim
330	pruritus	_	_	I-Claim
331	severity	_	_	I-Claim
332	.	_	_	I-Claim


0	Recombinant	_	_	B-Claim
1	human	_	_	I-Claim
2	erythropoietin	_	_	I-Claim
3	(	_	_	I-Claim
4	r-HuEPO	_	_	I-Claim
5	)	_	_	I-Claim
6	corrects	_	_	I-Claim
7	cancer-related	_	_	I-Claim
8	anemia	_	_	I-Claim
9	and	_	_	I-Claim
10	,	_	_	I-Claim
11	thereby	_	_	I-Claim
12	,	_	_	I-Claim
13	improves	_	_	I-Claim
14	quality	_	_	I-Claim
15	of	_	_	I-Claim
16	life	_	_	I-Claim
17	.	_	_	I-Claim

18	The	_	_	O
19	purpose	_	_	O
20	of	_	_	O
21	the	_	_	O
22	present	_	_	O
23	study	_	_	O
24	was	_	_	O
25	to	_	_	O
26	measure	_	_	O
27	the	_	_	O
28	impact	_	_	O
29	of	_	_	O
30	erythropoietin	_	_	O
31	on	_	_	O
32	hemoglobin	_	_	O
33	and	_	_	O
34	mood	_	_	O
35	state	_	_	O
36	in	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	metastatic	_	_	O
40	breast	_	_	O
41	cancer	_	_	O
42	and	_	_	O
43	mild	_	_	O
44	anemia	_	_	O
45	(	_	_	O
46	Hgb	_	_	O
47	<	_	_	O
48	12.0	_	_	O
49	g/dL	_	_	O
50	)	_	_	O
51	.	_	_	O

52	Women	_	_	O
53	were	_	_	O
54	randomized	_	_	O
55	to	_	_	O
56	receive	_	_	O
57	usual	_	_	O
58	care	_	_	O
59	(	_	_	O
60	G1	_	_	O
61	)	_	_	O
62	or	_	_	O
63	usual	_	_	O
64	care	_	_	O
65	plus	_	_	O
66	r-HuEPO	_	_	O
67	(	_	_	O
68	G2	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Usual	_	_	O
72	care	_	_	O
73	included	_	_	O
74	transfusions	_	_	O
75	as	_	_	O
76	necessary	_	_	O
77	and	_	_	O
78	fatigue	_	_	O
79	education	_	_	O
80	.	_	_	O

81	R-HuEPO	_	_	O
82	was	_	_	O
83	begun	_	_	O
84	at	_	_	O
85	40,000U	_	_	O
86	subcutaneously	_	_	O
87	per	_	_	O
88	week	_	_	O
89	.	_	_	O

90	At	_	_	O
91	4	_	_	O
92	weeks	_	_	O
93	,	_	_	O
94	the	_	_	O
95	dose	_	_	O
96	was	_	_	O
97	increased	_	_	O
98	to	_	_	O
99	60,000U	_	_	O
100	if	_	_	O
101	Hgb	_	_	O
102	had	_	_	O
103	not	_	_	O
104	increased	_	_	O
105	>	_	_	O
106	or	_	_	O
107	=	_	_	O
108	1.0	_	_	O
109	g/dL	_	_	O
110	.	_	_	O

111	The	_	_	O
112	drug	_	_	O
113	was	_	_	O
114	discontinued	_	_	O
115	at	_	_	O
116	8	_	_	O
117	weeks	_	_	O
118	if	_	_	O
119	hemoglobin	_	_	O
120	improvement	_	_	O
121	was	_	_	O
122	<	_	_	O
123	1.0	_	_	O
124	g/dL	_	_	O
125	.	_	_	O

126	The	_	_	O
127	study	_	_	O
128	was	_	_	O
129	terminated	_	_	O
130	early	_	_	O
131	(	_	_	O
132	n	_	_	O
133	=	_	_	O
134	27	_	_	O
135	,	_	_	O
136	G1	_	_	O
137	=	_	_	O
138	13	_	_	O
139	,	_	_	O
140	G2	_	_	O
141	=	_	_	O
142	14	_	_	O
143	)	_	_	O
144	when	_	_	O
145	4/14	_	_	O
146	(	_	_	O
147	28.5	_	_	O
148	%	_	_	O
149	)	_	_	O
150	subjects	_	_	O
151	in	_	_	O
152	G2	_	_	O
153	developed	_	_	O
154	thrombotic	_	_	O
155	events	_	_	O
156	(	_	_	O
157	deep	_	_	O
158	vein	_	_	O
159	thrombosis	_	_	O
160	[	_	_	O
161	DVT	_	_	O
162	]	_	_	O
163	in	_	_	O
164	1	_	_	O
165	;	_	_	O
166	DVT	_	_	O
167	plus	_	_	O
168	pulmonary	_	_	O
169	embolism	_	_	O
170	[	_	_	O
171	PE	_	_	O
172	]	_	_	O
173	in	_	_	O
174	1	_	_	O
175	;	_	_	O
176	DVT	_	_	O
177	plus	_	_	O
178	PE	_	_	O
179	1	_	_	O
180	month	_	_	O
181	after	_	_	O
182	drug	_	_	O
183	discontinuation	_	_	O
184	in	_	_	O
185	1	_	_	O
186	;	_	_	O
187	and	_	_	O
188	brachial	_	_	O
189	vein	_	_	O
190	thrombosis	_	_	O
191	with	_	_	O
192	infected	_	_	O
193	Mediport	_	_	O
194	in	_	_	O
195	1	_	_	O
196	)	_	_	O
197	.	_	_	O

198	In	_	_	B-Premise
199	all	_	_	I-Premise
200	four	_	_	I-Premise
201	patients	_	_	I-Premise
202	,	_	_	I-Premise
203	Hgb	_	_	I-Premise
204	levels	_	_	I-Premise
205	were	_	_	I-Premise
206	normal	_	_	I-Premise
207	at	_	_	I-Premise
208	the	_	_	I-Premise
209	time	_	_	I-Premise
210	of	_	_	I-Premise
211	the	_	_	I-Premise
212	event	_	_	I-Premise
213	.	_	_	I-Premise

214	No	_	_	B-Premise
215	patient	_	_	I-Premise
216	in	_	_	I-Premise
217	G1	_	_	I-Premise
218	developed	_	_	I-Premise
219	a	_	_	I-Premise
220	thrombotic	_	_	I-Premise
221	event	_	_	I-Premise
222	.	_	_	I-Premise

223	There	_	_	B-Premise
224	were	_	_	I-Premise
225	no	_	_	I-Premise
226	significant	_	_	I-Premise
227	differences	_	_	I-Premise
228	in	_	_	I-Premise
229	demographic	_	_	I-Premise
230	characteristics	_	_	I-Premise
231	or	_	_	I-Premise
232	current	_	_	I-Premise
233	chemotherapy	_	_	I-Premise
234	regimen	_	_	I-Premise
235	in	_	_	I-Premise
236	G1	_	_	I-Premise
237	vs.	_	_	I-Premise
238	G2	_	_	I-Premise
239	.	_	_	I-Premise

240	The	_	_	O
241	decision	_	_	O
242	to	_	_	O
243	terminate	_	_	O
244	the	_	_	O
245	trial	_	_	O
246	was	_	_	O
247	made	_	_	O
248	after	_	_	O
249	considerable	_	_	O
250	deliberation	_	_	O
251	.	_	_	O

252	The	_	_	B-Premise
253	increased	_	_	I-Premise
254	incidence	_	_	I-Premise
255	of	_	_	I-Premise
256	thrombotic	_	_	I-Premise
257	events	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	r-HuEPO	_	_	I-Premise
261	(	_	_	I-Premise
262	G2	_	_	I-Premise
263	)	_	_	I-Premise
264	arm	_	_	I-Premise
265	of	_	_	I-Premise
266	this	_	_	I-Premise
267	study	_	_	I-Premise
268	exceeds	_	_	I-Premise
269	that	_	_	I-Premise
270	in	_	_	I-Premise
271	prior	_	_	I-Premise
272	studies	_	_	I-Premise
273	in	_	_	I-Premise
274	this	_	_	I-Premise
275	population	_	_	I-Premise
276	and	_	_	I-Premise
277	prior	_	_	I-Premise
278	r-HuEPO	_	_	I-Premise
279	trials	_	_	I-Premise
280	.	_	_	I-Premise

281	This	_	_	B-Claim
282	may	_	_	I-Claim
283	relate	_	_	I-Claim
284	to	_	_	I-Claim
285	the	_	_	I-Claim
286	administration	_	_	I-Claim
287	of	_	_	I-Claim
288	r-HuEPO	_	_	I-Claim
289	in	_	_	I-Claim
290	this	_	_	I-Claim
291	high-risk	_	_	I-Claim
292	population	_	_	I-Claim
293	,	_	_	I-Claim
294	but	_	_	B-Claim
295	the	_	_	I-Claim
296	small	_	_	I-Claim
297	sample	_	_	I-Claim
298	size	_	_	I-Claim
299	and	_	_	I-Claim
300	possible	_	_	I-Claim
301	predisposing	_	_	I-Claim
302	risk	_	_	I-Claim
303	factors	_	_	I-Claim
304	preclude	_	_	I-Claim
305	definitive	_	_	I-Claim
306	conclusions	_	_	I-Claim
307	.	_	_	I-Claim


0	Shoulder	_	_	O
1	pain	_	_	O
2	and	_	_	O
3	disability	_	_	O
4	are	_	_	O
5	well	_	_	O
6	recognized	_	_	O
7	complications	_	_	O
8	associated	_	_	O
9	with	_	_	O
10	surgery	_	_	O
11	for	_	_	O
12	head	_	_	O
13	and	_	_	O
14	neck	_	_	O
15	cancer	_	_	O
16	.	_	_	O

17	This	_	_	O
18	study	_	_	O
19	was	_	_	O
20	designed	_	_	O
21	to	_	_	O
22	examine	_	_	O
23	the	_	_	O
24	effects	_	_	O
25	of	_	_	O
26	progressive	_	_	O
27	resistance	_	_	O
28	exercise	_	_	O
29	training	_	_	O
30	(	_	_	O
31	PRET	_	_	O
32	)	_	_	O
33	on	_	_	O
34	upper	_	_	O
35	extremity	_	_	O
36	pain	_	_	O
37	and	_	_	O
38	dysfunction	_	_	O
39	in	_	_	O
40	postsurgical	_	_	O
41	head	_	_	O
42	and	_	_	O
43	neck	_	_	O
44	cancer	_	_	O
45	survivors	_	_	O
46	.	_	_	O

47	Fifty-two	_	_	O
48	head	_	_	O
49	and	_	_	O
50	neck	_	_	O
51	cancer	_	_	O
52	survivors	_	_	O
53	were	_	_	O
54	assigned	_	_	O
55	randomly	_	_	O
56	to	_	_	O
57	PRET	_	_	O
58	(	_	_	O
59	n	_	_	O
60	=	_	_	O
61	27	_	_	O
62	)	_	_	O
63	or	_	_	O
64	a	_	_	O
65	standardized	_	_	O
66	therapeutic	_	_	O
67	exercise	_	_	O
68	protocol	_	_	O
69	(	_	_	O
70	TP	_	_	O
71	)	_	_	O
72	(	_	_	O
73	n	_	_	O
74	=	_	_	O
75	25	_	_	O
76	)	_	_	O
77	for	_	_	O
78	12	_	_	O
79	weeks	_	_	O
80	.	_	_	O

81	The	_	_	O
82	primary	_	_	O
83	endpoint	_	_	O
84	was	_	_	O
85	change	_	_	O
86	in	_	_	O
87	patient-rated	_	_	O
88	shoulder	_	_	O
89	pain	_	_	O
90	and	_	_	O
91	disability	_	_	O
92	from	_	_	O
93	baseline	_	_	O
94	to	_	_	O
95	postintervention	_	_	O
96	.	_	_	O

97	Secondary	_	_	O
98	endpoints	_	_	O
99	were	_	_	O
100	upper	_	_	O
101	extremity	_	_	O
102	strength	_	_	O
103	and	_	_	O
104	endurance	_	_	O
105	,	_	_	O
106	range	_	_	O
107	of	_	_	O
108	motion	_	_	O
109	,	_	_	O
110	fatigue	_	_	O
111	,	_	_	O
112	and	_	_	O
113	quality	_	_	O
114	of	_	_	O
115	life	_	_	O
116	.	_	_	O

117	Follow-up	_	_	O
118	assessment	_	_	O
119	for	_	_	O
120	the	_	_	O
121	primary	_	_	O
122	outcome	_	_	O
123	was	_	_	O
124	92	_	_	O
125	%	_	_	O
126	,	_	_	O
127	and	_	_	O
128	adherence	_	_	O
129	to	_	_	O
130	the	_	_	O
131	supervised	_	_	O
132	PRET	_	_	O
133	and	_	_	O
134	TP	_	_	O
135	programs	_	_	O
136	were	_	_	O
137	95	_	_	O
138	%	_	_	O
139	and	_	_	O
140	87	_	_	O
141	%	_	_	O
142	,	_	_	O
143	respectively	_	_	O
144	.	_	_	O

145	On	_	_	B-Premise
146	the	_	_	I-Premise
147	basis	_	_	I-Premise
148	of	_	_	I-Premise
149	intention-to-treat	_	_	I-Premise
150	analyses	_	_	I-Premise
151	,	_	_	I-Premise
152	PRET	_	_	I-Premise
153	was	_	_	I-Premise
154	superior	_	_	I-Premise
155	to	_	_	I-Premise
156	TP	_	_	I-Premise
157	for	_	_	I-Premise
158	improving	_	_	I-Premise
159	shoulder	_	_	I-Premise
160	pain	_	_	I-Premise
161	and	_	_	I-Premise
162	disability	_	_	I-Premise
163	(	_	_	I-Premise
164	-9.6	_	_	I-Premise
165	;	_	_	I-Premise
166	95	_	_	I-Premise
167	%	_	_	I-Premise
168	confidence	_	_	I-Premise
169	interval	_	_	I-Premise
170	[	_	_	I-Premise
171	95	_	_	I-Premise
172	%	_	_	I-Premise
173	CI	_	_	I-Premise
174	]	_	_	I-Premise
175	,	_	_	I-Premise
176	-16.4	_	_	I-Premise
177	to	_	_	I-Premise
178	-4.5	_	_	I-Premise
179	;	_	_	I-Premise
180	P	_	_	I-Premise
181	=	_	_	I-Premise
182	.001	_	_	I-Premise
183	)	_	_	I-Premise
184	,	_	_	I-Premise
185	upper	_	_	I-Premise
186	extremity	_	_	I-Premise
187	strength	_	_	I-Premise
188	(	_	_	I-Premise
189	+10.8	_	_	I-Premise
190	kg	_	_	I-Premise
191	;	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	,	_	_	I-Premise
196	5.4-16.2	_	_	I-Premise
197	kg	_	_	I-Premise
198	;	_	_	I-Premise
199	P	_	_	I-Premise
200	<	_	_	I-Premise
201	.001	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	and	_	_	I-Premise
205	upper	_	_	I-Premise
206	extremity	_	_	I-Premise
207	endurance	_	_	I-Premise
208	(	_	_	I-Premise
209	+194	_	_	I-Premise
210	repetitions	_	_	I-Premise
211	x	_	_	I-Premise
212	kg	_	_	I-Premise
213	;	_	_	I-Premise
214	95	_	_	I-Premise
215	%	_	_	I-Premise
216	CI	_	_	I-Premise
217	,	_	_	I-Premise
218	10-378	_	_	I-Premise
219	repetitions	_	_	I-Premise
220	x	_	_	I-Premise
221	kg	_	_	I-Premise
222	;	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.039	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Changes	_	_	B-Premise
229	in	_	_	I-Premise
230	neck	_	_	I-Premise
231	dissection	_	_	I-Premise
232	impairment	_	_	I-Premise
233	,	_	_	I-Premise
234	fatigue	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	quality	_	_	I-Premise
238	of	_	_	I-Premise
239	life	_	_	I-Premise
240	favored	_	_	I-Premise
241	the	_	_	I-Premise
242	PRET	_	_	I-Premise
243	group	_	_	I-Premise
244	but	_	_	B-Premise
245	did	_	_	I-Premise
246	not	_	_	I-Premise
247	reach	_	_	I-Premise
248	statistical	_	_	I-Premise
249	significance	_	_	I-Premise
250	.	_	_	I-Premise

251	The	_	_	B-Premise
252	PRET	_	_	I-Premise
253	program	_	_	I-Premise
254	significantly	_	_	I-Premise
255	reduced	_	_	I-Premise
256	shoulder	_	_	I-Premise
257	pain	_	_	I-Premise
258	and	_	_	I-Premise
259	disability	_	_	I-Premise
260	and	_	_	I-Premise
261	improved	_	_	I-Premise
262	upper	_	_	I-Premise
263	extremity	_	_	I-Premise
264	muscular	_	_	I-Premise
265	strength	_	_	I-Premise
266	and	_	_	I-Premise
267	endurance	_	_	I-Premise
268	in	_	_	I-Premise
269	head	_	_	I-Premise
270	and	_	_	I-Premise
271	neck	_	_	I-Premise
272	cancer	_	_	I-Premise
273	survivors	_	_	I-Premise
274	who	_	_	I-Premise
275	had	_	_	I-Premise
276	shoulder	_	_	I-Premise
277	dysfunction	_	_	I-Premise
278	because	_	_	I-Premise
279	of	_	_	I-Premise
280	spinal	_	_	I-Premise
281	accessory	_	_	I-Premise
282	nerve	_	_	I-Premise
283	damage	_	_	I-Premise
284	.	_	_	I-Premise

285	Clinicians	_	_	B-Claim
286	should	_	_	I-Claim
287	consider	_	_	I-Claim
288	the	_	_	I-Claim
289	addition	_	_	I-Claim
290	of	_	_	I-Claim
291	PRET	_	_	I-Claim
292	in	_	_	I-Claim
293	the	_	_	I-Claim
294	rehabilitation	_	_	I-Claim
295	of	_	_	I-Claim
296	postsurgical	_	_	I-Claim
297	head	_	_	I-Claim
298	and	_	_	I-Claim
299	neck	_	_	I-Claim
300	cancer	_	_	I-Claim
301	survivors	_	_	I-Claim
302	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	impact	_	_	O
4	of	_	_	O
5	advanced	_	_	O
6	practice	_	_	O
7	nurse	_	_	O
8	(	_	_	O
9	APN	_	_	O
10	)	_	_	O
11	-administered	_	_	O
12	low-level	_	_	O
13	laser	_	_	O
14	therapy	_	_	O
15	(	_	_	O
16	LLLT	_	_	O
17	)	_	_	O
18	as	_	_	O
19	both	_	_	O
20	a	_	_	O
21	stand-alone	_	_	O
22	and	_	_	O
23	complementary	_	_	O
24	treatment	_	_	O
25	for	_	_	O
26	arm	_	_	O
27	volume	_	_	O
28	,	_	_	O
29	symptoms	_	_	O
30	,	_	_	O
31	and	_	_	O
32	quality	_	_	O
33	of	_	_	O
34	life	_	_	O
35	(	_	_	O
36	QOL	_	_	O
37	)	_	_	O
38	in	_	_	O
39	women	_	_	O
40	with	_	_	O
41	breast	_	_	O
42	cancer-related	_	_	O
43	lymphedema	_	_	O
44	.	_	_	O

45	A	_	_	O
46	three-group	_	_	O
47	,	_	_	O
48	pilot	_	_	O
49	,	_	_	O
50	randomized	_	_	O
51	clinical	_	_	O
52	trial	_	_	O
53	.	_	_	O

54	A	_	_	O
55	private	_	_	O
56	rehabilitation	_	_	O
57	practice	_	_	O
58	in	_	_	O
59	the	_	_	O
60	southeastern	_	_	O
61	United	_	_	O
62	States	_	_	O
63	.	_	_	O

64	46	_	_	O
65	breast	_	_	O
66	cancer	_	_	O
67	survivors	_	_	O
68	with	_	_	O
69	treatment-related	_	_	O
70	lymphedema	_	_	O
71	.	_	_	O

72	Patients	_	_	O
73	were	_	_	O
74	screened	_	_	O
75	for	_	_	O
76	eligibility	_	_	O
77	and	_	_	O
78	then	_	_	O
79	randomized	_	_	O
80	to	_	_	O
81	either	_	_	O
82	manual	_	_	O
83	lymphatic	_	_	O
84	drainage	_	_	O
85	(	_	_	O
86	MLD	_	_	O
87	)	_	_	O
88	for	_	_	O
89	40	_	_	O
90	minutes	_	_	O
91	,	_	_	O
92	LLLT	_	_	O
93	for	_	_	O
94	20	_	_	O
95	minutes	_	_	O
96	,	_	_	O
97	or	_	_	O
98	20	_	_	O
99	minutes	_	_	O
100	of	_	_	O
101	MLD	_	_	O
102	followed	_	_	O
103	by	_	_	O
104	20	_	_	O
105	minutes	_	_	O
106	of	_	_	O
107	LLLT	_	_	O
108	.	_	_	O

109	Compression	_	_	O
110	bandaging	_	_	O
111	was	_	_	O
112	applied	_	_	O
113	after	_	_	O
114	each	_	_	O
115	treatment	_	_	O
116	.	_	_	O

117	Data	_	_	O
118	were	_	_	O
119	collected	_	_	O
120	pretreatment	_	_	O
121	,	_	_	O
122	daily	_	_	O
123	,	_	_	O
124	weekly	_	_	O
125	,	_	_	O
126	and	_	_	O
127	at	_	_	O
128	the	_	_	O
129	end	_	_	O
130	of	_	_	O
131	treatment	_	_	O
132	.	_	_	O

133	Independent	_	_	O
134	variables	_	_	O
135	consisted	_	_	O
136	of	_	_	O
137	three	_	_	O
138	types	_	_	O
139	of	_	_	O
140	APN-administered	_	_	O
141	lymphedema	_	_	O
142	treatment	_	_	O
143	.	_	_	O

144	Outcome	_	_	O
145	variables	_	_	O
146	included	_	_	O
147	limb	_	_	O
148	volume	_	_	O
149	,	_	_	O
150	extracellular	_	_	O
151	fluid	_	_	O
152	,	_	_	O
153	psychological	_	_	O
154	and	_	_	O
155	physical	_	_	O
156	symptoms	_	_	O
157	,	_	_	O
158	and	_	_	O
159	QOL	_	_	O
160	.	_	_	O

161	No	_	_	B-Premise
162	statistically	_	_	I-Premise
163	significant	_	_	I-Premise
164	between-group	_	_	I-Premise
165	differences	_	_	I-Premise
166	were	_	_	I-Premise
167	found	_	_	I-Premise
168	in	_	_	I-Premise
169	volume	_	_	I-Premise
170	reduction	_	_	I-Premise
171	;	_	_	I-Premise
172	however	_	_	B-Premise
173	,	_	_	I-Premise
174	all	_	_	I-Premise
175	groups	_	_	I-Premise
176	had	_	_	I-Premise
177	clinically	_	_	I-Premise
178	and	_	_	I-Premise
179	statistically	_	_	I-Premise
180	significant	_	_	I-Premise
181	reduction	_	_	I-Premise
182	in	_	_	I-Premise
183	volume	_	_	I-Premise
184	.	_	_	I-Premise

185	No	_	_	B-Premise
186	group	_	_	I-Premise
187	differences	_	_	I-Premise
188	were	_	_	I-Premise
189	noted	_	_	I-Premise
190	in	_	_	I-Premise
191	psychological	_	_	I-Premise
192	and	_	_	I-Premise
193	physical	_	_	I-Premise
194	symptoms	_	_	I-Premise
195	or	_	_	I-Premise
196	QOL	_	_	I-Premise
197	;	_	_	I-Premise
198	however	_	_	B-Premise
199	,	_	_	I-Premise
200	treatment-related	_	_	I-Premise
201	improvements	_	_	I-Premise
202	were	_	_	I-Premise
203	noted	_	_	I-Premise
204	in	_	_	I-Premise
205	symptom	_	_	I-Premise
206	burden	_	_	I-Premise
207	within	_	_	I-Premise
208	all	_	_	I-Premise
209	groups	_	_	I-Premise
210	.	_	_	I-Premise

211	Skin	_	_	B-Premise
212	improvement	_	_	I-Premise
213	was	_	_	I-Premise
214	noted	_	_	I-Premise
215	in	_	_	I-Premise
216	each	_	_	I-Premise
217	group	_	_	I-Premise
218	that	_	_	I-Premise
219	received	_	_	I-Premise
220	LLLT	_	_	I-Premise
221	.	_	_	I-Premise

222	LLLT	_	_	B-Claim
223	with	_	_	I-Claim
224	bandaging	_	_	I-Claim
225	may	_	_	I-Claim
226	offer	_	_	I-Claim
227	a	_	_	I-Claim
228	time-saving	_	_	I-Claim
229	therapeutic	_	_	I-Claim
230	option	_	_	I-Claim
231	to	_	_	I-Claim
232	conventional	_	_	I-Claim
233	MLD	_	_	I-Claim
234	.	_	_	I-Claim

235	Alternatively	_	_	O
236	,	_	_	O
237	compression	_	_	B-Claim
238	bandaging	_	_	I-Claim
239	alone	_	_	I-Claim
240	could	_	_	I-Claim
241	account	_	_	I-Claim
242	for	_	_	I-Claim
243	the	_	_	I-Claim
244	demonstrated	_	_	I-Claim
245	volume	_	_	I-Claim
246	reduction	_	_	I-Claim
247	.	_	_	I-Claim

248	APNs	_	_	B-Claim
249	can	_	_	I-Claim
250	effectively	_	_	I-Claim
251	treat	_	_	I-Claim
252	lymphedema	_	_	I-Claim
253	.	_	_	I-Claim

254	APNs	_	_	O
255	in	_	_	O
256	private	_	_	O
257	healthcare	_	_	O
258	practices	_	_	O
259	can	_	_	O
260	serve	_	_	O
261	as	_	_	O
262	valuable	_	_	O
263	research	_	_	O
264	collaborators	_	_	O
265	.	_	_	O

266	Lasers	_	_	B-Claim
267	may	_	_	I-Claim
268	provide	_	_	I-Claim
269	effective	_	_	I-Claim
270	,	_	_	I-Claim
271	less	_	_	I-Claim
272	burdensome	_	_	I-Claim
273	treatment	_	_	I-Claim
274	for	_	_	I-Claim
275	lymphedema	_	_	I-Claim
276	.	_	_	I-Claim

277	APNs	_	_	B-Claim
278	with	_	_	I-Claim
279	lymphedema	_	_	I-Claim
280	certification	_	_	I-Claim
281	can	_	_	I-Claim
282	effectively	_	_	I-Claim
283	treat	_	_	I-Claim
284	this	_	_	I-Claim
285	patient	_	_	I-Claim
286	population	_	_	I-Claim
287	with	_	_	I-Claim
288	the	_	_	I-Claim
289	use	_	_	I-Claim
290	of	_	_	I-Claim
291	LLLT	_	_	I-Claim
292	.	_	_	I-Claim

293	In	_	_	O
294	addition	_	_	O
295	,	_	_	O
296	bioelectrical	_	_	B-Claim
297	impedance	_	_	I-Claim
298	and	_	_	I-Claim
299	tape	_	_	I-Claim
300	measurements	_	_	I-Claim
301	can	_	_	I-Claim
302	be	_	_	I-Claim
303	used	_	_	I-Claim
304	to	_	_	I-Claim
305	assess	_	_	I-Claim
306	lymphedema	_	_	I-Claim
307	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	patients	_	_	O
3	with	_	_	O
4	stage	_	_	O
5	I-III	_	_	O
6	non-small	_	_	O
7	cell	_	_	O
8	lung	_	_	O
9	cancer	_	_	O
10	(	_	_	O
11	NSCLC	_	_	O
12	)	_	_	O
13	who	_	_	O
14	are	_	_	O
15	not	_	_	O
16	suitable	_	_	O
17	for	_	_	O
18	curative	_	_	O
19	radical	_	_	O
20	chemoradiation	_	_	O
21	therapy	_	_	O
22	.	_	_	O

23	There	_	_	O
24	are	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	an	_	_	O
28	isolated	_	_	O
29	solitary	_	_	O
30	extracranial	_	_	O
31	metastasis	_	_	O
32	who	_	_	O
33	have	_	_	O
34	improved	_	_	O
35	outcomes	_	_	O
36	compared	_	_	O
37	with	_	_	O
38	those	_	_	O
39	with	_	_	O
40	cranial	_	_	O
41	or	_	_	O
42	multiple	_	_	O
43	metastases	_	_	O
44	.	_	_	O

45	Patients	_	_	O
46	of	_	_	O
47	good	_	_	O
48	performance	_	_	O
49	status	_	_	O
50	receiving	_	_	O
51	moderate	_	_	O
52	dose	_	_	O
53	radiation	_	_	O
54	therapy	_	_	O
55	have	_	_	O
56	improved	_	_	O
57	survival	_	_	O
58	.	_	_	O

59	Two	_	_	O
60	regimens	_	_	O
61	of	_	_	O
62	moderate	_	_	O
63	dose	_	_	O
64	chemoradiation	_	_	O
65	therapy	_	_	O
66	for	_	_	O
67	such	_	_	O
68	patients	_	_	O
69	were	_	_	O
70	compared	_	_	O
71	in	_	_	O
72	a	_	_	O
73	randomized	_	_	O
74	phase	_	_	O
75	II	_	_	O
76	trial	_	_	O
77	.	_	_	O

78	Patients	_	_	O
79	were	_	_	O
80	eligible	_	_	O
81	if	_	_	O
82	they	_	_	O
83	had	_	_	O
84	stage	_	_	O
85	I-IIIB	_	_	O
86	NSCLC	_	_	O
87	,	_	_	O
88	unsuitable	_	_	O
89	for	_	_	O
90	curative	_	_	O
91	therapy	_	_	O
92	,	_	_	O
93	or	_	_	O
94	stage	_	_	O
95	IV	_	_	O
96	with	_	_	O
97	a	_	_	O
98	PET-detected	_	_	O
99	extracranial	_	_	O
100	solitary	_	_	O
101	metastasis	_	_	O
102	.	_	_	O

103	Patients	_	_	O
104	were	_	_	O
105	randomized	_	_	O
106	to	_	_	O
107	the	_	_	O
108	following	_	_	O
109	groups-arm	_	_	O
110	A	_	_	O
111	:	_	_	O
112	40	_	_	O
113	Gy/20	_	_	O
114	fractions/4	_	_	O
115	weeks	_	_	O
116	with	_	_	O
117	concurrent	_	_	O
118	weekly	_	_	O
119	vinorelbine	_	_	O
120	25	_	_	O
121	mg/m	_	_	O
122	+	_	_	O
123	cisplatin	_	_	O
124	20	_	_	O
125	mg/m	_	_	O
126	or	_	_	O
127	arm	_	_	O
128	B	_	_	O
129	:	_	_	O
130	30	_	_	O
131	Gy/15	_	_	O
132	fractions/3	_	_	O
133	weeks	_	_	O
134	with	_	_	O
135	concurrent	_	_	O
136	weekly	_	_	O
137	gemcitabine	_	_	O
138	200	_	_	O
139	mg.	_	_	O
140	Primary	_	_	O
141	end	_	_	O
142	points	_	_	O
143	were	_	_	O
144	feasibility	_	_	O
145	,	_	_	O
146	response	_	_	O
147	rates	_	_	O
148	,	_	_	O
149	and	_	_	O
150	toxicity	_	_	O
151	.	_	_	O

152	Secondary	_	_	O
153	end	_	_	O
154	points	_	_	O
155	were	_	_	O
156	progression-free	_	_	O
157	survival	_	_	O
158	,	_	_	O
159	overall	_	_	O
160	survival	_	_	O
161	,	_	_	O
162	and	_	_	O
163	quality	_	_	O
164	of	_	_	O
165	life	_	_	O
166	.	_	_	O

167	Eighty-four	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	randomized	_	_	O
171	.	_	_	O

172	Compliance	_	_	O
173	was	_	_	O
174	above	_	_	O
175	90	_	_	O
176	%	_	_	O
177	for	_	_	O
178	both	_	_	O
179	arms	_	_	O
180	.	_	_	O

181	The	_	_	B-Premise
182	overall	_	_	I-Premise
183	response	_	_	I-Premise
184	rate	_	_	I-Premise
185	was	_	_	I-Premise
186	51	_	_	I-Premise
187	%	_	_	I-Premise
188	in	_	_	I-Premise
189	arm	_	_	I-Premise
190	A	_	_	I-Premise
191	and	_	_	I-Premise
192	38	_	_	I-Premise
193	%	_	_	I-Premise
194	in	_	_	I-Premise
195	arm	_	_	I-Premise
196	B	_	_	I-Premise
197	(	_	_	I-Premise
198	p	_	_	I-Premise
199	=	_	_	I-Premise
200	0.147	_	_	I-Premise
201	)	_	_	I-Premise
202	.	_	_	I-Premise

203	Grade	_	_	B-Premise
204	3/4	_	_	I-Premise
205	toxicity	_	_	I-Premise
206	in	_	_	I-Premise
207	both	_	_	I-Premise
208	arms	_	_	I-Premise
209	was	_	_	I-Premise
210	acceptable	_	_	I-Premise
211	.	_	_	I-Premise

212	There	_	_	B-Premise
213	was	_	_	I-Premise
214	no	_	_	I-Premise
215	difference	_	_	I-Premise
216	in	_	_	I-Premise
217	median	_	_	I-Premise
218	progression-free	_	_	I-Premise
219	survival	_	_	I-Premise
220	between	_	_	I-Premise
221	the	_	_	I-Premise
222	two	_	_	I-Premise
223	arms	_	_	I-Premise
224	(	_	_	I-Premise
225	5.5	_	_	I-Premise
226	versus	_	_	I-Premise
227	5.0	_	_	I-Premise
228	months	_	_	I-Premise
229	,	_	_	I-Premise
230	p	_	_	I-Premise
231	=	_	_	I-Premise
232	0.19	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	Patients	_	_	B-Premise
236	in	_	_	I-Premise
237	arm	_	_	I-Premise
238	A	_	_	I-Premise
239	had	_	_	I-Premise
240	longer	_	_	I-Premise
241	median	_	_	I-Premise
242	survival	_	_	I-Premise
243	but	_	_	B-Premise
244	this	_	_	I-Premise
245	did	_	_	I-Premise
246	not	_	_	I-Premise
247	reach	_	_	I-Premise
248	statistical	_	_	I-Premise
249	significance	_	_	I-Premise
250	(	_	_	I-Premise
251	13.1	_	_	I-Premise
252	versus	_	_	I-Premise
253	8.3	_	_	I-Premise
254	months	_	_	I-Premise
255	,	_	_	I-Premise
256	p	_	_	I-Premise
257	=	_	_	I-Premise
258	0.25	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	No	_	_	B-Claim
262	difference	_	_	I-Claim
263	in	_	_	I-Claim
264	quality	_	_	I-Claim
265	of	_	_	I-Claim
266	life	_	_	I-Claim
267	was	_	_	I-Claim
268	observed	_	_	I-Claim
269	.	_	_	I-Claim

270	Arm	_	_	O
271	A	_	_	O
272	was	_	_	O
273	chosen	_	_	O
274	for	_	_	O
275	a	_	_	O
276	future	_	_	O
277	phase	_	_	O
278	II	_	_	O
279	comparison	_	_	O
280	with	_	_	O
281	radiation	_	_	B-Claim
282	therapy	_	_	I-Claim
283	alone	_	_	I-Claim
284	as	_	_	I-Claim
285	it	_	_	I-Claim
286	demonstrated	_	_	I-Claim
287	a	_	_	I-Claim
288	response	_	_	I-Claim
289	rate	_	_	I-Claim
290	greater	_	_	I-Claim
291	than	_	_	I-Claim
292	50	_	_	I-Claim
293	%	_	_	I-Claim
294	,	_	_	I-Claim
295	and	_	_	I-Claim
296	data	_	_	I-Claim
297	suggested	_	_	I-Claim
298	that	_	_	I-Claim
299	arm	_	_	I-Claim
300	A	_	_	I-Claim
301	had	_	_	I-Claim
302	superior	_	_	I-Claim
303	survival	_	_	I-Claim
304	to	_	_	I-Claim
305	arm	_	_	I-Claim
306	B	_	_	I-Claim
307	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	whether	_	_	O
3	3-month	_	_	O
4	administration	_	_	O
5	of	_	_	O
6	CDB-2914	_	_	O
7	,	_	_	O
8	a	_	_	O
9	selective	_	_	O
10	progesterone	_	_	O
11	receptor	_	_	O
12	modulator	_	_	O
13	,	_	_	O
14	reduces	_	_	O
15	leiomyoma	_	_	O
16	size	_	_	O
17	and	_	_	O
18	symptoms	_	_	O
19	.	_	_	O

20	Premenopausal	_	_	O
21	women	_	_	O
22	with	_	_	O
23	symptomatic	_	_	O
24	uterine	_	_	O
25	leiomyomata	_	_	O
26	were	_	_	O
27	randomly	_	_	O
28	assigned	_	_	O
29	to	_	_	O
30	CDB-2914	_	_	O
31	at	_	_	O
32	10	_	_	O
33	mg	_	_	O
34	(	_	_	O
35	T1	_	_	O
36	)	_	_	O
37	or	_	_	O
38	20	_	_	O
39	mg	_	_	O
40	(	_	_	O
41	T2	_	_	O
42	)	_	_	O
43	daily	_	_	O
44	or	_	_	O
45	to	_	_	O
46	placebo	_	_	O
47	(	_	_	O
48	PLC	_	_	O
49	)	_	_	O
50	for	_	_	O
51	3	_	_	O
52	cycles	_	_	O
53	or	_	_	O
54	90-102	_	_	O
55	days	_	_	O
56	if	_	_	O
57	no	_	_	O
58	menses	_	_	O
59	occurred	_	_	O
60	.	_	_	O

61	The	_	_	O
62	primary	_	_	O
63	outcome	_	_	O
64	was	_	_	O
65	leiomyoma	_	_	O
66	volume	_	_	O
67	change	_	_	O
68	determined	_	_	O
69	by	_	_	O
70	magnetic	_	_	O
71	resonance	_	_	O
72	imaging	_	_	O
73	at	_	_	O
74	study	_	_	O
75	entry	_	_	O
76	and	_	_	O
77	within	_	_	O
78	2	_	_	O
79	weeks	_	_	O
80	of	_	_	O
81	hysterectomy	_	_	O
82	.	_	_	O

83	Secondary	_	_	O
84	outcomes	_	_	O
85	included	_	_	O
86	the	_	_	O
87	proportion	_	_	O
88	of	_	_	O
89	amenorrhea	_	_	O
90	,	_	_	O
91	change	_	_	O
92	in	_	_	O
93	hemoglobin	_	_	O
94	and	_	_	O
95	hematocrit	_	_	O
96	,	_	_	O
97	ovulation	_	_	O
98	inhibition	_	_	O
99	,	_	_	O
100	and	_	_	O
101	quality-of-life	_	_	O
102	assessment	_	_	O
103	.	_	_	O

104	Twenty-two	_	_	O
105	patients	_	_	O
106	were	_	_	O
107	allocated	_	_	O
108	,	_	_	O
109	and	_	_	O
110	18	_	_	O
111	completed	_	_	O
112	the	_	_	O
113	trial	_	_	O
114	.	_	_	O

115	Age	_	_	O
116	and	_	_	O
117	body	_	_	O
118	mass	_	_	O
119	index	_	_	O
120	were	_	_	O
121	similar	_	_	O
122	among	_	_	O
123	groups	_	_	O
124	.	_	_	O

125	Leiomyoma	_	_	O
126	volume	_	_	O
127	was	_	_	O
128	significantly	_	_	O
129	reduced	_	_	O
130	with	_	_	O
131	CDB-2914	_	_	O
132	administration	_	_	O
133	(	_	_	O
134	PLC	_	_	O
135	6	_	_	O
136	%	_	_	O
137	;	_	_	O
138	CDB-2914	_	_	O
139	-29	_	_	O
140	%	_	_	O
141	;	_	_	O
142	P=.01	_	_	O
143	)	_	_	O
144	,	_	_	O
145	decreasing	_	_	O
146	36	_	_	O
147	%	_	_	O
148	and	_	_	O
149	21	_	_	O
150	%	_	_	O
151	in	_	_	O
152	the	_	_	O
153	T1	_	_	O
154	and	_	_	O
155	T2	_	_	O
156	groups	_	_	O
157	,	_	_	O
158	respectively	_	_	O
159	.	_	_	O

160	During	_	_	O
161	treatment	_	_	O
162	,	_	_	O
163	hemoglobin	_	_	O
164	was	_	_	O
165	unchanged	_	_	O
166	,	_	_	O
167	and	_	_	O
168	the	_	_	O
169	median	_	_	O
170	estradiol	_	_	O
171	was	_	_	O
172	greater	_	_	O
173	than	_	_	O
174	50	_	_	O
175	pg/mL	_	_	O
176	in	_	_	O
177	all	_	_	O
178	groups	_	_	O
179	.	_	_	O

180	CDB-2914	_	_	O
181	eliminated	_	_	O
182	menstrual	_	_	O
183	bleeding	_	_	O
184	and	_	_	O
185	inhibited	_	_	O
186	ovulation	_	_	O
187	(	_	_	O
188	%	_	_	O
189	ovulatory	_	_	O
190	cycles	_	_	O
191	:	_	_	O
192	CDB-2914	_	_	O
193	,	_	_	O
194	20	_	_	O
195	%	_	_	O
196	;	_	_	O
197	PLC	_	_	O
198	,	_	_	O
199	83	_	_	O
200	%	_	_	O
201	;	_	_	O
202	P=.001	_	_	O
203	)	_	_	O
204	.	_	_	O

205	CDB-2914	_	_	O
206	improved	_	_	O
207	the	_	_	O
208	concern	_	_	O
209	scores	_	_	O
210	of	_	_	O
211	the	_	_	O
212	uterine	_	_	O
213	leiomyoma	_	_	O
214	symptom	_	_	O
215	quality-of-life	_	_	O
216	subscale	_	_	O
217	(	_	_	O
218	P=.04	_	_	O
219	)	_	_	O
220	.	_	_	O

221	One	_	_	O
222	CDB-2914	_	_	O
223	woman	_	_	O
224	developed	_	_	O
225	endometrial	_	_	O
226	cystic	_	_	O
227	hyperplasia	_	_	O
228	without	_	_	O
229	evidence	_	_	O
230	of	_	_	O
231	atypia	_	_	O
232	.	_	_	O

233	No	_	_	B-Premise
234	serious	_	_	I-Premise
235	adverse	_	_	I-Premise
236	events	_	_	I-Premise
237	were	_	_	I-Premise
238	reported	_	_	I-Premise
239	.	_	_	I-Premise

240	Compared	_	_	B-Premise
241	with	_	_	I-Premise
242	PLC	_	_	I-Premise
243	,	_	_	I-Premise
244	CDB-2914	_	_	I-Premise
245	significantly	_	_	I-Premise
246	reduced	_	_	I-Premise
247	leiomyoma	_	_	I-Premise
248	volume	_	_	I-Premise
249	after	_	_	I-Premise
250	three	_	_	I-Premise
251	cycles	_	_	I-Premise
252	,	_	_	I-Premise
253	or	_	_	I-Premise
254	90-102	_	_	I-Premise
255	days	_	_	I-Premise
256	.	_	_	I-Premise

257	CDB-2914	_	_	B-Premise
258	treatment	_	_	I-Premise
259	resulted	_	_	I-Premise
260	in	_	_	I-Premise
261	improvements	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	concern	_	_	I-Premise
265	subscale	_	_	I-Premise
266	of	_	_	I-Premise
267	the	_	_	I-Premise
268	Uterine	_	_	I-Premise
269	Fibroid	_	_	I-Premise
270	Symptom	_	_	I-Premise
271	Quality	_	_	I-Premise
272	of	_	_	I-Premise
273	Life	_	_	I-Premise
274	assessment	_	_	I-Premise
275	.	_	_	I-Premise

276	In	_	_	B-Claim
277	this	_	_	I-Claim
278	small	_	_	I-Claim
279	study	_	_	I-Claim
280	,	_	_	I-Claim
281	CDB-2914	_	_	I-Claim
282	was	_	_	I-Claim
283	well-tolerated	_	_	I-Claim
284	without	_	_	I-Claim
285	serious	_	_	I-Claim
286	adverse	_	_	I-Claim
287	events	_	_	I-Claim
288	.	_	_	I-Claim

289	Thus	_	_	B-Claim
290	,	_	_	I-Claim
291	there	_	_	I-Claim
292	may	_	_	I-Claim
293	be	_	_	I-Claim
294	a	_	_	I-Claim
295	role	_	_	I-Claim
296	for	_	_	I-Claim
297	CDB-2914	_	_	I-Claim
298	in	_	_	I-Claim
299	the	_	_	I-Claim
300	treatment	_	_	I-Claim
301	of	_	_	I-Claim
302	leiomyomata	_	_	I-Claim
303	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	effectiveness	_	_	O
5	of	_	_	O
6	a	_	_	O
7	topical	_	_	O
8	application	_	_	O
9	of	_	_	O
10	Xiaozheng	_	_	O
11	Zhitong	_	_	O
12	:	_	_	O
13	Paste	_	_	O
14	(	_	_	O
15	,	_	_	O
16	XZP	_	_	O
17	)	_	_	O
18	in	_	_	O
19	alleviating	_	_	O
20	the	_	_	O
21	cancerous	_	_	O
22	pain	_	_	O
23	of	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	middle/late	_	_	O
27	stage	_	_	O
28	cancer	_	_	O
29	By	_	_	O
30	:	_	_	O
31	adopting	_	_	O
32	a	_	_	O
33	random	_	_	O
34	number	_	_	O
35	table	_	_	O
36	,	_	_	O
37	124	_	_	O
38	patients	_	_	O
39	enrolled	_	_	O
40	were	_	_	O
41	randomized	_	_	O
42	into	_	_	O
43	the	_	_	O
44	treatment	_	_	O
45	group	_	_	O
46	(	_	_	O
47	64	_	_	O
48	patients	_	_	O
49	)	_	_	O
50	and	_	_	O
51	the	_	_	O
52	control	_	_	O
53	group	_	_	O
54	(	_	_	O
55	60	_	_	O
56	patients	_	_	O
57	)	_	_	O
58	.	_	_	O

59	In	_	_	O
60	addition	_	_	O
61	to	_	_	O
62	the	_	_	O
63	basic	_	_	O
64	therapy	_	_	O
65	[	_	_	O
66	including	_	_	O
67	the	_	_	O
68	three-ladder	_	_	O
69	(	_	_	O
70	3L	_	_	O
71	)	_	_	O
72	analgesia	_	_	O
73	]	_	_	O
74	used	_	_	O
75	in	_	_	O
76	both	_	_	O
77	groups	_	_	O
78	,	_	_	O
79	topical	_	_	O
80	application	_	_	O
81	of	_	_	O
82	XZP	_	_	O
83	was	_	_	O
84	given	_	_	O
85	to	_	_	O
86	patients	_	_	O
87	in	_	_	O
88	the	_	_	O
89	treatment	_	_	O
90	group	_	_	O
91	for	_	_	O
92	pain	_	_	O
93	alleviation	_	_	O
94	.	_	_	O

95	The	_	_	O
96	analgesic	_	_	O
97	efficacy	_	_	O
98	was	_	_	O
99	recorded	_	_	O
100	in	_	_	O
101	terms	_	_	O
102	of	_	_	O
103	pain	_	_	O
104	intensity	_	_	O
105	,	_	_	O
106	analgesia	_	_	O
107	initiating	_	_	O
108	time	_	_	O
109	and	_	_	O
110	sustaining	_	_	O
111	time	_	_	O
112	,	_	_	O
113	and	_	_	O
114	the	_	_	O
115	optimal	_	_	O
116	analgesic	_	_	O
117	effect	_	_	O
118	revealing	_	_	O
119	time	_	_	O
120	.	_	_	O

121	Meanwhile	_	_	O
122	,	_	_	O
123	the	_	_	O
124	quality	_	_	O
125	of	_	_	O
126	life	_	_	O
127	(	_	_	O
128	QOL	_	_	O
129	)	_	_	O
130	and	_	_	O
131	adverse	_	_	O
132	reactions	_	_	O
133	that	_	_	O
134	occurred	_	_	O
135	in	_	_	O
136	patients	_	_	O
137	were	_	_	O
138	recorded	_	_	O
139	as	_	_	O
140	well	_	_	O
141	.	_	_	O

142	The	_	_	B-Premise
143	total	_	_	I-Premise
144	effective	_	_	I-Premise
145	rate	_	_	I-Premise
146	in	_	_	I-Premise
147	the	_	_	I-Premise
148	treatment	_	_	I-Premise
149	group	_	_	I-Premise
150	was	_	_	I-Premise
151	:	_	_	I-Premise
152	84.38	_	_	I-Premise
153	%	_	_	I-Premise
154	(	_	_	I-Premise
155	54/64	_	_	I-Premise
156	)	_	_	I-Premise
157	,	_	_	I-Premise
158	and	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	control	_	_	I-Premise
162	group	_	_	I-Premise
163	it	_	_	I-Premise
164	was	_	_	I-Premise
165	88.33	_	_	I-Premise
166	%	_	_	I-Premise
167	(	_	_	I-Premise
168	53/60	_	_	I-Premise
169	)	_	_	I-Premise
170	,	_	_	I-Premise
171	showing	_	_	I-Premise
172	no	_	_	I-Premise
173	significant	_	_	I-Premise
174	difference	_	_	I-Premise
175	between	_	_	I-Premise
176	them	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	>	_	_	I-Premise
180	0.05	_	_	I-Premise
181	)	_	_	I-Premise
182	,	_	_	I-Premise
183	but	_	_	B-Premise
184	the	_	_	I-Premise
185	analgesia	_	_	I-Premise
186	initiating	_	_	I-Premise
187	time	_	_	I-Premise
188	and	_	_	I-Premise
189	the	_	_	I-Premise
190	optimal	_	_	I-Premise
191	analgesia	_	_	I-Premise
192	effect	_	_	I-Premise
193	revealing	_	_	I-Premise
194	time	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	treatment	_	_	I-Premise
198	group	_	_	I-Premise
199	were	_	_	I-Premise
200	significantly	_	_	I-Premise
201	shorter	_	_	I-Premise
202	(	_	_	I-Premise
203	both	_	_	I-Premise
204	P	_	_	I-Premise
205	<	_	_	I-Premise
206	0.01	_	_	I-Premise
207	)	_	_	I-Premise
208	.	_	_	I-Premise

209	Moreover	_	_	O
210	,	_	_	O
211	XZP	_	_	B-Premise
212	was	_	_	I-Premise
213	better	_	_	I-Premise
214	in	_	_	I-Premise
215	improving	_	_	I-Premise
216	patients	_	_	I-Premise
217	'	_	_	I-Premise
218	QOL	_	_	I-Premise
219	,	_	_	I-Premise
220	showing	_	_	I-Premise
221	more	_	_	I-Premise
222	significant	_	_	I-Premise
223	improvements	_	_	I-Premise
224	in	_	_	I-Premise
225	the	_	_	I-Premise
226	treatment	_	_	I-Premise
227	group	_	_	I-Premise
228	than	_	_	I-Premise
229	those	_	_	I-Premise
230	in	_	_	I-Premise
231	the	_	_	I-Premise
232	control	_	_	I-Premise
233	group	_	_	I-Premise
234	in	_	_	I-Premise
235	aspects	_	_	I-Premise
236	of	_	_	I-Premise
237	mental	_	_	I-Premise
238	condition	_	_	I-Premise
239	,	_	_	I-Premise
240	walking	_	_	I-Premise
241	capacity	_	_	I-Premise
242	,	_	_	I-Premise
243	working	_	_	I-Premise
244	capacity	_	_	I-Premise
245	,	_	_	I-Premise
246	social	_	_	I-Premise
247	acceptability	_	_	I-Premise
248	,	_	_	I-Premise
249	sleep	_	_	I-Premise
250	and	_	_	I-Premise
251	joy	_	_	I-Premise
252	of	_	_	I-Premise
253	living	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	<	_	_	I-Premise
257	0.05	_	_	I-Premise
258	or	_	_	I-Premise
259	P	_	_	I-Premise
260	<	_	_	I-Premise
261	0.01	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Lower	_	_	B-Premise
265	incidence	_	_	I-Premise
266	of	_	_	I-Premise
267	adverse	_	_	I-Premise
268	reactions	_	_	I-Premise
269	,	_	_	I-Premise
270	such	_	_	I-Premise
271	as	_	_	I-Premise
272	nausea	_	_	I-Premise
273	,	_	_	I-Premise
274	vomiting	_	_	I-Premise
275	,	_	_	I-Premise
276	mouth	_	_	I-Premise
277	dryness	_	_	I-Premise
278	,	_	_	I-Premise
279	dizziness	_	_	I-Premise
280	,	_	_	I-Premise
281	etc.	_	_	I-Premise
282	,	_	_	I-Premise
283	especially	_	_	I-Premise
284	constipation	_	_	I-Premise
285	,	_	_	I-Premise
286	was	_	_	I-Premise
287	noted	_	_	I-Premise
288	in	_	_	I-Premise
289	the	_	_	I-Premise
290	treatment	_	_	I-Premise
291	group	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	<	_	_	I-Premise
295	0.05	_	_	I-Premise
296	or	_	_	I-Premise
297	P	_	_	I-Premise
298	<	_	_	I-Premise
299	0.01	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	Applying	_	_	B-Claim
303	an	_	_	I-Claim
304	external	_	_	I-Claim
305	compress	_	_	I-Claim
306	:	_	_	I-Claim
307	of	_	_	I-Claim
308	XZP	_	_	I-Claim
309	showed	_	_	I-Claim
310	a	_	_	I-Claim
311	synergistic	_	_	I-Claim
312	action	_	_	I-Claim
313	with	_	_	I-Claim
314	3L	_	_	I-Claim
315	analgesia	_	_	I-Claim
316	for	_	_	I-Claim
317	shortening	_	_	I-Claim
318	the	_	_	I-Claim
319	initiating	_	_	I-Claim
320	time	_	_	I-Claim
321	and	_	_	I-Claim
322	the	_	_	I-Claim
323	optimal	_	_	I-Claim
324	effect	_	_	I-Claim
325	revealing	_	_	I-Claim
326	time	_	_	I-Claim
327	,	_	_	I-Claim
328	and	_	_	I-Claim
329	could	_	_	I-Claim
330	evidently	_	_	I-Claim
331	enhance	_	_	I-Claim
332	patients	_	_	I-Claim
333	'	_	_	I-Claim
334	QOL	_	_	I-Claim
335	with	_	_	I-Claim
336	fewer	_	_	I-Claim
337	adverse	_	_	I-Claim
338	reactions	_	_	I-Claim
339	.	_	_	I-Claim


0	Metal	_	_	O
1	stent	_	_	O
2	placement	_	_	O
3	and	_	_	O
4	single	_	_	O
5	dose	_	_	O
6	brachytherapy	_	_	O
7	are	_	_	O
8	commonly	_	_	O
9	used	_	_	O
10	treatment	_	_	O
11	modalities	_	_	O
12	for	_	_	O
13	the	_	_	O
14	palliation	_	_	O
15	of	_	_	O
16	inoperable	_	_	O
17	oesophageal	_	_	O
18	carcinoma	_	_	O
19	.	_	_	O

20	We	_	_	O
21	investigated	_	_	O
22	generic	_	_	O
23	and	_	_	O
24	disease-specific	_	_	O
25	health-related	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	(	_	_	O
30	HRQoL	_	_	O
31	)	_	_	O
32	after	_	_	O
33	these	_	_	O
34	palliative	_	_	O
35	treatments	_	_	O
36	.	_	_	O

37	Patients	_	_	O
38	with	_	_	O
39	dysphagia	_	_	O
40	from	_	_	O
41	inoperable	_	_	O
42	oesophageal	_	_	O
43	carcinoma	_	_	O
44	were	_	_	O
45	randomised	_	_	O
46	to	_	_	O
47	placement	_	_	O
48	of	_	_	O
49	a	_	_	O
50	covered	_	_	O
51	Ultraflex	_	_	O
52	stent	_	_	O
53	(	_	_	O
54	n	_	_	O
55	=	_	_	O
56	108	_	_	O
57	)	_	_	O
58	or	_	_	O
59	single	_	_	O
60	dose	_	_	O
61	(	_	_	O
62	12	_	_	O
63	Gy	_	_	O
64	)	_	_	O
65	brachytherapy	_	_	O
66	(	_	_	O
67	n	_	_	O
68	=	_	_	O
69	101	_	_	O
70	)	_	_	O
71	.	_	_	O

72	We	_	_	O
73	obtained	_	_	O
74	longitudinal	_	_	O
75	data	_	_	O
76	on	_	_	O
77	disease-specific	_	_	O
78	(	_	_	O
79	dysphagia	_	_	O
80	score	_	_	O
81	,	_	_	O
82	European	_	_	O
83	Organisation	_	_	O
84	for	_	_	O
85	Research	_	_	O
86	and	_	_	O
87	Treatment	_	_	O
88	of	_	_	O
89	Cancer	_	_	O
90	(	_	_	O
91	EORTC	_	_	O
92	)	_	_	O
93	OES-23	_	_	O
94	,	_	_	O
95	visual	_	_	O
96	analogue	_	_	O
97	pain	_	_	O
98	scale	_	_	O
99	)	_	_	O
100	and	_	_	O
101	generic	_	_	O
102	(	_	_	O
103	EORTC	_	_	O
104	Quality	_	_	O
105	of	_	_	O
106	Life-Core	_	_	O
107	30	_	_	O
108	Questionnaire	_	_	O
109	(	_	_	O
110	QLQ-C30	_	_	O
111	)	_	_	O
112	,	_	_	O
113	Euroqol	_	_	O
114	(	_	_	O
115	EQ	_	_	O
116	)	_	_	O
117	-5D	_	_	O
118	)	_	_	O
119	HRQoL	_	_	O
120	at	_	_	O
121	monthly	_	_	O
122	home	_	_	O
123	visits	_	_	O
124	by	_	_	O
125	a	_	_	O
126	specially-trained	_	_	O
127	research	_	_	O
128	nurse	_	_	O
129	.	_	_	O

130	We	_	_	O
131	compared	_	_	O
132	HRQoL	_	_	O
133	between	_	_	O
134	the	_	_	O
135	two	_	_	O
136	treatments	_	_	O
137	and	_	_	O
138	analysed	_	_	O
139	changes	_	_	O
140	in	_	_	O
141	HRQoL	_	_	O
142	during	_	_	O
143	follow-up	_	_	O
144	.	_	_	O

145	Dysphagia	_	_	B-Premise
146	improved	_	_	I-Premise
147	more	_	_	I-Premise
148	rapidly	_	_	I-Premise
149	after	_	_	I-Premise
150	stent	_	_	I-Premise
151	placement	_	_	I-Premise
152	than	_	_	I-Premise
153	after	_	_	I-Premise
154	brachytherapy	_	_	I-Premise
155	,	_	_	I-Premise
156	but	_	_	B-Premise
157	long-term	_	_	I-Premise
158	relief	_	_	I-Premise
159	of	_	_	I-Premise
160	dysphagia	_	_	I-Premise
161	was	_	_	I-Premise
162	better	_	_	I-Premise
163	after	_	_	I-Premise
164	brachytherapy	_	_	I-Premise
165	.	_	_	I-Premise

166	For	_	_	B-Premise
167	generic	_	_	I-Premise
168	HRQoL	_	_	I-Premise
169	,	_	_	I-Premise
170	there	_	_	I-Premise
171	was	_	_	I-Premise
172	an	_	_	I-Premise
173	overall	_	_	I-Premise
174	significant	_	_	I-Premise
175	difference	_	_	I-Premise
176	in	_	_	I-Premise
177	favour	_	_	I-Premise
178	of	_	_	I-Premise
179	brachytherapy	_	_	I-Premise
180	on	_	_	I-Premise
181	four	_	_	I-Premise
182	out	_	_	I-Premise
183	of	_	_	I-Premise
184	five	_	_	I-Premise
185	functional	_	_	I-Premise
186	scales	_	_	I-Premise
187	of	_	_	I-Premise
188	the	_	_	I-Premise
189	EORTC	_	_	I-Premise
190	QLQ-C30	_	_	I-Premise
191	(	_	_	I-Premise
192	role	_	_	I-Premise
193	,	_	_	I-Premise
194	emotional	_	_	I-Premise
195	,	_	_	I-Premise
196	cognitive	_	_	I-Premise
197	and	_	_	I-Premise
198	social	_	_	I-Premise
199	)	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	<	_	_	I-Premise
203	0.05	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Generic	_	_	B-Premise
207	HRQoL	_	_	I-Premise
208	deteriorated	_	_	I-Premise
209	over	_	_	I-Premise
210	time	_	_	I-Premise
211	on	_	_	I-Premise
212	all	_	_	I-Premise
213	functional	_	_	I-Premise
214	scales	_	_	I-Premise
215	of	_	_	I-Premise
216	the	_	_	I-Premise
217	EORTC	_	_	I-Premise
218	QLQ	_	_	I-Premise
219	C-30	_	_	I-Premise
220	and	_	_	I-Premise
221	EQ-5D	_	_	I-Premise
222	,	_	_	I-Premise
223	in	_	_	I-Premise
224	particular	_	_	I-Premise
225	physical	_	_	I-Premise
226	and	_	_	I-Premise
227	role	_	_	I-Premise
228	functioning	_	_	I-Premise
229	(	_	_	I-Premise
230	on	_	_	I-Premise
231	average	_	_	I-Premise
232	-23	_	_	I-Premise
233	and	_	_	I-Premise
234	-24	_	_	I-Premise
235	on	_	_	I-Premise
236	a	_	_	I-Premise
237	100	_	_	I-Premise
238	points	_	_	I-Premise
239	scale	_	_	I-Premise
240	during	_	_	I-Premise
241	0.5	_	_	I-Premise
242	years	_	_	I-Premise
243	of	_	_	I-Premise
244	follow-up	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	This	_	_	B-Premise
248	decline	_	_	I-Premise
249	was	_	_	I-Premise
250	more	_	_	I-Premise
251	pronounced	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	stent	_	_	I-Premise
255	group	_	_	I-Premise
256	.	_	_	I-Premise

257	Major	_	_	B-Premise
258	improvements	_	_	I-Premise
259	were	_	_	I-Premise
260	seen	_	_	I-Premise
261	on	_	_	I-Premise
262	the	_	_	I-Premise
263	dysphagia	_	_	I-Premise
264	and	_	_	I-Premise
265	eating	_	_	I-Premise
266	scales	_	_	I-Premise
267	of	_	_	I-Premise
268	the	_	_	I-Premise
269	EORTC	_	_	I-Premise
270	OES-23	_	_	I-Premise
271	,	_	_	I-Premise
272	in	_	_	I-Premise
273	contrast	_	_	I-Premise
274	to	_	_	I-Premise
275	other	_	_	I-Premise
276	scales	_	_	I-Premise
277	of	_	_	I-Premise
278	this	_	_	I-Premise
279	disease-specific	_	_	I-Premise
280	measure	_	_	I-Premise
281	,	_	_	I-Premise
282	which	_	_	I-Premise
283	remained	_	_	I-Premise
284	almost	_	_	I-Premise
285	stable	_	_	I-Premise
286	during	_	_	I-Premise
287	follow-up	_	_	I-Premise
288	.	_	_	I-Premise

289	Reported	_	_	B-Premise
290	levels	_	_	I-Premise
291	of	_	_	I-Premise
292	chest	_	_	I-Premise
293	or	_	_	I-Premise
294	abdominal	_	_	I-Premise
295	pain	_	_	I-Premise
296	remained	_	_	I-Premise
297	stable	_	_	I-Premise
298	during	_	_	I-Premise
299	follow-up	_	_	I-Premise
300	in	_	_	I-Premise
301	both	_	_	I-Premise
302	treatment	_	_	I-Premise
303	groups	_	_	I-Premise
304	,	_	_	I-Premise
305	general	_	_	B-Premise
306	pain	_	_	I-Premise
307	levels	_	_	I-Premise
308	increased	_	_	I-Premise
309	to	_	_	I-Premise
310	a	_	_	I-Premise
311	minor	_	_	I-Premise
312	extent	_	_	I-Premise
313	.	_	_	I-Premise

314	The	_	_	B-Claim
315	effects	_	_	I-Claim
316	of	_	_	I-Claim
317	single	_	_	I-Claim
318	dose	_	_	I-Claim
319	brachytherapy	_	_	I-Claim
320	on	_	_	I-Claim
321	HRQoL	_	_	I-Claim
322	compared	_	_	I-Claim
323	favourably	_	_	I-Claim
324	to	_	_	I-Claim
325	those	_	_	I-Claim
326	of	_	_	I-Claim
327	stent	_	_	I-Claim
328	placement	_	_	I-Claim
329	for	_	_	I-Claim
330	the	_	_	I-Claim
331	palliation	_	_	I-Claim
332	of	_	_	I-Claim
333	oesophageal	_	_	I-Claim
334	cancer	_	_	I-Claim
335	.	_	_	I-Claim

336	Future	_	_	B-Claim
337	studies	_	_	I-Claim
338	on	_	_	I-Claim
339	palliative	_	_	I-Claim
340	care	_	_	I-Claim
341	for	_	_	I-Claim
342	oesophageal	_	_	I-Claim
343	cancer	_	_	I-Claim
344	should	_	_	I-Claim
345	at	_	_	I-Claim
346	least	_	_	I-Claim
347	include	_	_	I-Claim
348	generic	_	_	I-Claim
349	HRQoL	_	_	I-Claim
350	scales	_	_	I-Claim
351	,	_	_	I-Claim
352	since	_	_	B-Premise
353	these	_	_	I-Premise
354	were	_	_	I-Premise
355	more	_	_	I-Premise
356	responsive	_	_	I-Premise
357	in	_	_	I-Premise
358	measuring	_	_	I-Premise
359	patients	_	_	I-Premise
360	'	_	_	I-Premise
361	functioning	_	_	I-Premise
362	and	_	_	I-Premise
363	well-being	_	_	I-Premise
364	during	_	_	I-Premise
365	follow-up	_	_	I-Premise
366	than	_	_	I-Premise
367	disease-specific	_	_	I-Premise
368	HRQoL	_	_	I-Premise
369	scales	_	_	I-Premise
370	.	_	_	I-Premise


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	'Casodex	_	_	O
8	'	_	_	O
9	monotherapy	_	_	O
10	(	_	_	O
11	150	_	_	O
12	mg	_	_	O
13	daily	_	_	O
14	)	_	_	O
15	for	_	_	O
16	metastatic	_	_	O
17	and	_	_	O
18	locally	_	_	O
19	advanced	_	_	O
20	prostate	_	_	O
21	cancer	_	_	O
22	.	_	_	O

23	A	_	_	O
24	total	_	_	O
25	of	_	_	O
26	1,453	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	either	_	_	O
30	confirmed	_	_	O
31	metastatic	_	_	O
32	disease	_	_	O
33	(	_	_	O
34	M1	_	_	O
35	)	_	_	O
36	,	_	_	O
37	or	_	_	O
38	T3/T4	_	_	O
39	non-metastatic	_	_	O
40	disease	_	_	O
41	with	_	_	O
42	elevated	_	_	O
43	prostate-specific	_	_	O
44	antigen	_	_	O
45	(	_	_	O
46	M0	_	_	O
47	)	_	_	O
48	were	_	_	O
49	recruited	_	_	O
50	into	_	_	O
51	one	_	_	O
52	of	_	_	O
53	two	_	_	O
54	identical	_	_	O
55	,	_	_	O
56	multicentre	_	_	O
57	,	_	_	O
58	randomised	_	_	O
59	studies	_	_	O
60	to	_	_	O
61	compare	_	_	O
62	'Casodex	_	_	O
63	'	_	_	O
64	150	_	_	O
65	mg/day	_	_	O
66	with	_	_	O
67	castration	_	_	O
68	.	_	_	O

69	The	_	_	O
70	protocols	_	_	O
71	allowed	_	_	O
72	for	_	_	O
73	combined	_	_	O
74	analysis	_	_	O
75	.	_	_	O

76	At	_	_	B-Premise
77	a	_	_	I-Premise
78	median	_	_	I-Premise
79	follow-up	_	_	I-Premise
80	period	_	_	I-Premise
81	of	_	_	I-Premise
82	approximately	_	_	I-Premise
83	100	_	_	I-Premise
84	weeks	_	_	I-Premise
85	for	_	_	I-Premise
86	both	_	_	I-Premise
87	studies	_	_	I-Premise
88	,	_	_	I-Premise
89	'Casodex	_	_	I-Premise
90	'	_	_	I-Premise
91	150	_	_	I-Premise
92	mg	_	_	I-Premise
93	was	_	_	I-Premise
94	found	_	_	I-Premise
95	to	_	_	I-Premise
96	be	_	_	I-Premise
97	less	_	_	I-Premise
98	effective	_	_	I-Premise
99	than	_	_	I-Premise
100	castration	_	_	I-Premise
101	in	_	_	I-Premise
102	patients	_	_	I-Premise
103	with	_	_	I-Premise
104	metastatic	_	_	I-Premise
105	disease	_	_	I-Premise
106	(	_	_	I-Premise
107	M1	_	_	I-Premise
108	)	_	_	I-Premise
109	at	_	_	I-Premise
110	entry	_	_	I-Premise
111	(	_	_	I-Premise
112	hazard	_	_	I-Premise
113	ratio	_	_	I-Premise
114	of	_	_	I-Premise
115	1.30	_	_	I-Premise
116	for	_	_	I-Premise
117	time	_	_	I-Premise
118	to	_	_	I-Premise
119	death	_	_	I-Premise
120	)	_	_	I-Premise
121	with	_	_	I-Premise
122	a	_	_	I-Premise
123	difference	_	_	I-Premise
124	in	_	_	I-Premise
125	median	_	_	I-Premise
126	survival	_	_	I-Premise
127	of	_	_	I-Premise
128	6	_	_	I-Premise
129	weeks	_	_	I-Premise
130	.	_	_	I-Premise

131	In	_	_	B-Premise
132	symptomatic	_	_	I-Premise
133	M1	_	_	I-Premise
134	patients	_	_	I-Premise
135	,	_	_	I-Premise
136	'Casodex	_	_	I-Premise
137	'	_	_	I-Premise
138	was	_	_	I-Premise
139	associated	_	_	I-Premise
140	with	_	_	I-Premise
141	a	_	_	I-Premise
142	statistically	_	_	I-Premise
143	significant	_	_	I-Premise
144	improvement	_	_	I-Premise
145	in	_	_	I-Premise
146	subjective	_	_	I-Premise
147	response	_	_	I-Premise
148	(	_	_	I-Premise
149	70	_	_	I-Premise
150	%	_	_	I-Premise
151	)	_	_	I-Premise
152	compared	_	_	I-Premise
153	with	_	_	I-Premise
154	castration	_	_	I-Premise
155	(	_	_	I-Premise
156	58	_	_	I-Premise
157	%	_	_	I-Premise
158	)	_	_	I-Premise
159	.	_	_	I-Premise

160	Analysis	_	_	B-Premise
161	of	_	_	I-Premise
162	a	_	_	I-Premise
163	validated	_	_	I-Premise
164	quality-of-life	_	_	I-Premise
165	questionnaire	_	_	I-Premise
166	proved	_	_	I-Premise
167	an	_	_	I-Premise
168	advantage	_	_	I-Premise
169	for	_	_	I-Premise
170	'Casodex	_	_	I-Premise
171	'	_	_	I-Premise
172	in	_	_	I-Premise
173	sexual	_	_	I-Premise
174	interest	_	_	I-Premise
175	and	_	_	I-Premise
176	physical	_	_	I-Premise
177	capacity	_	_	I-Premise
178	.	_	_	I-Premise

179	'Casodex	_	_	B-Premise
180	'	_	_	I-Premise
181	had	_	_	I-Premise
182	a	_	_	I-Premise
183	substantially	_	_	I-Premise
184	lower	_	_	I-Premise
185	incidence	_	_	I-Premise
186	of	_	_	I-Premise
187	hot	_	_	I-Premise
188	flushes	_	_	I-Premise
189	compared	_	_	I-Premise
190	to	_	_	I-Premise
191	castration	_	_	I-Premise
192	(	_	_	I-Premise
193	6-13	_	_	I-Premise
194	%	_	_	I-Premise
195	compared	_	_	I-Premise
196	with	_	_	I-Premise
197	39-44	_	_	I-Premise
198	%	_	_	I-Premise
199	)	_	_	I-Premise
200	and	_	_	I-Premise
201	the	_	_	I-Premise
202	most	_	_	I-Premise
203	commonly	_	_	I-Premise
204	reported	_	_	I-Premise
205	adverse	_	_	I-Premise
206	events	_	_	I-Premise
207	were	_	_	I-Premise
208	those	_	_	I-Premise
209	expected	_	_	I-Premise
210	for	_	_	I-Premise
211	a	_	_	I-Premise
212	potent	_	_	I-Premise
213	antiandrogen	_	_	I-Premise
214	.	_	_	I-Premise

215	However	_	_	O
216	,	_	_	O
217	in	_	_	B-Claim
218	patients	_	_	I-Claim
219	with	_	_	I-Claim
220	M0	_	_	I-Claim
221	disease	_	_	I-Claim
222	at	_	_	I-Claim
223	entry	_	_	I-Claim
224	,	_	_	I-Claim
225	the	_	_	I-Claim
226	data	_	_	I-Claim
227	are	_	_	I-Claim
228	still	_	_	I-Claim
229	immature	_	_	I-Claim
230	with	_	_	I-Claim
231	only	_	_	I-Claim
232	13	_	_	I-Claim
233	%	_	_	I-Claim
234	of	_	_	I-Claim
235	M0	_	_	I-Claim
236	patients	_	_	I-Claim
237	having	_	_	I-Claim
238	died	_	_	I-Claim
239	.	_	_	I-Claim

240	An	_	_	B-Claim
241	initial	_	_	I-Claim
242	analysis	_	_	I-Claim
243	of	_	_	I-Claim
244	this	_	_	I-Claim
245	immature	_	_	I-Claim
246	data	_	_	I-Claim
247	has	_	_	I-Claim
248	suggested	_	_	I-Claim
249	that	_	_	I-Claim
250	the	_	_	I-Claim
251	results	_	_	I-Claim
252	in	_	_	I-Claim
253	these	_	_	I-Claim
254	patients	_	_	I-Claim
255	may	_	_	I-Claim
256	be	_	_	I-Claim
257	different	_	_	I-Claim
258	to	_	_	I-Claim
259	those	_	_	I-Claim
260	obtained	_	_	I-Claim
261	in	_	_	I-Claim
262	patients	_	_	I-Claim
263	with	_	_	I-Claim
264	M1	_	_	I-Claim
265	disease	_	_	I-Claim
266	.	_	_	I-Claim

267	A	_	_	O
268	further	_	_	O
269	survival	_	_	O
270	analysis	_	_	O
271	in	_	_	O
272	patients	_	_	O
273	with	_	_	O
274	M0	_	_	O
275	disease	_	_	O
276	is	_	_	O
277	therefore	_	_	O
278	planned	_	_	O
279	when	_	_	O
280	the	_	_	O
281	data	_	_	O
282	are	_	_	O
283	more	_	_	O
284	mature	_	_	O
285	.	_	_	O

286	'Casodex	_	_	B-Claim
287	'	_	_	I-Claim
288	150	_	_	I-Claim
289	mg	_	_	I-Claim
290	is	_	_	I-Claim
291	less	_	_	I-Claim
292	effective	_	_	I-Claim
293	than	_	_	I-Claim
294	castration	_	_	I-Claim
295	in	_	_	I-Claim
296	patients	_	_	I-Claim
297	with	_	_	I-Claim
298	M1	_	_	I-Claim
299	disease	_	_	I-Claim
300	.	_	_	I-Claim

301	However	_	_	O
302	,	_	_	O
303	'Casodex	_	_	B-Claim
304	'	_	_	I-Claim
305	has	_	_	I-Claim
306	shown	_	_	I-Claim
307	a	_	_	I-Claim
308	benefit	_	_	I-Claim
309	in	_	_	I-Claim
310	terms	_	_	I-Claim
311	of	_	_	I-Claim
312	quality	_	_	I-Claim
313	of	_	_	I-Claim
314	life	_	_	I-Claim
315	and	_	_	I-Claim
316	subjective	_	_	I-Claim
317	response	_	_	I-Claim
318	when	_	_	I-Claim
319	compared	_	_	I-Claim
320	to	_	_	I-Claim
321	castration	_	_	I-Claim
322	and	_	_	I-Claim
323	has	_	_	I-Claim
324	an	_	_	I-Claim
325	acceptable	_	_	I-Claim
326	tolerability	_	_	I-Claim
327	profile	_	_	I-Claim
328	.	_	_	I-Claim

329	Thus	_	_	B-Claim
330	'Casodex	_	_	I-Claim
331	'	_	_	I-Claim
332	150	_	_	I-Claim
333	mg	_	_	I-Claim
334	monotherapy	_	_	I-Claim
335	is	_	_	I-Claim
336	an	_	_	I-Claim
337	option	_	_	I-Claim
338	for	_	_	I-Claim
339	patients	_	_	I-Claim
340	with	_	_	I-Claim
341	M1	_	_	I-Claim
342	prostate	_	_	I-Claim
343	cancer	_	_	I-Claim
344	for	_	_	I-Claim
345	whom	_	_	I-Claim
346	surgical	_	_	I-Claim
347	or	_	_	I-Claim
348	medical	_	_	I-Claim
349	castration	_	_	I-Claim
350	is	_	_	I-Claim
351	not	_	_	I-Claim
352	indicated	_	_	I-Claim
353	or	_	_	I-Claim
354	is	_	_	I-Claim
355	not	_	_	I-Claim
356	acceptable	_	_	I-Claim
357	.	_	_	I-Claim


0	We	_	_	O
1	compared	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	effects	_	_	O
5	and	_	_	O
6	impact	_	_	O
7	on	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	of	_	_	O
15	patients	_	_	O
16	who	_	_	O
17	received	_	_	O
18	a	_	_	O
19	3-month	_	_	O
20	course	_	_	O
21	of	_	_	O
22	flutamide	_	_	O
23	monotherapy	_	_	O
24	before	_	_	O
25	radical	_	_	O
26	prostatectomy	_	_	O
27	with	_	_	O
28	those	_	_	O
29	who	_	_	O
30	received	_	_	O
31	a	_	_	O
32	3-month	_	_	O
33	course	_	_	O
34	of	_	_	O
35	luteinizing	_	_	O
36	hormone-releasing	_	_	O
37	hormone	_	_	O
38	(	_	_	O
39	LHRH	_	_	O
40	)	_	_	O
41	agonist	_	_	O
42	monotherapy	_	_	O
43	.	_	_	O

44	Thirty-seven	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	non-metastatic	_	_	O
48	prostate	_	_	O
49	cancer	_	_	O
50	were	_	_	O
51	enrolled	_	_	O
52	in	_	_	O
53	this	_	_	O
54	study	_	_	O
55	(	_	_	O
56	19	_	_	O
57	,	_	_	O
58	flutamide	_	_	O
59	;	_	_	O
60	18	_	_	O
61	,	_	_	O
62	LHRH	_	_	O
63	agonist	_	_	O
64	)	_	_	O
65	.	_	_	O

66	The	_	_	O
67	rates	_	_	O
68	of	_	_	O
69	change	_	_	O
70	of	_	_	O
71	serum	_	_	O
72	prostate-specific	_	_	O
73	antigen	_	_	O
74	(	_	_	O
75	PSA	_	_	O
76	)	_	_	O
77	and	_	_	O
78	testosterone	_	_	O
79	levels	_	_	O
80	,	_	_	O
81	downsizing	_	_	O
82	of	_	_	O
83	prostate	_	_	O
84	volume	_	_	O
85	,	_	_	O
86	the	_	_	O
87	rate	_	_	O
88	of	_	_	O
89	organ	_	_	O
90	confined	_	_	O
91	disease	_	_	O
92	,	_	_	O
93	adverse	_	_	O
94	effects	_	_	O
95	and	_	_	O
96	perioperative	_	_	O
97	scores	_	_	O
98	measured	_	_	O
99	using	_	_	O
100	the	_	_	O
101	European	_	_	O
102	Organization	_	_	O
103	for	_	_	O
104	Research	_	_	O
105	and	_	_	O
106	Treatment	_	_	O
107	of	_	_	O
108	Cancer	_	_	O
109	Prostate	_	_	O
110	Cancer	_	_	O
111	Quality	_	_	O
112	of	_	_	O
113	Life	_	_	O
114	Questionnaire	_	_	O
115	(	_	_	O
116	EORTC-P	_	_	O
117	)	_	_	O
118	and	_	_	O
119	the	_	_	O
120	Sapporo	_	_	O
121	Medical	_	_	O
122	University	_	_	O
123	Sexual	_	_	O
124	Function	_	_	O
125	Questionnaire	_	_	O
126	(	_	_	O
127	SMUF	_	_	O
128	)	_	_	O
129	were	_	_	O
130	analyzed	_	_	O
131	.	_	_	O

132	At	_	_	B-Premise
133	radical	_	_	I-Premise
134	prostatectomy	_	_	I-Premise
135	,	_	_	I-Premise
136	pathological	_	_	I-Premise
137	variables	_	_	I-Premise
138	were	_	_	I-Premise
139	not	_	_	I-Premise
140	significantly	_	_	I-Premise
141	different	_	_	I-Premise
142	in	_	_	I-Premise
143	the	_	_	I-Premise
144	two	_	_	I-Premise
145	groups	_	_	I-Premise
146	.	_	_	I-Premise

147	Serum	_	_	B-Premise
148	testosterone	_	_	I-Premise
149	level	_	_	I-Premise
150	was	_	_	I-Premise
151	significantly	_	_	I-Premise
152	higher	_	_	I-Premise
153	(	_	_	I-Premise
154	mean	_	_	I-Premise
155	359.2	_	_	I-Premise
156	compared	_	_	I-Premise
157	to	_	_	I-Premise
158	10.5	_	_	I-Premise
159	,	_	_	I-Premise
160	P	_	_	I-Premise
161	<	_	_	I-Premise
162	0.001	_	_	I-Premise
163	)	_	_	I-Premise
164	,	_	_	I-Premise
165	complete	_	_	B-Premise
166	response	_	_	I-Premise
167	rate	_	_	I-Premise
168	of	_	_	I-Premise
169	PSA	_	_	I-Premise
170	(	_	_	I-Premise
171	13	_	_	I-Premise
172	%	_	_	I-Premise
173	compared	_	_	I-Premise
174	to	_	_	I-Premise
175	57	_	_	I-Premise
176	%	_	_	I-Premise
177	,	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	0.028	_	_	I-Premise
181	)	_	_	I-Premise
182	and	_	_	I-Premise
183	rate	_	_	I-Premise
184	of	_	_	I-Premise
185	downsizing	_	_	I-Premise
186	of	_	_	I-Premise
187	prostate	_	_	I-Premise
188	volume	_	_	I-Premise
189	(	_	_	I-Premise
190	mean	_	_	I-Premise
191	,	_	_	I-Premise
192	-17.7	_	_	I-Premise
193	%	_	_	I-Premise
194	compared	_	_	I-Premise
195	to	_	_	I-Premise
196	-35.4	_	_	I-Premise
197	%	_	_	I-Premise
198	,	_	_	I-Premise
199	P	_	_	I-Premise
200	=	_	_	I-Premise
201	0.038	_	_	I-Premise
202	)	_	_	I-Premise
203	were	_	_	I-Premise
204	significantly	_	_	I-Premise
205	lower	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	flutamide	_	_	I-Premise
209	group	_	_	I-Premise
210	than	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	LHRH	_	_	I-Premise
214	group	_	_	I-Premise
215	.	_	_	I-Premise

216	After	_	_	B-Premise
217	neoadjuvant	_	_	I-Premise
218	hormone	_	_	I-Premise
219	therapy	_	_	I-Premise
220	,	_	_	I-Premise
221	the	_	_	I-Premise
222	scores	_	_	I-Premise
223	on	_	_	I-Premise
224	the	_	_	I-Premise
225	sexual	_	_	I-Premise
226	problem	_	_	I-Premise
227	domain	_	_	I-Premise
228	of	_	_	I-Premise
229	EORTC-P	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	0.033	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	sexual	_	_	I-Premise
237	desire	_	_	I-Premise
238	score	_	_	I-Premise
239	of	_	_	I-Premise
240	SMUF	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.021	_	_	I-Premise
245	)	_	_	I-Premise
246	were	_	_	I-Premise
247	significantly	_	_	I-Premise
248	higher	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	flutamide	_	_	I-Premise
252	group	_	_	I-Premise
253	than	_	_	I-Premise
254	in	_	_	I-Premise
255	the	_	_	I-Premise
256	LHRH	_	_	I-Premise
257	group	_	_	I-Premise
258	.	_	_	I-Premise

259	At	_	_	B-Premise
260	a	_	_	I-Premise
261	median	_	_	I-Premise
262	follow-up	_	_	I-Premise
263	of	_	_	I-Premise
264	34	_	_	I-Premise
265	months	_	_	I-Premise
266	after	_	_	I-Premise
267	prostatectomy	_	_	I-Premise
268	,	_	_	I-Premise
269	biochemical	_	_	I-Premise
270	failure-free	_	_	I-Premise
271	survival	_	_	I-Premise
272	rate	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	flutamide	_	_	I-Premise
276	group	_	_	I-Premise
277	did	_	_	I-Premise
278	not	_	_	I-Premise
279	differ	_	_	I-Premise
280	from	_	_	I-Premise
281	that	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	LHRH	_	_	I-Premise
285	group	_	_	I-Premise
286	.	_	_	I-Premise

287	This	_	_	B-Claim
288	study	_	_	I-Claim
289	suggests	_	_	I-Claim
290	that	_	_	I-Claim
291	flutamide	_	_	I-Claim
292	monotherapy	_	_	I-Claim
293	can	_	_	I-Claim
294	be	_	_	I-Claim
295	an	_	_	I-Claim
296	acceptable	_	_	I-Claim
297	modality	_	_	I-Claim
298	as	_	_	I-Claim
299	an	_	_	I-Claim
300	option	_	_	I-Claim
301	for	_	_	I-Claim
302	neoadjuvant	_	_	I-Claim
303	hormone	_	_	I-Claim
304	therapy	_	_	I-Claim
305	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	two	_	_	O
3	cisplatin	_	_	O
4	based	_	_	O
5	chemotherapy	_	_	O
6	schedules	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	advanced	_	_	O
11	non-small-cell	_	_	O
12	lung	_	_	O
13	cancer	_	_	O
14	(	_	_	O
15	NSCLC	_	_	O
16	)	_	_	O
17	.	_	_	O

18	A	_	_	O
19	total	_	_	O
20	of	_	_	O
21	332	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	advanced	_	_	O
25	NSCLC	_	_	O
26	were	_	_	O
27	randomized	_	_	O
28	to	_	_	O
29	receive	_	_	O
30	cisplatin	_	_	O
31	80	_	_	O
32	mg/m2	_	_	O
33	on	_	_	O
34	day	_	_	O
35	1	_	_	O
36	either	_	_	O
37	in	_	_	O
38	combination	_	_	O
39	with	_	_	O
40	teniposide	_	_	O
41	100	_	_	O
42	mg/m2	_	_	O
43	on	_	_	O
44	days	_	_	O
45	1	_	_	O
46	,	_	_	O
47	3	_	_	O
48	,	_	_	O
49	and	_	_	O
50	5	_	_	O
51	(	_	_	O
52	arm	_	_	O
53	A	_	_	O
54	)	_	_	O
55	or	_	_	O
56	paclitaxel	_	_	O
57	175	_	_	O
58	mg/m2	_	_	O
59	by	_	_	O
60	3-hour	_	_	O
61	infusion	_	_	O
62	on	_	_	O
63	day	_	_	O
64	1	_	_	O
65	(	_	_	O
66	arm	_	_	O
67	B	_	_	O
68	)	_	_	O
69	;	_	_	O
70	cycles	_	_	O
71	were	_	_	O
72	repeated	_	_	O
73	every	_	_	O
74	3	_	_	O
75	weeks	_	_	O
76	.	_	_	O

77	Fifteen	_	_	O
78	patients	_	_	O
79	were	_	_	O
80	ineligible	_	_	O
81	;	_	_	O
82	patient	_	_	O
83	characteristics	_	_	O
84	were	_	_	O
85	well	_	_	O
86	balanced	_	_	O
87	between	_	_	O
88	the	_	_	O
89	two	_	_	O
90	arms	_	_	O
91	:	_	_	O
92	71	_	_	O
93	%	_	_	O
94	were	_	_	O
95	male	_	_	O
96	,	_	_	O
97	71	_	_	O
98	%	_	_	O
99	had	_	_	O
100	less	_	_	O
101	than	_	_	O
102	5	_	_	O
103	%	_	_	O
104	weight	_	_	O
105	loss	_	_	O
106	,	_	_	O
107	89	_	_	O
108	%	_	_	O
109	had	_	_	O
110	a	_	_	O
111	World	_	_	O
112	Health	_	_	O
113	Organization	_	_	O
114	(	_	_	O
115	WHO	_	_	O
116	)	_	_	O
117	performance	_	_	O
118	status	_	_	O
119	of	_	_	O
120	0	_	_	O
121	to	_	_	O
122	1	_	_	O
123	,	_	_	O
124	51	_	_	O
125	%	_	_	O
126	had	_	_	O
127	adenocarcinoma	_	_	O
128	,	_	_	O
129	and	_	_	O
130	61	_	_	O
131	%	_	_	O
132	had	_	_	O
133	stage	_	_	O
134	IV	_	_	O
135	disease	_	_	O
136	.	_	_	O

137	Hematologic	_	_	B-Premise
138	toxicity	_	_	I-Premise
139	was	_	_	I-Premise
140	significantly	_	_	I-Premise
141	more	_	_	I-Premise
142	severe	_	_	I-Premise
143	in	_	_	I-Premise
144	arm	_	_	I-Premise
145	A	_	_	I-Premise
146	(	_	_	I-Premise
147	leukopenia	_	_	I-Premise
148	,	_	_	I-Premise
149	neutropenia	_	_	I-Premise
150	,	_	_	I-Premise
151	and	_	_	I-Premise
152	thrombocytopenia	_	_	I-Premise
153	grade	_	_	I-Premise
154	3	_	_	I-Premise
155	or	_	_	I-Premise
156	4	_	_	I-Premise
157	:	_	_	I-Premise
158	66	_	_	I-Premise
159	%	_	_	I-Premise
160	v	_	_	I-Premise
161	19	_	_	I-Premise
162	%	_	_	I-Premise
163	,	_	_	I-Premise
164	83	_	_	I-Premise
165	%	_	_	I-Premise
166	v	_	_	I-Premise
167	55	_	_	I-Premise
168	%	_	_	I-Premise
169	,	_	_	I-Premise
170	36	_	_	I-Premise
171	%	_	_	I-Premise
172	v	_	_	I-Premise
173	2	_	_	I-Premise
174	%	_	_	I-Premise
175	in	_	_	I-Premise
176	arms	_	_	I-Premise
177	A	_	_	I-Premise
178	and	_	_	I-Premise
179	B	_	_	I-Premise
180	,	_	_	I-Premise
181	respectively	_	_	I-Premise
182	)	_	_	I-Premise
183	,	_	_	I-Premise
184	which	_	_	I-Premise
185	resulted	_	_	I-Premise
186	in	_	_	I-Premise
187	more	_	_	I-Premise
188	febrile	_	_	I-Premise
189	neutropenia	_	_	I-Premise
190	(	_	_	I-Premise
191	27	_	_	I-Premise
192	%	_	_	I-Premise
193	v	_	_	I-Premise
194	3	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	arms	_	_	I-Premise
198	A	_	_	I-Premise
199	and	_	_	I-Premise
200	B	_	_	I-Premise
201	,	_	_	I-Premise
202	respectively	_	_	I-Premise
203	)	_	_	I-Premise
204	,	_	_	I-Premise
205	dose	_	_	I-Premise
206	reductions	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	treatment	_	_	I-Premise
210	delays	_	_	I-Premise
211	.	_	_	I-Premise

212	There	_	_	B-Premise
213	were	_	_	I-Premise
214	a	_	_	I-Premise
215	total	_	_	I-Premise
216	of	_	_	I-Premise
217	nine	_	_	I-Premise
218	toxic	_	_	I-Premise
219	deaths	_	_	I-Premise
220	,	_	_	I-Premise
221	six	_	_	I-Premise
222	due	_	_	I-Premise
223	to	_	_	I-Premise
224	neutropenic	_	_	I-Premise
225	sepsis	_	_	I-Premise
226	:	_	_	I-Premise
227	five	_	_	I-Premise
228	in	_	_	I-Premise
229	arm	_	_	I-Premise
230	A	_	_	I-Premise
231	and	_	_	I-Premise
232	one	_	_	I-Premise
233	in	_	_	I-Premise
234	arm	_	_	I-Premise
235	B	_	_	I-Premise
236	.	_	_	I-Premise

237	In	_	_	B-Premise
238	contrast	_	_	I-Premise
239	,	_	_	I-Premise
240	arthralgia/myalgia	_	_	I-Premise
241	(	_	_	I-Premise
242	grade	_	_	I-Premise
243	2	_	_	I-Premise
244	or	_	_	I-Premise
245	3	_	_	I-Premise
246	,	_	_	I-Premise
247	4	_	_	I-Premise
248	%	_	_	I-Premise
249	v	_	_	I-Premise
250	17	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	,	_	_	I-Premise
254	peripheral	_	_	I-Premise
255	neurotoxicity	_	_	I-Premise
256	(	_	_	I-Premise
257	grade	_	_	I-Premise
258	2	_	_	I-Premise
259	or	_	_	I-Premise
260	3	_	_	I-Premise
261	,	_	_	I-Premise
262	6	_	_	I-Premise
263	%	_	_	I-Premise
264	v	_	_	I-Premise
265	29	_	_	I-Premise
266	%	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	and	_	_	I-Premise
270	hypersensitivity	_	_	I-Premise
271	reactions	_	_	I-Premise
272	(	_	_	I-Premise
273	1	_	_	I-Premise
274	%	_	_	I-Premise
275	v	_	_	I-Premise
276	7	_	_	I-Premise
277	%	_	_	I-Premise
278	,	_	_	I-Premise
279	all	_	_	I-Premise
280	grades	_	_	I-Premise
281	)	_	_	I-Premise
282	were	_	_	I-Premise
283	significantly	_	_	I-Premise
284	more	_	_	I-Premise
285	frequent	_	_	I-Premise
286	in	_	_	I-Premise
287	arm	_	_	I-Premise
288	B	_	_	I-Premise
289	.	_	_	I-Premise

290	The	_	_	B-Claim
291	frequency	_	_	I-Claim
292	and	_	_	I-Claim
293	severity	_	_	I-Claim
294	of	_	_	I-Claim
295	other	_	_	I-Claim
296	toxicities	_	_	I-Claim
297	were	_	_	I-Claim
298	comparable	_	_	I-Claim
299	between	_	_	I-Claim
300	the	_	_	I-Claim
301	two	_	_	I-Claim
302	arms	_	_	I-Claim
303	.	_	_	I-Claim

304	Responses	_	_	B-Premise
305	were	_	_	I-Premise
306	one	_	_	I-Premise
307	complete	_	_	I-Premise
308	and	_	_	I-Premise
309	44	_	_	I-Premise
310	partial	_	_	I-Premise
311	on	_	_	I-Premise
312	arm	_	_	I-Premise
313	A	_	_	I-Premise
314	(	_	_	I-Premise
315	28	_	_	I-Premise
316	%	_	_	I-Premise
317	)	_	_	I-Premise
318	and	_	_	I-Premise
319	two	_	_	I-Premise
320	complete	_	_	I-Premise
321	and	_	_	I-Premise
322	61	_	_	I-Premise
323	partial	_	_	I-Premise
324	(	_	_	I-Premise
325	41	_	_	I-Premise
326	%	_	_	I-Premise
327	)	_	_	I-Premise
328	on	_	_	I-Premise
329	arm	_	_	I-Premise
330	B	_	_	I-Premise
331	(	_	_	I-Premise
332	P	_	_	I-Premise
333	=	_	_	I-Premise
334	.018	_	_	I-Premise
335	)	_	_	I-Premise
336	.	_	_	I-Premise

337	There	_	_	B-Premise
338	was	_	_	I-Premise
339	no	_	_	I-Premise
340	significant	_	_	I-Premise
341	difference	_	_	I-Premise
342	in	_	_	I-Premise
343	survival	_	_	I-Premise
344	,	_	_	I-Premise
345	with	_	_	I-Premise
346	median	_	_	I-Premise
347	and	_	_	I-Premise
348	1-year	_	_	I-Premise
349	survivals	_	_	I-Premise
350	9.9	_	_	I-Premise
351	versus	_	_	I-Premise
352	9.7	_	_	I-Premise
353	months	_	_	I-Premise
354	and	_	_	I-Premise
355	41	_	_	I-Premise
356	%	_	_	I-Premise
357	versus	_	_	I-Premise
358	43	_	_	I-Premise
359	%	_	_	I-Premise
360	,	_	_	I-Premise
361	respectively	_	_	I-Premise
362	in	_	_	I-Premise
363	arm	_	_	I-Premise
364	A	_	_	I-Premise
365	and	_	_	I-Premise
366	B.	_	_	I-Premise
367	Progression-free	_	_	B-Premise
368	survival	_	_	I-Premise
369	was	_	_	I-Premise
370	4.9	_	_	I-Premise
371	and	_	_	I-Premise
372	5.4	_	_	I-Premise
373	months	_	_	I-Premise
374	in	_	_	I-Premise
375	arm	_	_	I-Premise
376	A	_	_	I-Premise
377	and	_	_	I-Premise
378	B	_	_	I-Premise
379	,	_	_	I-Premise
380	respectively	_	_	I-Premise
381	.	_	_	I-Premise

382	Selected	_	_	O
383	centers	_	_	O
384	participated	_	_	O
385	in	_	_	O
386	a	_	_	O
387	quality-of-life	_	_	O
388	(	_	_	O
389	QoL	_	_	O
390	)	_	_	O
391	assessment	_	_	O
392	,	_	_	O
393	which	_	_	O
394	was	_	_	O
395	performed	_	_	O
396	by	_	_	O
397	the	_	_	O
398	European	_	_	O
399	Organization	_	_	O
400	for	_	_	O
401	Research	_	_	O
402	and	_	_	O
403	Treatment	_	_	O
404	of	_	_	O
405	Cancer	_	_	O
406	(	_	_	O
407	EORTC	_	_	O
408	)	_	_	O
409	QLQ-C30	_	_	O
410	and	_	_	O
411	LC-13	_	_	O
412	administered	_	_	O
413	at	_	_	O
414	baseline	_	_	O
415	and	_	_	O
416	every	_	_	O
417	6	_	_	O
418	weeks	_	_	O
419	thereafter	_	_	O
420	.	_	_	O

421	Arm	_	_	B-Premise
422	B	_	_	I-Premise
423	achieved	_	_	I-Premise
424	a	_	_	I-Premise
425	better	_	_	I-Premise
426	score	_	_	I-Premise
427	at	_	_	I-Premise
428	week	_	_	I-Premise
429	6	_	_	I-Premise
430	for	_	_	I-Premise
431	emotional	_	_	I-Premise
432	,	_	_	I-Premise
433	cognitive	_	_	I-Premise
434	and	_	_	I-Premise
435	social	_	_	I-Premise
436	functioning	_	_	I-Premise
437	,	_	_	I-Premise
438	global	_	_	I-Premise
439	health	_	_	I-Premise
440	status	_	_	I-Premise
441	,	_	_	I-Premise
442	fatigue	_	_	I-Premise
443	,	_	_	I-Premise
444	and	_	_	I-Premise
445	appetite	_	_	I-Premise
446	loss	_	_	I-Premise
447	,	_	_	I-Premise
448	which	_	_	I-Premise
449	was	_	_	I-Premise
450	lost	_	_	I-Premise
451	at	_	_	I-Premise
452	12	_	_	I-Premise
453	weeks	_	_	I-Premise
454	.	_	_	I-Premise

455	In	_	_	B-Claim
456	conclusion	_	_	I-Claim
457	,	_	_	I-Claim
458	arm	_	_	I-Claim
459	B	_	_	I-Claim
460	appears	_	_	I-Claim
461	superior	_	_	I-Claim
462	to	_	_	I-Claim
463	arm	_	_	I-Claim
464	A	_	_	I-Claim
465	with	_	_	I-Claim
466	regard	_	_	I-Claim
467	to	_	_	I-Claim
468	response	_	_	I-Claim
469	rate	_	_	I-Claim
470	,	_	_	I-Claim
471	side	_	_	I-Claim
472	effects	_	_	I-Claim
473	,	_	_	I-Claim
474	and	_	_	I-Claim
475	QoL	_	_	I-Claim
476	.	_	_	I-Claim

477	Although	_	_	B-Claim
478	survival	_	_	I-Claim
479	was	_	_	I-Claim
480	not	_	_	I-Claim
481	improved	_	_	I-Claim
482	,	_	_	I-Claim
483	arm	_	_	B-Claim
484	B	_	_	I-Claim
485	offers	_	_	I-Claim
486	a	_	_	I-Claim
487	better	_	_	I-Claim
488	palliation	_	_	I-Claim
489	for	_	_	I-Claim
490	advanced	_	_	I-Claim
491	NSCLC	_	_	I-Claim
492	patients	_	_	I-Claim
493	than	_	_	I-Claim
494	arm	_	_	I-Claim
495	A	_	_	I-Claim
496	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	if	_	_	O
3	raising	_	_	O
4	baseline	_	_	O
5	and	_	_	O
6	maintaining	_	_	O
7	hemoglobin	_	_	O
8	(	_	_	O
9	Hb	_	_	O
10	)	_	_	O
11	levels	_	_	O
12	with	_	_	O
13	red	_	_	O
14	blood	_	_	O
15	cell	_	_	O
16	(	_	_	O
17	RBC	_	_	O
18	)	_	_	O
19	transfusion	_	_	O
20	could	_	_	O
21	improve	_	_	O
22	the	_	_	O
23	outcomes	_	_	O
24	of	_	_	O
25	chemotherapy	_	_	O
26	for	_	_	O
27	advanced	_	_	O
28	gastric	_	_	O
29	cancer	_	_	O
30	(	_	_	O
31	AGC	_	_	O
32	)	_	_	O
33	.	_	_	O

34	Patients	_	_	O
35	were	_	_	O
36	randomized	_	_	O
37	to	_	_	O
38	receive	_	_	O
39	RBC	_	_	O
40	transfusion	_	_	O
41	to	_	_	O
42	maintain	_	_	O
43	their	_	_	O
44	Hb	_	_	O
45	levels	_	_	O
46	>	_	_	O
47	or=10	_	_	O
48	g/dl	_	_	O
49	(	_	_	O
50	arm	_	_	O
51	1	_	_	O
52	)	_	_	O
53	or	_	_	O
54	>	_	_	O
55	or=12	_	_	O
56	(	_	_	O
57	arm	_	_	O
58	2	_	_	O
59	)	_	_	O
60	before	_	_	O
61	the	_	_	O
62	start	_	_	O
63	of	_	_	O
64	their	_	_	O
65	5-fluorouracil-based	_	_	O
66	first-line	_	_	O
67	chemotherapy	_	_	O
68	.	_	_	O

69	Objective	_	_	O
70	response	_	_	O
71	,	_	_	O
72	KPS	_	_	O
73	and	_	_	O
74	quality	_	_	O
75	of	_	_	O
76	life	_	_	O
77	(	_	_	O
78	QOL	_	_	O
79	)	_	_	O
80	data	_	_	O
81	were	_	_	O
82	measured	_	_	O
83	.	_	_	O

84	For	_	_	O
85	87	_	_	O
86	patients	_	_	O
87	enrolled	_	_	O
88	,	_	_	O
89	mean	_	_	O
90	baseline	_	_	O
91	Hb	_	_	O
92	was	_	_	O
93	10.1	_	_	O
94	g/dl	_	_	O
95	,	_	_	O
96	and	_	_	O
97	54	_	_	O
98	patients	_	_	O
99	received	_	_	O
100	RBC	_	_	O
101	prior	_	_	O
102	to	_	_	O
103	chemotherapy	_	_	O
104	initiation	_	_	O
105	.	_	_	O

106	Despite	_	_	O
107	transfusion	_	_	O
108	,	_	_	O
109	we	_	_	O
110	failed	_	_	O
111	to	_	_	O
112	maintain	_	_	O
113	the	_	_	O
114	Hb	_	_	O
115	level	_	_	O
116	above	_	_	O
117	the	_	_	O
118	predefined	_	_	O
119	target	_	_	O
120	range	_	_	O
121	.	_	_	O

122	Eighteen	_	_	B-Premise
123	patients	_	_	I-Premise
124	experienced	_	_	I-Premise
125	brief	_	_	I-Premise
126	and	_	_	I-Premise
127	reversible	_	_	I-Premise
128	adverse	_	_	I-Premise
129	events	_	_	I-Premise
130	during	_	_	I-Premise
131	transfusion	_	_	I-Premise
132	,	_	_	I-Premise
133	including	_	_	I-Premise
134	two	_	_	I-Premise
135	patients	_	_	I-Premise
136	with	_	_	I-Premise
137	acute	_	_	I-Premise
138	pulmonary	_	_	I-Premise
139	edema	_	_	I-Premise
140	.	_	_	I-Premise

141	KPS	_	_	B-Premise
142	was	_	_	I-Premise
143	improved	_	_	I-Premise
144	from	_	_	I-Premise
145	baseline	_	_	I-Premise
146	to	_	_	I-Premise
147	post-chemotherapy	_	_	I-Premise
148	in	_	_	I-Premise
149	both	_	_	I-Premise
150	arms	_	_	I-Premise
151	.	_	_	I-Premise

152	QOL	_	_	B-Premise
153	data	_	_	I-Premise
154	showed	_	_	I-Premise
155	improvement	_	_	I-Premise
156	in	_	_	I-Premise
157	some	_	_	I-Premise
158	symptom	_	_	I-Premise
159	scores	_	_	I-Premise
160	,	_	_	I-Premise
161	but	_	_	B-Premise
162	there	_	_	I-Premise
163	was	_	_	I-Premise
164	no	_	_	I-Premise
165	difference	_	_	I-Premise
166	in	_	_	I-Premise
167	the	_	_	I-Premise
168	QOL	_	_	I-Premise
169	scores	_	_	I-Premise
170	between	_	_	I-Premise
171	the	_	_	I-Premise
172	two	_	_	I-Premise
173	arms	_	_	I-Premise
174	at	_	_	I-Premise
175	baseline	_	_	I-Premise
176	and	_	_	I-Premise
177	all	_	_	I-Premise
178	four	_	_	I-Premise
179	cycles	_	_	I-Premise
180	of	_	_	I-Premise
181	treatment	_	_	I-Premise
182	.	_	_	I-Premise

183	Similar	_	_	B-Premise
184	response	_	_	I-Premise
185	rates	_	_	I-Premise
186	were	_	_	I-Premise
187	observed	_	_	I-Premise
188	in	_	_	I-Premise
189	both	_	_	I-Premise
190	arms	_	_	I-Premise
191	(	_	_	I-Premise
192	arm	_	_	I-Premise
193	1	_	_	I-Premise
194	,	_	_	I-Premise
195	30	_	_	I-Premise
196	%	_	_	I-Premise
197	;	_	_	I-Premise
198	arm	_	_	I-Premise
199	2	_	_	I-Premise
200	,	_	_	I-Premise
201	35	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	Both	_	_	B-Premise
206	arms	_	_	I-Premise
207	showed	_	_	I-Premise
208	similar	_	_	I-Premise
209	chemotherapy	_	_	I-Premise
210	duration	_	_	I-Premise
211	(	_	_	I-Premise
212	3.8	_	_	I-Premise
213	and	_	_	I-Premise
214	4.1	_	_	I-Premise
215	months	_	_	I-Premise
216	,	_	_	I-Premise
217	respectively	_	_	I-Premise
218	)	_	_	I-Premise
219	,	_	_	I-Premise
220	progression-free	_	_	I-Premise
221	survival	_	_	I-Premise
222	(	_	_	I-Premise
223	4.0	_	_	I-Premise
224	and	_	_	I-Premise
225	4.1	_	_	I-Premise
226	months	_	_	I-Premise
227	)	_	_	I-Premise
228	and	_	_	I-Premise
229	overall	_	_	I-Premise
230	survival	_	_	I-Premise
231	(	_	_	I-Premise
232	9.9	_	_	I-Premise
233	and	_	_	I-Premise
234	9.3	_	_	I-Premise
235	months	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	Red	_	_	B-Claim
239	blood	_	_	I-Claim
240	cell	_	_	I-Claim
241	transfusion	_	_	I-Claim
242	achieving	_	_	I-Claim
243	Hb	_	_	I-Claim
244	level	_	_	I-Claim
245	above	_	_	I-Claim
246	10	_	_	I-Claim
247	g/dl	_	_	I-Claim
248	might	_	_	I-Claim
249	contribute	_	_	I-Claim
250	to	_	_	I-Claim
251	the	_	_	I-Claim
252	improvement	_	_	I-Claim
253	of	_	_	I-Claim
254	the	_	_	I-Claim
255	KPS	_	_	I-Claim
256	and	_	_	I-Claim
257	QOL	_	_	I-Claim
258	seen	_	_	I-Claim
259	in	_	_	I-Claim
260	patients	_	_	I-Claim
261	with	_	_	I-Claim
262	AGC	_	_	I-Claim
263	.	_	_	I-Claim

264	The	_	_	B-Claim
265	observation	_	_	I-Claim
266	of	_	_	I-Claim
267	equivalent	_	_	I-Claim
268	outcomes	_	_	I-Claim
269	at	_	_	I-Claim
270	the	_	_	I-Claim
271	two	_	_	I-Claim
272	target	_	_	I-Claim
273	Hb	_	_	I-Claim
274	levels	_	_	I-Claim
275	supports	_	_	I-Claim
276	the	_	_	I-Claim
277	feasibility	_	_	I-Claim
278	of	_	_	I-Claim
279	anemia	_	_	I-Claim
280	correction	_	_	I-Claim
281	to	_	_	I-Claim
282	Hb	_	_	I-Claim
283	10	_	_	I-Claim
284	g/dl	_	_	I-Claim
285	,	_	_	I-Claim
286	which	_	_	I-Claim
287	merits	_	_	I-Claim
288	further	_	_	I-Claim
289	evaluation	_	_	I-Claim
290	.	_	_	O


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	cisplatin	_	_	O
4	plus	_	_	O
5	paclitaxel	_	_	O
6	(	_	_	O
7	C+P	_	_	O
8	)	_	_	O
9	improved	_	_	O
10	response	_	_	O
11	rate	_	_	O
12	,	_	_	O
13	progression-free	_	_	O
14	survival	_	_	O
15	(	_	_	O
16	PFS	_	_	O
17	)	_	_	O
18	,	_	_	O
19	or	_	_	O
20	survival	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	cisplatin	_	_	O
24	alone	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	stage	_	_	O
29	IVB	_	_	O
30	,	_	_	O
31	recurrent	_	_	O
32	,	_	_	O
33	or	_	_	O
34	persistent	_	_	O
35	squamous	_	_	O
36	cell	_	_	O
37	carcinoma	_	_	O
38	of	_	_	O
39	the	_	_	O
40	cervix	_	_	O
41	.	_	_	O

42	PATIENTS	_	_	O
43	AND	_	_	O
44	METHODS	_	_	O
45	Eligible	_	_	O
46	:	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	measurable	_	_	O
50	disease	_	_	O
51	,	_	_	O
52	performance	_	_	O
53	status	_	_	O
54	(	_	_	O
55	PS	_	_	O
56	)	_	_	O
57	0	_	_	O
58	to	_	_	O
59	2	_	_	O
60	,	_	_	O
61	and	_	_	O
62	adequate	_	_	O
63	hematologic	_	_	O
64	,	_	_	O
65	hepatic	_	_	O
66	,	_	_	O
67	and	_	_	O
68	renal	_	_	O
69	function	_	_	O
70	received	_	_	O
71	either	_	_	O
72	cisplatin	_	_	O
73	50	_	_	O
74	mg/m2	_	_	O
75	or	_	_	O
76	C+P	_	_	O
77	(	_	_	O
78	cisplatin	_	_	O
79	50	_	_	O
80	mg/m2	_	_	O
81	plus	_	_	O
82	paclitaxel	_	_	O
83	135	_	_	O
84	mg/m2	_	_	O
85	)	_	_	O
86	every	_	_	O
87	3	_	_	O
88	weeks	_	_	O
89	for	_	_	O
90	six	_	_	O
91	cycles	_	_	O
92	.	_	_	O

93	Tumor	_	_	O
94	measurements	_	_	O
95	and	_	_	O
96	quality-of-life	_	_	O
97	(	_	_	O
98	QOL	_	_	O
99	)	_	_	O
100	assessments	_	_	O
101	were	_	_	O
102	obtained	_	_	O
103	before	_	_	O
104	each	_	_	O
105	treatment	_	_	O
106	cycle	_	_	O
107	.	_	_	O

108	Of	_	_	O
109	280	_	_	O
110	patients	_	_	O
111	entered	_	_	O
112	,	_	_	O
113	6	_	_	O
114	%	_	_	O
115	were	_	_	O
116	ineligible	_	_	O
117	.	_	_	O

118	Among	_	_	O
119	264	_	_	O
120	eligible	_	_	O
121	patients	_	_	O
122	,	_	_	O
123	134	_	_	O
124	received	_	_	O
125	cisplatin	_	_	O
126	and	_	_	O
127	130	_	_	O
128	received	_	_	O
129	C+P	_	_	O
130	.	_	_	O

131	Groups	_	_	O
132	were	_	_	O
133	well	_	_	O
134	matched	_	_	O
135	with	_	_	O
136	respect	_	_	O
137	to	_	_	O
138	age	_	_	O
139	,	_	_	O
140	ethnicity	_	_	O
141	,	_	_	O
142	PS	_	_	O
143	,	_	_	O
144	tumor	_	_	O
145	grade	_	_	O
146	,	_	_	O
147	disease	_	_	O
148	site	_	_	O
149	,	_	_	O
150	and	_	_	O
151	number	_	_	O
152	of	_	_	O
153	cycles	_	_	O
154	received	_	_	O
155	.	_	_	O

156	The	_	_	O
157	majority	_	_	O
158	of	_	_	O
159	all	_	_	O
160	patients	_	_	O
161	had	_	_	O
162	prior	_	_	O
163	radiation	_	_	O
164	therapy	_	_	O
165	(	_	_	O
166	cisplatin	_	_	O
167	,	_	_	O
168	92	_	_	O
169	%	_	_	O
170	;	_	_	O
171	C+P	_	_	O
172	,	_	_	O
173	91	_	_	O
174	%	_	_	O
175	)	_	_	O
176	.	_	_	O

177	Objective	_	_	B-Premise
178	responses	_	_	I-Premise
179	occurred	_	_	I-Premise
180	in	_	_	I-Premise
181	19	_	_	I-Premise
182	%	_	_	I-Premise
183	(	_	_	I-Premise
184	6	_	_	I-Premise
185	%	_	_	I-Premise
186	complete	_	_	I-Premise
187	plus	_	_	I-Premise
188	13	_	_	I-Premise
189	%	_	_	I-Premise
190	partial	_	_	I-Premise
191	)	_	_	I-Premise
192	of	_	_	I-Premise
193	patients	_	_	I-Premise
194	receiving	_	_	I-Premise
195	cisplatin	_	_	I-Premise
196	versus	_	_	I-Premise
197	36	_	_	I-Premise
198	%	_	_	I-Premise
199	(	_	_	I-Premise
200	15	_	_	I-Premise
201	%	_	_	I-Premise
202	complete	_	_	I-Premise
203	plus	_	_	I-Premise
204	21	_	_	I-Premise
205	%	_	_	I-Premise
206	partial	_	_	I-Premise
207	)	_	_	I-Premise
208	receiving	_	_	I-Premise
209	C+P	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	=	_	_	I-Premise
213	.002	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	The	_	_	B-Premise
217	median	_	_	I-Premise
218	PFS	_	_	I-Premise
219	was	_	_	I-Premise
220	2.8	_	_	I-Premise
221	and	_	_	I-Premise
222	4.8	_	_	I-Premise
223	months	_	_	I-Premise
224	,	_	_	I-Premise
225	respectively	_	_	I-Premise
226	,	_	_	I-Premise
227	for	_	_	I-Premise
228	cisplatin	_	_	I-Premise
229	versus	_	_	I-Premise
230	C+P	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	<	_	_	I-Premise
234	.001	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	There	_	_	B-Premise
238	was	_	_	I-Premise
239	no	_	_	I-Premise
240	difference	_	_	I-Premise
241	in	_	_	I-Premise
242	median	_	_	I-Premise
243	survival	_	_	I-Premise
244	(	_	_	I-Premise
245	8.8	_	_	I-Premise
246	months	_	_	I-Premise
247	v	_	_	I-Premise
248	9.7	_	_	I-Premise
249	months	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Grade	_	_	B-Premise
253	3	_	_	I-Premise
254	to	_	_	I-Premise
255	4	_	_	I-Premise
256	anemia	_	_	I-Premise
257	and	_	_	I-Premise
258	neutropenia	_	_	I-Premise
259	were	_	_	I-Premise
260	more	_	_	I-Premise
261	common	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	combination	_	_	I-Premise
265	arm	_	_	I-Premise
266	.	_	_	I-Premise

267	There	_	_	B-Premise
268	was	_	_	I-Premise
269	no	_	_	I-Premise
270	significant	_	_	I-Premise
271	difference	_	_	I-Premise
272	in	_	_	I-Premise
273	QOL	_	_	I-Premise
274	scores	_	_	I-Premise
275	,	_	_	I-Premise
276	although	_	_	B-Premise
277	a	_	_	I-Premise
278	disproportionate	_	_	I-Premise
279	number	_	_	I-Premise
280	of	_	_	I-Premise
281	patients	_	_	I-Premise
282	(	_	_	I-Premise
283	cisplatin	_	_	I-Premise
284	,	_	_	I-Premise
285	n	_	_	I-Premise
286	=	_	_	I-Premise
287	50	_	_	I-Premise
288	;	_	_	I-Premise
289	C+P	_	_	I-Premise
290	,	_	_	I-Premise
291	n	_	_	I-Premise
292	=	_	_	I-Premise
293	33	_	_	I-Premise
294	)	_	_	I-Premise
295	dropped	_	_	I-Premise
296	out	_	_	I-Premise
297	of	_	_	I-Premise
298	the	_	_	I-Premise
299	QOL	_	_	I-Premise
300	component	_	_	I-Premise
301	,	_	_	I-Premise
302	presumably	_	_	I-Premise
303	because	_	_	I-Premise
304	of	_	_	I-Premise
305	increasing	_	_	I-Premise
306	disease	_	_	I-Premise
307	,	_	_	I-Premise
308	deteriorating	_	_	I-Premise
309	health	_	_	I-Premise
310	status	_	_	I-Premise
311	,	_	_	I-Premise
312	or	_	_	I-Premise
313	early	_	_	I-Premise
314	death	_	_	I-Premise
315	.	_	_	I-Premise

316	C+P	_	_	B-Claim
317	is	_	_	I-Claim
318	superior	_	_	I-Claim
319	to	_	_	I-Claim
320	cisplatin	_	_	I-Claim
321	alone	_	_	I-Claim
322	with	_	_	I-Claim
323	respect	_	_	I-Claim
324	to	_	_	I-Claim
325	response	_	_	I-Claim
326	rate	_	_	I-Claim
327	and	_	_	I-Claim
328	PFS	_	_	I-Claim
329	with	_	_	I-Claim
330	sustained	_	_	I-Claim
331	QOL	_	_	I-Claim
332	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	docetaxel	_	_	O
4	plus	_	_	O
5	platinum	_	_	O
6	regimens	_	_	O
7	improve	_	_	O
8	survival	_	_	O
9	and	_	_	O
10	affect	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	(	_	_	O
15	QoL	_	_	O
16	)	_	_	O
17	in	_	_	O
18	advanced	_	_	O
19	non-small-cell	_	_	O
20	lung	_	_	O
21	cancer	_	_	O
22	(	_	_	O
23	NSCLC	_	_	O
24	)	_	_	O
25	compared	_	_	O
26	with	_	_	O
27	vinorelbine	_	_	O
28	plus	_	_	O
29	cisplatin	_	_	O
30	as	_	_	O
31	first-line	_	_	O
32	chemotherapy	_	_	O
33	.	_	_	O

34	Patients	_	_	O
35	(	_	_	O
36	n	_	_	O
37	=	_	_	O
38	1,218	_	_	O
39	)	_	_	O
40	with	_	_	O
41	stage	_	_	O
42	IIIB	_	_	O
43	to	_	_	O
44	IV	_	_	O
45	NSCLC	_	_	O
46	were	_	_	O
47	randomly	_	_	O
48	assigned	_	_	O
49	to	_	_	O
50	receive	_	_	O
51	docetaxel	_	_	O
52	75	_	_	O
53	mg/m2	_	_	O
54	and	_	_	O
55	cisplatin	_	_	O
56	75	_	_	O
57	mg/m2	_	_	O
58	every	_	_	O
59	3	_	_	O
60	weeks	_	_	O
61	(	_	_	O
62	DC	_	_	O
63	)	_	_	O
64	;	_	_	O
65	docetaxel	_	_	O
66	75	_	_	O
67	mg/m2	_	_	O
68	and	_	_	O
69	carboplatin	_	_	O
70	area	_	_	O
71	under	_	_	O
72	the	_	_	O
73	curve	_	_	O
74	of	_	_	O
75	6	_	_	O
76	mg/mL	_	_	O
77	*	_	_	O
78	min	_	_	O
79	every	_	_	O
80	3	_	_	O
81	weeks	_	_	O
82	(	_	_	O
83	DCb	_	_	O
84	)	_	_	O
85	;	_	_	O
86	or	_	_	O
87	vinorelbine	_	_	O
88	25	_	_	O
89	mg/m2/wk	_	_	O
90	and	_	_	O
91	cisplatin	_	_	O
92	100	_	_	O
93	mg/m2	_	_	O
94	every	_	_	O
95	4	_	_	O
96	weeks	_	_	O
97	(	_	_	O
98	VC	_	_	O
99	)	_	_	O
100	.	_	_	O

101	Patients	_	_	B-Premise
102	treated	_	_	I-Premise
103	with	_	_	I-Premise
104	DC	_	_	I-Premise
105	had	_	_	I-Premise
106	a	_	_	I-Premise
107	median	_	_	I-Premise
108	survival	_	_	I-Premise
109	of	_	_	I-Premise
110	11.3	_	_	I-Premise
111	v	_	_	I-Premise
112	10.1	_	_	I-Premise
113	months	_	_	I-Premise
114	for	_	_	I-Premise
115	VC-treated	_	_	I-Premise
116	patients	_	_	I-Premise
117	(	_	_	I-Premise
118	P	_	_	I-Premise
119	=.044	_	_	I-Premise
120	;	_	_	I-Premise
121	hazard	_	_	I-Premise
122	ratio	_	_	I-Premise
123	,	_	_	I-Premise
124	1.183	_	_	I-Premise
125	[	_	_	I-Premise
126	97.2	_	_	I-Premise
127	%	_	_	I-Premise
128	confidence	_	_	I-Premise
129	interval	_	_	I-Premise
130	,	_	_	I-Premise
131	0.989	_	_	I-Premise
132	to	_	_	I-Premise
133	1.416	_	_	I-Premise
134	]	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	The	_	_	B-Premise
138	2-year	_	_	I-Premise
139	survival	_	_	I-Premise
140	rate	_	_	I-Premise
141	was	_	_	I-Premise
142	21	_	_	I-Premise
143	%	_	_	I-Premise
144	for	_	_	I-Premise
145	DC-treated	_	_	I-Premise
146	patients	_	_	I-Premise
147	and	_	_	I-Premise
148	14	_	_	I-Premise
149	%	_	_	I-Premise
150	for	_	_	I-Premise
151	VC-treated	_	_	I-Premise
152	patients	_	_	I-Premise
153	.	_	_	I-Premise

154	Overall	_	_	B-Premise
155	response	_	_	I-Premise
156	rate	_	_	I-Premise
157	was	_	_	I-Premise
158	31.6	_	_	I-Premise
159	%	_	_	I-Premise
160	for	_	_	I-Premise
161	DC-treated	_	_	I-Premise
162	patients	_	_	I-Premise
163	v	_	_	I-Premise
164	24.5	_	_	I-Premise
165	%	_	_	I-Premise
166	for	_	_	I-Premise
167	VC-treated	_	_	I-Premise
168	patients	_	_	I-Premise
169	(	_	_	I-Premise
170	P	_	_	I-Premise
171	=.029	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	Median	_	_	B-Premise
175	survival	_	_	I-Premise
176	(	_	_	I-Premise
177	9.4	_	_	I-Premise
178	v	_	_	I-Premise
179	9.9	_	_	I-Premise
180	months	_	_	I-Premise
181	[	_	_	I-Premise
182	for	_	_	I-Premise
183	VC	_	_	I-Premise
184	]	_	_	I-Premise
185	;	_	_	I-Premise
186	P	_	_	I-Premise
187	=.657	_	_	I-Premise
188	;	_	_	I-Premise
189	hazard	_	_	I-Premise
190	ratio	_	_	I-Premise
191	,	_	_	I-Premise
192	1.048	_	_	I-Premise
193	[	_	_	I-Premise
194	97.2	_	_	I-Premise
195	confidence	_	_	I-Premise
196	interval	_	_	I-Premise
197	,	_	_	I-Premise
198	0.877	_	_	I-Premise
199	to	_	_	I-Premise
200	1.253	_	_	I-Premise
201	]	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	response	_	_	I-Premise
205	(	_	_	I-Premise
206	23.9	_	_	I-Premise
207	%	_	_	I-Premise
208	)	_	_	I-Premise
209	with	_	_	I-Premise
210	DCb	_	_	I-Premise
211	were	_	_	I-Premise
212	similar	_	_	I-Premise
213	to	_	_	I-Premise
214	those	_	_	I-Premise
215	results	_	_	I-Premise
216	for	_	_	I-Premise
217	VC	_	_	I-Premise
218	.	_	_	I-Premise

219	Neutropenia	_	_	B-Premise
220	,	_	_	I-Premise
221	thrombocytopenia	_	_	I-Premise
222	,	_	_	I-Premise
223	infection	_	_	I-Premise
224	,	_	_	I-Premise
225	and	_	_	I-Premise
226	febrile	_	_	I-Premise
227	neutropenia	_	_	I-Premise
228	were	_	_	I-Premise
229	similar	_	_	I-Premise
230	with	_	_	I-Premise
231	all	_	_	I-Premise
232	three	_	_	I-Premise
233	regimens	_	_	I-Premise
234	.	_	_	I-Premise

235	Grade	_	_	B-Premise
236	3	_	_	I-Premise
237	to	_	_	I-Premise
238	4	_	_	I-Premise
239	anemia	_	_	I-Premise
240	,	_	_	I-Premise
241	nausea	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	vomiting	_	_	I-Premise
245	were	_	_	I-Premise
246	more	_	_	I-Premise
247	common	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	.01	_	_	I-Premise
252	)	_	_	I-Premise
253	with	_	_	I-Premise
254	VC	_	_	I-Premise
255	than	_	_	I-Premise
256	with	_	_	I-Premise
257	DC	_	_	I-Premise
258	or	_	_	I-Premise
259	DCb	_	_	I-Premise
260	.	_	_	I-Premise

261	Patients	_	_	B-Premise
262	treated	_	_	I-Premise
263	with	_	_	I-Premise
264	either	_	_	I-Premise
265	docetaxel	_	_	I-Premise
266	regimen	_	_	I-Premise
267	had	_	_	I-Premise
268	consistently	_	_	I-Premise
269	improved	_	_	I-Premise
270	QoL	_	_	I-Premise
271	compared	_	_	I-Premise
272	with	_	_	I-Premise
273	VC-treated	_	_	I-Premise
274	patients	_	_	I-Premise
275	,	_	_	I-Premise
276	who	_	_	I-Premise
277	experienced	_	_	I-Premise
278	deterioration	_	_	I-Premise
279	in	_	_	I-Premise
280	QoL	_	_	I-Premise
281	.	_	_	I-Premise

282	DC	_	_	B-Claim
283	resulted	_	_	I-Claim
284	in	_	_	I-Claim
285	a	_	_	I-Claim
286	more	_	_	I-Claim
287	favorable	_	_	I-Claim
288	overall	_	_	I-Claim
289	response	_	_	I-Claim
290	and	_	_	I-Claim
291	survival	_	_	I-Claim
292	rate	_	_	I-Claim
293	than	_	_	I-Claim
294	VC	_	_	I-Claim
295	.	_	_	I-Claim

296	Both	_	_	B-Claim
297	DC	_	_	I-Claim
298	and	_	_	I-Claim
299	DCb	_	_	I-Claim
300	were	_	_	I-Claim
301	better	_	_	I-Claim
302	tolerated	_	_	I-Claim
303	and	_	_	I-Claim
304	provided	_	_	I-Claim
305	patients	_	_	I-Claim
306	with	_	_	I-Claim
307	consistently	_	_	I-Claim
308	improved	_	_	I-Claim
309	QoL	_	_	I-Claim
310	compared	_	_	I-Claim
311	with	_	_	I-Claim
312	VC	_	_	I-Claim
313	.	_	_	I-Claim

314	These	_	_	B-Claim
315	findings	_	_	I-Claim
316	demonstrate	_	_	I-Claim
317	that	_	_	I-Claim
318	a	_	_	I-Claim
319	docetaxel	_	_	I-Claim
320	plus	_	_	I-Claim
321	platinum	_	_	I-Claim
322	combination	_	_	I-Claim
323	is	_	_	I-Claim
324	an	_	_	I-Claim
325	effective	_	_	I-Claim
326	treatment	_	_	I-Claim
327	option	_	_	I-Claim
328	with	_	_	I-Claim
329	a	_	_	I-Claim
330	favorable	_	_	I-Claim
331	therapeutic	_	_	I-Claim
332	index	_	_	I-Claim
333	for	_	_	I-Claim
334	first-line	_	_	I-Claim
335	treatment	_	_	I-Claim
336	of	_	_	I-Claim
337	advanced	_	_	I-Claim
338	or	_	_	I-Claim
339	metastatic	_	_	I-Claim
340	NSCLC	_	_	I-Claim
341	.	_	_	I-Claim


0	Tivozanib	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	potent	_	_	I-Claim
4	and	_	_	I-Claim
5	selective	_	_	I-Claim
6	tyrosine	_	_	I-Claim
7	kinase	_	_	I-Claim
8	inhibitor	_	_	I-Claim
9	of	_	_	I-Claim
10	vascular	_	_	I-Claim
11	endothelial	_	_	I-Claim
12	growth	_	_	I-Claim
13	factor	_	_	I-Claim
14	receptor	_	_	I-Claim
15	1	_	_	I-Claim
16	(	_	_	I-Claim
17	VEGFR1	_	_	I-Claim
18	)	_	_	I-Claim
19	,	_	_	I-Claim
20	-2	_	_	I-Claim
21	,	_	_	I-Claim
22	and	_	_	I-Claim
23	-3	_	_	I-Claim
24	.	_	_	I-Claim

25	This	_	_	O
26	phase	_	_	O
27	III	_	_	O
28	trial	_	_	O
29	compared	_	_	O
30	tivozanib	_	_	O
31	with	_	_	O
32	sorafenib	_	_	O
33	as	_	_	O
34	initial	_	_	O
35	targeted	_	_	O
36	therapy	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	metastatic	_	_	O
41	renal	_	_	O
42	cell	_	_	O
43	carcinoma	_	_	O
44	(	_	_	O
45	RCC	_	_	O
46	)	_	_	O
47	.	_	_	O

48	Patients	_	_	O
49	with	_	_	O
50	metastatic	_	_	O
51	RCC	_	_	O
52	,	_	_	O
53	with	_	_	O
54	a	_	_	O
55	clear	_	_	O
56	cell	_	_	O
57	component	_	_	O
58	,	_	_	O
59	prior	_	_	O
60	nephrectomy	_	_	O
61	,	_	_	O
62	measurable	_	_	O
63	disease	_	_	O
64	,	_	_	O
65	and	_	_	O
66	0	_	_	O
67	or	_	_	O
68	1	_	_	O
69	prior	_	_	O
70	therapies	_	_	O
71	for	_	_	O
72	metastatic	_	_	O
73	RCC	_	_	O
74	were	_	_	O
75	randomly	_	_	O
76	assigned	_	_	O
77	to	_	_	O
78	tivozanib	_	_	O
79	or	_	_	O
80	sorafenib	_	_	O
81	.	_	_	O

82	Prior	_	_	O
83	VEGF-targeted	_	_	O
84	therapy	_	_	O
85	and	_	_	O
86	mammalian	_	_	O
87	target	_	_	O
88	of	_	_	O
89	rapamycin	_	_	O
90	inhibitor	_	_	O
91	were	_	_	O
92	not	_	_	O
93	permitted	_	_	O
94	.	_	_	O

95	The	_	_	O
96	primary	_	_	O
97	end	_	_	O
98	point	_	_	O
99	was	_	_	O
100	progression-free	_	_	O
101	survival	_	_	O
102	(	_	_	O
103	PFS	_	_	O
104	)	_	_	O
105	by	_	_	O
106	independent	_	_	O
107	review	_	_	O
108	.	_	_	O

109	A	_	_	O
110	total	_	_	O
111	of	_	_	O
112	517	_	_	O
113	patients	_	_	O
114	were	_	_	O
115	randomly	_	_	O
116	assigned	_	_	O
117	to	_	_	O
118	tivozanib	_	_	O
119	(	_	_	O
120	n	_	_	O
121	=	_	_	O
122	260	_	_	O
123	)	_	_	O
124	or	_	_	O
125	sorafenib	_	_	O
126	(	_	_	O
127	n	_	_	O
128	=	_	_	O
129	257	_	_	O
130	)	_	_	O
131	.	_	_	O

132	PFS	_	_	B-Premise
133	was	_	_	I-Premise
134	longer	_	_	I-Premise
135	with	_	_	I-Premise
136	tivozanib	_	_	I-Premise
137	than	_	_	I-Premise
138	with	_	_	I-Premise
139	sorafenib	_	_	I-Premise
140	in	_	_	I-Premise
141	the	_	_	I-Premise
142	overall	_	_	I-Premise
143	population	_	_	I-Premise
144	(	_	_	I-Premise
145	median	_	_	I-Premise
146	,	_	_	I-Premise
147	11.9	_	_	I-Premise
148	v	_	_	I-Premise
149	9.1	_	_	I-Premise
150	months	_	_	I-Premise
151	;	_	_	I-Premise
152	hazard	_	_	I-Premise
153	ratio	_	_	I-Premise
154	[	_	_	I-Premise
155	HR	_	_	I-Premise
156	]	_	_	I-Premise
157	,	_	_	I-Premise
158	0.797	_	_	I-Premise
159	;	_	_	I-Premise
160	95	_	_	I-Premise
161	%	_	_	I-Premise
162	CI	_	_	I-Premise
163	,	_	_	I-Premise
164	0.639	_	_	I-Premise
165	to	_	_	I-Premise
166	0.993	_	_	I-Premise
167	;	_	_	I-Premise
168	P	_	_	I-Premise
169	=	_	_	I-Premise
170	.042	_	_	I-Premise
171	)	_	_	I-Premise
172	.	_	_	I-Premise

173	One	_	_	O
174	hundred	_	_	O
175	fifty-six	_	_	O
176	patients	_	_	O
177	(	_	_	O
178	61	_	_	O
179	%	_	_	O
180	)	_	_	O
181	who	_	_	O
182	progressed	_	_	O
183	on	_	_	O
184	sorafenib	_	_	O
185	crossed	_	_	O
186	over	_	_	O
187	to	_	_	O
188	receive	_	_	O
189	tivozanib	_	_	O
190	.	_	_	O

191	The	_	_	B-Premise
192	final	_	_	I-Premise
193	overall	_	_	I-Premise
194	survival	_	_	I-Premise
195	(	_	_	I-Premise
196	OS	_	_	I-Premise
197	)	_	_	I-Premise
198	analysis	_	_	I-Premise
199	showed	_	_	I-Premise
200	a	_	_	I-Premise
201	trend	_	_	I-Premise
202	toward	_	_	I-Premise
203	longer	_	_	I-Premise
204	survival	_	_	I-Premise
205	on	_	_	I-Premise
206	the	_	_	I-Premise
207	sorafenib	_	_	I-Premise
208	arm	_	_	I-Premise
209	than	_	_	I-Premise
210	on	_	_	I-Premise
211	the	_	_	I-Premise
212	tivozanib	_	_	I-Premise
213	arm	_	_	I-Premise
214	(	_	_	I-Premise
215	median	_	_	I-Premise
216	,	_	_	I-Premise
217	29.3	_	_	I-Premise
218	v	_	_	I-Premise
219	28.8	_	_	I-Premise
220	months	_	_	I-Premise
221	;	_	_	I-Premise
222	HR	_	_	I-Premise
223	,	_	_	I-Premise
224	1.245	_	_	I-Premise
225	;	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	CI	_	_	I-Premise
229	,	_	_	I-Premise
230	0.954	_	_	I-Premise
231	to	_	_	I-Premise
232	1.624	_	_	I-Premise
233	;	_	_	I-Premise
234	P	_	_	I-Premise
235	=	_	_	I-Premise
236	.105	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Adverse	_	_	B-Premise
240	events	_	_	I-Premise
241	(	_	_	I-Premise
242	AEs	_	_	I-Premise
243	)	_	_	I-Premise
244	more	_	_	I-Premise
245	common	_	_	I-Premise
246	with	_	_	I-Premise
247	tivozanib	_	_	I-Premise
248	than	_	_	I-Premise
249	with	_	_	I-Premise
250	sorafenib	_	_	I-Premise
251	were	_	_	I-Premise
252	hypertension	_	_	I-Premise
253	(	_	_	I-Premise
254	44	_	_	I-Premise
255	%	_	_	I-Premise
256	v	_	_	I-Premise
257	34	_	_	I-Premise
258	%	_	_	I-Premise
259	)	_	_	I-Premise
260	and	_	_	I-Premise
261	dysphonia	_	_	I-Premise
262	(	_	_	I-Premise
263	21	_	_	I-Premise
264	%	_	_	I-Premise
265	v	_	_	I-Premise
266	5	_	_	I-Premise
267	%	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	AEs	_	_	B-Premise
271	more	_	_	I-Premise
272	common	_	_	I-Premise
273	with	_	_	I-Premise
274	sorafenib	_	_	I-Premise
275	than	_	_	I-Premise
276	with	_	_	I-Premise
277	tivozanib	_	_	I-Premise
278	were	_	_	I-Premise
279	hand-foot	_	_	I-Premise
280	skin	_	_	I-Premise
281	reaction	_	_	I-Premise
282	(	_	_	I-Premise
283	54	_	_	I-Premise
284	%	_	_	I-Premise
285	v	_	_	I-Premise
286	14	_	_	I-Premise
287	%	_	_	I-Premise
288	)	_	_	I-Premise
289	and	_	_	I-Premise
290	diarrhea	_	_	I-Premise
291	(	_	_	I-Premise
292	33	_	_	I-Premise
293	%	_	_	I-Premise
294	v	_	_	I-Premise
295	23	_	_	I-Premise
296	%	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Tivozanib	_	_	B-Claim
300	demonstrated	_	_	I-Claim
301	improved	_	_	I-Claim
302	PFS	_	_	I-Claim
303	,	_	_	I-Claim
304	but	_	_	I-Claim
305	not	_	_	I-Claim
306	OS	_	_	I-Claim
307	,	_	_	I-Claim
308	and	_	_	I-Claim
309	a	_	_	I-Claim
310	differentiated	_	_	I-Claim
311	safety	_	_	I-Claim
312	profile	_	_	I-Claim
313	,	_	_	I-Claim
314	compared	_	_	I-Claim
315	with	_	_	I-Claim
316	sorafenib	_	_	I-Claim
317	,	_	_	I-Claim
318	as	_	_	I-Claim
319	initial	_	_	I-Claim
320	targeted	_	_	I-Claim
321	therapy	_	_	I-Claim
322	for	_	_	I-Claim
323	metastatic	_	_	I-Claim
324	RCC	_	_	I-Claim
325	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	health-related	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	narrow	_	_	O
11	gastric	_	_	O
12	tube	_	_	O
13	and	_	_	O
14	whole	_	_	O
15	stomach	_	_	O
16	reconstructions	_	_	O
17	after	_	_	O
18	oncologic	_	_	O
19	esophagectomy	_	_	O
20	.	_	_	O

21	In	_	_	O
22	a	_	_	O
23	prospective	_	_	O
24	randomized	_	_	O
25	single-center	_	_	O
26	study	_	_	O
27	from	_	_	O
28	2007	_	_	O
29	to	_	_	O
30	2008	_	_	O
31	,	_	_	O
32	104	_	_	O
33	patients	_	_	O
34	underwent	_	_	O
35	esophagectomy	_	_	O
36	for	_	_	O
37	cancer	_	_	O
38	.	_	_	O

39	To	_	_	O
40	assess	_	_	O
41	health-related	_	_	O
42	quality	_	_	O
43	of	_	_	O
44	life	_	_	O
45	,	_	_	O
46	the	_	_	O
47	questionnaire	_	_	O
48	(	_	_	O
49	European	_	_	O
50	Organization	_	_	O
51	for	_	_	O
52	Research	_	_	O
53	and	_	_	O
54	Treatment	_	_	O
55	of	_	_	O
56	Cancer	_	_	O
57	Quality	_	_	O
58	of	_	_	O
59	Life	_	_	O
60	Questionnaire	_	_	O
61	Core	_	_	O
62	30	_	_	O
63	and	_	_	O
64	the	_	_	O
65	Oesophagus-Specific	_	_	O
66	Quality	_	_	O
67	of	_	_	O
68	Life	_	_	O
69	Questionnaire	_	_	O
70	18	_	_	O
71	)	_	_	O
72	was	_	_	O
73	administered	_	_	O
74	at	_	_	O
75	3	_	_	O
76	weeks	_	_	O
77	,	_	_	O
78	6	_	_	O
79	months	_	_	O
80	,	_	_	O
81	1	_	_	O
82	year	_	_	O
83	,	_	_	O
84	and	_	_	O
85	2	_	_	O
86	years	_	_	O
87	after	_	_	O
88	surgery	_	_	O
89	.	_	_	O

90	The	_	_	B-Premise
91	perioperative	_	_	I-Premise
92	complication	_	_	I-Premise
93	rate	_	_	I-Premise
94	was	_	_	I-Premise
95	26.9	_	_	I-Premise
96	%	_	_	I-Premise
97	in	_	_	I-Premise
98	narrow	_	_	I-Premise
99	gastric	_	_	I-Premise
100	tube	_	_	I-Premise
101	group	_	_	I-Premise
102	and	_	_	I-Premise
103	48.1	_	_	I-Premise
104	%	_	_	I-Premise
105	in	_	_	I-Premise
106	whole	_	_	I-Premise
107	stomach	_	_	I-Premise
108	group	_	_	I-Premise
109	(	_	_	I-Premise
110	P	_	_	I-Premise
111	=	_	_	I-Premise
112	0.31	_	_	I-Premise
113	)	_	_	I-Premise
114	.	_	_	I-Premise

115	At	_	_	B-Premise
116	the	_	_	I-Premise
117	time	_	_	I-Premise
118	of	_	_	I-Premise
119	3	_	_	I-Premise
120	weeks	_	_	I-Premise
121	after	_	_	I-Premise
122	surgery	_	_	I-Premise
123	,	_	_	I-Premise
124	the	_	_	I-Premise
125	reflux	_	_	I-Premise
126	and	_	_	I-Premise
127	dyspnea	_	_	I-Premise
128	scores	_	_	I-Premise
129	were	_	_	I-Premise
130	higher	_	_	I-Premise
131	in	_	_	I-Premise
132	whole	_	_	I-Premise
133	stomach	_	_	I-Premise
134	group	_	_	I-Premise
135	than	_	_	I-Premise
136	in	_	_	I-Premise
137	narrow	_	_	I-Premise
138	gastric	_	_	I-Premise
139	tube	_	_	I-Premise
140	group	_	_	I-Premise
141	,	_	_	I-Premise
142	which	_	_	I-Premise
143	meant	_	_	I-Premise
144	that	_	_	I-Premise
145	the	_	_	I-Premise
146	patients	_	_	I-Premise
147	in	_	_	I-Premise
148	whole	_	_	I-Premise
149	stomach	_	_	I-Premise
150	group	_	_	I-Premise
151	suffered	_	_	I-Premise
152	more	_	_	I-Premise
153	severe	_	_	I-Premise
154	problem	_	_	I-Premise
155	.	_	_	I-Premise

156	At	_	_	B-Premise
157	the	_	_	I-Premise
158	time	_	_	I-Premise
159	of	_	_	I-Premise
160	6	_	_	I-Premise
161	months	_	_	I-Premise
162	and	_	_	I-Premise
163	1	_	_	I-Premise
164	year	_	_	I-Premise
165	after	_	_	I-Premise
166	surgery	_	_	I-Premise
167	,	_	_	I-Premise
168	the	_	_	I-Premise
169	reflux	_	_	I-Premise
170	scores	_	_	I-Premise
171	were	_	_	I-Premise
172	lower	_	_	I-Premise
173	in	_	_	I-Premise
174	narrow	_	_	I-Premise
175	gastric	_	_	I-Premise
176	tube	_	_	I-Premise
177	group	_	_	I-Premise
178	than	_	_	I-Premise
179	in	_	_	I-Premise
180	whole	_	_	I-Premise
181	stomach	_	_	I-Premise
182	group	_	_	I-Premise
183	,	_	_	I-Premise
184	which	_	_	I-Premise
185	revealed	_	_	I-Premise
186	that	_	_	I-Premise
187	there	_	_	I-Premise
188	were	_	_	I-Premise
189	less	_	_	I-Premise
190	problems	_	_	I-Premise
191	of	_	_	I-Premise
192	reflux	_	_	I-Premise
193	in	_	_	I-Premise
194	the	_	_	I-Premise
195	patients	_	_	I-Premise
196	of	_	_	I-Premise
197	narrow	_	_	I-Premise
198	gastric	_	_	I-Premise
199	tube	_	_	I-Premise
200	group	_	_	I-Premise
201	;	_	_	I-Premise
202	meanwhile	_	_	O
203	,	_	_	O
204	the	_	_	B-Premise
205	score	_	_	I-Premise
206	of	_	_	I-Premise
207	physical	_	_	I-Premise
208	function	_	_	I-Premise
209	scale	_	_	I-Premise
210	in	_	_	I-Premise
211	narrow	_	_	I-Premise
212	gastric	_	_	I-Premise
213	tube	_	_	I-Premise
214	group	_	_	I-Premise
215	was	_	_	I-Premise
216	higher	_	_	I-Premise
217	conversely	_	_	I-Premise
218	,	_	_	I-Premise
219	which	_	_	I-Premise
220	suggested	_	_	I-Premise
221	that	_	_	I-Premise
222	the	_	_	I-Premise
223	patients	_	_	I-Premise
224	gain	_	_	I-Premise
225	a	_	_	I-Premise
226	better	_	_	I-Premise
227	status	_	_	I-Premise
228	in	_	_	I-Premise
229	physical	_	_	I-Premise
230	function	_	_	I-Premise
231	.	_	_	I-Premise

232	Nausea	_	_	B-Premise
233	and	_	_	I-Premise
234	vomiting	_	_	I-Premise
235	is	_	_	I-Premise
236	the	_	_	I-Premise
237	only	_	_	I-Premise
238	notable	_	_	I-Premise
239	symptom	_	_	I-Premise
240	that	_	_	I-Premise
241	was	_	_	I-Premise
242	worse	_	_	I-Premise
243	in	_	_	I-Premise
244	whole	_	_	I-Premise
245	stomach	_	_	I-Premise
246	group	_	_	I-Premise
247	at	_	_	I-Premise
248	the	_	_	I-Premise
249	time	_	_	I-Premise
250	of	_	_	I-Premise
251	2	_	_	I-Premise
252	years	_	_	I-Premise
253	after	_	_	I-Premise
254	surgery	_	_	I-Premise
255	,	_	_	I-Premise
256	which	_	_	O
257	suggested	_	_	O
258	that	_	_	O
259	patients	_	_	B-Claim
260	in	_	_	I-Claim
261	whole	_	_	I-Claim
262	stomach	_	_	I-Claim
263	group	_	_	I-Claim
264	suffered	_	_	I-Claim
265	more	_	_	I-Claim
266	severe	_	_	I-Claim
267	nausea	_	_	I-Claim
268	and	_	_	I-Claim
269	vomiting	_	_	I-Claim
270	.	_	_	I-Claim

271	Narrow	_	_	B-Claim
272	gastric	_	_	I-Claim
273	tube	_	_	I-Claim
274	reconstruction	_	_	I-Claim
275	may	_	_	I-Claim
276	be	_	_	I-Claim
277	a	_	_	I-Claim
278	good	_	_	I-Claim
279	alternative	_	_	I-Claim
280	choice	_	_	I-Claim
281	for	_	_	I-Claim
282	patients	_	_	I-Claim
283	undergoing	_	_	I-Claim
284	oncologic	_	_	I-Claim
285	esophagectomy	_	_	I-Claim
286	in	_	_	I-Claim
287	view	_	_	I-Claim
288	of	_	_	I-Claim
289	better	_	_	I-Claim
290	health-related	_	_	I-Claim
291	quality	_	_	I-Claim
292	of	_	_	I-Claim
293	life	_	_	I-Claim
294	after	_	_	I-Claim
295	the	_	_	I-Claim
296	surgery	_	_	I-Claim
297	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	trial	_	_	O
3	compared	_	_	O
4	three	_	_	O
5	chemotherapy	_	_	O
6	regimens	_	_	O
7	in	_	_	O
8	the	_	_	O
9	first-line	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	advanced	_	_	O
13	colorectal	_	_	O
14	cancer	_	_	O
15	,	_	_	O
16	in	_	_	O
17	terms	_	_	O
18	of	_	_	O
19	their	_	_	O
20	effect	_	_	O
21	on	_	_	O
22	overall	_	_	O
23	and	_	_	O
24	progression-free	_	_	O
25	survival	_	_	O
26	;	_	_	O
27	other	_	_	O
28	endpoints	_	_	O
29	included	_	_	O
30	toxicity	_	_	O
31	,	_	_	O
32	symptom	_	_	O
33	palliation	_	_	O
34	,	_	_	O
35	and	_	_	O
36	quality	_	_	O
37	of	_	_	O
38	life	_	_	O
39	.	_	_	O

40	905	_	_	O
41	patients	_	_	O
42	were	_	_	O
43	randomly	_	_	O
44	assigned	_	_	O
45	the	_	_	O
46	de	_	_	O
47	Gramont	_	_	O
48	regimen	_	_	O
49	(	_	_	O
50	n=303	_	_	O
51	;	_	_	O
52	folinic	_	_	O
53	acid	_	_	O
54	200	_	_	O
55	mg/m	_	_	O
56	(	_	_	O
57	2	_	_	O
58	)	_	_	O
59	,	_	_	O
60	fluorouracil	_	_	O
61	bolus	_	_	O
62	400	_	_	O
63	mg/m	_	_	O
64	(	_	_	O
65	2	_	_	O
66	)	_	_	O
67	,	_	_	O
68	and	_	_	O
69	infusion	_	_	O
70	600	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	on	_	_	O
76	days	_	_	O
77	1	_	_	O
78	and	_	_	O
79	2	_	_	O
80	,	_	_	O
81	repeated	_	_	O
82	every	_	_	O
83	14	_	_	O
84	days	_	_	O
85	)	_	_	O
86	,	_	_	O
87	the	_	_	O
88	Lokich	_	_	O
89	regimen	_	_	O
90	(	_	_	O
91	n=301	_	_	O
92	;	_	_	O
93	protracted	_	_	O
94	venous	_	_	O
95	infusion	_	_	O
96	of	_	_	O
97	fluorouracil	_	_	O
98	300	_	_	O
99	mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	daily	_	_	O
104	)	_	_	O
105	,	_	_	O
106	or	_	_	O
107	raltitrexed	_	_	O
108	(	_	_	O
109	n=301	_	_	O
110	;	_	_	O
111	3	_	_	O
112	mg/m	_	_	O
113	(	_	_	O
114	2	_	_	O
115	)	_	_	O
116	intravenously	_	_	O
117	every	_	_	O
118	21	_	_	O
119	days	_	_	O
120	)	_	_	O
121	.	_	_	O

122	Analyses	_	_	O
123	were	_	_	O
124	by	_	_	O
125	intention	_	_	O
126	to	_	_	O
127	treat	_	_	O
128	.	_	_	O

129	Median	_	_	O
130	follow-up	_	_	O
131	of	_	_	O
132	survivors	_	_	O
133	was	_	_	O
134	67	_	_	O
135	weeks	_	_	O
136	.	_	_	O

137	For	_	_	B-Premise
138	the	_	_	I-Premise
139	de	_	_	I-Premise
140	Gramont	_	_	I-Premise
141	,	_	_	I-Premise
142	Lokich	_	_	I-Premise
143	,	_	_	I-Premise
144	and	_	_	I-Premise
145	raltitrexed	_	_	I-Premise
146	groups	_	_	I-Premise
147	,	_	_	I-Premise
148	respectively	_	_	I-Premise
149	,	_	_	I-Premise
150	median	_	_	I-Premise
151	survival	_	_	I-Premise
152	was	_	_	I-Premise
153	294	_	_	I-Premise
154	,	_	_	I-Premise
155	302	_	_	I-Premise
156	,	_	_	I-Premise
157	and	_	_	I-Premise
158	266	_	_	I-Premise
159	days	_	_	I-Premise
160	.	_	_	I-Premise

161	The	_	_	B-Premise
162	hazard	_	_	I-Premise
163	ratios	_	_	I-Premise
164	for	_	_	I-Premise
165	overall	_	_	I-Premise
166	survival	_	_	I-Premise
167	were	_	_	I-Premise
168	0.88	_	_	I-Premise
169	(	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	0.70-1.12	_	_	I-Premise
174	,	_	_	I-Premise
175	p=0.17	_	_	I-Premise
176	)	_	_	I-Premise
177	for	_	_	I-Premise
178	de	_	_	I-Premise
179	Gramont	_	_	I-Premise
180	versus	_	_	I-Premise
181	Lokich	_	_	I-Premise
182	,	_	_	I-Premise
183	and	_	_	I-Premise
184	0.99	_	_	I-Premise
185	(	_	_	I-Premise
186	0.79-1.25	_	_	I-Premise
187	,	_	_	I-Premise
188	p=0.94	_	_	I-Premise
189	)	_	_	I-Premise
190	for	_	_	I-Premise
191	de	_	_	I-Premise
192	Gramont	_	_	I-Premise
193	versus	_	_	I-Premise
194	raltitrexed	_	_	I-Premise
195	.	_	_	I-Premise

196	An	_	_	B-Premise
197	increase	_	_	I-Premise
198	in	_	_	I-Premise
199	treatment-related	_	_	I-Premise
200	deaths	_	_	I-Premise
201	was	_	_	I-Premise
202	seen	_	_	I-Premise
203	on	_	_	I-Premise
204	raltitrexed	_	_	I-Premise
205	(	_	_	I-Premise
206	de	_	_	I-Premise
207	Gramont	_	_	I-Premise
208	one	_	_	I-Premise
209	,	_	_	I-Premise
210	Lokich	_	_	I-Premise
211	two	_	_	I-Premise
212	,	_	_	I-Premise
213	raltitrexed	_	_	I-Premise
214	18	_	_	I-Premise
215	)	_	_	I-Premise
216	due	_	_	I-Premise
217	to	_	_	I-Premise
218	combined	_	_	I-Premise
219	gastrointestinal	_	_	I-Premise
220	and	_	_	I-Premise
221	haematological	_	_	I-Premise
222	toxicity	_	_	I-Premise
223	.	_	_	I-Premise

224	Patients	_	_	B-Premise
225	'	_	_	I-Premise
226	assessment	_	_	I-Premise
227	of	_	_	I-Premise
228	quality	_	_	I-Premise
229	of	_	_	I-Premise
230	life	_	_	I-Premise
231	showed	_	_	I-Premise
232	that	_	_	I-Premise
233	raltitrexed	_	_	I-Premise
234	was	_	_	I-Premise
235	inferior	_	_	I-Premise
236	to	_	_	I-Premise
237	the	_	_	I-Premise
238	fluorouracil-based	_	_	I-Premise
239	regimens	_	_	I-Premise
240	,	_	_	I-Premise
241	especially	_	_	I-Premise
242	in	_	_	I-Premise
243	terms	_	_	I-Premise
244	of	_	_	I-Premise
245	palliation	_	_	I-Premise
246	and	_	_	I-Premise
247	functioning	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Claim
250	deGramont	_	_	I-Claim
251	and	_	_	I-Claim
252	Lokich	_	_	I-Claim
253	regimens	_	_	I-Claim
254	were	_	_	I-Claim
255	similar	_	_	I-Claim
256	in	_	_	I-Claim
257	terms	_	_	I-Claim
258	of	_	_	I-Claim
259	survival	_	_	I-Claim
260	,	_	_	I-Claim
261	quality	_	_	I-Claim
262	of	_	_	I-Claim
263	life	_	_	I-Claim
264	,	_	_	I-Claim
265	and	_	_	I-Claim
266	response	_	_	I-Claim
267	rates	_	_	I-Claim
268	.	_	_	I-Claim

269	The	_	_	B-Claim
270	Lokich	_	_	I-Claim
271	regimen	_	_	I-Claim
272	was	_	_	I-Claim
273	associated	_	_	I-Claim
274	with	_	_	I-Claim
275	more	_	_	I-Claim
276	central	_	_	I-Claim
277	line	_	_	I-Claim
278	complications	_	_	I-Claim
279	and	_	_	I-Claim
280	hand-foot	_	_	I-Claim
281	syndrome	_	_	I-Claim
282	.	_	_	I-Claim

283	Raltitrexed	_	_	B-Claim
284	showed	_	_	I-Claim
285	similar	_	_	I-Claim
286	response	_	_	I-Claim
287	rates	_	_	I-Claim
288	and	_	_	I-Claim
289	overall	_	_	I-Claim
290	survival	_	_	I-Claim
291	to	_	_	I-Claim
292	the	_	_	I-Claim
293	de	_	_	I-Claim
294	Gramont	_	_	I-Claim
295	regimen	_	_	I-Claim
296	and	_	_	I-Claim
297	was	_	_	I-Claim
298	easier	_	_	I-Claim
299	to	_	_	I-Claim
300	administer	_	_	I-Claim
301	,	_	_	I-Claim
302	but	_	_	B-Claim
303	resulted	_	_	I-Claim
304	in	_	_	I-Claim
305	greater	_	_	I-Claim
306	toxicity	_	_	I-Claim
307	and	_	_	I-Claim
308	inferior	_	_	I-Claim
309	quality	_	_	I-Claim
310	of	_	_	I-Claim
311	life	_	_	I-Claim
312	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aims	_	_	O
3	to	_	_	O
4	describe	_	_	O
5	and	_	_	O
6	compare	_	_	O
7	health-related	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	HRQL	_	_	O
13	)	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	node-positive	_	_	O
18	and	_	_	O
19	high-risk	_	_	O
20	node-negative	_	_	O
21	HER2-positive	_	_	O
22	early	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	receiving	_	_	O
26	adjuvant	_	_	O
27	docetaxel	_	_	O
28	and	_	_	O
29	trastuzumab-based	_	_	O
30	or	_	_	O
31	docetaxel-based	_	_	O
32	regimens	_	_	O
33	alone	_	_	O
34	.	_	_	O

35	Eligible	_	_	O
36	patients	_	_	O
37	(	_	_	O
38	n	_	_	O
39	=	_	_	O
40	3,222	_	_	O
41	)	_	_	O
42	were	_	_	O
43	randomly	_	_	O
44	assigned	_	_	O
45	to	_	_	O
46	either	_	_	O
47	four	_	_	O
48	cycles	_	_	O
49	of	_	_	O
50	adjuvant	_	_	O
51	doxorubicin	_	_	O
52	and	_	_	O
53	cyclophosphamide	_	_	O
54	followed	_	_	O
55	by	_	_	O
56	four	_	_	O
57	cycles	_	_	O
58	of	_	_	O
59	docetaxel	_	_	O
60	(	_	_	O
61	ACT	_	_	O
62	)	_	_	O
63	or	_	_	O
64	one	_	_	O
65	of	_	_	O
66	two	_	_	O
67	trastuzumab-containing	_	_	O
68	regimens	_	_	O
69	:	_	_	O
70	adjuvant	_	_	O
71	doxorubicin	_	_	O
72	and	_	_	O
73	cyclophosphamide	_	_	O
74	followed	_	_	O
75	by	_	_	O
76	docetaxel	_	_	O
77	plus	_	_	O
78	trastuzumab	_	_	O
79	administered	_	_	O
80	for	_	_	O
81	1	_	_	O
82	year	_	_	O
83	(	_	_	O
84	ACTH	_	_	O
85	)	_	_	O
86	or	_	_	O
87	six	_	_	O
88	cycles	_	_	O
89	of	_	_	O
90	docetaxel	_	_	O
91	plus	_	_	O
92	carboplatin	_	_	O
93	combined	_	_	O
94	with	_	_	O
95	trastuzumab	_	_	O
96	administered	_	_	O
97	for	_	_	O
98	1	_	_	O
99	year	_	_	O
100	(	_	_	O
101	TCH	_	_	O
102	)	_	_	O
103	.	_	_	O

104	The	_	_	O
105	European	_	_	O
106	Organization	_	_	O
107	for	_	_	O
108	Research	_	_	O
109	and	_	_	O
110	Treatment	_	_	O
111	of	_	_	O
112	Cancer	_	_	O
113	(	_	_	O
114	EORTC	_	_	O
115	)	_	_	O
116	Quality	_	_	O
117	of	_	_	O
118	Life	_	_	O
119	Questionnaire	_	_	O
120	C30	_	_	O
121	and	_	_	O
122	BR-23	_	_	O
123	were	_	_	O
124	administered	_	_	O
125	at	_	_	O
126	baseline	_	_	O
127	,	_	_	O
128	the	_	_	O
129	start	_	_	O
130	of	_	_	O
131	cycle	_	_	O
132	4	_	_	O
133	(	_	_	O
134	mid	_	_	O
135	)	_	_	O
136	,	_	_	O
137	and	_	_	O
138	the	_	_	O
139	end	_	_	O
140	of	_	_	O
141	chemotherapy	_	_	O
142	(	_	_	O
143	EOC	_	_	O
144	)	_	_	O
145	,	_	_	O
146	as	_	_	O
147	well	_	_	O
148	as	_	_	O
149	at	_	_	O
150	6	_	_	O
151	,	_	_	O
152	12	_	_	O
153	,	_	_	O
154	and	_	_	O
155	24	_	_	O
156	months	_	_	O
157	after	_	_	O
158	chemotherapy	_	_	O
159	.	_	_	O

160	Compliance	_	_	B-Premise
161	rates	_	_	I-Premise
162	for	_	_	I-Premise
163	the	_	_	I-Premise
164	EORTC	_	_	I-Premise
165	questionnaires	_	_	I-Premise
166	were	_	_	I-Premise
167	acceptable	_	_	I-Premise
168	at	_	_	I-Premise
169	72	_	_	I-Premise
170	%	_	_	I-Premise
171	-93	_	_	I-Premise
172	%	_	_	I-Premise
173	of	_	_	I-Premise
174	eligible	_	_	I-Premise
175	patients	_	_	I-Premise
176	out	_	_	I-Premise
177	to	_	_	I-Premise
178	the	_	_	I-Premise
179	12-month	_	_	I-Premise
180	assessment	_	_	I-Premise
181	.	_	_	I-Premise

182	Systemic	_	_	B-Premise
183	side	_	_	I-Premise
184	effect	_	_	I-Premise
185	(	_	_	I-Premise
186	SE	_	_	I-Premise
187	)	_	_	I-Premise
188	change	_	_	I-Premise
189	scores	_	_	I-Premise
190	were	_	_	I-Premise
191	significantly	_	_	I-Premise
192	improved	_	_	I-Premise
193	for	_	_	I-Premise
194	TCH-treated	_	_	I-Premise
195	patients	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	ACTH	_	_	I-Premise
199	and	_	_	I-Premise
200	ACT	_	_	I-Premise
201	at	_	_	I-Premise
202	EOC	_	_	I-Premise
203	,	_	_	I-Premise
204	suggesting	_	_	I-Premise
205	improved	_	_	I-Premise
206	tolerability	_	_	I-Premise
207	.	_	_	I-Premise

208	Physical	_	_	B-Premise
209	functioning	_	_	I-Premise
210	(	_	_	I-Premise
211	PF	_	_	I-Premise
212	)	_	_	I-Premise
213	was	_	_	I-Premise
214	only	_	_	I-Premise
215	slightly	_	_	I-Premise
216	worse	_	_	I-Premise
217	at	_	_	I-Premise
218	midpoint	_	_	I-Premise
219	for	_	_	I-Premise
220	those	_	_	I-Premise
221	receiving	_	_	I-Premise
222	TCH	_	_	I-Premise
223	,	_	_	I-Premise
224	compared	_	_	I-Premise
225	with	_	_	I-Premise
226	patients	_	_	I-Premise
227	who	_	_	I-Premise
228	were	_	_	I-Premise
229	just	_	_	I-Premise
230	starting	_	_	I-Premise
231	on	_	_	I-Premise
232	taxane	_	_	I-Premise
233	in	_	_	I-Premise
234	an	_	_	I-Premise
235	ACTH	_	_	I-Premise
236	regimen	_	_	I-Premise
237	,	_	_	I-Premise
238	but	_	_	I-Premise
239	was	_	_	I-Premise
240	otherwise	_	_	I-Premise
241	similar	_	_	I-Premise
242	between	_	_	I-Premise
243	arms	_	_	I-Premise
244	.	_	_	I-Premise

245	All	_	_	B-Claim
246	treatment	_	_	I-Claim
247	arms	_	_	I-Claim
248	recovered	_	_	I-Claim
249	from	_	_	I-Claim
250	the	_	_	I-Claim
251	deterioration	_	_	I-Claim
252	in	_	_	I-Claim
253	SE	_	_	I-Claim
254	,	_	_	I-Claim
255	PF	_	_	I-Claim
256	,	_	_	I-Claim
257	and	_	_	I-Claim
258	Global	_	_	I-Claim
259	Health	_	_	I-Claim
260	Scale	_	_	I-Claim
261	scores	_	_	I-Claim
262	by	_	_	I-Claim
263	1	_	_	I-Claim
264	year	_	_	I-Claim
265	and	_	_	I-Claim
266	median	_	_	I-Claim
267	future	_	_	I-Claim
268	perspective	_	_	I-Claim
269	change	_	_	I-Claim
270	scores	_	_	I-Claim
271	continued	_	_	I-Claim
272	to	_	_	I-Claim
273	improve	_	_	I-Claim
274	throughout	_	_	I-Claim
275	treatment	_	_	I-Claim
276	and	_	_	I-Claim
277	follow-up	_	_	I-Claim
278	.	_	_	I-Claim

279	HRQL	_	_	B-Claim
280	outcomes	_	_	I-Claim
281	for	_	_	I-Claim
282	adjuvant	_	_	I-Claim
283	docetaxel	_	_	I-Claim
284	and	_	_	I-Claim
285	trastuzumab-based	_	_	I-Claim
286	regimens	_	_	I-Claim
287	are	_	_	I-Claim
288	favorable	_	_	I-Claim
289	and	_	_	I-Claim
290	support	_	_	I-Claim
291	TCH	_	_	I-Claim
292	as	_	_	I-Claim
293	a	_	_	I-Claim
294	more	_	_	I-Claim
295	tolerable	_	_	I-Claim
296	treatment	_	_	I-Claim
297	option	_	_	I-Claim
298	.	_	_	I-Claim


0	Patients	_	_	O
1	undergoing	_	_	O
2	gastrectomy	_	_	O
3	because	_	_	O
4	of	_	_	O
5	stomach	_	_	O
6	cancer	_	_	O
7	often	_	_	O
8	face	_	_	O
9	weight	_	_	O
10	loss	_	_	O
11	in	_	_	O
12	the	_	_	O
13	perioperational	_	_	O
14	period	_	_	O
15	,	_	_	O
16	which	_	_	O
17	can	_	_	O
18	lead	_	_	O
19	to	_	_	O
20	malnutrition	_	_	O
21	and	_	_	O
22	negative	_	_	O
23	treatment	_	_	O
24	outcomes	_	_	O
25	.	_	_	O

26	The	_	_	O
27	purpose	_	_	O
28	of	_	_	O
29	this	_	_	O
30	study	_	_	O
31	was	_	_	O
32	to	_	_	O
33	develop	_	_	O
34	a	_	_	O
35	patient	_	_	O
36	participation-based	_	_	O
37	dietary	_	_	O
38	intervention	_	_	O
39	(	_	_	O
40	PPDI	_	_	O
41	)	_	_	O
42	and	_	_	O
43	evaluate	_	_	O
44	its	_	_	O
45	effects	_	_	O
46	on	_	_	O
47	patient	_	_	O
48	outcomes	_	_	O
49	.	_	_	O

50	This	_	_	O
51	was	_	_	O
52	a	_	_	O
53	prospective	_	_	O
54	,	_	_	O
55	randomized	_	_	O
56	controlled	_	_	O
57	trial	_	_	O
58	in	_	_	O
59	which	_	_	O
60	the	_	_	O
61	patients	_	_	O
62	were	_	_	O
63	recruited	_	_	O
64	in	_	_	O
65	a	_	_	O
66	cancer	_	_	O
67	center	_	_	O
68	in	_	_	O
69	South	_	_	O
70	Korea	_	_	O
71	.	_	_	O

72	The	_	_	O
73	participants	_	_	O
74	(	_	_	O
75	N	_	_	O
76	=	_	_	O
77	56	_	_	O
78	)	_	_	O
79	,	_	_	O
80	who	_	_	O
81	underwent	_	_	O
82	gastrectomy	_	_	O
83	with	_	_	O
84	stomach	_	_	O
85	cancer	_	_	O
86	stage	_	_	O
87	I	_	_	O
88	to	_	_	O
89	III	_	_	O
90	,	_	_	O
91	were	_	_	O
92	randomly	_	_	O
93	assigned	_	_	O
94	into	_	_	O
95	either	_	_	O
96	the	_	_	O
97	experimental	_	_	O
98	or	_	_	O
99	the	_	_	O
100	control	_	_	O
101	group	_	_	O
102	.	_	_	O

103	The	_	_	O
104	PPDI	_	_	O
105	,	_	_	O
106	which	_	_	O
107	was	_	_	O
108	given	_	_	O
109	on	_	_	O
110	the	_	_	O
111	day	_	_	O
112	before	_	_	O
113	the	_	_	O
114	hospital	_	_	O
115	discharge	_	_	O
116	,	_	_	O
117	comprised	_	_	O
118	2	_	_	O
119	face-to-face	_	_	O
120	and	_	_	O
121	2	_	_	O
122	telephone	_	_	O
123	interventions	_	_	O
124	.	_	_	O

125	The	_	_	O
126	outcome	_	_	O
127	variables	_	_	O
128	included	_	_	O
129	body	_	_	O
130	weight	_	_	O
131	,	_	_	O
132	body	_	_	O
133	mass	_	_	O
134	index	_	_	O
135	,	_	_	O
136	muscle	_	_	O
137	mass	_	_	O
138	,	_	_	O
139	the	_	_	O
140	Patient-Generated	_	_	O
141	Subjective	_	_	O
142	Global	_	_	O
143	Assessment	_	_	O
144	,	_	_	O
145	Dietary	_	_	O
146	Symptom	_	_	O
147	Scale	_	_	O
148	,	_	_	O
149	Functional	_	_	O
150	Assessment	_	_	O
151	Cancer	_	_	O
152	Therapy-General	_	_	O
153	,	_	_	O
154	Karnofsky	_	_	O
155	Performance	_	_	O
156	Status	_	_	O
157	,	_	_	O
158	Adherence	_	_	O
159	to	_	_	O
160	Dietary	_	_	O
161	Guidelines	_	_	O
162	Scale	_	_	O
163	,	_	_	O
164	Scale	_	_	O
165	of	_	_	O
166	Dietary	_	_	O
167	Knowledge	_	_	O
168	,	_	_	O
169	Patient	_	_	O
170	Satisfaction	_	_	O
171	Scale	_	_	O
172	,	_	_	O
173	and	_	_	O
174	a	_	_	O
175	3-day	_	_	O
176	food	_	_	O
177	diary	_	_	O
178	.	_	_	O

179	Participants	_	_	B-Premise
180	in	_	_	I-Premise
181	the	_	_	I-Premise
182	PPDI	_	_	I-Premise
183	intervention	_	_	I-Premise
184	demonstrated	_	_	I-Premise
185	significant	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	<	_	_	I-Premise
189	.05	_	_	I-Premise
190	)	_	_	I-Premise
191	reductions	_	_	I-Premise
192	in	_	_	I-Premise
193	adverse	_	_	I-Premise
194	dietary	_	_	I-Premise
195	symptoms	_	_	I-Premise
196	and	_	_	I-Premise
197	significant	_	_	I-Premise
198	improvements	_	_	I-Premise
199	(	_	_	I-Premise
200	P	_	_	I-Premise
201	<	_	_	I-Premise
202	.05	_	_	I-Premise
203	)	_	_	I-Premise
204	in	_	_	I-Premise
205	functional	_	_	I-Premise
206	status	_	_	I-Premise
207	,	_	_	I-Premise
208	performance	_	_	I-Premise
209	status	_	_	I-Premise
210	,	_	_	I-Premise
211	dietary	_	_	I-Premise
212	intake	_	_	I-Premise
213	,	_	_	I-Premise
214	adherence	_	_	I-Premise
215	to	_	_	I-Premise
216	dietary	_	_	I-Premise
217	guidelines	_	_	I-Premise
218	,	_	_	I-Premise
219	dietary	_	_	I-Premise
220	knowledge	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	satisfaction	_	_	I-Premise
224	with	_	_	I-Premise
225	the	_	_	I-Premise
226	intervention	_	_	I-Premise
227	as	_	_	I-Premise
228	compared	_	_	I-Premise
229	with	_	_	I-Premise
230	the	_	_	I-Premise
231	control	_	_	I-Premise
232	group	_	_	I-Premise
233	over	_	_	I-Premise
234	time	_	_	I-Premise
235	.	_	_	I-Premise

236	The	_	_	B-Claim
237	PPDI	_	_	I-Claim
238	was	_	_	I-Claim
239	an	_	_	I-Claim
240	effective	_	_	I-Claim
241	dietary	_	_	I-Claim
242	intervention	_	_	I-Claim
243	for	_	_	I-Claim
244	patients	_	_	I-Claim
245	undergoing	_	_	I-Claim
246	a	_	_	I-Claim
247	gastrectomy	_	_	I-Claim
248	for	_	_	I-Claim
249	gastric	_	_	I-Claim
250	cancer	_	_	I-Claim
251	and	_	_	I-Claim
252	deserves	_	_	I-Claim
253	additional	_	_	I-Claim
254	study	_	_	I-Claim
255	in	_	_	I-Claim
256	other	_	_	I-Claim
257	populations	_	_	I-Claim
258	of	_	_	I-Claim
259	patients	_	_	I-Claim
260	.	_	_	I-Claim

261	Incorporating	_	_	B-Claim
262	patients	_	_	I-Claim
263	'	_	_	I-Claim
264	perspectives	_	_	I-Claim
265	into	_	_	I-Claim
266	a	_	_	I-Claim
267	dietary	_	_	I-Claim
268	intervention	_	_	I-Claim
269	after	_	_	I-Claim
270	gastrectomy	_	_	I-Claim
271	for	_	_	I-Claim
272	gastric	_	_	I-Claim
273	cancer	_	_	I-Claim
274	may	_	_	I-Claim
275	contribute	_	_	I-Claim
276	to	_	_	I-Claim
277	improved	_	_	I-Claim
278	patient	_	_	I-Claim
279	outcomes	_	_	I-Claim
280	and	_	_	I-Claim
281	quality	_	_	I-Claim
282	care	_	_	I-Claim
283	.	_	_	I-Claim


0	Colonic	_	_	O
1	pouches	_	_	O
2	have	_	_	O
3	been	_	_	O
4	used	_	_	O
5	for	_	_	O
6	20	_	_	O
7	years	_	_	O
8	to	_	_	O
9	provide	_	_	O
10	reservoir	_	_	O
11	function	_	_	O
12	after	_	_	O
13	reconstructive	_	_	O
14	proctectomy	_	_	O
15	for	_	_	O
16	rectal	_	_	O
17	cancer	_	_	O
18	.	_	_	O

19	More	_	_	B-Claim
20	recently	_	_	I-Claim
21	coloplasty	_	_	I-Claim
22	has	_	_	I-Claim
23	been	_	_	I-Claim
24	advocated	_	_	I-Claim
25	as	_	_	I-Claim
26	an	_	_	I-Claim
27	alternative	_	_	I-Claim
28	to	_	_	I-Claim
29	a	_	_	I-Claim
30	colonic	_	_	I-Claim
31	pouch	_	_	I-Claim
32	.	_	_	I-Claim

33	However	_	_	O
34	there	_	_	O
35	have	_	_	O
36	been	_	_	O
37	no	_	_	O
38	long-term	_	_	O
39	randomized	_	_	O
40	,	_	_	O
41	controlled	_	_	O
42	trials	_	_	O
43	to	_	_	O
44	compare	_	_	O
45	functional	_	_	O
46	outcomes	_	_	O
47	of	_	_	O
48	coloplasty	_	_	O
49	,	_	_	O
50	colonic	_	_	O
51	J-Pouch	_	_	O
52	(	_	_	O
53	JP	_	_	O
54	)	_	_	O
55	,	_	_	O
56	or	_	_	O
57	a	_	_	O
58	straight	_	_	O
59	anastomosis	_	_	O
60	(	_	_	O
61	SA	_	_	O
62	)	_	_	O
63	after	_	_	O
64	the	_	_	O
65	treatment	_	_	O
66	of	_	_	O
67	low	_	_	O
68	rectal	_	_	O
69	cancer	_	_	O
70	.	_	_	O

71	:	_	_	O
72	To	_	_	O
73	compare	_	_	O
74	the	_	_	O
75	complications	_	_	O
76	,	_	_	O
77	long-term	_	_	O
78	functional	_	_	O
79	outcome	_	_	O
80	,	_	_	O
81	and	_	_	O
82	quality	_	_	O
83	of	_	_	O
84	life	_	_	O
85	(	_	_	O
86	QOL	_	_	O
87	)	_	_	O
88	of	_	_	O
89	patients	_	_	O
90	undergoing	_	_	O
91	a	_	_	O
92	coloplasty	_	_	O
93	,	_	_	O
94	JP	_	_	O
95	,	_	_	O
96	or	_	_	O
97	an	_	_	O
98	SA	_	_	O
99	in	_	_	O
100	reconstruction	_	_	O
101	of	_	_	O
102	the	_	_	O
103	lower	_	_	O
104	gastrointestinal	_	_	O
105	tract	_	_	O
106	after	_	_	O
107	proctectomy	_	_	O
108	for	_	_	O
109	low	_	_	O
110	rectal	_	_	O
111	cancer	_	_	O
112	.	_	_	O

113	A	_	_	O
114	multicenter	_	_	O
115	study	_	_	O
116	enrolled	_	_	O
117	patients	_	_	O
118	with	_	_	O
119	low	_	_	O
120	rectal	_	_	O
121	cancer	_	_	O
122	,	_	_	O
123	who	_	_	O
124	were	_	_	O
125	randomized	_	_	O
126	intraoperatively	_	_	O
127	to	_	_	O
128	coloplasty	_	_	O
129	(	_	_	O
130	CP-1	_	_	O
131	)	_	_	O
132	or	_	_	O
133	SA	_	_	O
134	if	_	_	O
135	JP	_	_	O
136	was	_	_	O
137	not	_	_	O
138	feasible	_	_	O
139	,	_	_	O
140	or	_	_	O
141	JP	_	_	O
142	or	_	_	O
143	coloplasty	_	_	O
144	(	_	_	O
145	CP-2	_	_	O
146	)	_	_	O
147	if	_	_	O
148	a	_	_	O
149	JP	_	_	O
150	was	_	_	O
151	feasible	_	_	O
152	.	_	_	O

153	Patients	_	_	O
154	were	_	_	O
155	followed	_	_	O
156	for	_	_	O
157	24	_	_	O
158	months	_	_	O
159	with	_	_	O
160	SF-36	_	_	O
161	surveys	_	_	O
162	to	_	_	O
163	evaluate	_	_	O
164	the	_	_	O
165	QOL	_	_	O
166	.	_	_	O

167	Bowel	_	_	O
168	function	_	_	O
169	was	_	_	O
170	measured	_	_	O
171	quantitatively	_	_	O
172	and	_	_	O
173	using	_	_	O
174	Fecal	_	_	O
175	Incontinence	_	_	O
176	Severity	_	_	O
177	Index	_	_	O
178	(	_	_	O
179	FISI	_	_	O
180	)	_	_	O
181	.	_	_	O

182	Urinary	_	_	O
183	function	_	_	O
184	and	_	_	O
185	sexual	_	_	O
186	function	_	_	O
187	were	_	_	O
188	also	_	_	O
189	assessed	_	_	O
190	.	_	_	O

191	Three	_	_	O
192	hundred	_	_	O
193	sixty-four	_	_	O
194	patients	_	_	O
195	were	_	_	O
196	randomized	_	_	O
197	.	_	_	O

198	All	_	_	O
199	patients	_	_	O
200	were	_	_	O
201	evaluated	_	_	O
202	for	_	_	O
203	complications	_	_	O
204	and	_	_	O
205	recurrence	_	_	O
206	.	_	_	O

207	Mean	_	_	O
208	age	_	_	O
209	was	_	_	O
210	60	_	_	O
211	+/-12	_	_	O
212	years	_	_	O
213	,	_	_	O
214	71	_	_	O
215	%	_	_	O
216	were	_	_	O
217	male	_	_	O
218	.	_	_	O

219	Twenty-three	_	_	B-Premise
220	(	_	_	I-Premise
221	7.4	_	_	I-Premise
222	%	_	_	I-Premise
223	)	_	_	I-Premise
224	died	_	_	I-Premise
225	within	_	_	I-Premise
226	24	_	_	I-Premise
227	months	_	_	I-Premise
228	of	_	_	I-Premise
229	surgery	_	_	I-Premise
230	.	_	_	I-Premise

231	No	_	_	B-Premise
232	significant	_	_	I-Premise
233	difference	_	_	I-Premise
234	was	_	_	I-Premise
235	observed	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	complications	_	_	I-Premise
239	among	_	_	I-Premise
240	the	_	_	I-Premise
241	4	_	_	I-Premise
242	groups	_	_	I-Premise
243	.	_	_	I-Premise

244	Two	_	_	O
245	hundred	_	_	O
246	ninety-seven	_	_	O
247	of	_	_	O
248	364	_	_	O
249	were	_	_	O
250	evaluated	_	_	O
251	for	_	_	O
252	functional	_	_	O
253	outcome	_	_	O
254	at	_	_	O
255	24	_	_	O
256	months	_	_	O
257	.	_	_	O

258	There	_	_	B-Premise
259	was	_	_	I-Premise
260	no	_	_	I-Premise
261	difference	_	_	I-Premise
262	in	_	_	I-Premise
263	bowel	_	_	I-Premise
264	function	_	_	I-Premise
265	between	_	_	I-Premise
266	the	_	_	I-Premise
267	CP-1	_	_	I-Premise
268	and	_	_	I-Premise
269	SA	_	_	I-Premise
270	groups	_	_	I-Premise
271	.	_	_	I-Premise

272	JP	_	_	B-Premise
273	patients	_	_	I-Premise
274	had	_	_	I-Premise
275	fewer	_	_	I-Premise
276	bowel	_	_	I-Premise
277	movements	_	_	I-Premise
278	,	_	_	I-Premise
279	less	_	_	I-Premise
280	clustering	_	_	I-Premise
281	,	_	_	I-Premise
282	used	_	_	I-Premise
283	fewer	_	_	I-Premise
284	pads	_	_	I-Premise
285	and	_	_	I-Premise
286	had	_	_	I-Premise
287	a	_	_	I-Premise
288	lower	_	_	I-Premise
289	FISI	_	_	I-Premise
290	than	_	_	I-Premise
291	the	_	_	I-Premise
292	CP-2	_	_	I-Premise
293	group	_	_	I-Premise
294	.	_	_	I-Premise

295	Other	_	_	B-Premise
296	parameters	_	_	I-Premise
297	were	_	_	I-Premise
298	not	_	_	I-Premise
299	statistically	_	_	I-Premise
300	different	_	_	I-Premise
301	.	_	_	I-Premise

302	QOL	_	_	B-Premise
303	scores	_	_	I-Premise
304	at	_	_	I-Premise
305	24	_	_	I-Premise
306	months	_	_	I-Premise
307	were	_	_	I-Premise
308	similar	_	_	I-Premise
309	for	_	_	I-Premise
310	each	_	_	I-Premise
311	of	_	_	I-Premise
312	the	_	_	I-Premise
313	4	_	_	I-Premise
314	groups	_	_	I-Premise
315	.	_	_	I-Premise

316	In	_	_	B-Claim
317	patients	_	_	I-Claim
318	undergoing	_	_	I-Claim
319	a	_	_	I-Claim
320	restorative	_	_	I-Claim
321	resection	_	_	I-Claim
322	for	_	_	I-Claim
323	low	_	_	I-Claim
324	rectal	_	_	I-Claim
325	cancer	_	_	I-Claim
326	,	_	_	I-Claim
327	a	_	_	I-Claim
328	colonic	_	_	I-Claim
329	JP	_	_	I-Claim
330	offers	_	_	I-Claim
331	significant	_	_	I-Claim
332	advantages	_	_	I-Claim
333	in	_	_	I-Claim
334	function	_	_	I-Claim
335	over	_	_	I-Claim
336	an	_	_	I-Claim
337	SA	_	_	I-Claim
338	or	_	_	I-Claim
339	a	_	_	I-Claim
340	coloplasty	_	_	I-Claim
341	.	_	_	I-Claim

342	In	_	_	B-Claim
343	patients	_	_	I-Claim
344	who	_	_	I-Claim
345	can	_	_	I-Claim
346	not	_	_	I-Claim
347	have	_	_	I-Claim
348	a	_	_	I-Claim
349	pouch	_	_	I-Claim
350	,	_	_	I-Claim
351	coloplasty	_	_	I-Claim
352	seems	_	_	I-Claim
353	not	_	_	I-Claim
354	to	_	_	I-Claim
355	improve	_	_	I-Claim
356	the	_	_	I-Claim
357	bowel	_	_	I-Claim
358	function	_	_	I-Claim
359	of	_	_	I-Claim
360	patients	_	_	I-Claim
361	over	_	_	I-Claim
362	that	_	_	I-Claim
363	with	_	_	I-Claim
364	an	_	_	I-Claim
365	SA	_	_	I-Claim
366	.	_	_	I-Claim


0	Combined	_	_	B-Claim
1	radiation	_	_	I-Claim
2	therapy	_	_	I-Claim
3	and	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	after	_	_	I-Claim
6	surgery	_	_	I-Claim
7	,	_	_	I-Claim
8	compared	_	_	I-Claim
9	with	_	_	I-Claim
10	postsurgical	_	_	I-Claim
11	radiation	_	_	I-Claim
12	therapy	_	_	I-Claim
13	alone	_	_	I-Claim
14	,	_	_	I-Claim
15	has	_	_	I-Claim
16	been	_	_	I-Claim
17	shown	_	_	I-Claim
18	to	_	_	I-Claim
19	improve	_	_	I-Claim
20	disease-free	_	_	I-Claim
21	survival	_	_	I-Claim
22	and	_	_	I-Claim
23	overall	_	_	I-Claim
24	survival	_	_	I-Claim
25	significantly	_	_	I-Claim
26	among	_	_	I-Claim
27	patients	_	_	I-Claim
28	with	_	_	I-Claim
29	poor-prognosis	_	_	I-Claim
30	(	_	_	I-Claim
31	i.e.	_	_	I-Claim
32	,	_	_	I-Claim
33	advanced	_	_	I-Claim
34	stage	_	_	I-Claim
35	disease	_	_	I-Claim
36	or	_	_	I-Claim
37	metastasis	_	_	I-Claim
38	to	_	_	I-Claim
39	regional	_	_	I-Claim
40	lymph	_	_	I-Claim
41	nodes	_	_	I-Claim
42	)	_	_	I-Claim
43	resectable	_	_	I-Claim
44	rectal	_	_	I-Claim
45	cancer	_	_	I-Claim
46	.	_	_	I-Claim

47	However	_	_	B-Claim
48	,	_	_	I-Claim
49	the	_	_	I-Claim
50	combined	_	_	I-Claim
51	therapy	_	_	I-Claim
52	is	_	_	I-Claim
53	associated	_	_	I-Claim
54	with	_	_	I-Claim
55	more	_	_	I-Claim
56	toxic	_	_	I-Claim
57	effects	_	_	I-Claim
58	,	_	_	I-Claim
59	raising	_	_	I-Claim
60	the	_	_	I-Claim
61	question	_	_	I-Claim
62	of	_	_	I-Claim
63	whether	_	_	I-Claim
64	the	_	_	I-Claim
65	benefits	_	_	I-Claim
66	of	_	_	I-Claim
67	the	_	_	I-Claim
68	treatment	_	_	I-Claim
69	justify	_	_	I-Claim
70	its	_	_	I-Claim
71	quality-of-life	_	_	I-Claim
72	costs	_	_	I-Claim
73	for	_	_	I-Claim
74	the	_	_	I-Claim
75	individual	_	_	I-Claim
76	patient	_	_	I-Claim
77	.	_	_	I-Claim

78	To	_	_	O
79	assess	_	_	O
80	the	_	_	O
81	trade-offs	_	_	O
82	between	_	_	O
83	improved	_	_	O
84	survival	_	_	O
85	and	_	_	O
86	increased	_	_	O
87	treatment	_	_	O
88	toxicity	_	_	O
89	,	_	_	O
90	we	_	_	O
91	reanalyzed	_	_	O
92	data	_	_	O
93	from	_	_	O
94	a	_	_	O
95	randomized	_	_	O
96	clinical	_	_	O
97	trial	_	_	O
98	that	_	_	O
99	compared	_	_	O
100	the	_	_	O
101	efficacy	_	_	O
102	of	_	_	O
103	combined	_	_	O
104	adjuvant	_	_	O
105	chemotherapy	_	_	O
106	and	_	_	O
107	radiation	_	_	O
108	therapy	_	_	O
109	with	_	_	O
110	adjuvant	_	_	O
111	radiation	_	_	O
112	therapy	_	_	O
113	alone	_	_	O
114	in	_	_	O
115	the	_	_	O
116	treatment	_	_	O
117	of	_	_	O
118	patients	_	_	O
119	with	_	_	O
120	poor-prognosis	_	_	O
121	resectable	_	_	O
122	rectal	_	_	O
123	cancer	_	_	O
124	.	_	_	O

125	The	_	_	O
126	data	_	_	O
127	were	_	_	O
128	from	_	_	O
129	a	_	_	O
130	North	_	_	O
131	Central	_	_	O
132	Cancer	_	_	O
133	Treatment	_	_	O
134	Group	_	_	O
135	trial	_	_	O
136	in	_	_	O
137	which	_	_	O
138	204	_	_	O
139	patients	_	_	O
140	with	_	_	O
141	poor-prognosis	_	_	O
142	rectal	_	_	O
143	cancer	_	_	O
144	were	_	_	O
145	randomly	_	_	O
146	assigned	_	_	O
147	to	_	_	O
148	receive	_	_	O
149	either	_	_	O
150	postoperative	_	_	O
151	radiation	_	_	O
152	therapy	_	_	O
153	alone	_	_	O
154	or	_	_	O
155	radiation	_	_	O
156	therapy	_	_	O
157	plus	_	_	O
158	fluorouracil-based	_	_	O
159	chemotherapy	_	_	O
160	.	_	_	O

161	A	_	_	O
162	quality-adjusted	_	_	O
163	time	_	_	O
164	without	_	_	O
165	symptoms	_	_	O
166	or	_	_	O
167	toxicity	_	_	O
168	(	_	_	O
169	Q-TWiST	_	_	O
170	)	_	_	O
171	analysis	_	_	O
172	was	_	_	O
173	used	_	_	O
174	to	_	_	O
175	account	_	_	O
176	for	_	_	O
177	freedom	_	_	O
178	from	_	_	O
179	symptomatic	_	_	O
180	disease	_	_	O
181	and	_	_	O
182	from	_	_	O
183	early	_	_	O
184	and	_	_	O
185	late	_	_	O
186	side	_	_	O
187	effects	_	_	O
188	of	_	_	O
189	treatment	_	_	O
190	.	_	_	O

191	All	_	_	O
192	reported	_	_	O
193	P	_	_	O
194	values	_	_	O
195	are	_	_	O
196	two-sided	_	_	O
197	.	_	_	O

198	As	_	_	B-Premise
199	reported	_	_	I-Premise
200	previously	_	_	I-Premise
201	,	_	_	I-Premise
202	the	_	_	I-Premise
203	combined	_	_	I-Premise
204	therapy	_	_	I-Premise
205	reduced	_	_	I-Premise
206	the	_	_	I-Premise
207	risk	_	_	I-Premise
208	of	_	_	I-Premise
209	relapse	_	_	I-Premise
210	by	_	_	I-Premise
211	34	_	_	I-Premise
212	%	_	_	I-Premise
213	(	_	_	I-Premise
214	95	_	_	I-Premise
215	%	_	_	I-Premise
216	confidence	_	_	I-Premise
217	interval	_	_	I-Premise
218	[	_	_	I-Premise
219	CI	_	_	I-Premise
220	]	_	_	I-Premise
221	=	_	_	I-Premise
222	12	_	_	I-Premise
223	%	_	_	I-Premise
224	-50	_	_	I-Premise
225	%	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.0016	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	reduced	_	_	I-Premise
233	the	_	_	I-Premise
234	overall	_	_	I-Premise
235	death	_	_	I-Premise
236	rate	_	_	I-Premise
237	by	_	_	I-Premise
238	29	_	_	I-Premise
239	%	_	_	I-Premise
240	(	_	_	I-Premise
241	95	_	_	I-Premise
242	%	_	_	I-Premise
243	CI	_	_	I-Premise
244	=	_	_	I-Premise
245	7	_	_	I-Premise
246	%	_	_	I-Premise
247	-45	_	_	I-Premise
248	%	_	_	I-Premise
249	;	_	_	I-Premise
250	P	_	_	I-Premise
251	=	_	_	I-Premise
252	.025	_	_	I-Premise
253	)	_	_	I-Premise
254	in	_	_	I-Premise
255	comparison	_	_	I-Premise
256	with	_	_	I-Premise
257	adjuvant	_	_	I-Premise
258	radiation	_	_	I-Premise
259	therapy	_	_	I-Premise
260	alone	_	_	I-Premise
261	.	_	_	I-Premise

262	In	_	_	B-Premise
263	the	_	_	I-Premise
264	5	_	_	I-Premise
265	years	_	_	I-Premise
266	following	_	_	I-Premise
267	assignment	_	_	I-Premise
268	to	_	_	I-Premise
269	treatment	_	_	I-Premise
270	,	_	_	I-Premise
271	patients	_	_	I-Premise
272	who	_	_	I-Premise
273	received	_	_	I-Premise
274	the	_	_	I-Premise
275	combined	_	_	I-Premise
276	therapy	_	_	I-Premise
277	had	_	_	I-Premise
278	more	_	_	I-Premise
279	time	_	_	I-Premise
280	with	_	_	I-Premise
281	toxicity	_	_	I-Premise
282	(	_	_	I-Premise
283	3.1	_	_	I-Premise
284	months	_	_	I-Premise
285	;	_	_	I-Premise
286	95	_	_	I-Premise
287	%	_	_	I-Premise
288	CI	_	_	I-Premise
289	=	_	_	I-Premise
290	2.0-4.1	_	_	I-Premise
291	months	_	_	I-Premise
292	)	_	_	I-Premise
293	,	_	_	I-Premise
294	shorter	_	_	I-Premise
295	survival	_	_	I-Premise
296	after	_	_	I-Premise
297	relapse	_	_	I-Premise
298	(	_	_	I-Premise
299	3.6	_	_	I-Premise
300	months	_	_	I-Premise
301	less	_	_	I-Premise
302	;	_	_	I-Premise
303	95	_	_	I-Premise
304	%	_	_	I-Premise
305	CI	_	_	I-Premise
306	=	_	_	I-Premise
307	0.9-6.3	_	_	I-Premise
308	months	_	_	I-Premise
309	less	_	_	I-Premise
310	)	_	_	I-Premise
311	,	_	_	I-Premise
312	and	_	_	I-Premise
313	more	_	_	I-Premise
314	TWiST	_	_	I-Premise
315	(	_	_	I-Premise
316	6.1	_	_	I-Premise
317	months	_	_	I-Premise
318	;	_	_	I-Premise
319	95	_	_	I-Premise
320	%	_	_	I-Premise
321	CI	_	_	I-Premise
322	=	_	_	I-Premise
323	0.2-12.0	_	_	I-Premise
324	months	_	_	I-Premise
325	)	_	_	I-Premise
326	than	_	_	I-Premise
327	patients	_	_	I-Premise
328	who	_	_	I-Premise
329	received	_	_	I-Premise
330	adjuvant	_	_	I-Premise
331	radiation	_	_	I-Premise
332	therapy	_	_	I-Premise
333	alone	_	_	I-Premise
334	.	_	_	I-Premise

335	Despite	_	_	B-Claim
336	an	_	_	I-Claim
337	increase	_	_	I-Claim
338	in	_	_	I-Claim
339	the	_	_	I-Claim
340	amount	_	_	I-Claim
341	of	_	_	I-Claim
342	time	_	_	I-Claim
343	that	_	_	I-Claim
344	individuals	_	_	I-Claim
345	spent	_	_	I-Claim
346	with	_	_	I-Claim
347	early	_	_	I-Claim
348	and	_	_	I-Claim
349	late	_	_	I-Claim
350	toxic	_	_	I-Claim
351	effects	_	_	I-Claim
352	,	_	_	I-Claim
353	the	_	_	I-Claim
354	Q-TWiST	_	_	I-Claim
355	analysis	_	_	I-Claim
356	indicated	_	_	I-Claim
357	that	_	_	I-Claim
358	the	_	_	I-Claim
359	combined	_	_	I-Claim
360	therapy	_	_	I-Claim
361	conferred	_	_	I-Claim
362	significantly	_	_	I-Claim
363	greater	_	_	I-Claim
364	benefit	_	_	I-Claim
365	for	_	_	I-Claim
366	a	_	_	I-Claim
367	wide	_	_	I-Claim
368	range	_	_	I-Claim
369	of	_	_	I-Claim
370	patient	_	_	I-Claim
371	preferences	_	_	I-Claim
372	about	_	_	I-Claim
373	living	_	_	I-Claim
374	with	_	_	I-Claim
375	the	_	_	I-Claim
376	toxicity	_	_	I-Claim
377	of	_	_	I-Claim
378	treatment	_	_	I-Claim
379	or	_	_	I-Claim
380	the	_	_	I-Claim
381	symptoms	_	_	I-Claim
382	of	_	_	I-Claim
383	overt	_	_	I-Claim
384	disease	_	_	I-Claim
385	.	_	_	I-Claim

386	Use	_	_	B-Claim
387	of	_	_	I-Claim
388	combined	_	_	I-Claim
389	chemotherapy	_	_	I-Claim
390	and	_	_	I-Claim
391	radiation	_	_	I-Claim
392	therapy	_	_	I-Claim
393	as	_	_	I-Claim
394	an	_	_	I-Claim
395	adjuvant	_	_	I-Claim
396	to	_	_	I-Claim
397	surgery	_	_	I-Claim
398	for	_	_	I-Claim
399	patients	_	_	I-Claim
400	with	_	_	I-Claim
401	poor-prognosis	_	_	I-Claim
402	resectable	_	_	I-Claim
403	rectal	_	_	I-Claim
404	cancer	_	_	I-Claim
405	is	_	_	I-Claim
406	justified	_	_	I-Claim
407	,	_	_	I-Claim
408	since	_	_	B-Premise
409	the	_	_	I-Premise
410	improved	_	_	I-Premise
411	outcome	_	_	I-Premise
412	in	_	_	I-Premise
413	terms	_	_	I-Premise
414	of	_	_	I-Premise
415	delayed	_	_	I-Premise
416	recurrence	_	_	I-Premise
417	and	_	_	I-Premise
418	increased	_	_	I-Premise
419	survival	_	_	I-Premise
420	balances	_	_	I-Premise
421	the	_	_	I-Premise
422	time	_	_	I-Premise
423	spent	_	_	I-Premise
424	with	_	_	I-Premise
425	early	_	_	I-Premise
426	and	_	_	I-Premise
427	late	_	_	I-Premise
428	toxic	_	_	I-Premise
429	effects	_	_	I-Premise
430	.	_	_	I-Premise

431	The	_	_	B-Claim
432	Q-TWiST	_	_	I-Claim
433	method	_	_	I-Claim
434	is	_	_	I-Claim
435	an	_	_	I-Claim
436	excellent	_	_	I-Claim
437	way	_	_	I-Claim
438	to	_	_	I-Claim
439	compare	_	_	I-Claim
440	treatment	_	_	I-Claim
441	outcomes	_	_	I-Claim
442	that	_	_	I-Claim
443	include	_	_	I-Claim
444	quality-of-life	_	_	I-Claim
445	considerations	_	_	I-Claim
446	.	_	_	I-Claim


0	Malnutrition	_	_	B-Claim
1	occurs	_	_	I-Claim
2	frequently	_	_	I-Claim
3	in	_	_	I-Claim
4	patients	_	_	I-Claim
5	with	_	_	I-Claim
6	cancer	_	_	I-Claim
7	of	_	_	I-Claim
8	the	_	_	I-Claim
9	gastrointestinal	_	_	I-Claim
10	(	_	_	I-Claim
11	GI	_	_	I-Claim
12	)	_	_	I-Claim
13	or	_	_	I-Claim
14	head	_	_	I-Claim
15	and	_	_	I-Claim
16	neck	_	_	I-Claim
17	area	_	_	I-Claim
18	and	_	_	I-Claim
19	can	_	_	I-Claim
20	lead	_	_	I-Claim
21	to	_	_	I-Claim
22	negative	_	_	I-Claim
23	outcomes	_	_	I-Claim
24	.	_	_	I-Claim

25	The	_	_	O
26	aim	_	_	O
27	of	_	_	O
28	this	_	_	O
29	study	_	_	O
30	is	_	_	O
31	to	_	_	O
32	determine	_	_	O
33	the	_	_	O
34	impact	_	_	O
35	of	_	_	O
36	early	_	_	O
37	and	_	_	O
38	intensive	_	_	O
39	nutrition	_	_	O
40	intervention	_	_	O
41	(	_	_	O
42	NI	_	_	O
43	)	_	_	O
44	on	_	_	O
45	body	_	_	O
46	weight	_	_	O
47	,	_	_	O
48	body	_	_	O
49	composition	_	_	O
50	,	_	_	O
51	nutritional	_	_	O
52	status	_	_	O
53	,	_	_	O
54	global	_	_	O
55	quality	_	_	O
56	of	_	_	O
57	life	_	_	O
58	(	_	_	O
59	QoL	_	_	O
60	)	_	_	O
61	and	_	_	O
62	physical	_	_	O
63	function	_	_	O
64	compared	_	_	O
65	to	_	_	O
66	usual	_	_	O
67	practice	_	_	O
68	in	_	_	O
69	oncology	_	_	O
70	outpatients	_	_	O
71	receiving	_	_	O
72	radiotherapy	_	_	O
73	to	_	_	O
74	the	_	_	O
75	GI	_	_	O
76	or	_	_	O
77	head	_	_	O
78	and	_	_	O
79	neck	_	_	O
80	area	_	_	O
81	.	_	_	O

82	Outpatients	_	_	O
83	commencing	_	_	O
84	at	_	_	O
85	least	_	_	O
86	20	_	_	O
87	fractions	_	_	O
88	of	_	_	O
89	radiotherapy	_	_	O
90	to	_	_	O
91	the	_	_	O
92	GI	_	_	O
93	or	_	_	O
94	head	_	_	O
95	and	_	_	O
96	neck	_	_	O
97	area	_	_	O
98	were	_	_	O
99	randomised	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	intensive	_	_	O
103	,	_	_	O
104	individualised	_	_	O
105	nutrition	_	_	O
106	counselling	_	_	O
107	by	_	_	O
108	a	_	_	O
109	dietitian	_	_	O
110	using	_	_	O
111	a	_	_	O
112	standard	_	_	O
113	protocol	_	_	O
114	and	_	_	O
115	oral	_	_	O
116	supplements	_	_	O
117	if	_	_	O
118	required	_	_	O
119	,	_	_	O
120	or	_	_	O
121	the	_	_	O
122	usual	_	_	O
123	practice	_	_	O
124	of	_	_	O
125	the	_	_	O
126	centre	_	_	O
127	(	_	_	O
128	general	_	_	O
129	advice	_	_	O
130	and	_	_	O
131	nutrition	_	_	O
132	booklet	_	_	O
133	)	_	_	O
134	.	_	_	O

135	Outcome	_	_	O
136	parameters	_	_	O
137	were	_	_	O
138	measured	_	_	O
139	at	_	_	O
140	baseline	_	_	O
141	and	_	_	O
142	4	_	_	O
143	,	_	_	O
144	8	_	_	O
145	and	_	_	O
146	12	_	_	O
147	weeks	_	_	O
148	after	_	_	O
149	commencing	_	_	O
150	radiotherapy	_	_	O
151	using	_	_	O
152	valid	_	_	O
153	and	_	_	O
154	reliable	_	_	O
155	tools	_	_	O
156	.	_	_	O

157	A	_	_	O
158	total	_	_	O
159	of	_	_	O
160	60	_	_	O
161	patients	_	_	O
162	(	_	_	O
163	51	_	_	O
164	M	_	_	O
165	:	_	_	O
166	9	_	_	O
167	F	_	_	O
168	;	_	_	O
169	mean	_	_	O
170	age	_	_	O
171	61.9+/-14.0	_	_	O
172	years	_	_	O
173	)	_	_	O
174	were	_	_	O
175	randomised	_	_	O
176	to	_	_	O
177	receive	_	_	O
178	either	_	_	O
179	NI	_	_	O
180	(	_	_	O
181	n=29	_	_	O
182	)	_	_	O
183	or	_	_	O
184	usual	_	_	O
185	care	_	_	O
186	(	_	_	O
187	UC	_	_	O
188	)	_	_	O
189	(	_	_	O
190	n=31	_	_	O
191	)	_	_	O
192	.	_	_	O

193	The	_	_	B-Premise
194	NI	_	_	I-Premise
195	group	_	_	I-Premise
196	had	_	_	I-Premise
197	statistically	_	_	I-Premise
198	smaller	_	_	I-Premise
199	deteriorations	_	_	I-Premise
200	in	_	_	I-Premise
201	weight	_	_	I-Premise
202	(	_	_	I-Premise
203	P	_	_	I-Premise
204	<	_	_	I-Premise
205	0.001	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	nutritional	_	_	I-Premise
209	status	_	_	I-Premise
210	(	_	_	I-Premise
211	P=0.020	_	_	I-Premise
212	)	_	_	I-Premise
213	and	_	_	I-Premise
214	global	_	_	I-Premise
215	QoL	_	_	I-Premise
216	(	_	_	I-Premise
217	P=0.009	_	_	I-Premise
218	)	_	_	I-Premise
219	compared	_	_	I-Premise
220	with	_	_	I-Premise
221	those	_	_	I-Premise
222	receiving	_	_	I-Premise
223	UC	_	_	I-Premise
224	.	_	_	I-Premise

225	Clinically	_	_	B-Premise
226	,	_	_	I-Premise
227	but	_	_	I-Premise
228	not	_	_	I-Premise
229	statistically	_	_	I-Premise
230	significant	_	_	I-Premise
231	differences	_	_	I-Premise
232	in	_	_	I-Premise
233	fat-free	_	_	I-Premise
234	mass	_	_	I-Premise
235	were	_	_	I-Premise
236	observed	_	_	I-Premise
237	between	_	_	I-Premise
238	the	_	_	I-Premise
239	groups	_	_	I-Premise
240	(	_	_	I-Premise
241	P=0.195	_	_	I-Premise
242	)	_	_	I-Premise
243	.	_	_	I-Premise

244	Early	_	_	B-Claim
245	and	_	_	I-Claim
246	intensive	_	_	I-Claim
247	NI	_	_	I-Claim
248	appears	_	_	I-Claim
249	beneficial	_	_	I-Claim
250	in	_	_	I-Claim
251	terms	_	_	I-Claim
252	of	_	_	I-Claim
253	minimising	_	_	I-Claim
254	weight	_	_	I-Claim
255	loss	_	_	I-Claim
256	,	_	_	I-Claim
257	deterioration	_	_	I-Claim
258	in	_	_	I-Claim
259	nutritional	_	_	I-Claim
260	status	_	_	I-Claim
261	,	_	_	I-Claim
262	global	_	_	I-Claim
263	QoL	_	_	I-Claim
264	and	_	_	I-Claim
265	physical	_	_	I-Claim
266	function	_	_	I-Claim
267	in	_	_	I-Claim
268	oncology	_	_	I-Claim
269	outpatients	_	_	I-Claim
270	receiving	_	_	I-Claim
271	radiotherapy	_	_	I-Claim
272	to	_	_	I-Claim
273	the	_	_	I-Claim
274	GI	_	_	I-Claim
275	or	_	_	I-Claim
276	head	_	_	I-Claim
277	and	_	_	I-Claim
278	neck	_	_	I-Claim
279	area	_	_	I-Claim
280	.	_	_	I-Claim

281	Weight	_	_	B-Claim
282	maintenance	_	_	I-Claim
283	in	_	_	I-Claim
284	this	_	_	I-Claim
285	population	_	_	I-Claim
286	leads	_	_	I-Claim
287	to	_	_	I-Claim
288	beneficial	_	_	I-Claim
289	outcomes	_	_	I-Claim
290	and	_	_	I-Claim
291	suggests	_	_	I-Claim
292	that	_	_	I-Claim
293	this	_	_	I-Claim
294	,	_	_	I-Claim
295	rather	_	_	I-Claim
296	than	_	_	I-Claim
297	weight	_	_	I-Claim
298	gain	_	_	I-Claim
299	,	_	_	I-Claim
300	may	_	_	I-Claim
301	be	_	_	I-Claim
302	a	_	_	I-Claim
303	more	_	_	I-Claim
304	appropriate	_	_	I-Claim
305	aim	_	_	I-Claim
306	of	_	_	I-Claim
307	NI	_	_	I-Claim
308	.	_	_	I-Claim


0	There	_	_	O
1	is	_	_	O
2	a	_	_	O
3	paucity	_	_	O
4	of	_	_	O
5	methodologically	_	_	O
6	robust	_	_	O
7	vocational	_	_	O
8	rehabilitation	_	_	O
9	(	_	_	O
10	VR	_	_	O
11	)	_	_	O
12	intervention	_	_	O
13	trials	_	_	O
14	.	_	_	O

15	This	_	_	O
16	study	_	_	O
17	assessed	_	_	O
18	the	_	_	O
19	feasibility	_	_	O
20	and	_	_	O
21	acceptability	_	_	O
22	of	_	_	O
23	a	_	_	O
24	VR	_	_	O
25	trial	_	_	O
26	of	_	_	O
27	women	_	_	O
28	with	_	_	O
29	breast	_	_	O
30	cancer	_	_	O
31	to	_	_	O
32	inform	_	_	O
33	the	_	_	O
34	development	_	_	O
35	of	_	_	O
36	a	_	_	O
37	larger	_	_	O
38	interventional	_	_	O
39	study	_	_	O
40	.	_	_	O

41	Women	_	_	O
42	were	_	_	O
43	recruited	_	_	O
44	in	_	_	O
45	Scotland	_	_	O
46	and	_	_	O
47	randomised	_	_	O
48	to	_	_	O
49	either	_	_	O
50	a	_	_	O
51	case	_	_	O
52	management	_	_	O
53	VR	_	_	O
54	service	_	_	O
55	or	_	_	O
56	to	_	_	O
57	usual	_	_	O
58	care	_	_	O
59	.	_	_	O

60	Data	_	_	O
61	were	_	_	O
62	collected	_	_	O
63	on	_	_	O
64	eligibility	_	_	O
65	,	_	_	O
66	recruitment	_	_	O
67	and	_	_	O
68	attrition	_	_	O
69	rates	_	_	O
70	to	_	_	O
71	assess	_	_	O
72	trial	_	_	O
73	feasibility	_	_	O
74	,	_	_	O
75	and	_	_	O
76	interviews	_	_	O
77	conducted	_	_	O
78	to	_	_	O
79	determine	_	_	O
80	trial	_	_	O
81	acceptability	_	_	O
82	.	_	_	O

83	Sick	_	_	O
84	leave	_	_	O
85	days	_	_	O
86	(	_	_	O
87	primary	_	_	O
88	outcome	_	_	O
89	)	_	_	O
90	were	_	_	O
91	self-reported	_	_	O
92	via	_	_	O
93	postal	_	_	O
94	questionnaire	_	_	O
95	every	_	_	O
96	4	_	_	O
97	weeks	_	_	O
98	during	_	_	O
99	the	_	_	O
100	first	_	_	O
101	6	_	_	O
102	months	_	_	O
103	post-surgery	_	_	O
104	and	_	_	O
105	at	_	_	O
106	12	_	_	O
107	months	_	_	O
108	.	_	_	O

109	Secondary	_	_	O
110	outcome	_	_	O
111	measures	_	_	O
112	were	_	_	O
113	change	_	_	O
114	in	_	_	O
115	employment	_	_	O
116	pattern	_	_	O
117	,	_	_	O
118	quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	and	_	_	O
122	fatigue	_	_	O
123	.	_	_	O

124	Of	_	_	O
125	the	_	_	O
126	1,114	_	_	O
127	women	_	_	O
128	assessed	_	_	O
129	for	_	_	O
130	eligibility	_	_	O
131	,	_	_	O
132	163	_	_	O
133	(	_	_	O
134	15	_	_	O
135	%	_	_	O
136	)	_	_	O
137	were	_	_	O
138	eligible	_	_	O
139	.	_	_	O

140	The	_	_	O
141	main	_	_	O
142	reason	_	_	O
143	for	_	_	O
144	ineligibility	_	_	O
145	was	_	_	O
146	age	_	_	O
147	(	_	_	O
148	>	_	_	O
149	65	_	_	O
150	years	_	_	O
151	,	_	_	O
152	n	_	_	O
153	=	_	_	O
154	637	_	_	O
155	,	_	_	O
156	67	_	_	O
157	%	_	_	O
158	)	_	_	O
159	.	_	_	O

160	Of	_	_	O
161	those	_	_	O
162	eligible	_	_	O
163	,	_	_	O
164	111	_	_	O
165	(	_	_	O
166	68	_	_	O
167	%	_	_	O
168	)	_	_	O
169	received	_	_	O
170	study	_	_	O
171	information	_	_	O
172	,	_	_	O
173	of	_	_	O
174	which	_	_	O
175	23	_	_	O
176	(	_	_	O
177	21	_	_	O
178	%	_	_	O
179	)	_	_	O
180	consented	_	_	O
181	to	_	_	O
182	participate	_	_	O
183	in	_	_	O
184	the	_	_	O
185	study	_	_	O
186	.	_	_	O

187	Data	_	_	O
188	for	_	_	O
189	18	_	_	O
190	(	_	_	O
191	78	_	_	O
192	%	_	_	O
193	)	_	_	O
194	women	_	_	O
195	were	_	_	O
196	analysed	_	_	O
197	(	_	_	O
198	intervention	_	_	O
199	:	_	_	O
200	n	_	_	O
201	=	_	_	O
202	7	_	_	O
203	;	_	_	O
204	control	_	_	O
205	:	_	_	O
206	n	_	_	O
207	=	_	_	O
208	11	_	_	O
209	)	_	_	O
210	.	_	_	O

211	Participants	_	_	B-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	intervention	_	_	I-Premise
215	group	_	_	I-Premise
216	reported	_	_	I-Premise
217	,	_	_	I-Premise
218	on	_	_	I-Premise
219	average	_	_	I-Premise
220	,	_	_	I-Premise
221	53	_	_	I-Premise
222	fewer	_	_	I-Premise
223	days	_	_	I-Premise
224	of	_	_	I-Premise
225	sick	_	_	I-Premise
226	leave	_	_	I-Premise
227	over	_	_	I-Premise
228	the	_	_	I-Premise
229	first	_	_	I-Premise
230	6	_	_	I-Premise
231	months	_	_	I-Premise
232	post-surgery	_	_	I-Premise
233	than	_	_	I-Premise
234	those	_	_	I-Premise
235	in	_	_	I-Premise
236	the	_	_	I-Premise
237	control	_	_	I-Premise
238	group	_	_	I-Premise
239	;	_	_	I-Premise
240	however	_	_	B-Premise
241	,	_	_	I-Premise
242	this	_	_	I-Premise
243	difference	_	_	I-Premise
244	was	_	_	I-Premise
245	not	_	_	I-Premise
246	statistically	_	_	I-Premise
247	significant	_	_	I-Premise
248	(	_	_	I-Premise
249	p	_	_	I-Premise
250	=	_	_	I-Premise
251	0.122	_	_	I-Premise
252	;	_	_	I-Premise
253	95	_	_	I-Premise
254	%	_	_	I-Premise
255	confidence	_	_	I-Premise
256	interval	_	_	I-Premise
257	-15.8	_	_	I-Premise
258	,	_	_	I-Premise
259	122.0	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	No	_	_	B-Premise
263	statistically	_	_	I-Premise
264	significant	_	_	I-Premise
265	differences	_	_	I-Premise
266	were	_	_	I-Premise
267	found	_	_	I-Premise
268	for	_	_	I-Premise
269	secondary	_	_	I-Premise
270	outcomes	_	_	I-Premise
271	.	_	_	I-Premise

272	Interviews	_	_	B-Premise
273	with	_	_	I-Premise
274	trial	_	_	I-Premise
275	participants	_	_	I-Premise
276	indicated	_	_	I-Premise
277	that	_	_	I-Premise
278	trial	_	_	I-Premise
279	procedures	_	_	I-Premise
280	,	_	_	I-Premise
281	including	_	_	I-Premise
282	recruitment	_	_	I-Premise
283	,	_	_	I-Premise
284	randomisation	_	_	I-Premise
285	and	_	_	I-Premise
286	research	_	_	I-Premise
287	instruments	_	_	I-Premise
288	,	_	_	I-Premise
289	were	_	_	I-Premise
290	acceptable	_	_	I-Premise
291	.	_	_	I-Premise

292	Conducting	_	_	B-Claim
293	a	_	_	I-Claim
294	pragmatic	_	_	I-Claim
295	trial	_	_	I-Claim
296	of	_	_	I-Claim
297	effectiveness	_	_	I-Claim
298	of	_	_	I-Claim
299	a	_	_	I-Claim
300	VR	_	_	I-Claim
301	intervention	_	_	I-Claim
302	among	_	_	I-Claim
303	cancer	_	_	I-Claim
304	survivors	_	_	I-Claim
305	is	_	_	I-Claim
306	both	_	_	I-Claim
307	feasible	_	_	I-Claim
308	and	_	_	I-Claim
309	acceptable	_	_	I-Claim
310	,	_	_	I-Claim
311	but	_	_	B-Claim
312	more	_	_	I-Claim
313	research	_	_	I-Claim
314	about	_	_	I-Claim
315	the	_	_	I-Claim
316	exact	_	_	I-Claim
317	components	_	_	I-Claim
318	of	_	_	I-Claim
319	a	_	_	I-Claim
320	VR	_	_	I-Claim
321	intervention	_	_	I-Claim
322	and	_	_	I-Claim
323	choice	_	_	I-Claim
324	of	_	_	I-Claim
325	outcomes	_	_	I-Claim
326	to	_	_	I-Claim
327	measure	_	_	I-Claim
328	effectiveness	_	_	I-Claim
329	is	_	_	I-Claim
330	required	_	_	I-Claim
331	.	_	_	I-Claim

332	VR	_	_	B-Claim
333	to	_	_	I-Claim
334	assist	_	_	I-Claim
335	breast	_	_	I-Claim
336	cancer	_	_	I-Claim
337	patients	_	_	I-Claim
338	in	_	_	I-Claim
339	the	_	_	I-Claim
340	return	_	_	I-Claim
341	to	_	_	I-Claim
342	work	_	_	I-Claim
343	process	_	_	I-Claim
344	is	_	_	I-Claim
345	an	_	_	I-Claim
346	important	_	_	I-Claim
347	component	_	_	I-Claim
348	of	_	_	I-Claim
349	cancer	_	_	I-Claim
350	survivorship	_	_	I-Claim
351	plans	_	_	I-Claim
352	.	_	_	I-Claim


0	Intravenous	_	_	O
1	(	_	_	O
2	IV	_	_	O
3	)	_	_	O
4	granulocyte	_	_	O
5	colony	_	_	O
6	stimulating	_	_	O
7	factor	_	_	O
8	(	_	_	O
9	G-CSF	_	_	O
10	)	_	_	O
11	might	_	_	O
12	be	_	_	O
13	safer	_	_	O
14	and	_	_	O
15	more	_	_	O
16	convenient	_	_	O
17	than	_	_	O
18	subcutaneous	_	_	O
19	(	_	_	O
20	SC	_	_	O
21	)	_	_	O
22	administration	_	_	O
23	to	_	_	O
24	hospitalized	_	_	O
25	hemato-oncological	_	_	O
26	patients	_	_	O
27	receiving	_	_	O
28	chemotherapy	_	_	O
29	.	_	_	O

30	To	_	_	O
31	compare	_	_	O
32	IV	_	_	O
33	vs.	_	_	O
34	SC	_	_	O
35	G-CSF	_	_	O
36	administration	_	_	O
37	,	_	_	O
38	we	_	_	O
39	conducted	_	_	O
40	a	_	_	O
41	randomized	_	_	O
42	,	_	_	O
43	open-label	_	_	O
44	trial	_	_	O
45	.	_	_	O

46	We	_	_	O
47	included	_	_	O
48	inpatients	_	_	O
49	receiving	_	_	O
50	chemotherapy	_	_	O
51	for	_	_	O
52	acute	_	_	O
53	myeloid	_	_	O
54	leukemia	_	_	O
55	,	_	_	O
56	acute	_	_	O
57	lymphoblastic	_	_	O
58	leukemia	_	_	O
59	,	_	_	O
60	lymphoma	_	_	O
61	or	_	_	O
62	multiple	_	_	O
63	myeloma	_	_	O
64	,	_	_	O
65	and	_	_	O
66	allogeneic	_	_	O
67	or	_	_	O
68	autologous	_	_	O
69	hematopoietic	_	_	O
70	cell	_	_	O
71	transplantation	_	_	O
72	(	_	_	O
73	HCT	_	_	O
74	)	_	_	O
75	.	_	_	O

76	Patients	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	5	_	_	O
81	mcg/kg	_	_	O
82	single	_	_	O
83	daily	_	_	O
84	dose	_	_	O
85	of	_	_	O
86	IV	_	_	O
87	bolus	_	_	O
88	versus	_	_	O
89	SC	_	_	O
90	filgrastim	_	_	O
91	given	_	_	O
92	for	_	_	O
93	its	_	_	O
94	clinical	_	_	O
95	indications	_	_	O
96	.	_	_	O

97	Patients	_	_	O
98	were	_	_	O
99	crossed-over	_	_	O
100	to	_	_	O
101	the	_	_	O
102	alternate	_	_	O
103	study	_	_	O
104	arm	_	_	O
105	on	_	_	O
106	the	_	_	O
107	subsequent	_	_	O
108	chemotherapy	_	_	O
109	course	_	_	O
110	.	_	_	O

111	The	_	_	O
112	primary	_	_	O
113	outcomes	_	_	O
114	were	_	_	O
115	time	_	_	O
116	from	_	_	O
117	initiation	_	_	O
118	of	_	_	O
119	filgrastim	_	_	O
120	to	_	_	O
121	recovery	_	_	O
122	of	_	_	O
123	stable	_	_	O
124	neutrophil	_	_	O
125	count	_	_	O
126	of	_	_	O
127	>	_	_	O
128	500	_	_	O
129	cells/L	_	_	O
130	and	_	_	O
131	a	_	_	O
132	composite	_	_	O
133	clinical	_	_	O
134	outcome	_	_	O
135	of	_	_	O
136	infection	_	_	O
137	or	_	_	O
138	death	_	_	O
139	assessed	_	_	O
140	for	_	_	O
141	the	_	_	O
142	first	_	_	O
143	course	_	_	O
144	post-randomization	_	_	O
145	.	_	_	O

146	The	_	_	O
147	study	_	_	O
148	was	_	_	O
149	stopped	_	_	O
150	on	_	_	O
151	the	_	_	O
152	second	_	_	O
153	interim	_	_	O
154	analysis	_	_	O
155	.	_	_	O

156	Of	_	_	O
157	120	_	_	O
158	patients	_	_	O
159	randomized	_	_	O
160	,	_	_	O
161	118	_	_	O
162	were	_	_	O
163	evaluated	_	_	O
164	in	_	_	O
165	the	_	_	O
166	first	_	_	O
167	treatment	_	_	O
168	course	_	_	O
169	.	_	_	O

170	The	_	_	B-Premise
171	mean	_	_	I-Premise
172	time	_	_	I-Premise
173	to	_	_	I-Premise
174	neutropenia	_	_	I-Premise
175	resolution	_	_	I-Premise
176	was	_	_	I-Premise
177	longer	_	_	I-Premise
178	with	_	_	I-Premise
179	IV	_	_	I-Premise
180	G-CSF	_	_	I-Premise
181	[	_	_	I-Premise
182	7.9	_	_	I-Premise
183	days	_	_	I-Premise
184	,	_	_	I-Premise
185	95	_	_	I-Premise
186	%	_	_	I-Premise
187	confidence	_	_	I-Premise
188	interval	_	_	I-Premise
189	(	_	_	I-Premise
190	CI	_	_	I-Premise
191	)	_	_	I-Premise
192	6.6-9.1	_	_	I-Premise
193	]	_	_	I-Premise
194	compared	_	_	I-Premise
195	with	_	_	I-Premise
196	SC	_	_	I-Premise
197	G-CSF	_	_	I-Premise
198	(	_	_	I-Premise
199	5.4	_	_	I-Premise
200	days	_	_	I-Premise
201	,	_	_	I-Premise
202	95	_	_	I-Premise
203	%	_	_	I-Premise
204	CI	_	_	I-Premise
205	4.6-6.2	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	log-rank	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	0.001	_	_	I-Premise
212	.	_	_	I-Premise

213	Longer	_	_	B-Premise
214	neutropenia	_	_	I-Premise
215	duration	_	_	I-Premise
216	was	_	_	I-Premise
217	observed	_	_	I-Premise
218	in	_	_	I-Premise
219	all	_	_	I-Premise
220	patient	_	_	I-Premise
221	subgroups	_	_	I-Premise
222	,	_	_	I-Premise
223	except	_	_	B-Premise
224	for	_	_	I-Premise
225	patients	_	_	I-Premise
226	undergoing	_	_	I-Premise
227	autologous	_	_	I-Premise
228	HCT	_	_	I-Premise
229	.	_	_	I-Premise

230	There	_	_	B-Premise
231	was	_	_	I-Premise
232	no	_	_	I-Premise
233	significant	_	_	I-Premise
234	difference	_	_	I-Premise
235	between	_	_	I-Premise
236	groups	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	occurrence	_	_	I-Premise
240	of	_	_	I-Premise
241	infection	_	_	I-Premise
242	or	_	_	I-Premise
243	death	_	_	I-Premise
244	,	_	_	I-Premise
245	but	_	_	B-Premise
246	more	_	_	I-Premise
247	deaths	_	_	I-Premise
248	were	_	_	I-Premise
249	observed	_	_	I-Premise
250	with	_	_	I-Premise
251	IV	_	_	I-Premise
252	(	_	_	I-Premise
253	4/57	_	_	I-Premise
254	,	_	_	I-Premise
255	7	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	versus	_	_	I-Premise
259	SC	_	_	I-Premise
260	(	_	_	I-Premise
261	1/61	_	_	I-Premise
262	,	_	_	I-Premise
263	1.6	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	G-CSF	_	_	I-Premise
267	administration	_	_	I-Premise
268	,	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	0.196	_	_	I-Premise
272	.	_	_	I-Premise

273	Similar	_	_	O
274	results	_	_	O
275	were	_	_	O
276	observed	_	_	O
277	when	_	_	O
278	all	_	_	O
279	158	_	_	O
280	courses	_	_	O
281	following	_	_	O
282	cross-over	_	_	O
283	were	_	_	O
284	analyzed	_	_	O
285	.	_	_	O

286	Patients	_	_	B-Claim
287	reported	_	_	I-Claim
288	similar	_	_	I-Claim
289	pain	_	_	I-Claim
290	and	_	_	I-Claim
291	satisfaction	_	_	I-Claim
292	scores	_	_	I-Claim
293	in	_	_	I-Claim
294	both	_	_	I-Claim
295	groups	_	_	I-Claim
296	.	_	_	I-Claim

297	Bolus	_	_	B-Claim
298	IV	_	_	I-Claim
299	administration	_	_	I-Claim
300	of	_	_	I-Claim
301	G-CSF	_	_	I-Claim
302	results	_	_	I-Claim
303	in	_	_	I-Claim
304	longer	_	_	I-Claim
305	neutropenia	_	_	I-Claim
306	duration	_	_	I-Claim
307	than	_	_	I-Claim
308	SC	_	_	I-Claim
309	administration	_	_	I-Claim
310	,	_	_	I-Claim
311	with	_	_	I-Claim
312	no	_	_	I-Claim
313	difference	_	_	I-Claim
314	in	_	_	I-Claim
315	clinical	_	_	I-Claim
316	or	_	_	I-Claim
317	quality-of-life	_	_	I-Claim
318	measures	_	_	I-Claim
319	.	_	_	I-Claim


0	Fatigue	_	_	B-Claim
1	has	_	_	I-Claim
2	a	_	_	I-Claim
3	significant	_	_	I-Claim
4	impact	_	_	I-Claim
5	on	_	_	I-Claim
6	the	_	_	I-Claim
7	quality	_	_	I-Claim
8	of	_	_	I-Claim
9	life	_	_	I-Claim
10	(	_	_	I-Claim
11	QOL	_	_	I-Claim
12	)	_	_	I-Claim
13	of	_	_	I-Claim
14	cancer	_	_	I-Claim
15	patients	_	_	I-Claim
16	.	_	_	I-Claim

17	Recent	_	_	B-Claim
18	research	_	_	I-Claim
19	has	_	_	I-Claim
20	suggested	_	_	I-Claim
21	that	_	_	I-Claim
22	physical	_	_	I-Claim
23	activity	_	_	I-Claim
24	can	_	_	I-Claim
25	reduce	_	_	I-Claim
26	fatigue	_	_	I-Claim
27	in	_	_	I-Claim
28	patients	_	_	I-Claim
29	receiving	_	_	I-Claim
30	active	_	_	I-Claim
31	cancer	_	_	I-Claim
32	treatment	_	_	I-Claim
33	.	_	_	I-Claim

34	In	_	_	O
35	this	_	_	O
36	project	_	_	O
37	,	_	_	O
38	we	_	_	O
39	examined	_	_	O
40	the	_	_	O
41	impact	_	_	O
42	that	_	_	O
43	participation	_	_	O
44	in	_	_	O
45	a	_	_	O
46	randomized	_	_	O
47	controlled	_	_	O
48	trial	_	_	O
49	of	_	_	O
50	a	_	_	O
51	multidisciplinary	_	_	O
52	intervention	_	_	O
53	designed	_	_	O
54	to	_	_	O
55	impact	_	_	O
56	overall	_	_	O
57	QOL	_	_	O
58	had	_	_	O
59	on	_	_	O
60	fatigue	_	_	O
61	for	_	_	O
62	advanced	_	_	O
63	cancer	_	_	O
64	patients	_	_	O
65	actively	_	_	O
66	receiving	_	_	O
67	treatment	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	with	_	_	O
71	newly	_	_	O
72	diagnosed	_	_	O
73	cancer	_	_	O
74	were	_	_	O
75	randomly	_	_	O
76	assigned	_	_	O
77	to	_	_	O
78	an	_	_	O
79	8-session	_	_	O
80	structured	_	_	O
81	multidisciplinary	_	_	O
82	intervention	_	_	O
83	or	_	_	O
84	a	_	_	O
85	standard-care	_	_	O
86	arm	_	_	O
87	at	_	_	O
88	the	_	_	O
89	beginning	_	_	O
90	of	_	_	O
91	their	_	_	O
92	course	_	_	O
93	of	_	_	O
94	radiotherapy	_	_	O
95	(	_	_	O
96	RT	_	_	O
97	)	_	_	O
98	designed	_	_	O
99	to	_	_	O
100	impact	_	_	O
101	QOL	_	_	O
102	.	_	_	O

103	Ninety-minute	_	_	O
104	sessions	_	_	O
105	were	_	_	O
106	led	_	_	O
107	by	_	_	O
108	either	_	_	O
109	a	_	_	O
110	psychiatrist	_	_	O
111	or	_	_	O
112	psychologist	_	_	O
113	,	_	_	O
114	collaborating	_	_	O
115	with	_	_	O
116	a	_	_	O
117	nurse	_	_	O
118	,	_	_	O
119	physical	_	_	O
120	therapist	_	_	O
121	,	_	_	O
122	chaplain	_	_	O
123	,	_	_	O
124	or	_	_	O
125	social	_	_	O
126	worker	_	_	O
127	,	_	_	O
128	depending	_	_	O
129	on	_	_	O
130	the	_	_	O
131	session	_	_	O
132	's	_	_	O
133	theme	_	_	O
134	.	_	_	O

135	The	_	_	O
136	fatigue	_	_	O
137	assessments	_	_	O
138	used	_	_	O
139	in	_	_	O
140	this	_	_	O
141	trial	_	_	O
142	included	_	_	O
143	the	_	_	O
144	Linear	_	_	O
145	Analogue	_	_	O
146	Self	_	_	O
147	Assessment	_	_	O
148	(	_	_	O
149	LASA	_	_	O
150	)	_	_	O
151	,	_	_	O
152	the	_	_	O
153	Profile	_	_	O
154	of	_	_	O
155	Mood	_	_	O
156	States	_	_	O
157	(	_	_	O
158	POMS	_	_	O
159	)	_	_	O
160	,	_	_	O
161	Spielberger	_	_	O
162	's	_	_	O
163	State-Trait	_	_	O
164	Anxiety	_	_	O
165	Inventory	_	_	O
166	(	_	_	O
167	STAI	_	_	O
168	)	_	_	O
169	,	_	_	O
170	and	_	_	O
171	the	_	_	O
172	Symptom	_	_	O
173	Distress	_	_	O
174	Scale	_	_	O
175	(	_	_	O
176	SDS	_	_	O
177	)	_	_	O
178	.	_	_	O

179	There	_	_	O
180	were	_	_	O
181	115	_	_	O
182	participants	_	_	O
183	enrolled	_	_	O
184	and	_	_	O
185	the	_	_	O
186	2	_	_	O
187	randomization	_	_	O
188	arms	_	_	O
189	were	_	_	O
190	well	_	_	O
191	balanced	_	_	O
192	in	_	_	O
193	terms	_	_	O
194	of	_	_	O
195	baseline	_	_	O
196	characteristics	_	_	O
197	and	_	_	O
198	treatment	_	_	O
199	received	_	_	O
200	except	_	_	O
201	for	_	_	O
202	increased	_	_	O
203	commuting	_	_	O
204	distance	_	_	O
205	for	_	_	O
206	the	_	_	O
207	patients	_	_	O
208	in	_	_	O
209	the	_	_	O
210	intervention	_	_	O
211	arm	_	_	O
212	(	_	_	O
213	P	_	_	O
214	=	_	_	O
215	0.042	_	_	O
216	)	_	_	O
217	.	_	_	O

218	Most	_	_	B-Premise
219	of	_	_	I-Premise
220	scores	_	_	I-Premise
221	indicated	_	_	I-Premise
222	less	_	_	I-Premise
223	fatigue	_	_	I-Premise
224	(	_	_	I-Premise
225	higher	_	_	I-Premise
226	score	_	_	I-Premise
227	)	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	standard	_	_	I-Premise
231	treatment	_	_	I-Premise
232	group	_	_	I-Premise
233	,	_	_	I-Premise
234	but	_	_	B-Premise
235	there	_	_	I-Premise
236	were	_	_	I-Premise
237	no	_	_	I-Premise
238	statistically	_	_	I-Premise
239	significant	_	_	I-Premise
240	differences	_	_	I-Premise
241	found	_	_	I-Premise
242	at	_	_	I-Premise
243	baseline	_	_	I-Premise
244	and	_	_	I-Premise
245	weeks	_	_	I-Premise
246	4	_	_	I-Premise
247	,	_	_	I-Premise
248	8	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	27	_	_	I-Premise
252	except	_	_	I-Premise
253	for	_	_	I-Premise
254	SDS	_	_	I-Premise
255	at	_	_	I-Premise
256	week	_	_	I-Premise
257	8	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	=	_	_	I-Premise
261	0.018	_	_	I-Premise
262	)	_	_	I-Premise
263	with	_	_	I-Premise
264	less	_	_	I-Premise
265	patients	_	_	I-Premise
266	reporting	_	_	I-Premise
267	significant	_	_	I-Premise
268	fatigue	_	_	I-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	standard	_	_	I-Premise
272	treatment	_	_	I-Premise
273	arm	_	_	I-Premise
274	.	_	_	I-Premise

275	For	_	_	B-Premise
276	the	_	_	I-Premise
277	entire	_	_	I-Premise
278	participant	_	_	I-Premise
279	population	_	_	I-Premise
280	,	_	_	I-Premise
281	fatigue	_	_	I-Premise
282	levels	_	_	I-Premise
283	initially	_	_	I-Premise
284	worsened	_	_	I-Premise
285	with	_	_	I-Premise
286	radiotherapy	_	_	I-Premise
287	,	_	_	I-Premise
288	stabilized	_	_	I-Premise
289	at	_	_	I-Premise
290	week	_	_	I-Premise
291	8	_	_	I-Premise
292	,	_	_	I-Premise
293	and	_	_	I-Premise
294	returned	_	_	I-Premise
295	to	_	_	I-Premise
296	baseline	_	_	I-Premise
297	by	_	_	I-Premise
298	week	_	_	I-Premise
299	27	_	_	I-Premise
300	.	_	_	I-Premise

301	Disease	_	_	B-Premise
302	site	_	_	I-Premise
303	,	_	_	I-Premise
304	chemotherapy	_	_	I-Premise
305	use	_	_	I-Premise
306	,	_	_	I-Premise
307	and	_	_	I-Premise
308	radiotherapy	_	_	I-Premise
309	dose	_	_	I-Premise
310	did	_	_	I-Premise
311	not	_	_	I-Premise
312	have	_	_	I-Premise
313	a	_	_	I-Premise
314	significant	_	_	I-Premise
315	impact	_	_	I-Premise
316	on	_	_	I-Premise
317	fatigue	_	_	I-Premise
318	levels	_	_	I-Premise
319	.	_	_	I-Premise

320	Radiotherapy	_	_	B-Premise
321	initially	_	_	I-Premise
322	caused	_	_	I-Premise
323	a	_	_	I-Premise
324	worsening	_	_	I-Premise
325	of	_	_	I-Premise
326	fatigue	_	_	I-Premise
327	but	_	_	I-Premise
328	with	_	_	I-Premise
329	time	_	_	I-Premise
330	fatigue	_	_	I-Premise
331	levels	_	_	I-Premise
332	returned	_	_	I-Premise
333	to	_	_	I-Premise
334	baseline	_	_	I-Premise
335	.	_	_	O

336	Clinically	_	_	B-Claim
337	,	_	_	I-Claim
338	this	_	_	I-Claim
339	structured	_	_	I-Claim
340	multidisciplinary	_	_	I-Claim
341	intervention	_	_	I-Claim
342	had	_	_	I-Claim
343	no	_	_	I-Claim
344	impact	_	_	I-Claim
345	on	_	_	I-Claim
346	fatigue	_	_	I-Claim
347	,	_	_	I-Claim
348	and	_	_	O
349	there	_	_	B-Claim
350	was	_	_	I-Claim
351	the	_	_	I-Claim
352	suggestion	_	_	I-Claim
353	the	_	_	I-Claim
354	multiple	_	_	I-Claim
355	sessions	_	_	I-Claim
356	may	_	_	I-Claim
357	have	_	_	I-Claim
358	contributed	_	_	I-Claim
359	to	_	_	I-Claim
360	worse	_	_	I-Claim
361	fatigue	_	_	I-Claim
362	during	_	_	I-Claim
363	active	_	_	I-Claim
364	cancer	_	_	I-Claim
365	treatment	_	_	I-Claim
366	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aims	_	_	O
3	to	_	_	O
4	evaluate	_	_	O
5	the	_	_	O
6	feasibility	_	_	O
7	and	_	_	O
8	efficacy	_	_	O
9	of	_	_	O
10	an	_	_	O
11	8-week	_	_	O
12	supervised	_	_	O
13	exercise	_	_	O
14	program	_	_	O
15	in	_	_	O
16	de-conditioned	_	_	O
17	cancer	_	_	O
18	survivors	_	_	O
19	within	_	_	O
20	2-6	_	_	O
21	months	_	_	O
22	of	_	_	O
23	chemotherapy	_	_	O
24	completion	_	_	O
25	.	_	_	O

26	Participants	_	_	O
27	were	_	_	O
28	randomly	_	_	O
29	assigned	_	_	O
30	to	_	_	O
31	an	_	_	O
32	8-week	_	_	O
33	,	_	_	O
34	twice-weekly	_	_	O
35	,	_	_	O
36	supervised	_	_	O
37	aerobic	_	_	O
38	exercise	_	_	O
39	training	_	_	O
40	regime	_	_	O
41	(	_	_	O
42	n	_	_	O
43	=	_	_	O
44	23	_	_	O
45	)	_	_	O
46	or	_	_	O
47	a	_	_	O
48	usual	_	_	O
49	care	_	_	O
50	group	_	_	O
51	(	_	_	O
52	n	_	_	O
53	=	_	_	O
54	20	_	_	O
55	)	_	_	O
56	.	_	_	O

57	Feasibility	_	_	O
58	was	_	_	O
59	assessed	_	_	O
60	by	_	_	O
61	recruitment	_	_	O
62	rate	_	_	O
63	,	_	_	O
64	program	_	_	O
65	adherence	_	_	O
66	and	_	_	O
67	participant	_	_	O
68	feedback	_	_	O
69	.	_	_	O

70	The	_	_	O
71	primary	_	_	O
72	outcome	_	_	O
73	was	_	_	O
74	aerobic	_	_	O
75	fitness	_	_	O
76	assessed	_	_	O
77	by	_	_	O
78	the	_	_	O
79	Modified	_	_	O
80	Bruce	_	_	O
81	fitness	_	_	O
82	test	_	_	O
83	at	_	_	O
84	baseline	_	_	O
85	(	_	_	O
86	0	_	_	O
87	weeks	_	_	O
88	)	_	_	O
89	,	_	_	O
90	post-intervention	_	_	O
91	(	_	_	O
92	8	_	_	O
93	weeks	_	_	O
94	)	_	_	O
95	and	_	_	O
96	at	_	_	O
97	3-month	_	_	O
98	follow-up	_	_	O
99	.	_	_	O

100	Secondary	_	_	O
101	outcomes	_	_	O
102	included	_	_	O
103	physical	_	_	O
104	activity	_	_	O
105	,	_	_	O
106	waist	_	_	O
107	circumference	_	_	O
108	,	_	_	O
109	fatigue	_	_	O
110	and	_	_	O
111	quality	_	_	O
112	of	_	_	O
113	life	_	_	O
114	.	_	_	O

115	The	_	_	O
116	recruitment	_	_	O
117	rate	_	_	O
118	was	_	_	O
119	81	_	_	O
120	%	_	_	O
121	and	_	_	O
122	adherence	_	_	O
123	to	_	_	O
124	the	_	_	O
125	supervised	_	_	O
126	exercise	_	_	O
127	was	_	_	O
128	78.3	_	_	O
129	%	_	_	O
130	.	_	_	O

131	Meaningful	_	_	B-Premise
132	differences	_	_	I-Premise
133	in	_	_	I-Premise
134	aerobic	_	_	I-Premise
135	fitness	_	_	I-Premise
136	between	_	_	I-Premise
137	the	_	_	I-Premise
138	exercise	_	_	I-Premise
139	and	_	_	I-Premise
140	usual	_	_	I-Premise
141	care	_	_	I-Premise
142	groups	_	_	I-Premise
143	at	_	_	I-Premise
144	both	_	_	I-Premise
145	the	_	_	I-Premise
146	8-week	_	_	I-Premise
147	[	_	_	I-Premise
148	mean	_	_	I-Premise
149	3.0	_	_	I-Premise
150	mL	_	_	I-Premise
151	kg	_	_	I-Premise
152	(	_	_	I-Premise
153	-1	_	_	I-Premise
154	)	_	_	I-Premise
155	min	_	_	I-Premise
156	(	_	_	I-Premise
157	-1	_	_	I-Premise
158	)	_	_	I-Premise
159	(	_	_	I-Premise
160	95	_	_	I-Premise
161	%	_	_	I-Premise
162	CI	_	_	I-Premise
163	-1.1-7.0	_	_	I-Premise
164	)	_	_	I-Premise
165	]	_	_	I-Premise
166	and	_	_	I-Premise
167	3-month	_	_	I-Premise
168	follow-up	_	_	I-Premise
169	[	_	_	I-Premise
170	2.1	_	_	I-Premise
171	mL	_	_	I-Premise
172	kg	_	_	I-Premise
173	(	_	_	I-Premise
174	-1	_	_	I-Premise
175	)	_	_	I-Premise
176	min	_	_	I-Premise
177	(	_	_	I-Premise
178	-1	_	_	I-Premise
179	)	_	_	I-Premise
180	(	_	_	I-Premise
181	-2.3-6.6	_	_	I-Premise
182	)	_	_	I-Premise
183	]	_	_	I-Premise
184	were	_	_	I-Premise
185	found	_	_	I-Premise
186	,	_	_	I-Premise
187	although	_	_	B-Premise
188	these	_	_	I-Premise
189	differences	_	_	I-Premise
190	did	_	_	I-Premise
191	not	_	_	I-Premise
192	achieve	_	_	I-Premise
193	statistical	_	_	I-Premise
194	significance	_	_	I-Premise
195	(	_	_	I-Premise
196	p	_	_	I-Premise
197	values	_	_	I-Premise
198	>	_	_	I-Premise
199	0.14	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Self-reported	_	_	B-Premise
203	physical	_	_	I-Premise
204	activity	_	_	I-Premise
205	increased	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	exercise	_	_	I-Premise
209	group	_	_	I-Premise
210	(	_	_	I-Premise
211	EG	_	_	I-Premise
212	)	_	_	I-Premise
213	compared	_	_	I-Premise
214	to	_	_	I-Premise
215	the	_	_	I-Premise
216	usual	_	_	I-Premise
217	care	_	_	I-Premise
218	group	_	_	I-Premise
219	at	_	_	I-Premise
220	both	_	_	I-Premise
221	8-week	_	_	I-Premise
222	(	_	_	I-Premise
223	p	_	_	I-Premise
224	=	_	_	I-Premise
225	0.01	_	_	I-Premise
226	)	_	_	I-Premise
227	and	_	_	I-Premise
228	3-month	_	_	I-Premise
229	follow-up	_	_	I-Premise
230	(	_	_	I-Premise
231	p	_	_	I-Premise
232	=	_	_	I-Premise
233	0.03	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	significant	_	_	I-Premise
237	differences	_	_	I-Premise
238	in	_	_	I-Premise
239	favour	_	_	I-Premise
240	of	_	_	I-Premise
241	the	_	_	I-Premise
242	EG	_	_	I-Premise
243	were	_	_	I-Premise
244	found	_	_	I-Premise
245	for	_	_	I-Premise
246	physical	_	_	I-Premise
247	well-being	_	_	I-Premise
248	at	_	_	I-Premise
249	both	_	_	I-Premise
250	the	_	_	I-Premise
251	8-week	_	_	I-Premise
252	(	_	_	I-Premise
253	p	_	_	I-Premise
254	=	_	_	I-Premise
255	0.03	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	3-month	_	_	I-Premise
259	follow-up	_	_	I-Premise
260	(	_	_	I-Premise
261	p	_	_	I-Premise
262	=	_	_	I-Premise
263	0.04	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	Improvements	_	_	B-Premise
267	in	_	_	I-Premise
268	fatigue	_	_	I-Premise
269	(	_	_	I-Premise
270	p	_	_	I-Premise
271	=	_	_	I-Premise
272	0.01	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	total	_	_	I-Premise
276	quality	_	_	I-Premise
277	of	_	_	I-Premise
278	life	_	_	I-Premise
279	plus	_	_	I-Premise
280	fatigue	_	_	I-Premise
281	(	_	_	I-Premise
282	p	_	_	I-Premise
283	=	_	_	I-Premise
284	0.04	_	_	I-Premise
285	)	_	_	I-Premise
286	,	_	_	I-Premise
287	and	_	_	I-Premise
288	a	_	_	I-Premise
289	composite	_	_	I-Premise
290	physical	_	_	I-Premise
291	functioning	_	_	I-Premise
292	score	_	_	I-Premise
293	(	_	_	I-Premise
294	p	_	_	I-Premise
295	=	_	_	I-Premise
296	0.01	_	_	I-Premise
297	)	_	_	I-Premise
298	at	_	_	I-Premise
299	the	_	_	I-Premise
300	3-month	_	_	I-Premise
301	follow-up	_	_	I-Premise
302	were	_	_	I-Premise
303	also	_	_	I-Premise
304	found	_	_	I-Premise
305	.	_	_	I-Premise

306	The	_	_	B-Claim
307	PEACH	_	_	I-Claim
308	trial	_	_	I-Claim
309	suggests	_	_	I-Claim
310	that	_	_	I-Claim
311	8	_	_	I-Claim
312	weeks	_	_	I-Claim
313	of	_	_	I-Claim
314	supervised	_	_	I-Claim
315	aerobic	_	_	I-Claim
316	exercise	_	_	I-Claim
317	training	_	_	I-Claim
318	was	_	_	I-Claim
319	feasible	_	_	I-Claim
320	and	_	_	I-Claim
321	may	_	_	I-Claim
322	improve	_	_	I-Claim
323	aerobic	_	_	I-Claim
324	fitness	_	_	I-Claim
325	,	_	_	I-Claim
326	fatigue	_	_	I-Claim
327	and	_	_	I-Claim
328	quality	_	_	I-Claim
329	of	_	_	I-Claim
330	life	_	_	I-Claim
331	in	_	_	I-Claim
332	de-conditioned	_	_	I-Claim
333	cancer	_	_	I-Claim
334	survivors	_	_	I-Claim
335	during	_	_	I-Claim
336	the	_	_	I-Claim
337	early	_	_	I-Claim
338	survivorship	_	_	I-Claim
339	phase	_	_	I-Claim
340	.	_	_	I-Claim

341	Exercise	_	_	B-Claim
342	interventions	_	_	I-Claim
343	commenced	_	_	I-Claim
344	in	_	_	I-Claim
345	the	_	_	I-Claim
346	early	_	_	I-Claim
347	survivorship	_	_	I-Claim
348	phase	_	_	I-Claim
349	appear	_	_	I-Claim
350	safe	_	_	I-Claim
351	,	_	_	I-Claim
352	feasible	_	_	I-Claim
353	and	_	_	I-Claim
354	may	_	_	I-Claim
355	lead	_	_	I-Claim
356	to	_	_	I-Claim
357	improvements	_	_	I-Claim
358	in	_	_	I-Claim
359	QOL	_	_	I-Claim
360	and	_	_	I-Claim
361	fatigue	_	_	I-Claim
362	.	_	_	I-Claim


0	Tumor	_	_	B-Claim
1	necrosis	_	_	I-Claim
2	factor-alpha	_	_	I-Claim
3	(	_	_	I-Claim
4	TNF-alpha	_	_	I-Claim
5	)	_	_	I-Claim
6	is	_	_	I-Claim
7	a	_	_	I-Claim
8	putative	_	_	I-Claim
9	mediator	_	_	I-Claim
10	of	_	_	I-Claim
11	the	_	_	I-Claim
12	cancer	_	_	I-Claim
13	anorexia/weight	_	_	I-Claim
14	loss	_	_	I-Claim
15	syndrome	_	_	I-Claim
16	.	_	_	I-Claim

17	The	_	_	O
18	current	_	_	O
19	study	_	_	O
20	was	_	_	O
21	designed	_	_	O
22	to	_	_	O
23	determine	_	_	O
24	whether	_	_	O
25	etanercept	_	_	O
26	(	_	_	O
27	a	_	_	O
28	dimeric	_	_	O
29	fusion	_	_	O
30	protein	_	_	O
31	consisting	_	_	O
32	of	_	_	O
33	the	_	_	O
34	extracellular	_	_	O
35	ligand-binding	_	_	O
36	portion	_	_	O
37	of	_	_	O
38	the	_	_	O
39	human	_	_	O
40	75-kilodalton	_	_	O
41	TNF	_	_	O
42	receptor	_	_	O
43	linked	_	_	O
44	to	_	_	O
45	the	_	_	O
46	Fc	_	_	O
47	portion	_	_	O
48	of	_	_	O
49	human	_	_	O
50	immunoglobulin	_	_	O
51	[	_	_	O
52	Ig	_	_	O
53	]	_	_	O
54	G1	_	_	O
55	)	_	_	O
56	could	_	_	O
57	palliate	_	_	O
58	this	_	_	O
59	syndrome	_	_	O
60	.	_	_	O

61	A	_	_	O
62	total	_	_	O
63	of	_	_	O
64	63	_	_	O
65	evaluable	_	_	O
66	patients	_	_	O
67	were	_	_	O
68	randomly	_	_	O
69	assigned	_	_	O
70	to	_	_	O
71	receive	_	_	O
72	either	_	_	O
73	etanercept	_	_	O
74	at	_	_	O
75	a	_	_	O
76	dose	_	_	O
77	of	_	_	O
78	25	_	_	O
79	mg	_	_	O
80	subcutaneously	_	_	O
81	twice	_	_	O
82	weekly	_	_	O
83	versus	_	_	O
84	a	_	_	O
85	comparably	_	_	O
86	administered	_	_	O
87	placebo	_	_	O
88	.	_	_	O

89	All	_	_	O
90	patients	_	_	O
91	had	_	_	O
92	an	_	_	O
93	incurable	_	_	O
94	malignancy	_	_	O
95	,	_	_	O
96	acknowledged	_	_	O
97	loss	_	_	O
98	of	_	_	O
99	weight	_	_	O
100	and/or	_	_	O
101	appetite	_	_	O
102	as	_	_	O
103	a	_	_	O
104	concern	_	_	O
105	,	_	_	O
106	and	_	_	O
107	reported	_	_	O
108	a	_	_	O
109	weight	_	_	O
110	loss	_	_	O
111	of	_	_	O
112	>	_	_	O
113	2.27	_	_	O
114	kg	_	_	O
115	over	_	_	O
116	2	_	_	O
117	months	_	_	O
118	and/or	_	_	O
119	a	_	_	O
120	daily	_	_	O
121	intake	_	_	O
122	of	_	_	O
123	<	_	_	O
124	20	_	_	O
125	calories/kg	_	_	O
126	body	_	_	O
127	weight	_	_	O
128	.	_	_	O

129	Over	_	_	B-Premise
130	time	_	_	I-Premise
131	,	_	_	I-Premise
132	weight	_	_	I-Premise
133	gain	_	_	I-Premise
134	was	_	_	I-Premise
135	found	_	_	I-Premise
136	to	_	_	I-Premise
137	be	_	_	I-Premise
138	minimal	_	_	I-Premise
139	in	_	_	I-Premise
140	both	_	_	I-Premise
141	treatment	_	_	I-Premise
142	arms	_	_	I-Premise
143	;	_	_	I-Premise
144	no	_	_	I-Premise
145	patient	_	_	I-Premise
146	gained	_	_	I-Premise
147	>	_	_	I-Premise
148	or=10	_	_	I-Premise
149	%	_	_	I-Premise
150	of	_	_	I-Premise
151	their	_	_	I-Premise
152	baseline	_	_	I-Premise
153	weight	_	_	I-Premise
154	.	_	_	I-Premise

155	Previously	_	_	B-Premise
156	validated	_	_	I-Premise
157	appetite	_	_	I-Premise
158	questionnaires	_	_	I-Premise
159	revealed	_	_	I-Premise
160	negligible	_	_	I-Premise
161	improvements	_	_	I-Premise
162	in	_	_	I-Premise
163	both	_	_	I-Premise
164	treatment	_	_	I-Premise
165	arms	_	_	I-Premise
166	.	_	_	I-Premise

167	The	_	_	B-Premise
168	median	_	_	I-Premise
169	survival	_	_	I-Premise
170	was	_	_	I-Premise
171	also	_	_	I-Premise
172	comparable	_	_	I-Premise
173	(	_	_	I-Premise
174	175	_	_	I-Premise
175	days	_	_	I-Premise
176	vs	_	_	I-Premise
177	148	_	_	I-Premise
178	days	_	_	I-Premise
179	in	_	_	I-Premise
180	etanercept-treated	_	_	I-Premise
181	and	_	_	I-Premise
182	placebo-exposed	_	_	I-Premise
183	patients	_	_	I-Premise
184	,	_	_	I-Premise
185	respectively	_	_	I-Premise
186	;	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	.82	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	Finally	_	_	O
193	,	_	_	O
194	preliminary	_	_	B-Premise
195	data	_	_	I-Premise
196	regarding	_	_	I-Premise
197	adverse	_	_	I-Premise
198	events	_	_	I-Premise
199	demonstrated	_	_	I-Premise
200	that	_	_	I-Premise
201	patients	_	_	I-Premise
202	treated	_	_	I-Premise
203	with	_	_	I-Premise
204	etanercept	_	_	I-Premise
205	had	_	_	I-Premise
206	higher	_	_	I-Premise
207	rates	_	_	I-Premise
208	of	_	_	I-Premise
209	neurotoxicity	_	_	I-Premise
210	(	_	_	I-Premise
211	29	_	_	I-Premise
212	%	_	_	I-Premise
213	vs	_	_	I-Premise
214	0	_	_	I-Premise
215	%	_	_	I-Premise
216	)	_	_	I-Premise
217	but	_	_	I-Premise
218	lower	_	_	I-Premise
219	rates	_	_	I-Premise
220	of	_	_	I-Premise
221	anemia	_	_	I-Premise
222	(	_	_	I-Premise
223	0	_	_	I-Premise
224	%	_	_	I-Premise
225	vs	_	_	I-Premise
226	19	_	_	I-Premise
227	%	_	_	I-Premise
228	)	_	_	I-Premise
229	and	_	_	I-Premise
230	thrombocytopenia	_	_	I-Premise
231	(	_	_	I-Premise
232	0	_	_	I-Premise
233	%	_	_	I-Premise
234	vs	_	_	I-Premise
235	14	_	_	I-Premise
236	%	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Infection	_	_	B-Premise
240	rates	_	_	I-Premise
241	were	_	_	I-Premise
242	negligible	_	_	I-Premise
243	in	_	_	I-Premise
244	both	_	_	I-Premise
245	groups	_	_	I-Premise
246	.	_	_	I-Premise

247	Genotyping	_	_	B-Premise
248	for	_	_	I-Premise
249	TNF-alpha-238	_	_	I-Premise
250	and	_	_	I-Premise
251	TNF-alpha-308	_	_	I-Premise
252	polymorphisms	_	_	I-Premise
253	revealed	_	_	I-Premise
254	no	_	_	I-Premise
255	clinical	_	_	I-Premise
256	significance	_	_	I-Premise
257	for	_	_	I-Premise
258	these	_	_	I-Premise
259	genotypes	_	_	I-Premise
260	,	_	_	I-Premise
261	except	_	_	I-Premise
262	for	_	_	I-Premise
263	a	_	_	I-Premise
264	preliminary	_	_	I-Premise
265	association	_	_	I-Premise
266	between	_	_	I-Premise
267	presence	_	_	I-Premise
268	of	_	_	I-Premise
269	the	_	_	I-Premise
270	-238	_	_	I-Premise
271	G/A	_	_	I-Premise
272	genotype	_	_	I-Premise
273	and	_	_	I-Premise
274	relatively	_	_	I-Premise
275	less	_	_	I-Premise
276	favorable	_	_	I-Premise
277	survival	_	_	I-Premise
278	.	_	_	I-Premise

279	Etanercept	_	_	B-Claim
280	,	_	_	I-Claim
281	as	_	_	I-Claim
282	prescribed	_	_	I-Claim
283	in	_	_	I-Claim
284	the	_	_	I-Claim
285	current	_	_	I-Claim
286	trial	_	_	I-Claim
287	,	_	_	I-Claim
288	does	_	_	I-Claim
289	not	_	_	I-Claim
290	appear	_	_	I-Claim
291	to	_	_	I-Claim
292	palliate	_	_	I-Claim
293	the	_	_	I-Claim
294	cancer	_	_	I-Claim
295	anorexia/weight	_	_	I-Claim
296	loss	_	_	I-Claim
297	syndrome	_	_	I-Claim
298	in	_	_	I-Claim
299	patients	_	_	I-Claim
300	with	_	_	I-Claim
301	advanced	_	_	I-Claim
302	disease	_	_	I-Claim
303	.	_	_	I-Claim


0	Hepatic	_	_	O
1	metastases	_	_	O
2	derive	_	_	O
3	most	_	_	O
4	of	_	_	O
5	their	_	_	O
6	blood	_	_	O
7	supply	_	_	O
8	from	_	_	O
9	the	_	_	O
10	hepatic	_	_	O
11	artery	_	_	O
12	;	_	_	O
13	therefore	_	_	O
14	,	_	_	O
15	for	_	_	B-Claim
16	patients	_	_	I-Claim
17	with	_	_	I-Claim
18	hepatic	_	_	I-Claim
19	metastases	_	_	I-Claim
20	from	_	_	I-Claim
21	colorectal	_	_	I-Claim
22	cancer	_	_	I-Claim
23	,	_	_	I-Claim
24	hepatic	_	_	I-Claim
25	arterial	_	_	I-Claim
26	infusion	_	_	I-Claim
27	(	_	_	I-Claim
28	HAI	_	_	I-Claim
29	)	_	_	I-Claim
30	of	_	_	I-Claim
31	chemotherapy	_	_	I-Claim
32	may	_	_	I-Claim
33	improve	_	_	I-Claim
34	outcome	_	_	I-Claim
35	.	_	_	I-Claim

36	In	_	_	O
37	a	_	_	O
38	multi-institutional	_	_	O
39	trial	_	_	O
40	,	_	_	O
41	135	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	randomly	_	_	O
45	assigned	_	_	O
46	to	_	_	O
47	receive	_	_	O
48	HAI	_	_	O
49	versus	_	_	O
50	systemic	_	_	O
51	bolus	_	_	O
52	fluorouracil	_	_	O
53	and	_	_	O
54	leucovorin	_	_	O
55	.	_	_	O

56	The	_	_	O
57	primary	_	_	O
58	end	_	_	O
59	point	_	_	O
60	was	_	_	O
61	survival	_	_	O
62	;	_	_	O
63	secondary	_	_	O
64	end	_	_	O
65	points	_	_	O
66	were	_	_	O
67	response	_	_	O
68	,	_	_	O
69	recurrence	_	_	O
70	,	_	_	O
71	toxicity	_	_	O
72	,	_	_	O
73	quality	_	_	O
74	of	_	_	O
75	life	_	_	O
76	,	_	_	O
77	cost	_	_	O
78	,	_	_	O
79	and	_	_	O
80	the	_	_	O
81	influence	_	_	O
82	of	_	_	O
83	molecular	_	_	O
84	markers	_	_	O
85	.	_	_	O

86	Overall	_	_	B-Premise
87	survival	_	_	I-Premise
88	was	_	_	I-Premise
89	significantly	_	_	I-Premise
90	longer	_	_	I-Premise
91	for	_	_	I-Premise
92	HAI	_	_	I-Premise
93	versus	_	_	I-Premise
94	systemic	_	_	I-Premise
95	treatment	_	_	I-Premise
96	(	_	_	I-Premise
97	median	_	_	I-Premise
98	,	_	_	I-Premise
99	24.4	_	_	I-Premise
100	v	_	_	I-Premise
101	20	_	_	I-Premise
102	months	_	_	I-Premise
103	;	_	_	I-Premise
104	P	_	_	I-Premise
105	=	_	_	I-Premise
106	.0034	_	_	I-Premise
107	)	_	_	I-Premise
108	,	_	_	I-Premise
109	as	_	_	I-Premise
110	were	_	_	I-Premise
111	response	_	_	I-Premise
112	rates	_	_	I-Premise
113	(	_	_	I-Premise
114	47	_	_	I-Premise
115	%	_	_	I-Premise
116	and	_	_	I-Premise
117	24	_	_	I-Premise
118	%	_	_	I-Premise
119	;	_	_	I-Premise
120	P	_	_	I-Premise
121	=	_	_	I-Premise
122	.012	_	_	I-Premise
123	)	_	_	I-Premise
124	and	_	_	I-Premise
125	time	_	_	I-Premise
126	to	_	_	I-Premise
127	hepatic	_	_	I-Premise
128	progression	_	_	I-Premise
129	(	_	_	I-Premise
130	THP	_	_	I-Premise
131	;	_	_	I-Premise
132	9.8	_	_	I-Premise
133	v	_	_	I-Premise
134	7.3	_	_	I-Premise
135	months	_	_	I-Premise
136	;	_	_	I-Premise
137	P	_	_	I-Premise
138	=	_	_	I-Premise
139	.034	_	_	I-Premise
140	)	_	_	I-Premise
141	.	_	_	I-Premise

142	Time	_	_	B-Premise
143	to	_	_	I-Premise
144	extrahepatic	_	_	I-Premise
145	progression	_	_	I-Premise
146	(	_	_	I-Premise
147	7.7	_	_	I-Premise
148	v	_	_	I-Premise
149	14.8	_	_	I-Premise
150	months	_	_	I-Premise
151	;	_	_	I-Premise
152	P	_	_	I-Premise
153	=	_	_	I-Premise
154	.029	_	_	I-Premise
155	)	_	_	I-Premise
156	was	_	_	I-Premise
157	significantly	_	_	I-Premise
158	shorter	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	HAI	_	_	I-Premise
162	group	_	_	I-Premise
163	.	_	_	I-Premise

164	Quality-of-life	_	_	B-Premise
165	measurements	_	_	I-Premise
166	showed	_	_	I-Premise
167	improved	_	_	I-Premise
168	physical	_	_	I-Premise
169	functioning	_	_	I-Premise
170	in	_	_	I-Premise
171	the	_	_	I-Premise
172	HAI	_	_	I-Premise
173	group	_	_	I-Premise
174	at	_	_	I-Premise
175	the	_	_	I-Premise
176	3-	_	_	I-Premise
177	and	_	_	I-Premise
178	6-month	_	_	I-Premise
179	follow-up	_	_	I-Premise
180	assessments	_	_	I-Premise
181	.	_	_	I-Premise

182	Toxicity	_	_	B-Premise
183	included	_	_	I-Premise
184	grade	_	_	I-Premise
185	>	_	_	I-Premise
186	or	_	_	I-Premise
187	=	_	_	I-Premise
188	3	_	_	I-Premise
189	neutropenia	_	_	I-Premise
190	(	_	_	I-Premise
191	2	_	_	I-Premise
192	%	_	_	I-Premise
193	and	_	_	I-Premise
194	45	_	_	I-Premise
195	%	_	_	I-Premise
196	;	_	_	I-Premise
197	P	_	_	I-Premise
198	<	_	_	I-Premise
199	.01	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	stomatitis	_	_	I-Premise
203	(	_	_	I-Premise
204	0	_	_	I-Premise
205	%	_	_	I-Premise
206	and	_	_	I-Premise
207	24	_	_	I-Premise
208	%	_	_	I-Premise
209	;	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	.01	_	_	I-Premise
213	)	_	_	I-Premise
214	,	_	_	I-Premise
215	and	_	_	I-Premise
216	bilirubin	_	_	I-Premise
217	elevation	_	_	I-Premise
218	(	_	_	I-Premise
219	18.6	_	_	I-Premise
220	%	_	_	I-Premise
221	and	_	_	I-Premise
222	0	_	_	I-Premise
223	;	_	_	I-Premise
224	P	_	_	I-Premise
225	<	_	_	I-Premise
226	.01	_	_	I-Premise
227	)	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	HAI	_	_	I-Premise
231	and	_	_	I-Premise
232	systemic	_	_	I-Premise
233	treatment	_	_	I-Premise
234	groups	_	_	I-Premise
235	,	_	_	I-Premise
236	respectively	_	_	I-Premise
237	.	_	_	I-Premise

238	A	_	_	B-Premise
239	greater	_	_	I-Premise
240	proportion	_	_	I-Premise
241	of	_	_	I-Premise
242	men	_	_	I-Premise
243	versus	_	_	I-Premise
244	women	_	_	I-Premise
245	receiving	_	_	I-Premise
246	HAI	_	_	I-Premise
247	experienced	_	_	I-Premise
248	biliary	_	_	I-Premise
249	toxicity	_	_	I-Premise
250	(	_	_	I-Premise
251	37	_	_	I-Premise
252	%	_	_	I-Premise
253	and	_	_	I-Premise
254	15	_	_	I-Premise
255	%	_	_	I-Premise
256	,	_	_	I-Premise
257	respectively	_	_	I-Premise
258	;	_	_	I-Premise
259	P	_	_	I-Premise
260	=	_	_	I-Premise
261	.05	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	For	_	_	B-Premise
265	HAI	_	_	I-Premise
266	patients	_	_	I-Premise
267	with	_	_	I-Premise
268	thymidylate	_	_	I-Premise
269	synthase	_	_	I-Premise
270	levels	_	_	I-Premise
271	in	_	_	I-Premise
272	tumor	_	_	I-Premise
273	less	_	_	I-Premise
274	than	_	_	I-Premise
275	or	_	_	I-Premise
276	>	_	_	I-Premise
277	or	_	_	I-Premise
278	=	_	_	I-Premise
279	4	_	_	I-Premise
280	,	_	_	I-Premise
281	the	_	_	I-Premise
282	median	_	_	I-Premise
283	survival	_	_	I-Premise
284	was	_	_	I-Premise
285	24	_	_	I-Premise
286	and	_	_	I-Premise
287	14	_	_	I-Premise
288	months	_	_	I-Premise
289	,	_	_	I-Premise
290	respectively	_	_	I-Premise
291	(	_	_	I-Premise
292	P	_	_	I-Premise
293	=	_	_	I-Premise
294	.17	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	HAI	_	_	B-Claim
298	therapy	_	_	I-Claim
299	increased	_	_	I-Claim
300	overall	_	_	I-Claim
301	survival	_	_	I-Claim
302	,	_	_	I-Claim
303	response	_	_	I-Claim
304	rate	_	_	I-Claim
305	,	_	_	I-Claim
306	THP	_	_	I-Claim
307	,	_	_	I-Claim
308	and	_	_	I-Claim
309	was	_	_	I-Claim
310	associated	_	_	I-Claim
311	with	_	_	I-Claim
312	better	_	_	I-Claim
313	physical	_	_	I-Claim
314	functioning	_	_	I-Claim
315	compared	_	_	I-Claim
316	with	_	_	I-Claim
317	systemic	_	_	I-Claim
318	therapy	_	_	I-Claim
319	.	_	_	I-Claim

320	Additional	_	_	B-Claim
321	studies	_	_	I-Claim
322	need	_	_	I-Claim
323	to	_	_	I-Claim
324	address	_	_	I-Claim
325	the	_	_	I-Claim
326	overall	_	_	I-Claim
327	benefit	_	_	I-Claim
328	and	_	_	I-Claim
329	cost	_	_	I-Claim
330	of	_	_	I-Claim
331	new	_	_	I-Claim
332	chemotherapy	_	_	I-Claim
333	agents	_	_	I-Claim
334	versus	_	_	I-Claim
335	HAI	_	_	I-Claim
336	alone	_	_	I-Claim
337	or	_	_	I-Claim
338	the	_	_	I-Claim
339	combination	_	_	I-Claim
340	of	_	_	I-Claim
341	HAI	_	_	I-Claim
342	with	_	_	I-Claim
343	new	_	_	I-Claim
344	agents	_	_	I-Claim
345	.	_	_	I-Claim


0	Previous	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	demonstrated	_	_	O
4	that	_	_	O
5	both	_	_	O
6	anastrozole	_	_	O
7	and	_	_	O
8	letrozole	_	_	O
9	are	_	_	O
10	well	_	_	O
11	tolerated	_	_	O
12	.	_	_	O

13	Letrozole	_	_	O
14	suppresses	_	_	O
15	estrogen	_	_	O
16	to	_	_	O
17	a	_	_	O
18	greater	_	_	O
19	degree	_	_	O
20	than	_	_	O
21	anastrozole	_	_	O
22	in	_	_	O
23	the	_	_	O
24	serum	_	_	O
25	and	_	_	O
26	breast	_	_	O
27	tumor	_	_	O
28	.	_	_	O

29	Concerns	_	_	O
30	have	_	_	O
31	been	_	_	O
32	raised	_	_	O
33	that	_	_	O
34	greater	_	_	O
35	potency	_	_	O
36	may	_	_	O
37	adversely	_	_	O
38	affect	_	_	O
39	patients	_	_	O
40	'	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	(	_	_	O
45	QOL	_	_	O
46	)	_	_	O
47	.	_	_	O

48	One	_	_	O
49	hundred	_	_	O
50	eighty-one	_	_	O
51	postmenopausal	_	_	O
52	women	_	_	O
53	with	_	_	O
54	invasive	_	_	O
55	estrogen	_	_	O
56	receptor-positive	_	_	O
57	breast	_	_	O
58	cancers	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	receive	_	_	O
63	either	_	_	O
64	12	_	_	O
65	weeks	_	_	O
66	of	_	_	O
67	letrozole	_	_	O
68	followed	_	_	O
69	by	_	_	O
70	12	_	_	O
71	weeks	_	_	O
72	of	_	_	O
73	anastrozole	_	_	O
74	or	_	_	O
75	the	_	_	O
76	reverse	_	_	O
77	sequence	_	_	O
78	.	_	_	O

79	One	_	_	O
80	hundred	_	_	O
81	and	_	_	O
82	six	_	_	O
83	received	_	_	O
84	immediate	_	_	O
85	adjuvant	_	_	O
86	aromatase	_	_	O
87	inhibitors	_	_	O
88	(	_	_	O
89	AIs	_	_	O
90	)	_	_	O
91	following	_	_	O
92	surgery	_	_	O
93	,	_	_	O
94	and	_	_	O
95	75	_	_	O
96	received	_	_	O
97	extended	_	_	O
98	adjuvant	_	_	O
99	therapy	_	_	O
100	.	_	_	O

101	The	_	_	O
102	Functional	_	_	O
103	Assessment	_	_	O
104	of	_	_	O
105	Cancer	_	_	O
106	Therapy	_	_	O
107	Endocrine	_	_	O
108	Subscale	_	_	O
109	(	_	_	O
110	FACT-B-ES	_	_	O
111	)	_	_	O
112	QOL	_	_	O
113	questionnaires	_	_	O
114	were	_	_	O
115	completed	_	_	O
116	to	_	_	O
117	assess	_	_	O
118	QOL	_	_	O
119	on	_	_	O
120	each	_	_	O
121	drug	_	_	O
122	.	_	_	O

123	Additional	_	_	O
124	side-effect	_	_	O
125	profiles	_	_	O
126	were	_	_	O
127	collected	_	_	O
128	.	_	_	O

129	Each	_	_	O
130	patient	_	_	O
131	completed	_	_	O
132	a	_	_	O
133	patient	_	_	O
134	preference	_	_	O
135	form	_	_	O
136	.	_	_	O

137	Twenty-one	_	_	O
138	patients	_	_	O
139	withdrew	_	_	O
140	before	_	_	O
141	study	_	_	O
142	end	_	_	O
143	,	_	_	O
144	10/179	_	_	O
145	(	_	_	O
146	5.6	_	_	O
147	%	_	_	O
148	)	_	_	O
149	while	_	_	O
150	taking	_	_	O
151	letrozole	_	_	O
152	and	_	_	O
153	4/173	_	_	O
154	(	_	_	O
155	2.3	_	_	O
156	%	_	_	O
157	)	_	_	O
158	while	_	_	O
159	taking	_	_	O
160	anastrozole	_	_	O
161	(	_	_	O
162	P	_	_	O
163	=	_	_	O
164	0.12	_	_	O
165	)	_	_	O
166	.	_	_	O

167	Tamoxifen-nave	_	_	B-Premise
168	patients	_	_	I-Premise
169	had	_	_	I-Premise
170	a	_	_	I-Premise
171	higher	_	_	I-Premise
172	mean	_	_	I-Premise
173	ES	_	_	I-Premise
174	(	_	_	I-Premise
175	endocrine	_	_	I-Premise
176	symptoms	_	_	I-Premise
177	subscale	_	_	I-Premise
178	)	_	_	I-Premise
179	score	_	_	I-Premise
180	at	_	_	I-Premise
181	entry	_	_	I-Premise
182	versus	_	_	I-Premise
183	those	_	_	I-Premise
184	having	_	_	I-Premise
185	extended	_	_	I-Premise
186	therapy	_	_	I-Premise
187	(	_	_	I-Premise
188	66.0	_	_	I-Premise
189	vs.	_	_	I-Premise
190	61.9	_	_	I-Premise
191	;	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0.001	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	There	_	_	B-Premise
198	was	_	_	I-Premise
199	no	_	_	I-Premise
200	significant	_	_	I-Premise
201	change	_	_	I-Premise
202	in	_	_	I-Premise
203	FACT-B-ES	_	_	I-Premise
204	(	_	_	I-Premise
205	overall	_	_	I-Premise
206	)	_	_	I-Premise
207	scores	_	_	I-Premise
208	or	_	_	I-Premise
209	ES	_	_	I-Premise
210	scores	_	_	I-Premise
211	while	_	_	I-Premise
212	patients	_	_	I-Premise
213	were	_	_	I-Premise
214	taking	_	_	I-Premise
215	anastrozole	_	_	I-Premise
216	or	_	_	I-Premise
217	letrozole	_	_	I-Premise
218	and	_	_	I-Premise
219	no	_	_	I-Premise
220	significant	_	_	I-Premise
221	differences	_	_	I-Premise
222	between	_	_	I-Premise
223	drugs	_	_	I-Premise
224	.	_	_	I-Premise

225	Nearly	_	_	B-Premise
226	80	_	_	I-Premise
227	%	_	_	I-Premise
228	of	_	_	I-Premise
229	patients	_	_	I-Premise
230	reported	_	_	I-Premise
231	one	_	_	I-Premise
232	or	_	_	I-Premise
233	more	_	_	I-Premise
234	side	_	_	I-Premise
235	effects	_	_	I-Premise
236	with	_	_	I-Premise
237	either	_	_	I-Premise
238	agent	_	_	I-Premise
239	.	_	_	I-Premise

240	No	_	_	B-Premise
241	differences	_	_	I-Premise
242	in	_	_	I-Premise
243	frequency	_	_	I-Premise
244	,	_	_	I-Premise
245	grade	_	_	I-Premise
246	,	_	_	I-Premise
247	or	_	_	I-Premise
248	range	_	_	I-Premise
249	of	_	_	I-Premise
250	side	_	_	I-Premise
251	effects	_	_	I-Premise
252	were	_	_	I-Premise
253	seen	_	_	I-Premise
254	between	_	_	I-Premise
255	drugs	_	_	I-Premise
256	.	_	_	I-Premise

257	Of	_	_	O
258	160	_	_	O
259	patients	_	_	O
260	,	_	_	O
261	49	_	_	O
262	(	_	_	O
263	30.6	_	_	O
264	%	_	_	O
265	)	_	_	O
266	preferred	_	_	O
267	letrozole	_	_	O
268	,	_	_	O
269	57	_	_	O
270	(	_	_	O
271	35.6	_	_	O
272	%	_	_	O
273	)	_	_	O
274	preferred	_	_	O
275	anastrozole	_	_	O
276	,	_	_	O
277	and	_	_	O
278	54	_	_	O
279	(	_	_	O
280	33.8	_	_	O
281	%	_	_	O
282	)	_	_	O
283	had	_	_	O
284	no	_	_	O
285	preference	_	_	O
286	(	_	_	O
287	P	_	_	O
288	=	_	_	O
289	0.26	_	_	O
290	,	_	_	O
291	Pearson	_	_	O
292	's	_	_	O
293	Chi-squared	_	_	O
294	test	_	_	O
295	)	_	_	O
296	.	_	_	O

297	In	_	_	O
298	conclusion	_	_	O
299	,	_	_	O
300	both	_	_	B-Claim
301	AIs	_	_	I-Claim
302	are	_	_	I-Claim
303	equally	_	_	I-Claim
304	well	_	_	I-Claim
305	tolerated	_	_	I-Claim
306	.	_	_	I-Claim

307	There	_	_	B-Claim
308	were	_	_	I-Claim
309	no	_	_	I-Claim
310	significant	_	_	I-Claim
311	differences	_	_	I-Claim
312	in	_	_	I-Claim
313	QOL	_	_	I-Claim
314	scores	_	_	I-Claim
315	between	_	_	I-Claim
316	the	_	_	I-Claim
317	two	_	_	I-Claim
318	drugs	_	_	I-Claim
319	.	_	_	I-Claim


0	Patient-reported	_	_	O
1	symptoms	_	_	O
2	and	_	_	O
3	health-related	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	(	_	_	O
8	QoL	_	_	O
9	)	_	_	O
10	benefits	_	_	O
11	were	_	_	O
12	investigated	_	_	O
13	in	_	_	O
14	a	_	_	O
15	randomized	_	_	O
16	,	_	_	O
17	phase	_	_	O
18	III	_	_	O
19	trial	_	_	O
20	of	_	_	O
21	afatinib	_	_	O
22	or	_	_	O
23	cisplatin/pemetrexed	_	_	O
24	.	_	_	O

25	Three	_	_	O
26	hundred	_	_	O
27	forty-five	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	advanced	_	_	O
31	epidermal	_	_	O
32	growth	_	_	O
33	factor	_	_	O
34	receptor	_	_	O
35	(	_	_	O
36	EGFR	_	_	O
37	)	_	_	O
38	mutation-positive	_	_	O
39	lung	_	_	O
40	adenocarcinoma	_	_	O
41	were	_	_	O
42	randomly	_	_	O
43	assigned	_	_	O
44	2:1	_	_	O
45	to	_	_	O
46	afatinib	_	_	O
47	40	_	_	O
48	mg	_	_	O
49	per	_	_	O
50	day	_	_	O
51	or	_	_	O
52	up	_	_	O
53	to	_	_	O
54	six	_	_	O
55	cycles	_	_	O
56	of	_	_	O
57	cisplatin/pemetrexed	_	_	O
58	.	_	_	O

59	Lung	_	_	O
60	cancer	_	_	O
61	symptoms	_	_	O
62	and	_	_	O
63	health-related	_	_	O
64	QoL	_	_	O
65	were	_	_	O
66	assessed	_	_	O
67	every	_	_	O
68	21	_	_	O
69	days	_	_	O
70	until	_	_	O
71	progression	_	_	O
72	using	_	_	O
73	the	_	_	O
74	European	_	_	O
75	Organisation	_	_	O
76	for	_	_	O
77	Research	_	_	O
78	and	_	_	O
79	Treatment	_	_	O
80	of	_	_	O
81	Cancer	_	_	O
82	Quality	_	_	O
83	of	_	_	O
84	Life	_	_	O
85	Questionnaire	_	_	O
86	C30	_	_	O
87	and	_	_	O
88	Lung	_	_	O
89	Cancer-13	_	_	O
90	questionnaires	_	_	O
91	.	_	_	O

92	Analyses	_	_	O
93	of	_	_	O
94	cough	_	_	O
95	,	_	_	O
96	dyspnea	_	_	O
97	,	_	_	O
98	and	_	_	O
99	pain	_	_	O
100	were	_	_	O
101	preplanned	_	_	O
102	,	_	_	O
103	including	_	_	O
104	percentage	_	_	O
105	of	_	_	O
106	patients	_	_	O
107	who	_	_	O
108	improved	_	_	O
109	on	_	_	O
110	therapy	_	_	O
111	,	_	_	O
112	time	_	_	O
113	to	_	_	O
114	deterioration	_	_	O
115	of	_	_	O
116	symptoms	_	_	O
117	,	_	_	O
118	and	_	_	O
119	change	_	_	O
120	in	_	_	O
121	symptoms	_	_	O
122	over	_	_	O
123	time	_	_	O
124	.	_	_	O

125	Questionnaire	_	_	O
126	compliance	_	_	O
127	was	_	_	O
128	high	_	_	O
129	.	_	_	O

130	Compared	_	_	B-Premise
131	with	_	_	I-Premise
132	chemotherapy	_	_	I-Premise
133	,	_	_	I-Premise
134	afatinib	_	_	I-Premise
135	significantly	_	_	I-Premise
136	delayed	_	_	I-Premise
137	the	_	_	I-Premise
138	time	_	_	I-Premise
139	to	_	_	I-Premise
140	deterioration	_	_	I-Premise
141	for	_	_	I-Premise
142	cough	_	_	I-Premise
143	(	_	_	I-Premise
144	hazard	_	_	I-Premise
145	ratio	_	_	I-Premise
146	[	_	_	I-Premise
147	HR	_	_	I-Premise
148	]	_	_	I-Premise
149	,	_	_	I-Premise
150	0.60	_	_	I-Premise
151	;	_	_	I-Premise
152	95	_	_	I-Premise
153	%	_	_	I-Premise
154	CI	_	_	I-Premise
155	,	_	_	I-Premise
156	0.41	_	_	I-Premise
157	to	_	_	I-Premise
158	0.87	_	_	I-Premise
159	;	_	_	I-Premise
160	P	_	_	I-Premise
161	=	_	_	I-Premise
162	.007	_	_	I-Premise
163	)	_	_	I-Premise
164	and	_	_	I-Premise
165	dyspnea	_	_	I-Premise
166	(	_	_	I-Premise
167	HR	_	_	I-Premise
168	,	_	_	I-Premise
169	0.68	_	_	I-Premise
170	;	_	_	I-Premise
171	95	_	_	I-Premise
172	%	_	_	I-Premise
173	CI	_	_	I-Premise
174	,	_	_	I-Premise
175	0.50	_	_	I-Premise
176	to	_	_	I-Premise
177	0.93	_	_	I-Premise
178	;	_	_	I-Premise
179	P	_	_	I-Premise
180	=	_	_	I-Premise
181	.015	_	_	I-Premise
182	)	_	_	I-Premise
183	,	_	_	I-Premise
184	but	_	_	I-Premise
185	not	_	_	I-Premise
186	pain	_	_	I-Premise
187	(	_	_	I-Premise
188	HR	_	_	I-Premise
189	,	_	_	I-Premise
190	0.83	_	_	I-Premise
191	;	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	,	_	_	I-Premise
196	0.62	_	_	I-Premise
197	to	_	_	I-Premise
198	1.10	_	_	I-Premise
199	;	_	_	I-Premise
200	P	_	_	I-Premise
201	=	_	_	I-Premise
202	.19	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	More	_	_	B-Premise
206	patients	_	_	I-Premise
207	on	_	_	I-Premise
208	afatinib	_	_	I-Premise
209	(	_	_	I-Premise
210	64	_	_	I-Premise
211	%	_	_	I-Premise
212	)	_	_	I-Premise
213	versus	_	_	I-Premise
214	chemotherapy	_	_	I-Premise
215	(	_	_	I-Premise
216	50	_	_	I-Premise
217	%	_	_	I-Premise
218	)	_	_	I-Premise
219	experienced	_	_	I-Premise
220	improvements	_	_	I-Premise
221	in	_	_	I-Premise
222	dyspnea	_	_	I-Premise
223	scores	_	_	I-Premise
224	(	_	_	I-Premise
225	P	_	_	I-Premise
226	=	_	_	I-Premise
227	.010	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Differences	_	_	B-Premise
231	in	_	_	I-Premise
232	mean	_	_	I-Premise
233	scores	_	_	I-Premise
234	over	_	_	I-Premise
235	time	_	_	I-Premise
236	significantly	_	_	I-Premise
237	favored	_	_	I-Premise
238	afatinib	_	_	I-Premise
239	over	_	_	I-Premise
240	chemotherapy	_	_	I-Premise
241	for	_	_	I-Premise
242	cough	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	.001	_	_	I-Premise
247	)	_	_	I-Premise
248	and	_	_	I-Premise
249	dyspnea	_	_	I-Premise
250	(	_	_	I-Premise
251	P	_	_	I-Premise
252	<	_	_	I-Premise
253	.001	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Afatinib	_	_	B-Premise
257	showed	_	_	I-Premise
258	significantly	_	_	I-Premise
259	better	_	_	I-Premise
260	mean	_	_	I-Premise
261	scores	_	_	I-Premise
262	over	_	_	I-Premise
263	time	_	_	I-Premise
264	in	_	_	I-Premise
265	global	_	_	I-Premise
266	health	_	_	I-Premise
267	status/QoL	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.015	_	_	I-Premise
272	)	_	_	I-Premise
273	and	_	_	I-Premise
274	physical	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	<	_	_	I-Premise
278	.001	_	_	I-Premise
279	)	_	_	I-Premise
280	,	_	_	I-Premise
281	role	_	_	I-Premise
282	(	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	.004	_	_	I-Premise
286	)	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	cognitive	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	=	_	_	I-Premise
293	.007	_	_	I-Premise
294	)	_	_	I-Premise
295	functioning	_	_	I-Premise
296	compared	_	_	I-Premise
297	with	_	_	I-Premise
298	chemotherapy	_	_	I-Premise
299	.	_	_	I-Premise

300	Fatigue	_	_	B-Premise
301	and	_	_	I-Premise
302	nausea	_	_	I-Premise
303	were	_	_	I-Premise
304	worse	_	_	I-Premise
305	with	_	_	I-Premise
306	chemotherapy	_	_	I-Premise
307	,	_	_	I-Premise
308	whereas	_	_	I-Premise
309	diarrhea	_	_	I-Premise
310	,	_	_	I-Premise
311	dysphagia	_	_	I-Premise
312	,	_	_	I-Premise
313	and	_	_	I-Premise
314	sore	_	_	I-Premise
315	mouth	_	_	I-Premise
316	were	_	_	I-Premise
317	worse	_	_	I-Premise
318	with	_	_	I-Premise
319	afatinib	_	_	I-Premise
320	(	_	_	I-Premise
321	all	_	_	I-Premise
322	P	_	_	I-Premise
323	<	_	_	I-Premise
324	.01	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	In	_	_	B-Claim
328	patients	_	_	I-Claim
329	with	_	_	I-Claim
330	lung	_	_	I-Claim
331	adenocarcinoma	_	_	I-Claim
332	with	_	_	I-Claim
333	EGFR	_	_	I-Claim
334	mutations	_	_	I-Claim
335	,	_	_	I-Claim
336	first-line	_	_	I-Claim
337	afatinib	_	_	I-Claim
338	was	_	_	I-Claim
339	associated	_	_	I-Claim
340	with	_	_	I-Claim
341	better	_	_	I-Claim
342	control	_	_	I-Claim
343	of	_	_	I-Claim
344	cough	_	_	I-Claim
345	and	_	_	I-Claim
346	dyspnea	_	_	I-Claim
347	compared	_	_	I-Claim
348	with	_	_	I-Claim
349	chemotherapy	_	_	I-Claim
350	,	_	_	I-Claim
351	although	_	_	I-Claim
352	diarrhea	_	_	I-Claim
353	,	_	_	I-Claim
354	dysphagia	_	_	I-Claim
355	,	_	_	I-Claim
356	and	_	_	I-Claim
357	sore	_	_	I-Claim
358	mouth	_	_	I-Claim
359	were	_	_	I-Claim
360	worse	_	_	I-Claim
361	.	_	_	I-Claim

362	Global	_	_	B-Claim
363	health	_	_	I-Claim
364	status/QoL	_	_	I-Claim
365	was	_	_	I-Claim
366	also	_	_	I-Claim
367	improved	_	_	I-Claim
368	over	_	_	I-Claim
369	time	_	_	I-Claim
370	with	_	_	I-Claim
371	afatinib	_	_	I-Claim
372	compared	_	_	I-Claim
373	with	_	_	I-Claim
374	chemotherapy	_	_	I-Claim
375	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	effects	_	_	O
10	on	_	_	O
11	health-related	_	_	O
12	quality	_	_	O
13	of	_	_	O
14	life	_	_	O
15	(	_	_	O
16	HRQOL	_	_	O
17	)	_	_	O
18	of	_	_	O
19	two	_	_	O
20	treatment	_	_	O
21	regimens	_	_	O
22	in	_	_	O
23	the	_	_	O
24	TEX	_	_	O
25	trial	_	_	O
26	during	_	_	O
27	9	_	_	O
28	month	_	_	O
29	from	_	_	O
30	random	_	_	O
31	assignment	_	_	O
32	,	_	_	O
33	with	_	_	O
34	emphasis	_	_	O
35	on	_	_	O
36	the	_	_	O
37	2-	_	_	O
38	and	_	_	O
39	9-months	_	_	O
40	assessments	_	_	O
41	.	_	_	O

42	A	_	_	O
43	total	_	_	O
44	of	_	_	O
45	287	_	_	O
46	patients	_	_	O
47	were	_	_	O
48	randomized	_	_	O
49	to	_	_	O
50	treatment	_	_	O
51	in	_	_	O
52	3-week	_	_	O
53	cycles	_	_	O
54	with	_	_	O
55	either	_	_	O
56	epirubicin	_	_	O
57	plus	_	_	O
58	paclitaxel	_	_	O
59	(	_	_	O
60	ET	_	_	O
61	,	_	_	O
62	143	_	_	O
63	patients	_	_	O
64	)	_	_	O
65	,	_	_	O
66	or	_	_	O
67	epirubicin	_	_	O
68	,	_	_	O
69	paclitaxel	_	_	O
70	and	_	_	O
71	capecitabine	_	_	O
72	(	_	_	O
73	TEX	_	_	O
74	,	_	_	O
75	144	_	_	O
76	patients	_	_	O
77	)	_	_	O
78	.	_	_	O

79	HRQOL	_	_	O
80	was	_	_	O
81	assessed	_	_	O
82	by	_	_	O
83	the	_	_	O
84	EORTC-QLQ	_	_	O
85	C30	_	_	O
86	and	_	_	O
87	EORTC	_	_	O
88	QLQ-BR23	_	_	O
89	questionnaires	_	_	O
90	at	_	_	O
91	five	_	_	O
92	points	_	_	O
93	during	_	_	O
94	9	_	_	O
95	months	_	_	O
96	.	_	_	O

97	A	_	_	O
98	total	_	_	O
99	of	_	_	O
100	252	_	_	O
101	(	_	_	O
102	88	_	_	O
103	%	_	_	O
104	)	_	_	O
105	completed	_	_	O
106	questionnaires	_	_	O
107	before	_	_	O
108	randomization	_	_	O
109	.	_	_	O

110	Response	_	_	O
111	rate	_	_	O
112	for	_	_	O
113	the	_	_	O
114	following	_	_	O
115	assessments	_	_	O
116	was	_	_	O
117	>	_	_	O
118	75	_	_	O
119	%	_	_	O
120	.	_	_	O

121	There	_	_	B-Premise
122	were	_	_	I-Premise
123	no	_	_	I-Premise
124	statistically	_	_	I-Premise
125	significant	_	_	I-Premise
126	differences	_	_	I-Premise
127	between	_	_	I-Premise
128	the	_	_	I-Premise
129	TEX	_	_	I-Premise
130	group	_	_	I-Premise
131	and	_	_	I-Premise
132	the	_	_	I-Premise
133	ET	_	_	I-Premise
134	group	_	_	I-Premise
135	on	_	_	I-Premise
136	any	_	_	I-Premise
137	of	_	_	I-Premise
138	the	_	_	I-Premise
139	subscales	_	_	I-Premise
140	2	_	_	I-Premise
141	months	_	_	I-Premise
142	after	_	_	I-Premise
143	randomization	_	_	I-Premise
144	.	_	_	I-Premise

145	Small	_	_	B-Premise
146	clinical	_	_	I-Premise
147	differences	_	_	I-Premise
148	(	_	_	I-Premise
149	5-10	_	_	I-Premise
150	points	_	_	I-Premise
151	)	_	_	I-Premise
152	in	_	_	I-Premise
153	favor	_	_	I-Premise
154	of	_	_	I-Premise
155	the	_	_	I-Premise
156	ET	_	_	I-Premise
157	group	_	_	I-Premise
158	were	_	_	I-Premise
159	found	_	_	I-Premise
160	for	_	_	I-Premise
161	global	_	_	I-Premise
162	quality	_	_	I-Premise
163	of	_	_	I-Premise
164	life	_	_	I-Premise
165	,	_	_	I-Premise
166	role	_	_	I-Premise
167	functioning	_	_	I-Premise
168	,	_	_	I-Premise
169	social	_	_	I-Premise
170	functioning	_	_	I-Premise
171	,	_	_	I-Premise
172	and	_	_	I-Premise
173	insomnia	_	_	I-Premise
174	.	_	_	I-Premise

175	At	_	_	B-Premise
176	the	_	_	I-Premise
177	9-months	_	_	I-Premise
178	assessment	_	_	I-Premise
179	,	_	_	I-Premise
180	the	_	_	I-Premise
181	TEX	_	_	I-Premise
182	group	_	_	I-Premise
183	scored	_	_	I-Premise
184	statistically	_	_	I-Premise
185	significantly	_	_	I-Premise
186	higher	_	_	I-Premise
187	on	_	_	I-Premise
188	global	_	_	I-Premise
189	quality	_	_	I-Premise
190	of	_	_	I-Premise
191	life	_	_	I-Premise
192	and	_	_	I-Premise
193	physical	_	_	I-Premise
194	functioning	_	_	I-Premise
195	.	_	_	I-Premise

196	Small	_	_	B-Premise
197	clinically	_	_	I-Premise
198	significant	_	_	I-Premise
199	differences	_	_	I-Premise
200	were	_	_	I-Premise
201	found	_	_	I-Premise
202	for	_	_	I-Premise
203	global	_	_	I-Premise
204	quality	_	_	I-Premise
205	of	_	_	I-Premise
206	life	_	_	I-Premise
207	,	_	_	I-Premise
208	physical	_	_	I-Premise
209	functioning	_	_	I-Premise
210	,	_	_	I-Premise
211	role	_	_	I-Premise
212	functioning	_	_	I-Premise
213	,	_	_	I-Premise
214	emotional	_	_	I-Premise
215	functioning	_	_	I-Premise
216	,	_	_	I-Premise
217	dyspnoea	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	insomnia	_	_	I-Premise
221	,	_	_	I-Premise
222	all	_	_	I-Premise
223	in	_	_	I-Premise
224	favour	_	_	I-Premise
225	of	_	_	I-Premise
226	the	_	_	I-Premise
227	TEX	_	_	I-Premise
228	group	_	_	I-Premise
229	.	_	_	I-Premise

230	At	_	_	B-Claim
231	the	_	_	I-Claim
232	2-months	_	_	I-Claim
233	assessment	_	_	I-Claim
234	,	_	_	I-Claim
235	when	_	_	I-Claim
236	side-effects	_	_	I-Claim
237	of	_	_	I-Claim
238	chemotherapy	_	_	I-Claim
239	were	_	_	I-Claim
240	present	_	_	I-Claim
241	,	_	_	I-Claim
242	patients	_	_	I-Claim
243	in	_	_	I-Claim
244	the	_	_	I-Claim
245	TEX	_	_	I-Claim
246	group	_	_	I-Claim
247	appeared	_	_	I-Claim
248	to	_	_	I-Claim
249	fare	_	_	I-Claim
250	a	_	_	I-Claim
251	bit	_	_	I-Claim
252	worse	_	_	I-Claim
253	than	_	_	I-Claim
254	those	_	_	I-Claim
255	receiving	_	_	I-Claim
256	ET	_	_	I-Claim
257	.	_	_	I-Claim

258	However	_	_	O
259	,	_	_	O
260	after	_	_	B-Claim
261	9	_	_	I-Claim
262	months	_	_	I-Claim
263	,	_	_	I-Claim
264	when	_	_	I-Claim
265	the	_	_	I-Claim
266	patients	_	_	I-Claim
267	had	_	_	I-Claim
268	adapted	_	_	I-Claim
269	to	_	_	I-Claim
270	treatment	_	_	I-Claim
271	,	_	_	I-Claim
272	the	_	_	I-Claim
273	TEX	_	_	I-Claim
274	group	_	_	I-Claim
275	seemed	_	_	I-Claim
276	to	_	_	I-Claim
277	have	_	_	I-Claim
278	a	_	_	I-Claim
279	slightly	_	_	I-Claim
280	better	_	_	I-Claim
281	quality	_	_	I-Claim
282	of	_	_	I-Claim
283	life	_	_	I-Claim
284	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	laparoscopy-assisted	_	_	O
9	distal	_	_	O
10	gastrectomy	_	_	O
11	(	_	_	O
12	LADG	_	_	O
13	)	_	_	O
14	compared	_	_	O
15	to	_	_	O
16	open	_	_	O
17	distal	_	_	O
18	gastrectomy	_	_	O
19	(	_	_	O
20	ODG	_	_	O
21	)	_	_	O
22	in	_	_	O
23	the	_	_	O
24	treatment	_	_	O
25	of	_	_	O
26	early	_	_	O
27	gastric	_	_	O
28	cancer	_	_	O
29	with	_	_	O
30	respect	_	_	O
31	to	_	_	O
32	survival	_	_	O
33	,	_	_	O
34	surgical	_	_	O
35	outcomes	_	_	O
36	,	_	_	O
37	complications	_	_	O
38	,	_	_	O
39	and	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	QOL	_	_	O
45	)	_	_	O
46	.	_	_	O

47	One	_	_	O
48	hundred	_	_	O
49	sixty-four	_	_	O
50	patients	_	_	O
51	with	_	_	O
52	cT1N0M0	_	_	O
53	and	_	_	O
54	cT1N1M0	_	_	O
55	distal	_	_	O
56	gastric	_	_	O
57	cancer	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	to	_	_	O
62	either	_	_	O
63	the	_	_	O
64	LADG	_	_	O
65	group	_	_	O
66	or	_	_	O
67	the	_	_	O
68	ODG	_	_	O
69	group	_	_	O
70	.	_	_	O

71	The	_	_	O
72	primary	_	_	O
73	end	_	_	O
74	point	_	_	O
75	was	_	_	O
76	the	_	_	O
77	5-year	_	_	O
78	disease-free	_	_	O
79	survival	_	_	O
80	(	_	_	O
81	DFS	_	_	O
82	)	_	_	O
83	rate	_	_	O
84	.	_	_	O

85	Complications	_	_	O
86	were	_	_	O
87	classified	_	_	O
88	using	_	_	O
89	the	_	_	O
90	accordion	_	_	O
91	severity	_	_	O
92	classification	_	_	O
93	of	_	_	O
94	postoperative	_	_	O
95	complications	_	_	O
96	scheme	_	_	O
97	.	_	_	O

98	QOL	_	_	O
99	was	_	_	O
100	measured	_	_	O
101	using	_	_	O
102	the	_	_	O
103	European	_	_	O
104	Organization	_	_	O
105	for	_	_	O
106	Research	_	_	O
107	and	_	_	O
108	Treatment	_	_	O
109	of	_	_	O
110	Cancer	_	_	O
111	QLQ-C30	_	_	O
112	and	_	_	O
113	QLQ-STO22	_	_	O
114	preoperatively	_	_	O
115	and	_	_	O
116	postoperatively	_	_	O
117	during	_	_	O
118	regular	_	_	O
119	follow-up	_	_	O
120	visits	_	_	O
121	.	_	_	O

122	This	_	_	O
123	trial	_	_	O
124	is	_	_	O
125	registered	_	_	O
126	at	_	_	O
127	ClinicalTrials.gov	_	_	O
128	.	_	_	O

129	The	_	_	O
130	median	_	_	O
131	(	_	_	O
132	range	_	_	O
133	)	_	_	O
134	follow-up	_	_	O
135	period	_	_	O
136	was	_	_	O
137	74.3	_	_	O
138	(	_	_	O
139	24.8-90.8	_	_	O
140	)	_	_	O
141	months	_	_	O
142	.	_	_	O

143	The	_	_	B-Premise
144	LADG	_	_	I-Premise
145	and	_	_	I-Premise
146	ODG	_	_	I-Premise
147	groups	_	_	I-Premise
148	showed	_	_	I-Premise
149	similar	_	_	I-Premise
150	survival	_	_	I-Premise
151	[	_	_	I-Premise
152	5-year	_	_	I-Premise
153	DFS	_	_	I-Premise
154	rate	_	_	I-Premise
155	:	_	_	I-Premise
156	98.8	_	_	I-Premise
157	%	_	_	I-Premise
158	vs.	_	_	I-Premise
159	97.6	_	_	I-Premise
160	%	_	_	I-Premise
161	,	_	_	I-Premise
162	respectively	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	=	_	_	I-Premise
166	0.514	_	_	I-Premise
167	)	_	_	I-Premise
168	,	_	_	I-Premise
169	5-year	_	_	I-Premise
170	overall	_	_	I-Premise
171	survival	_	_	I-Premise
172	(	_	_	I-Premise
173	OS	_	_	I-Premise
174	)	_	_	I-Premise
175	rate	_	_	I-Premise
176	:	_	_	I-Premise
177	97.6	_	_	I-Premise
178	vs.	_	_	I-Premise
179	96.3	_	_	I-Premise
180	%	_	_	I-Premise
181	,	_	_	I-Premise
182	respectively	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	0.721	_	_	I-Premise
187	)	_	_	I-Premise
188	]	_	_	I-Premise
189	or	_	_	I-Premise
190	overall	_	_	I-Premise
191	complication	_	_	I-Premise
192	rate	_	_	I-Premise
193	(	_	_	I-Premise
194	29.3	_	_	I-Premise
195	vs.	_	_	I-Premise
196	42.7	_	_	I-Premise
197	%	_	_	I-Premise
198	,	_	_	I-Premise
199	respectively	_	_	I-Premise
200	;	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	0.073	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Mild	_	_	B-Premise
207	complications	_	_	I-Premise
208	were	_	_	I-Premise
209	significantly	_	_	I-Premise
210	less	_	_	I-Premise
211	frequent	_	_	I-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	LADG	_	_	I-Premise
215	group	_	_	I-Premise
216	than	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	ODG	_	_	I-Premise
220	group	_	_	I-Premise
221	(	_	_	I-Premise
222	23.2	_	_	I-Premise
223	vs.	_	_	I-Premise
224	41.5	_	_	I-Premise
225	%	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0.012	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	The	_	_	B-Premise
233	rates	_	_	I-Premise
234	of	_	_	I-Premise
235	moderate	_	_	I-Premise
236	,	_	_	I-Premise
237	severe	_	_	I-Premise
238	,	_	_	I-Premise
239	and	_	_	I-Premise
240	long-term	_	_	I-Premise
241	complications	_	_	I-Premise
242	(	_	_	I-Premise
243	i.e.	_	_	I-Premise
244	,	_	_	I-Premise
245	31	_	_	I-Premise
246	days	_	_	I-Premise
247	to	_	_	I-Premise
248	5	_	_	I-Premise
249	years	_	_	I-Premise
250	after	_	_	I-Premise
251	surgery	_	_	I-Premise
252	)	_	_	I-Premise
253	did	_	_	I-Premise
254	not	_	_	I-Premise
255	differ	_	_	I-Premise
256	significantly	_	_	I-Premise
257	between	_	_	I-Premise
258	groups	_	_	I-Premise
259	.	_	_	I-Premise

260	No	_	_	B-Premise
261	clinically	_	_	I-Premise
262	meaningful	_	_	I-Premise
263	differences	_	_	I-Premise
264	were	_	_	I-Premise
265	detected	_	_	I-Premise
266	between	_	_	I-Premise
267	the	_	_	I-Premise
268	two	_	_	I-Premise
269	groups	_	_	I-Premise
270	in	_	_	I-Premise
271	long-term	_	_	I-Premise
272	QOL	_	_	I-Premise
273	.	_	_	I-Premise

274	LADG	_	_	B-Claim
275	showed	_	_	I-Claim
276	similar	_	_	I-Claim
277	DFS	_	_	I-Claim
278	and	_	_	I-Claim
279	OS	_	_	I-Claim
280	compared	_	_	I-Claim
281	to	_	_	I-Claim
282	ODG	_	_	I-Claim
283	in	_	_	I-Claim
284	treating	_	_	I-Claim
285	early	_	_	I-Claim
286	gastric	_	_	I-Claim
287	cancer	_	_	I-Claim
288	.	_	_	I-Claim

289	Marginal	_	_	B-Claim
290	benefits	_	_	I-Claim
291	in	_	_	I-Claim
292	mild	_	_	I-Claim
293	complications	_	_	I-Claim
294	were	_	_	I-Claim
295	observed	_	_	I-Claim
296	with	_	_	I-Claim
297	LADG	_	_	I-Claim
298	.	_	_	I-Claim

299	LADG	_	_	B-Claim
300	did	_	_	I-Claim
301	not	_	_	I-Claim
302	show	_	_	I-Claim
303	advantages	_	_	I-Claim
304	over	_	_	I-Claim
305	ODG	_	_	I-Claim
306	regarding	_	_	I-Claim
307	other	_	_	I-Claim
308	complications	_	_	I-Claim
309	and	_	_	I-Claim
310	long-term	_	_	I-Claim
311	QOL	_	_	I-Claim
312	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	economic	_	_	O
6	efficiency	_	_	O
7	of	_	_	O
8	a	_	_	O
9	multimedia	_	_	O
10	,	_	_	O
11	multimodal	_	_	O
12	physical	_	_	O
13	activity	_	_	O
14	program	_	_	O
15	for	_	_	O
16	women	_	_	O
17	undergoing	_	_	O
18	adjuvant	_	_	O
19	therapy	_	_	O
20	following	_	_	O
21	surgery	_	_	O
22	for	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	.	_	_	O

26	We	_	_	O
27	conducted	_	_	O
28	a	_	_	O
29	randomized	_	_	O
30	trial	_	_	O
31	with	_	_	O
32	concurrent	_	_	O
33	incremental	_	_	O
34	cost-effectiveness	_	_	O
35	analysis	_	_	O
36	and	_	_	O
37	blinded	_	_	O
38	baseline	_	_	O
39	,	_	_	O
40	3	_	_	O
41	,	_	_	O
42	6	_	_	O
43	and	_	_	O
44	12-month	_	_	O
45	follow-up	_	_	O
46	assessments	_	_	O
47	amongst	_	_	O
48	women	_	_	O
49	undergoing	_	_	O
50	adjuvant	_	_	O
51	therapy	_	_	O
52	following	_	_	O
53	surgery	_	_	O
54	for	_	_	O
55	breast	_	_	O
56	cancer	_	_	O
57	(	_	_	O
58	n	_	_	O
59	=	_	_	O
60	89	_	_	O
61	)	_	_	O
62	.	_	_	O

63	The	_	_	O
64	intervention	_	_	O
65	was	_	_	O
66	a	_	_	O
67	multimedia	_	_	O
68	,	_	_	O
69	multimodal	_	_	O
70	exercise	_	_	O
71	program	_	_	O
72	comprising	_	_	O
73	strength	_	_	O
74	,	_	_	O
75	balance	_	_	O
76	and	_	_	O
77	endurance	_	_	O
78	training	_	_	O
79	elements	_	_	O
80	.	_	_	O

81	The	_	_	O
82	control	_	_	O
83	was	_	_	O
84	sham	_	_	O
85	flexibility	_	_	O
86	and	_	_	O
87	relaxation	_	_	O
88	program	_	_	O
89	delivered	_	_	O
90	using	_	_	O
91	similar	_	_	O
92	materials	_	_	O
93	.	_	_	O

94	The	_	_	O
95	primary	_	_	O
96	outcome	_	_	O
97	was	_	_	O
98	health-related	_	_	O
99	quality	_	_	O
100	of	_	_	O
101	life	_	_	O
102	(	_	_	O
103	EQ-5D	_	_	O
104	&	_	_	O
105	amp	_	_	O
106	;	_	_	O
107	VAS	_	_	O
108	,	_	_	O
109	EORTC	_	_	O
110	C30	_	_	O
111	,	_	_	O
112	BR23	_	_	O
113	)	_	_	O
114	.	_	_	O

115	Economic	_	_	O
116	outcomes	_	_	O
117	included	_	_	O
118	direct	_	_	O
119	health	_	_	O
120	care	_	_	O
121	costs	_	_	O
122	and	_	_	O
123	productivity	_	_	O
124	gains	_	_	O
125	and	_	_	O
126	losses	_	_	O
127	.	_	_	O

128	Participants	_	_	B-Premise
129	in	_	_	I-Premise
130	the	_	_	I-Premise
131	intervention	_	_	I-Premise
132	group	_	_	I-Premise
133	demonstrated	_	_	I-Premise
134	greater	_	_	I-Premise
135	improvement	_	_	I-Premise
136	in	_	_	I-Premise
137	health-related	_	_	I-Premise
138	quality	_	_	I-Premise
139	of	_	_	I-Premise
140	life	_	_	I-Premise
141	between	_	_	I-Premise
142	baseline	_	_	I-Premise
143	and	_	_	I-Premise
144	the	_	_	I-Premise
145	3-month	_	_	I-Premise
146	assessment	_	_	I-Premise
147	[	_	_	I-Premise
148	mean	_	_	I-Premise
149	(	_	_	I-Premise
150	sd	_	_	I-Premise
151	)	_	_	I-Premise
152	EQ-5D	_	_	I-Premise
153	VAS	_	_	I-Premise
154	(	_	_	I-Premise
155	0-100	_	_	I-Premise
156	)	_	_	I-Premise
157	baseline	_	_	I-Premise
158	:	_	_	I-Premise
159	72.6	_	_	I-Premise
160	(	_	_	I-Premise
161	15.6	_	_	I-Premise
162	)	_	_	I-Premise
163	,	_	_	I-Premise
164	3	_	_	I-Premise
165	month	_	_	I-Premise
166	:	_	_	I-Premise
167	80.6	_	_	I-Premise
168	(	_	_	I-Premise
169	11.6	_	_	I-Premise
170	)	_	_	I-Premise
171	]	_	_	I-Premise
172	when	_	_	I-Premise
173	compared	_	_	I-Premise
174	to	_	_	I-Premise
175	control	_	_	I-Premise
176	group	_	_	I-Premise
177	participants	_	_	I-Premise
178	[	_	_	I-Premise
179	baseline	_	_	I-Premise
180	:	_	_	I-Premise
181	77.5	_	_	I-Premise
182	(	_	_	I-Premise
183	13.5	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	3	_	_	I-Premise
187	month	_	_	I-Premise
188	:	_	_	I-Premise
189	74.1	_	_	I-Premise
190	(	_	_	I-Premise
191	20.6	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	P	_	_	I-Premise
195	=	_	_	I-Premise
196	0.006	_	_	I-Premise
197	]	_	_	I-Premise
198	and	_	_	I-Premise
199	also	_	_	I-Premise
200	improved	_	_	I-Premise
201	more	_	_	I-Premise
202	in	_	_	I-Premise
203	terms	_	_	I-Premise
204	of	_	_	I-Premise
205	physical	_	_	I-Premise
206	function	_	_	I-Premise
207	[	_	_	I-Premise
208	mean	_	_	I-Premise
209	(	_	_	I-Premise
210	sd	_	_	I-Premise
211	)	_	_	I-Premise
212	EORTC	_	_	I-Premise
213	C30	_	_	I-Premise
214	physical	_	_	I-Premise
215	function	_	_	I-Premise
216	scale	_	_	I-Premise
217	intervention	_	_	I-Premise
218	(	_	_	I-Premise
219	0-100	_	_	I-Premise
220	)	_	_	I-Premise
221	baseline	_	_	I-Premise
222	:	_	_	I-Premise
223	84.9	_	_	I-Premise
224	(	_	_	I-Premise
225	14.8	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	3	_	_	I-Premise
229	month	_	_	I-Premise
230	:	_	_	I-Premise
231	86.9	_	_	I-Premise
232	(	_	_	I-Premise
233	10.7	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	control	_	_	I-Premise
237	baseline	_	_	I-Premise
238	:	_	_	I-Premise
239	91.3	_	_	I-Premise
240	(	_	_	I-Premise
241	9.6	_	_	I-Premise
242	)	_	_	I-Premise
243	,	_	_	I-Premise
244	3	_	_	I-Premise
245	month	_	_	I-Premise
246	:	_	_	I-Premise
247	86.7	_	_	I-Premise
248	(	_	_	I-Premise
249	14.9	_	_	I-Premise
250	)	_	_	I-Premise
251	,	_	_	I-Premise
252	P	_	_	I-Premise
253	=	_	_	I-Premise
254	0.02	_	_	I-Premise
255	]	_	_	I-Premise
256	.	_	_	I-Premise

257	These	_	_	O
258	improvements	_	_	O
259	were	_	_	O
260	not	_	_	O
261	sustained	_	_	O
262	beyond	_	_	O
263	this	_	_	O
264	point	_	_	O
265	.	_	_	O

266	Upper	_	_	B-Premise
267	limb	_	_	I-Premise
268	volumes	_	_	I-Premise
269	were	_	_	I-Premise
270	also	_	_	I-Premise
271	lower	_	_	I-Premise
272	amongst	_	_	I-Premise
273	intervention	_	_	I-Premise
274	group	_	_	I-Premise
275	participants	_	_	I-Premise
276	.	_	_	I-Premise

277	However	_	_	O
278	,	_	_	O
279	there	_	_	B-Premise
280	was	_	_	I-Premise
281	low	_	_	I-Premise
282	probability	_	_	I-Premise
283	that	_	_	I-Premise
284	the	_	_	I-Premise
285	intervention	_	_	I-Premise
286	would	_	_	I-Premise
287	be	_	_	I-Premise
288	both	_	_	I-Premise
289	less	_	_	I-Premise
290	costly	_	_	I-Premise
291	and	_	_	I-Premise
292	more	_	_	I-Premise
293	effective	_	_	I-Premise
294	than	_	_	I-Premise
295	the	_	_	I-Premise
296	control	_	_	I-Premise
297	condition	_	_	I-Premise
298	(	_	_	I-Premise
299	range	_	_	I-Premise
300	probability	_	_	I-Premise
301	=	_	_	I-Premise
302	0.05-50.02	_	_	I-Premise
303	%	_	_	I-Premise
304	depending	_	_	I-Premise
305	on	_	_	I-Premise
306	approach	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	Provision	_	_	B-Claim
310	of	_	_	I-Claim
311	multimodal	_	_	I-Claim
312	exercise	_	_	I-Claim
313	programs	_	_	I-Claim
314	will	_	_	I-Claim
315	improve	_	_	I-Claim
316	the	_	_	I-Claim
317	short-term	_	_	I-Claim
318	health	_	_	I-Claim
319	of	_	_	I-Claim
320	women	_	_	I-Claim
321	undergoing	_	_	I-Claim
322	adjuvant	_	_	I-Claim
323	therapy	_	_	I-Claim
324	for	_	_	I-Claim
325	breast	_	_	I-Claim
326	cancer	_	_	I-Claim
327	but	_	_	I-Claim
328	are	_	_	I-Claim
329	of	_	_	I-Claim
330	questionable	_	_	I-Claim
331	economic	_	_	I-Claim
332	efficiency	_	_	I-Claim
333	.	_	_	I-Claim


0	Somatostatin	_	_	O
1	analogs	_	_	O
2	act	_	_	O
3	directly	_	_	O
4	on	_	_	O
5	breast	_	_	O
6	cancer	_	_	O
7	cells	_	_	O
8	and	_	_	O
9	indirectly	_	_	O
10	on	_	_	O
11	insulin	_	_	O
12	and	_	_	O
13	insulin-like	_	_	O
14	growth	_	_	O
15	factor	_	_	O
16	1	_	_	O
17	(	_	_	O
18	IGF-1	_	_	O
19	)	_	_	O
20	levels	_	_	O
21	.	_	_	O

22	This	_	_	O
23	trial	_	_	O
24	was	_	_	O
25	undertaken	_	_	O
26	to	_	_	O
27	assess	_	_	O
28	whether	_	_	O
29	octreotide	_	_	B-Claim
30	would	_	_	I-Claim
31	lower	_	_	I-Claim
32	insulin	_	_	I-Claim
33	and	_	_	I-Claim
34	IGF-1	_	_	I-Claim
35	levels	_	_	I-Claim
36	and	_	_	I-Claim
37	reduce	_	_	I-Claim
38	risk	_	_	I-Claim
39	of	_	_	I-Claim
40	breast	_	_	I-Claim
41	cancer	_	_	I-Claim
42	recurrence	_	_	I-Claim
43	.	_	_	I-Claim

44	The	_	_	O
45	NCIC	_	_	O
46	CTG	_	_	O
47	MA.14	_	_	O
48	(	_	_	O
49	NCIC	_	_	O
50	Clinical	_	_	O
51	Trials	_	_	O
52	Group	_	_	O
53	MA.14	_	_	O
54	)	_	_	O
55	trial	_	_	O
56	randomly	_	_	O
57	assigned	_	_	O
58	postmenopausal	_	_	O
59	women	_	_	O
60	to	_	_	O
61	5	_	_	O
62	years	_	_	O
63	of	_	_	O
64	tamoxifen	_	_	O
65	20	_	_	O
66	mg	_	_	O
67	daily	_	_	O
68	(	_	_	O
69	TAM	_	_	O
70	)	_	_	O
71	or	_	_	O
72	TAM	_	_	O
73	plus	_	_	O
74	2	_	_	O
75	years	_	_	O
76	of	_	_	O
77	octreotide	_	_	O
78	90	_	_	O
79	mg	_	_	O
80	depot	_	_	O
81	intramuscular	_	_	O
82	injections	_	_	O
83	monthly	_	_	O
84	(	_	_	O
85	TAM-OCT	_	_	O
86	)	_	_	O
87	as	_	_	O
88	adjuvant	_	_	O
89	therapy	_	_	O
90	.	_	_	O

91	The	_	_	O
92	primary	_	_	O
93	end	_	_	O
94	point	_	_	O
95	was	_	_	O
96	event-free	_	_	O
97	survival	_	_	O
98	(	_	_	O
99	EFS	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Secondary	_	_	O
103	end	_	_	O
104	points	_	_	O
105	were	_	_	O
106	relapse-free	_	_	O
107	survival	_	_	O
108	(	_	_	O
109	RFS	_	_	O
110	)	_	_	O
111	,	_	_	O
112	overall	_	_	O
113	survival	_	_	O
114	(	_	_	O
115	OS	_	_	O
116	)	_	_	O
117	,	_	_	O
118	toxicity	_	_	O
119	,	_	_	O
120	and	_	_	O
121	effects	_	_	O
122	of	_	_	O
123	treatment	_	_	O
124	on	_	_	O
125	IGF	_	_	O
126	physiology	_	_	O
127	.	_	_	O

128	Among	_	_	O
129	667	_	_	O
130	women	_	_	O
131	with	_	_	O
132	a	_	_	O
133	median	_	_	O
134	follow-up	_	_	O
135	of	_	_	O
136	7.9	_	_	O
137	years	_	_	O
138	,	_	_	O
139	220	_	_	O
140	events	_	_	O
141	occurred-108	_	_	O
142	with	_	_	O
143	TAM-OCT	_	_	O
144	and	_	_	O
145	112	_	_	O
146	with	_	_	O
147	TAM	_	_	O
148	.	_	_	O

149	Adjusted	_	_	B-Premise
150	hazard	_	_	I-Premise
151	ratios	_	_	I-Premise
152	(	_	_	I-Premise
153	HRs	_	_	I-Premise
154	;	_	_	I-Premise
155	TAM-OCT	_	_	I-Premise
156	to	_	_	I-Premise
157	TAM	_	_	I-Premise
158	)	_	_	I-Premise
159	were	_	_	I-Premise
160	0.93	_	_	I-Premise
161	for	_	_	I-Premise
162	EFS	_	_	I-Premise
163	(	_	_	I-Premise
164	95	_	_	I-Premise
165	%	_	_	I-Premise
166	CI	_	_	I-Premise
167	,	_	_	I-Premise
168	0.71	_	_	I-Premise
169	to	_	_	I-Premise
170	1.22	_	_	I-Premise
171	;	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.62	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	0.84	_	_	I-Premise
178	for	_	_	I-Premise
179	RFS	_	_	I-Premise
180	(	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	CI	_	_	I-Premise
184	,	_	_	I-Premise
185	0.59	_	_	I-Premise
186	to	_	_	I-Premise
187	1.18	_	_	I-Premise
188	;	_	_	I-Premise
189	P	_	_	I-Premise
190	=	_	_	I-Premise
191	.31	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	and	_	_	I-Premise
195	0.97	_	_	I-Premise
196	for	_	_	I-Premise
197	OS	_	_	I-Premise
198	(	_	_	I-Premise
199	95	_	_	I-Premise
200	%	_	_	I-Premise
201	CI	_	_	I-Premise
202	,	_	_	I-Premise
203	0.69	_	_	I-Premise
204	to	_	_	I-Premise
205	1.37	_	_	I-Premise
206	;	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	.86	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	Among	_	_	B-Premise
213	patients	_	_	I-Premise
214	with	_	_	I-Premise
215	normal	_	_	I-Premise
216	baseline	_	_	I-Premise
217	gallbladder	_	_	I-Premise
218	imaging	_	_	I-Premise
219	,	_	_	I-Premise
220	cholecystectomy	_	_	I-Premise
221	was	_	_	I-Premise
222	required	_	_	I-Premise
223	in	_	_	I-Premise
224	23.0	_	_	I-Premise
225	%	_	_	I-Premise
226	of	_	_	I-Premise
227	those	_	_	I-Premise
228	receiving	_	_	I-Premise
229	TAM-OCT	_	_	I-Premise
230	but	_	_	I-Premise
231	in	_	_	I-Premise
232	only	_	_	I-Premise
233	1.4	_	_	I-Premise
234	%	_	_	I-Premise
235	of	_	_	I-Premise
236	those	_	_	I-Premise
237	receiving	_	_	I-Premise
238	TAM	_	_	I-Premise
239	(	_	_	I-Premise
240	P	_	_	I-Premise
241	<	_	_	I-Premise
242	.001	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	At	_	_	B-Premise
246	4	_	_	I-Premise
247	months	_	_	I-Premise
248	,	_	_	I-Premise
249	TAM-OCT	_	_	I-Premise
250	had	_	_	I-Premise
251	significantly	_	_	I-Premise
252	(	_	_	I-Premise
253	P	_	_	I-Premise
254	<	_	_	I-Premise
255	.001	_	_	I-Premise
256	)	_	_	I-Premise
257	lowered	_	_	I-Premise
258	IGF-1	_	_	I-Premise
259	,	_	_	I-Premise
260	IGF	_	_	I-Premise
261	binding	_	_	I-Premise
262	protein	_	_	I-Premise
263	3	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	C-peptide	_	_	I-Premise
267	levels	_	_	I-Premise
268	.	_	_	I-Premise

269	Older	_	_	B-Premise
270	age	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	=	_	_	I-Premise
274	.02	_	_	I-Premise
275	)	_	_	I-Premise
276	,	_	_	I-Premise
277	tumor	_	_	I-Premise
278	size	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	=	_	_	I-Premise
282	.001	_	_	I-Premise
283	)	_	_	I-Premise
284	,	_	_	I-Premise
285	nodal	_	_	I-Premise
286	status	_	_	I-Premise
287	(	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	.01	_	_	I-Premise
291	)	_	_	I-Premise
292	,	_	_	I-Premise
293	high	_	_	I-Premise
294	C-peptide	_	_	I-Premise
295	levels	_	_	I-Premise
296	(	_	_	I-Premise
297	P	_	_	I-Premise
298	<	_	_	I-Premise
299	.001	_	_	I-Premise
300	)	_	_	I-Premise
301	,	_	_	I-Premise
302	and	_	_	I-Premise
303	higher	_	_	I-Premise
304	body	_	_	I-Premise
305	mass	_	_	I-Premise
306	index	_	_	I-Premise
307	(	_	_	I-Premise
308	BMI	_	_	I-Premise
309	)	_	_	I-Premise
310	in	_	_	I-Premise
311	models	_	_	I-Premise
312	excluding	_	_	I-Premise
313	C-peptide	_	_	I-Premise
314	(	_	_	I-Premise
315	P	_	_	I-Premise
316	<	_	_	I-Premise
317	.001	_	_	I-Premise
318	)	_	_	I-Premise
319	were	_	_	I-Premise
320	associated	_	_	I-Premise
321	with	_	_	I-Premise
322	poorer	_	_	I-Premise
323	EFS	_	_	I-Premise
324	in	_	_	I-Premise
325	multivariate	_	_	I-Premise
326	analysis	_	_	I-Premise
327	.	_	_	I-Premise

328	Octreotide-related	_	_	O
329	changes	_	_	O
330	in	_	_	O
331	circulating	_	_	O
332	IGF-1	_	_	O
333	and	_	_	O
334	C-peptide	_	_	O
335	levels	_	_	O
336	were	_	_	O
337	statistically	_	_	O
338	significant	_	_	O
339	.	_	_	O

340	Octreotide	_	_	B-Claim
341	did	_	_	I-Claim
342	not	_	_	I-Claim
343	add	_	_	I-Claim
344	significant	_	_	I-Claim
345	clinical	_	_	I-Claim
346	benefit	_	_	I-Claim
347	.	_	_	I-Claim

348	High	_	_	B-Claim
349	C-peptide	_	_	I-Claim
350	levels	_	_	I-Claim
351	(	_	_	I-Claim
352	surrogate	_	_	I-Claim
353	for	_	_	I-Claim
354	insulin	_	_	I-Claim
355	secretion	_	_	I-Claim
356	rate	_	_	I-Claim
357	)	_	_	I-Claim
358	and	_	_	I-Claim
359	high	_	_	I-Claim
360	BMI	_	_	I-Claim
361	were	_	_	I-Claim
362	associated	_	_	I-Claim
363	with	_	_	I-Claim
364	poor	_	_	I-Claim
365	outcome	_	_	I-Claim
366	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	few	_	_	O
3	reports	_	_	O
4	about	_	_	O
5	the	_	_	O
6	course	_	_	O
7	of	_	_	O
8	vestibular	_	_	O
9	schwannoma	_	_	O
10	(	_	_	O
11	VS	_	_	O
12	)	_	_	O
13	patients	_	_	O
14	following	_	_	O
15	gamma	_	_	O
16	knife	_	_	O
17	radiosurgery	_	_	O
18	(	_	_	O
19	GKRS	_	_	O
20	)	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	the	_	_	O
24	course	_	_	O
25	following	_	_	O
26	conservative	_	_	O
27	management	_	_	O
28	(	_	_	O
29	CM	_	_	O
30	)	_	_	O
31	.	_	_	O

32	In	_	_	O
33	this	_	_	O
34	study	_	_	O
35	,	_	_	O
36	we	_	_	O
37	present	_	_	O
38	prospectively	_	_	O
39	collected	_	_	O
40	data	_	_	O
41	of	_	_	O
42	237	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	unilateral	_	_	O
46	VS	_	_	O
47	extending	_	_	O
48	outside	_	_	O
49	the	_	_	O
50	internal	_	_	O
51	acoustic	_	_	O
52	canal	_	_	O
53	who	_	_	O
54	received	_	_	O
55	either	_	_	O
56	GKRS	_	_	O
57	(	_	_	O
58	113	_	_	O
59	)	_	_	O
60	or	_	_	O
61	CM	_	_	O
62	(	_	_	O
63	124	_	_	O
64	)	_	_	O
65	.	_	_	O

66	The	_	_	O
67	aim	_	_	O
68	was	_	_	O
69	to	_	_	O
70	measure	_	_	O
71	the	_	_	O
72	effect	_	_	O
73	of	_	_	O
74	GKRS	_	_	O
75	compared	_	_	O
76	with	_	_	O
77	the	_	_	O
78	natural	_	_	O
79	course	_	_	O
80	on	_	_	O
81	tumor	_	_	O
82	growth	_	_	O
83	rate	_	_	O
84	and	_	_	O
85	hearing	_	_	O
86	loss	_	_	O
87	.	_	_	O

88	Secondary	_	_	O
89	end	_	_	O
90	points	_	_	O
91	were	_	_	O
92	postinclusion	_	_	O
93	additional	_	_	O
94	treatment	_	_	O
95	,	_	_	O
96	quality	_	_	O
97	of	_	_	O
98	life	_	_	O
99	(	_	_	O
100	QoL	_	_	O
101	)	_	_	O
102	,	_	_	O
103	and	_	_	O
104	symptom	_	_	O
105	development	_	_	O
106	.	_	_	O

107	The	_	_	O
108	patients	_	_	O
109	underwent	_	_	O
110	magnetic	_	_	O
111	resonance	_	_	O
112	imaging	_	_	O
113	scans	_	_	O
114	,	_	_	O
115	clinical	_	_	O
116	examination	_	_	O
117	,	_	_	O
118	and	_	_	O
119	QoL	_	_	O
120	assessment	_	_	O
121	by	_	_	O
122	SF-36	_	_	O
123	questionnaire	_	_	O
124	.	_	_	O

125	Statistics	_	_	O
126	were	_	_	O
127	performed	_	_	O
128	by	_	_	O
129	using	_	_	O
130	Spearman	_	_	O
131	correlation	_	_	O
132	coefficient	_	_	O
133	,	_	_	O
134	Kaplan-Meier	_	_	O
135	plot	_	_	O
136	,	_	_	O
137	Poisson	_	_	O
138	regression	_	_	O
139	model	_	_	O
140	,	_	_	O
141	mixed	_	_	O
142	linear	_	_	O
143	regression	_	_	O
144	models	_	_	O
145	,	_	_	O
146	and	_	_	O
147	mixed	_	_	O
148	logistic	_	_	O
149	regression	_	_	O
150	models	_	_	O
151	.	_	_	O

152	Mean	_	_	O
153	follow-up	_	_	O
154	time	_	_	O
155	was	_	_	O
156	55.0	_	_	O
157	months	_	_	O
158	(	_	_	O
159	26.1	_	_	O
160	standard	_	_	O
161	deviation	_	_	O
162	,	_	_	O
163	range	_	_	O
164	10-132	_	_	O
165	)	_	_	O
166	.	_	_	O

167	Thirteen	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	lost	_	_	O
171	to	_	_	O
172	follow-up	_	_	O
173	.	_	_	O

174	Serviceable	_	_	B-Premise
175	hearing	_	_	I-Premise
176	was	_	_	I-Premise
177	lost	_	_	I-Premise
178	in	_	_	I-Premise
179	54	_	_	I-Premise
180	of	_	_	I-Premise
181	71	_	_	I-Premise
182	(	_	_	I-Premise
183	76	_	_	I-Premise
184	%	_	_	I-Premise
185	)	_	_	I-Premise
186	(	_	_	I-Premise
187	CM	_	_	I-Premise
188	)	_	_	I-Premise
189	and	_	_	I-Premise
190	34	_	_	I-Premise
191	of	_	_	I-Premise
192	53	_	_	I-Premise
193	(	_	_	I-Premise
194	64	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	(	_	_	I-Premise
198	GKRS	_	_	I-Premise
199	)	_	_	I-Premise
200	patients	_	_	I-Premise
201	during	_	_	I-Premise
202	the	_	_	I-Premise
203	study	_	_	I-Premise
204	period	_	_	I-Premise
205	(	_	_	I-Premise
206	not	_	_	I-Premise
207	significant	_	_	I-Premise
208	,	_	_	I-Premise
209	log-rank	_	_	I-Premise
210	test	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	There	_	_	B-Premise
214	was	_	_	I-Premise
215	a	_	_	I-Premise
216	significant	_	_	I-Premise
217	reduction	_	_	I-Premise
218	in	_	_	I-Premise
219	tumor	_	_	I-Premise
220	volume	_	_	I-Premise
221	over	_	_	I-Premise
222	time	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	GKRS	_	_	I-Premise
226	group	_	_	I-Premise
227	.	_	_	I-Premise

228	The	_	_	B-Premise
229	need	_	_	I-Premise
230	for	_	_	I-Premise
231	treatment	_	_	I-Premise
232	following	_	_	I-Premise
233	initial	_	_	I-Premise
234	GKRS	_	_	I-Premise
235	or	_	_	I-Premise
236	CM	_	_	I-Premise
237	differed	_	_	I-Premise
238	at	_	_	I-Premise
239	highly	_	_	I-Premise
240	significant	_	_	I-Premise
241	levels	_	_	I-Premise
242	(	_	_	I-Premise
243	log-rank	_	_	I-Premise
244	test	_	_	I-Premise
245	,	_	_	I-Premise
246	P	_	_	I-Premise
247	<	_	_	I-Premise
248	.001	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	Symptom	_	_	B-Premise
252	and	_	_	I-Premise
253	QoL	_	_	I-Premise
254	development	_	_	I-Premise
255	did	_	_	I-Premise
256	not	_	_	I-Premise
257	differ	_	_	I-Premise
258	significantly	_	_	I-Premise
259	between	_	_	I-Premise
260	the	_	_	I-Premise
261	groups	_	_	I-Premise
262	.	_	_	I-Premise

263	In	_	_	B-Claim
264	VS	_	_	I-Claim
265	patients	_	_	I-Claim
266	,	_	_	I-Claim
267	GKRS	_	_	I-Claim
268	reduces	_	_	I-Claim
269	the	_	_	I-Claim
270	tumor	_	_	I-Claim
271	growth	_	_	I-Claim
272	rate	_	_	I-Claim
273	and	_	_	I-Claim
274	thereby	_	_	I-Claim
275	the	_	_	I-Claim
276	incidence	_	_	I-Claim
277	rate	_	_	I-Claim
278	of	_	_	I-Claim
279	new	_	_	I-Claim
280	treatment	_	_	I-Claim
281	about	_	_	I-Claim
282	tenfold	_	_	I-Claim
283	.	_	_	I-Claim

284	Hearing	_	_	B-Claim
285	is	_	_	I-Claim
286	lost	_	_	I-Claim
287	at	_	_	I-Claim
288	similar	_	_	I-Claim
289	rates	_	_	I-Claim
290	in	_	_	I-Claim
291	both	_	_	I-Claim
292	groups	_	_	I-Claim
293	.	_	_	I-Claim

294	Symptoms	_	_	B-Claim
295	and	_	_	I-Claim
296	QoL	_	_	I-Claim
297	seem	_	_	I-Claim
298	not	_	_	I-Claim
299	to	_	_	I-Claim
300	be	_	_	I-Claim
301	significantly	_	_	I-Claim
302	affected	_	_	I-Claim
303	by	_	_	I-Claim
304	GKRS	_	_	I-Claim
305	.	_	_	I-Claim


0	The	_	_	O
1	AGO-ETC	_	_	O
2	trial	_	_	O
3	compared	_	_	O
4	5-year	_	_	O
5	relapse-free	_	_	O
6	survival	_	_	O
7	of	_	_	O
8	intense	_	_	O
9	dose-dense	_	_	O
10	(	_	_	O
11	IDD	_	_	O
12	)	_	_	O
13	sequential	_	_	O
14	chemotherapy	_	_	O
15	with	_	_	O
16	epirubicin	_	_	O
17	(	_	_	O
18	E	_	_	O
19	)	_	_	O
20	,	_	_	O
21	paclitaxel	_	_	O
22	(	_	_	O
23	T	_	_	O
24	)	_	_	O
25	,	_	_	O
26	and	_	_	O
27	cyclophosphamide	_	_	O
28	(	_	_	O
29	C	_	_	O
30	)	_	_	O
31	(	_	_	O
32	IDD-ETC	_	_	O
33	)	_	_	O
34	every	_	_	O
35	2	_	_	O
36	weeks	_	_	O
37	vs	_	_	O
38	conventional	_	_	O
39	scheduled	_	_	O
40	epirubicin/cyclophosphamide	_	_	O
41	followed	_	_	O
42	by	_	_	O
43	paclitaxel	_	_	O
44	(	_	_	O
45	ECT	_	_	O
46	)	_	_	O
47	(	_	_	O
48	every	_	_	O
49	3	_	_	O
50	weeks	_	_	O
51	)	_	_	O
52	as	_	_	O
53	adjuvant	_	_	O
54	treatment	_	_	O
55	in	_	_	O
56	high-risk	_	_	O
57	breast	_	_	O
58	cancer	_	_	O
59	patients	_	_	O
60	.	_	_	O

61	The	_	_	O
62	objective	_	_	O
63	of	_	_	O
64	this	_	_	O
65	study	_	_	O
66	was	_	_	O
67	to	_	_	O
68	evaluate	_	_	O
69	the	_	_	O
70	safety	_	_	O
71	and	_	_	O
72	efficacy	_	_	O
73	of	_	_	O
74	epoetin	_	_	O
75	alfa	_	_	O
76	in	_	_	O
77	a	_	_	O
78	second	_	_	O
79	randomization	_	_	O
80	of	_	_	O
81	the	_	_	O
82	intense	_	_	O
83	dose-dense	_	_	O
84	arm	_	_	O
85	.	_	_	O

86	One	_	_	O
87	thousand	_	_	O
88	two	_	_	O
89	hundred	_	_	O
90	eighty-four	_	_	O
91	patients	_	_	O
92	were	_	_	O
93	enrolled	_	_	O
94	;	_	_	O
95	658	_	_	O
96	patients	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	the	_	_	O
102	IDD-ETC	_	_	O
103	treatment	_	_	O
104	group	_	_	O
105	.	_	_	O

106	Within	_	_	O
107	the	_	_	O
108	IDD-ETC	_	_	O
109	group	_	_	O
110	,	_	_	O
111	324	_	_	O
112	patients	_	_	O
113	were	_	_	O
114	further	_	_	O
115	randomly	_	_	O
116	assigned	_	_	O
117	to	_	_	O
118	the	_	_	O
119	epoetin	_	_	O
120	alfa	_	_	O
121	group	_	_	O
122	,	_	_	O
123	and	_	_	O
124	319	_	_	O
125	were	_	_	O
126	randomly	_	_	O
127	assigned	_	_	O
128	to	_	_	O
129	the	_	_	O
130	non-erythropoiesis-stimulating	_	_	O
131	agent	_	_	O
132	(	_	_	O
133	ESA	_	_	O
134	)	_	_	O
135	control	_	_	O
136	group	_	_	O
137	.	_	_	O

138	Primary	_	_	O
139	efficacy	_	_	O
140	endpoints	_	_	O
141	included	_	_	O
142	change	_	_	O
143	in	_	_	O
144	hemoglobin	_	_	O
145	level	_	_	O
146	from	_	_	O
147	baseline	_	_	O
148	to	_	_	O
149	Cycle	_	_	O
150	9	_	_	O
151	and	_	_	O
152	the	_	_	O
153	percentage	_	_	O
154	of	_	_	O
155	subjects	_	_	O
156	requiring	_	_	O
157	red	_	_	O
158	blood	_	_	O
159	cell	_	_	O
160	transfusion	_	_	O
161	.	_	_	O

162	Relapse-free	_	_	O
163	survival	_	_	O
164	,	_	_	O
165	overall	_	_	O
166	survival	_	_	O
167	,	_	_	O
168	and	_	_	O
169	intramammary	_	_	O
170	relapse	_	_	O
171	were	_	_	O
172	secondary	_	_	O
173	endpoints	_	_	O
174	estimated	_	_	O
175	with	_	_	O
176	Kaplan-Meier	_	_	O
177	and	_	_	O
178	Cox	_	_	O
179	regression	_	_	O
180	methods	_	_	O
181	.	_	_	O

182	Except	_	_	O
183	for	_	_	O
184	the	_	_	O
185	primary	_	_	O
186	hypothesis	_	_	O
187	,	_	_	O
188	all	_	_	O
189	statistical	_	_	O
190	tests	_	_	O
191	were	_	_	O
192	two-sided	_	_	O
193	.	_	_	O

194	Epoetin	_	_	B-Premise
195	alfa	_	_	I-Premise
196	avoided	_	_	I-Premise
197	the	_	_	I-Premise
198	decrease	_	_	I-Premise
199	in	_	_	I-Premise
200	hemoglobin	_	_	I-Premise
201	level	_	_	I-Premise
202	(	_	_	I-Premise
203	no	_	_	I-Premise
204	decrease	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	epoetin	_	_	I-Premise
208	alfa	_	_	I-Premise
209	group	_	_	I-Premise
210	vs	_	_	I-Premise
211	-2.20g/dL	_	_	I-Premise
212	change	_	_	I-Premise
213	for	_	_	I-Premise
214	the	_	_	I-Premise
215	control	_	_	I-Premise
216	group	_	_	I-Premise
217	;	_	_	I-Premise
218	P	_	_	I-Premise
219	<	_	_	I-Premise
220	.001	_	_	I-Premise
221	)	_	_	I-Premise
222	and	_	_	I-Premise
223	statistically	_	_	I-Premise
224	significantly	_	_	I-Premise
225	reduced	_	_	I-Premise
226	the	_	_	I-Premise
227	percentage	_	_	I-Premise
228	of	_	_	I-Premise
229	subjects	_	_	I-Premise
230	requiring	_	_	I-Premise
231	red	_	_	I-Premise
232	blood	_	_	I-Premise
233	cell	_	_	I-Premise
234	transfusion	_	_	I-Premise
235	(	_	_	I-Premise
236	12.8	_	_	I-Premise
237	%	_	_	I-Premise
238	vs	_	_	I-Premise
239	28.1	_	_	I-Premise
240	%	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	<	_	_	I-Premise
244	.0001	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	The	_	_	B-Premise
248	incidence	_	_	I-Premise
249	of	_	_	I-Premise
250	thrombotic	_	_	I-Premise
251	events	_	_	I-Premise
252	was	_	_	I-Premise
253	7	_	_	I-Premise
254	%	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	epoetin	_	_	I-Premise
258	alfa	_	_	I-Premise
259	arm	_	_	I-Premise
260	vs	_	_	I-Premise
261	3	_	_	I-Premise
262	%	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	control	_	_	I-Premise
266	arm	_	_	I-Premise
267	.	_	_	I-Premise

268	After	_	_	B-Premise
269	a	_	_	I-Premise
270	median	_	_	I-Premise
271	follow-up	_	_	I-Premise
272	of	_	_	I-Premise
273	62	_	_	I-Premise
274	months	_	_	I-Premise
275	,	_	_	I-Premise
276	epoetin	_	_	I-Premise
277	alfa	_	_	I-Premise
278	treatment	_	_	I-Premise
279	did	_	_	I-Premise
280	not	_	_	I-Premise
281	affect	_	_	I-Premise
282	overall	_	_	I-Premise
283	survival	_	_	I-Premise
284	,	_	_	I-Premise
285	relapse-free	_	_	I-Premise
286	survival	_	_	I-Premise
287	,	_	_	I-Premise
288	or	_	_	I-Premise
289	intramammary	_	_	I-Premise
290	relapse	_	_	I-Premise
291	.	_	_	I-Premise

292	Epoetin	_	_	B-Claim
293	alfa	_	_	I-Claim
294	resulted	_	_	I-Claim
295	in	_	_	I-Claim
296	improved	_	_	I-Claim
297	hemoglobin	_	_	I-Claim
298	levels	_	_	I-Claim
299	and	_	_	I-Claim
300	decreased	_	_	I-Claim
301	transfusions	_	_	I-Claim
302	without	_	_	I-Claim
303	an	_	_	I-Claim
304	impact	_	_	I-Claim
305	on	_	_	I-Claim
306	relapse-free	_	_	I-Claim
307	or	_	_	I-Claim
308	overall	_	_	I-Claim
309	survival	_	_	I-Claim
310	.	_	_	I-Claim

311	However	_	_	B-Claim
312	,	_	_	I-Claim
313	epoetin	_	_	I-Claim
314	alfa	_	_	I-Claim
315	had	_	_	I-Claim
316	an	_	_	I-Claim
317	adverse	_	_	I-Claim
318	effect	_	_	I-Claim
319	,	_	_	I-Claim
320	resulting	_	_	I-Claim
321	in	_	_	I-Claim
322	increased	_	_	I-Claim
323	thrombosis	_	_	I-Claim
324	.	_	_	I-Claim


0	Capecitabine/taxane	_	_	O
1	combinations	_	_	O
2	are	_	_	O
3	highly	_	_	O
4	active	_	_	O
5	in	_	_	O
6	metastatic	_	_	O
7	breast	_	_	O
8	cancer	_	_	O
9	(	_	_	O
10	MBC	_	_	O
11	)	_	_	O
12	.	_	_	O

13	We	_	_	O
14	conducted	_	_	O
15	a	_	_	O
16	randomized	_	_	O
17	,	_	_	O
18	phase	_	_	O
19	III	_	_	O
20	,	_	_	O
21	noninferiority	_	_	O
22	trial	_	_	O
23	comparing	_	_	O
24	capecitabine	_	_	O
25	plus	_	_	O
26	paclitaxel	_	_	O
27	(	_	_	O
28	XP	_	_	O
29	)	_	_	O
30	with	_	_	O
31	epirubicin	_	_	O
32	plus	_	_	O
33	paclitaxel	_	_	O
34	(	_	_	O
35	EP	_	_	O
36	)	_	_	O
37	as	_	_	O
38	first-line	_	_	O
39	therapy	_	_	O
40	for	_	_	O
41	MBC	_	_	O
42	,	_	_	O
43	regarding	_	_	O
44	progression-free	_	_	O
45	survival	_	_	O
46	(	_	_	O
47	PFS	_	_	O
48	)	_	_	O
49	as	_	_	O
50	primary	_	_	O
51	efficacy	_	_	O
52	endpoint	_	_	O
53	.	_	_	O

54	Females	_	_	O
55	who	_	_	O
56	had	_	_	O
57	received	_	_	O
58	no	_	_	O
59	prior	_	_	O
60	chemotherapy	_	_	O
61	for	_	_	O
62	MBC	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	six	_	_	O
67	3-weekly	_	_	O
68	cycles	_	_	O
69	of	_	_	O
70	XP	_	_	O
71	(	_	_	O
72	capecitabine	_	_	O
73	1000	_	_	O
74	mg/m	_	_	O
75	(	_	_	O
76	2	_	_	O
77	)	_	_	O
78	b.i.d.	_	_	O
79	,	_	_	O
80	days	_	_	O
81	1-14	_	_	O
82	;	_	_	O
83	paclitaxel	_	_	O
84	175	_	_	O
85	mg/m	_	_	O
86	(	_	_	O
87	2	_	_	O
88	)	_	_	O
89	3-h	_	_	O
90	infusion	_	_	O
91	,	_	_	O
92	day	_	_	O
93	1	_	_	O
94	)	_	_	O
95	or	_	_	O
96	EP	_	_	O
97	(	_	_	O
98	epirubicin	_	_	O
99	60	_	_	O
100	mg/m	_	_	O
101	(	_	_	O
102	2	_	_	O
103	)	_	_	O
104	1-h	_	_	O
105	infusion	_	_	O
106	,	_	_	O
107	day	_	_	O
108	1	_	_	O
109	;	_	_	O
110	paclitaxel	_	_	O
111	as	_	_	O
112	above	_	_	O
113	)	_	_	O
114	.	_	_	O

115	Secondary	_	_	O
116	endpoints	_	_	O
117	included	_	_	O
118	response	_	_	O
119	rate	_	_	O
120	,	_	_	O
121	overall	_	_	O
122	survival	_	_	O
123	,	_	_	O
124	tolerability	_	_	O
125	,	_	_	O
126	and	_	_	O
127	quality	_	_	O
128	of	_	_	O
129	life	_	_	O
130	(	_	_	O
131	QoL	_	_	O
132	)	_	_	O
133	.	_	_	O

134	Each	_	_	O
135	arm	_	_	O
136	included	_	_	O
137	170	_	_	O
138	patients	_	_	O
139	,	_	_	O
140	most	_	_	O
141	of	_	_	O
142	whom	_	_	O
143	received	_	_	O
144	all	_	_	O
145	six	_	_	O
146	cycles	_	_	O
147	as	_	_	O
148	planned	_	_	O
149	.	_	_	O

150	The	_	_	O
151	difference	_	_	O
152	in	_	_	O
153	means	_	_	O
154	of	_	_	O
155	(	_	_	O
156	logarithmic	_	_	O
157	)	_	_	O
158	PFS	_	_	O
159	times	_	_	O
160	(	_	_	O
161	-0.205	_	_	O
162	)	_	_	O
163	did	_	_	O
164	not	_	_	O
165	meet	_	_	O
166	the	_	_	O
167	pre-defined	_	_	O
168	level	_	_	O
169	for	_	_	O
170	noninferiority	_	_	O
171	(	_	_	O
172	-0.186	_	_	O
173	)	_	_	O
174	.	_	_	O

175	However	_	_	O
176	,	_	_	O
177	PFS	_	_	B-Premise
178	was	_	_	I-Premise
179	similar	_	_	I-Premise
180	in	_	_	I-Premise
181	the	_	_	I-Premise
182	two	_	_	I-Premise
183	arms	_	_	I-Premise
184	[	_	_	I-Premise
185	HR	_	_	I-Premise
186	:	_	_	I-Premise
187	XP	_	_	I-Premise
188	vs.	_	_	I-Premise
189	EP	_	_	I-Premise
190	:	_	_	I-Premise
191	1.012	_	_	I-Premise
192	(	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	0.785-1.304	_	_	I-Premise
197	)	_	_	I-Premise
198	;	_	_	I-Premise
199	median	_	_	I-Premise
200	10.4	_	_	I-Premise
201	months	_	_	I-Premise
202	XP	_	_	I-Premise
203	vs.	_	_	I-Premise
204	9.2	_	_	I-Premise
205	months	_	_	I-Premise
206	EP	_	_	I-Premise
207	]	_	_	I-Premise
208	.	_	_	I-Premise

209	Overall	_	_	B-Premise
210	survival	_	_	I-Premise
211	was	_	_	I-Premise
212	also	_	_	I-Premise
213	similar	_	_	I-Premise
214	[	_	_	I-Premise
215	HR	_	_	I-Premise
216	1.027	_	_	I-Premise
217	(	_	_	I-Premise
218	95	_	_	I-Premise
219	%	_	_	I-Premise
220	CI	_	_	I-Premise
221	0.740-1.424	_	_	I-Premise
222	)	_	_	I-Premise
223	;	_	_	I-Premise
224	median	_	_	I-Premise
225	22.0	_	_	I-Premise
226	vs.	_	_	I-Premise
227	26.1	_	_	I-Premise
228	months	_	_	I-Premise
229	]	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	response	_	_	I-Premise
233	rate	_	_	I-Premise
234	was	_	_	I-Premise
235	47	_	_	I-Premise
236	%	_	_	I-Premise
237	versus	_	_	I-Premise
238	42	_	_	I-Premise
239	%	_	_	I-Premise
240	.	_	_	I-Premise

241	Both	_	_	B-Premise
242	regimens	_	_	I-Premise
243	were	_	_	I-Premise
244	tolerable	_	_	I-Premise
245	:	_	_	I-Premise
246	there	_	_	I-Premise
247	were	_	_	I-Premise
248	more	_	_	I-Premise
249	grade	_	_	I-Premise
250	3/4	_	_	I-Premise
251	diarrhea	_	_	I-Premise
252	and	_	_	I-Premise
253	grade	_	_	I-Premise
254	3	_	_	I-Premise
255	hand-foot	_	_	I-Premise
256	syndromes	_	_	I-Premise
257	with	_	_	I-Premise
258	XP	_	_	I-Premise
259	and	_	_	I-Premise
260	more	_	_	I-Premise
261	grade	_	_	I-Premise
262	3/4	_	_	I-Premise
263	hematologic	_	_	I-Premise
264	toxicities	_	_	I-Premise
265	with	_	_	I-Premise
266	EP	_	_	I-Premise
267	.	_	_	I-Premise

268	There	_	_	B-Premise
269	were	_	_	I-Premise
270	no	_	_	I-Premise
271	major	_	_	I-Premise
272	differences	_	_	I-Premise
273	in	_	_	I-Premise
274	QoL	_	_	I-Premise
275	.	_	_	I-Premise

276	Although	_	_	B-Claim
277	,	_	_	I-Claim
278	noninferiority	_	_	I-Claim
279	of	_	_	I-Claim
280	XP	_	_	I-Claim
281	to	_	_	I-Claim
282	EP	_	_	I-Claim
283	was	_	_	I-Claim
284	formally	_	_	I-Claim
285	not	_	_	I-Claim
286	proven	_	_	I-Claim
287	,	_	_	I-Claim
288	first-line	_	_	B-Claim
289	XP	_	_	I-Claim
290	was	_	_	I-Claim
291	active	_	_	I-Claim
292	and	_	_	I-Claim
293	feasible	_	_	I-Claim
294	.	_	_	I-Claim

295	XP	_	_	B-Claim
296	is	_	_	I-Claim
297	a	_	_	I-Claim
298	valid	_	_	I-Claim
299	first-line	_	_	I-Claim
300	alternative	_	_	I-Claim
301	to	_	_	I-Claim
302	anthracycline/taxane	_	_	I-Claim
303	regimens	_	_	I-Claim
304	,	_	_	I-Claim
305	especially	_	_	I-Claim
306	in	_	_	I-Claim
307	patients	_	_	I-Claim
308	previously	_	_	I-Claim
309	treated	_	_	I-Claim
310	with	_	_	I-Claim
311	adjuvant	_	_	I-Claim
312	anthracyclines	_	_	I-Claim
313	.	_	_	I-Claim


0	Androgen	_	_	B-Claim
1	deprivation	_	_	I-Claim
2	therapy	_	_	I-Claim
3	is	_	_	I-Claim
4	a	_	_	I-Claim
5	common	_	_	I-Claim
6	treatment	_	_	I-Claim
7	in	_	_	I-Claim
8	men	_	_	I-Claim
9	with	_	_	I-Claim
10	prostate	_	_	I-Claim
11	cancer	_	_	I-Claim
12	that	_	_	I-Claim
13	may	_	_	I-Claim
14	cause	_	_	I-Claim
15	fatigue	_	_	I-Claim
16	,	_	_	I-Claim
17	functional	_	_	I-Claim
18	decline	_	_	I-Claim
19	,	_	_	I-Claim
20	increased	_	_	I-Claim
21	body	_	_	I-Claim
22	fatness	_	_	I-Claim
23	,	_	_	I-Claim
24	and	_	_	I-Claim
25	loss	_	_	I-Claim
26	of	_	_	I-Claim
27	lean	_	_	I-Claim
28	body	_	_	I-Claim
29	tissue	_	_	I-Claim
30	.	_	_	I-Claim

31	These	_	_	B-Claim
32	physical	_	_	I-Claim
33	changes	_	_	I-Claim
34	can	_	_	I-Claim
35	negatively	_	_	I-Claim
36	affect	_	_	I-Claim
37	health-related	_	_	I-Claim
38	quality	_	_	I-Claim
39	of	_	_	I-Claim
40	life	_	_	I-Claim
41	.	_	_	I-Claim

42	Resistance	_	_	B-Claim
43	exercise	_	_	I-Claim
44	may	_	_	I-Claim
45	help	_	_	I-Claim
46	to	_	_	I-Claim
47	counter	_	_	I-Claim
48	some	_	_	I-Claim
49	of	_	_	I-Claim
50	these	_	_	I-Claim
51	side	_	_	I-Claim
52	effects	_	_	I-Claim
53	by	_	_	I-Claim
54	reducing	_	_	I-Claim
55	fatigue	_	_	I-Claim
56	,	_	_	I-Claim
57	elevating	_	_	I-Claim
58	mood	_	_	I-Claim
59	,	_	_	I-Claim
60	building	_	_	I-Claim
61	muscle	_	_	I-Claim
62	mass	_	_	I-Claim
63	,	_	_	I-Claim
64	and	_	_	I-Claim
65	reducing	_	_	I-Claim
66	body	_	_	I-Claim
67	fat	_	_	I-Claim
68	.	_	_	I-Claim

69	In	_	_	O
70	a	_	_	O
71	two-site	_	_	O
72	study	_	_	O
73	,	_	_	O
74	155	_	_	O
75	men	_	_	O
76	with	_	_	O
77	prostate	_	_	O
78	cancer	_	_	O
79	who	_	_	O
80	were	_	_	O
81	scheduled	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	androgen	_	_	O
85	deprivation	_	_	O
86	therapy	_	_	O
87	for	_	_	O
88	at	_	_	O
89	least	_	_	O
90	3	_	_	O
91	months	_	_	O
92	after	_	_	O
93	recruitment	_	_	O
94	were	_	_	O
95	randomly	_	_	O
96	assigned	_	_	O
97	to	_	_	O
98	an	_	_	O
99	intervention	_	_	O
100	group	_	_	O
101	that	_	_	O
102	participated	_	_	O
103	in	_	_	O
104	a	_	_	O
105	resistance	_	_	O
106	exercise	_	_	O
107	program	_	_	O
108	three	_	_	O
109	times	_	_	O
110	per	_	_	O
111	week	_	_	O
112	for	_	_	O
113	12	_	_	O
114	weeks	_	_	O
115	(	_	_	O
116	82	_	_	O
117	men	_	_	O
118	)	_	_	O
119	or	_	_	O
120	to	_	_	O
121	a	_	_	O
122	waiting	_	_	O
123	list	_	_	O
124	control	_	_	O
125	group	_	_	O
126	(	_	_	O
127	73	_	_	O
128	men	_	_	O
129	)	_	_	O
130	.	_	_	O

131	The	_	_	O
132	primary	_	_	O
133	outcomes	_	_	O
134	were	_	_	O
135	fatigue	_	_	O
136	and	_	_	O
137	disease-specific	_	_	O
138	quality	_	_	O
139	of	_	_	O
140	life	_	_	O
141	as	_	_	O
142	assessed	_	_	O
143	by	_	_	O
144	self-reported	_	_	O
145	questionnaires	_	_	O
146	after	_	_	O
147	12	_	_	O
148	weeks	_	_	O
149	.	_	_	O

150	Secondary	_	_	O
151	outcomes	_	_	O
152	were	_	_	O
153	muscular	_	_	O
154	fitness	_	_	O
155	and	_	_	O
156	body	_	_	O
157	composition	_	_	O
158	.	_	_	O

159	Men	_	_	B-Premise
160	assigned	_	_	I-Premise
161	to	_	_	I-Premise
162	resistance	_	_	I-Premise
163	exercise	_	_	I-Premise
164	had	_	_	I-Premise
165	less	_	_	I-Premise
166	interference	_	_	I-Premise
167	from	_	_	I-Premise
168	fatigue	_	_	I-Premise
169	on	_	_	I-Premise
170	activities	_	_	I-Premise
171	of	_	_	I-Premise
172	daily	_	_	I-Premise
173	living	_	_	I-Premise
174	(	_	_	I-Premise
175	P	_	_	I-Premise
176	=.002	_	_	I-Premise
177	)	_	_	I-Premise
178	and	_	_	I-Premise
179	higher	_	_	I-Premise
180	quality	_	_	I-Premise
181	of	_	_	I-Premise
182	life	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	=.001	_	_	I-Premise
186	)	_	_	I-Premise
187	than	_	_	I-Premise
188	men	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	control	_	_	I-Premise
192	group	_	_	I-Premise
193	.	_	_	I-Premise

194	Men	_	_	B-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	intervention	_	_	I-Premise
198	group	_	_	I-Premise
199	demonstrated	_	_	I-Premise
200	higher	_	_	I-Premise
201	levels	_	_	I-Premise
202	of	_	_	I-Premise
203	upper	_	_	I-Premise
204	body	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	=.009	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	lower	_	_	I-Premise
211	body	_	_	I-Premise
212	(	_	_	I-Premise
213	P	_	_	I-Premise
214	<	_	_	I-Premise
215	.001	_	_	I-Premise
216	)	_	_	I-Premise
217	muscular	_	_	I-Premise
218	fitness	_	_	I-Premise
219	than	_	_	I-Premise
220	men	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	control	_	_	I-Premise
224	group	_	_	I-Premise
225	.	_	_	I-Premise

226	The	_	_	B-Premise
227	12-week	_	_	I-Premise
228	resistance	_	_	I-Premise
229	exercise	_	_	I-Premise
230	intervention	_	_	I-Premise
231	did	_	_	I-Premise
232	not	_	_	I-Premise
233	improve	_	_	I-Premise
234	body	_	_	I-Premise
235	composition	_	_	I-Premise
236	as	_	_	I-Premise
237	measured	_	_	I-Premise
238	by	_	_	I-Premise
239	changes	_	_	I-Premise
240	in	_	_	I-Premise
241	body	_	_	I-Premise
242	weight	_	_	I-Premise
243	,	_	_	I-Premise
244	body	_	_	I-Premise
245	mass	_	_	I-Premise
246	index	_	_	I-Premise
247	,	_	_	I-Premise
248	waist	_	_	I-Premise
249	circumference	_	_	I-Premise
250	,	_	_	I-Premise
251	or	_	_	I-Premise
252	subcutaneous	_	_	I-Premise
253	skinfolds	_	_	I-Premise
254	.	_	_	I-Premise

255	Resistance	_	_	B-Claim
256	exercise	_	_	I-Claim
257	reduces	_	_	I-Claim
258	fatigue	_	_	I-Claim
259	and	_	_	I-Claim
260	improves	_	_	I-Claim
261	quality	_	_	I-Claim
262	of	_	_	I-Claim
263	life	_	_	I-Claim
264	and	_	_	I-Claim
265	muscular	_	_	I-Claim
266	fitness	_	_	I-Claim
267	in	_	_	I-Claim
268	men	_	_	I-Claim
269	with	_	_	I-Claim
270	prostate	_	_	I-Claim
271	cancer	_	_	I-Claim
272	receiving	_	_	I-Claim
273	androgen	_	_	I-Claim
274	deprivation	_	_	I-Claim
275	therapy	_	_	I-Claim
276	.	_	_	I-Claim

277	This	_	_	B-Claim
278	form	_	_	I-Claim
279	of	_	_	I-Claim
280	exercise	_	_	I-Claim
281	can	_	_	I-Claim
282	be	_	_	I-Claim
283	an	_	_	I-Claim
284	important	_	_	I-Claim
285	component	_	_	I-Claim
286	of	_	_	I-Claim
287	supportive	_	_	I-Claim
288	care	_	_	I-Claim
289	for	_	_	I-Claim
290	these	_	_	I-Claim
291	patients	_	_	I-Claim
292	.	_	_	I-Claim


0	Morbidity	_	_	B-Claim
1	is	_	_	I-Claim
2	an	_	_	I-Claim
3	important	_	_	I-Claim
4	issue	_	_	I-Claim
5	in	_	_	I-Claim
6	cancer	_	_	I-Claim
7	research	_	_	I-Claim
8	.	_	_	I-Claim

9	The	_	_	B-Claim
10	observer-based	_	_	I-Claim
11	toxicity	_	_	I-Claim
12	scoring	_	_	I-Claim
13	system	_	_	I-Claim
14	used	_	_	I-Claim
15	by	_	_	I-Claim
16	DAHANCA	_	_	I-Claim
17	(	_	_	I-Claim
18	the	_	_	I-Claim
19	Danish	_	_	I-Claim
20	head	_	_	I-Claim
21	and	_	_	I-Claim
22	neck	_	_	I-Claim
23	cancer	_	_	I-Claim
24	study	_	_	I-Claim
25	group	_	_	I-Claim
26	)	_	_	I-Claim
27	has	_	_	I-Claim
28	proved	_	_	I-Claim
29	itself	_	_	I-Claim
30	sensitive	_	_	I-Claim
31	to	_	_	I-Claim
32	differences	_	_	I-Claim
33	in	_	_	I-Claim
34	toxicity	_	_	I-Claim
35	in	_	_	I-Claim
36	a	_	_	I-Claim
37	large	_	_	I-Claim
38	randomised	_	_	I-Claim
39	study	_	_	I-Claim
40	,	_	_	I-Claim
41	but	_	_	B-Claim
42	like	_	_	I-Claim
43	other	_	_	I-Claim
44	toxicity	_	_	I-Claim
45	scoring	_	_	I-Claim
46	systems	_	_	I-Claim
47	it	_	_	I-Claim
48	has	_	_	I-Claim
49	not	_	_	I-Claim
50	been	_	_	I-Claim
51	formally	_	_	I-Claim
52	validated	_	_	I-Claim
53	.	_	_	I-Claim

54	Conversely	_	_	O
55	,	_	_	O
56	the	_	_	O
57	EORTC	_	_	O
58	quality	_	_	O
59	of	_	_	O
60	life	_	_	O
61	questionnaire	_	_	O
62	(	_	_	O
63	QLQ	_	_	O
64	)	_	_	O
65	has	_	_	O
66	been	_	_	O
67	validated	_	_	O
68	as	_	_	O
69	a	_	_	O
70	tool	_	_	O
71	for	_	_	O
72	collecting	_	_	O
73	information	_	_	O
74	about	_	_	O
75	the	_	_	O
76	consequences	_	_	O
77	of	_	_	O
78	disease	_	_	O
79	and	_	_	O
80	treatment	_	_	O
81	on	_	_	O
82	the	_	_	O
83	well	_	_	O
84	being	_	_	O
85	of	_	_	O
86	cancer	_	_	O
87	patients	_	_	O
88	.	_	_	O

89	The	_	_	O
90	purpose	_	_	O
91	of	_	_	O
92	this	_	_	O
93	study	_	_	O
94	was	_	_	O
95	to	_	_	O
96	examine	_	_	O
97	the	_	_	O
98	relationship	_	_	O
99	between	_	_	O
100	the	_	_	O
101	two	_	_	O
102	methods	_	_	O
103	of	_	_	O
104	side	_	_	O
105	effect	_	_	O
106	recording	_	_	O
107	.	_	_	O

108	One	_	_	O
109	hundred	_	_	O
110	and	_	_	O
111	sixteen	_	_	O
112	recurrence	_	_	O
113	free	_	_	O
114	patients	_	_	O
115	with	_	_	O
116	laryngeal	_	_	O
117	(	_	_	O
118	n=44	_	_	O
119	)	_	_	O
120	,	_	_	O
121	pharyngeal	_	_	O
122	(	_	_	O
123	n=34	_	_	O
124	)	_	_	O
125	and	_	_	O
126	oral	_	_	O
127	cavity	_	_	O
128	(	_	_	O
129	n=38	_	_	O
130	)	_	_	O
131	cancer	_	_	O
132	attending	_	_	O
133	follow-up	_	_	O
134	after	_	_	O
135	radiotherapy	_	_	O
136	(	_	_	O
137	n=83	_	_	O
138	)	_	_	O
139	or	_	_	O
140	surgery	_	_	O
141	(	_	_	O
142	n=33	_	_	O
143	)	_	_	O
144	completed	_	_	O
145	EORTC	_	_	O
146	C30	_	_	O
147	,	_	_	O
148	the	_	_	O
149	core	_	_	O
150	questionnaire	_	_	O
151	concerning	_	_	O
152	general	_	_	O
153	symptoms	_	_	O
154	and	_	_	O
155	function	_	_	O
156	and	_	_	O
157	EORTC	_	_	O
158	H	_	_	O
159	&	_	_	O
160	amp	_	_	O
161	;	_	_	O
162	N35	_	_	O
163	the	_	_	O
164	head	_	_	O
165	and	_	_	O
166	neck	_	_	O
167	specific	_	_	O
168	questionnaire	_	_	O
169	.	_	_	O

170	The	_	_	O
171	attending	_	_	O
172	physicians	_	_	O
173	in	_	_	O
174	the	_	_	O
175	follow-up	_	_	O
176	clinic	_	_	O
177	evaluated	_	_	O
178	and	_	_	O
179	recorded	_	_	O
180	DAHANCA	_	_	O
181	toxicity	_	_	O
182	scores	_	_	O
183	on	_	_	O
184	the	_	_	O
185	same	_	_	O
186	patients	_	_	O
187	.	_	_	O

188	The	_	_	B-Premise
189	DAHANCA	_	_	I-Premise
190	toxicity	_	_	I-Premise
191	scoring	_	_	I-Premise
192	system	_	_	I-Premise
193	and	_	_	I-Premise
194	the	_	_	I-Premise
195	EORTC	_	_	I-Premise
196	QLQ	_	_	I-Premise
197	correlated	_	_	I-Premise
198	with	_	_	I-Premise
199	several	_	_	I-Premise
200	clinical	_	_	I-Premise
201	endpoints	_	_	I-Premise
202	.	_	_	I-Premise

203	The	_	_	B-Premise
204	conceptually	_	_	I-Premise
205	similar	_	_	I-Premise
206	endpoints	_	_	I-Premise
207	of	_	_	I-Premise
208	the	_	_	I-Premise
209	two	_	_	I-Premise
210	methods	_	_	I-Premise
211	correlated	_	_	I-Premise
212	significantly	_	_	I-Premise
213	.	_	_	I-Premise

214	The	_	_	B-Premise
215	objective	_	_	I-Premise
216	endpoints	_	_	I-Premise
217	of	_	_	I-Premise
218	the	_	_	I-Premise
219	DAHANCA	_	_	I-Premise
220	scoring	_	_	I-Premise
221	system	_	_	I-Premise
222	were	_	_	I-Premise
223	only	_	_	I-Premise
224	correlated	_	_	I-Premise
225	with	_	_	I-Premise
226	quality	_	_	I-Premise
227	of	_	_	I-Premise
228	life	_	_	I-Premise
229	endpoints	_	_	I-Premise
230	to	_	_	I-Premise
231	a	_	_	I-Premise
232	very	_	_	I-Premise
233	low	_	_	I-Premise
234	degree	_	_	I-Premise
235	.	_	_	I-Premise

236	The	_	_	B-Premise
237	DAHANCA	_	_	I-Premise
238	toxicity	_	_	I-Premise
239	scores	_	_	I-Premise
240	had	_	_	I-Premise
241	a	_	_	I-Premise
242	low	_	_	I-Premise
243	sensitivity	_	_	I-Premise
244	(	_	_	I-Premise
245	0.48-0.74	_	_	I-Premise
246	)	_	_	I-Premise
247	in	_	_	I-Premise
248	detecting	_	_	I-Premise
249	equivalent	_	_	I-Premise
250	subjective	_	_	I-Premise
251	complaints	_	_	I-Premise
252	from	_	_	I-Premise
253	the	_	_	I-Premise
254	questionnaires	_	_	I-Premise
255	and	_	_	I-Premise
256	the	_	_	I-Premise
257	observer-based	_	_	I-Premise
258	scoring	_	_	I-Premise
259	system	_	_	I-Premise
260	severely	_	_	I-Premise
261	underestimated	_	_	I-Premise
262	patient	_	_	I-Premise
263	complaints	_	_	I-Premise
264	.	_	_	I-Premise

265	A	_	_	B-Premise
266	specific	_	_	I-Premise
267	patient	_	_	I-Premise
268	group	_	_	I-Premise
269	where	_	_	I-Premise
270	the	_	_	I-Premise
271	DAHANCA	_	_	I-Premise
272	score	_	_	I-Premise
273	had	_	_	I-Premise
274	a	_	_	I-Premise
275	higher	_	_	I-Premise
276	tendency	_	_	I-Premise
277	to	_	_	I-Premise
278	fail	_	_	I-Premise
279	could	_	_	I-Premise
280	not	_	_	I-Premise
281	be	_	_	I-Premise
282	detected	_	_	I-Premise
283	.	_	_	I-Premise

284	The	_	_	B-Claim
285	DAHANCA	_	_	I-Claim
286	toxicity	_	_	I-Claim
287	score	_	_	I-Claim
288	is	_	_	I-Claim
289	an	_	_	I-Claim
290	effective	_	_	I-Claim
291	instrument	_	_	I-Claim
292	in	_	_	I-Claim
293	assessing	_	_	I-Claim
294	objective	_	_	I-Claim
295	treatment	_	_	I-Claim
296	induced	_	_	I-Claim
297	toxicity	_	_	I-Claim
298	in	_	_	I-Claim
299	head	_	_	I-Claim
300	and	_	_	I-Claim
301	neck	_	_	I-Claim
302	cancer	_	_	I-Claim
303	patients	_	_	I-Claim
304	but	_	_	I-Claim
305	insensitive	_	_	I-Claim
306	and	_	_	I-Claim
307	non-specific	_	_	I-Claim
308	with	_	_	I-Claim
309	regard	_	_	I-Claim
310	to	_	_	I-Claim
311	patient	_	_	I-Claim
312	assessed	_	_	I-Claim
313	subjective	_	_	I-Claim
314	endpoints	_	_	I-Claim
315	.	_	_	I-Claim

316	This	_	_	B-Claim
317	weakness	_	_	I-Claim
318	seems	_	_	I-Claim
319	inherent	_	_	I-Claim
320	in	_	_	I-Claim
321	an	_	_	I-Claim
322	observer-based	_	_	I-Claim
323	scoring	_	_	I-Claim
324	system	_	_	I-Claim
325	,	_	_	I-Claim
326	and	_	_	I-Claim
327	will	_	_	I-Claim
328	probably	_	_	I-Claim
329	also	_	_	I-Claim
330	apply	_	_	I-Claim
331	to	_	_	I-Claim
332	newer	_	_	I-Claim
333	ones	_	_	I-Claim
334	like	_	_	I-Claim
335	CTCAE	_	_	I-Claim
336	3.0	_	_	I-Claim
337	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	protracted	_	_	O
3	venous	_	_	O
4	infusion	_	_	O
5	(	_	_	O
6	PVI	_	_	O
7	)	_	_	O
8	fluorouracil	_	_	O
9	(	_	_	O
10	5-FU	_	_	O
11	)	_	_	O
12	with	_	_	O
13	PVI	_	_	O
14	5-FU	_	_	O
15	plus	_	_	O
16	mitomycin	_	_	O
17	(	_	_	O
18	MMC	_	_	O
19	)	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	advanced	_	_	O
24	pancreatic	_	_	O
25	cancer	_	_	O
26	in	_	_	O
27	a	_	_	O
28	multicenter	_	_	O
29	,	_	_	O
30	prospectively	_	_	O
31	randomized	_	_	O
32	study	_	_	O
33	.	_	_	O

34	Two	_	_	O
35	hundred	_	_	O
36	eight	_	_	O
37	patients	_	_	O
38	were	_	_	O
39	randomized	_	_	O
40	to	_	_	O
41	PVI	_	_	O
42	5-FU	_	_	O
43	(	_	_	O
44	300	_	_	O
45	mg/m	_	_	O
46	(	_	_	O
47	2	_	_	O
48	)	_	_	O
49	/d	_	_	O
50	for	_	_	O
51	a	_	_	O
52	maximum	_	_	O
53	of	_	_	O
54	24	_	_	O
55	weeks	_	_	O
56	)	_	_	O
57	or	_	_	O
58	PVI	_	_	O
59	5-FU	_	_	O
60	plus	_	_	O
61	MMC	_	_	O
62	(	_	_	O
63	7	_	_	O
64	mg/m	_	_	O
65	(	_	_	O
66	2	_	_	O
67	)	_	_	O
68	every	_	_	O
69	6	_	_	O
70	weeks	_	_	O
71	for	_	_	O
72	four	_	_	O
73	courses	_	_	O
74	)	_	_	O
75	.	_	_	O

76	The	_	_	O
77	major	_	_	O
78	end	_	_	O
79	points	_	_	O
80	were	_	_	O
81	tumor	_	_	O
82	response	_	_	O
83	,	_	_	O
84	survival	_	_	O
85	,	_	_	O
86	toxicity	_	_	O
87	,	_	_	O
88	and	_	_	O
89	quality	_	_	O
90	of	_	_	O
91	life	_	_	O
92	(	_	_	O
93	QOL	_	_	O
94	)	_	_	O
95	.	_	_	O

96	The	_	_	O
97	two	_	_	O
98	treatment	_	_	O
99	groups	_	_	O
100	were	_	_	O
101	balanced	_	_	O
102	for	_	_	O
103	baseline	_	_	O
104	demographic	_	_	O
105	factors	_	_	O
106	,	_	_	O
107	and	_	_	O
108	62	_	_	O
109	%	_	_	O
110	had	_	_	O
111	metastatic	_	_	O
112	disease	_	_	O
113	.	_	_	O

114	The	_	_	B-Premise
115	overall	_	_	I-Premise
116	response	_	_	I-Premise
117	rate	_	_	I-Premise
118	was	_	_	I-Premise
119	8.4	_	_	I-Premise
120	%	_	_	I-Premise
121	(	_	_	I-Premise
122	95	_	_	I-Premise
123	%	_	_	I-Premise
124	confidence	_	_	I-Premise
125	interval	_	_	I-Premise
126	[	_	_	I-Premise
127	CI	_	_	I-Premise
128	]	_	_	I-Premise
129	)	_	_	I-Premise
130	3.2	_	_	I-Premise
131	%	_	_	I-Premise
132	to	_	_	I-Premise
133	13.7	_	_	I-Premise
134	%	_	_	I-Premise
135	for	_	_	I-Premise
136	patients	_	_	I-Premise
137	treated	_	_	I-Premise
138	with	_	_	I-Premise
139	PVI	_	_	I-Premise
140	5-FU	_	_	I-Premise
141	alone	_	_	I-Premise
142	compared	_	_	I-Premise
143	with	_	_	I-Premise
144	17.6	_	_	I-Premise
145	%	_	_	I-Premise
146	;	_	_	I-Premise
147	95	_	_	I-Premise
148	%	_	_	I-Premise
149	CI	_	_	I-Premise
150	10.3	_	_	I-Premise
151	%	_	_	I-Premise
152	to	_	_	I-Premise
153	25.1	_	_	I-Premise
154	%	_	_	I-Premise
155	for	_	_	I-Premise
156	PVI	_	_	I-Premise
157	5-FU	_	_	I-Premise
158	plus	_	_	I-Premise
159	MMC	_	_	I-Premise
160	(	_	_	I-Premise
161	P	_	_	I-Premise
162	=.04	_	_	I-Premise
163	)	_	_	I-Premise
164	.	_	_	I-Premise

165	Median	_	_	B-Premise
166	failure-free	_	_	I-Premise
167	survival	_	_	I-Premise
168	was	_	_	I-Premise
169	2.8	_	_	I-Premise
170	months	_	_	I-Premise
171	for	_	_	I-Premise
172	PVI	_	_	I-Premise
173	5-FU	_	_	I-Premise
174	and	_	_	I-Premise
175	3.8	_	_	I-Premise
176	months	_	_	I-Premise
177	for	_	_	I-Premise
178	PVI	_	_	I-Premise
179	5-FU	_	_	I-Premise
180	plus	_	_	I-Premise
181	MMC	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	=.14	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	Median	_	_	B-Premise
188	survival	_	_	I-Premise
189	was	_	_	I-Premise
190	5.1	_	_	I-Premise
191	months	_	_	I-Premise
192	for	_	_	I-Premise
193	PVI	_	_	I-Premise
194	5-FU	_	_	I-Premise
195	and	_	_	I-Premise
196	6.5	_	_	I-Premise
197	months	_	_	I-Premise
198	for	_	_	I-Premise
199	PVI	_	_	I-Premise
200	5-FU	_	_	I-Premise
201	plus	_	_	I-Premise
202	MMC	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=.34	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Toxicities	_	_	B-Premise
209	in	_	_	I-Premise
210	both	_	_	I-Premise
211	arms	_	_	I-Premise
212	were	_	_	I-Premise
213	mild	_	_	I-Premise
214	.	_	_	I-Premise

215	There	_	_	B-Premise
216	was	_	_	I-Premise
217	an	_	_	I-Premise
218	increased	_	_	I-Premise
219	incidence	_	_	I-Premise
220	of	_	_	I-Premise
221	neutropenia	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	5-FU	_	_	I-Premise
225	plus	_	_	I-Premise
226	MMC	_	_	I-Premise
227	arm	_	_	I-Premise
228	(	_	_	I-Premise
229	P	_	_	I-Premise
230	<	_	_	I-Premise
231	.01	_	_	I-Premise
232	)	_	_	I-Premise
233	,	_	_	I-Premise
234	although	_	_	I-Premise
235	no	_	_	I-Premise
236	differences	_	_	I-Premise
237	in	_	_	I-Premise
238	infection	_	_	I-Premise
239	were	_	_	I-Premise
240	seen	_	_	I-Premise
241	.	_	_	I-Premise

242	No	_	_	B-Premise
243	patients	_	_	I-Premise
244	developed	_	_	I-Premise
245	hemolytic	_	_	I-Premise
246	uremic	_	_	I-Premise
247	syndrome	_	_	I-Premise
248	.	_	_	I-Premise

249	Global	_	_	B-Claim
250	QOL	_	_	I-Claim
251	improved	_	_	I-Claim
252	significantly	_	_	I-Claim
253	after	_	_	I-Claim
254	24	_	_	I-Claim
255	weeks	_	_	I-Claim
256	of	_	_	I-Claim
257	treatment	_	_	I-Claim
258	compared	_	_	I-Claim
259	with	_	_	I-Claim
260	baseline	_	_	I-Claim
261	for	_	_	I-Claim
262	patients	_	_	I-Claim
263	receiving	_	_	I-Claim
264	5-FU	_	_	I-Claim
265	plus	_	_	I-Claim
266	MMC	_	_	I-Claim
267	,	_	_	I-Claim
268	although	_	_	B-Premise
269	there	_	_	I-Premise
270	was	_	_	I-Premise
271	no	_	_	I-Premise
272	statistically	_	_	I-Premise
273	significant	_	_	I-Premise
274	difference	_	_	I-Premise
275	in	_	_	I-Premise
276	QOL	_	_	I-Premise
277	between	_	_	I-Premise
278	arms	_	_	I-Premise
279	.	_	_	I-Premise

280	PVI	_	_	B-Claim
281	5-FU	_	_	I-Claim
282	plus	_	_	I-Claim
283	MMC	_	_	I-Claim
284	resulted	_	_	I-Claim
285	in	_	_	I-Claim
286	a	_	_	I-Claim
287	superior	_	_	I-Claim
288	response	_	_	I-Claim
289	rate	_	_	I-Claim
290	in	_	_	I-Claim
291	comparison	_	_	I-Claim
292	with	_	_	I-Claim
293	PVI	_	_	I-Claim
294	5-FU	_	_	I-Claim
295	alone	_	_	I-Claim
296	in	_	_	I-Claim
297	advanced	_	_	I-Claim
298	pancreatic	_	_	I-Claim
299	cancer	_	_	I-Claim
300	,	_	_	I-Claim
301	but	_	_	B-Claim
302	this	_	_	I-Claim
303	did	_	_	I-Claim
304	not	_	_	I-Claim
305	translate	_	_	I-Claim
306	into	_	_	I-Claim
307	a	_	_	I-Claim
308	survival	_	_	I-Claim
309	advantage	_	_	I-Claim
310	.	_	_	I-Claim

311	These	_	_	B-Claim
312	results	_	_	I-Claim
313	emphasize	_	_	I-Claim
314	the	_	_	I-Claim
315	importance	_	_	I-Claim
316	of	_	_	I-Claim
317	chemotherapy	_	_	I-Claim
318	in	_	_	I-Claim
319	this	_	_	I-Claim
320	setting	_	_	I-Claim
321	and	_	_	I-Claim
322	the	_	_	I-Claim
323	continuing	_	_	I-Claim
324	value	_	_	I-Claim
325	of	_	_	I-Claim
326	the	_	_	I-Claim
327	fluoropyrimidines	_	_	I-Claim
328	in	_	_	I-Claim
329	pancreatic	_	_	I-Claim
330	cancer	_	_	I-Claim
331	.	_	_	I-Claim


0	Research	_	_	B-Claim
1	suggests	_	_	I-Claim
2	that	_	_	I-Claim
3	stress-reduction	_	_	I-Claim
4	programs	_	_	I-Claim
5	tailored	_	_	I-Claim
6	to	_	_	I-Claim
7	the	_	_	I-Claim
8	cancer	_	_	I-Claim
9	setting	_	_	I-Claim
10	help	_	_	I-Claim
11	patients	_	_	I-Claim
12	cope	_	_	I-Claim
13	with	_	_	I-Claim
14	the	_	_	I-Claim
15	effects	_	_	I-Claim
16	of	_	_	I-Claim
17	treatment	_	_	I-Claim
18	and	_	_	I-Claim
19	improve	_	_	I-Claim
20	their	_	_	I-Claim
21	quality	_	_	I-Claim
22	of	_	_	I-Claim
23	life	_	_	I-Claim
24	.	_	_	I-Claim

25	Yoga	_	_	O
26	,	_	_	O
27	an	_	_	O
28	ancient	_	_	O
29	Eastern	_	_	O
30	science	_	_	O
31	,	_	_	O
32	incorporates	_	_	O
33	stress-reduction	_	_	O
34	techniques	_	_	O
35	that	_	_	O
36	include	_	_	O
37	regulated	_	_	O
38	breathing	_	_	O
39	,	_	_	O
40	visual	_	_	O
41	imagery	_	_	O
42	,	_	_	O
43	and	_	_	O
44	meditation	_	_	O
45	as	_	_	O
46	well	_	_	O
47	as	_	_	O
48	various	_	_	O
49	postures	_	_	O
50	.	_	_	O

51	The	_	_	O
52	authors	_	_	O
53	examined	_	_	O
54	the	_	_	O
55	effects	_	_	O
56	of	_	_	O
57	the	_	_	O
58	Tibetan	_	_	O
59	yoga	_	_	O
60	(	_	_	O
61	TY	_	_	O
62	)	_	_	O
63	practices	_	_	O
64	of	_	_	O
65	Tsa	_	_	O
66	lung	_	_	O
67	and	_	_	O
68	Trul	_	_	O
69	khor	_	_	O
70	,	_	_	O
71	which	_	_	O
72	incorporate	_	_	O
73	controlled	_	_	O
74	breathing	_	_	O
75	and	_	_	O
76	visualization	_	_	O
77	,	_	_	O
78	mindfulness	_	_	O
79	techniques	_	_	O
80	,	_	_	O
81	and	_	_	O
82	low-impact	_	_	O
83	postures	_	_	O
84	in	_	_	O
85	patients	_	_	O
86	with	_	_	O
87	lymphoma	_	_	O
88	.	_	_	O

89	Thirty-nine	_	_	O
90	patients	_	_	O
91	with	_	_	O
92	lymphoma	_	_	O
93	who	_	_	O
94	were	_	_	O
95	undergoing	_	_	O
96	treatment	_	_	O
97	or	_	_	O
98	who	_	_	O
99	had	_	_	O
100	concluded	_	_	O
101	treatment	_	_	O
102	within	_	_	O
103	the	_	_	O
104	past	_	_	O
105	12	_	_	O
106	months	_	_	O
107	were	_	_	O
108	assigned	_	_	O
109	to	_	_	O
110	a	_	_	O
111	TY	_	_	O
112	group	_	_	O
113	or	_	_	O
114	to	_	_	O
115	a	_	_	O
116	wait-list	_	_	O
117	control	_	_	O
118	group	_	_	O
119	.	_	_	O

120	Patients	_	_	O
121	in	_	_	O
122	the	_	_	O
123	TY	_	_	O
124	group	_	_	O
125	participated	_	_	O
126	in	_	_	O
127	7	_	_	O
128	weekly	_	_	O
129	yoga	_	_	O
130	sessions	_	_	O
131	,	_	_	O
132	and	_	_	O
133	patients	_	_	O
134	in	_	_	O
135	the	_	_	O
136	wait-list	_	_	O
137	control	_	_	O
138	group	_	_	O
139	were	_	_	O
140	free	_	_	O
141	to	_	_	O
142	participate	_	_	O
143	in	_	_	O
144	the	_	_	O
145	TY	_	_	O
146	program	_	_	O
147	after	_	_	O
148	the	_	_	O
149	3-month	_	_	O
150	follow-up	_	_	O
151	assessment	_	_	O
152	.	_	_	O

153	Eighty	_	_	O
154	nine	_	_	O
155	percent	_	_	O
156	of	_	_	O
157	TY	_	_	O
158	participants	_	_	O
159	completed	_	_	O
160	at	_	_	O
161	least	_	_	O
162	2-3	_	_	O
163	three	_	_	O
164	yoga	_	_	O
165	sessions	_	_	O
166	,	_	_	O
167	and	_	_	O
168	58	_	_	O
169	%	_	_	O
170	completed	_	_	O
171	at	_	_	O
172	least	_	_	O
173	5	_	_	O
174	sessions	_	_	O
175	.	_	_	O

176	Patients	_	_	B-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	TY	_	_	I-Premise
180	group	_	_	I-Premise
181	reported	_	_	I-Premise
182	significantly	_	_	I-Premise
183	lower	_	_	I-Premise
184	sleep	_	_	I-Premise
185	disturbance	_	_	I-Premise
186	scores	_	_	I-Premise
187	during	_	_	I-Premise
188	follow-up	_	_	I-Premise
189	compared	_	_	I-Premise
190	with	_	_	I-Premise
191	patients	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	wait-list	_	_	I-Premise
195	control	_	_	I-Premise
196	group	_	_	I-Premise
197	(	_	_	I-Premise
198	5.8	_	_	I-Premise
199	vs.	_	_	I-Premise
200	8.1	_	_	I-Premise
201	;	_	_	I-Premise
202	P	_	_	I-Premise
203	<	_	_	I-Premise
204	0.004	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	This	_	_	B-Premise
208	included	_	_	I-Premise
209	better	_	_	I-Premise
210	subjective	_	_	I-Premise
211	sleep	_	_	I-Premise
212	quality	_	_	I-Premise
213	(	_	_	I-Premise
214	P	_	_	I-Premise
215	<	_	_	I-Premise
216	0.02	_	_	I-Premise
217	)	_	_	I-Premise
218	,	_	_	I-Premise
219	faster	_	_	I-Premise
220	sleep	_	_	I-Premise
221	latency	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	<	_	_	I-Premise
225	0.01	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	longer	_	_	I-Premise
229	sleep	_	_	I-Premise
230	duration	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	<	_	_	I-Premise
234	0.03	_	_	I-Premise
235	)	_	_	I-Premise
236	,	_	_	I-Premise
237	and	_	_	I-Premise
238	less	_	_	I-Premise
239	use	_	_	I-Premise
240	of	_	_	I-Premise
241	sleep	_	_	I-Premise
242	medications	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	0.02	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	There	_	_	B-Premise
250	were	_	_	I-Premise
251	no	_	_	I-Premise
252	significant	_	_	I-Premise
253	differences	_	_	I-Premise
254	between	_	_	I-Premise
255	groups	_	_	I-Premise
256	in	_	_	I-Premise
257	terms	_	_	I-Premise
258	of	_	_	I-Premise
259	intrusion	_	_	I-Premise
260	or	_	_	I-Premise
261	avoidance	_	_	I-Premise
262	,	_	_	I-Premise
263	state	_	_	I-Premise
264	anxiety	_	_	I-Premise
265	,	_	_	I-Premise
266	depression	_	_	I-Premise
267	,	_	_	I-Premise
268	or	_	_	I-Premise
269	fatigue	_	_	I-Premise
270	.	_	_	I-Premise

271	The	_	_	B-Claim
272	participation	_	_	I-Claim
273	rates	_	_	I-Claim
274	suggested	_	_	I-Claim
275	that	_	_	I-Claim
276	a	_	_	I-Claim
277	TY	_	_	I-Claim
278	program	_	_	I-Claim
279	is	_	_	I-Claim
280	feasible	_	_	I-Claim
281	for	_	_	I-Claim
282	patients	_	_	I-Claim
283	with	_	_	I-Claim
284	cancer	_	_	I-Claim
285	and	_	_	I-Claim
286	that	_	_	I-Claim
287	such	_	_	I-Claim
288	a	_	_	I-Claim
289	program	_	_	I-Claim
290	significantly	_	_	I-Claim
291	improves	_	_	I-Claim
292	sleep-related	_	_	I-Claim
293	outcomes	_	_	I-Claim
294	.	_	_	I-Claim

295	However	_	_	B-Premise
296	,	_	_	I-Premise
297	there	_	_	I-Premise
298	were	_	_	I-Premise
299	no	_	_	I-Premise
300	significant	_	_	I-Premise
301	differences	_	_	I-Premise
302	between	_	_	I-Premise
303	groups	_	_	I-Premise
304	for	_	_	I-Premise
305	the	_	_	I-Premise
306	other	_	_	I-Premise
307	outcomes	_	_	I-Premise
308	.	_	_	I-Premise


0	Bone	_	_	B-Claim
1	metastases	_	_	I-Claim
2	occur	_	_	I-Claim
3	in	_	_	I-Claim
4	most	_	_	I-Claim
5	women	_	_	I-Claim
6	with	_	_	I-Claim
7	advanced	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	and	_	_	I-Claim
11	can	_	_	I-Claim
12	lead	_	_	I-Claim
13	to	_	_	I-Claim
14	considerable	_	_	I-Claim
15	morbidity	_	_	I-Claim
16	and	_	_	I-Claim
17	a	_	_	I-Claim
18	rapid	_	_	I-Claim
19	deterioration	_	_	I-Claim
20	in	_	_	I-Claim
21	the	_	_	I-Claim
22	patient	_	_	I-Claim
23	's	_	_	I-Claim
24	quality	_	_	I-Claim
25	of	_	_	I-Claim
26	life	_	_	I-Claim
27	.	_	_	I-Claim

28	It	_	_	O
29	was	_	_	O
30	the	_	_	O
31	aim	_	_	O
32	of	_	_	O
33	the	_	_	O
34	present	_	_	O
35	study	_	_	O
36	to	_	_	O
37	assess	_	_	O
38	changes	_	_	O
39	in	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	and	_	_	O
44	bone	_	_	O
45	pain	_	_	O
46	due	_	_	O
47	to	_	_	O
48	intravenous	_	_	O
49	(	_	_	O
50	i.v	_	_	O
51	.	_	_	O
52	)	_	_	O

53	ibandronate	_	_	O
54	,	_	_	O
55	a	_	_	O
56	potent	_	_	O
57	third-generation	_	_	O
58	bisphosphonate	_	_	O
59	.	_	_	O

60	In	_	_	O
61	a	_	_	O
62	phase	_	_	O
63	III	_	_	O
64	randomised	_	_	O
65	,	_	_	O
66	double-blind	_	_	O
67	,	_	_	O
68	placebo-controlled	_	_	O
69	trial	_	_	O
70	in	_	_	O
71	patients	_	_	O
72	with	_	_	O
73	bone	_	_	O
74	metastases	_	_	O
75	due	_	_	O
76	to	_	_	O
77	breast	_	_	O
78	cancer	_	_	O
79	,	_	_	O
80	466	_	_	O
81	women	_	_	O
82	were	_	_	O
83	randomised	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	placebo	_	_	O
87	,	_	_	O
88	2	_	_	O
89	mg	_	_	O
90	ibandronate	_	_	O
91	or	_	_	O
92	6	_	_	O
93	mg	_	_	O
94	ibandronate	_	_	O
95	for	_	_	O
96	up	_	_	O
97	to	_	_	O
98	96	_	_	O
99	weeks	_	_	O
100	.	_	_	O

101	Treatment	_	_	O
102	was	_	_	O
103	administered	_	_	O
104	i.v	_	_	O
105	.	_	_	O

106	at	_	_	O
107	3-	_	_	O
108	or	_	_	O
109	4-weekly	_	_	O
110	intervals	_	_	O
111	.	_	_	O

112	Clinical	_	_	O
113	endpoints	_	_	O
114	included	_	_	O
115	the	_	_	O
116	incidence	_	_	O
117	of	_	_	O
118	adverse	_	_	O
119	events	_	_	O
120	,	_	_	O
121	quality	_	_	O
122	of	_	_	O
123	life	_	_	O
124	(	_	_	O
125	assessed	_	_	O
126	using	_	_	O
127	the	_	_	O
128	European	_	_	O
129	Organisation	_	_	O
130	for	_	_	O
131	the	_	_	O
132	Research	_	_	O
133	and	_	_	O
134	Treatment	_	_	O
135	of	_	_	O
136	Cancer	_	_	O
137	(	_	_	O
138	EORTC	_	_	O
139	)	_	_	O
140	Quality	_	_	O
141	of	_	_	O
142	Life	_	_	O
143	Scale	_	_	O
144	-	_	_	O
145	Core	_	_	O
146	30	_	_	O
147	questionnaire	_	_	O
148	(	_	_	O
149	QLQ-C30	_	_	O
150	)	_	_	O
151	)	_	_	O
152	,	_	_	O
153	and	_	_	O
154	bone	_	_	O
155	pain	_	_	O
156	(	_	_	O
157	assessed	_	_	O
158	on	_	_	O
159	a	_	_	O
160	5-point	_	_	O
161	scale	_	_	O
162	from	_	_	O
163	0=none	_	_	O
164	to	_	_	O
165	4=intolerable	_	_	O
166	)	_	_	O
167	.	_	_	O

168	Ibandronate	_	_	B-Premise
169	was	_	_	I-Premise
170	generally	_	_	I-Premise
171	well	_	_	I-Premise
172	tolerated	_	_	I-Premise
173	.	_	_	I-Premise

174	Compared	_	_	B-Premise
175	with	_	_	I-Premise
176	baseline	_	_	I-Premise
177	measurements	_	_	I-Premise
178	,	_	_	I-Premise
179	the	_	_	I-Premise
180	bone	_	_	I-Premise
181	pain	_	_	I-Premise
182	score	_	_	I-Premise
183	was	_	_	I-Premise
184	increased	_	_	I-Premise
185	at	_	_	I-Premise
186	the	_	_	I-Premise
187	last	_	_	I-Premise
188	assessment	_	_	I-Premise
189	in	_	_	I-Premise
190	both	_	_	I-Premise
191	the	_	_	I-Premise
192	placebo	_	_	I-Premise
193	and	_	_	I-Premise
194	2	_	_	I-Premise
195	mg	_	_	I-Premise
196	ibandronate	_	_	I-Premise
197	groups	_	_	I-Premise
198	,	_	_	I-Premise
199	but	_	_	B-Premise
200	was	_	_	I-Premise
201	significantly	_	_	I-Premise
202	reduced	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	patients	_	_	I-Premise
206	receiving	_	_	I-Premise
207	6	_	_	I-Premise
208	mg	_	_	I-Premise
209	ibandronate	_	_	I-Premise
210	(	_	_	I-Premise
211	-0.28+/-1.11	_	_	I-Premise
212	,	_	_	I-Premise
213	P	_	_	I-Premise
214	<	_	_	I-Premise
215	0.001	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	A	_	_	B-Premise
219	significant	_	_	I-Premise
220	improvement	_	_	I-Premise
221	in	_	_	I-Premise
222	quality	_	_	I-Premise
223	of	_	_	I-Premise
224	life	_	_	I-Premise
225	was	_	_	I-Premise
226	demonstrated	_	_	I-Premise
227	for	_	_	I-Premise
228	patients	_	_	I-Premise
229	treated	_	_	I-Premise
230	with	_	_	I-Premise
231	ibandronate	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	<	_	_	I-Premise
235	0.05	_	_	I-Premise
236	)	_	_	I-Premise
237	for	_	_	I-Premise
238	all	_	_	I-Premise
239	global	_	_	I-Premise
240	health	_	_	I-Premise
241	status	_	_	I-Premise
242	.	_	_	I-Premise

243	Overall	_	_	B-Premise
244	,	_	_	I-Premise
245	at	_	_	I-Premise
246	the	_	_	I-Premise
247	last	_	_	I-Premise
248	assessment	_	_	I-Premise
249	,	_	_	I-Premise
250	the	_	_	I-Premise
251	6	_	_	I-Premise
252	mg	_	_	I-Premise
253	ibandronate	_	_	I-Premise
254	group	_	_	I-Premise
255	showed	_	_	I-Premise
256	significantly	_	_	I-Premise
257	better	_	_	I-Premise
258	functioning	_	_	I-Premise
259	compared	_	_	I-Premise
260	with	_	_	I-Premise
261	placebo	_	_	I-Premise
262	(	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	0.004	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	I-Premise
269	had	_	_	I-Premise
270	significantly	_	_	I-Premise
271	better	_	_	I-Premise
272	scores	_	_	I-Premise
273	on	_	_	I-Premise
274	the	_	_	I-Premise
275	domains	_	_	I-Premise
276	of	_	_	I-Premise
277	physical	_	_	I-Premise
278	,	_	_	I-Premise
279	emotional	_	_	I-Premise
280	,	_	_	I-Premise
281	and	_	_	I-Premise
282	social	_	_	I-Premise
283	functioning	_	_	I-Premise
284	,	_	_	I-Premise
285	and	_	_	I-Premise
286	in	_	_	I-Premise
287	global	_	_	I-Premise
288	health	_	_	I-Premise
289	status	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	<	_	_	I-Premise
293	0.05	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	Significant	_	_	B-Premise
297	improvements	_	_	I-Premise
298	in	_	_	I-Premise
299	the	_	_	I-Premise
300	symptoms	_	_	I-Premise
301	of	_	_	I-Premise
302	fatigue	_	_	I-Premise
303	and	_	_	I-Premise
304	pain	_	_	I-Premise
305	were	_	_	I-Premise
306	also	_	_	I-Premise
307	observed	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	6	_	_	I-Premise
311	mg	_	_	I-Premise
312	ibandronate	_	_	I-Premise
313	group	_	_	I-Premise
314	.	_	_	I-Premise

315	I.v	_	_	B-Claim
316	.	_	_	I-Claim

317	ibandronate	_	_	I-Claim
318	treatment	_	_	I-Claim
319	leads	_	_	I-Claim
320	to	_	_	I-Claim
321	significant	_	_	I-Claim
322	improvements	_	_	I-Claim
323	in	_	_	I-Claim
324	quality	_	_	I-Claim
325	of	_	_	I-Claim
326	life	_	_	I-Claim
327	,	_	_	I-Claim
328	and	_	_	I-Claim
329	is	_	_	I-Claim
330	an	_	_	I-Claim
331	effective	_	_	I-Claim
332	and	_	_	I-Claim
333	well-tolerated	_	_	I-Claim
334	palliative	_	_	I-Claim
335	treatment	_	_	I-Claim
336	in	_	_	I-Claim
337	patients	_	_	I-Claim
338	with	_	_	I-Claim
339	bone	_	_	I-Claim
340	metastases	_	_	I-Claim
341	due	_	_	I-Claim
342	to	_	_	I-Claim
343	breast	_	_	I-Claim
344	cancer	_	_	I-Claim
345	.	_	_	I-Claim


0	Advice	_	_	B-Claim
1	to	_	_	I-Claim
2	rest	_	_	I-Claim
3	and	_	_	I-Claim
4	take	_	_	I-Claim
5	things	_	_	I-Claim
6	easy	_	_	I-Claim
7	if	_	_	I-Claim
8	patients	_	_	I-Claim
9	become	_	_	I-Claim
10	fatigued	_	_	I-Claim
11	during	_	_	I-Claim
12	radiotherapy	_	_	I-Claim
13	may	_	_	I-Claim
14	be	_	_	I-Claim
15	detrimental	_	_	I-Claim
16	.	_	_	I-Claim

17	Aerobic	_	_	B-Premise
18	walking	_	_	I-Premise
19	improves	_	_	I-Premise
20	physical	_	_	I-Premise
21	functioning	_	_	I-Premise
22	and	_	_	I-Premise
23	has	_	_	I-Premise
24	been	_	_	I-Premise
25	an	_	_	I-Premise
26	intervention	_	_	I-Premise
27	for	_	_	I-Premise
28	chemotherapy-related	_	_	I-Premise
29	fatigue	_	_	I-Premise
30	.	_	_	I-Premise

31	A	_	_	O
32	prospective	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	,	_	_	O
36	controlled	_	_	O
37	trial	_	_	O
38	was	_	_	O
39	performed	_	_	O
40	to	_	_	O
41	determine	_	_	O
42	whether	_	_	O
43	aerobic	_	_	O
44	exercise	_	_	O
45	would	_	_	O
46	reduce	_	_	O
47	the	_	_	O
48	incidence	_	_	O
49	of	_	_	O
50	fatigue	_	_	O
51	and	_	_	O
52	prevent	_	_	O
53	deterioration	_	_	O
54	in	_	_	O
55	physical	_	_	O
56	functioning	_	_	O
57	during	_	_	O
58	radiotherapy	_	_	O
59	for	_	_	O
60	localized	_	_	O
61	prostate	_	_	O
62	carcinoma	_	_	O
63	.	_	_	O

64	Sixty-six	_	_	O
65	men	_	_	O
66	were	_	_	O
67	randomized	_	_	O
68	before	_	_	O
69	they	_	_	O
70	received	_	_	O
71	radical	_	_	O
72	radiotherapy	_	_	O
73	for	_	_	O
74	localized	_	_	O
75	prostate	_	_	O
76	carcinoma	_	_	O
77	,	_	_	O
78	with	_	_	O
79	33	_	_	O
80	men	_	_	O
81	randomized	_	_	O
82	to	_	_	O
83	an	_	_	O
84	exercise	_	_	O
85	group	_	_	O
86	and	_	_	O
87	33	_	_	O
88	men	_	_	O
89	randomized	_	_	O
90	to	_	_	O
91	a	_	_	O
92	control	_	_	O
93	group	_	_	O
94	.	_	_	O

95	Outcome	_	_	O
96	measures	_	_	O
97	were	_	_	O
98	fatigue	_	_	O
99	and	_	_	O
100	distance	_	_	O
101	walked	_	_	O
102	in	_	_	O
103	a	_	_	O
104	modified	_	_	O
105	shuttle	_	_	O
106	test	_	_	O
107	before	_	_	O
108	and	_	_	O
109	after	_	_	O
110	radiotherapy	_	_	O
111	.	_	_	O

112	There	_	_	B-Premise
113	were	_	_	I-Premise
114	no	_	_	I-Premise
115	significant	_	_	I-Premise
116	between	_	_	I-Premise
117	group	_	_	I-Premise
118	differences	_	_	I-Premise
119	noted	_	_	I-Premise
120	with	_	_	I-Premise
121	regard	_	_	I-Premise
122	to	_	_	I-Premise
123	fatigue	_	_	I-Premise
124	scores	_	_	I-Premise
125	at	_	_	I-Premise
126	baseline	_	_	I-Premise
127	(	_	_	I-Premise
128	P	_	_	I-Premise
129	=	_	_	I-Premise
130	0.55	_	_	I-Premise
131	)	_	_	I-Premise
132	or	_	_	I-Premise
133	after	_	_	I-Premise
134	4	_	_	I-Premise
135	weeks	_	_	I-Premise
136	of	_	_	I-Premise
137	radiotherapy	_	_	I-Premise
138	(	_	_	I-Premise
139	P	_	_	I-Premise
140	=	_	_	I-Premise
141	0.18	_	_	I-Premise
142	)	_	_	I-Premise
143	.	_	_	I-Premise

144	Men	_	_	B-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	control	_	_	I-Premise
148	group	_	_	I-Premise
149	had	_	_	I-Premise
150	significant	_	_	I-Premise
151	increases	_	_	I-Premise
152	in	_	_	I-Premise
153	fatigue	_	_	I-Premise
154	scores	_	_	I-Premise
155	from	_	_	I-Premise
156	baseline	_	_	I-Premise
157	to	_	_	I-Premise
158	the	_	_	I-Premise
159	end	_	_	I-Premise
160	of	_	_	I-Premise
161	radiotherapy	_	_	I-Premise
162	(	_	_	I-Premise
163	P	_	_	I-Premise
164	=	_	_	I-Premise
165	0.013	_	_	I-Premise
166	)	_	_	I-Premise
167	,	_	_	I-Premise
168	with	_	_	I-Premise
169	no	_	_	I-Premise
170	significant	_	_	I-Premise
171	increases	_	_	I-Premise
172	observed	_	_	I-Premise
173	in	_	_	I-Premise
174	the	_	_	I-Premise
175	exercise	_	_	I-Premise
176	group	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	0.203	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	A	_	_	B-Premise
184	nonsignificant	_	_	I-Premise
185	reduction	_	_	I-Premise
186	(	_	_	I-Premise
187	2.4	_	_	I-Premise
188	%	_	_	I-Premise
189	)	_	_	I-Premise
190	in	_	_	I-Premise
191	shuttle	_	_	I-Premise
192	test	_	_	I-Premise
193	distance	_	_	I-Premise
194	at	_	_	I-Premise
195	the	_	_	I-Premise
196	end	_	_	I-Premise
197	of	_	_	I-Premise
198	radiotherapy	_	_	I-Premise
199	was	_	_	I-Premise
200	observed	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	control	_	_	I-Premise
204	group	_	_	I-Premise
205	;	_	_	I-Premise
206	however	_	_	I-Premise
207	,	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	exercise	_	_	I-Premise
211	group	_	_	I-Premise
212	,	_	_	I-Premise
213	there	_	_	I-Premise
214	was	_	_	I-Premise
215	a	_	_	I-Premise
216	significant	_	_	I-Premise
217	increase	_	_	I-Premise
218	(	_	_	I-Premise
219	13.2	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	in	_	_	I-Premise
223	distance	_	_	I-Premise
224	walked	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	0.0003	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	Men	_	_	B-Premise
232	who	_	_	I-Premise
233	followed	_	_	I-Premise
234	advice	_	_	I-Premise
235	to	_	_	I-Premise
236	rest	_	_	I-Premise
237	and	_	_	I-Premise
238	take	_	_	I-Premise
239	things	_	_	I-Premise
240	easy	_	_	I-Premise
241	if	_	_	I-Premise
242	they	_	_	I-Premise
243	became	_	_	I-Premise
244	fatigued	_	_	I-Premise
245	demonstrated	_	_	I-Premise
246	a	_	_	I-Premise
247	slight	_	_	I-Premise
248	deterioration	_	_	I-Premise
249	in	_	_	I-Premise
250	physical	_	_	I-Premise
251	functioning	_	_	I-Premise
252	and	_	_	I-Premise
253	a	_	_	I-Premise
254	significant	_	_	I-Premise
255	increase	_	_	I-Premise
256	in	_	_	I-Premise
257	fatigue	_	_	I-Premise
258	at	_	_	I-Premise
259	the	_	_	I-Premise
260	end	_	_	I-Premise
261	of	_	_	I-Premise
262	radiotherapy	_	_	I-Premise
263	.	_	_	I-Premise

264	Home-based	_	_	B-Claim
265	,	_	_	I-Claim
266	moderate-intensity	_	_	I-Claim
267	walking	_	_	I-Claim
268	produced	_	_	I-Claim
269	a	_	_	I-Claim
270	significant	_	_	I-Claim
271	improvement	_	_	I-Claim
272	in	_	_	I-Claim
273	physical	_	_	I-Claim
274	functioning	_	_	I-Claim
275	with	_	_	I-Claim
276	no	_	_	I-Claim
277	significant	_	_	I-Claim
278	increase	_	_	I-Claim
279	in	_	_	I-Claim
280	fatigue	_	_	I-Claim
281	.	_	_	I-Claim

282	Improved	_	_	B-Claim
283	physical	_	_	I-Claim
284	functioning	_	_	I-Claim
285	may	_	_	I-Claim
286	be	_	_	I-Claim
287	necessary	_	_	I-Claim
288	to	_	_	I-Claim
289	combat	_	_	I-Claim
290	radiation	_	_	I-Claim
291	fatigue	_	_	I-Claim
292	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	exercise	_	_	O
6	training	_	_	O
7	on	_	_	O
8	cardiopulmonary	_	_	O
9	function	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	(	_	_	O
15	QOL	_	_	O
16	)	_	_	O
17	in	_	_	O
18	postmenopausal	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	survivors	_	_	O
22	who	_	_	O
23	had	_	_	O
24	completed	_	_	O
25	surgery	_	_	O
26	,	_	_	O
27	radiotherapy	_	_	O
28	,	_	_	O
29	and/or	_	_	O
30	chemotherapy	_	_	O
31	with	_	_	O
32	or	_	_	O
33	without	_	_	O
34	current	_	_	O
35	hormone	_	_	O
36	therapy	_	_	O
37	use	_	_	O
38	.	_	_	O

39	Fifty-three	_	_	O
40	postmenopausal	_	_	O
41	breast	_	_	O
42	cancer	_	_	O
43	survivors	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	an	_	_	O
49	exercise	_	_	O
50	(	_	_	O
51	n	_	_	O
52	=	_	_	O
53	25	_	_	O
54	)	_	_	O
55	or	_	_	O
56	control	_	_	O
57	(	_	_	O
58	n	_	_	O
59	=	_	_	O
60	28	_	_	O
61	)	_	_	O
62	group	_	_	O
63	.	_	_	O

64	The	_	_	O
65	exercise	_	_	O
66	group	_	_	O
67	trained	_	_	O
68	on	_	_	O
69	cycle	_	_	O
70	ergometers	_	_	O
71	three	_	_	O
72	times	_	_	O
73	per	_	_	O
74	week	_	_	O
75	for	_	_	O
76	15	_	_	O
77	weeks	_	_	O
78	at	_	_	O
79	a	_	_	O
80	power	_	_	O
81	output	_	_	O
82	that	_	_	O
83	elicited	_	_	O
84	the	_	_	O
85	ventilatory	_	_	O
86	equivalent	_	_	O
87	for	_	_	O
88	carbon	_	_	O
89	dioxide	_	_	O
90	.	_	_	O

91	The	_	_	O
92	control	_	_	O
93	group	_	_	O
94	did	_	_	O
95	not	_	_	O
96	train	_	_	O
97	.	_	_	O

98	The	_	_	O
99	primary	_	_	O
100	outcomes	_	_	O
101	were	_	_	O
102	changes	_	_	O
103	in	_	_	O
104	peak	_	_	O
105	oxygen	_	_	O
106	consumption	_	_	O
107	and	_	_	O
108	overall	_	_	O
109	QOL	_	_	O
110	from	_	_	O
111	baseline	_	_	O
112	to	_	_	O
113	postintervention	_	_	O
114	.	_	_	O

115	Peak	_	_	O
116	oxygen	_	_	O
117	consumption	_	_	O
118	was	_	_	O
119	assessed	_	_	O
120	by	_	_	O
121	a	_	_	O
122	graded	_	_	O
123	exercise	_	_	O
124	test	_	_	O
125	using	_	_	O
126	gas	_	_	O
127	exchange	_	_	O
128	analysis	_	_	O
129	.	_	_	O

130	Overall	_	_	O
131	QOL	_	_	O
132	was	_	_	O
133	assessed	_	_	O
134	by	_	_	O
135	the	_	_	O
136	Functional	_	_	O
137	Assessment	_	_	O
138	of	_	_	O
139	Cancer	_	_	O
140	Therapy-Breast	_	_	O
141	scale	_	_	O
142	.	_	_	O

143	Fifty-two	_	_	O
144	participants	_	_	O
145	completed	_	_	O
146	the	_	_	O
147	trial	_	_	O
148	.	_	_	O

149	The	_	_	O
150	exercise	_	_	O
151	group	_	_	O
152	completed	_	_	O
153	98.4	_	_	O
154	%	_	_	O
155	of	_	_	O
156	the	_	_	O
157	exercise	_	_	O
158	sessions	_	_	O
159	.	_	_	O

160	Baseline	_	_	O
161	values	_	_	O
162	for	_	_	O
163	peak	_	_	O
164	oxygen	_	_	O
165	consumption	_	_	O
166	(	_	_	O
167	P	_	_	O
168	=.254	_	_	O
169	)	_	_	O
170	and	_	_	O
171	overall	_	_	O
172	QOL	_	_	O
173	(	_	_	O
174	P	_	_	O
175	=.286	_	_	O
176	)	_	_	O
177	did	_	_	O
178	not	_	_	O
179	differ	_	_	O
180	between	_	_	O
181	groups	_	_	O
182	.	_	_	O

183	Peak	_	_	B-Premise
184	oxygen	_	_	I-Premise
185	consumption	_	_	I-Premise
186	increased	_	_	I-Premise
187	by	_	_	I-Premise
188	0.24	_	_	I-Premise
189	L/min	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	exercise	_	_	I-Premise
193	group	_	_	I-Premise
194	,	_	_	I-Premise
195	whereas	_	_	B-Premise
196	it	_	_	I-Premise
197	decreased	_	_	I-Premise
198	by	_	_	I-Premise
199	0.05	_	_	I-Premise
200	L/min	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	control	_	_	I-Premise
204	group	_	_	I-Premise
205	(	_	_	I-Premise
206	mean	_	_	I-Premise
207	difference	_	_	I-Premise
208	,	_	_	I-Premise
209	0.29	_	_	I-Premise
210	L/min	_	_	I-Premise
211	;	_	_	I-Premise
212	95	_	_	I-Premise
213	%	_	_	I-Premise
214	confidence	_	_	I-Premise
215	interval	_	_	I-Premise
216	[	_	_	I-Premise
217	CI	_	_	I-Premise
218	]	_	_	I-Premise
219	,	_	_	I-Premise
220	0.18	_	_	I-Premise
221	to	_	_	I-Premise
222	0.40	_	_	I-Premise
223	;	_	_	I-Premise
224	P	_	_	I-Premise
225	<	_	_	I-Premise
226	.001	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	Overall	_	_	B-Premise
230	QOL	_	_	I-Premise
231	increased	_	_	I-Premise
232	by	_	_	I-Premise
233	9.1	_	_	I-Premise
234	points	_	_	I-Premise
235	in	_	_	I-Premise
236	the	_	_	I-Premise
237	exercise	_	_	I-Premise
238	group	_	_	I-Premise
239	compared	_	_	I-Premise
240	with	_	_	I-Premise
241	0.3	_	_	I-Premise
242	points	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	control	_	_	I-Premise
246	group	_	_	I-Premise
247	(	_	_	I-Premise
248	mean	_	_	I-Premise
249	difference	_	_	I-Premise
250	,	_	_	I-Premise
251	8.8	_	_	I-Premise
252	points	_	_	I-Premise
253	;	_	_	I-Premise
254	95	_	_	I-Premise
255	%	_	_	I-Premise
256	CI	_	_	I-Premise
257	,	_	_	I-Premise
258	3.6	_	_	I-Premise
259	to	_	_	I-Premise
260	14.0	_	_	I-Premise
261	;	_	_	I-Premise
262	P	_	_	I-Premise
263	=.001	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	Pearson	_	_	B-Premise
267	correlations	_	_	I-Premise
268	indicated	_	_	I-Premise
269	that	_	_	I-Premise
270	change	_	_	I-Premise
271	in	_	_	I-Premise
272	peak	_	_	I-Premise
273	oxygen	_	_	I-Premise
274	consumption	_	_	I-Premise
275	correlated	_	_	I-Premise
276	with	_	_	I-Premise
277	change	_	_	I-Premise
278	in	_	_	I-Premise
279	overall	_	_	I-Premise
280	QOL	_	_	I-Premise
281	(	_	_	I-Premise
282	r	_	_	I-Premise
283	=	_	_	I-Premise
284	0.45	_	_	I-Premise
285	;	_	_	I-Premise
286	P	_	_	I-Premise
287	<	_	_	I-Premise
288	.01	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Exercise	_	_	B-Claim
292	training	_	_	I-Claim
293	had	_	_	I-Claim
294	beneficial	_	_	I-Claim
295	effects	_	_	I-Claim
296	on	_	_	I-Claim
297	cardiopulmonary	_	_	I-Claim
298	function	_	_	I-Claim
299	and	_	_	I-Claim
300	QOL	_	_	I-Claim
301	in	_	_	I-Claim
302	postmenopausal	_	_	I-Claim
303	breast	_	_	I-Claim
304	cancer	_	_	I-Claim
305	survivors	_	_	I-Claim
306	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	,	_	_	O
3	double-blind	_	_	O
4	,	_	_	O
5	placebo-controlled	_	_	O
6	clinical	_	_	O
7	trial	_	_	O
8	assessed	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	epoetin	_	_	O
13	alfa	_	_	O
14	on	_	_	O
15	transfusion	_	_	O
16	requirements	_	_	O
17	,	_	_	O
18	hematopoietic	_	_	O
19	parameters	_	_	O
20	,	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QOL	_	_	O
26	)	_	_	O
27	,	_	_	O
28	and	_	_	O
29	safety	_	_	O
30	in	_	_	O
31	anemic	_	_	O
32	cancer	_	_	O
33	patients	_	_	O
34	receiving	_	_	O
35	nonplatinum	_	_	O
36	chemotherapy	_	_	O
37	.	_	_	O

38	The	_	_	O
39	study	_	_	O
40	also	_	_	O
41	explored	_	_	O
42	a	_	_	O
43	possible	_	_	O
44	relationship	_	_	O
45	between	_	_	O
46	increased	_	_	O
47	hemoglobin	_	_	O
48	and	_	_	O
49	survival	_	_	O
50	.	_	_	O

51	Three	_	_	O
52	hundred	_	_	O
53	seventy-five	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	solid	_	_	O
57	or	_	_	O
58	nonmyeloid	_	_	O
59	hematologic	_	_	O
60	malignancies	_	_	O
61	and	_	_	O
62	hemoglobin	_	_	O
63	levels	_	_	O
64	<	_	_	O
65	or	_	_	O
66	=	_	_	O
67	10.5	_	_	O
68	g/dL	_	_	O
69	,	_	_	O
70	or	_	_	O
71	greater	_	_	O
72	than	_	_	O
73	10.5	_	_	O
74	g/dL	_	_	O
75	but	_	_	O
76	<	_	_	O
77	or	_	_	O
78	=	_	_	O
79	12.0	_	_	O
80	g/dL	_	_	O
81	after	_	_	O
82	a	_	_	O
83	hemoglobin	_	_	O
84	decrease	_	_	O
85	of	_	_	O
86	>	_	_	O
87	or	_	_	O
88	=	_	_	O
89	1.5	_	_	O
90	g/dL	_	_	O
91	per	_	_	O
92	cycle	_	_	O
93	since	_	_	O
94	starting	_	_	O
95	chemotherapy	_	_	O
96	,	_	_	O
97	were	_	_	O
98	randomized	_	_	O
99	2:1	_	_	O
100	to	_	_	O
101	epoetin	_	_	O
102	alfa	_	_	O
103	150	_	_	O
104	to	_	_	O
105	300	_	_	O
106	IU/kg	_	_	O
107	(	_	_	O
108	n	_	_	O
109	=	_	_	O
110	251	_	_	O
111	)	_	_	O
112	or	_	_	O
113	placebo	_	_	O
114	(	_	_	O
115	n	_	_	O
116	=	_	_	O
117	124	_	_	O
118	)	_	_	O
119	three	_	_	O
120	times	_	_	O
121	per	_	_	O
122	week	_	_	O
123	subcutaneously	_	_	O
124	for	_	_	O
125	12	_	_	O
126	to	_	_	O
127	24	_	_	O
128	weeks	_	_	O
129	.	_	_	O

130	The	_	_	O
131	primary	_	_	O
132	end	_	_	O
133	point	_	_	O
134	was	_	_	O
135	proportion	_	_	O
136	of	_	_	O
137	patients	_	_	O
138	transfused	_	_	O
139	;	_	_	O
140	secondary	_	_	O
141	end	_	_	O
142	points	_	_	O
143	were	_	_	O
144	change	_	_	O
145	in	_	_	O
146	hemoglobin	_	_	O
147	and	_	_	O
148	QOL	_	_	O
149	.	_	_	O

150	The	_	_	O
151	protocol	_	_	O
152	was	_	_	O
153	amended	_	_	O
154	before	_	_	O
155	unblinding	_	_	O
156	to	_	_	O
157	prospectively	_	_	O
158	collect	_	_	O
159	and	_	_	O
160	assess	_	_	O
161	survival	_	_	O
162	data	_	_	O
163	12	_	_	O
164	months	_	_	O
165	after	_	_	O
166	the	_	_	O
167	last	_	_	O
168	patient	_	_	O
169	completed	_	_	O
170	the	_	_	O
171	study	_	_	O
172	.	_	_	O

173	Epoetin	_	_	B-Premise
174	alfa	_	_	I-Premise
175	,	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	placebo	_	_	I-Premise
179	,	_	_	I-Premise
180	significantly	_	_	I-Premise
181	decreased	_	_	I-Premise
182	transfusion	_	_	I-Premise
183	requirements	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=.0057	_	_	I-Premise
187	)	_	_	I-Premise
188	and	_	_	I-Premise
189	increased	_	_	I-Premise
190	hemoglobin	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	<	_	_	I-Premise
194	.001	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	Improvement	_	_	B-Premise
198	of	_	_	I-Premise
199	all	_	_	I-Premise
200	primary	_	_	I-Premise
201	cancer-	_	_	I-Premise
202	and	_	_	I-Premise
203	anemia-specific	_	_	I-Premise
204	QOL	_	_	I-Premise
205	domains	_	_	I-Premise
206	,	_	_	I-Premise
207	including	_	_	I-Premise
208	energy	_	_	I-Premise
209	level	_	_	I-Premise
210	,	_	_	I-Premise
211	ability	_	_	I-Premise
212	to	_	_	I-Premise
213	do	_	_	I-Premise
214	daily	_	_	I-Premise
215	activities	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	fatigue	_	_	I-Premise
219	,	_	_	I-Premise
220	was	_	_	I-Premise
221	significantly	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	<	_	_	I-Premise
225	.01	_	_	I-Premise
226	)	_	_	I-Premise
227	greater	_	_	I-Premise
228	for	_	_	I-Premise
229	epoetin	_	_	I-Premise
230	alfa	_	_	I-Premise
231	versus	_	_	I-Premise
232	placebo	_	_	I-Premise
233	patients	_	_	I-Premise
234	.	_	_	I-Premise

235	Although	_	_	O
236	the	_	_	O
237	study	_	_	O
238	was	_	_	O
239	not	_	_	O
240	powered	_	_	O
241	for	_	_	O
242	survival	_	_	O
243	as	_	_	O
244	an	_	_	O
245	end	_	_	O
246	point	_	_	O
247	,	_	_	O
248	Kaplan-Meier	_	_	B-Premise
249	estimates	_	_	I-Premise
250	showed	_	_	I-Premise
251	a	_	_	I-Premise
252	trend	_	_	I-Premise
253	in	_	_	I-Premise
254	overall	_	_	I-Premise
255	survival	_	_	I-Premise
256	favoring	_	_	I-Premise
257	epoetin	_	_	I-Premise
258	alfa	_	_	I-Premise
259	(	_	_	I-Premise
260	P	_	_	I-Premise
261	=.13	_	_	I-Premise
262	,	_	_	I-Premise
263	log-rank	_	_	I-Premise
264	test	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	O
268	Cox	_	_	B-Premise
269	regression	_	_	I-Premise
270	analysis	_	_	I-Premise
271	showed	_	_	I-Premise
272	an	_	_	I-Premise
273	estimated	_	_	I-Premise
274	hazards	_	_	I-Premise
275	ratio	_	_	I-Premise
276	of	_	_	I-Premise
277	1.309	_	_	I-Premise
278	(	_	_	I-Premise
279	P	_	_	I-Premise
280	=.052	_	_	I-Premise
281	)	_	_	I-Premise
282	favoring	_	_	I-Premise
283	epoetin	_	_	I-Premise
284	alfa	_	_	I-Premise
285	.	_	_	I-Premise

286	Adverse	_	_	B-Premise
287	events	_	_	I-Premise
288	were	_	_	I-Premise
289	comparable	_	_	I-Premise
290	between	_	_	I-Premise
291	groups	_	_	I-Premise
292	.	_	_	I-Premise

293	Epoetin	_	_	B-Claim
294	alfa	_	_	I-Claim
295	safely	_	_	I-Claim
296	and	_	_	I-Claim
297	effectively	_	_	I-Claim
298	ameliorates	_	_	I-Claim
299	anemia	_	_	I-Claim
300	and	_	_	I-Claim
301	significantly	_	_	I-Claim
302	improves	_	_	I-Claim
303	QOL	_	_	I-Claim
304	in	_	_	I-Claim
305	cancer	_	_	I-Claim
306	patients	_	_	I-Claim
307	receiving	_	_	I-Claim
308	nonplatinum	_	_	I-Claim
309	chemotherapy	_	_	I-Claim
310	.	_	_	I-Claim

311	Encouraging	_	_	B-Claim
312	results	_	_	I-Claim
313	regarding	_	_	I-Claim
314	increased	_	_	I-Claim
315	survival	_	_	I-Claim
316	warrant	_	_	I-Claim
317	another	_	_	I-Claim
318	trial	_	_	I-Claim
319	designed	_	_	I-Claim
320	to	_	_	I-Claim
321	confirm	_	_	I-Claim
322	these	_	_	I-Claim
323	findings	_	_	I-Claim
324	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	relative	_	_	O
5	dose-intensity	_	_	O
6	of	_	_	O
7	cyclophosphamide	_	_	O
8	,	_	_	O
9	doxorubicin	_	_	O
10	,	_	_	O
11	vincristine	_	_	O
12	,	_	_	O
13	and	_	_	O
14	prednisone	_	_	O
15	(	_	_	O
16	CHOP	_	_	O
17	)	_	_	O
18	chemotherapy	_	_	O
19	could	_	_	O
20	be	_	_	O
21	improved	_	_	O
22	by	_	_	O
23	prophylactic	_	_	O
24	administration	_	_	O
25	of	_	_	O
26	granulocyte	_	_	O
27	colony-stimulating	_	_	O
28	factor	_	_	O
29	(	_	_	O
30	G-CSF	_	_	O
31	)	_	_	O
32	in	_	_	O
33	elderly	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	aggressive	_	_	O
37	non-Hodgkin	_	_	O
38	's	_	_	O
39	lymphoma	_	_	O
40	(	_	_	O
41	NHL	_	_	O
42	)	_	_	O
43	.	_	_	O

44	Patients	_	_	O
45	aged	_	_	O
46	65	_	_	O
47	to	_	_	O
48	90	_	_	O
49	years	_	_	O
50	(	_	_	O
51	median	_	_	O
52	,	_	_	O
53	72	_	_	O
54	years	_	_	O
55	)	_	_	O
56	with	_	_	O
57	stage	_	_	O
58	II	_	_	O
59	to	_	_	O
60	IV	_	_	O
61	aggressive	_	_	O
62	NHL	_	_	O
63	were	_	_	O
64	randomly	_	_	O
65	assigned	_	_	O
66	to	_	_	O
67	receive	_	_	O
68	standard	_	_	O
69	CHOP	_	_	O
70	every	_	_	O
71	3	_	_	O
72	weeks	_	_	O
73	or	_	_	O
74	CHOP	_	_	O
75	plus	_	_	O
76	G-CSF	_	_	O
77	every	_	_	O
78	3	_	_	O
79	weeks	_	_	O
80	on	_	_	O
81	days	_	_	O
82	2	_	_	O
83	to	_	_	O
84	11	_	_	O
85	of	_	_	O
86	each	_	_	O
87	cycle	_	_	O
88	.	_	_	O

89	In	_	_	B-Premise
90	389	_	_	I-Premise
91	eligible	_	_	I-Premise
92	patients	_	_	I-Premise
93	,	_	_	I-Premise
94	the	_	_	I-Premise
95	relative	_	_	I-Premise
96	dose	_	_	I-Premise
97	intensities	_	_	I-Premise
98	(	_	_	I-Premise
99	RDIs	_	_	I-Premise
100	)	_	_	I-Premise
101	of	_	_	I-Premise
102	cyclophosphamide	_	_	I-Premise
103	(	_	_	I-Premise
104	median	_	_	I-Premise
105	,	_	_	I-Premise
106	96.3	_	_	I-Premise
107	%	_	_	I-Premise
108	v	_	_	I-Premise
109	93.9	_	_	I-Premise
110	%	_	_	I-Premise
111	;	_	_	I-Premise
112	P	_	_	I-Premise
113	=.01	_	_	I-Premise
114	)	_	_	I-Premise
115	and	_	_	I-Premise
116	doxorubicin	_	_	I-Premise
117	(	_	_	I-Premise
118	median	_	_	I-Premise
119	,	_	_	I-Premise
120	95.4	_	_	I-Premise
121	%	_	_	I-Premise
122	v	_	_	I-Premise
123	93.3	_	_	I-Premise
124	%	_	_	I-Premise
125	;	_	_	I-Premise
126	P	_	_	I-Premise
127	=.04	_	_	I-Premise
128	)	_	_	I-Premise
129	were	_	_	I-Premise
130	higher	_	_	I-Premise
131	in	_	_	I-Premise
132	patients	_	_	I-Premise
133	treated	_	_	I-Premise
134	with	_	_	I-Premise
135	CHOP	_	_	I-Premise
136	plus	_	_	I-Premise
137	G-CSF	_	_	I-Premise
138	.	_	_	I-Premise

139	The	_	_	B-Premise
140	complete	_	_	I-Premise
141	response	_	_	I-Premise
142	rates	_	_	I-Premise
143	were	_	_	I-Premise
144	55	_	_	I-Premise
145	%	_	_	I-Premise
146	and	_	_	I-Premise
147	52	_	_	I-Premise
148	%	_	_	I-Premise
149	for	_	_	I-Premise
150	CHOP	_	_	I-Premise
151	and	_	_	I-Premise
152	CHOP	_	_	I-Premise
153	plus	_	_	I-Premise
154	G-CSF	_	_	I-Premise
155	,	_	_	I-Premise
156	respectively	_	_	I-Premise
157	(	_	_	I-Premise
158	P	_	_	I-Premise
159	=.63	_	_	I-Premise
160	)	_	_	I-Premise
161	.	_	_	I-Premise

162	The	_	_	B-Premise
163	actuarial	_	_	I-Premise
164	overall	_	_	I-Premise
165	survival	_	_	I-Premise
166	at	_	_	I-Premise
167	5	_	_	I-Premise
168	years	_	_	I-Premise
169	was	_	_	I-Premise
170	22	_	_	I-Premise
171	%	_	_	I-Premise
172	with	_	_	I-Premise
173	CHOP	_	_	I-Premise
174	alone	_	_	I-Premise
175	,	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	24	_	_	I-Premise
179	%	_	_	I-Premise
180	with	_	_	I-Premise
181	CHOP	_	_	I-Premise
182	plus	_	_	I-Premise
183	G-CSF	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=.76	_	_	I-Premise
187	)	_	_	I-Premise
188	,	_	_	I-Premise
189	with	_	_	I-Premise
190	a	_	_	I-Premise
191	median	_	_	I-Premise
192	follow-up	_	_	I-Premise
193	of	_	_	I-Premise
194	33	_	_	I-Premise
195	months	_	_	I-Premise
196	.	_	_	I-Premise

197	Patients	_	_	B-Premise
198	treated	_	_	I-Premise
199	with	_	_	I-Premise
200	CHOP	_	_	I-Premise
201	plus	_	_	I-Premise
202	G-CSF	_	_	I-Premise
203	had	_	_	I-Premise
204	an	_	_	I-Premise
205	identical	_	_	I-Premise
206	incidence	_	_	I-Premise
207	of	_	_	I-Premise
208	infections	_	_	I-Premise
209	,	_	_	I-Premise
210	with	_	_	I-Premise
211	World	_	_	I-Premise
212	Health	_	_	I-Premise
213	Organization	_	_	I-Premise
214	grade	_	_	I-Premise
215	3	_	_	I-Premise
216	to	_	_	I-Premise
217	4	_	_	I-Premise
218	(	_	_	I-Premise
219	34	_	_	I-Premise
220	of	_	_	I-Premise
221	1,191	_	_	I-Premise
222	cycles	_	_	I-Premise
223	v	_	_	I-Premise
224	36	_	_	I-Premise
225	of	_	_	I-Premise
226	1,195	_	_	I-Premise
227	cycles	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Only	_	_	B-Premise
231	the	_	_	I-Premise
232	cumulative	_	_	I-Premise
233	days	_	_	I-Premise
234	with	_	_	I-Premise
235	antibiotics	_	_	I-Premise
236	were	_	_	I-Premise
237	fewer	_	_	I-Premise
238	with	_	_	I-Premise
239	CHOP	_	_	I-Premise
240	plus	_	_	I-Premise
241	G-CSF	_	_	I-Premise
242	(	_	_	I-Premise
243	median	_	_	I-Premise
244	,	_	_	I-Premise
245	0	_	_	I-Premise
246	v	_	_	I-Premise
247	6	_	_	I-Premise
248	days	_	_	I-Premise
249	;	_	_	I-Premise
250	P	_	_	I-Premise
251	=.006	_	_	I-Premise
252	)	_	_	I-Premise
253	than	_	_	I-Premise
254	with	_	_	I-Premise
255	CHOP	_	_	I-Premise
256	alone	_	_	I-Premise
257	.	_	_	I-Premise

258	The	_	_	B-Premise
259	number	_	_	I-Premise
260	of	_	_	I-Premise
261	hospital	_	_	I-Premise
262	admissions	_	_	I-Premise
263	and	_	_	I-Premise
264	the	_	_	I-Premise
265	number	_	_	I-Premise
266	of	_	_	I-Premise
267	days	_	_	I-Premise
268	in	_	_	I-Premise
269	hospital	_	_	I-Premise
270	were	_	_	I-Premise
271	not	_	_	I-Premise
272	different	_	_	I-Premise
273	.	_	_	I-Premise

274	In	_	_	B-Claim
275	elderly	_	_	I-Claim
276	patients	_	_	I-Claim
277	,	_	_	I-Claim
278	G-CSF	_	_	I-Claim
279	improved	_	_	I-Claim
280	the	_	_	I-Claim
281	RDI	_	_	I-Claim
282	of	_	_	I-Claim
283	CHOP	_	_	I-Claim
284	,	_	_	I-Claim
285	but	_	_	B-Premise
286	this	_	_	I-Premise
287	did	_	_	I-Premise
288	not	_	_	I-Premise
289	lead	_	_	I-Premise
290	to	_	_	I-Premise
291	a	_	_	I-Premise
292	higher	_	_	I-Premise
293	complete	_	_	I-Premise
294	response	_	_	I-Premise
295	rate	_	_	I-Premise
296	or	_	_	I-Premise
297	better	_	_	I-Premise
298	overall	_	_	I-Premise
299	survival	_	_	I-Premise
300	.	_	_	I-Premise

301	G-CSF	_	_	B-Claim
302	did	_	_	I-Claim
303	not	_	_	I-Claim
304	prevent	_	_	I-Claim
305	serious	_	_	I-Claim
306	infections	_	_	I-Claim
307	.	_	_	I-Claim


0	The	_	_	O
1	study	_	_	O
2	was	_	_	O
3	designed	_	_	O
4	to	_	_	O
5	compare	_	_	O
6	the	_	_	O
7	effects	_	_	O
8	of	_	_	O
9	treatment	_	_	O
10	with	_	_	O
11	a	_	_	O
12	combination	_	_	O
13	of	_	_	O
14	trastuzumab	_	_	O
15	(	_	_	O
16	Herceptin	_	_	O
17	;	_	_	O
18	Genentech	_	_	O
19	,	_	_	O
20	Inc	_	_	O
21	,	_	_	O
22	South	_	_	O
23	San	_	_	O
24	Francisco	_	_	O
25	,	_	_	O
26	CA	_	_	O
27	)	_	_	O
28	and	_	_	O
29	chemotherapy	_	_	O
30	versus	_	_	O
31	chemotherapy	_	_	O
32	alone	_	_	O
33	on	_	_	O
34	health-related	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	(	_	_	O
39	HRQL	_	_	O
40	)	_	_	O
41	in	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	HER-2/neu	_	_	O
45	overexpressing	_	_	O
46	,	_	_	O
47	metastatic	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	.	_	_	O

51	A	_	_	O
52	sample	_	_	O
53	of	_	_	O
54	400	_	_	O
55	patients	_	_	O
56	,	_	_	O
57	not	_	_	O
58	previously	_	_	O
59	treated	_	_	O
60	for	_	_	O
61	metastatic	_	_	O
62	disease	_	_	O
63	and	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	either	_	_	O
68	trastuzumab	_	_	O
69	plus	_	_	O
70	chemotherapy	_	_	O
71	(	_	_	O
72	208	_	_	O
73	patients	_	_	O
74	)	_	_	O
75	or	_	_	O
76	chemotherapy	_	_	O
77	alone	_	_	O
78	(	_	_	O
79	192	_	_	O
80	patients	_	_	O
81	)	_	_	O
82	,	_	_	O
83	completed	_	_	O
84	the	_	_	O
85	European	_	_	O
86	Organization	_	_	O
87	for	_	_	O
88	Research	_	_	O
89	and	_	_	O
90	Treatment	_	_	O
91	Care	_	_	O
92	Quality	_	_	O
93	of	_	_	O
94	Life	_	_	O
95	Questionnaire	_	_	O
96	at	_	_	O
97	baseline	_	_	O
98	and	_	_	O
99	on	_	_	O
100	at	_	_	O
101	least	_	_	O
102	one	_	_	O
103	subsequent	_	_	O
104	occasion	_	_	O
105	at	_	_	O
106	8	_	_	O
107	,	_	_	O
108	20	_	_	O
109	,	_	_	O
110	32	_	_	O
111	,	_	_	O
112	44	_	_	O
113	,	_	_	O
114	and	_	_	O
115	56	_	_	O
116	weeks	_	_	O
117	.	_	_	O

118	HRQL	_	_	O
119	improvement	_	_	O
120	or	_	_	O
121	worsening	_	_	O
122	was	_	_	O
123	defined	_	_	O
124	as	_	_	O
125	a	_	_	O
126	>	_	_	O
127	or=	_	_	O
128	10-point	_	_	O
129	change	_	_	O
130	(	_	_	O
131	range	_	_	O
132	,	_	_	O
133	0	_	_	O
134	to	_	_	O
135	100	_	_	O
136	points	_	_	O
137	)	_	_	O
138	in	_	_	O
139	the	_	_	O
140	scores	_	_	O
141	of	_	_	O
142	six	_	_	O
143	preselected	_	_	O
144	domains	_	_	O
145	(	_	_	O
146	global	_	_	O
147	quality	_	_	O
148	of	_	_	O
149	life	_	_	O
150	[	_	_	O
151	QOL	_	_	O
152	]	_	_	O
153	,	_	_	O
154	physical	_	_	O
155	,	_	_	O
156	role	_	_	O
157	,	_	_	O
158	social	_	_	O
159	,	_	_	O
160	and	_	_	O
161	emotional	_	_	O
162	functioning	_	_	O
163	,	_	_	O
164	and	_	_	O
165	fatigue	_	_	O
166	)	_	_	O
167	.	_	_	O

168	Stable	_	_	O
169	HRQL	_	_	O
170	was	_	_	O
171	defined	_	_	O
172	as	_	_	O
173	a	_	_	O
174	change	_	_	O
175	of	_	_	O
176	less	_	_	O
177	than	_	_	O
178	10	_	_	O
179	.	_	_	O

180	A	_	_	O
181	Bonferroni	_	_	O
182	correction	_	_	O
183	was	_	_	O
184	applied	_	_	O
185	for	_	_	O
186	multiple	_	_	O
187	testing	_	_	O
188	.	_	_	O

189	After	_	_	B-Premise
190	completion	_	_	I-Premise
191	of	_	_	I-Premise
192	chemotherapy	_	_	I-Premise
193	,	_	_	I-Premise
194	patients	_	_	I-Premise
195	treated	_	_	I-Premise
196	with	_	_	I-Premise
197	trastuzumab	_	_	I-Premise
198	and	_	_	I-Premise
199	chemotherapy	_	_	I-Premise
200	reported	_	_	I-Premise
201	significant	_	_	I-Premise
202	improvement	_	_	I-Premise
203	in	_	_	I-Premise
204	fatigue	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	.05	_	_	I-Premise
209	)	_	_	I-Premise
210	as	_	_	I-Premise
211	compared	_	_	I-Premise
212	with	_	_	I-Premise
213	their	_	_	I-Premise
214	baseline	_	_	I-Premise
215	scores	_	_	I-Premise
216	.	_	_	I-Premise

217	Higher	_	_	B-Premise
218	proportions	_	_	I-Premise
219	of	_	_	I-Premise
220	patients	_	_	I-Premise
221	receiving	_	_	I-Premise
222	the	_	_	I-Premise
223	combined	_	_	I-Premise
224	therapy	_	_	I-Premise
225	achieved	_	_	I-Premise
226	improvement	_	_	I-Premise
227	in	_	_	I-Premise
228	global	_	_	I-Premise
229	QOL	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	.05	_	_	I-Premise
234	)	_	_	I-Premise
235	than	_	_	I-Premise
236	did	_	_	I-Premise
237	patients	_	_	I-Premise
238	treated	_	_	I-Premise
239	with	_	_	I-Premise
240	chemotherapy	_	_	I-Premise
241	alone	_	_	I-Premise
242	.	_	_	I-Premise

243	Higher	_	_	B-Premise
244	proportions	_	_	I-Premise
245	of	_	_	I-Premise
246	the	_	_	I-Premise
247	combined	_	_	I-Premise
248	therapy	_	_	I-Premise
249	group	_	_	I-Premise
250	also	_	_	I-Premise
251	achieved	_	_	I-Premise
252	improvement	_	_	I-Premise
253	in	_	_	I-Premise
254	physical	_	_	I-Premise
255	and	_	_	I-Premise
256	role	_	_	I-Premise
257	functioning	_	_	I-Premise
258	and	_	_	I-Premise
259	in	_	_	I-Premise
260	fatigue	_	_	I-Premise
261	as	_	_	I-Premise
262	compared	_	_	I-Premise
263	with	_	_	I-Premise
264	the	_	_	I-Premise
265	chemotherapy	_	_	I-Premise
266	group	_	_	I-Premise
267	,	_	_	I-Premise
268	but	_	_	B-Premise
269	the	_	_	I-Premise
270	differences	_	_	I-Premise
271	were	_	_	I-Premise
272	not	_	_	I-Premise
273	statistically	_	_	I-Premise
274	significant	_	_	I-Premise
275	.	_	_	I-Premise

276	There	_	_	B-Premise
277	were	_	_	I-Premise
278	no	_	_	I-Premise
279	differences	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	proportions	_	_	I-Premise
283	of	_	_	I-Premise
284	patients	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	two	_	_	I-Premise
288	groups	_	_	I-Premise
289	that	_	_	I-Premise
290	reported	_	_	I-Premise
291	worsening	_	_	I-Premise
292	.	_	_	I-Premise

293	Statistically	_	_	B-Claim
294	significantly	_	_	I-Claim
295	higher	_	_	I-Claim
296	proportions	_	_	I-Claim
297	of	_	_	I-Claim
298	patients	_	_	I-Claim
299	treated	_	_	I-Claim
300	with	_	_	I-Claim
301	a	_	_	I-Claim
302	combination	_	_	I-Claim
303	of	_	_	I-Claim
304	trastuzumab	_	_	I-Claim
305	and	_	_	I-Claim
306	chemotherapy	_	_	I-Claim
307	reported	_	_	I-Claim
308	improved	_	_	I-Claim
309	global	_	_	I-Claim
310	QOL	_	_	I-Claim
311	than	_	_	I-Claim
312	did	_	_	I-Claim
313	patients	_	_	I-Claim
314	treated	_	_	I-Claim
315	by	_	_	I-Claim
316	chemotherapy	_	_	I-Claim
317	alone	_	_	I-Claim
318	.	_	_	I-Claim